<SEC-DOCUMENT>0001731122-24-001578.txt : 20241010
<SEC-HEADER>0001731122-24-001578.hdr.sgml : 20241010
<ACCEPTANCE-DATETIME>20241010163306
ACCESSION NUMBER:		0001731122-24-001578
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20241010
DATE AS OF CHANGE:		20241010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RENOVARO INC.
		CENTRAL INDEX KEY:			0001527728
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				452259340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38758
		FILM NUMBER:		241365568

	BUSINESS ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		45 39179840

	MAIL ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RENOVARO BIOSCIENCES INC.
		DATE OF NAME CHANGE:	20230807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Enochian Biosciences Inc.
		DATE OF NAME CHANGE:	20230804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Renovaro Biosciences Inc.
		DATE OF NAME CHANGE:	20230802
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>e5986_10-k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:RENB="http://renovarobio.com/20240630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02F_US%2DGAAP%2D2024%2D(with%2DECD)_rempres -->
<!-- Field: Set; Name: xdx; ID: xdx_037_RENB_renovarobio.com_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20230701_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DDocumentFiscalYearFocus_2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001527728 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000004" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001527728</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0284" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="RENB:StockIssuedPursuantToWarrantsExercisedValue" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:StockIssuedPursuantToWarrantsExercisedValue" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:StockIssuedPursuantToWarrantsExercisedValue" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:EarnoutSharesIssuedValue" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:EarnoutSharesIssuedValue" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:EarnoutSharesIssuedValue" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:SharesIssuedForInterestOnNotesPayableExtensionValue" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:SharesIssuedForInterestOnNotesPayableExtensionValue" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:SharesIssuedForInterestOnNotesPayableExtensionValue" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0379" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0492" unitRef="Shares" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="renb-20240630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-07-01to2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-122017-11-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-12</xbrli:startDate>
        <xbrli:endDate>2017-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-182018-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-18</xbrli:startDate>
        <xbrli:endDate>2018-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-192022-06-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-19</xbrli:startDate>
        <xbrli:endDate>2022-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-172023-04-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-17</xbrli:startDate>
        <xbrli:endDate>2023-04-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-14_custom_MarchNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-14_custom_MarchNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_MarchNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_MarchNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-11_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-102024-01-11_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-10</xbrli:startDate>
        <xbrli:endDate>2024-01-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-092024-01-12_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-09</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-29_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-012023-12-29_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-012023-12-29_custom_PrivatePlacement1Member_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PrivatePlacement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-012023-12-29_custom_PrivatePlacement2Member_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PrivatePlacement2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-302024-01-31_custom_PrivatePlacement3Member_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PrivatePlacement3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-30</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-05_custom_Note2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-052023-10-05_custom_Note2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-05</xbrli:startDate>
        <xbrli:endDate>2023-10-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-11_custom_Note2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_Note2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_custom_Note2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_Note2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-06_custom_ConvertibleNotesPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-052020-02-06_custom_ConvertibleNotesPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-05</xbrli:startDate>
        <xbrli:endDate>2020-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-29</xbrli:startDate>
        <xbrli:endDate>2022-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-252023-06-26_custom_AmendedAndRestatedSecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-25</xbrli:startDate>
        <xbrli:endDate>2023-06-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-252023-06-26_us-gaap_WarrantMember_custom_AmendedAndRestatedSecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-25</xbrli:startDate>
        <xbrli:endDate>2023-06-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-262024-06-04_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-26</xbrli:startDate>
        <xbrli:endDate>2024-06-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-04_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-05_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-042024-02-05_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-04</xbrli:startDate>
        <xbrli:endDate>2024-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_RSBioApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:RSBioApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_RSBioApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">RENB:AccruedExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:RSBioApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_RSBioApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:RSBioApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">RENB:AccruedExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-212023-11-22_custom_LoanAgreementMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-21</xbrli:startDate>
        <xbrli:endDate>2023-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_BridgeLoanMember_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-02</xbrli:startDate>
        <xbrli:endDate>2023-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-02_custom_November2023NoteMember_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-16_custom_November2023NoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-16_custom_November2023NoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_November2023NoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_November2023NoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-292020-03-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-29</xbrli:startDate>
        <xbrli:endDate>2020-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-11_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-162022-05-17_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-16</xbrli:startDate>
        <xbrli:endDate>2022-05-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-17_srt_MinimumMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-17_srt_MaximumMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-17_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-26_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-252023-06-26_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-25</xbrli:startDate>
        <xbrli:endDate>2023-06-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreements1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SubscriptionAgreements1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_custom_Note2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:Note2020Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-292023-11-30_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-29</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_UnitedStatesTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_UnitedStatesTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-292023-08-01_custom_PreferredStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-29</xbrli:startDate>
        <xbrli:endDate>2023-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-01_custom_PreferredStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PreferredStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_Investor1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:Investor1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-042024-04-05_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-04</xbrli:startDate>
        <xbrli:endDate>2024-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-192024-02-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-19</xbrli:startDate>
        <xbrli:endDate>2024-02-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-19</xbrli:startDate>
        <xbrli:endDate>2024-02-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-15_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:StockPurchaseAgreementOfRenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-032023-12-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-03</xbrli:startDate>
        <xbrli:endDate>2023-12-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-222023-10-23_custom_AdvisoryServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:AdvisoryServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-22</xbrli:startDate>
        <xbrli:endDate>2023-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-262023-09-28_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-26</xbrli:startDate>
        <xbrli:endDate>2023-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-272023-07-28_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-27</xbrli:startDate>
        <xbrli:endDate>2023-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-26_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-252023-06-26_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-25</xbrli:startDate>
        <xbrli:endDate>2023-06-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-26_custom_OneWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:OneWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20_us-gaap_CommonStockMember_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:LincolnParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-262023-04-27_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-26</xbrli:startDate>
        <xbrli:endDate>2023-04-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-302023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-30</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_OneWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:OneWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-10_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-092023-02-10_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-09</xbrli:startDate>
        <xbrli:endDate>2023-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-292022-12-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-29</xbrli:startDate>
        <xbrli:endDate>2022-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-132022-07-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-13</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_custom_RenovaroBioPharmaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RenovaroBioPharmaIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-132022-07-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-13</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-132022-07-14_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-13</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DanDritDenmarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:DanDritDenmarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RenovaroDenmarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RenovaroDenmarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_RenovaroDenmarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RenovaroDenmarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-02-06_custom_EquityIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:EquityIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_Employees1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:Employees1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_ConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:ConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_ConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:ConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PlanOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:PlanOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-30</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-05</xbrli:startDate>
        <xbrli:endDate>2020-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-142019-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-14</xbrli:startDate>
        <xbrli:endDate>2019-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-242021-08-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-24</xbrli:startDate>
        <xbrli:endDate>2021-08-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-092021-09-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-09</xbrli:startDate>
        <xbrli:endDate>2021-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_MarkDybulMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:MarkDybulMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-16_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-16_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RENBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RENCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-032024-10-02_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-03</xbrli:startDate>
        <xbrli:endDate>2024-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-02_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-312024-08-01_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-31</xbrli:startDate>
        <xbrli:endDate>2024-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-22</xbrli:startDate>
        <xbrli:endDate>2024-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>United
states</b></span>&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20230701__20240630_zKYh3eOL1zEf"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90E_edei--DocumentAnnualReport_c20230701__20240630" title="Document Annual Report"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span><span style="text-transform: uppercase"><b>&#160;ANNUAL
report under section 13 Or 15(</b></span><b>d<span style="text-transform: uppercase">) of the securities exchange act of 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_90D_edei--DocumentPeriodEndDate_c20230701__20240630_zesYPgbousGb"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20230701__20240630" title="Current Fiscal Year End Date"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:datemonthdayen" id="Fact000017" name="dei:CurrentFiscalYearEndDate">June 30</ix:nonNumeric></span>, 2024</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_905_edei--DocumentTransitionReport_c20230701__20240630" title="Document Transition Report"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span><span style="text-transform: uppercase"><b>&#160;TRANSITION
report under section 13 Or 15(</b></span><b>d<span style="text-transform: uppercase">) of the securities exchange act of 1934 </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number <b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityFileNumber_c20230701__20240630_ziT7VlgQd2Nd"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000020" name="dei:EntityFileNumber">001-38758</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20230701__20240630" title="Entity Registrant Name"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000022" name="dei:EntityRegistrantName">RENOVARO INC.</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Name of registrant in its charter) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 50%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20230701__20240630_zLDAsFhuAkH5"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20230701__20240630_z0mABslxpLCh"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000024" name="dei:EntityTaxIdentificationNumber">45-2559340</ix:nonNumeric></span> </span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of <br/>
incorporation or organization) </span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer <br/>
Identification No.) </span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--EntityAddressAddressLine1_c20230701__20240630_zfm3RW6uaypb"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000025" name="dei:EntityAddressAddressLine1">2080 Century Park East</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20230701__20240630_zm9Sg1anCTYf"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000026" name="dei:EntityAddressAddressLine2">Suite 906</ix:nonNumeric> </span><br/>
<span id="xdx_903_edei--EntityAddressCityOrTown_c20230701__20240630_zG9cQ4XSz0l4"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000027" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230701__20240630_zyj2XXBZg7Cb"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000028" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--EntityAddressPostalZipCode_c20230701__20240630_z6uCGdVRgHRc"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000029" name="dei:EntityAddressPostalZipCode">90067</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices) </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">+1(<span id="xdx_902_edei--CityAreaCode_c20230701__20240630_zsrc2Grit5g6"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000030" name="dei:CityAreaCode">305</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20230701__20240630_zCppQJGPgawl"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000031" name="dei:LocalPhoneNumber">918-1980</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 34%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on Which Registered</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20230701__20240630_zKsQbmGiCFyf"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000032" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20230701__20240630_zMdELCIv8q1f"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000033" name="dei:TradingSymbol">RENB</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_901_edei--SecurityExchangeName_c20230701__20240630_zjwdI1lyNI59"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(g) of the Act: Common Stock,
$0.0001 par value</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> <span id="xdx_90C_edei--EntityWellKnownSeasonedIssuer_c20230701__20240630_zOU9v3WrKCOe"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000035" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>&#160;<span id="xdx_902_edei--EntityVoluntaryFilers_c20230701__20240630_zggepMrZ31Vk"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000036" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the last 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_903_edei--EntityCurrentReportingStatus_c20230701__20240630_zBFTr8nHuu5k"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000037" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
<span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> No&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically,
if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;<span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20230701__20240630_zlx0wjEZu2hj"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000038" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
No&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See
the definitions of &#8220;large-accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%"><span style="font-size: 10pt">Large accelerated filer </span></td>
    <td style="width: 20%"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 30%"><span style="font-size: 10pt">Accelerated filer </span></td>
    <td style="width: 20%"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><span id="xdx_904_edei--EntityFilerCategory_c20230701__20240630" title="Entity Filer Category"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000040" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> </span></td>
    <td><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</span></td>
    <td><span style="font-size: 10pt">Smaller reporting company </span></td>
    <td><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_908_edei--EntitySmallBusiness_c20230701__20240630" title="Entity Small Business"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Emerging growth company</span></td>
    <td><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20230701__20240630" title="Entity Emerging Growth Company"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000044" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_902_edei--IcfrAuditorAttestationFlag_dbF_c20230701__20240630_zo4ugxdUX2Vg"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000045" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If securities are registered pursuant to Section 12(b)
of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of
an error to previously issued financial statements. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_908_edei--DocumentFinStmtErrorCorrectionFlag_dbF_c20230701__20240630_zsSrW2w81GQ1"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000046" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
<span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Act). <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span> Yes <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_901_edei--EntityShellCompany_dbF_c20230701__20240630_zScYNsu94MKf"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000047" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span>
No</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 31, 2023, the aggregate market value of
the voting and non-voting common equity held by non-affiliates was $<span id="xdx_901_edei--EntityPublicFloat_iI_c20231231_zMClnPh10u3j"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,193,356</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of October 3, 2024, the number of shares outstanding of the registrant&#8217;s
common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) was <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20241003_zwaRXuC4Pjbg" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-10-03" id="Fact000050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">156,193,912</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONTENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Page</i></span></td></tr>
<tr>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Forward-Looking
Statements</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002"><b>Part I</b></a></span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Business</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Risk Factors</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Unresolved
Staff Comments</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C</span></td>
<td style="vertical-align: bottom"><a href="#h_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity Risk Management and Strategy&#160;</span></a></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>54</td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine Safety
Disclosures</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009"><b>Part II</b></a></span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5 </span></td>
<td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market
for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Selected
Financial Data</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Management&#8217;s
Discussion and Analysis of Financial Condition and Results Of Operations</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Quantitative
and Qualitative Disclosures About Market Risk</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Financial
Statements and Supplementary Data</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Changes
In and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Controls
and Procedures</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018"><b>Part III</b></a></span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Directors,
Executive Officers and Corporate Governance</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Executive
Compensation</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Certain
Relationships and Related Transactions and Director Independence</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14 </span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Principal
Accountant Fees and Services</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024"><b>Part IV</b></a></span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Exhibits,
Financial Statement Schedules</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
<tr style="background-color: White">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Signatures
and Certifications</a></span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_001"></span>Cautionary Language Regarding Forward-Looking Statements and Industry
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">This Annual Report on Form 10-K
contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 regarding
the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified
by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are based upon our current assumptions,
expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking
statements by the following words: &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;approximately,&#8221; &#8220;estimate,&#8221;
&#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential&#8221; or the negative of these terms or other comparable terminology,
although the absence of these words does not necessarily mean that a statement is not forward-looking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Forward-looking statements include,
but are not limited to, statements concerning:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Our ability to continue as a going concern and ability to raise additional capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our continuous incurrence of losses as a pre-clinical-stage biotechnology company with no products that have achieved regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Our ability to generate revenue if we fail to develop marketable product;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our dependence on substantial additional financing to support the research, development, licensing, manufacture, and marketing of product candidates and products, and the possibility that unforeseen operational costs will arise;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The dilutive effect on stockholders&#8217; ownership interests of the Company raising capital through an equity issuance in connection with future equity financing or equity debt agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our dependence on the services of experts, including third parties to research and develop product candidates in cooperation with our employees and officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The difficulty or impossibility of predicting future clinical trial results and regulatory outcomes of our products based upon our pre-clinical or earlier clinical trial performance;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The application of heightened regulatory and commercial scrutiny to our AI-based technology, gene, cell, and immunotherapy products given their novel nature and concomitant potential for actual or perceived safety issues;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to compete in rapidly developing fields, and the potential impact to our financial condition, product marketability, and operational capacities of a competitor receiving regulatory approval before us, or a competitor developing more advanced or efficacious products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Potential delays or total failures of third parties, such as universities, non-profits, and clinical research centers, to perform obligations on which our product research and development rely;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The impact on our competitive position, business operations, and financial condition of implementation of amended healthcare laws and regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The dependence of certain of our pipelines on intellectual property licensed from licensors, and the severe adverse impact to our business operations of a disruption of one of our licensing relationships;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The potential monetary costs of defending our intellectual property rights in a dispute, and the possibility that an intellectual property dispute will not be settled in our favor;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The possibility that our patents and patent applications, even if unchallenged, will not sufficiently protect or provide exclusive use of our intellectual property, which could jeopardize our ability to commercialize our products and dissuade companies from subsequently collaborating with us;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The negative impact to our competitive position and the value of our technology of our failure to protect trade secrets through the use of non-disclosure and confidentiality agreements, or the unavailability of adequate recourse for breach of such agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The fluctuation and volatility of the market price of our Common Stock due to its limited public market, and the possibility that these issues will compound and strain our stockholders&#8217; ability to resell their Common Stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our significant dependence on sophisticated management with highly technical expertise to oversee business operations, and our ability to attract and retain qualified personnel to sustain growth;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to adapt to future growth by training an expanding employee base and shifting away from reliance on third-party contractors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The risk of liability arising from claims of environmental damage, personal injury, and property damages in connection with our research and development activities, including those that involve the use of hazardous materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The possibility that enforcement actions to suspend or severely restrict our business operations will be brought against the Company for our failure to comply with laws or regulations and the potential costs of defending against such actions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our reliance on adequate maintenance of the security and integrity of our information technology systems to effectively operate our business; and </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Such other factors as discussed throughout Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Part I, Item 1A. Risk Factors herein.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A forward-looking statement is
neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. You should
not place undue reliance on forward-looking statements, which speak only as of the date of this Annual Report. Forward-looking statements
involve known and unknown risks, uncertainties, and other factors, including without limitation the risks and uncertainties described
below the heading &#8220;Item 1.A. Risk Factors&#8221; in this report, that may cause our actual results, performance, or achievements
to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
The forward-looking statements included herein are based on current expectations and assumptions that involve numerous risks and uncertainties.
Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to
the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe
that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore,
there can be no assurance that the forward-looking statements included in this Annual Report will prove to be accurate. Given these risks
and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any or all of the forward-looking
statements contained in this Annual Report and any other public statement made by us, including by our management, may turn out to be
incorrect. We are including this cautionary note to make applicable and take advantage of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Information regarding market and
industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally
based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and
other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties
accompanying any estimates of future market size, revenue and market acceptance of products and services. Except as required by U.S. federal
securities laws, we have no obligation to update forward-looking information to reflect actual results or changes in assumptions or other
factors that could affect those statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In February 2024, the Company changed
its corporate name from Renovaro BioSciences Inc. to Renovaro Inc. The Company will not distinguish between its prior and current corporate
name and will refer to the Company&#8217;s current corporate name throughout this Annual Report on Form 10-K. <span style="background-color: white">As
such, unless expressly indicated or the context requires otherwise, the terms &#8220;Renovaro,&#8221; &#8220;company,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; and &#8220;our&#8221; in this document refer to Renovaro Inc., a Delaware corporation, and, where appropriate, its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_002"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Unless otherwise indicated or
the context otherwise requires, all references in this prospectus to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Renovaro&#8221;
or the &#8220;Company&#8221; are to Renovaro Inc., a Delaware corporation together with its wholly owned subsidiaries, Renovaro Biosciences,
Inc., a Delaware corporation (&#8220;Renovaro Biosciences&#8221;), GEDi Cube Intl Ltd, a private limited company incorporated under the
laws of England and Wales (&#8220;GEDi Cube UK&#8221;), GEDi Cube B.V., a Dutch private limited company, Grace Systems B.V., a Dutch private
limited company, Renovaro Biosciences Denmark ApS, a Danish limited company, organized under the Danish Act on Limited Companies of the
Kingdom of Denmark, and Renovaro Technologies, Inc., a Nevada corporation (&#8220;Renovaro Technologies&#8221;).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_003"></span>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Our Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Inc. operates through two subsidiaries, Renovaro Biosciences and Renovaro Cube. Renovaro Cube refers to GediCube Intl. Ltd. and its wholly
owned subsidiaries GediCube, B.V. and Grace Systems B.V., which were acquired on February 13, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><b>Renovaro
Biosciences Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers,
and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. As a result of our
acquisition of GEDi Cube Intl on February 13, 2024, we have shifted the Company&#8217;s primary focus and resources to the development
of the GEDi Cube Intl technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Therapeutic Technologies</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Bioscience aims to train the immune system to allow a person to better
fight diseases through allogeneic cell and/or gene therapy. Our vision is for a world with healthy longevity, and free from toxic chemotherapy,
for those with cancer and other serious diseases. Renovaro Biosciences will seek to leverage general principles and advances in the knowledge
of the immune response to engineer cells with enhanced attributes to promote the recognition and elimination of disease cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="text-decoration: underline">Allogeneic Cell Therapy
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The strategic benefit of the allogeneic cell therapy technologies is to potentially
allow for the manufacture of large, &#8220;off-the-shelf&#8221; banks of therapeutic cells that are readily available on demand by healthcare
professionals, to potentially decrease the time between diagnosis and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="text-decoration: underline">Gene Therapy</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences may also seek to explore various approaches for gene therapy
design elements to potentially eliminate virus-infected or cancer cells by the modulation of the patient&#8217;s immune system. Upon injecting
into the patients, these genetically engineered allogeneic cells have little to no risk of passing those modifications to the patient
since they are terminally differentiated with locked functionality to activate the host immune system. Gene modified allogeneic cells
are expected to be rejected naturally once they activate the patient&#8217;s immune system therefore will have a very short survival time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Renovaro Biosciences Focus Areas:</span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">Oncology:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">RENB-DC11: Genetically modified
Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Solid Tumors; specifically Pancreatic tumors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Allogeneic Cell Therapy Platform
&#8211; Completed pre-IND, IND-enabling phase.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Based
on learnings from our internal research, literature reviews of ongoing clinical development for solid tumors, and recent advances in immune
modulation, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission
from some of the deadliest solid tumors such as pancreatic, liver, triple negative breast and head &amp; neck cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The platform may one day enable broad immune enhancements that are combined
with cancer specific antigens that could be applicable to a wide range of solid tumors. This approach allows us to quickly adapt our approach
to any patient solid tumor using the same banked allogenic drug substance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><span style="text-decoration: underline">RENB-DC20: Genetically modified Allogeneic Dendritic
Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of Triple Negative Breast Cancer</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Triple Negative Breast Cancer (TNBC) is a subtype of breast cancer that is negative
for estrogens receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2). TNBC is
characterized by its unique molecular profile, aggressive nature, and distinct metastatic patterns that lack targeted therapies. TNBC
is well known for its aggressive behavior and is characterized by onset at a younger age, high mean tumor size, and higher-grade tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Based upon
our internal research, literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation,
we believe we may have the ability to design an innovative therapeutic vaccination platform that could potentially be used to treat some
of the deadliest and hard-to-treat solid tumors that include triple negative breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">Infectious Diseases:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">RENB-HV12:
Genetically Modified Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of HIV; A Chronic
Infectious Disease</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The oncology therapeutic vaccine
technology could potentially be adapted to target infectious disease antigens and be a viable therapeutic approach in difficult to treat
chronic infectious diseases. As described above, the engineered allogenic dendritic cell drug substance is thought to be able to be loaded
with various cancer antigens for specific solid tumors but could or may be loaded with infectious disease antigens to elicit a more robust
immune response to viruses and other difficult to treat infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Renovaro Cube Overview</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube is an AI-driven healthcare
technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed a proprietary
AI platform that analyzes genetics using Explainable AI (as defined below) to provide earlier and more accurate cancer diagnosis. This
platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. This approach
is combined with differential molecular capabilities that are designed to identify, differentiate and pinpoint the exact source. Renovaro
Cube&#8217;s process also involves the mining of biomarker panels, which are integrated into a machine learning library referred to as
&#8220;RenovaroCube&#8221; to further enhance diagnosis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube also aims to utilize
its proprietary AI platform in the development of commercial products to support clinical, research and pharmaceutical organizations that
are trying to improve patient care through precision diagnosis, prediction of success of therapy, new drug discovery, treatment protocols
or clinical trials. Specifically, Renovaro Cube is focused on developing products and services aimed at (i) early cancer characterization,
(ii) personalized treatment selection, (iii) prediction and tracking response to therapies, (iv) recurrence detection and efficacy monitoring,
and (v) ultimately, drug discovery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube was initially incorporated as Grace Systems B.V. (&#8220;Grace Systems&#8221;)
in 2013 under the laws of the Netherlands to develop unique data mining algorithms to enable banking, finance and government entities
to extract business insights from data. Grace Systems began applying its algorithms to biological data in 2018 to uncover cancer-associated
patterns. Beginning in 2018, Grace Systems pivoted its platform to focus only on healthcare. Renovaro Cube has focused on developing its
AI technology for early cancer detection.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube has now focused on
commercialization of its AI technology. Renovaro Cube believes that it has developed a unique approach to the early detection and diagnosis
of cancer and its recurrence and, in time, other rare diseases through the systematic analysis of data using AI technologies, data mining
procedures and algorithms for health technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">Renovaro Cube&#8217;s technology has been trained on complex heterogeneous cancer
data and appears to find patterns associated with cancer in public and private data resources. With the help of Renovaro Cube&#8217;s
algorithms, discovered patterns may be translated into biomarkers that can be used in a clinical setting to target various aspects of
cancer diagnosis and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Renovaro Cube&#8217;s Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">Renovaro Cube&#8217;s product development
focuses on four core areas:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Early Detection. </b>Multi-cancer early detection (&#8220;MCED&#8221;) blood tests are advanced diagnostic tools that analyze cell-derived molecules present in the bloodstream. These tests specifically look for abnormal genetic, epigenetic or proteomic patterns of these cell-derived molecules, which can indicate the presence of cancer cells. By examining the molecules shed from various cells, including cancer cells, MCED tests aim to detect cancer at an early stage. This approach holds promise for improving cancer detection and potentially saving lives.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Recurrence of cancer</b>. A recurrence refers to the return of cancer after a period of remission.
A cancer recurrence happens because, in spite of the efforts to kill the cancer, some cells may remain, which grow and eventually cause
symptoms. In rare instances, a patient may develop a new cancer that&#8217;s completely unrelated to the originally diagnosed cancer,
which is referred to as a second primary cancer. An early warning system could help to identify a recurrence as early as possible, thereby
helping to accelerate any treatment and diagnosis. The different types of recurrence include:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Local recurrence,</b>&#160;meaning that the cancer has returned in the same place it first started;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Regional recurrence</b>, meaning that the cancer has returned to the lymph nodes near the place it first started; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Distant recurrence</b>, meaning the cancer has returned in another part of the body.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Response to treatment. </b>At Renovaro Cube we aim to develop a new array of diagnostic products that
can accurately identify patients that are going to respond or fail to a certain drug. In highly toxic therapies it will not only increase
survival but it will also reduce unnecessary exposure to chemotherapy. Furthermore, the costs for cancer drugs are usually very high.
Providing the right therapy to the right patient will therefore significantly reduce the costs of medicine in cancer. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Clinical trials</b>. Clinical trials involve a type of research that studies new tests and treatments and evaluates their effects on human health outcomes. People volunteer to take part in clinical trials to test medical interventions including drugs, cells and other biological products, surgical procedures, radiological procedures, devices, behavioral treatments and preventive care. Clinical trials are carefully designed, reviewed and completed, and need to be approved before they can start.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt">In response to these four core
areas, the key components of Renovaro Cube&#8217;s product development are to build a software and hardware platform that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Uses data science to develop novel insights into the characterization of diseases such as cancer. Renovaro Cube intends to apply its proprietary technology to biological data from multiple sources to enable the typification (or classification) of disease entities and sub-entities to provide insights about the nature and behavior of diseases to payers, providers, pharmaceutical companies and patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Enables more accurate diagnosis and earlier detection of cancer and other diseases with the goal of maximizing outcomes and minimizing the costs of treatment. Renovaro Cube intends to develop a system to understand the smallest fragments of cancer in the blood of the patient. Presently, Renovaro Cube is developing a product to analyze results from liquid biopsy run through an Oxford Nanopore Sequencer. We expect the Renovaro Cube product will subsequently identify, train and validate explainable biomarkers, panels and models on different molecular layers. Multiple models will be individually trained for optimal stratification through the entire health journey, ensuring the right accuracy for a therapeutic decision in every stage. Renovaro Cube will integrate different modalities and molecular data sources into a differential diagnostic report. Diagnostics and prognosis will be explainable with quality control reports and biomarker insights for different disciplines ensuring maximum trust and insight in medical decision making.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assists in clinical trials with patient cohort selection and response tracking,
to be used by companies like Renovaro Biosciences in their patient cohort selection for their clinical trials, by looking at which patients
are reacting positively, negatively and have no reaction. This data becomes more important through the progression of the different phases
of drug development, as more and more patients are added. Renovaro Cube will provide multi-omic data analysis, looking for specific changes
in the patients that might indicate a change in their molecular make-up. This can then be used for the next phase of a clinical trial
to look for the specific molecular data that has showed a positive reaction in the previous phase. It also provides insights for more
effective response tracking, which Renovaro Cube believes is important to the providers of care as well as the development and evaluation
of new pharmaceuticals and immune therapies in clinical trials. Patient response to treatment can be used to focus the target audience
for drugs in development and in subsequent clinical practice. As Renovaro Cube collects more data, longitudinal about treatment and response,
it will have the ability to train prognostic models to give an insight in disease progression and treatment response, both critical for
enrolling in clinical trials and eventually every treatment. Because Renovaro Cube consists of many independently trained and validated
models, it will have the ability to assist in virtually every therapeutic decision, for different subtypes and groups (stratifications).
The multi-omics and multi-modal pipelines could allow the use of multiple combinations of tissue samples and diagnostic platforms. The
detailed diagnostic reports will allow and support insights for multiple disciplines such as cancer biology, genomics and pathology to
look at underpinning biomarkers, pathways and clinical annotations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Provides insight into patients who have had cancer previously. These insights will provide for more effective
recurrence monitoring, which Renovaro Cube believes is important to the providers of care and patients during follow-up monitoring of
remissions. Renovaro Cube anticipates that payers want to detect and re-treat recurrences at the earliest possible stage to maximize patients&#8217;
outcomes in terms of time and cost and that, similarly, patients with a recurrence are keen to re-engage with effective treatment at the
earliest opportunity. A key aspect of this will be taking blood from the patients, sequencing this blood and running it through the Renovaro
Cube platform which will identify if the patient has any indication of the recurrence of the same or a new cancer. For recurrence monitoring,
Renovaro Cube will focus on a highly sensitive combination of lab and information technology. Lab protocols, sequence post processing
and machine learning are all designed, trained and validated to get the best signal with the highest sensitivity to catch early signals
of recurrence. This will be done on a regular basis allowing surveillance analysis over time.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Includes biomarker panels that will be extended to include as many layers of genetic information (multi-omics) as possible including mutation, gene expression, methylation status, fragmentomics, nucleosome mapping, collectively named multi-omics, with the goal to reach the highest accuracy possible, both in terms of sensitivity and specificity of each individual biomarker panel. This provides a non-invasive alternative for the current complex, expensive and cumbersome procedures.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Create value through advancing more sophisticated typification of diseases in an effort to address some of the pressing problems faced by modern healthcare, including healthcare costs, an aging population and developments in medical technology that produce a stream of increasingly sophisticated treatments requiring more precise targeting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt">One additional key focus of Renovaro
Cube is its multi-modal, data analysis. Multi-modal data encompasses the whole aspect of data from a patient perspective, whether genomics,
imaging, phenotypic or even wearable data, which can be cross analyzed to produce data that could not be previously produced. Renovaro
Cube intends to use multi-modal data to bring new insights to the clinical and research teams trying to understand what to do next with
the patient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Renovaro Cube&#8217;s Technology
and Techniques </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube is dedicated to the
development of early cancer detection blood tests and expects to develop partnerships with third-party laboratories across the United
Kingdom, the Netherlands and the rest of Europe and will also expand to the United States. Renovaro Cube is focused on developing diagnostic
tests and test kits that would analyze samples derived from non-invasive liquid biopsy samples and intends to perform these tests from
a Renovaro&#8217;s dedicated fully certified service laboratory and engage third-party laboratories to perform these tests for end-users.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For this purpose, Renovaro Cube
has developed an AI platform that aims to leverage expertise in both biological and computational sciences and to go beyond traditional
tumor signals by detecting the body&#8217;s early warning signs of cancer. Renovaro Cube&#8217;s goal is to provide accurate and reliable
tests that can aid in the early diagnosis and treatment of cancer. Renovaro Cube&#8217;s AI technology is created to detect a wide range
of biological signs to enhance the accuracy and sensitivity of early cancer detection and, thereby, enable earlier intervention and potentially
improved patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube&#8217;s AI technology
aims to address three critical facets of medical needs within the domain of cancer diagnosis (as illustrated  below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">type-specific cancer detection;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pan-cancer detection; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">patient stratification.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 235.5pt; width: 415.5pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Moreover, the versatility of Renovaro
Cube&#8217;s AI technology extends to encompass the realm of rare cancers, including cases such as cancer of unknown primary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Leveraging DNA methylation data,
Renovaro Cube has identified and validated biomarker panels tailored for the detection of a wide range of cancers, including bladder,
breast, colon, prostate, thyroid, head and neck, liver, kidney and lung cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The foundational architecture of
Renovaro Cube&#8217;s AI technology is engineered to facilitate comprehensive pan-cancer analysis through its extensive record of informative
biomarkers discovered across a diverse array of cancer types. This comprehensive repository empowers Renovaro Cube&#8217;s AI technology
to swiftly cross-reference biomarkers and explore molecular commonalities and distinctions that span multiple tumor categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For example, the capabilities of
Renovaro Cube&#8217;s AI technology have unearthed biomarkers capable of pinpointing a specific subgroup of thyroid cancer patients characterized
by a distinct genomic alteration, the neurotrophic tyrosine receptor kinase (&#8220;NTRK&#8221;) gene fusion. Identification of these
NTRK-positive patients provides an actionable therapeutic target.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Uses of Renovaro Cube&#8217;s AI Technology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt">Renovaro Cube has developed its AI platform to support:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">AI-assisted patient diagnostics;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">multi-omic data analysis;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">genome-wide or targeted analysis;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">pan-cancer analysis;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">different technology platforms (sequence or array);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">tracking of each sample;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">AI-guided biomarker discovery for single or multiple cancer types; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">logs of analysis steps and outcomes (data preparation, discovery, validation).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube&#8217;s AI platform
is an enterprise software platform that is distinguished from its competitors&#8217; technology by its core attributes encompassing AI-guided
analysis and meticulous record-keeping of data handling procedures within audit trails, logs, and data discoveries. Renovaro Cube designed
this technology to support and validate every phase of the process, from the initial handling of raw data to the creation of essential
biomarker panels. Renovaro Cube&#8217;s AI platform also facilitates the integration of data originating from diverse sources, including
public databases and collaborative partnership data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Illustrated below is the three-phase
workflow behind Renovaro Cube&#8217;s AI platform for biomarker discovery using DNA methylation data. This workflow commences with the
identification of pertinent single- and multi-omic data best suited to address the specific inquiries of Renovaro Cube&#8217;s clients,
and the subsequent stages involve the meticulous pre-processing and loading of this data into the platform. This process culminates in
the availability of a dashboard offering the client insights into the data&#8217;s characteristics, such as data quality, the technology
employed, and associated metadata.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_003.jpg" alt="" style="height: 276pt; width: 426.75pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase I of the workflow behind Renovaro Cube&#8217;s AI platform primarily centers on the pivotal process of biomarker discovery. This intricate procedure unfolds through the application of data mining algorithms and statistical methodologies integrated into the AI platform. The paramount objective of Phase I is to reduce the plethora of genomic features displaying variations across samples, which is accomplished by systematically eliminating extraneous or inconsequential features while preserving those features that exhibit the greatest potential for accurately detecting cancer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase II of the workflow builds upon the foundation of selected biomarkers by focusing on understanding the dynamic interplay among these chosen biomarkers, culminating in the creation of composite panels. The goal of Phase II is to pinpoint biomarker combinations that not only demonstrate robustness in detecting cancer but also maintain their efficacy across diverse contexts. Renovaro Cube believes that its AI algorithms are adept at uncovering multiple combinations across a spectrum of panels, which is supported by Renovaro Cube&#8217;s AI-guided panel mining, a proprietary combinatorial optimization technique used by Renovaro Cube&#8217;s AI technology. This approach, coupled with the capacity to explore numerous panels, significantly enhances the likelihood of discovering panels that align with specific metric criteria, such as sensitivity, specificity, precision, and recall and allows for tailoring criteria to align with clients&#8217; unique needs, such as the number of biomarkers included per panel, or the inclusion of biomarkers associated with the expression of specific genes. The performance of the top-tier panels is further fine-tuned through the application of machine learning models. Subsequently, the efficacy of these biomarker panels in detecting cancer is validated through independent data sets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px">&#160;</td>
<td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify">Phase III of the workflow involves Renovaro Cube&#8217;s collaboration with its clinical partners to validate the performance of the biomarker panels. Through this collaboration, Renovaro Cube can confirm the utility and accuracy of its biomarker panels in real-world clinical contexts. &#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>AI-Assisted Diagnostics</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The process of biomarker discovery
facilitated by Renovaro Cube&#8217;s AI technology has yielded a set of data that enables scrutiny of the genomic distinctions and commonalities
inherent in diverse cancer types. This data set can support the diagnosis of cancers when their type or origin remains unidentified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In addition to this role in biomarker
discovery and the development of diagnostic tests, Renovaro Cube&#8217;s AI technology also integrates AI-guided molecular profiling of
patient samples and furnishes diagnostic patient reports. These diagnostic reports reflect the outcomes of molecular profiling, coupled
with interpretations provided by Renovaro Cube&#8217;s team, to facilitate the process of cancer diagnostics by a qualified healthcare
provider, who can consider these reports in the context of a patient&#8217;s medical history, clinical signs, and symptoms, among other
factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>Quality Control Process</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube undertakes post-processing
of data generated from sequence and arrays to ensure accurate and meaningful results. These post-processing steps for omic data include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Quality Control</span>: Quality control is performed to assess the overall data quality and to identify any technical issues or anomalies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Normalization</span>: arrays can introduce various sources of technical variation, such as batch effects, intensity variations, and probe-specific biases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Quality Filtering</span>: After genotype calling, additional quality filtering may be performed to remove low-quality SNPs based on criteria like call rates, minor allele frequency, Hardy-Weinberg equilibrium p-values, and linkage disequilibrium.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Other post-processing steps may
include genotype calling, population stratification and association analysis. Specific post-processing steps may vary depending on the
type of array used, the study design, and the analytical goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Planning for Commercialization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="text-decoration: underline">Partnerships in Development</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">To enhance multi-omic and multi-modal
capacity, and to work to validate those capabilities with human samples including liquid-biopsy-based tests/test kits, Renovaro Cube is
actively pursuing relationships with leading academic cancer centers, pathology and imagery centers in Europe, the USA and the Middle
East. In certain cases, scopes of work are in process. This is a very attractive model for partners to be involved with Renovaro Cube
to perform multi-omics genetic analysis using liquid biopsies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Resources</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube intends to hire additional staff to increase the speed and velocity
of its organization, including the development of the AI platform and the opportunities to deploy the AI platform for research perspective
and ultimately for clinical practice and into clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In addition, Renovaro Cube intends
to build out its infrastructure by leasing space for storage, networking and hosting facilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Target Market</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube&#8217;s intended
customers will be hospitals, clinics, insurance companies, pharmaceutical companies, biotech companies, research centers, physicians and
individual patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube aims to utilize its
AI technology to commercialize products and test kits for healthcare providers, hospitals, clinics and doctors that will expedite diagnosis
and the selection of appropriate treatment for various types of cancer. Renovaro Cube intends to differentiate its products based on the
following factors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Proprietary and unique panel mining algorithms to create multiple biomarker stratifications per cancer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Explainable AI, offering traceability between the prediction and the exact biomarkers, panels and genes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Differential diagnosis, inclusion and exclusion of cancer types based on facts; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Precision diagnosis, with a high accuracy percentage with machine-learning tuning.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The multi-omic design of Renovaro
Cube&#8217;s AI platform enables the use of different molecular layers, such as epigenomics, transcriptomics, and metabolomics, together
with genomics and clinical data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Panel Mining </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The unique panel mining technique
in Renovaro Cube&#8217;s technology repeatedly investigates genes to identify relevant biomarkers. The proprietary technique in Renovaro
Cube&#8217;s technology not only searches for individual biomarkers, but also integrates validated panels for different cancer types into
the &#8220;RenovaroCube&#8221; machine learning library. This process enables precision diagnosis, by including one cancer and excluding
others based on statistically, scientifically and clinically validated machine-learning panels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Panel mining is designed to combine
biomarkers into panels in such a way that the final panel meets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">performance metric criteria;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">technical criteria, such as a minimum or maximum number of biomarkers for the selected assay;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">biological criteria, non-annotated genes inclusion; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">stratification criteria.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Explainable AI</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The term &#8220;Explainable AI&#8221;
refers to the ability of an AI system or model to provide human-understandable explanations for its decision-making process or predictions.
This feature aims to bridge the gap between the &#8220;black box&#8221; nature of many AI algorithms and the need for transparency, interpretability,
and accountability in AI applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In traditional machine learning
approaches, such as deep neural networks, the internal workings of the model can be complex and difficult to interpret. This lack of interpretability
poses challenges in critical domains where decisions have significant implications, such as healthcare.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube believes that Explainable
AI is crucial for ensuring transparency, fairness, and accountability in AI systems. Renovaro Cube&#8217;s AI platform includes Explainable
AI by design. All data points, calculations and results are traceable, and all calculations are verifiable and reproducible with the same
result.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Disease prognosis is one of the
diagnostic capabilities of the Explainable AI feature of Renovaro Cube&#8217;s technology. Disease prognosis gives more insight for a
specific patient that empowers healthcare providers, patients, and their families to make well-informed decisions about treatment, care,
and future planning, thereby enhancing patient-centered care, optimizing resource utilization, and contributing to improved patient outcomes
and quality of life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Differential Diagnosis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube&#8217;s AI platform
offers differential diagnosis by design due to its approach with a multitude of models for different diseases and the ability to include
and exclude diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Diseases like cancer are very homogenous,
meaning that markers like TP53 or BRCA are expressed with multiple cancers. To address this homogeneity, differential diagnosis distinguishes
between two or more conditions or diseases that share similar signs, symptoms or characteristics. The goal of differential diagnosis is
to consider and evaluate all possible diagnoses for the patient&#8217;s symptoms to determine the most likely cause. Differential diagnosis
therefore aims to identify the underlying condition accurately and guide appropriate treatment and management strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Differential diagnosis is important for several reasons:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Accurate Diagnosis</span>: Differential diagnosis helps healthcare professionals arrive at the correct diagnosis by systematically considering all possible explanations for the patient&#8217;s symptoms. This ensures that the appropriate treatment and interventions are provided, leading to better patient outcomes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Avoiding Misdiagnosis</span>: Many medical conditions have similar or overlapping symptoms, and misdiagnosis can have serious consequences. Differential diagnosis helps to avoid misdiagnosing one condition as another, preventing unnecessary treatments, delays in appropriate care or potential harm to the patient.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Tailored Treatment</span>: Different conditions require different treatments. Identifying the correct diagnosis through differential diagnosis allows healthcare professionals to develop a targeted treatment plan based on the specific condition, improving the chances of successful management and recovery.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Avoiding Overtreatment or Undertreatment</span>: Some conditions may require aggressive interventions, while others may resolve with minimal treatment or simply require symptomatic management. Differential diagnosis helps prevent overtreating or undertreating patients by ensuring that interventions are appropriate for the specific condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Identifying Underlying Causes</span>: In some cases, multiple conditions may present with similar symptoms, but the underlying causes may be distinct. Differential diagnosis helps identify the root cause of the symptoms, which is crucial for implementing effective long-term management strategies and preventing complications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In summary, differential diagnosis
is a critical process in healthcare that supports accurate identification of the underlying condition, tailored treatment plans, and improved
patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Precision Diagnostics</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Precision diagnostics and personalized
care is about focusing on what is required for a specific patient, what are their individual needs, how can we understand more about them
to be more precise when delivering care and identifying the right clinical pathway to move them through treatment. Renovaro Cube technology
will bring a high level of detail with multi-omic data, allowing individual genes and different possible cancers under suspicion to be
identified. Due to the structure of the data produced, Renovaro Cube can bring it into any format of user interface, documentation, or
database. We expect to provide the flexibility to respond to the different requirements for delivering data to the right person at the
right place at the right time. We will comply to user interface guidance and usability regulations (WC3C) to ensure that they meet the
correct standards to enable the data to be displayed, read and understood. Personalized care is what we all in the healthcare system are
striving for, we are one component that can make a huge difference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Future Development </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In driving towards future commercialization,
Renovaro Cube intends to undertake or continue the following activities to enable the development of its AI platform, bolster the credibility
of this platform and open up revenue opportunities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Increase in-kind contribution projects with hospitals, research centers and pharmaceutical
companies, focusing on rare disease, cancer diagnosis and other opportunities for clinical trials; it is expected that the investments
required for these activities will be leveraged by non-dilutive funding instruments to de-risk individual projects and product development routes,</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Work to develop long-term strategic partnerships with clinical organizations, research centers and pharmaceutical companies to advance existing research in multi-modal analysis and open potential revenue streams;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Develop Renovaro Cube&#8217;s multi-modal, multi-omics platform architecture and first prototypes, with the goal of providing integrated multi-modal solutions that would be sold as a fully deployed and fully supported solution, subject to compliance with regulatory standards for hosting and support and for production of algorithms being deployed in a clinical environment;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Build Renovaro Cube&#8217;s service and support models for its AI platform;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Build or lease a &#8220;supercomputer&#8221; that will be utilized for processing genomic data, the training of algorithms and the development of Renovaro Cube&#8217;s solutions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue business development across key territories in the Europe, Middle East, and Africa (&#8220;EMEA&#8221;) region, starting in the United Kingdom, the Netherlands and Germany, under the management of in-country managers supported by centralized teams in Amsterdam and London and progress to rolling out in the US leveraging the Renovaro US based staff;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Deploy a sequencing lab in the EMEA region that will allow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expand its team to include biomedical scientists,
    data scientists, machine-learning engineers, specialized medical doctors (oncologist, geneticist), high-performance-computer engineers
    and software engineers.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"><span style="font-family: Symbol">&#183;
    </span>&#160;Renovaro Cube plans to establish a state-of-the-art fully certified (CLIA and ISO standards) service laboratories to perform
    liquid biopsies in a multi-omic approach for third parties (primarily research and academic institutes) and provide data analysis at the
    same time. This activity serves two important goals:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt"><span style="font-family: Symbol">&#183;</span>&#160;&#160;
    It provides immediate revenues for the company providing a superior service for multi-omic sequencing servicing using Oxford Nanopore
    Technologies for an attractive pricing and high-end services also applicable for liquid biopsies.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt"><span style="font-family: Symbol">&#183;</span>&#160;&#160;
    The Cube needs data to expand the indications, application and improve the capabilities of the system. Acquiring this data is a lengthy
    and expensive. We anticipate a significant number of clients will provide data sharing for a reduced price. The outcomes can be published
    collaboratively, and the potential products will be commercialized by Renovaro Cube. The partner will receive royalties.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"><span style="font-family: Symbol">&#183;
    </span>&#160;&#160; A first service laboratory will be established in the Netherlands and rapidly expanded to other sites in the EU, US
    and rest of the world.</p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;&#160;</p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Patents and licenses are key to
our business. Our strategy is to file patent applications to protect technology, inventions, and improvements to inventions that we consider
important for the development of our business. We rely on a combination of patent, copyright, trademark, and trade secret laws, as well
as continuing technological innovations, proprietary knowledge, and various third-party agreements, including, without limitation, confidentiality
agreements, materials transfer agreements, research agreements, and licensing agreements, to establish and protect our proprietary rights.
We aim to take advantage of all of the intellectual property rights that are available to us and seek the protection of those rights so
that we can fully exploit our innovations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We also protect our proprietary information by requiring our employees, consultants,
contractors, and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective
employment or engagement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Assigned Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 16, 2022, the USPTO issued
U.S. Patent No. 11,413,338 B2, &#8220;Methods and Compositions Using Recombinant Dendritic Cells for Cancer Therapy&#8221;, pertaining
to methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous
proteins. This patent protects <b>RENB-DC11: </b><i>Genetically modified Allogeneic Dendritic Cells as Potential Product for Long-term
Remission of Solid Tumors &#8211; Starting with Pancreatic Cancer</i> and potential future products <b>RENB-DC-12XX: </b><i>Genetically
modified Allogeneic Dendritic Cells as Potential Product for Long-term Remission of Additional Indications</i> for twenty years. The Company
owns this patent application, through assignment as of July 15, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 17, 2020, a patent titled &#8220;Allogeneic
T-Cell-Based HIV Vaccine to Induce Cellular and Humoral Immunity&#8221;, US 2021/0030795 A1 for the composition and method of use concepts
for RENB-HV-12. was filed. The Company owns this patent application, through assignment as of September 28, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>In-Licensed Technology</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><b>Trade Secrets and Proprietary Know-How</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition to intellectual property
protected by patents and copyrights, we have trade secrets and proprietary know-how relating to our products, production processes, and
future strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Renovaro Cube operates in a highly
competitive market with several companies developing AI-driven diagnostic platforms for early disease detection and personalized medicine.
Key competitors include Grail, Freenome, and Owkin, each utilizing advanced AI and machine learning to analyze multi-omic data for cancer
detection. While these companies focus primarily on specific diagnostic approaches, Renovaro Cube differentiates itself through its unique,
disease-agnostic AI platform that integrates various molecular data sources for differential diagnosis. Our platform&#8217;s explainable
AI system, capable of providing actionable insights and personalized treatment options, offers a distinct advantage. Despite the crowded
landscape, Renovaro Cube's scalable technology, multi-omics capabilities, and ability to process diverse biopsy sources position it as
a versatile leader in precision diagnostics, allowing us to address a broader range of clinical and research needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;<b><i>FDA Review and Approval
</i></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Government authorities in the United
States, at the federal, state, and local levels, and in other countries extensively regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval
monitoring and reporting, marketing and export and import of therapeutic products such as those we are developing. Any products we develop
are likely to require regulatory review and allowance to proceed prior to conducting clinical trials and additional regulatory approvals
prior to commercialization. In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (FDCA) and the
Public Health Service Act (PHSA) and their implementing regulations govern, among other things, biopharmaceutical testing, manufacturing,
safety, efficacy, labeling, storage, recordkeeping, advertising, and other promotional practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Obtaining FDA approval is a costly
and time-consuming process. FDA approval requires that preclinical studies be conducted in the laboratory and in animal model systems
to gain preliminary information on efficacy and to identify any major safety concerns. The results of these studies are then submitted
as a part of an IND, which the FDA must review and allow before human clinical trials can start. The IND includes a detailed description
of the proposed clinical investigations. An independent Institutional Review Board (&#8220;IRB&#8221;) must also review and approve the
clinical protocol and each clinical site.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;&#160;A company must submit
an IND for each investigational medical product and specific indication(s) and must conduct clinical studies to demonstrate the safety
and efficacy of the product necessary to obtain FDA approval. The FDA receives reports on the progress of each phase of clinical testing
and may require the modification, suspension, or termination of clinical trials if an unwarranted risk is observed in participants including
patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Obtaining FDA approval prior to
marketing a biopharmaceutical product in the United States typically requires multiple phases of clinical trials to demonstrate the safety
and efficacy of the product candidate. Clinical trials are how experimental treatments are evaluated in humans and are conducted following
preclinical testing. Clinical trials may be conducted within the United States or in foreign countries. If clinical trials are conducted
in foreign countries, the products under development as well as the trials are subject to regulations of the FDA and/or its regulatory
counterparts in the other countries. Upon successful completion of clinical trials, approval to market the treatment for a particular
patient population may be requested from the FDA in the United States and/or its counterparts in other countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Applications submitted to the FDA
are subject to an unpredictable and potentially prolonged approval process. Despite good-faith communication and collaboration between
the applicant and the FDA during the development process, the FDA may decide, upon final review of the data, that the application does
not satisfy its criteria for approval or requires additional product development or further preclinical or clinical studies. Even if FDA
regulatory approval(s) are obtained, a marketed product is subject to continual review, and later discovery of previously unknown problems
or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal
of the product from the market as well as possible civil or criminal sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Sponsors of clinical trials are
required to register, and report results for, all controlled, clinical investigations, other than Phase 1 investigations, of a product
subject to FDA regulation. Trial registration may require public disclosure of certain confidential commercial development data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The process of obtaining regulatory
approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure
of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include,
among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls
or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals
of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have
a material adverse effect on our business, financial condition, results of operations and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 36pt"><b><i>Other Healthcare
Laws and Compliance Regulations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Although we currently do not have
any products on the market, we may also be subject to additional healthcare regulations and enforcement by the federal government and
by authorities in the states and foreign jurisdictions in which we conduct our business. In the United States, among other things, the
research, manufacturing, distribution, sale and promotion of pharmaceutical and biological products are potentially subject to regulation
and enforcement by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid
Services (&#8220;CMS&#8221;), other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector
General), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational
Safety and Health Administration, the Environmental Protection Agency, state Attorneys General and other state and local government agencies.
Our current and future business activities, including for example, sales, marketing, and scientific/educational grant programs, must comply
with health care regulatory laws, as applicable, including, without limitation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal anti-kickback statute, which is a criminal statute that makes it a felony for individuals or entities to knowingly and willfully offer or pay, or to solicit or receive, direct or indirect remuneration, in order to induce the purchase, order, lease, or recommending of items or services, or the referral of patients for services, that are reimbursed under a federal health care program, including Medicare and Medicaid; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal False Claims Act, which prohibits, among other things, individuals and entities from knowingly submitting, or causing to be submitted, false or fraudulent claims for payment of government funds, with penalties that include three times the government&#8217;s damages plus civil penalties for each false claim; in addition, the False Claims Act permits a person with knowledge of fraud, referred to as a qui tam plaintiff, to file a lawsuit on behalf of the government against the person or business that committed the fraud, and, if the action is successful, the qui tam plaintiff is rewarded with a percentage of the recovery; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical suppliers to report annually to CMS information related to payments and other transfers of value to physicians, other healthcare professionals and teaching hospitals, and ownership and investment interests held by physicians and other healthcare professionals and their immediate family members; and</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws which may impose stricter requirements than federal law and may apply to items or services reimbursed by any payor (including commercial insurers and cash-paying patients); state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare professionals and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare professionals or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">If our operations are found to
be in violation of any of such laws or any other governmental laws or regulations that apply, they may be subject to penalties, including,
without limitation, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, exclusion
from participation in federal and state healthcare programs, additional program integrity obligations, individual imprisonment, injunctions,
recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, refusal to permit
us to enter into supply contracts, including government contracts, contractual damages, reputational harm, administrative burdens, diminished
profits, and future earnings, any of which could have a material adverse effect on our business, financial condition, result of operations,
and cash flows. These additional healthcare regulations could affect our current and future arrangements with healthcare professionals,
principal investigators, consultants, customers and third-party payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Moreover, the introduction of legislation,
implementation of new regulations, or enforcement of existing regulations that have a negative impact on the commercial prospects for
the types of products we are developing could negatively impact our share price and our ability to raise capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 36pt"><b><i>Coverage and Reimbursement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In the United States, third-party
payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers
and other organizations. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the
cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may
limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all the FDA-approved
drugs for a particular indication. Third-party payor coverage may be more limited than the purposes for which the FDA or foreign regulatory
authorities approve the product. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that
other payors will also provide coverage for the drug product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Further, third-party payers are
increasingly challenging the price of medical products and services, and there is increasing pressure on biotechnology companies to reduce
healthcare costs. If purchasers or users of our products are not able to obtain adequate reimbursement for the cost of using our products,
they may forgo or reduce their use. Significant uncertainty exists as to the reimbursement status of newly approved healthcare products,
and whether adequate third-party coverage will be available. Our inability to promptly obtain coverage and profitable payment rates from
both government funded and private payors for future products we develop could have a material adverse effect on our operating results,
our ability to raise capital needed to commercialize potential products, and our overall financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 36pt"><b><i>Healthcare Reform</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In March 2010, former President
Obama signed into law The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act
of 2010 (collectively, the &#8220;Affordable Care Act&#8221;), which substantially changed the way healthcare is financed by both governmental
and private insurers in the United States, and significantly affected the pharmaceutical industry. The Affordable Care Act contains a
number of provisions, including those governing enrollments in federal healthcare programs, reimbursement adjustments and fraud and abuse
changes. Additionally, the Affordable Care Act increases the minimum level of Medicaid rebates payable by manufacturers of brand name
drugs; requires collection of rebates for drugs paid by Medicaid managed care organizations; requires manufacturers to participate in
a coverage gap discount program, under which they must agree to offer point-of-sale discounts off negotiated prices of applicable brand
drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered
under Medicare Part&#160;D; and imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded
prescription drugs&#8221; to specified federal government programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Since its enactment, there have
been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges
and amendments to the Affordable Care Act in the future. Other legislative changes have been proposed and adopted since the Affordable
Care Act was enacted, including aggregate reductions of Medicare payments to providers and reduced payments to several types of Medicare
providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their
marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more
transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing
regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing&#160;cost disclosure and transparency measures, and, in some cases, proposing to encourage importation
from other countries and bulk purchasing.&#160;We cannot predict what healthcare reform initiatives may be adopted in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We also are subject to various
federal, state, and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices,
the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds
and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future
legislation or administrative action cannot be accurately predicted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Renovaro
Cube&#8217;s <i>AI</i>-guided diagnostic platform operates within a highly regulated environment, particularly as it involves health data
and medical diagnostics. As a Software as a Medical Device (SaMD), the platform will require compliance with various regional regulations,
including but not limited to the U.S. Food and Drug Administration (FDA) guidelines and European Union Medical Device Regulation (MDR).
Our regulatory strategy involves a meticulous development process, adhering to international standards such as for quality management
systems. Key elements include rigorous clinical validation, cybersecurity, data privacy (in compliance with HIPAA and GDPR), and quality
control to ensure patient safety and diagnostic accuracy. Post-market surveillance and continuous improvement will be integral to maintaining
compliance and effectiveness as we aim for global commercialization. Given the rapidly evolving regulatory landscape for AI-driven diagnostics,
Renovaro Cube remains committed to working closely with regulatory bodies to navigate the approval processes and to address ethical considerations,
ensuring that our products meet the highest standards of safety and efficacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>Foreign Corrupt
Practices Act</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our business activities may be
subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations, or rules of other
countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value,
either directly or indirectly, to a non-U.S. government official to influence official action, or otherwise obtain or retain business.
The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the
corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore
involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries,
the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government
entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. There is no certainty
that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with
all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations
could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those
of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries,
implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions
on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products,
and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees,
and our business, prospects, operating results, and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024, we had 25
full-time employees. The Company has streamlined the organization to focus on its oncology therapeutic vaccine and artificial intelligence
driven healthcare technology. The Company has tailored its workforce to focus on these therapies and technology. We believe that we have
good relations with our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">On February 13, 2024, Renovaro Inc. acquired Renovaro
Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly owned subsidiary pursuant to a stock purchase agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We trade on the NASDAQ Capital
Market under the ticker &#8220;RENB.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our website is http://www.renovarobio.com.
We make available free of charge, on or through our website, our annual, quarterly, and current reports and any amendments to those reports
filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the SEC. Information contained in our website is not part of, nor incorporated by reference into, this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>Item 1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the risks and uncertainties
that could cause our business, financial condition or operating results to be harmed. We encourage you to carefully review the full risk
factors contained in this report in their entirety for additional information regarding these risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Raising additional capital may cause dilution to our existing stockholders or restrict our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">From time to time, we may be subject to legal proceedings, regulatory investigations or disputes, and governmental inquiries that could cause us to incur significant expenses, divert our management&#8217;s attention, and materially harm our business, financial condition, and operating results.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Negative publicity has had and may continue to have a negative impact on our business and may have a long-term effect on our relationships with our customers, partners and collaborators.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Renovaro Biosciences is a pre-clinical biotechnology company and may never be able to successfully develop marketable products or generate any revenue. We have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The market for artificial intelligence -based (&#8220;AI&#8221;) healthcare solutions is new and unproven and may decline or experience limited growth, and concerns over the use of AI may hinder the adoption of AI technologies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Regulators and legislators may limit our ability to develop or implement our AI algorithms and may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, reputation, and financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The results of pre-clinical studies or earlier clinical studies are not necessarily predictive of future results, and if we fail to demonstrate efficacy in our pre-clinical studies and/or clinical trials in the future our future business prospects, financial condition and operating results will be materially adversely affected.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our reliance on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with them.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have limited experience in drug development and may not be able to successfully
develop any drugs, which would cause us to cease our therapeutic development activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have licensed a portion of our intellectual property from our licensors. If we breach any of our license agreements with these licensors, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party claims of intellectual property infringement
    may prevent or delay our development and commercialization efforts.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We use AI in our business, and challenges relating to the development and use of AI, including generative AI, could result in competitive harm, reputational harm, and legal liability, and adversely affect our results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have limited corporate infrastructure and may experience difficulties in managing growth.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have experienced and may continue to experience significant turnover in our management and executive leadership, which creates uncertainty and could harm our ability to operate our business effectively.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If serious adverse events or other undesirable side
    effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay our clinical development and
    commercialization of some or all of our product candidates.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Sales of a substantial number of shares of our Common Stock in the public market could cause our stock price to fall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Investing in our Common Stock involves a high degree
of risk. Investors should carefully consider all of the risk factors and uncertainties described below, in addition to the other information
contained in this Annual Report on Form 10-K, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes, before investing
in our Common Stock. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The risks described below may not be the only ones
relating to our Company and additional risks that we currently believe are immaterial may also affect us. If any of these risks, including
those described below, materialize, our business, competitive position, reputation, financial condition, results of operations, cash flows
and future prospects could be seriously harmed. In these circumstances, the market price of our Common Stock could decline, and investors
may lose all or a part of their investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Financial Position and Capital
Requirements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>We have incurred substantial
losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro is a pre-clinical-stage biotechnology company and AI-driven healthcare
technology company. Investment in biotechnology related to genetically modified cells is highly speculative because it entails substantial
upfront capital expenditures and significant risk that a product candidate will fail to prove effective, gain regulatory approval or become
commercially viable. We do not have any products approved by regulatory authorities and have not generated any revenues from product sales
or otherwise to date, and have incurred significant research, development and other expenses related to our ongoing operations and expect
to continue to incur such expenses. As a result, we have not been profitable and have incurred significant operating losses in every reporting
period since our inception. For the years ended June 30, 2024, and 2023, respectively, we reported a net loss of $80,650,172 and $39,684,056.
We had an accumulated deficit of $325 million and $244 million as of June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We do not expect to generate revenues
for the foreseeable future. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate
these losses to increase as we continue to research, develop, and seek regulatory approvals for our product candidates and any additional
product candidates we may acquire, in-license or develop, and potentially begin to commercialize product candidates that may achieve regulatory
approval. We may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect
our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to
generate revenues. If any of our product candidates fails in clinical studies or does not gain regulatory approval, or if approved, fails
to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods. We anticipate that our expenses will increase in the future as we continue to invest in research
and development of our existing product candidates, investigate and potentially acquire new product candidates and expand our manufacturing
and commercialization activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><i>There is substantial
doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our consolidated financial statements as of June 30, 2024, have been prepared
under the assumption that we will continue as a going concern for the next twelve months. As of June 30, 2024, we had cash and cash equivalents
of $220,467 and an accumulated deficit of $325 million. We do not believe that our cash and cash equivalents are sufficient for the next
twelve months. As a result of our financial condition and other factors described herein, there is substantial doubt about our ability
to continue as a going concern. Our ability to continue as a going concern will depend on our ability to obtain additional funding, as
to which no assurances can be given. We continue to analyze various alternatives, including potentially obtaining debt or equity financings
or other arrangements. Our future success depends on our ability to raise capital. We cannot be certain that raising additional capital,
whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or,
if available, will be on terms acceptable to us. If we issue additional securities to raise funds, these securities may have rights, preferences,
or privileges senior to those of our Common Stock, and our current shareholders may experience dilution. If we are unable to obtain funds
when needed or on acceptable terms, we may be required to curtail our current development programs, cut operating costs, forgo future
development and other opportunities, or even terminate our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>We will require substantial
additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit,
reduce or terminate our product development or commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We expect to expend substantial
resources for the foreseeable future to continue the pre-clinical development of our cell, gene and immunotherapy product candidates,
and the advancement and potential expansion of our pre-clinical research pipeline. We also expect to continue to expend resources for
the development and manufacturing of product candidates and the technology we have licensed or have a right to license from our licensors.&#160;These
expenditures will include costs associated with research and development, potentially acquiring or licensing new product candidates or
technologies, conducting pre-clinical and clinical studies and potentially obtaining regulatory approvals and manufacturing products,
as well as marketing and selling products approved for sale, if any. Under the terms of certain of our license agreements, we are obligated
to make payments upon the achievement of certain development, regulatory and commercial milestones.&#160;We will also need to make significant
expenditures to develop a commercial organization capable of sales, marketing, and distribution for any products, if any, that we intend
to sell ourselves in the markets in which we choose to commercialize on our own. In addition, other unanticipated costs may arise. Because
the design and outcome of our ongoing, planned and anticipated pre-clinical and clinical studies is highly uncertain, we cannot reasonably
estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our future capital requirements
depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 20px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs and payments associated with license agreements for our potential products and technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of conducting pre-clinical and clinical studies and the costs of manufacturing our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates, if clinical studies are successful, including any costs from post-market requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of commercialization activities for our product candidates, if any of these product candidates is approved for sale, including marketing, sales and distribution costs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the timing, receipt and amount of sales of, or royalties on, our future products, if any.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Additional funds may not be available
when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be
required to delay, limit, reduce or terminate preclinical studies, clinical studies, or other development activities for one or more of
our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other
activities that may be necessary to commercialize our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Raising additional capital
may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Until such time as we can generate
substantial product revenues, we may attempt to finance our cash needs through equity offerings, debt financings, government and/or other
third-party grants or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances,
and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
our investors&#8217; ownership interest will be diluted. Debt financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more clinical research or development
programs, which would adversely impact our potential revenues, future results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>From time to time, we may
be subject to legal proceedings, regulatory investigations or disputes, and governmental inquiries that could cause us to incur significant
expenses, divert our management&#8217;s attention, and materially harm our business, financial condition, and operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">From time to time, we may be subject
to claims, lawsuits, government investigations, and other proceedings involving intellectual property, privacy, securities, tax, labor
and employment, and other matters that could adversely affect our business operations and financial condition. Recently, we have seen
a rise in the number and significance of these disputes and inquiries. The arrest and indictment of Serhat G&#252;mr&#252;kc&#252;, a
co-founder of the Company, has, and could in the future, subject us to regulatory proceedings and litigation by governance agencies and
private litigants brought against us, that regardless of their merits, could harm our reputation, divert management&#8217;s attention
from our operations and result in substantial legal fees and other costs. Additionally, we have in the past been subject to intense media
scrutiny, which exposes us to increasing regulation, government investigations, legal actions, and penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We have also been named in several
lawsuits related to Mr. G&#252;mr&#252;kc&#252;. For example, the Company and certain of its current and former officers have been named
in securities class actions by purported stockholders of ours, alleging defendants violated Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact
in connection with the Company&#8217;s relationship with Mr. G&#252;mr&#252;kc&#252; and its commercial prospects. In addition, two stockholders
filed stockholder&#160;derivative&#160;action lawsuits purportedly on behalf of the Company against certain of our executive officers
and the members of our Board of Directors alleging violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also
setting out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Additionally,
from time to time, we may be, and currently are, subject to inquiries from regulators in which they seek information about us. Such further
inquiries could result in more formal investigations or allegations, which could adversely impact our business, financial condition, and
operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Litigation, regulatory proceedings, such as the investigations described above, as
well as the related class action claims and lawsuits, and securities matters that we are currently facing or could face, can be protracted
and expensive, and have results that are difficult to predict. Certain of these matters include speculative claims for substantial or
indeterminate amounts of damages and include claims for injunctive relief. Additionally, our legal costs for any of these matters, either
alone or in the aggregate, could be significant. Adverse outcomes with respect to any of these legal or regulatory proceedings may result
in significant settlement costs or judgments, penalties, and fines. Even if these proceedings are resolved in our favor, the time and
resources necessary to resolve them could divert the resources of our management and require significant expenditures. See&#160;<i>Note
10 - Commitments and Contingencies</i>&#160;in the Notes to our Consolidated Financial Statements in Part II, Item 8 of this Annual Report
on Form 10-K and the section titled &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The results of litigation, investigations,
claims, and regulatory proceedings cannot be predicted with certainty, and determining reserves for pending litigation and other legal
and regulatory matters requires significant judgment. There can be no assurance that our expectations will prove correct, and even if
these matters are resolved in our favor or without significant cash settlements, these matters, and the time and resources necessary to
litigate or resolve them, could harm our business, financial condition, and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Negative publicity has had
and may continue to have a negative impact on our business and may have a long-term effect on our relationships with our customers, partners
and collaborators.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our business and reputation have
been negatively affected by negative publicity resulting from the arrest and indictment of Serhat G&#252;mr&#252;kc&#252;, a co-founder
of the Company and an inventor of some of the Company&#8217;s intellectual property. If we are unable to rebuild the trust of our collaborators,
research institutions and investors, and if further negative publicity continues, we could experience a substantial negative impact on
our business. We have experienced claims and litigation as a consequence of these matters, including stockholder class actions in connection
with a decline in our stock price and litigation with Mr. G&#252;mr&#252;kc&#252;. Related legal expenses of defending these claims have
negatively impacted our operating results. Continuing higher legal fees, potential new claims, liabilities from existing cases and continuing
negative publicity could continue to have a negative impact on our operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Limited Operating History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>Renovaro Biosciences is a
pre-clinical biotechnology company and may never be able to successfully develop marketable products or generate any revenue. We have
a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance
that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Renovaro Biosciences is an early-stage
biotechnology company and has not generated any revenues to date. All of our product candidates are in the discovery stage or pre-clinical
development stage. Moreover, we cannot be certain that our research and development efforts will be successful or, if successful, that
our potential treatments will ever be approved for sale to generate commercial revenues. Our therapeutic pipeline includes cell, gene
and immunotherapy involving genetically modified cells targeted to treat cancer and HIV, and we rely on third parties under contract in
the development of product candidates in our pipeline. There is no guarantee that we will be able to manage and fund the development of
a pipeline with multiple target conditions, nor that third parties will meet their obligations to us in connection with our research and
development. We and certain third parties, on which we rely, have no relevant operating history upon which an evaluation of our performance
and prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to,
risks of unforeseen capital requirements, failure of treatments either in non-clinical testing or in clinical trials, failure to establish
business relationships, failure of our third parties to meet their obligations to us and competitive disadvantages against larger and
more established companies. If we fail to become profitable, we may suspend or cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube is an artificial intelligence (&#8220;AI&#8221;)-driven healthcare technology company operating in a rapidly evolving field and has
a limited operating history, which makes it difficult to evaluate Renovaro Cube&#8217;s current business and predict Renovaro Cube&#8217;s
future performance.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube is an AI-driven healthcare technology company operating in a rapidly evolving field and, having commenced operations in&#160;2013,
has a limited operating history. Renovaro Cube shifted its business from the financial technology (or FinTech) industry to cancer diagnostics
in 2018. We currently do not have a commercial product for sale. We have never generated any revenue relating to our cancer diagnostics
AI platform. Renovaro Cube&#8217;s short operating history makes any assessment of its current business or future success and viability
subject to significant uncertainty. We expect to encounter risks and difficulties, including those frequently experienced by&#160;early-stage&#160;companies
in rapidly evolving fields. If we do not address these risks and difficulties successfully, our business will suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube has a history of net losses and anticipates that it may continue to incur net losses for the foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">Grace
Systems (Renovaro Cube&#8217;s predecessor) has primarily incurred net losses since its inception in 2013 and has never generated any
revenue relating to its cancer diagnostics AI platform. Renovaro Cube anticipates that it may continue to incur primarily net losses in
the foreseeable future. Renovaro Cube has invested significant financial resources in research and development activities, including to
develop its technology and investigational products and plan for commercial launch of its AI platform. The amount of Renovaro Cube&#8217;s
future net losses will depend, in part, on the level of Renovaro Cube&#8217;s future expenditures and its ability to generate revenue
following the commercialization of its AI platform. Moreover, Renovaro Cube&#8217;s net losses may fluctuate significantly from quarter
to quarter and year to year, such that a&#160;period-to-period&#160;comparison of Renovaro Cube&#8217;s results of operations may not
be a good indication of Renovaro Cube&#8217;s future performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube expects to continue to incur significant expenses and operating losses for the foreseeable future if, and as, it:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">attracts, hires, and retains qualified personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">continues its research and development activities;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">initiates and conducts additional clinical validation to support the development and commercialization of its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">expands its technological and operating capabilities and introduces laboratory capacity as Renovaro Cube prepares for commercial scale;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">seeks regulatory approvals and any other marketing authorizations or clearances that may be necessary or desired for its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">establishes sales, marketing and distribution infrastructure to commercialize its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">acquires or&#160;in-licenses&#160;additional intellectual property and technologies;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">makes milestone, royalty, or other payments due under any license or collaboration agreements;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">obtains, maintains, protects and enforces its intellectual property portfolio, including intellectual property obtained through license agreements;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">provides additional infrastructure to support its continued research and development operations and any planned commercialization efforts in the future;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">as part of the combined company, meets the requirements and demands of being a public company; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">defends against any product liability claims or other lawsuits related to its products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube has never generated revenue from its cancer diagnostics AI platform, and does not expect any&#160;near-term&#160;revenue to offset
Renovaro Cube&#8217;s ongoing operating expenses, and may never be able to maintain profitability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s ability to generate revenue from product sales and maintain
profitability in the future depends on its ability to commercialize its products. While Renovaro Cube plans to commercially launch its
AI platform in the European Union and United Kingdom in 2024, Renovaro Cube cannot be certain that it will be able to do so successfully
as planned, if at all, and Renovaro Cube&#8217;s failure to do so would prevent Renovaro Cube from generating revenue. Furthermore, even
if Renovaro Cube is able to launch its AI platform or other products in a timely manner, Renovaro Cube may not be able to generate sufficient
revenue to offset its costs and maintain profitability. Renovaro Cube&#8217;s ability to generate future revenue from product sales depends
heavily on its success in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">completing clinical development and additional validation of Renovaro Cube&#8217;s products and continuing to improve product performance and expand product features over time;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">seeking, obtaining and maintaining marketing approvals, clearances, licenses, or exemptions that may be necessary or desired for any future products that Renovaro Cube develops;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">establishing a sales force, marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner sufficient to launch and commercialize its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">obtaining market acceptance by consumers, including&#160;self-insured&#160;employers, integrated health systems, healthcare providers, patients and&#160;third-party&#160;payors;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">establishing and maintaining supply and manufacturing relationships with third parties that can timely and consistently provide adequate, in both amount and quality, products and services to support clinical development and the market demand for Renovaro Cube&#8217;s future products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">achieving adequate coverage or reimbursement recognition from governments, health insurance organizations and other&#160;third-party&#160;payors for products that Renovaro Cube launches;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">addressing any technological and market developments, including competing products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which Renovaro Cube may enter, and maintaining such existing or future arrangements;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">achieving general adoption and acceptance of Renovaro Cube&#8217;s products by the medical community;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">maintaining, protecting and expanding Renovaro Cube&#8217;s portfolio of intellectual property rights, including patents, trade secrets,&#160;know-how&#160;and trademarks;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">defending against&#160;third-party&#160;interference or infringement claims, if any; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">attracting, hiring and retaining qualified personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube anticipates incurring substantial costs to commercialize Renovaro Cube&#8217;s products. Renovaro Cube&#8217;s expenses could increase
beyond expectations if it is required by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), the European Medicines Agency
(the &#8220;EMA&#8221;), the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) or other regulatory agencies to
delay its launch, narrow or change its intended use or product claims, modify or expand its clinical validation, perform future additional
clinical validation, either&#160;pre-&#160;or&#160;post-approval, or conduct clinical trials. Even if Renovaro Cube is able to generate
revenue from the sale of any products, Renovaro Cube may not become profitable and may need to continue to obtain additional funding to
continue its operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Even
if we commercially launch Renovaro Cube&#8217;s AI platform and other products, they may fail to achieve the degree of market acceptance
necessary for commercial success.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The commercial
success of Renovaro Cube&#8217;s AI platform and other future products will depend upon the degree of market acceptance by consumers,
including&#160;self-insured&#160;employers, integrated health systems, healthcare providers, patients and, over the&#160;long-term,&#160;third-party&#160;payors.
The degree of market acceptance of Renovaro Cube&#8217;s products will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the performance and clinical utility of its products as demonstrated in clinical validation and published in&#160;peer-reviewed&#160;journals;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Renovaro Cube&#8217;s ability to demonstrate the clinical utility of its products and their potential advantages to the medical community;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the ability of Renovaro Cube&#8217;s products to demonstrate the same performance in&#160;real-world&#160;intended use populations as in clinical validation;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the willingness of consumers, including&#160;self-insured&#160;employers, integrated health systems, healthcare providers, patients and others in the medical community to utilize Renovaro Cube&#8217;s products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the willingness of commercial&#160;third-party&#160;payors and government payors to cover and reimburse for Renovaro Cube&#8217;s products, the scope and amount of which will likely affect an individual&#8217;s willingness or ability to pay for Renovaro Cube&#8217;s products and likely heavily influence healthcare providers&#8217; decisions to recommend Renovaro Cube&#8217;s products;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">with respect to products under development that Renovaro Cube intends to launch for use in a broad asymptomatic population, the concern that such products could lead to&#160;over-diagnosis&#160;or a high&#160;false-positive&#160;rate and unnecessary medical procedures and costs;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the introduction of competing products, including the expansion of the capabilities of existing products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the market acceptance of existing competitive products, including tests that are currently reimbursed;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">publicity concerning Renovaro Cube&#8217;s products or competing products; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the strength of Renovaro Cube&#8217;s marketing and distribution support.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The failure
of Renovaro Cube&#8217;s AI platform, once introduced, to be listed in physician guidelines or any future clinical validation to produce
favorable results or to be published in&#160;peer-reviewed&#160;journals could limit the adoption of its AI platform. In addition, healthcare
providers and&#160;third-party&#160;payors, including Medicare, may rely on physician guidelines issued by industry groups, medical societies
and other key organizations, such as the U.S. Preventive Services Task Force, before utilizing or reimbursing the cost of any diagnostic
or screening test. Although Renovaro Cube has conducted prior clinical validation of its AI platform, this platform is not yet, and may
never be, listed in any such guidelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Further,
if Renovaro Cube&#8217;s products and the technology underlying them do not receive sufficient favorable exposure in&#160;peer-reviewed&#160;publications,
the rate of physician and market acceptance of Renovaro Cube&#8217;s products and positive reimbursement or coverage decisions for Renovaro
Cube&#8217;s products could be negatively affected. The publication of clinical data in&#160;peer-reviewed&#160;journals is a crucial
step in commercializing and obtaining reimbursement or coverage for Renovaro Cube&#8217;s products, and Renovaro Cube&#8217;s inability
to control when, if ever, results are published may delay or limit Renovaro Cube&#8217;s ability to derive sufficient revenues from any
of its products that are developed using data from a clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Failure
to achieve broad market acceptance of Renovaro Cube&#8217;s products, once launched, would materially harm Renovaro Cube&#8217;s business,
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube may be unable to develop and commercialize new products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube continues to expand its research and development efforts to use its proprietary AI platform to develop new products, including in
disease areas beyond cancer. The commercialization of any new products will require the completion of certain clinical development activities,
regulatory activities and the expenditure of additional cash resources. Renovaro Cube cannot assure you that it can successfully complete
the clinical development of any such products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube also cannot assure you that it will be able to reduce its expenditures sufficiently, generate sufficient revenue from products that
it successfully commercializes or otherwise mitigate the risks associated with its business to raise enough capital to develop and commercialize
new products. In addition, once Renovaro Cube&#8217;s development efforts for a product are completed, commercialization efforts, including
allocation of resources necessary to comply with applicable laws and regulations, will require significant expenditures. Any failure by
Renovaro Cube to develop and commercialize new products could have a material adverse effect on Renovaro Cube&#8217;s ability to implement
its strategy and grow its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>One
of the key elements of Renovaro Cube&#8217;s strategy is to expand access to its tests by pursuing reimbursement and/or coverage from&#160;third-party&#160;payors.
If Renovaro Cube&#8217;s products do not receive adequate coverage or reimbursement from&#160;third-party&#160;payors, its ability to
expand access to its tests beyond its initial sales channels and its overall commercial success will be limited.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube anticipates that it will not have&#160;broad-based&#160;coverage or reimbursement at the initial commercial launch. However, a key
element to Renovaro Cube&#8217;s strategy is to expand access to its tests by pursuing coverage and/or reimbursement by&#160;third-party&#160;payors,
including government payors. Coverage and reimbursement by&#160;third-party&#160;payors, including managed care organizations, private
health insurers and government healthcare programs, such as Medicare and Medicaid in the United States and similar programs in other countries,
for the types of early detection and post-diagnosis service tests that Renovaro Cube provides can be limited and uncertain. Healthcare
providers may not order Renovaro Cube&#8217;s products unless&#160;third-party&#160;payors cover or provide adequate reimbursement for
a substantial portion of the price of Renovaro Cube&#8217;s products. If Renovaro Cube is not able to obtain adequate coverage or an acceptable
level of reimbursement for its products from&#160;third-party&#160;payors, there could be a greater&#160;co-insurance&#160;or&#160;co-payment&#160;obligation
for any individual for whom a test is ordered. The individual may be forced to pay the entire cost of a test&#160;out-of-pocket,&#160;which
could dissuade physicians from ordering Renovaro Cube&#8217;s products and, if ordered, could result in delay in, or decreased likelihood
of, Renovaro Cube&#8217;s collection of payment. Renovaro Cube believes its revenue and revenue growth will depend on its success in achieving
broad coverage and adequate reimbursement for its products from&#160;third-party&#160;payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Coverage
and reimbursement by a&#160;third-party&#160;payor may depend on a number of factors, including a payor&#8217;s determination that a product
is appropriate, medically necessary and&#160;cost-effective.&#160;Each payor will make its own decision as to whether to establish a policy
or enter into a contract to cover Renovaro Cube&#8217;s products and the amount it will reimburse for such products. Any determination
by a payor to cover and the amount it will reimburse for Renovaro Cube&#8217;s products would likely be made on an&#160;indication-by-indication&#160;basis.
For example, because Renovaro Cube intends to cover a broad asymptomatic population with its future products which could potentially generate
a significant number of&#160;false-positive&#160;results on an absolute basis, Renovaro Cube may face additional scrutiny in obtaining
reimbursement from&#160;third-party&#160;payors given the additional costs of further diagnostic workup. As a result, obtaining approvals
from&#160;third-party&#160;payors to cover Renovaro Cube&#8217;s products and establishing adequate coding recognition and reimbursement
levels is an unpredictable, challenging,&#160;time-consuming&#160;and costly process and Renovaro Cube may never be successful. If&#160;third-party&#160;payors
do not provide adequate coverage or reimbursement for Renovaro Cube&#8217;s products, Renovaro Cube&#8217;s ability to succeed commercially
will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Even if
Renovaro Cube establishes relationships with payors to provide its products at negotiated rates, such agreements would not obligate any
healthcare providers to order its products or guarantee that it would receive reimbursement for its products from these or any other payors
at adequate levels. Thus, these payor relationships, or any similar relationships, may not result in acceptable levels of coverage or
reimbursement for Renovaro Cube&#8217;s products or meaningful increases in the number of billable tests it sells to healthcare providers.
Renovaro Cube believes it may take several years to achieve coverage or adequate reimbursement with a majority of&#160;third-party&#160;payors,
including with those payors offering negotiated rates. In addition, Renovaro Cube cannot predict whether, under what circumstances, or
at what payment levels payors will cover or reimburse for its products. If Renovaro Cube fails to establish and maintain&#160;broad-based&#160;coverage
or reimbursement for its products, its ability to expand access to its products, generate increased revenue and grow its test volume and
customer base will be limited and its overall commercial success will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>If
Renovaro Cube&#8217;s products, or the products of its competitors, directly or indirectly result in harm or injury to patients, Renovaro
Cube could be subject to significant reputational and liability risks, and its operating results, reputation and business could suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s success will depend on the market&#8217;s confidence that its developed products can provide reliable,&#160;high-quality&#160;results,
once such products are launched. Renovaro Cube believes that patients, physicians and regulators are likely to be particularly sensitive
to errors in the use of its products or failure of its products to perform as described, and there can be no guarantee that its products
will meet their expectations. Renovaro Cube&#8217;s initial product is intended to be used to detect a cancer signal in patients, but
its results are not diagnostic. If a cancer signal is detected, the product would be used to localize the origin of the cancer signal.
A &#8220;cancer signal detected&#8221; test result would need to be followed up by appropriate diagnostic methods. Because this product
cannot detect all cancer signals, and may not detect signals for all cancer types, a negative test would not rule out the presence of
cancer. Additionally, a patient undergoing unnecessary diagnostic tests on the basis of a&#160;false-positive&#160;result or an erroneous
location of cancer signal result could expose Renovaro Cube to significant liability and reputational risks notwithstanding the emotional
and mental health effects to which the patient may be exposed. Similarly, a patient who receives a cancer diagnosis shortly following
a &#8220;no cancer signal detected&#8221; test result may create negative publicity about Renovaro Cube&#8217;s product, which would discourage
adoption. Performance failures could establish a negative perception of Renovaro Cube&#8217;s products among physicians, patients and
regulators, jeopardize Renovaro Cube&#8217;s ability to successfully commercialize its products, impair Renovaro Cube&#8217;s ability
to obtain regulatory approvals or secure favorable coverage or reimbursement, or otherwise result in reputational harm. In addition, Renovaro
Cube may be subject to legal claims arising from any errors in the use, manufacture, design, labelling or performance of its products,
including any&#160;false-positive&#160;or&#160;false-negative&#160;results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">In addition,
other companies are developing competing cancer detection tests and technologies focused on improving cancer care with cancer detection
tests and&#160;post-diagnostic&#160;products. If any tests marketed or being developed by Renovaro Cube&#8217;s competitors that are similar
to its products do not perform in accordance with expectations or cause harm or injury to patients, such failure to perform, harm or injury
may result in lower confidence in early disease detection and&#160;post-diagnosis&#160;tests in general, which could potentially adversely
affect confidence in Renovaro Cube&#8217;s products and result in an adverse impact on its operating results and reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>If Renovaro Cube&#8217;s
facilities or those of its&#160;third-party&#160;collaborators become inoperable, Renovaro Cube&#8217;s ability to provide its products
will be significantly impaired and its business will be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube relies on its&#160;third-party&#160;collaborators, consultants, contractors, vendors, suppliers and service providers. The facilities
of these partners could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, tornadoes, hurricanes,
fires, extreme weather conditions, medical epidemics, pandemics, global conflict, war and other natural or&#160;man-made&#160;disasters
or business interruptions. In addition, they may be affected by government shutdowns, changes to applicable laws, regulations and policies,
or withdrawn funding. The occurrence of any of these business disruptions could seriously harm their ability to complete their contracted
services to Renovaro Cube, which may adversely impact its operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube&#8217;s business and results of operations will suffer if it fails to compete effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The testing
and diagnostic products industry is intensely competitive. Renovaro Cube has competitors both in Europe and abroad, including Grail, Inc.,
Exact Sciences Corporation, Freenome, Inc. and Thrive Earlier Detection Corp., that have stated that they are developing tests designed
to detect cancer. Renovaro Cube&#8217;s competitors have, or may have, substantially greater financial, technical and other resources,
such as larger research and development staff and&#160;well-established&#160;marketing and sales forces, and they may operate in jurisdictions
where lower standards of evidence are required to bring products to market. Renovaro Cube&#8217;s competitors may succeed in developing,
acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective or less costly than Renovaro Cube&#8217;s
products. In addition, established medical technology, biotechnology, or pharmaceutical companies may invest heavily to accelerate the
discovery and development of tests that could make Renovaro Cube&#8217;s products less competitive than Renovaro Cube anticipates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s ability to compete successfully will depend largely on its ability to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr>
<td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully commercialize its products;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrate compelling advantages in the performance and convenience of its products, including on a cost-competitive basis;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve market acceptance of its products by consumers, including&#160;self-insured&#160;employers, integrated health systems, healthcare providers and patients;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve adequate coverage or reimbursement by&#160;third-party&#160;payors for its products;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differentiate its product from the other tests and products of current and potential competitors;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract qualified scientific, data science, clinical development, product development and commercial personnel;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain, maintain, defend and enforce patents and other intellectual property rights and claims as necessary for its products;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain any necessary or desirable clearance or approval from regulators in Europe, the United Kingdom, the United States and other jurisdictions;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully collaborate with institutions in the discovery, development and commercialization of its products; and</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully expand its operations and implement a successful sales and marketing strategy to support commercialization.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube may not be able to compete effectively if Renovaro Cube is unable to accomplish one or more of these or similar objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>If
Renovaro Cube cannot enter new collaborations in a timely manner and on acceptable terms, its efforts to develop and commercialize its
products could be delayed or adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">From time
to time, Renovaro Cube expects to engage in discussions with potential development and/or commercial collaborators that may or may not
lead to collaborations. However, Renovaro Cube cannot guarantee that any discussions will result in development or commercial collaborations.
Further, once news of discussions regarding possible collaborations are known in the general public, regardless of whether the news is
accurate, failure to announce a collaboration agreement, or the entity&#8217;s announcement of a collaboration with an entity other than
Renovaro Cube, could result in adverse speculation about Renovaro Cube, its products or its technology, resulting in harm to its reputation
and its business. In addition, establishing collaborations is difficult and&#160;time-consuming&#160;and may require Renovaro Cube&#8217;s
significant financial investment. Potential collaborators may elect not to work with Renovaro Cube based on their assessment of its financial,
regulatory, or intellectual property position. Even if Renovaro Cube establishes new collaborations, they may not result in the successful
development or commercialization of its products or technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>If
Renovaro Cube is unable to establish sales and marketing capabilities, it may not be successful in commercializing Renovaro Cube&#8217;s
products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube has only limited sales and marketing infrastructures and no experience as a company in the sale, marketing and distribution of screening
or diagnostic tests. In preparation of a commercial launch, Renovaro Cube is rapidly hiring additional personnel in Renovaro Cube&#8217;s
sales and marketing organization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Factors that may inhibit
Renovaro Cube&#8217;s efforts to commercialize any of its products include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs
    and other support personnel;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to persuade adequate numbers of customers, including healthcare systems and healthcare providers, to
    use its products;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to price its products at a sufficient price point to ensure an adequate and attractive level of profitability;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    inability to effectively market to, collaborate with, and secure coverage or reimbursement from&#160;third-party&#160;payors;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    failure to comply with applicable regulatory requirements governing the sale, marketing, reimbursement and commercialization of its
    products; and</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent commercialization organization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to the Development of Our Product
Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s products are not subject to FDA or other government regulatory
clearance or approval if they are not intended to be used for the diagnosis, treatment or prevention of disease. However, as Renovaro
Cube expands its product line to encompass products that are intended to be used for the diagnosis of disease, certain of its products
will become subject to regulation by the FDA, or comparable international agencies, including requirements for regulatory clearance or
approval of such products before they can be marketed. Such regulatory approval processes or clearances may be expensive, time-consuming,
and uncertain, and Renovaro Cube&#8217;s failure to obtain or comply with such approvals and clearances could have an adverse effect on
its business, financial condition, and operating results. In addition, changes to the current regulatory framework, including the imposition
of additional or new regulations, could arise at any time during the development or marketing of Renovaro Cube&#8217;s future products,
which may negatively affect its ability to obtain or maintain FDA or comparable regulatory approval of its products, if required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Diagnostic
products are regulated as medical devices by the FDA and comparable international agencies and may require either clearance from the FDA
or such other comparable agencies following the 510(k) pre-market notification process or pre-market approval from the FDA, in each case
prior to marketing. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. If Renovaro Cube
fails to obtain, or experiences significant delays in obtaining, regulatory approvals for diagnostic products that it develops in the
future, Renovaro Cube may not be able to launch or successfully commercialize such products in a timely manner, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">In addition, if Renovaro Cube&#8217;s products labelled as &#8220;For Research
Use Only. Not for use in diagnostic procedures,&#8221; or RUO, are used, or could be used, for the diagnosis of disease, the regulatory
requirements related to marketing, selling, and supporting such products could change or be uncertain, even if such use by Renovaro Cube&#8217;s
customers is without its consent. If the FDA or other regulatory agencies assert that any of Renovaro Cube&#8217;s RUO products are subject
to regulatory clearance or approval, Renovaro Cube&#8217;s business, financial condition, and results of operations could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"><b><i>Regulatory and legislative
developments on the use of AI and machine learning could adversely affect Renovaro Cube&#8217;s use of such technologies in its platform
and other products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">As with
many technological innovations, artificial intelligence presents risks and challenges that could affect its adoption, and therefore our
business. Uncertainty in the legal regulatory regime relating to AI may require significant resources to modify and maintain business
practices to comply with U.S. and non-U.S. laws, the nature of which cannot be determined at this time. It is possible that new laws and
regulations will be adopted in the United Kingdom, the European Union, the United States and/or other foreign jurisdictions, or that existing
laws and regulations may be interpreted in ways that would affect the operation of Renovaro Cube&#8217;s AI platform and data analytics
and the way in which Renovaro Cube uses AI and machine learning technology. Further, the cost to comply with such laws or regulations
could be significant and would increase Renovaro Cube&#8217;s operating expenses, which could adversely affect its business, financial
condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">For example,
in Europe, on April 21, 2021, the European Commission proposed a regulation seeking to establish a comprehensive, risk-based governance
framework for AI in the European Union market. The proposed legislation is intended to apply to companies that develop, use and/ or provide
AI in the European Union and includes requirements around transparency, conformity assessments and monitoring, risk assessments, human
oversight, security and accuracy, and proposes fines for breach of up to 6% of worldwide annual turnover. In addition, on September 28,
2022, the European Commission proposed the AI Liability Directive and the revised Product Liability Directive seeking to establish a harmonized
civil liability regime for AI in the European Union in order to facilitate civil claims in respect of harm caused by AI and to include
AI-enabled products within the scope of the European Union&#8217;s existing product liability regime. If enacted, this regulatory framework
is expected to have a material impact on the way AI is regulated in the European Union, and together with developing guidance and/or decisions
in this area, may affect Renovaro Cube&#8217;s use of AI and its ability to provide and to improve its services, require additional compliance
measures and changes to its operations and processes, result in increased compliance costs and potential increases in civil claims against
Renovaro Cube, and could adversely affect its business, operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
30, 2023, the Biden administration issued an Executive Order on the Safe, Secure and Trustworthy Development and Use of AI, emphasizing
the need for transparency, accountability, and fairness in the development and use of AI, including in the healthcare industry. The order
seeks to balance fostering innovation with addressing risks associated with AI by providing eight guiding principles and priorities, such
as ensuring that consumers are protected from fraud, discrimination, and privacy risks related to AI. The order also calls for future
regulations from various agencies, such as the Department of Commerce (to draft guidance for detecting and authenticating AI content)
and the Federal Trade Commission (to ensure fair competition and reduce consumer harm). In alignment with the order, other agencies have
published guidance. Other jurisdictions may decide to adopt similar or more restrictive legislation that may render the use of such technologies
challenging.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The FTC
has issued a report expressing a concern regarding AI and bias across industry sectors, including in the healthcare space, and has suggested
that such bias could lead to unfair and deceptive practices, among other concerns. Any changes to our ability to use AI or concerns about
bias could require us to modify our products and services or could have other negative financial impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">These
compliance obligations may make it harder for us to conduct our business using AI, lead to regulatory fines or penalties, require us to
change our product offerings or business practices, or prevent or limit our use of AI. If we cannot use AI, or if our use of AI is restricted,
our business may be less efficient, or we may be at a competitive disadvantage. Though we have taken steps to be thoughtful in our development,
training, and implementation of machine learning, including taking steps to comply with the laws and frameworks discussed above, our machine
learning-related processing could pose certain risks to our end-users, including patients, clinicians, and healthcare institutions, and
it is not guaranteed that regulators will agree with our approach to limiting these risks or to our compliance more generally. Any of
these factors could adversely affect our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The results of pre-clinical
studies or earlier clinical studies are not necessarily predictive of future results, and if we fail to demonstrate efficacy in our pre-clinical
studies and/or clinical trials in the future our future business prospects, financial condition and operating results will be materially
adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The success of our therapeutic
research and development efforts will depend upon our ability to demonstrate the efficacy of the treatments in our pipeline in pre-clinical
studies, as well as in clinical trials following IND approval by the FDA. Pre-clinical studies involve testing potential product candidates
in appropriate non-human disease models to demonstrate efficacy and safety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Success in pre-clinical studies
does not ensure that later clinical studies will generate adequate data to demonstrate the efficacy and safety of an investigational drug.
Currently, several of our product candidates, including RENB-DC-11, our genetically-modified allogeneic dendritic therapeutic vaccination
platform for solid tumors, and RENB-HV-12, our therapeutic HIV vaccine, are currently in various stages of pre-clinical development with
ongoing and planned pre-clinical studies in conjunction with research institutions and third parties. Despite preliminary data we believe
is positive, this does not guarantee that any of these products will proceed to the clinical stage or to approval for commercial use.
A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us,
have suffered significant setbacks in clinical studies, even after seeing promising results in earlier preclinical or clinical studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Regulatory agencies evaluate non-clinical
data carefully before they will approve clinical testing in humans. If certain non-clinical data reveals potential safety issues or the
results are inconsistent with an expectation of the potential product candidates&#8217; efficacy in humans, the regulatory agencies may
require additional more rigorous testing before allowing human clinical trials. This additional testing will increase program expenses
and extend timelines. We may decide to suspend further testing on our potential products or abandon the product lines altogether if, in
the judgment of our management and advisors, the pre-clinical test results do not support further development, as we did with our pan-coronavirus
and influenza product lines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Our novel gene, cell and
immunotherapy product candidates and new therapeutic approaches could result in heightened regulatory scrutiny, delays in clinical development
or delays in our ability to achieve regulatory approval or commercialization of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences&#8217; future
success is dependent on the successful development of novel gene, cell and immunotherapy product candidates. Because these programs, particularly
our pipeline of allogeneic T-cell product candidates that are bioengineered from healthy donor cells, represent a new approach to immunotherapy
for the treatment of cancer and other diseases, developing and commercializing our product candidates subject us to a number of challenges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Moreover, actual or perceived safety
issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to
participate in clinical studies, or if approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment
mechanics. The FDA or other applicable regulatory authorities may ask for specific post-market requirements, and additional information
informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>We face significant competition
in an environment of rapid technological change and there is the possibility that our competitors may achieve regulatory approval before
us or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability
to successfully market or commercialize our product candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The development of treatments in
the fields of cancer and HIV is highly competitive and many pharmaceutical and biotechnology companies, academic institutions, governmental
agencies, and other public and private research organizations may pursue the research and development of technologies, drugs or other
therapeutic products for the treatment of some or all of the diseases we are targeting. Nearly all of our competitors have greater capital
resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining
regulatory approval and pharmaceutical product manufacturing and marketing than we do. Techniques in gene, cell and immunotherapy are
subject to rapid technological change and development and are significantly affected by existing rival products and medical procedures,
new product introductions and the market activities of other participants. With additional resources, our competitors may be able to respond
to rapid and significant technological changes faster than we can. The future success of Renovaro Biosciences will depend in large part
on our ability to maintain a competitive position with respect to these technologies. We may also face competition from products, which
have already been approved and accepted by the medical community for the treatment of these same indications. If we are unable to compete
effectively with any existing products, new treatment methods and new technologies, we may be unable to commercialize therapeutic products
that we may develop in the future, which could adversely impact our potential revenues, results of operations and financial condition
or lead to abandonment of product candidates in our pipeline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Our reliance on third parties,
such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays
in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with them.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In the course of the development
of our pipeline, we have and expect to continue to engage university laboratories, non-profit organizations, independent contractors,
other biotechnology companies or clinical manufacturing organizations to conduct and manage research and development, pre-clinical and
clinical studies and to manufacture materials for us to be used in pre-clinical and clinical testing. Due to engagements with these organizations,
many important aspects of our research have been and will be out of our direct control. If any of these organizations we may engage in
the future, fail to perform their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical trials
in a satisfactory manner, we may face delays in completing our clinical trials, as well as commercialization of any of our product candidates.
Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials, regulatory
filings and the potential market approval of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Changes in healthcare law
and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy, may negatively
impact our ability to generate revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><span style="background-color: white">In
the United States and some foreign jurisdictions, there have been a number of proposed legislative and regulatory changes related to the
healthcare system that could affect our ability to profitably sell or commercialize our product candidates for which we obtain marketing
approval in the future. The potential pricing and reimbursement environment for our product candidates may change in the future and become
more challenging due to, among other reasons, policies advanced by the current or any new presidential administration, federal agencies,
healthcare legislation passed by Congress, or fiscal challenges faced by all levels of government health administration authorities, or
by similar changes in foreign countries.</span> The implementation of any such changes could have a material adverse effect on our competitive
position, business, financial condition, results of operations, and prospects, including our share price and ability to raise capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>We have limited experience
in drug development and may not be able to successfully develop any drugs, which would cause us to cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We have never successfully developed
a new drug and brought it to market. Our management and clinical teams have experience in drug development, but they may not be able to
successfully develop any drugs. Our ability to achieve revenues and profitability in our business will depend on, among other things,
our ability to develop products internally or to obtain rights to them from others on favorable terms; complete laboratory testing and
human studies; obtain and maintain necessary intellectual property rights to our products; successfully complete regulatory review to
obtain requisite governmental agency approvals; enter into arrangements with third parties to manufacture our products on our behalf;
and enter into arrangements with third parties to provide sales and marketing functions. If we are unable to achieve these objectives,
we will be forced to cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Disruptions at the FDA and
other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key
leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely
manner or at all, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The ability of the FDA to review and approve new products can be affected by
a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment
of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result.
In addition, government funding of other government agencies that fund research and development activities is subject to the political
process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Our gene therapy product candidates
are still in development and will require extensive clinical testing before we are prepared to submit an application for marketing approval
to regulatory authorities. We cannot predict with any certainty if or when we might submit any such application for regulatory approval
for our product candidates or whether any such application will be approved by the applicable regulatory authority in our target markets.
Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements.
For instance, regulatory authorities may not agree with our proposed endpoints for any clinical trials of our gene therapy product candidates,
which may delay the commencement of our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Clinical trials are expensive,
time-consuming, difficult to design and implement, and involve an uncertain outcome.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Our therapeutic product candidates are still in development and will require
extensive clinical testing before we are prepared to submit an application for marketing approval to regulatory authorities. We cannot
predict with any certainty if or when we might submit any such application for regulatory approval of our product candidates or whether
any such application will be approved by the applicable regulatory authority in our target markets. Human clinical trials are expensive
and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, regulatory
authorities may not agree with our proposed endpoints for any clinical trials of our product candidates, which may delay the commencement
of our clinical trials. The clinical trial process is also time-consuming. We estimate that clinical trials of our product candidates
will take at least several years to complete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">A number of companies in the biopharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier trials, and in the regulatory approval process. In addition, the design of a clinical trial, such as endpoints,
inclusion and exclusion criteria, statistical analysis plans, data access protocols and trial sizing, can determine whether its results
will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well
advanced. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior
to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate revenues may be delayed.
In addition, any delays in our clinical trials could increase our costs, cause a drop in our stock price, slow down the approval process
and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial
condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Enrollment and retention
of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple
factors outside our control.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We may encounter delays in enrolling,
or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable
to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on
many factors, including the size of the patient population, the nature of the trial protocol, the effectiveness of our patient recruitment
efforts, delays in enrollment due to travel or quarantine policies, the existing body of safety and efficacy data with respect to the
study candidate, the perceived risks and benefits of gene therapy approaches for the treatment of certain diseases, the number and nature
of competing existing treatments for our target indications, the number and nature of ongoing trials for other product candidates in development
for our target indications, perceived risk of the delivery procedure, patients with pre-existing conditions that preclude their participation
in any trial, the proximity of patients to clinical sites and the eligibility criteria for the study. Furthermore, the results we have
reported in clinical trials to date and any other results we may report in clinical trials of any of our gene therapy product candidates
in the future may make it difficult or impossible to recruit and retain patients in other clinical trials of those gene therapy product
candidates. Similarly, negative results reported by our competitors about their product candidates may negatively affect patient recruitment
in our clinical trials. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or
both, which could have a harmful effect on our ability to develop our gene therapy product candidates or could render further development
impossible. In addition, we expect to rely on clinical trial sites to ensure proper and timely conduct of our future clinical trials and,
while we intend to enter into agreements governing their services, we will be limited in our ability to control their actual performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Technology and Intellectual
Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>We have licensed a portion
of our intellectual property from our licensors. If we breach any of our license agreements with these licensors, or otherwise experience
disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We hold rights under license agreements
with our licensors that are important to our business. Our research and development platform is built, in part, around patent rights licensed
from such licensors. Under our existing license agreements, we are subject to various obligations, including diligence obligations with
respect to development and commercialization activities, provision of support with respect to development of licensed intellectual property,
prosecution of intellectual property protection, payment obligations upon achievement of certain milestones and royalties on product sales.
In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and
might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology
covered by these license agreements. If any of these licenses are terminated, or if the underlying patents fail to provide the intended
exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical
to ours and we may be required to cease our development and commercialization of product candidates covered by any such licenses. Any
of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations,
and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Moreover, disputes may arise regarding
intellectual property subject to a licensing agreement, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 20px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 20px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under license agreements and other interpretation-related issues;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    obligations due to licensors under license agreements and other disputes related to the obligations for payment related to intellectual
    property protection;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our product candidates, technology and processes infringe on intellectual property of a licensor that is not subject
    to a licensing agreement;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under license agreements and what activities satisfy those diligence obligations; </span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us; and</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In addition, the agreements under
which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The resolution of any contract
interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property
or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could
have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over
intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable
terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse
effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual property
licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or even
be prohibited from developing, manufacturing or selling products requiring these rights or licenses. There is also a risk that legal disputes
may arise as to the rights to technology developed in collaboration with other parties, all with attendant risk, distraction, expense,
and lack of predictability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>If we are unable to obtain
and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection
is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely
affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We rely upon a combination of patents,
trademarks, trade secrets and confidentiality agreements &#8211; either that we own or possess or that are owned or possessed by our licensors
that are licensed to us &#8211; to protect the intellectual property related to our technology and product candidates. When we refer to
&#8220;our&#8221; technologies, inventions, patents, provisional patents, patent applications or other intellectual property rights, we
are referring to both the rights that we own or possess as well as those that we license, many of which are critical to our intellectual
property protection and our business. For example, the product candidates and platform technology we have licensed from our licensors
are protected primarily by patent or patent applications of our licensors that we have licensed and as confidential know-how and trade
secrets. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies and
erode or negate any competitive advantage we may have.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The patentability of inventions
and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific
and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by
the U.S. Patent and Trademark Office, or USPTO, and non-U.S. patent offices in granting patents are not always applied uniformly or predictably.
For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology
patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There is no assurance that all
potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where
searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application
from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability
of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability
of such claim. We also may not be able to obtain full patent protection from provisional patents for which we have sought or will seek
further patent protection. As a consequence of these and other factors, our patent applications may fail to result in issued patents with
claims that cover our product candidates in the U.S. or in other countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Even if patents have issued or
do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the
validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable.
No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Even if unchallenged, our patents
and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity
for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products
on an independent basis which have the same effect as our product candidates and which do not infringe our patents or other intellectual
property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If
the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened,
it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We may also desire to seek a license
from a third party who owns intellectual property that may be useful for providing exclusivity for our product candidates, or for providing
the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to
obtain a license from such a third party on commercially reasonable terms, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In addition, the United States
Patent and Trademark Office (USPTO) and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured
by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We and our licensors have filed
a number of patent applications covering our product candidates or methods of using or making those product candidates. We cannot offer
any assurances about which, if any, patents will be issued with respect to these pending patent applications, the breadth of any such
patents that are ultimately issued or whether any issued patents will be found invalid and unenforceable or will be threatened by third
parties. Because patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some
remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to a product
candidate. We or our licensors may also become involved in proceedings regarding our patents, including patent infringement lawsuits,
interference or derivation proceedings, oppositions, and <i>inter partes </i>and post-grant review proceedings before the USPTO, the European
Patent Office and other non-U.S. patent offices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Third-party claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our success will depend in part
on our ability to commercialize our product candidates without infringing the proprietary rights of others. While some of the intellectual
property utilized in our product candidates is owned, some is licensed from our licensors, who hold patents and provisional patents in
their names. We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not exist or
could be issued which would have an adverse effect on our ability to market our technology or maintain our competitive position with respect
to our technology. We also cannot be sure that patents or provisional patents filed by others are valid or will be upheld if challenged.
It is possible that there are additional patents that may cover certain other aspects of technology used in our product candidates that
is not covered by our licensed intellectual property. If our licensed technology or other subject matter are claimed under other United
States patents or other international patents or are otherwise protected by third party proprietary rights, we or our licensors may be
subject to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights or we may be
required to obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances
that we would be successful in a challenge or be able to obtain such licenses or that such licenses, if available, could be obtained on
commercially reasonable terms. Furthermore, the failure to succeed in a challenge, develop a commercially viable alternative or obtain
needed licenses could have significant adverse consequences to the development of our pipeline. Adverse consequences include delays in
marketing some or all of our product candidates based on our technology or the inability to proceed with the development, manufacture
or sale of products requiring such licenses. If we defend ourselves against charges of patent infringement or to protect our proprietary
rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are typically
protracted with no certainty of success. An adverse outcome could subject us to significant liabilities to third parties and force us
to curtail or cease the research and development of our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Parties making claims against us
may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product
candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial
diversion of resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial
damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products
or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Additionally,
parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they
have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.
In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on
our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition
and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Issues in the development
and use of&#160;AI, including machine learning and computer vision, in Renovaro Cube&#8217;s AI platform may result in reputational harm
or liability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">AI is
integrated into Renovaro Cube&#8217;s platform and is a significant element of its business offerings going forward. As with many developing
technologies, AI presents risks, challenges and unintended consequences that could affect its further development, adoption, and use,
and therefore Renovaro Cube&#8217;s business. AI algorithms and training methodologies may be flawed. Data sets may be insufficient, of
poor quality, or contain biased information. Inappropriate or controversial data practices by data scientists, engineers, and end-users&#160;of
Renovaro Cube&#8217;s systems could impair the acceptance of AI solutions. If the analyses that AI applications assist in producing are
deficient or inaccurate, Renovaro Cube could be subjected to competitive harm, potential legal liability, and brand or reputational harm.
Some uses of AI present ethical issues, and Renovaro Cube&#8217;s judgment as to the ethical concerns may not be perceived as accurate.
While Renovaro Cube aims to develop and use AI responsibly and attempts to identify and mitigate ethical and legal issues presented by
its use, Renovaro Cube may be unsuccessful in identifying or resolving issues before they arise. If Renovaro Cube uses AI as part of its
platform in a manner that is controversial or perceived as unethical, this may lead to adverse results for Renovaro Cube&#8217;s financial
condition and operations or the financial condition and operations of its collaborators or vendors, which may further lead to Renovaro
Cube experiencing competitive harm, legal liability and brand or reputational harm. In addition, AI-related issues, deficiencies and/or
failures could give rise to legal and/or regulatory action, including with respect to proposed legislation regulating AI in jurisdictions
such as the European Union and others, and as a result of new applications of existing data protection, privacy, intellectual property,
and other laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Failure
of, or defects in, Renovaro Cube&#8217;s machine learning and&#160;cloud-based&#160;computing infrastructure, or increased regulation
in the machine learning space, could impair Renovaro Cube&#8217;s ability to process its data, develop products, or provide test results,
and harm its business and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The design,
development, maintenance and operation of Renovaro Cube&#8217;s technology over time is expensive and complex, and may involve unforeseen
difficulties including material performance problems, undetected defects or errors. Overcoming technical obstacles and correcting defects
or errors could prove to be impossible or impracticable, and the costs incurred may be substantial and adversely affect Renovaro Cube&#8217;s
results of operations. Additionally, regulation in the machine learning space is constantly evolving and may make it difficult for Renovaro
Cube to continue using its machine learning approach. If Renovaro Cube&#8217;s technology does not function reliably, fails to meet expectations
in terms of performance, or cannot be fully utilized due to increasing regulation, Renovaro Cube may be unable to provide, or its customers
may stop using, its products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube currently hosts all of its data on, and conducts its data analysis through, local&#160;hosting facilities. Any technical problems
or outages that may arise in connection with these hosting facilities could result in the loss of Renovaro Cube&#8217;s data or delayed
or ineffective data processing. A variety of factors, including infrastructure changes, human or software errors, viruses, malware, security
attacks, fraud, spikes in customer usage, or denial of service issues could cause interruptions in Renovaro Cube&#8217;s service. Such
service interruptions may reduce or inhibit Renovaro Cube&#8217;s ability to provide its products, delay any further clinical validation
and any future clinical studies, and damage its relationships with its customers. Renovaro Cube could also be exposed to potential lawsuits,
liability claims or regulatory actions, if, for example, Renovaro Cube&#8217;s local servers experienced a data privacy breach. If Renovaro
Cube was required to transfer its data to an alternative hosting provider, the transfer and acclimation to the new provider could result
in significant business delays and require additional resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Real or perceived errors,
failures, or bugs in Renovaro Cube&#8217;s platform and future products could adversely affect its business, results of operations, financial
condition, and growth prospects.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube&#8217;s platform
is, and its future products will be, complex, and therefore, undetected errors, failures, bugs, or defects may be present in such platform
or products or occur in the future in its platform or products, its technology or software or the technology or software Renovaro Cube
licenses from third parties, including open source software, especially when updates or new products are released. Such software and technology
is used in information technology (&#8220;IT&#8221;) environments with different operating systems, system management software, devices,
databases, servers, storage, middleware, custom and third-party applications, and equipment and networking configurations, which may cause
errors, failures, bugs, or defects in the IT environment into which such software and technology is deployed. This diversity increases
the likelihood of errors, failures, bugs, or defects in those IT environments. Some of the features in Renovaro Cube&#8217;s platform
are powered by machine learning and&#160;AI, which depend on datasets and algorithms that could be flawed, including through inaccurate,
insufficient, outdated, or biased data. Despite testing by Renovaro Cube, real or perceived errors, failures, bugs, or defects may not
be found until Renovaro Cube&#8217;s customers use its products. Real or perceived errors, failures, bugs, or defects in Renovaro Cube&#8217;s
products could result in negative publicity, loss of or delay in market acceptance of its platform or future products and harm to its
brand, loss of investor confidence, weakening of its competitive position, claims by customers for losses sustained by them, or failure
to meet the stated service level commitments in its customer agreements. In such an event, Renovaro Cube may be required, or may choose,
for customer relations or other reasons, to expend significant additional resources in order to help correct the problem. Any real or
perceived errors, failures, bugs, or defects in Renovaro Cube&#8217;s products could also impair its ability to attract new customers,
retain existing customers, or expand their use of its products, which would adversely affect Renovaro Cube&#8217;s business, results of
operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube may also be subject
to liability claims for damages related to real or perceived errors, failures, bugs, or defects in its platform or future products. A
material liability claim or other occurrence that harms Renovaro Cube&#8217;s reputation or decreases market acceptance of its platform
or future products may harm its business and results of operations. Finally, since some of Renovaro Cube&#8217;s customers use its products
for compliance reasons, any errors, failures, bugs, defects, disruptions in service or other performance problems with Renovaro Cube&#8217;s
products may damage its customers&#8217; businesses and could hurt its reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube&#8217;s internal computer systems, or those expected to be used by its third-party research institution collaborators or other contractors
or consultants, may fail or suffer security breaches.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Despite
the implementation of security and&#160;back-up&#160;measures, Renovaro Cube&#8217;s internal computer, server and other information technology
systems as well as those of its&#160;third-party&#160;collaborators, consultants, contractors, suppliers and service providers, may be
vulnerable to damage from physical or electronic&#160;break-ins,&#160;computer viruses, malware, ransomware, denial of service and other&#160;cyber-attacks&#160;or
disruptive incidents that could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive and/or proprietary
data, including personal and health information, and could subject Renovaro Cube to significant liabilities, regulatory and enforcement
actions and reputational damage. For example, the loss of clinical study data from future clinical studies could result in delays in any
regulatory clearance or approval efforts and significantly increase Renovaro Cube&#8217;s costs to recover or reproduce the data, and
subsequently commercialize its future products. If Renovaro Cube or its&#160;third-party&#160;collaborators, consultants, contractors,
suppliers or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or
disclosure of personal or health information, Renovaro Cube may have to notify physicians, patients, partners, collaborators, government
authorities and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions and litigation,
any of which could harm Renovaro Cube&#8217;s business and reputation. Likewise, Renovaro Cube relies on its&#160;third-party&#160;research
institution collaborators and other third parties to conduct clinical validation, and similar events relating to their computer systems
could also have a material adverse effect on Renovaro Cube&#8217;s business. To the extent that any disruption or security breach were
to result in a loss of, or damage to, Renovaro Cube&#8217;s data or systems, or inappropriate or unauthorized access to or disclosure
or use of confidential, proprietary, or other sensitive, personal, or health information, Renovaro Cube could incur liability and suffer
reputational harm, and the development and commercialization of its products could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s insurance policies may not be adequate to compensate it for the potential losses arising from such disruptions, failure,
or security breach. In addition, such insurance may not be available to Renovaro Cube in the future on economically reasonable terms,
or at all. Further, Renovaro Cube&#8217;s insurance may not cover all claims made against it and defending a suit, regardless of its merit,
could be costly, divert management attention and harm Renovaro Cube&#8217;s reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>If
Renovaro Cube is unable to protect the confidentiality of its trade secrets, Renovaro Cube&#8217;s business and competitive position would
be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube relies on trade secrets and confidentiality agreements to protect its know-how,&#160;technology, data and other proprietary information
and to maintain its competitive position. Trade secrets and&#160;know-how&#160;can be difficult to protect. Renovaro Cube expects its
trade secrets and&#160;know-how&#160;to, over time, be disseminated within the industry through independent development, the publication
of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube seeks to protect these trade secrets and other proprietary technology, in part, by entering into&#160;non-disclosure&#160;and confidentiality
agreements with parties who have access to them, such as Renovaro Cube&#8217;s employees, directors, corporate collaborators, outside
scientific collaborators, contract research organizations (&#8220;CROs&#8221;), contract manufacturers, suppliers, service providers,
consultants, advisors and other third parties. Renovaro Cube also enters into confidentiality and invention or patent assignment agreements
with its employees and consultants, and reminds departing employees when they leave their employment of their continuing confidentiality
obligations. Renovaro Cube cannot guarantee that it has entered into such agreements with each party that may have, or have had, access
to Renovaro Cube&#8217;s trade secrets or proprietary technology and processes. Despite Renovaro Cube&#8217;s efforts, any of these parties
may breach the agreements and disclose Renovaro Cube&#8217;s proprietary information, including Renovaro Cube&#8217;s trade secrets, and
Renovaro Cube may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated
a trade secret is difficult, expensive, and&#160;time-consuming,&#160;and the outcome is unpredictable. Some courts outside The Netherlands
are less willing or unwilling to protect trade secrets. For example, in China, claims regarding infringement or misappropriation of trade
secrets are difficult to prove, and consequently plaintiffs are rarely successful in bringing these claims. If any of Renovaro Cube&#8217;s
trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, Renovaro Cube would have no
right to prevent them from using that technology or information to compete with Renovaro Cube. If any of Renovaro Cube&#8217;s trade secrets
were to be misappropriated by, disclosed to, or independently developed by a competitor or other third party, Renovaro Cube&#8217;s competitive
position could be materially and adversely harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube has and may enter into collaboration, license, contract research and/or manufacturing relationships with contract organizations that
operate in certain countries that are at heightened risk of <span style="background-color: white">theft of technology, data and intellectual
property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors.
Accordingly, Renovaro Cube&#8217;s efforts to protect and enforce Renovaro Cube&#8217;s intellectual property rights around the world
may be inadequate to obtain a significant commercial advantage from the intellectual property that Renovaro Cube develops or licenses,
and Renovaro Cube may be at heightened risk of losing its proprietary intellectual property rights around the world, including outside
of such countries, to the extent such theft or intrusion destroys the proprietary nature of its intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>We
depend on our information technology and telecommunications systems and those of third parties, the failure or disruption of which could
harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">We depend
on information technology and telecommunications systems, including those provided by third parties and their vendors, for significant
elements of our operations, such as our information management systems, research and development, scientific and medical data analysis
and general administrative activities. In addition, our&#160;third-party&#160;service providers depend upon technology and telecommunications
systems provided by outside vendors. We expect to expand and strengthen a number of enterprise software systems that affect a broad range
of business processes and functions, including, for example, systems handling human resources, financial controls and reporting, customer
relationship management, regulatory compliance, security controls and other infrastructure operations. These expansions may prove more
difficult than we expect and could cause disruptions in our operations or additional expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Information technology and telecommunications
systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and
natural disasters. Moreover, despite network security and&#160;back-up&#160;measures, some of our servers are potentially vulnerable to
physical or electronic&#160;break-ins,&#160;computer viruses and similar disruptive events. Despite the precautionary measures we have
taken to detect and prevent or solve problems that could affect our information technology and telecommunications systems, failures or
significant downtime of these systems or those used by its&#160;third-party&#160;service providers and their vendors could prevent us
from conducting tests, preparing and providing our orts to future customers, billing payors, conducting research and development activities,
maintaining our financial controls and other reporting functions, and managing the administrative aspects of our business. In addition,
the loss of formulas or data from completed, ongoing or planned pre-clinical studies could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were
to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and further development of our product candidates could be delayed. Any disruption or loss of information technology
or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Intellectual
property litigation may lead to unfavorable publicity that harms our reputation.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">During
the course of any intellectual property litigation, there could be public
announcements of the initiation of the litigation as well as results of hearings, rulings on motions and other interim proceedings in
the litigation. Such announcements could harm our reputation, the perceived value of our intellectual property or the potential market
for our products, which could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube&#8217;s success depends on its ability to develop and commercialize its technology without infringing, misappropriating, or otherwise
violating the intellectual property of third parties. Third parties may initiate legal proceedings alleging that Renovaro Cube is infringing
their intellectual property rights, and if they prevail, could block sales of Renovaro Cube&#8217;s products and force Renovaro Cube to
make large damages and/or royalty payments, which could have a material adverse effect on the success of its business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s commercial success in part depends upon its ability, and the ability of its collaborators, to market, sell and distribute
Renovaro Cube&#8217;s products and use Renovaro Cube&#8217;s proprietary technologies without infringing, misappropriating or otherwise
violating the proprietary rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology,
diagnostic and pharmaceutical industries. Renovaro Cube may become party to, or threatened with, future adversarial proceedings or litigation
regarding intellectual property rights with respect to its products, including interference proceedings before the United Kingdom <span style="background-color: white">Intellectual
Property&#160;Office, the European Patent Office</span>, the United States Patent and Trademark Office and similar bodies in other jurisdictions.
Third parties may assert infringement claims against Renovaro Cube based on existing patents or patents that may be issued in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">If Renovaro
Cube is found to infringe, misappropriate, or otherwise violate a third party&#8217;s intellectual property rights, it could be required
to obtain a license from such third party to continue developing, marketing, selling and distributing Renovaro Cube&#8217;s products,
or to cease using the infringing technology. However, Renovaro Cube may not be able to obtain any required license on commercially reasonable
terms or at all. Even if Renovaro Cube were able to obtain a license, it could be&#160;non-exclusive,&#160;thereby giving Renovaro Cube&#8217;s
competitors access to the same technologies licensed to Renovaro Cube. In addition, Renovaro Cube could be found liable for monetary damages,
including treble damages if it is found to have willfully infringed a patent and attorneys&#8217; fees if the court finds the case to
be exceptional. A finding of infringement, misappropriation, or other violation could prevent Renovaro Cube from commercializing its products
or force Renovaro Cube to cease some of its operations, which could materially harm its business. Claims that Renovaro Cube has misappropriated
the confidential information or trade secrets of third parties could have a similar negative impact on Renovaro Cube&#8217;s business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Even if
resolved in Renovaro Cube&#8217;s favor, litigation or other legal proceedings relating to intellectual property claims may cause Renovaro
Cube to incur significant expenses and could distract Renovaro Cube&#8217;s personnel from their normal responsibilities. Such litigation
or proceedings could substantially increase Renovaro Cube&#8217;s operating losses and reduce the resources available for development
activities or any future sales, marketing, or distribution activities. Renovaro Cube may not have sufficient financial or other resources
to conduct such litigation or proceedings adequately. Some of Renovaro Cube&#8217;s competitors may be able to sustain the costs of such
litigation or proceedings more effectively than Renovaro Cube can because of their greater financial resources and more mature and developed
intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could have a material adverse effect on Renovaro Cube&#8217;s ability to compete in the market place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube&#8217;s use of&#160;open-source&#160;software could subject Renovaro Cube&#8217;s proprietary technology to unwanted&#160;open-source&#160;license
conditions that could negatively impact its business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">A portion
of Renovaro Cube&#8217;s technology capabilities incorporates&#160;open-source&#160;software, and Renovaro Cube may incorporate&#160;open-source&#160;software
into other offerings or products in the future. If an author or other third party that distributed such&#160;open-source&#160;software
to Renovaro Cube were to allege that Renovaro Cube had not complied with the conditions of one or more of these licenses, Renovaro Cube
could be required to incur significant legal expenses defending against such allegations. Further, the outcome of such litigation may
be particularly uncertain in some cases, because there is little legal precedent governing the interpretation of certain terms of common
open source licenses. In addition, if Renovaro Cube combines its proprietary software with&#160;open-source&#160;software in a certain
manner and makes it available to others, under some&#160;open-source&#160;licenses, it could be required to license or make available
the source code of its proprietary software, which could substantially help its competitors develop products that are similar to or better
than Renovaro Cube&#8217;s and harm its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>The
success and growth of Renovaro Cube&#8217;s business depends upon its ability to continuously innovate and develop new products and technologies.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s solution is a technology-driven platform that relies on innovation to remain competitive. The process of developing new technologies
and products is complex, and Renovaro Cube has built and seeks to further develop its own technology using the latest in&#160;AI&#160;and
machine learning, cloud-based technologies and other tools to differentiate Renovaro Cube&#8217;s products and technologies. In addition,
Renovaro Cube&#8217;s dedication to incorporating technological advancements into its AI platform requires significant financial and personnel
resources and talent. Renovaro Cube&#8217;s development efforts with respect to these initiatives could distract management from current
operations and could divert capital and other resources from other growth initiatives important to Renovaro Cube&#8217;s business. Renovaro
Cube operates in an industry experiencing rapid technological change and frequent product introductions. Renovaro Cube may not be able
to make technological improvements as quickly as demanded by its customers, or Renovaro Cube may not be able to accurately predict the
demand or growth of its technological investments, which could harm its ability to attract customers and have a material and adverse effect
on its business, results of operations, financial condition and future prospects. In addition, Renovaro Cube may not be able to effectively
implement new technology-driven products and services as quickly as its competitors or be successful in marketing these products and services
to potential customers. If Renovaro Cube is unable to successfully and timely innovate, Renovaro Cube could experience reputational damage
and decreased demand for its AI platform and other products and technologies and its growth, business, results of operations, financial
condition and future prospects could be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube&#8217;s AI platform and other related products may become obsolete due to fast growing technological innovations or the entry of
competitors with more financial and brand power.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">AI is a fast growing industry and
Renovaro Cube must successfully adapt and manage technological advancements in AI and&#160;AI-related&#160;markets, as well as effectively
compete with the emergence of additional competitors in the AI industry in order to maintain and grow Renovaro Cube&#8217;s AI business
and products. Thus, the success of Renovaro Cube&#8217;s AI platform, other products and business depends in large part on its ability
to keep pace with rapid technological changes in the development and implementation of AI products. For example, the development of groundbreaking
technological innovations in AI, or innovations that would render AI obsolete, would harm Renovaro Cube&#8217;s business and make its
platform or other products less durable. Further, the entry of competitors into the AI market that have more financial and brand power
could cause Renovaro Cube&#8217;s share of the market to be significantly reduced thereby negatively affecting its business, operating
results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>We may not be able to protect
our intellectual property rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Filing, prosecuting and defending
patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling
or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to
territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Risks Related to Employee
Matters and Managing Growth </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>We have limited corporate
infrastructure and may experience difficulties in managing growth. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024, we had 25
full time employees. We rely on third-party contractors for the provision of professional, scientific, regulatory, and other services.
As our development and commercialization plans and strategies develop, we may need additional managerial, scientific, operational, financial,
and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day operations
and devote a substantial amount of time to managing these growth activities. We might not be able to effectively manage the expansion
of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities, loss
of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and
may divert financial resources from other projects, such as the development of our current and potential future product candidates. If
our management is unable to effectively manage our growth, our expenses may increase more than expected and our ability to generate and
grow revenue could be reduced and we might not be able to implement our business strategy. Our future financial performance, our ability
to commercialize product candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to
effectively manage any future growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Management
and employee turnover creates uncertainties and could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">We have
experienced significant turnover in our executive leadership and management in recent years. Changes to strategic or operating goals,
which oftentimes occur with the appointment of new executives and board members, can create uncertainty, may negatively impact our ability
to execute quickly and effectively, and may ultimately be unsuccessful. In addition, executive leadership transition periods are often
difficult as the new executives gain detailed knowledge of our operations, and friction can result from changes in strategy and management
style. Management turnover inherently causes some loss of institutional knowledge, which can negatively affect strategy and execution.
Until we integrate new personnel, and unless they are able to succeed in their positions, we may be unable to successfully manage and
grow our business, and our financial condition and ability to become profitable may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">As we
continue our exploration of strategic alternatives, we may experience additional turnover in our board and senior management. Departures
of our management team and board members have created, and will create if they continue, significant continuity risks and challenges to
our ability to operate our business, assess and manage risks and comply with applicable laws. If key members of our senior management
team depart, it will be important that we attract and retain qualified managers promptly and develop and implement an effective succession
plan. We expect to face significant competition in attracting experienced executives and other key personnel, and there can be no assurance
that we will be able to do so. Further, to the extent we experience additional management turnover, competition for top management is
high and it may take months to find a candidate that meets our requirements. If we are unable to attract and retain qualified management
personnel, our business could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">We also
experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Further, inflationary
pressure may increase our costs, including employee compensation costs or result in employee attrition to the extent our compensation
does not keep up with inflation, particularly if our competitors' compensation does.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube is highly dependent on its key personnel. If Renovaro Cube is not successful in attracting, motivating and retaining highly qualified
personnel, it may not be able to successfully implement its business strategy.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s ability to compete in the highly competitive AI-driven healthcare technology industry depends upon its ability to attract,
motivate and retain highly qualified personnel. Renovaro Cube is highly dependent on its executive management team and its scientific,
medical, technological and engineering personnel, all of whom have been working together as a group for only a limited period of time.
The loss of the services provided by any of Renovaro Cube&#8217;s executive officers, other key employees and other scientific and medical
advisors, and Renovaro Cube&#8217;s inability to find suitable replacements as needed, could result in delays in commercialization of
its products and harm its business. Renovaro Cube does not maintain &#8220;key person&#8221; insurance policies on the lives of these
individuals or the lives of any of its other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">Renovaro
Cube is headquartered in Amsterdam, the Netherlands, a region in which many other healthcare companies, technology companies and academic
and research institutions are headquartered. Competition for personnel is intense and the turnover rate can be high, which may limit Renovaro
Cube&#8217;s ability to hire and retain highly qualified personnel on acceptable terms or at all. Renovaro Cube expects that it may need
to recruit talent from outside of its region, and doing so may be costly and difficult. If Renovaro Cube is unable to attract and retain
highly qualified personnel, its ability to develop and commercialize its products may be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><b><i>If
Renovaro Cube is unable to scale its operations successfully to support demand for its products following the launch of its platform,
its business could suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">As and
to the extent demand increases beyond Renovaro Cube&#8217;s expectations following the launch of Renovaro Cube&#8217;s platform, Renovaro
Cube will likely need to start to ramp up operating capacity. Renovaro Cube will need to implement new infrastructure, data processing
capabilities, customer service, billing and systems processes, and expand Renovaro Cube&#8217;s internal quality assurance program and
technology to support operations on a larger scale. Renovaro Cube will also need collaboration arrangements with third-party laboratories
to process its physical tests or, if processing of such tests is not fully outsourced to support demand, will need to obtain equipment
and certified and licensed laboratory personnel to process these physical tests internally. Renovaro Cube may face difficulties increasing
the scale of its operations, including implementing changes in infrastructure or programs or acquiring additional equipment or personnel.
As Renovaro Cube refines its products and develops additional products, Renovaro Cube may need to introduce new equipment,&#160;implement
new systems, technology, controls and procedures, and hire personnel with different qualifications, licenses or certifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The value
of Renovaro Cube&#8217;s products will depend, in part, on Renovaro Cube&#8217;s ability to perform tests, whether through a licensed
provider or internally, and return results to providers on a timely basis and at an appropriate quality standard, and on Renovaro Cube&#8217;s
reputation for such timeliness and quality. Failure to establish necessary arrangements with licensed providers, to implement necessary
procedures, to transition to new equipment or processes, or to hire the appropriately qualified personnel could result in higher costs
of processing, longer turnaround times or an inability to meet market demand. There can be no assurance that Renovaro Cube or any such
licensed provider will be able to perform tests on a timely basis at a level consistent with demand, that Renovaro Cube will be able to
maintain the quality of its test results as Renovaro Cube scales its commercial operations, or that Renovaro Cube will be successful in
responding to the potential growing complexity of its operations, including the related data analysis requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">In addition,
Renovaro Cube&#8217;s growth may place a significant strain on its management, operating and financial systems, research and development,
and its sales, marketing, and administrative resources. As a result of Renovaro Cube&#8217;s growth, its operating costs may escalate
even faster than planned, and some of its internal systems may need to be enhanced or replaced. If Renovaro Cube cannot effectively manage
its expanding operations and its costs, Renovaro Cube may not be able to grow successfully or it may grow at a slower pace, and its business
could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube will need to grow the size and capabilities of its organization, and it may experience difficulties in managing this growth.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">As of
June 30, 2024, Renovaro Cube had 12 full-time employees and seven independent contractors. As Renovaro Cube&#8217;s growth plan and strategies
develop, it must add a significant number of additional managerial, operational, financial and other personnel. Future growth will impose
significant added responsibilities on members of management, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, retaining and motivating additional employees;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    its internal development efforts effectively, including creating compliant programs and processes, and managing the regulatory requirements
    for its products, while complying with its contractual obligations to contractors and other third parties;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanding
    its operational, financial and management controls, reporting systems and procedures; and</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    the increasing complexity associated with a larger organization and expanded operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s future financial performance and its ability to commercialize its products will depend, in part, on its ability to effectively
manage any future growth. Renovaro Cube&#8217;s management may also have to divert a disproportionate amount of its attention away from&#160;day-to-day&#160;activities
in order to manage these growth activities. Renovaro Cube&#8217;s ability to successfully manage its expected growth is uncertain given
the fact that Renovaro Cube has been in full operation as an independent company focusing on cancer diagnostics AI only since 2018. Renovaro
Cube&#8217;s executive management team&#8217;s lack of&#160;long-term&#160;experience working together may adversely impact their ability
to effectively manage its business and growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">If Renovaro
Cube is not able to effectively expand its organization by hiring new employees, it may not be able to successfully implement the tasks
necessary to commercialize its products, which would have a negative impact on Renovaro Cube&#8217;s business and result of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube&#8217;s employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube is exposed to the risk of fraud, misconduct, or other illegal activity by its employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to comply with
the rules and regulations of the Centers for Medicare &amp; Medicaid Services (the &#8220;CMS&#8221;), the FDA, the EMA, the MRHA and
other comparable regulatory authorities; provide true, complete and accurate information to such regulatory authorities; comply with manufacturing
and clinical laboratory standards; comply with healthcare fraud and abuse laws in the United Kingdom, Europe and, in the future, the United
States and similar fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities
to Renovaro Cube. When Renovaro Cube begins commercializing its products in the United Kingdom and Europe and, in the future, the United
States, its potential exposure under such laws will increase significantly, and its costs associated with compliance with such laws are
also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry
are subject to extensive laws designed to prevent fraud, kickbacks,&#160;self-dealing&#160;and other abusive practices, as well as&#160;off-label&#160;product
promotion. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion,
sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws
also involve the improper use of information obtained in the course of clinical validation, which could result in regulatory sanctions
and cause serious harm to Renovaro Cube&#8217;s reputation. Renovaro Cube has adopted a code of business conduct and ethics, but it is
not always possible to identify and deter misconduct by employees and third parties, and the precautions Renovaro Cube takes to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Renovaro Cube from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions
are instituted against Renovaro Cube, and Renovaro Cube is not successful in defending itself or asserting its rights, those actions could
have a significant impact on Renovaro Cube&#8217;s business, including the imposition of significant fines or other sanctions. Even if
it is later determined after an action is instituted against Renovaro Cube that Renovaro Cube was not in violation of these laws, Renovaro
Cube may be faced with negative publicity, incur significant expenses defending its actions and have to divert significant management
resources from other matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related To Our Business Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Our business plan may lead
to the initiation of one or more product development programs, the discontinuation of one or more development programs, or the execution
of one or more transactions that investors do not agree with or that investors do not perceive as favorable to their investment in our
Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We are pursuing a strategy to, dependent upon raising sufficient funding to
do so, leverage our clinical experience and expertise for the clinical development and regulatory approval of our gene therapy product
candidates and advance our AI-driven healthcare technology. As part of our ongoing business strategy, we continue to explore potential
opportunities to acquire or license new product candidates and to collaborate on our existing products in development. We cannot be certain
that our product candidates will be successfully developed, or that the early clinical trial results of our therapeutic product candidates
will be predictive of future clinical trial results. During 2022, we decided to abandon our pan-coronavirus and influenza pipelines as
the results did not support further development. We again may determine at any time that one or more of our in-licensed product candidates
is not suitable for continued development due to cost, feasibility of obtaining regulatory approvals or any other reason, and may terminate
the related license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our business plan requires us to
be successful in a number of challenging, uncertain and risky activities, including pursuing development of our gene therapy product candidates
in indications for which we have limited or no human clinical data, designing and executing a nonclinical and/or clinical development
program for our product candidates, building internal or outsourced gene therapy capabilities, converting early stage gene therapy research
efforts into clinical development opportunities, identifying additional promising new assets for development that are available for acquisition
or in-license and that fit our strategic focus and identifying potential partners to collaborate on our products. We may not be successful
at one or more of the activities required for us to execute this business plan. In addition, we may consider other strategic alternatives,
such as mergers, acquisitions, divestitures, joint ventures, partnerships and collaborations. We cannot be sure when or if any type of
transaction will result. Even if we pursue a transaction, such transaction may not be consistent with our stockholders&#8217; expectations
or may not ultimately be favorable for our stockholders, either in the shorter or longer term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our growth prospects and the future
value of our Company are primarily dependent on the progress of our ongoing and planned development programs for our product candidates
as well as the outcome of our ongoing business development efforts and pipeline progression, together with the amount of our remaining
available cash. The development of our product candidates and the outcome of our ongoing business development efforts and pipeline are
highly uncertain. We expect to continue to reassess and make changes to our existing development programs and pipeline strategy. Our plans
for our development programs may be affected by the results of competitors&#8217; clinical trials of product candidates addressing our
current target indications, and our business development efforts and pipeline progression may also be affected by the results of competitors&#8217;
ongoing research and development efforts. We may modify, expand or terminate some or all our development programs, clinical trials or
collaborative research programs at any time as a result of new competitive information or as the result of changes to our product pipeline
or business development strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>If serious adverse events
or other undesirable side effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay
our clinical development and commercialization of some or all of our product candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Undesirable side effects or safety
concerns caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt our clinical trials and
could result in a more restrictive label or the delay or denial of regulatory approval. If treatment-related serious adverse events (&#8220;SAEs&#8221;)
or other undesirable side effects or safety concerns, or unexpected characteristics attributable to our product candidates are observed
in any future clinical trials, they may adversely affect or delay our clinical development and commercialization of the effected product
candidate, and the occurrence of these events could have a material adverse effect on our business and financial prospects. Results of
our future clinical trials could reveal a high and unacceptable severity and prevalence of adverse side effects. In such an event, our
trials could be suspended or terminated, and the FDA or other regulatory agency could order us to cease further development of or deny
approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment
or the ability of enrolled patients to complete the trial or result in potential product liability claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Additionally, if any of our product
candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects or safety concerns caused
by these product candidates, a number of potentially significant negative consequences could result, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may withdraw, suspend, or limit approvals of such products and require us to take them off the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS
    or REMS-like plan to ensure that the benefits of the product outweigh its risks;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change
    the way a product is distributed or administered, conduct additional clinical trials, or change the labeling of a product;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to conduct additional post-marketing
    studies or surveillance;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to limitations on how we may promote
    the product;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of the product may decrease significantly;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to regulatory investigations,</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to government enforcement actions,
    litigation, or product liability claims; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our products may become less competitive, or our reputation
    may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Any of these events could prevent
us or any collaborators from achieving or maintaining market acceptance of our product candidates or could substantially increase commercialization
costs and expenses, which in turn could delay or prevent us from generating revenue from the sale of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>Renovaro
Cube&#8217;s business is subject to economic, political, regulatory and other risks associated with international operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s business is subject to risks associated with conducting business internationally. For example, some of Renovaro Cube&#8217;s
suppliers and parties with whom it has collaborative relationships are located outside of the Netherlands, including in the United Kingdom
and Israel. Accordingly, Renovaro Cube&#8217;s future results could be harmed by a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 20px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular&#160;foreign economies and markets;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    enforcing its contractual and intellectual property rights, especially in those foreign jurisdictions that do not respect and protect
    intellectual property rights to the same extent as the Netherlands;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in&#160;foreign&#160;laws,&#160;regulations and customs, tariffs and trade barriers;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in foreign currency exchange rates;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in a specific countries or region&#8217;s political or economic environment;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    consequences from changes in tax laws;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade
    protection measures, import or export licensing requirements or other restrictive actions by the Netherlands or foreign governments;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the Netherlands;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    associated with staffing and managing international operations, including differing labor relations; and</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from&#160;geo-political&#160;actions, including war and terrorism, pandemics, or natural disasters, including
    earthquakes, typhoons, floods and fires.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i></i></b></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b><i>If
we are sued for product or professional liability, we could face substantial liabilities that exceed our resources.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Renovaro
Cube&#8217;s business depends upon its ability to obtain reliable and accurate test results that incorporate rapidly evolving understanding
of how to interpret minute signals detected by Renovaro Cube&#8217;s assays as indications of potential presence of disease. Actual or
perceived errors resulting from laboratory or reporting errors, false positive or false negative test results, or the manufacture, design,
or labelling of Renovaro Cube&#8217;s products, could subject Renovaro Cube to product liability or professional liability claims. A product
liability or professional liability claim against Renovaro Cube could result in substantial damage and be costly and&#160;time-consuming&#160;to
defend. Any liability claim brought against Renovaro Cube, with or without merit, could increase its insurance rates or prevent it from
securing insurance coverage in the future. Additionally, any liability lawsuit could damage Renovaro Cube&#8217;s reputation or force
it to delay or suspend sales of its products. The occurrence of any of these events could have a material adverse effect on Renovaro Cube&#8217;s
business, results of operations, financial condition and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our stock price has been and will likely continue to be volatile
and may decline regardless of our operating performance.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our stock price has fluctuated in the past and can be expected to be volatile
in the future. From October 2, 2023, through October 2, 2024, the reported sale price of our Common Stock has fluctuated between $5.18
and $0.46 per share. The stock market in general and the market for biotechnology and technology companies in particular have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility,
investors may experience losses on their investment in our Common Stock. The market price of our Common Stock may be influenced by many
factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative publicity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our compliance with Nasdaq
    rules and regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of competitive
    products or technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions with
    respect to our product candidates or products or our competitors&#8217; product candidates or products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify; width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated changes
    in our growth rate relative to our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or
    our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical studies of our product candidates or those of our competitors;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the U.S. and other countries;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recruitment or departure of key personnel;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of expenses related
    to any of our product candidates or clinical development programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our efforts
    to in-license or acquire additional product candidates or products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated changes
    in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our financial
    results or those of companies that are perceived to be similar to us;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in the valuation
    of companies perceived by investors to be comparable to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inconsistent trading volume
    levels of our shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement or expectation
    of additional financing efforts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our Common Stock
    by us, our insiders or our other stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 20px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market conditions in the
    pharmaceutical and biotechnology sectors;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, industry
    and market conditions; and</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the other risks described
    in this &#8220;Risk Factors&#8221; section.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In addition, the stock markets in general, and the markets for biotechnology,
pharmaceutical and technology stocks in particular, have experienced significant volatility that has often been unrelated to the operating
performance of particular companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><i>Sales of a substantial number of shares of our
Common Stock in the public market could cause our stock price to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A significant portion of our Common
Stock is held in restricted form, and consequentially a minority of our outstanding Common Stock actively trades in the public markets.
Sales of a substantial number of such shares of our Common Stock in the public market could occur at any time. While a large majority
of such shares are unregistered and subject to volume restrictions on sale pursuant to Rule 144 under the Securities Act, these restrictions
could be lifted if any of our stockholders ceased to be bound by such restrictions. These sales, or the perception in the market that
the holders of a large number of shares intend to sell shares, could reduce the market price of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>We have incurred and will
continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public
company compliance programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As a public company, we have incurred
and will continue to incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange
Act, which require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business
and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Stock Market
to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment
and maintenance of effective disclosure and financial controls and changes in corporate governance practices. As a Smaller Reporting Company
and Non-accelerated Filer, we are able to take advantage of certain accommodations afforded to such companies, including being exempt
from the requirement to conduct an audit of our internal controls. In the event we no longer qualify as a Smaller Reporting Company and
Non-accelerated Filer, we will lose such accommodations, which could involve significant costs that could affect our operations. Changes
in reporting requirements, the current political environment and the potential for future regulatory reform may lead to substantial new
regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business
in ways we cannot currently anticipate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The rules and regulations applicable
to public companies have substantially increased our legal and financial compliance costs and make some activities more time-consuming
and costly. To the extent these requirements divert the attention of our management and personnel from other business concerns, they could
have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Because we do not anticipate
paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of potential
gain for our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We have never declared or paid
cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development
of our business. As a result, capital appreciation, if any, of our Common Stock will be the sole source of gain for our stockholders for
the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Future sales and issuances
of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution
of the percentage ownership of our stockholders and could cause our stock price to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We expect that significant additional
capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts of Common Stock
or securities convertible into or exchangeable for Common Stock in one or more transactions at prices and in a manner, we determine from
time to time. These future issuances of Common Stock or Common Stock-related securities, together with the exercise of outstanding options
or warrants, and any additional shares that may be issued in connection with acquisitions or licenses, if any, may result in material
dilution to our investors. Such sales may also result in material dilution to our existing stockholders, and new investors could gain
rights, preferences, and privileges senior to those of holders of our Common Stock. Pursuant to our equity incentive plans, our Compensation
Committee is authorized to grant equity-based incentive awards to our employees, non-employee directors and consultants. Future grants
of RSUs, options and other equity awards and issuances of Common Stock under our equity incentive plans will result in dilution and may
have an adverse effect on the market price of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Some terms of our charter
documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition
would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our Certificate of Incorporation,
and our Bylaws, as well as Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring
us, even if doing so would benefit our stockholders, or remove our current management. These include terms that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit our Board of Directors
    to issue up to 10,000,000 shares of preferred stock, with any rights, preferences, and privileges as they may designate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that all vacancies
    on our Board of Directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled
    by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that stockholders
    seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of
    stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s
    notice; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">do not provide for cumulative
    voting rights, thereby allowing the holders of a majority of the shares of Common Stock entitled to vote in any election of directors
    to elect all of the directors standing for election. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Any of the factors listed above
may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for
stockholders to replace members of our Board of Directors, who are responsible for appointing the members of our management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In addition, because we are incorporated
in Delaware, we are governed by Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from
acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may
not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock
for three years or, among other things, the Board of Directors has approved the transaction. Any term of our Certificate of Incorporation
or Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders
to receive a premium for their shares of our Common Stock and could also affect the price that some investors are willing to pay for our
Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>1B. Unresolved Staff Comments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><span id="h_001"></span>1C. Cybersecurity Risk Management and Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">Renovaro has established a comprehensive cybersecurity
risk management program aimed at safeguarding the confidentiality, integrity, and availability of our essential systems and information.
Central to our cybersecurity efforts is a robust incident response plan designed to address potential cyber incidents swiftly and effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">In designing and evaluating our cybersecurity initiatives,
we have adopted the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF 2.0) as a guiding principle. It's
important to clarify that our use of the NIST CSF 2.0 is for guidance purposes to frame our risk identification, assessment, and management
processes and does not equate to compliance with any specific technical standards or requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">Our cybersecurity framework is seamlessly integrated
broader enterprise risk management strategy, sharing methodologies, reporting mechanisms, and governance structures with other risk domains
including legal, compliance, strategic, operational, and financial risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt">Key components of our cybersecurity risk management program
include:</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/107% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting risk assessments to pinpoint material cybersecurity
threats to our critical systems, data, products, services, and overall IT infrastructure.</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A dedicated security team overseeing the risk assessment
processes, maintenance of security controls, and coordination of responses to cybersecurity incidents.</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement with external service providers to evaluate,
enhance, or support our security measures.</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive cybersecurity training programs for employees,
incident responders, and senior management to foster a culture of security awareness.</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An incident response plan outlining specific procedures
for managing cybersecurity incidents.</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A thorough third-party risk management process to evaluate
and manage risks associated with service providers, suppliers, and vendors.</span></td></tr></table>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 18pt">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 18pt">To date, we have not identified any cybersecurity
threats or past incidents that have had, or are likely to have, a material impact on our company's operations, business strategy, financial
performance, or results of operations.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 18pt">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><b>Cybersecurity Governance:</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">The governance of cybersecurity risks is
a critical function of our Board of Directors, with the Audit Committee (the "Committee") playing a key role in the oversight
of cybersecurity and related technology risks. The Committee is tasked with monitoring the effectiveness of our cybersecurity risk management
program as implemented by management.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">The Committee receives regular updates from
management on the state of cybersecurity risks facing the company. This includes briefings on any significant cyber incidents and ongoing
risk management efforts. These updates enable the Committee to provide informed reports on cybersecurity matters to the full Board.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from the Head of IT, internal technology teams, or external cybersecurity experts. These sessions
are part of the Board's commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">The responsibility for day-to-day management of cybersecurity
risks lies with our management team, including the Chief Financial Officer. This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber threats. Our approach includes regular updates
from internal security teams, leveraging intelligence from various sources, and utilizing advanced security tools to protect our digital
environment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_006"></span>Item 2. Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company currently leases the following properties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: normal 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Location</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 71%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2080 Century Park East, Suite 906 <br/>
    Los Angeles, CA 90067</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headquarters</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        Company entered into a Lease Agreement on June 19, 2018 for our corporate headquarters located at Century City Medical Plaza.
        We have a ten-year lease that was for approximately 2,453 square feet at this location. In February 2019, we extended our corporate
        headquarters to encompass the adjoining suite for approximately 1,101 square feet, bringing the total workspace to 3,554 square
        feet. The new base rent for this leased premises increases by 3% each year over the term, and ranges from $17,770 per month as
        of the date of the amendment until the end of the first year to $23,186 per month for the tenth year. The additional suite was
        in the form of an amendment to the original lease and will expire on the same date as the original lease. The Company was entitled
        to a total of $148,168 in contributions toward tenant improvements for both spaces.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fred.
                    Roeskestraat 115</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1076
    EE Amsterdam, The Netherlands</span></p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Cube</span></td>
    <td style="text-align: justify"/>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Renovaro
        Cube leases an office facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September
        1, 2023, with a maturity date of February 28, 2026. In determining lease asset values, the Company considers fixed and variable
        payment terms, prepayments, incentives, and options to extend, terminate or purchase.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>Item 3. Legal Proceedings </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i>Securities Class Action Litigation</i>.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#8220;Chow Action&#8221; and the latter, the
&#8220;Manici Action&#8221;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#8217;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#8217;s relationship
with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice, but the Chow action remains pending.&#160;On October
22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead plaintiff filed an amended complaint on December 15, 2023.
The Company has filed a motion to dismiss the amended complaint on March 15, 2024. The Court denied the Company&#8217;s motion to dismiss
on June 28, 2024. A mediation was held on September 17, 2024, and the parties have come to an agreement in principle to settle the class
action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i>Federal Derivative Litigation</i>.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California. On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United States District
Court for the District of Delaware. Both derivative actions recite similar underlying facts as those alleged in the Securities Class Action
Litigation. The actions, filed on behalf of the Company, name Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current
and former directors as defendants. The actions also name the Company as a nominal defendant. The actions allege violations of Sections
14(a) and 20(a) of the Securities Exchange Act of 1934 and also set out claims for breach of fiduciary duty, contribution and indemnification,
aiding and abetting, and gross mismanagement. Plaintiffs do not quantify any alleged injury, but seek damages, disgorgement, restitution,
and other costs and expenses. On January 24, 2023, the United States District Court for the Central District of California stayed the
Koenig matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On
April 4, 2023, the United States District Court for the District of Delaware stayed the Solak matter pending resolution of the defendants&#8217;
anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central
District of California denied defendants&#8217; motion to dismiss the Securities Class Action Litigation. The deadline for the parties
to file a proposed schedule or to continue the stay or proceedings in the Koenig matter is October 21, 2024. The deadline for the parties
to file a proposed schedule or to continue the stay or proceedings in the Solak matter is October 22, 2024. The defendants have not yet
responded to either complaint. The Company intends to contest these matters but expresses no opinion as to the likelihood of favorable
outcomes. Management is unable to determine the likelihood of a loss, including a possible range of losses, if any, arising from this
matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i>State Derivative Litigation</i>.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County, reciting
similar underlying facts as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the Company, names
Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and former directors as defendants. The action also names the
Company as a nominal defendant. The action sets out claims for breaches of fiduciary duty, contribution and indemnification, aiding and
abetting, and gross mismanagement. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other
costs and expenses. On January 20, 2023, the Court stayed the Midler matter pending resolution of the defendants&#8217; anticipated motion
to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California
denied defendants&#8217; motion to dismiss the Securities Class Action Litigation. The deadline for the parties to file a proposed schedule
or to continue the stay or proceedings in the Midler matter is October 23, 2024. The defendants have not yet responded to the complaint. The Company intends to contest this matter but expresses no opinion as to the likelihood of
a favorable outcome. Management is unable to determine the likelihood of a loss, including a possible range of losses, if any, arising
from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252;, William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio LLC (&#8220;G Tech&#8221;), SG &amp; AW Holdings,
LLC, and Seraph Research Institute (&#8220;SRI&#8221;) (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants
engaged in a &#8220;concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting
its Hepatitis B and SARS-CoV-2/influenza pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive
outcomes from various studies, and even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the
Company claims that it &#8220;paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221;
On April 21, 2023, defendants Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all,
of the Company&#8217;s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending
motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening
deadlines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including,
<i>inter alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License
Agreement, effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications,
effective as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently
scheduled to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while
pursuing its claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 1, 2021, the Company&#8217;s
former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District
of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and
Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company&#8217;s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Gr&#248;nfeldt-S&#248;rensen. On November 29, 2022,
the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24, 2023,
the court denied the motion for summary judgment. The court vacated the July 15, 2024 trial date and has yet to re-set the trial date.
The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (such trusts, collectively, the
&#8220;Trusts&#8221;) (collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery
of Delaware. In the Verified Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between
the Company, Weird Science, and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor
Rights Agreement required the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days
prior to filing a registration statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in
such registration statement. Plaintiffs alleged that the Company breached these registration rights by failing to provide the required
notice in connection with S-3 registration statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to
dismiss the Verified Complaint on September 15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white"></p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023. The Court scheduled oral argument on the motions to dismiss for November 15, 2024. The Company denies Plaintiffs&#8217;
allegations and intends to vigorously defend against the claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 24, 2023, counsel on
behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company&#8217;s
books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167;&#160;220 (&#8220;Section 220&#8221;).
The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company takes its
obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with those
obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On
January 19, 2024, Weird Science and Wittekind sent the Company&#8217;s Board of Directors a letter demanding it take corrective actions
with respect to twenty-one issues identified therein. On February 27, 2024, Weird Science and Wittekind sent the Company&#8217;s Board
of Directors a supplemental letter that expanded their demand for corrective actions to twenty-six issues. In response to these demand
letters, the Board of Directors initially formed a Special Committee (&#8220;Special Committee&#8221;) of independent directors on February
29, 2024. The Special Committee retained Stradling Yocca Carlson &amp; Rauth LLP as its counsel to investigate the issues identified in
the demand letters. The Special Committee&#8217;s investigation is ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On January
23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States District Court for the Central District
of California against certain officers, directors, and investors of the Company, as well as other defendants, in connection with, <i>inter
alia</i>, Weird Science and Wittekind&#8217;s demand for corrective action. Plaintiffs filed an amended complaint on June 21, 2024. The
First Amended Verified Stockholder Derivative Complaint (&#8220;Derivative Complaint&#8221;) alleges, among other claims, violations of
Section 13(d) and 14(a) and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims
of breach of fiduciary duty, corporate waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified
compensatory, exemplary, and punitive damages and certain injunctive relief. The Derivative Complaint names the Company as a nominal defendant.
On July 19, 2024, certain of the director defendants, who had agreed to waive service of the summons and Derivative Complaint, filed a
motion to dismiss the Derivative Complaint on a variety of procedural and substantive grounds. A hearing on the motion dismiss was held
on October 3, 2024 and the court subsequently took the motion under submission. The director defendants deny the allegations in the Derivative
Complaint and intend to vigorously defend against the claims asserted therein.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 21, 2024, the Company
filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>Item 4. Mine Safety Disclosures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_009"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_010"></span>Item 5. Market for Registrant&#8217;s Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity Securities </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Market Information and Holders of our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our Common Stock trades on the
Nasdaq Capital Market under the symbol &#8220;RENB&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of October 3, 2024, the Company had 156,193,912 shares of Common Stock
issued and approximately 197 stockholders of record. The actual number of stockholders is greater than this number of record holders and
includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 5, 2024, the Company issued&#160;33,760&#160;shares
of common stock for consulting services valued at $94,190.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 15, 2024, the Company
issued 50,000 shares of Common Stock for consulting services valued at $100,000.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Company Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company has not declared or paid any cash dividends on its Common Stock
and does not intend to declare or pay any cash dividends in the foreseeable future. The payment of dividends, if any, is within the discretion
of the Board and will depend on the Company&#8217;s earnings, if any, its capital requirements and financial condition and such other
factors as the Board may consider.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>Item 6. [Reserved]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>The following discussion of
our financial condition and results of operations should be read in conjunction with our financial statements, and the related notes to
those statements included elsewhere in this report. In addition to the historical financial information, the following discussion and
analysis contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those
anticipated in these forward-looking statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro
Inc. operates through two subsidiaries, Renovaro Biosciences and Renovaro Cube. Renovaro Cube refers to GediCube Intl. Ltd. and its wholly
owned subsidiary GediCube, B.V. and Grace Systems B.V., which were acquired on February 13, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro
Biosciences is a biotechnology company intending, if the necessary funding
is obtained, to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term
or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human
Immunodeficiency Virus (HIV) infections. As a result of our acquisition of GEDi Cube Intl on February 13, 2024, we have shifted the Company&#8217;s
primary focus and resources to the development of the GEDi Cube Intl technologies. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, our operations have been funded by sales of our securities and debt financing. We have never generated any sales revenue and we
expect this to continue until our products are approved for marketing in the United States and/or Europe. Even if we are successful in
having our products approved for sale in the United States and/or Europe, we cannot guarantee that a market for the products will develop.
We may never be profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June 14, 2024, the Company closed a private placement of the Company&#8217;s
Units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $0.0001 par value per share and (ii) one common
stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain investors. The Warrants are exercisable for five
years from the date of issuance and have an exercise price of $1.4726 and $1.4765 per share, payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">The Private Placement was completed
pursuant to Regulation S promulgated under the Securities Act of 1933, as amended (&#8220;Regulation S&#8221;). In connection with the
Private Placement, each Investor executed a subscription agreement (each, a &#8220;Subscription Agreement&#8221;) in the form of Exhibit
10.1 attached hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">In the Private Placement, the Company sold 3,939,299 Units at a price per
Unit equal to $1.4726 to a certain investor who settled debt and paid in cash an aggregate amount of $5,801,012 in consideration for the
Units. <span style="background-color: white">As of June 30, 2024, the Company issued 2,325,869 shares of Common Stock, $0.0001 par value,
at $1.4726 per share for aggregate proceeds to the Company of $3,425,075 in cash and settlement of  debt. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">Subsequently related to the
June 14, 2024, Private Placement, the Company sold 1,423,456 Units at a price per Unit equal to $1.4726 to a certain investor who paid
in cash and settled debt an aggregate amount of $2,096,181 in consideration for the Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">The Company intends to use
the net proceeds from the Private Placement for general corporate purposes. Each Subscription Agreement contains customary representations
and warranties of the Company and of each Investor, including that all Investors purchasing the Securities are not &#8220;U.S. persons&#8221;
as defined by Rule 902 of Regulation S. The Private Placement was made directly by the Company and no underwriter or placement agent was
engaged by the Company. The Company did not engage in general solicitation or advertising and did not offer the Securities to the public
in connection with the Private Placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Going Concern and Management&#8217;s Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements included elsewhere herein for the year ended June 30, 2024, were prepared under the assumption that we would continue
our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal
course of business. As of June 30, 2024, we had cash and cash equivalents of $220,467, an accumulated deficit of $324,679,425 and total
liabilities of $31,152,306. We have incurred losses from continuing operations, have used cash in our continuing operations, and are
dependent on additional financing to fund operations. These conditions raise substantial doubt about our ability to continue as a going
concern for one year after the date the financial statements are issued. The financial statements included elsewhere herein do not include
any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification
of liabilities that may result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has reduced overhead and administrative costs by streamlining the organization to focus around the development and validation of its
AI driven cancer diagnostics platform. The Company has tailored its workforce to focus on these activities. In addition, the Company
intends to attempt to secure additional required funding through equity or debt financing. However, there can be no assurance that the
Company will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on reasonable
terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders. If we
do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially
reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with
third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds
to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders
losing some or all of their investment in us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
that we may receive during fiscal 2025 is expected to be used to satisfy existing and future obligations and liabilities and working
capital needs, to support commercialization of our products and conduct the clinical and regulatory work to develop our product candidates,
and to begin building working capital reserves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Year ended June 30, 2024 compared to the year ended June 30, 2023.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following table sets forth
our revenues, expenses and net loss for the years ended June 30, 2024 and 2023. The financial information below is derived from our audited
consolidated financial statements included elsewhere in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase/(Decrease)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">24,557,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">15,318,198</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">9,239,410</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">60</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,708,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,165,197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,456,368</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,611,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,960,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">121,859</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113,496</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,363</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">81,639,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,556,891</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,082,405</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,639,296</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38,556,891</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,082,405</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in fair value of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,727,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,727,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,303,578</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,303,578</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Loss on extinguishment of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(419,182</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,011,322</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(580,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(430,978</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Gain (loss) on foreign currency transactions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,019</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest and other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,423,449</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(126,620</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,296,829</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,024</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Other Income (Expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">989,124</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,127,165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,116,289</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(188</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(80,650,172</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(39,684,056</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,966,116</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">103</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase/(Decrease)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-align: left; text-indent: -10pt">Net Loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(80,650,172</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(39,684,056</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(40,966,115</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">103</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Comprehensive Income (Loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Foreign Currency Translation, net of taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(140,964</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">554</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(141,518</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,545</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Comprehensive Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(80,791,136</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(39,683,502</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,107,634</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">104</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We are a pre-revenue, pre-clinical
biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses
since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our operating expenses for the
years ended June 30, 2024 and 2023 were $81,639,296 and $38,556,891, respectively, representing an increase of $43,082,405 or 112%. The
largest contributors to the increase in operating expenses for the year ended June 30, 2024, were the increase in the non-cash intangible
asset impairment of $23,651,000 (see Note 5 to the Financial Statements), increase in the non-cash goodwill impairment of $11,640,000
and the increase in general and administrative expenses of $9,239,410 partially offset by the decrease in research and development expenses
of $1,456,368 compared to the year ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">General and administrative expenses
for the years ended June 30, 2024 and 2023, were $24,557,608 and $15,318,198, respectively, representing an increase of $9,239,410, or
60%. The increase in general and administrative expenses is primarily related to increases in non-cash consulting fees of $4,664,190,
accrued expenses related to the GEDi Cube acquisition of $812,775, legal expenses of $1,360,761, investor relations expenses of $882,534,
consulting expenses of $661,998, marketing expenses of $303,730 and rent expenses of $413,802, partially offset by a decrease in compensation
and related expenses of $781,467.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Research and development expenses
for the years ended June 30, 2024, and 2023, were $2,708,829 and $4,165,197, respectively, representing a decrease of $1,456,368 or 35%.
The decrease in research and development expenses is primarily related to $2,090,957 in collaborating partner expenses&#160;with CDMO
and CROs related to discontinued product candidates, partially offset by an increase in consumables of $238,862 and consulting expenses
of $333,894.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Other Income (Expenses)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net other income (expenses) for the years ended June 30, 2024 and 2023 was
$989,124 and $(1,127,165), respectively, representing an increase of $2,116,289 or 188%. The increase in other income was due primarily
to the change in the fair value of the contingent consideration in the amount of $4,727,473, which resulted from the mark to market adjustment
on the remaining contingent consideration liability in the year ended June 30, 2024, offset by a loss on extinguishment of debt in the
amount of $1,303,578 and interest and other expense of $1,423,449.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net loss for the years ended June 30, 2024 and June 30, 2023 was $80,650,172
and $39,684,056, respectively, representing an increase in net loss of $40,966,116 or 103%. The increase in net loss was primarily due
to the increase of non-cash intangible asset impairment of $23,651,000, the non-cash goodwill impairment of $11,640,000 and the increase
in general and administrative expenses of $9,239,410 offset by the change in fair value of contingent consideration of $4,727,473 and
by the $1,456,368 decrease in research and development expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We have historically satisfied
our capital and liquidity requirements through funding from stockholders, the sale of our Common Stock and warrants, and debt financing.
We have never generated any sales revenue to support our operations, and we expect this to continue until our therapies or products are
approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies or products approved for
sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may never be
profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As noted above under the heading &#8220;Going Concern and Management&#8217;s
Plans,&#8221; through June 30, 2024, we have incurred substantial losses. We will need additional funds both in the next twelve months
and beyond for (a) research and development, (b) increases in personnel, (c) the purchase of equipment, and investment in the development
and validation of our technology. The availability of any required additional funding cannot be assured. In
addition, an adverse outcome in legal or regulatory proceedings in which we are currently involved or in the future may be involved could
adversely affect our liquidity and financial position. We may raise such funds from time to time through public or private sales of our
equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed
could materially adversely affect our growth plans and our financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024, the Company had $220,467 in cash and working capital
of $(28,312,274) as compared to $1,874,480 in cash and working capital of $(8,457,693) as of June 30, 2023. The decrease in cash of $1,654,013
is primarily due to the cost of operations of $10,971,430, notes receivable prior to acquisition of $1,255,600 and repayments of finance
agreement of $870,073, partially <span style="background-color: white">offset by funding totaling $11,387,528 related to private placements,
proceeds from note payables and the exercise of warrants during the</span> period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 15, 2024, the Company
closed a private placement of&#160;344,827&#160;shares of Common Stock, $0.0001&#160;par value, at $2.90 per share for aggregate proceeds
to the Company of $1,000,000&#160;in cash <span style="background-color: white">(see Note 9 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On August 1, 2023, the Company
closed a private placement of&#160;280,505&#160;units (the &#8220;<span style="text-decoration: underline">Units</span>&#8221;), each consisting of (i) one share of the Company&#8217;s
Series A Convertible Preferred Stock, (the &#8220;<span style="text-decoration: underline">Preferred Stock</span>&#8221;) and (ii) one common stock purchase warrant (each, a &#8220;<span style="text-decoration: underline">Warrant</span>&#8221;,
and together with the Units and the shares of Preferred Stock, the &#8220;<span style="text-decoration: underline">Securities</span>&#8221;) to purchase five shares of the Company&#8217;s
common stock, at a price per Unit equal to $7.13&#160;for aggregate proceeds to the Company of $2,000,000&#160;in cash. In addition, the
Company issued&#160;280,505&#160;Units in connection with the conversion of $2,000,000&#160;of the Promissory Note <span style="background-color: white">(see
Note 9 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">The Company issued an aggregate
of&#160;561,010&#160;shares of Preferred Stock, which were initially&#160;convertible into an aggregate of&#160;5,610,100&#160;shares
of common stock. In connection with the Private Placement, the Company sold Warrants to purchase an aggregate of&#160;2,805,050&#160;shares
of common stock. The Warrants are exercisable for five years from the date of issuance and have an exercise price of $0.65&#160;per share,
payable in cash <span style="background-color: white">(see Note 9 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Warrant Exercises</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">On December 4, 2023, the Company issued&#160;525,945&#160;shares
of Common Stock pursuant to warrants exercised for cash proceeds of $341,865 <span style="background-color: white">(see Note 9 to the
Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 20, 2024, 2,953,700
warrants outstanding were exercised at prices ranging from $0.53 to $0.65 per share and the aggregate $1,750,000 of a promissory note
held by the holder was applied to the exercise price of the warrants <span style="background-color: white">(see Note 9 to the Financial
Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 20, 2024, 471,699 warrants outstanding were exercised at $0.53
per share valued at $250,000. A promissory note held by the holder was applied to the exercise price of the warrants in lieu of cash proceeds
<span style="background-color: white">(see Note 9 to the Financial Statements).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>March 2024 Note &#8212;</i></b>
On March 14, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note in the amount
of $500,000 (the &#8220;March 2024 Note&#8221;). The March 2024 Note had an interest rate of 10% per annum and was due to mature on March
15, 2025. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the issue date prior to the maturity of the March 2024 Note. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The March 2024 Note was convertible at the option of the holder after a qualified offering.
If no qualified offering occurs prior to the maturity date, the March 2024 Note was to be repaid in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company
sold 344,966 of the Company&#8217;s units, each such unit consisting of (i) one share of the Company&#8217;s common stock, $0.0001 par
value per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock (a &#8220;Unit&#8221;), to
the holder of the March 2024 Note in consideration for the total $512,361 in principal amount and interest accrued under the March 2024
Note. The warrants are exercisable for five years from the date of issuance and have an exercise price of $1.4726 per share, payable in
cash (<span style="background-color: white">see Note 7 to the Financial Statements).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The 2024 Notes &#8212;</i></b>
On January 11, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note (the &#8220;January
2024 Note I&#8221;) in the amount of $460,000. The January 2024 Note I had an interest rate of 12% per annum and was due to mature on
January 11, 2025. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year
following the issue date prior to the maturity of the notes. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The January 2024 Note I was convertible either at the option of the holder or automatically
upon maturity into shares of the Company&#8217;s Common Stock at the conversion price of $3.38. On January 12, 2024, the Company entered
into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate principal amount of $125,000 (the
&#8220;January 2024 Note II&#8221;, and collectively with the January 2024 Note I, the &#8220;January 2024 Notes&#8221;). The Company
received a total of $125,000 in gross proceeds.&#160;The January 2024 Note II bears an interest rate of 12% per annum and shall mature
on December 29, 2024. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each
year following the issue date prior to the maturity of the January 2024 Note II. The January 2024 Note II is convertible either at the
option of the holder or automatically upon maturity into shares of the Company&#8217;s Common Stock at the Note Conversion Price of $3.38.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company sold
325,508 of the Company&#8217;s Units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $0.0001 par value
per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, to the holder of the January 2024
Note I in consideration for the total $483,460 in principal amount and interest accrued under the January 2024 Note I. The warrants are
exercisable for five years from the date of issuance and have an exercise price of $1.4726 per share, payable in cash The January 2024
Notes principal balance at June 30, 2024, is $125,000 <span style="background-color: white">(see Note 7 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>December 2023 Notes &#8212;
</i></b>Between December 1, 2023, and December 29, 2023, the Company entered into Subscription
Agreements with two investors to purchase Convertible Promissory Notes for an aggregate principal amount of $560,000 (the &#8220;December
Notes&#8221;). The Company received a total of $560,000 in gross proceeds, consisting of $440,000 and $100,000 from the private placement
prior to the end of the quarter ending December 31, 2023, and $20,000 received in January 2024.&#160;The December Notes bear an interest
rate of 12% per annum and shall mature one year after their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company
is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following the issue date prior
to the maturity of the December Notes. Notwithstanding the immediately foregoing, at the option of the holder, interest may accrue on
the December Notes on a quarterly basis. The December Notes are convertible into shares of the Company&#8217;s Common Stock in whole or
in part at any time and from time to time, after the original issue date and prior to the Maturity Date, at a conversion price of $3.38
per share. The December Notes will be accounted for under ASC 470-20.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, in a private
placement the Company sold 317,715 Units to an investor who surrendered and terminated $440,000 in aggregate principal amount and $28,453
of interest accrued on the December Notes and paid in cash an aggregate amount of $66,000 to the Company in consideration for the Units,
each such Unit consisting of (i) one share of the Company&#8217;s common stock, $0.0001 par value per share and (ii) one common stock
purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are exercisable for five years from the date of issuance
and have an exercise price of $1.4726 per share, payable in cash. The December Notes principal balance at June 30, 2024, is $120,000 <span style="background-color: white">(see
Note 7 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The 2023 Notes &#8212; </i></b>Between
September 5, 2023, and October 5, 2023, the Company entered into Subscription Agreements with five investors to purchase 5% Original Issue
Discount Convertible Promissory Notes (the &#8220;2023 Notes&#8221;) for an aggregate principal amount of $2,105,263. The Company received
a total of $2,000,000 in gross proceeds from the private placement, after taking into account the 5% original issue discount.&#160;The
discount of $105,263 was to be accreted over the life of the 2023 Notes. The 2023 Notes had an interest rate of 12% per annum and were
due to mature on September 5, 2024 (the &#8220;Maturity Date&#8221;). The Company was required to pay interest quarterly, in arrears,
in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest could accrue on the notes on a quarterly basis. The 2023 Notes were convertible
into shares of the Company&#8217;s Common Stock upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The 2023 Notes were subject to
mandatory conversion (&#8220;Mandatory Conversion&#8221;) in the event the Company closed an offering of its Common Stock and received
gross proceeds of not less than $10,000,000 (a &#8220;Qualified Offering&#8221;). The conversion price per share of Common Stock in the
case of a Mandatory Conversion was to be 95% of the offering price per share in the Qualified Offering, subject to a floor of $4.50 per
share.&#160;In addition, if no Qualified Offering occurred prior to the Maturity Date, the 2023 Notes were to automatically convert into
shares of Common Stock on the Maturity Date at a conversion price per share equal to the closing sale price of the Common Stock on the
Maturity Date, subject to a floor of $4.50 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On January 11, 2024, the Company
entered into an amendment with one of the investors of the 2023 Notes whereas the conversion terms were amended to provide for optional
conversion at a conversion price of $3.38 per share. All other terms of the Promissory Note remained the same. The Company treated this
as a modification for accounting purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company sold 1,546,449 Units to the holders of the 2023
Notes who surrendered and terminated $2,293,825 in aggregate principal amount and interest accrued thereon of the 2023 Notes and paid
in cash an aggregate amount of $443,575 (of which $318,063 was applied against the Company&#8217;s Promissory Notes), to the Company in
consideration for the Units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $0.0001 par value per share
and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are exercisable for five years
from the date of issuance and have an exercise price of $1.4726 and $1.4765 per share, payable in cash. The 2023 Notes principal balance
at June 30, 2024, is zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;&#160;For the year ended
June 30, 2024, discount amortization of $78,567 was charged to interest expense and $26,696 of discount amortization was charged to other
income and expense due to the early termination of the notes, respectively. In the year ended June 30, 2024, the Company recorded interest
expense of $189,614 related to the 2023 Notes. The 2023 Notes balance, net of discount at June 30, 2024 is zero <span style="background-color: white">(see
Note 7 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>The Convertible Notes &#8212;
</i></b>On February 6, 2020, the Company issued two Convertible Notes (the &#8220;Convertible Notes&#8221;) to Paseco ApS (the &#8220;Holder&#8221;),
a Danish limited company and an existing stockholder of the Company, each with a face value amount of $600,000, convertible into shares
of Common Stock. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023. Interest on the Convertible
Notes commenced accruing on the date of issuance at six percent (6%) per annum, computed on the basis of twelve 30-day months, and was
compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as
of such compound date. The interest was payable in cash on a semi-annual basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">The
<span style="background-color: white">conversion price was equal to $12.00&#160;per
share of Common Stock. The Holder did not exercise its conversion feature that expired on February 6, 2021. The Company evaluated the
Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not be
bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Effective December 30, 2022 (the
&#8220;Effective Date&#8221;), the Company amended and restated the Convertible Notes (the &#8220;Amended and Restated Secured Notes&#8221;).
Pursuant to the Amended and Restated Secured Notes, the due date was extended to February 28, 2024. The Amended and Restated Secured Notes
were convertible by the Holder if the Company consummated a public offering or private placement of Common Stock or securities convertible
into Common Stock. The conversion price was to be the price being paid by the investors in such offering. The interest rate was increased
to twelve percent (12%) per annum, which was prepaid by the Company in full on the date of amendment through the issuance of 198,439 shares
of the Company&#8217;s Common Stock: 29,419 shares for accrued interest up to the Effective Date and 169,020 shares related to the prepayment
of interest through the extension date of the Amended and Restated Secured Notes using the Common Stock closing market price on the Effective
Date, of $1.03. The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the
&#8220;Security Agreement&#8221;). The Company evaluated the Amended and Restated Secured Notes and conversion feature to determine the
appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480 - Distinguishing Liabilities from Equity,
the Company determined that the Amended and Restated Secured Notes embody an obligation that may require the Company to settle with the
issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a fixed monetary amount
of $1,200,000 known at inception. Accordingly, the Company recorded the Amended and Restated Secured Notes as share settled debt. The
total value of the shares issued was $204,392 which included $174,090 of prepaid interest and $30,302 for accrued interest as of December
30, 2022. On June 26, 2023, <span style="background-color: white">the Holder notified the Company that it wished to elect to exercise
its conversion right triggered by a private placement. Therefore, all outstanding $1,200,000 Amended and Restated Secured Notes were converted
into 2,264,150 shares of Common Stock and warrants to purchase 1,132,075 shares of Common Stock. There were no Amended and Restated Secured
Notes outstanding after the foregoing conversion. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white"> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
Payable </b>&#8212;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bridge
Loans &#8212; </i></b>Between March 26, 2024 and June 4, 2024 the Company issued Paseco ApS promissory notes (the &#8220;Notes&#8221;)
in the aggregate principal and interest accrued amount of $2,098,252. The Notes had an interest rate of 10% per annum and were to mature
between May 1, 2024, and August 1, 2024. The Notes were accounted for under ASC 470-20, and all proceeds received from the issuance was
recognized as a liability on the balance sheet. On June 14, 2024, the Company sold 1,424,862 Units at a price per Unit equal to $1.4726
to settle the bridge loan aggregate amount of $2,098,252. As of June 30, 2024 the Notes balance is zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 5, 2024, the Company entered into an agreement with RS Bio ApS,
a Danish entity controlled by the Company&#8217;s Chairman, Rene Sindlev (&#8220;RS Bio&#8221;) to issue a 5% Original Issue Discount
Secured Promissory Note for the principal amount of $105,263. The Company received $100,000 in gross proceeds after taking into account
the 5% original issue discount. The note bears an interest rate of 12% per annum and matured on March 1, 2024 and was extended to December
31, 2024. The obligations under this note are secured by the Amended and Restated Security Agreement. The Company is required to pay interest
on the maturity date. The note is accounted for under ASC 470-20, and all proceeds received from the issuance will be recognized as a
liability on the balance sheet net of discount. For the year ended June 30, 2024, discount amortization of $5,263 was charged to interest
expense. As of June 30, 2024, the Company accrued $6,316 of interest expense that is included in accrued expenses on the balance sheet.
The note balance, net of discount at June 30, 2024 was $105,263.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2024, the Company entered into an agreement with RS Bio to issue
a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315 (the &#8220;January 2024 Note&#8221;). The Company
received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The January 2024 Note bears
an interest rate of 12% per annum and matured on March 1, 2024 and was extended to December 31, 2024. The Company is required to pay interest
on the maturity date. The January 2024 Note will be accounted for under ASC 470-20, and all proceeds received from the issuance will be
recognized as a liability on the balance sheet net of discount. For the year ended June 30, 2024, discount amortization of $26,315 was
charged to interest expense. As of June 30, 2024, the Company accrued $31,579 of interest expense that is included in accrued expenses
on the balance sheet. The Note balance, net of discount at June 30, 2024 was $526,315. In connection with the entry into the January 2024
Note, the Company and Paseco ApS agreed to amend and restate a Security Agreement to add the Company&#8217;s obligations under the November
2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2023, Renovaro Cube entered into a loan agreement where the holder agreed to loan the Company up to &#163;500,000 (approximately
$624,000 USD). The note had a repayment date occurring the first business day after the first anniversary of the draw down of the loan.
The first draw down of &#163;250,000 occurred on November 27, 2023, and the second draw down of approximately &#163;250,000 occurred
on December 13, 2023. The Company paid interest on the loan at the rate of 10% per annum. Interest was accrued quarterly in arrears on
the last business day of March, June, September, and December and was payable on the repayment date. On June 14, 2024 the Company sold
454,708 Units to the holder and terminated $665,387 in aggregate principal amount and accrued interest and received in cash an aggregate
amount of $100,400 in consideration for the Units which was applied against the loan. For the year ended June 30, 2024, the Company recorded
$36,388 of interest expense related to this loan. The total amount of the loan at June 30, 2024, is zero <span style="background-color: white">(see
Note 7 to the Financial Statements).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into an agreement with RS Bio to
issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000 (the &#8220;November 2023 Note&#8221;). The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the Note. The November 2023 Note bears an interest rate of 12% per annum and was due to mature
on January 1, 2024 (the &#8220;Maturity Date&#8221;). On January 1, 2024, the Company entered into an amendment with RS Bio for the November
2023 Note to extend the maturity date to March 1, 2024 and was extended to December 31, 2024. The Company is required to pay interest
on the maturity date. The November 2023 Note will be accounted for under ASC 470-20, and all proceeds received from the issuance will
be recognized as a liability on the balance sheet net of discount. On February 16, 2024, the Company received notice from the holder to
exercise 471,699 warrants outstanding at $0.53 per share and apply $250,000 of the note balance to the exercise price of the warrants.
For the year ended June 30, 2024, discount amortization of $50,000 was charged to interest expense. As of June 30, 2024, the Company accrued
$69,083 of interest expense that is included in accrued expenses on the balance sheet. The November 2023 Note balance, net of discount
at June 30, 2024 is $750,000 <span style="background-color: white">(see Note 7 to the Financial Statements)</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $5,000,000 (the &#8220;Promissory
Note&#8221;) to the Holder. The principal amount of the Promissory Note was originally payable on November 30, 2021 (the &#8220;Maturity
Date&#8221;). The Promissory Note bore interest at a fixed rate of 6% per annum, computed based on the number of days between the Issuance
Date and the Maturity Date, and the interest was prepaid by the Company in full on the Issuance Date through the issuance of 188,485 shares
of the Company&#8217;s Common Stock based on the closing market price on that date for a total value of $501,370. The Company evaluated
the Promissory Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds
received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount
of $493,192, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest
method. The discount of $493,192 will be accreted over the life of the Promissory Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 11, 2021, the Company
entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory
Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 6% per annum, which was
prepaid by the Company in full on the date of the amendment through the issuance of 74,054 shares of the Company&#8217;s Common Stock
based on the closing market price on that date for a total value of $298,178.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On May 17, 2022, the Company entered
into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 and increased the interest rate from
6% to 12% per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year
of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022
until May 30, 2023 on the date of the amendment through the issuance of 47,115 shares of the Company&#8217;s Common Stock based on the
closing market price on that date for a total value of $299,178. All other accrued interest payable from May 30, 2023 to the Maturity
Date was required to be paid by the Company on May 30, 2023, at the option of the Holder in either (i) cash or (ii) shares of the Company&#8217;s
Common Stock, valued at the closing sale price of the Common Stock on the Nasdaq Capital Market on May 30, 2023. The Holder elected the
interest be paid in cash (the &#8220;Interest Payment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Effective December 30, 2022, the
Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company&#8217;s obligations under
the Promissory Note were secured by a Security Agreement. To secure the Company&#8217;s obligations under each of the Amended and Restated
Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted
a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of the Holder. Upon an Event of Default (as defined
in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession
of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.
(&#8220;Amended and Restated Security Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On June 12, 2023, the Holder notified
the Company that it wanted to apply the Interest Payment due to it towards the Company&#8217;s next private placement. Therefore, on June
26, 2023, in conjunction with the Company&#8217;s private placement, the Company issued (i) 567,588 shares of its Common Stock, par value
$0.0001 per share and (ii) warrants to purchase 283,794 shares of Common Stock at a purchase price of $0.53 per share and applied the
Interest Payment of $300,822 it owed to the Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><br/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 31, 2023, the Company and the Holder agreed to amend the Promissory
Note (the &#8220;Fourth Amendment&#8221;) to provide the Holder with limited conversion rights in connection with the Company&#8217;s
next private placement. Per the terms of the Fourth Amendment, the Holder could elect to convert $2 million of the outstanding principal
balance of the Promissory Note into the Units being offered in a private placement at the price per Unit being paid by the investors in
the private placement (the &#8220;Conversion Right&#8221;). On August 1, 2023, the Holder notified the Company of its election to exercise
the Conversion Right. As a result, $2 million of the outstanding principal balance of the Promissory Note was converted into 280,505 Units
at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible Preferred Stock of the Company and (ii) Warrants
to purchase an aggregate of 1,402,525 shares of Common Stock with an exercise price of $0.65 per share. The Series A Convertible Preferred
Stock acquired by the Holder was initially convertible into 2,805,050 shares of Common Stock. A $3 million principal balance remained
outstanding under the Promissory Note after the foregoing conversion. The Company concluded that in accordance with ASC 470-20-40-4, the
difference between the fair value of the Preferred Shares and warrants and the carrying value of the portion of the Note being converted
should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded in Other Income/Loss in the Statement of Operations.
On November 30, 2023, the Company and the Holder agreed to amend the Promissory Note (the &#8220;Fifth Amendment&#8221;) such that the
Company and the Holder extended the maturity of the original Promissory Note until February 29, 2024. In addition, all interest payable
from November 30, 2023 to the Maturity Date was payable and is currently payable by the Company as of November 30, 2023. On February 16,
2024, the Company received notice from the Holder to exercise 2,953,700 warrants outstanding ranging from $0.53 to $0.65 per share and
apply $1,750,000 of the note balance to the exercise price of the warrants. On February 29, 2024, the Company and the Holder agreed to
amend the Promissory Note (the &#8220;Sixth Amendment&#8221;) to where the Company and the Holder extended the maturity of the original
Promissory Note until May 1, 2024. On May 1, 2024, the Company and the Holder agreed to amend the Promissory Note (the &#8220;Seventh
Amendment&#8221;) to extend the maturity of the original Promissory Note until August 1, 2024. On June 14, 2024 the Holder requested the
Company repay $418,503 of the Promissory Note. The Company applied $100,440 and $318,063 owed to the Company pursuant to certain Subscription
Agreements. As such, payment of the 2020 Note Repayment decreased the principal amount by $418,503. For the year ended June 30, 2024 and
2023, discount amortization of $393,763 and $348,621 was charged to interest expense. The Promissory Note balance, net of discount at
June 30, 2024 is $824,418 (see Note 7 to the Financial
Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Year ended June 30, 2024 compared to the year ended June 30, 2023</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Following is a summary of the Company&#8217;s
cash flows provided by (used in) operating, investing, and financing activities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net Cash Used in Operating Activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(10,971,430</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(11,774,549</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Cash Used in Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,260,179</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29,774</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Cash Provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,517,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,515,056</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Effect of exchange rates on cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">60,141</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,395</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net (Decrease) in Cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,654,013</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,297,662</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024, we had cash and
cash equivalents of $220,467, a decrease of 1,654,013, when compared to the June 30, 2023 balance of $1,874,480. This decrease was primarily
due to cash used in operating activities, partially offset by cash provided by financing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We plan to use our cash and cash
equivalents to fund research and development, specifically to increase investment in the development and validation of our AI driven cancer
diagnostics platform. These activities will require an increase in selling, general and administrative costs, and research and development
costs to support the expected growth. As additional funds are required, we may raise such funds from time to time through public or private
sales of our equity or debt securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">Cash used in operating activities represents
the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow
is derived by adjusting our net loss for non-cash items and changes in operating assets and liabilities. </span>Net cash used in operating
activities for the years ended June 30, 2024 and 2023 was $10,971,430 and $11,774,549, respectively, representing a decrease of $803,119.
The decrease is primarily related to the changes in our operating assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net cash used in investing activities for the years ended June 30, 2024 and
2023 was $1,260,179 and $29,774, respectively, representing an increase of $1,230,405. The increase is primarily due to notes receivable
prior to acquisition of Renovaro Cube of $1,255,600 and purchases of equipment in the current year of $70,430, partially offset by the
cash acquired from the acquisition of Renovaro Cube of $65,851.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net cash provided by financing activities for the years ended June 30, 2024
and 2023 was $10,517,455 and $4,515,056, respectively, representing an increase of $6,002,399. The net cash provided by financing activities
in the current year consists primarily of $3,000,000 of proceeds from private placements, $8,045,663 from the issuance of notes, and $341,865
of proceeds from the exercise of warrants, partially offset by repayments of $870,073 under a finance agreement. <span style="background-color: white">The
prior year net cash from financing activities primarily consisted of $4,011,823 in proceeds from private placements, and $</span>1,625,000
of proceeds from the exercise of warrants, partially offset by repayments of $1,121,767 under a finance agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024, and 2023,
we had no off-balance sheet arrangements. We are not aware of any material transactions which are not disclosed in our consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Significant Accounting Policies and Critical Accounting Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our management&#8217;s discussion
and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make
estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis, we evaluate our
critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe
to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions
and conditions. Our most critical accounting estimates are detailed below, and our significant accounting policies are more fully described
in Note 1 of the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Intangible Assets - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Goodwill </b>- Goodwill is not
amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Impairment of Goodwill and Indefinite
Lived Intangible Assets</b> &#8211; We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. The annual fair value analysis performed on goodwill supported that
goodwill was impaired as of June 30, 2024. The Company recorded an impairment loss of $11,640,000 related to goodwill for the year ended
June 30, 2024 (see Note 5 to the financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For indefinite-lived intangible
assets, such as licenses acquired as an In-Process Research and Development (&#8220;IPR&amp;D&#8221;) asset, on an annual basis we determine
the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value.
For the years ended June 30, 2024 and 2023, the carrying value of the licenses acquired as an IPR&amp;D asset exceeded its fair value,
due to changes in the projected economic benefits to be realized from these assets. Therefore, the Company recorded impairment losses
of $42,611,000 and $18,960,000 during the years ended June 30, 2024 and 2023, respectively (see Note 5 to the financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The carrying values of IPR&amp;D
and goodwill at June 30, 2024, were&#160;zero and $159,330,161, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Fair Value of Financial Instruments
</b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of June 30, 2024. <span style="background-color: white">Level
3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition
of Renovaro Cube </span>(see Note 3.) There were no Level 1, 2, or 3 assets, nor any Level 1, 2, or 3 liabilities measured at fair value
on a recurring basis as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Stock-Based Compensation - </b>The
Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers, directors,
and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation &#8211;
Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2024 and 2023 were $4,673,129 and $3,535,051, respectively (see Note 9 to the
Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the
fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period (see Note 9 to the Financial Statements.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recently Enacted Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For a description of recent accounting
standards, including the expected dates of adoption and estimated effects, if any, on our consolidated financial statements, see &#8220;Note
1: Recent Accounting Pronouncements&#8221; in the financial statements included elsewhere in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_013"></span>Item 7A. Quantitative and Qualitative Disclosures about Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">The Company is a smaller reporting company and is not
required to provide this information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_014"></span>Item 8. Financial Statements and Supplementary
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Index to Consolidated Financial Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page
    </b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID:<span id="xdx_90F_edei--AuditorFirmId_c20230701__20240630_zX7YMLtIkpK7"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000051" name="dei:AuditorFirmId">3627</ix:nonNumeric></span>)</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets at June 30, 2024 and 2023</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Comprehensive Loss for the Years Ended June 30, 2024 and 2023</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statement of Stockholders&#8217; Equity for the Years Ended June 30, 2024 and 2023</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended June 30, 2024 and 2023</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-10</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 76; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="a_027"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">To the Board of Directors and Shareholders of Renovaro,
Inc.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="text-decoration: underline">Opinion on the
Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We have audited the accompanying consolidated balance
sheets of Renovaro, Inc. (&#8220;the Company&#8221;) as of June 30, 2024 and 2023, the related consolidated statements of operations,
comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended June 30, 2024 and the
related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements referred
to above present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results
of its operations and its cash flows for each of the years in the two-year period ended June 30, 2024, in conformity with accounting principles
generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="text-decoration: underline">Explanatory
Paragraph Regarding Going Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred
substantial recurring losses from operations, has used cash in the Company&#8217;s continuing operations, and is dependent on additional
financing to fund operations which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard
to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="text-decoration: underline">Basis for Opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="text-decoration: underline">Critical
Audit Matters</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The critical audit matters communicated below are
matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the
audit committee and that: (1) related to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the
financial statements, taken as a whole, and we are not, by communicating the critical matters below, providing separate opinions on the
critical audit matters or on the accounts or disclosures to which they relate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Goodwill Impairment Assessment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of June 30, 2024, the carrying value of goodwill
was $159,330,161 which related in its entirety to goodwill acquired in the GediCube Intl Ltd (&#8220;GediCube&#8221;) acquisition on February
13, 2024. In addition, during the year ended June 30, 2024, the Company fully impaired previously recorded goodwill totaling $11,640,000
related to the Company&#8217;s legacy RenB reporting unit. As described in notes 1 and 5 to the consolidated financial statements, the
Company tests goodwill for impairment annually at the reporting unit level, or more frequently if events or circumstances indicate it
is more likely than not that the fair value of a reporting unit is less than it&#8217;s carrying amount. The Company&#8217;s annual assessment
date is June 30, 2024. In relation to goodwill related to the GediCube acquisition, the Company performed a qualitative assessment on
such date and concluded that it was not more likely than not that the reporting unit&#8217;s fair value was less than its carrying amount.
To assess the goodwill of the RenB reporting unit for impairment, management estimated the fair value of goodwill using a discounted
cash flow model. The determination of the fair value requires management to make significant estimates and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>How the Critical Audit Matter was Addressed in
the Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We identified the evaluation of the impairment analysis
for goodwill as a critical audit matter because of the significant estimates and assumptions management makes in performing both the qualitative
assessment on goodwill for the GediCube related goodwill and determining the fair value of the goodwill for the RenB reporting unit. These
required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness
of such estimates and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Our audit procedures related to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
                                            relation to the GediCube goodwill, we evaluated the Company&#8217;s qualitative assessment
                                            by considering macroeconomic conditions, industry and market conditions, and other relevant
                                            entity specific factors.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
                                            relation to RenB goodwill, (1) we tested and evaluated the methods, data and significant
                                            assumptions used in developing the fair value of goodwill; and (2) we evaluated the reasonableness
                                            and consistency of the selected valuation methodology and assumptions utilized by the Company
                                            including the Company&#8217;s intent and ability to carry out a particular course of action.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">In addition, professionals with specialized skill and knowledge were utilized
by the Firm to assist in the performance of these procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On February 13, 2024, the Company completed a business
acquisition acquiring GediCube Intl Ltd. for consideration with a fair value of $156,599,131. The Company accounted for this acquisition
as a business combination and accordingly, the purchase price was allocated to the assets acquired and liabilities assumed at fair value
as of the transaction date. The consideration consisted of common stock with a fair value of $136,001,631 and contingent consideration
of approximately $20,557,500. The contingent consideration represents contingent shares to be issued to the seller upon the exercise of
conversion of common stock equivalents in the Company that existed at the acquisition date. The Company utilized a third-party valuation
specialist to assist in determining the fair value of contingent consideration issued. The fair value of the contingent consideration
liability was estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. We identified the estimation
of the fair value of the contingent consideration granted to be a critical audit matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We identified the estimation of the fair value of
the contingent consideration granted to be a critical audit matter because of the significant estimates and assumptions management made
to determine the fair value of certain of this element. This required a high degree of auditor judgment and an increased extent of effort
when performing audit procedures to evaluate the reasonableness of valuation methodologies applied and the assumptions used, such as stock
price, exercise price and volatility assumptions. In addition, the audit effort involved the use of professionals with specialized skill
and knowledge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>How the Critical Audit Matter Was Addressed in
the Audit </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Our audit procedures related to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Testing
                                            management&#8217;s process for developing the fair value measurements for contingent consideration.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Evaluating
                                            significant assumptions used by management in this fair value estimates including stock price,
                                            exercise price and volatility assumptions related to outstanding common stock equivalents.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Testing
                                            the accuracy and completeness of the common stock equivalents utilized in determining the
                                            fair value of the contingent consideration.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Obtaining
                                            the valuation report prepared by valuation specialist engaged by management to assist in
                                            the determination of fair values assigned to acquired contingent consideration and evaluating
                                            the qualifications of the specialist.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In addition, the audit effort involved the use of
professionals with specialized skills and knowledge to assist in evaluating the valuation methodologies deployed and the reasonableness
of the significant assumptions used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ <span id="xdx_90C_edei--AuditorName_c20230701__20240630_zijdMnGseYmk"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000052" name="dei:AuditorName">Sadler, Gibb &amp; Associates, LLC</ix:nonNumeric></span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have served as the Company&#8217;s auditor since 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_909_edei--AuditorLocation_c20230701__20240630_z80yGm1eBrO1"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000053" name="dei:AuditorLocation">Draper, UT</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">October 10, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_028"></span>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_zwEUWi7EDHl6" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20240630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_z1xUkwg32j1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zeO1tETS97Oa" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzUeu_zkNMqCKmHJe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-indent: -10pt">Cash</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,467</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,874,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InsuranceSettlementsReceivableCurrent_i02I_d0_maCzUeu_zlAgW1idPe24" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Insurance receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="AsOf2024-06-30" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,247</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="AsOf2023-06-30" id="Fact000065" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maCzUeu_zkDUj351er2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Prepaids and other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-06-30" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">668,929</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-06-30" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">690,925</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtCzUeu_maCzXZc_zg0nK7z9Ehgg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,997,643</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-06-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,565,405</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzXZc_zsHQ5jwTOQG9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Property and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,121</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-06-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">508,989</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsNoncurrentAbstract_i01B_zGTiEGDHPC62" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">OTHER ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_maCzmfR_z0k0oYdwnwga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Definite life intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-06-30" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,676</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_i02I_d0_maCzmfR_z4Nlw3Qh1Kbi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Indefinite life intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2024-06-30" id="Fact000082" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2023-06-30" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Goodwill_i02I_maCzmfR_zDhC2JZCbdT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-06-30" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,330,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-06-30" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepositsAssetsNoncurrent_i02I_maCzmfR_zC3HaQZBuOBb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Deposits and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-06-30" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-06-30" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,741</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzmfR_zu3fNbvFUmW5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Operating lease right-of-use assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,633</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">913,985</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCzmfR_maCzXZc_zc0mS3g4lJyg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Other Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-06-30" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,649,686</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-06-30" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,226,402</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iTI_mtCzXZc_zAD2wwIe2Emh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,129,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,300,796</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zwLKyQQ1xaSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zWFg0IDQBuae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableTradeCurrent_i02I_maCzN78_zvGprwAIzZgh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Accounts payable &#8211; trade</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-06-30" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,448,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2023-06-30" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,296,823</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzN78_zseF8dQGyoJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,311,324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-06-30" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">723,173</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzN78_zicCQPSLmEP8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-06-30" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ContingentConsiderationLiabilityCurrent_i02I_pp0p0_d0_maCzN78_z7MoxjWqVxb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000115" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,310,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationLiabilityCurrent" contextRef="AsOf2023-06-30" id="Fact000116" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_i02I_d0_maCzN78_z9lZqjTvITBh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-06-30" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-06-30" id="Fact000119" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzN78_zg2D5yZPUzgf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Current portion of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--NotesPayableRelatedPartiesNetCurrent_i02I_maCzN78_zt2TqwsKC6Z2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Notes payable &#8211; related parties, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:NotesPayableRelatedPartiesNetCurrent" contextRef="AsOf2024-06-30" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,205,996</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:NotesPayableRelatedPartiesNetCurrent" contextRef="AsOf2023-06-30" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,624,947</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_mtCzN78_maCzBiT_zfRgRzpYdR14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,309,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-06-30" id="Fact000128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,023,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zfDqJejWspgf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzm6m_zyqQrtRRZKW5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 30pt; text-align: left; text-indent: -10pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact000133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">842,389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">775,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_i02TI_pp0p0_mtCzm6m_maCzBiT_zuiBup3S1yth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Non-Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-06-30" id="Fact000136" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">842,389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-06-30" id="Fact000137" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">775,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i02TI_mtCzBiT_maLASEzxaF_zXGDM8IJXJu5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,152,306</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,798,685</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_pp0p0_d0_maCz7Aa_zUH6BDbVpdLb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630_zawhk9ZxgrN7" title="Preferred stock, par value"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230630_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630_znGOB8RJEqRc" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20230630_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_do_c20240630_zBK87NUcjRD4" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630_zBKEsHHcyu47" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_do_c20230630_zCXY5ULfTaHa" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230630_zFFUuLPsl0va" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000156" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000158" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-06-30" id="Fact000160" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30" id="Fact000162" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30" id="Fact000145" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30" id="Fact000146" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maCz7Aa_z4VWwSoCy8ye" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zoCSosP9MS4g" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230630_z9Tlc4YFiyN3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zsK9K2Dvz6Xi" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20230630_zBnnof6HinX8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span> </span>shares
    authorized, <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20240630_zXXUwraFaKi2" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zluWgvBvyDOg" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,027,245</ix:nonFraction></ix:nonFraction></span> </span>shares
    issued and outstanding at June 30, 2024; <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20230630_zeclS2cELK5d" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20230630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,698,144</ix:nonFraction></ix:nonFraction></span></span> shares
    issued and outstanding at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,371</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maCz7Aa_zMRkx1tzgl7c" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">456,811,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-06-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,554,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCz7Aa_z91cXnG3fg95" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">324,679,425</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,029,253</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCz7Aa_zsr31i3FlqYj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accumulated other comprehensive (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-06-30" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,846</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-06-30" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,882</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtCz7Aa_maLASEzxaF_zj5VVUdrnlhf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000192" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">131,977,144</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000193" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,502,111</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzxaF_z59GlXNcyqA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000195" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,129,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,300,796</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_029"></span>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_zpwMqQLrGFy2" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230701_20240630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20220701_20230630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zh7AUWmLdu4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzuO2_zJLtRVi3lHL2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,557,608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012023-06-30" id="Fact000202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,318,198</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzuO2_z96UnDuA7Ss7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,708,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012023-06-30" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,165,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i01_pp0p0_maCzuO2_zdwc0uGpjpj2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-07-01to2024-06-30" id="Fact000207" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2022-07-012023-06-30" id="Fact000208" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,960,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GoodwillImpairmentLoss_i01_pp0p0_d0_maCzuO2_zKHQ84Wklt02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000210" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-07-012023-06-30" id="Fact000211" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzuO2_zMyLhSY19RTk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-01to2024-06-30" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,859</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-07-012023-06-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,496</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzuO2_msCzHGi_zomR0gBWYlv6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-01to2024-06-30" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,639,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012023-06-30" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,556,891</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtCzHGi_maCz4nz_zctadrCTxwYd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,639,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012023-06-30" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,556,891</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zR5Whziefyo" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ChangeInFairValueOfContingentConsideration_i01_pp0p0_d0_maCzGcn_z73fz46YPThg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in fair value of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2023-07-01to2024-06-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,727,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2022-07-012023-06-30" id="Fact000226" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_d0_maCzGcn_zeNpRuVpSu1i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-07-01to2024-06-30" id="Fact000228" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,303,578</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-07-012023-06-30" id="Fact000229" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossOnExtinguishmentOfContingentConsiderationLiability_i01_d0_maCzGcn_zJaA8oxvxkF5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loss on extinguishment of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:LossOnExtinguishmentOfContingentConsiderationLiability" contextRef="From2023-07-01to2024-06-30" id="Fact000231" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RENB:LossOnExtinguishmentOfContingentConsiderationLiability" contextRef="From2022-07-012023-06-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">419,182</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--InterestExpenseNonoperating_i01N_di_msCzGcn_z207cWfHuKti" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-07-01to2024-06-30" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,011,322</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2022-07-012023-06-30" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,344</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--ForeignCurrencyTransactionGainLossRealized_i01_d0_maCzGcn_zsxuPhPf6Jge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Gain (loss) on foreign currency transactions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2023-07-01to2024-06-30" id="Fact000237" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2022-07-012023-06-30" id="Fact000238" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,019</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--InterestIncomeAndOtherIncomeExpense_i01_maCzGcn_z2mvUOl2sj1k" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest income and other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:InterestIncomeAndOtherIncomeExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000240" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,423,449</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:InterestIncomeAndOtherIncomeExpense" contextRef="From2022-07-012023-06-30" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">126,620</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_iT_mtCzGcn_maCz4nz_zPkKw0ry3mGg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Other Income (Expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">989,124</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-07-012023-06-30" id="Fact000244" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,127,165</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtCz4nz_zZ9OMPngKYc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,650,172</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30" id="Fact000247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,684,056</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">BASIC AND DILUTED NET LOSS PER COMMON SHARE</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20240630_pdd" title="BASIC NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_pdd" title="DILUTED NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-01to2024-06-30" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-01to2024-06-30" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.84</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20220701__20230630_pdd" title="BASIC NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20220701__20230630_pdd" title="DILUTED NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012023-06-30" id="Fact000253" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012023-06-30" id="Fact000255" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.71</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_pdd" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_pdd" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-01to2024-06-30" id="Fact000257" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-01to2024-06-30" id="Fact000259" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,248,090</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220701__20230630_pdd" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220701__20230630_pdd" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012023-06-30" id="Fact000261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012023-06-30" id="Fact000263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,265,362</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_030"></span>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_zElty7dBjQml" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_49C_20230701__20240630_zhlxmPdyhHc" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_49B_20220701__20230630_zpA79uk4HAXk" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--ProfitLoss_maCzFTz_zborHXERn8N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000265" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,650,172</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012023-06-30" id="Fact000266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,684,056</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_zE4lirW1cHc2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Comprehensive Income (Loss)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_iN_di_msCzFTz_z6wHEiSQngvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency translation, net of taxes</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2023-07-01to2024-06-30" id="Fact000271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,964</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2022-07-012023-06-30" id="Fact000272" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">554</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCzFTz_zIEYE65BvNAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive Loss</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-01to2024-06-30" id="Fact000274" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,791,136</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-07-012023-06-30" id="Fact000275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,683,502</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_031"></span>CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended June 30, 2024 and June 30, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zUgAgqnT6ro7" summary="xdx: Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="3" style="font-size: 12pt; text-align: center">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="3" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zHfTMn8TzDbf" style="font-size: 12pt; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zy1ESY3FS4K4" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zb6pP6vVQnOl" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zTpWa5tVUV13" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zSb81IqSK6F6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4B3_zzYoUn98JfG9" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>#
    of Preferred Shares</b></span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Preferred
    Shares Amount</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>#
    of Common Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Common
    Stock Amount</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Additional
    Paid-In Capital</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Accumulated
    Deficit</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Accumulated
    Other Comprehensive Income (Loss)</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Total</b></span></td></tr>
  <tr id="xdx_438_c20220701__20230630_eus-gaap--StockholdersEquity_iS_zMSAFOQYnG0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance
    June 30, 2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSmjw0xm0nU4" title="Beginning balance, shares" style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxYlG2FjXaO5" title="Beginning balance, shares" style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" id="Fact000286" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,007,082</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,302</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,989,179</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">204,345,197</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,436</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" id="Fact000282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,618,848</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedPursuantToWarrantsExercisedValue_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock
    issued pursuant to warrants exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98E_ecustom--StockIssuedPursuantToWarrantsExercisedShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEBswokjJGNg" title="Stock issued pursuant to warrants exercised, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedPursuantToWarrantsExercisedShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedPursuantToWarrantsExercisedValue" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedPursuantToWarrantsExercisedValue" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,624,875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedPursuantToWarrantsExercisedValue" contextRef="From2022-07-012023-06-30" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--EarnoutSharesIssuedValue_zDONAIC1VeI8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Earn-out
    shares issued</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98F_ecustom--EarnoutSharesIssuedShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMK6BsXmsn87" title="Earn-out shares issued, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:EarnoutSharesIssuedShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:EarnoutSharesIssuedValue" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:EarnoutSharesIssuedValue" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,762,375</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:EarnoutSharesIssuedValue" contextRef="From2022-07-012023-06-30" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,762,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--SharesIssuedForInterestOnNotesPayableExtensionValue_zBzLeU961DQl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares
    issued for interest on $1.2 million notes payable extension</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_989_ecustom--SharesIssuedForInterestOnNotesPayableExtensionShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc7sqYPNlPm8" title="Shares issued for interest on $1.2 million notes payable extension, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuedForInterestOnNotesPayableExtensionShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">198,439</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuedForInterestOnNotesPayableExtensionValue" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuedForInterestOnNotesPayableExtensionValue" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,372</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuedForInterestOnNotesPayableExtensionValue" contextRef="From2022-07-012023-06-30" id="Fact000311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,392</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue_z3d723PVJ9uc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of common stock and warrants under private placement offering</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_983_ecustom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxzEe4wlOBok" title="Issuance of common stock and warrants under private placement offering, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,832,452</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,011,339</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" contextRef="From2022-07-012023-06-30" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,011,822</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--RestrictedSharesIssuedForServicesRenderedValue_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Restricted
    shares issued for services rendered</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_987_ecustom--RestrictedSharesIssuedForServicesRenderedShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkZuxO8M6t4f" title="Restricted shares issued for services rendered, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,980</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2022-07-012023-06-30" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ziVH4WIilXT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Conversion
    of convertible promissory notes</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZTcri3Rm5aa" title="Conversion of convertible promissory notes, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,264,150</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,774</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-07-012023-06-30" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zthJLdiKE24e" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of restricted commitment shares</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zw3BzgmjkuY4" title="Issuance of restricted commitment shares, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">696,021</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,535,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,535,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,684,056</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30" id="Fact000363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,684,056</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Foreign
    currency translation adjustment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012023-06-30" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_43C_c20230701__20240630_eus-gaap--StockholdersEquity_iS_znV8UUoo85Jk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance
    June 30, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSYZycy6z17g" title="Beginning balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI313kJFDqOl" title="Beginning balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000381" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,698,144</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,371</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,554,875</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,029,253</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,882</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,502,111</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_iP3us-gaap--SharesOutstanding_zpQrWkiMEyHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of preferred stock and warrants in private placement</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_982_ecustom--IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLRG8hGjJ4X4" title="Issuance of preferred stock and warrants in private placement, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,999,972</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-01to2024-06-30" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_iP3custom--IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_zW4vshSZMkdk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of preferred stock and warrants for conversion of Note Payable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_983_ecustom--IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLS5Ul62QGvj" title="Issuance of preferred stock and warrants for conversion of Note Payable, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;<ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,999,973</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-01to2024-06-30" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,001</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--RestrictedSharesIssuedForServicesRenderedValue_zgv7wdpdMbOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Restricted
    shares issued for services rendered</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_986_ecustom--RestrictedSharesIssuedForServicesRenderedShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwbKVShCclZk" title="Restricted shares issued for services rendered, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,083,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,663,882</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-01to2024-06-30" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,664,190</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueExerciseOfWarrants_iP3custom--RestrictedSharesIssuedForServicesRenderedShares_z3GbWgaTg8Ak" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Exercise
    of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_iP3custom--StockIssuedDuringPeriodValueExerciseOfWarrants_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPd8lXWphlga" title="Exercise of warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedDuringPeriodSharesExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,344</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,341,470</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-01to2024-06-30" id="Fact000415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,341,866</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_iP3custom--StockIssuedDuringPeriodSharesExerciseOfWarrants_z42rw6hQsvq8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of common stock and warrants under private placement offering in settlement of debt</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98A_ecustom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_iP3custom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdac3XnbANZ2" title="Issuance of common stock and warrants under private placement offering in settlement of debt, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000426" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,660,042</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,575,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-01to2024-06-30" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,576,106</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--SharesIssuableForSettlementOfContingentConsiderationValue_iP3custom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_zR1xJdq4cr12" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares
    issuable for settlement of contingent consideration</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_984_ecustom--SharesIssuableForSettlementOfContingentConsideration_iP3custom--SharesIssuableForSettlementOfContingentConsiderationValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd2W0WDBCqJ2" title="Shares issuable for settlement of contingent consideration, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsideration" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000435" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,189,672</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,519,808</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-01to2024-06-30" id="Fact000433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,520,027</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfCommonStockPursuantToAcquisitionOfGediCube_iP3custom--SharesIssuableForSettlementOfContingentConsideration_zMqeMVNdtwB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of common stock pursuant to acquisition of GEDi Cube</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_983_ecustom--IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares_iP3custom--IssuanceOfCommonStockPursuantToAcquisitionOfGediCube_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zr0yKApWQ57l" title="Issuance of common stock pursuant to acquisition of GEDi Cube, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,834,183</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,083</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,994,548</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-01to2024-06-30" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_iP3custom--IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares_zf99tXMHwAM9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Preferred
    stock converted to common stock pursuant to acquisition of GEDi Cube</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_989_ecustom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_iP3custom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYI6YlMqXPAf" title="Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;(<ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000453" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">561,010</ix:nonFraction></span></td><td style="text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;(<ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000446" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56</ix:nonFraction></span></td><td style="text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_989_ecustom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4H7WUEG0QAl" title="Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,610,100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">561</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueOther_iP3custom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_zPPJCNTGTk16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of options for services rendered</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-01to2024-06-30" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z93ff6Qi83aj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-01to2024-06-30" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zSoXan6q0Ida" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,650,172</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,650,172</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_zQEfPCFufLxg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Foreign
    currency translation adjustment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span>&#8212;</td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000482" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">140,964</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-01to2024-06-30" id="Fact000483" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">140,964</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_43E_c20230701__20240630_eus-gaap--StockholdersEquity_iE_zpLgUDowdOEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance
    June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWmVcU3w4WH" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8212;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>$</b>&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFrKNoLJVpt4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,027,245</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,504</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">456,811,911</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000488" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">324,679,425</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000489" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,846</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,977,144</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;<b>The accompanying notes
are an integral part of these consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_032"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zrtToS6bKtv3" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_496_20230701__20240630_zPZjGfAKrdYd" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_490_20220701__20230630_zpiklbKuzno1" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_z69C5qaGOnnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_maCzjUq_zOmQ4wofTGW1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000499" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,650,172</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30" id="Fact000500" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,684,056</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zJigZKHIMrwb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--DepreciationAndAmortization_i02_maCzjUq_zDsa0EnisCwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-07-01to2024-06-30" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,859</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-07-012023-06-30" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,496</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ChangeInFairValueOfContingentConsideration_i02N_di0_msCzjUq_zsWzYIaGYsxf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in fair value of contingent consideration</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2023-07-01to2024-06-30" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,727,473</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2022-07-012023-06-30" id="Fact000509" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--LossOnExtinguishmentOfContingentConsiderationLiabilities_i02N_di0_msCzjUq_zSBU6UE2fPGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loss on extinguishment of contingent consideration liability</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LossOnExtinguishmentOfContingentConsiderationLiabilities" contextRef="From2023-07-01to2024-06-30" id="Fact000511" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LossOnExtinguishmentOfContingentConsiderationLiabilities" contextRef="From2022-07-012023-06-30" id="Fact000512" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">419,182</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--LossOnExtinguishmentOfDebt_i02N_di_msCzjUq_zn1CsdWWBgS6" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LossOnExtinguishmentOfDebt" contextRef="From2023-07-01to2024-06-30" id="Fact000514" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,303,578</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--NoncashStockbasedCompensationExpense_i02_maCzjUq_z6C5k4Ta1Tc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash stock-based compensation expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NoncashStockbasedCompensationExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NoncashStockbasedCompensationExpense" contextRef="From2022-07-012023-06-30" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,535,051</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--NoncashRestrictedSharesIssuedForServicesRendered_i02_maCzjUq_zFBv8MFLbmI" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash restricted shares issued for services rendered</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NoncashRestrictedSharesIssuedForServicesRendered" contextRef="From2023-07-01to2024-06-30" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,664,190</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NoncashRestrictedSharesIssuedForServicesRendered" contextRef="From2022-07-012023-06-30" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i02_maCzjUq_zIxaxZBoNma5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-07-01to2024-06-30" id="Fact000523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,611,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2022-07-012023-06-30" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,960,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--GoodwillImpairmentLoss_i02_d0_maCzjUq_zU7NffRiCLkk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Goodwill impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-07-012023-06-30" id="Fact000527" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--AmortizationOfDiscountOnNotePayable_i02_maCzjUq_zBJVYCrlKY53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Amortization of discount on note payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:AmortizationOfDiscountOnNotePayable" contextRef="From2023-07-01to2024-06-30" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,605</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:AmortizationOfDiscountOnNotePayable" contextRef="From2022-07-012023-06-30" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,621</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zUDoHzuulbOc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in assets and liabilities:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i03N_di_msCzjUq_zEAMuChGFLFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Insurance receivable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2023-07-01to2024-06-30" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,247</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2022-07-012023-06-30" id="Fact000536" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzjUq_zqkmagskOjX" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses/deposits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000538" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,082,267</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-07-012023-06-30" id="Fact000539" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,070,249</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzjUq_zw5jSoVRsqPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-07-01to2024-06-30" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,057,282</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-07-012023-06-30" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,894,955</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_d0_maCzjUq_zYqdGGVu8GY6" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Other current liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-07-01to2024-06-30" id="Fact000544" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2022-07-012023-06-30" id="Fact000545" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,060</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCzjUq_zA4PF9wXzL82" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Operating leases, net</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-07-01to2024-06-30" id="Fact000547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,284</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-07-012023-06-30" id="Fact000548" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,224</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i03_maCzjUq_zpr6oRbudqj3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued expenses</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2023-07-01to2024-06-30" id="Fact000550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,769,268</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2022-07-012023-06-30" id="Fact000551" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">578,809</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzjUq_maCzFSa_zbyQ7F9viW65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH USED IN OPERATING ACTIVITIES</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-01to2024-06-30" id="Fact000553" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,971,430</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-07-012023-06-30" id="Fact000554" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,774,549</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_iB_zYrmVT4tOE1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--PaymentsToAcquireNotesReceivable_i01N_di0_msCzdZK_zymADWZToq3j" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-style: normal; font-weight: normal; text-align: left; text-indent: -10pt">Notes receivable prior to acquisition</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireNotesReceivable" contextRef="From2023-07-01to2024-06-30" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,255,600</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireNotesReceivable" contextRef="From2022-07-012023-06-30" id="Fact000560" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--CashAcquiredFromAcquisition_i01_d0_maCzdZK_zKSzoDZ4C7m" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash received from acquisition, net</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2023-07-01to2024-06-30" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,851</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2022-07-012023-06-30" id="Fact000563" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzdZK_zy7MsdIRdFvk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Purchase of property and equipment</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-07-01to2024-06-30" id="Fact000565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,430</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,774</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtCzdZK_maCzFSa_zQbHxTdkcxhf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH USED IN INVESTING ACTIVITIES</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-07-01to2024-06-30" id="Fact000568" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,260,179</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-07-012023-06-30" id="Fact000569" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,774</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zVwc71Zh4lQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--RepaymentsOfFinanceAgreement_i01N_di_msCz8o0_zDR3QoIfiw6e" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Repayments of finance agreement</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:RepaymentsOfFinanceAgreement" contextRef="From2023-07-01to2024-06-30" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">870,073</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:RepaymentsOfFinanceAgreement" contextRef="From2022-07-012023-06-30" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,121,767</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_i01_maCz8o0_zlv9LotPjBh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Proceeds from exercise of warrants</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-07-01to2024-06-30" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,865</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-07-012023-06-30" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_pp0p0_maCz8o0_zRIpUfDu9Hd1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from private placements</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-07-01to2024-06-30" id="Fact000580" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-07-012023-06-30" id="Fact000581" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,011,823</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfDebt_i01_d0_maCz8o0_z3hnCbV0iJJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from issuance of promissory notes</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-07-01to2024-06-30" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,770,512</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-07-012023-06-30" id="Fact000584" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--ProceedsFromConvertibleDebt_i01_d0_maCz8o0_zH4RC8yhmZy9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from convertible notes payable</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-07-01to2024-06-30" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,151</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-07-012023-06-30" id="Fact000587" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCz8o0_maCzFSa_ztfUH0ALRDm8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-07-01to2024-06-30" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,517,455</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-07-012023-06-30" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,515,056</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCzFSa_zsSew5vv73A2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Effect of exchange rates on cash</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2023-07-01to2024-06-30" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,141</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2022-07-012023-06-30" id="Fact000593" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,395</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzFSa_zRJc4MUD5LM8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET INCREASE (DECREASE) IN CASH</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-07-01to2024-06-30" id="Fact000595" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,654,013</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-07-012023-06-30" id="Fact000596" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,297,662</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zAXGjbRX6pZ4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">CASH, BEGINNING OF PERIOD</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,874,480</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" id="Fact000599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,172,142</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zoGsejtsPrq5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">CASH, END OF PERIOD</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,467</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" id="Fact000602" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,874,480</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zAjWcxUSwksb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--CashPaidDuringYearForAbstract_i01B_zoSIkm1z7A0h" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash Paid during the year for:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--InterestPaidNet_i02_zA6iEcLHKfC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Interest</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-07-01to2024-06-30" id="Fact000610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,128</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-07-012023-06-30" id="Fact000611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,334</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxesPaidNet_i02_d0_zDMCUinxMBRc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income Taxes</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-07-01to2024-06-30" id="Fact000613" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-07-012023-06-30" id="Fact000614" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreement_i01_d0_zazEXOiRTOXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent Shares issued pursuant to Acquisition Agreement</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2023-07-01to2024-06-30" id="Fact000619" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2022-07-012023-06-30" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,762,500</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--SharesInLieuOfInterestOnMillionNotesPayableExtension_i01_d0_zldDBBn4I4Cf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares in lieu of interest on $1.2 million notes payable extension</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:SharesInLieuOfInterestOnMillionNotesPayableExtension" contextRef="From2023-07-01to2024-06-30" id="Fact000622" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:SharesInLieuOfInterestOnMillionNotesPayableExtension" contextRef="From2022-07-012023-06-30" id="Fact000623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,392</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_i01_z5Svt9MDbhs4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Finance agreement entered into in exchange for prepaid assets</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,834</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextRef="From2022-07-012023-06-30" id="Fact000626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,139,875</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--ConversionOfNotePayableForIssuanceOfPreferredStock_i01_d0_zzsCvYt1xA17" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Conversion of note payable for issuance of preferred stock</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ConversionOfNotePayableForIssuanceOfPreferredStock" contextRef="From2023-07-01to2024-06-30" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,001</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ConversionOfNotePayableForIssuanceOfPreferredStock" contextRef="From2022-07-012023-06-30" id="Fact000629" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--NotePayableSettledThroughNoncashExerciseOfWarrants_i01_d0_zyHf3IGm43Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Note payable settled through non-cash exercise of warrants</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NotePayableSettledThroughNoncashExerciseOfWarrants" contextRef="From2023-07-01to2024-06-30" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NotePayableSettledThroughNoncashExerciseOfWarrants" contextRef="From2022-07-012023-06-30" id="Fact000632" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--DebtDiscountRelatedToConvertiblePromissoryNotes_i01_d0_zykczQRI3jn1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Debt discount related to notes payable</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DebtDiscountRelatedToConvertiblePromissoryNotes" contextRef="From2023-07-01to2024-06-30" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,342</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DebtDiscountRelatedToConvertiblePromissoryNotes" contextRef="From2022-07-012023-06-30" id="Fact000635" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--CommonSharesIssuedUponAcquisition_i01_d0_zmhB7TdXmLG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common shares issued upon acquisition</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:CommonSharesIssuedUponAcquisition" contextRef="From2023-07-01to2024-06-30" id="Fact000637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:CommonSharesIssuedUponAcquisition" contextRef="From2022-07-012023-06-30" id="Fact000638" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--ContingentConsiderationIssuedUponAcquisition_i01_d0_zvffyuW2pBQ3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration issued upon acquisition</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationIssuedUponAcquisition" contextRef="From2023-07-01to2024-06-30" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationIssuedUponAcquisition" contextRef="From2022-07-012023-06-30" id="Fact000641" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--CommonSharesIssuedUponSettlementOfDebt_i01_d0_zVwbVTtw5sb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common shares issued upon settlement of debt</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:CommonSharesIssuedUponSettlementOfDebt" contextRef="From2023-07-01to2024-06-30" id="Fact000643" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,582,912</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">&#160;<ix:nonFraction name="RENB:CommonSharesIssuedUponSettlementOfDebt" contextRef="From2022-07-012023-06-30" id="Fact000644" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--EarnOutSharesIssuedInSettlementOfContingentLiability_i01_d0_zX7ALNzqR8qf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Earn out shares issued in settlement of contingent liability</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:EarnOutSharesIssuedInSettlementOfContingentLiability" contextRef="From2023-07-01to2024-06-30" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,520,027</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">&#160;<ix:nonFraction name="RENB:EarnOutSharesIssuedInSettlementOfContingentLiability" contextRef="From2022-07-012023-06-30" id="Fact000647" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--OptionsIssuedInSettlementOfDebt_i01_d0_zw3lua5cQRac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Options issued in settlement of debt</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:OptionsIssuedInSettlementOfDebt" contextRef="From2023-07-01to2024-06-30" id="Fact000649" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489,000</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">&#160;<ix:nonFraction name="RENB:OptionsIssuedInSettlementOfDebt" contextRef="From2022-07-012023-06-30" id="Fact000650" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--SettlementOfNotesPayable_i01_d0_z6YZGPr4stVj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Settlement of notes payable</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:SettlementOfNotesPayable" contextRef="From2023-07-01to2024-06-30" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,503</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">&#160;<ix:nonFraction name="RENB:SettlementOfNotesPayable" contextRef="From2022-07-012023-06-30" id="Fact000653" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_033"></span>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000655" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zrXbEPrplcx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_821_zhGp3RGLfcJf">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000657" name="RENB:BusinessPolicyTextBlock"><p id="xdx_840_ecustom--BusinessPolicyTextBlock_zCtkBTkm4538" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_865_z82mb7XDjm1a"><b>Business
</b></span><b>&#8211; </b>On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;). In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven
healthcare technology company that, if it can generate sufficient funding, will also continue to engage in the research and development
of pharmaceutical and biological products for the treatment of cancer and HIV with the intent to manufacture said products. On February
13, 2024, Renovaro Inc. acquired GEDi Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly owned subsidiary
pursuant to a stock purchase agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000659" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTPoI30TunA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_860_zqUWD5Hf2rW1">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000661" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zsCwLpRfduMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_zEYwhzNWWX1c">Principles of Consolidation</span>
&#8211; </b>For the years ended June 30, 2024 and 2023, the consolidated financial statements include the accounts and operations of Renovaro,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000663" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"><p id="xdx_840_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zmOlpHsTOpk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86A_zu4Y3q9DW8Se">Subsidiaries</span> &#8211; </b>Renovaro
Biosciences Inc. (&#8220;Renovaro Biosciences&#8221;), formerly Renovaro Biopharma Inc., was incorporated on May 19, 2017 in Delaware
and is a 100% owned subsidiary of Renovaro. Renovaro Biosciences owns a perpetual, fully paid-up, royalty-free, sublicensable, and sole
and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize
certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV
in humans, and research and development exclusively relating to HIV in humans. As of June 30, 2024 and June 30, 2023, zero and 1,250,000
shares of Common Stock, respectively, remain contingently issuable in connection with the acquisition of Renovaro Biosciences in February
2018 (the &#8220;Contingent Shares&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences Denmark ApS
(&#8220;Renovaro Denmark&#8221;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Renovaro subject to 185,053 shares of Common Stock of Renovaro held in escrow according to Danish
law (the &#8220;Escrow Shares&#8221;). As of June 30, 2024, there are <span id="xdx_902_ecustom--EscrowSharesRemaining_iI_c20240630_zPTtScEVzM09" title="Escrow shares remaining"><ix:nonFraction name="RENB:EscrowSharesRemaining" contextRef="AsOf2024-06-30" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,414</ix:nonFraction></span> Escrow Shares remaining (see Note 9.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 13, 2024, the Company
acquired <span id="xdx_901_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zv8GMXEb4Xc6" title="Acquisition percentage"><ix:nonFraction name="RENB:BusinessAcquisitionPercentage" contextRef="AsOf2024-02-13_custom_RenovaroCubeMember" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
12.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_230_zHxlRWNUMVj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div id="xdx_233_z5urpuHNTc36" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zqRc3QOVeCFi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zR5afu4ckV86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000671" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zUyeFCYi1Mn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86B_zKw8wsgRetn9">Use of Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000673" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zd0IBDoDmAv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_868_zz0esm3S9tD1">Functional Currency and Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;). The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of
these financial statements. The Company&#8217;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates
and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years ended June 30,
2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&#8217;
equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than
the functional currency are included in the statement of operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000675" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYzze4EMsqLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zmDCKPeMM7Q9">Cash and Cash Equivalents</span> </b>&#8211;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000677" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zXAySCjPuzqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_866_zivhDldXlM9l">Concentration of Credit Risk</span>
&#8211;</b> Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2024, and June 30, 2023, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000679" name="RENB:InsuranceReceivablePolicy"><p id="xdx_845_ecustom--InsuranceReceivablePolicy_z2nHO3Uaz1ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86E_zGoifVogyvLa">Insurance Receivable</span> &#8211;</b>
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000681" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_znZFYJ0dR5y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zGm4454iLvN8">Property and Equipment</span> </b>-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 4.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000683" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zqm81xJWC1Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zZy77FcQIkK1">Intangible Assets</span> - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000685" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zPTsAxhA9Zj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zvWXMaDKdB6c">Goodwill</span></b> - Goodwill is not
amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000687" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z2t7migVRUw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_ztLtjS9Gnd9a">Impairment of Goodwill and Indefinite
Lived Intangible Assets</span></b> &#8211; We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23D_zHdkH6affQuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div id="xdx_233_zGlPOJPUyF18" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zArxJ8b4LUZd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zJH0YMEH9n8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For indefinite life intangible
assets, such as IPR&amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the
IPR&amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023.
During the year ended June 30, 2024, the Company recorded an impairment loss of $42,611,000 related to the termination of the license
agreement with Weird Science LLC (see Note 5.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The carrying value of
IPR&amp;D and goodwill at June 30, 2024, were&#160;zero <span id="xdx_903_ecustom--InProcessResearchAndDevelopment_iI_c20240630_zgdNmgs40Mq4" title="In-process research and development" style="display: none"><ix:nonFraction name="RENB:InProcessResearchAndDevelopment" contextRef="AsOf2024-06-30" id="Fact000691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--Goodwill_iI_c20240630_zzUVZLh5FIY9" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-06-30" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,330,161</ix:nonFraction></span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000695" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zH3L3Gq0MHVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_869_zCJyAq8yKG0k">Impairment of Long-Lived
Assets</span> - </b>Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. <span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zfZ0RQu56Byk" title="Impairment of assets"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20220701__20230630_zC6SBvTVoZp5" title="Impairment of assets"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-07-01to2024-06-30" id="Fact000697" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-07-012023-06-30" id="Fact000699" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> impairment
of these assets was recorded during the year ended June 30, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000701" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zDYiDHm5Uj2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_86E_zcQPMq32T4Xg">Leases</span> -</b> In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000703" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zS59JGeVGI0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_z2M4Fvb45Zy3">Research and Development Expenses</span>
&#8211; </b>The Company expenses research and development costs incurred in formulating,
improving, validating, and creating alternative or modified processes related to and expanding the use of the Company&#8217;s technologies.
Research and development expenses for the years ended June 30, 2024 and 2023 amounted to $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_z6mknozksDMg" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000705" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,708,829</ix:nonFraction></span>, and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220701__20230630_zTNam0i3PUge" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012023-06-30" id="Fact000707" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,165,197</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000709" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zi8R7RVllzg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zYcYrZIRngO4">Income Taxes</span> </b>- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 8.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_230_ziOtjl9QsVFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div id="xdx_238_zNNfqS2VmPMf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zDo8Y3wyw42b" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_z8BrPr3SdLhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000713" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zIGW5pW0zBr" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zX0uNS8uJHd9">Loss Per Share</span></b> - The Company calculates earnings (loss) per share in accordance with FASB ASC
260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding
during each period. Diluted earnings per common share are based on shares outstanding (computed as for basic EPS) and potentially dilutive
common shares. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options
that have been granted but have not been exercised. The shares of Common Stock outstanding at June 30, 2024 and 2023 were <span id="xdx_906_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zw5OieCHee3g" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">152,837,573</ix:nonFraction></span>
and <span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20230630_ztcHsHRLkHg9" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="AsOf2023-06-30" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,698,144</ix:nonFraction></span>, respectively. Because of the net loss for each of the years ended June 30, 2024 and June 30, 2023, dilutive shares for
both periods were excluded from the diluted EPS calculation, as the effect of these potential shares of Common Stock is anti-dilutive.
The Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zeRkKRein5I1" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-01to2024-06-30" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,146,315</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z4zWBToR9xad" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012023-06-30" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,949,513</ix:nonFraction></span> potential shares of Common Stock excluded from the diluted EPS calculation for the years ended
June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000723" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJ4GG127mXq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zd3ygNizXXM1">Fair Value of Financial Instruments</span>
</b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of June 30, 2024. <span style="background-color: white">Level
3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition
of Renovaro Cube </span>(see Note 3.) There were no Level 1, 2, or 3 assets, nor any Level 1, 2, or 3 liabilities measured at fair value
on a recurring basis as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000725" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z7LWcUyS4ke3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_861_zA8jExqaafKd">Stock-Based Compensation</span>
- </b>The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation
&#8211; Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2024 and 2023 were $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zYradUXtK5s1" title="Stock based compensation costs"><span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z3hq54z74ox6" title="Stock based compensation costs"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember" id="Fact000727" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember" id="Fact000729" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></ix:nonFraction></span></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zBWxheZ7LN9k" title="Stock based compensation costs"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zZU080u0jNHd" title="Stock based compensation costs"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember" id="Fact000731" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember" id="Fact000733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,535,051</ix:nonFraction></ix:nonFraction></span></span>, respectively<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the
fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000735" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqM3IawMsYyf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86E_z5NM0CWTk5cl">New Accounting Pronouncements Not Yet Adopted</span></b>
- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_232_zJcmNEmcKYM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div id="xdx_23F_zPaZuMzNzqIj" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zS57l1xwvDt9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zbufX70zZUh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000739" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_808_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zhz44LYWtA0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8211; <span id="xdx_824_zOZIFnamK5Q3">GOING CONCERN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s consolidated financial statements are prepared using the
generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations,
has used cash in the Company&#8217;s continuing operations, and is dependent on additional financing to fund operations. The Company incurred
a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20240630_ztiR01iTTzzh" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000741" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">80,650,172</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20220701__20230630_zL7xBOLeMhrl" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30" id="Fact000743" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,684,056</ix:nonFraction></span> for the years ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the Company had
cash and cash equivalents of $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20240630_zeP5qrsfzeKd" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000745" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">220,467</ix:nonFraction></span> and an accumulated deficit of $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20240630_zhqkj7eOUeec" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000747" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">324,679,425</ix:nonFraction></span> and a working capital deficit of $<span id="xdx_90B_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20240630_zFKeA5k9g448" title="Working capital deficit"><ix:nonFraction name="RENB:WorkingCapitalDeficit" contextRef="AsOf2024-06-30" id="Fact000749" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,312,274</ix:nonFraction></span>. These conditions
raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements
are issued. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of
recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Management has reduced overhead and administrative costs by streamlining the organization
to focus around the development and validation of its AI driven cancer diagnostics platform. The Company has tailored its workforce to
focus on these activities. In addition, the Company intends to attempt to secure additional required funding through equity or debt financing.
However, there can be no assurance that the Company will be able to obtain any sources of funding. Such additional funding may not be
available or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant
additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our cash resources will be depleted
and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business,
stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained.
If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that
could result in our stockholders losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Funding that we may receive during
the fiscal year 2025 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000751" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zI3QC9EPZfqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_82F_zDC0EoQw7qMl">FAIR VALUE MEASUREMENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company accounts for fair value
measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1. Observable inputs
    such as quoted prices in active markets for identical assets or liabilities; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2. Inputs, other
    than quoted prices in active markets, that are observable either directly or indirectly; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3. Unobservable inputs
    in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There were no Level 1, 2 or 3 assets,
nor any Level 1 or 2 liabilities as of June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Level 3 liabilities held as of
June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2014, acquisition of <span style="background-color: white">Renovaro
Cube, (the &#8220;Acquisition&#8221;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) <span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKJXXo440qFc" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,834,183</ix:nonFraction></span>
shares of Common Stock, and (ii) the right to receive contingent shares pro rata upon the exercise of convertible notes, options, and
warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_z4uD6XkDdoFg" title="Contingent consideration liability was recorded at fair value"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-02-13_custom_RenovaroCubeMember" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></span> at the time
of acquisition and is subsequently remeasured to fair value at the end of each reporting period. At June 30, 2024, there were <span id="xdx_902_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zLeqic9sL7Q9" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2023-07-012024-06-30_custom_RenovaroCubeMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,613,301</ix:nonFraction></span>
contingent shares issuable in connection with the Acquisition of Renovaro Cube.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23C_z38qiuDF0thj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div id="xdx_235_zMfJWPlwXI9a" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zH0VuG8IfCY6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zqYb33sj7aE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The fair value of the contingent consideration liability is estimated using
a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs to the model are all contractual or observable
with the exception being volatility, which is computed based on the volatility of the Company&#8217;s underlying stock. The key inputs
to valuing the contingent consideration liability as of June 30, 2024, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000761" name="us-gaap:FairValueConcentrationOfRiskTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueConcentrationOfRiskTextBlock_zBnobOxz4Vtb" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B4_zsouarOEXVRg" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Price</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zwBLymJsiZka" title="Stock Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_BlackScholesOptionPricingModelMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.75</ix:nonFraction></span></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5eprAWv41Jc" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.46</ix:nonFraction></span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zhNeqFWgidrh" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">8.23</ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zP4z1pEBAC81" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">109</ix:nonFraction></span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zxf5r3wVt0b1" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">145</ix:nonFraction></span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Rate</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zs1GUyksvtoa" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.24</ix:nonFraction></span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ztV9JVnkrA8c" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.21</ix:nonFraction></span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividends</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zmMHK42S0KH2" title="Expected Dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-07-012024-06-30_custom_BlackScholesOptionPricingModelMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount Rate (Monte-Carlo model only)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zz2SMfb5pTuc" title="Discount Rate (Monte-Carlo model only)"><ix:nonFraction name="RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" contextRef="From2023-07-012024-06-30_custom_BlackScholesOptionPricingModelMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB4swLUudTNa" title="Expected Term (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" format="ixt-sec:duryear" id="Fact000781" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.47</ix:nonNumeric></span> &#8211; <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zD1KKMlnrDpk" title="Expected Term (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" format="ixt-sec:duryear" id="Fact000783" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">9.50</ix:nonNumeric></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At initial recognition of the contingent consideration,
the inputs were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Price</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTF6VMTXIC1f" title="Stock Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_InitialRecognitionMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.92</ix:nonFraction></span></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zSTSaYAmurm8" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_srt_MinimumMember_custom_InitialRecognitionMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.46</ix:nonFraction></span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zp3IzcJBaQYi" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_srt_MaximumMember_custom_InitialRecognitionMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.50</ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zFtT5leyyXs8" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">107</ix:nonFraction></span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zR4EEyr6Y2mh" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">133</ix:nonFraction></span>% </span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Rate</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z9Y2yH7mPZj1" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.22</ix:nonFraction></span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zPhGt6Kakbgd" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.14</ix:nonFraction></span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividends</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zXhsgKfhOyzd" title="Expected Dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-07-012024-06-30_custom_InitialRecognitionMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount Rate (Monte-Carlo model only)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zM7q92wv8mMa" title="Discount Rate (Monte-Carlo model only)"><ix:nonFraction name="RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" contextRef="From2023-07-012024-06-30_custom_InitialRecognitionMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z5r91EIdusQa" title="Expected Term (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember" format="ixt-sec:duryear" id="Fact000803" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.56</ix:nonNumeric></span> &#8211; <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zesDQI8RTnPg" title="Expected Term (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember" format="ixt-sec:duryear" id="Fact000805" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">9.88</ix:nonNumeric></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A9_zgey0t7etDXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise disclosed, the
fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following table sets forth
the Level 3 liability at June 30, 2024, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required,
this liability is classified based on the lowest level of input that is significant to the fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000807" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zbGfG4BLPOI2" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BA_z44FWU30YTme" style="display: none">Schedule of fair value measurement on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuxz3uOoLx22" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z20nVmD6NU5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5VPw7GjbsG4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z8wJR90B47wi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000809" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000810" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000811" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ContingentConsiderationInAcquisition_d0_zauLxMdQZTY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Contingent consideration in Acquisition</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationInAcquisition" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000813" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationInAcquisition" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000814" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationInAcquisition" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SettlementsContingentSharesToBeIssued_d0_znw14uWDtjk3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Settlements: contingent shares to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:SettlementsContingentSharesToBeIssued" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000817" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:SettlementsContingentSharesToBeIssued" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000818" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RENB:SettlementsContingentSharesToBeIssued" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000819" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,520,027</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zDIZ8nQTLE5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Fair value adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000821" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000822" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000823" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,727,473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zn6e3bHWfmch" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent Consideration Liability at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000825" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000826" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,310,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A8_z2d3TaRjobdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div id="xdx_239_zLkpMR754YN8" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zKvGijbQlKHa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><p id="xdx_23D_zy7FcTLsnNLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000830" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zNsmgqT8NJu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 - <span id="xdx_824_z9IzJrt77ZFd">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Property and equipment consisted of the following at
June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000832" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSqHudftYW62" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BB_zu3zrzDbwOw1" style="display: none">Schedule of property and equipment</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Useful Life</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2023</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment and instruments</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zFEWN9XGhgs" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember" format="ixt-sec:duryear" id="Fact000834" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zCo7vEy4AjXd" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember" format="ixt-sec:duryear" id="Fact000836" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zxDQdmzWigt4" title="Total" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember" id="Fact000838" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">639,998</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" title="Total" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-06-30_custom_LabEquipmentAndInstrumentsMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">576,298</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0g8PGI59Hu9" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" id="Fact000842" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzoMogLZBzs9" title="Total" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember" id="Fact000844" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,629</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Total" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-06-30_us-gaap_LeaseholdImprovementsMember" id="Fact000846" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,629</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture, fixtures, and equipment</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoX8NBYdyitg" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000848" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaetA179rV2g" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000850" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td>
<td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFJoCWYliyi8" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">195,834</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-06-30_us-gaap_FurnitureAndFixturesMember" id="Fact000854" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">172,861</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zxdkYuKTIwUf" title="Total" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30" id="Fact000856" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,060,461</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20230630_pp0p0" title="Total" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-06-30" id="Fact000858" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">973,788</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less accumulated depreciation</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_zBgNg0j2Pjz" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-06-30" id="Fact000860" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">578,340</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230630_z7O7Yv6Oclv5" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-06-30" id="Fact000862" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">464,799</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Property and Equipment</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zi2dTaTT79C8" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" id="Fact000864" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">482,121</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_c20230630_pp0p0" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-06-30" id="Fact000866" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">508,989</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Depreciation expense amounted to
$<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20230701__20240630_zEh2v9Hx0Lfk" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-07-01to2024-06-30" id="Fact000868" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">113,563</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220701__20230630_z45hClhsf17d" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-07-012023-06-30" id="Fact000870" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">107,321</ix:nonFraction></span> for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000872" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zsPsp0Xq5LKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_82F_zdg85Ykbdnwd">INTANGIBLE ASSETS AND GOODWILL</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024 and 2023, definite-life
intangible assets, net of accumulated amortization, consisted of patents on the Company&#8217;s products and processes of $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zEZlixppQ8Xj" title="Definite-life intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact000874" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,043</ix:nonFraction></span> and
$<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20230630_zb4u9PhxMBA4" title="Definite-life intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-06-30" id="Fact000876" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,676</ix:nonFraction></span>, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense
for the years ended June 30, 2024 and 2023 was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230701__20240630_zxorhqbGDqYe" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000878" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,296</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220701__20230630_zNT5FqBGRNJ2" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-07-012023-06-30" id="Fact000880" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,175</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024 and 2023, indefinite
life intangible assets consisted of a license agreement classified as In-Process Research and Development (&#8220;IPR&amp;D&#8221;) intangible
assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024 and 2023, definite-life
and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000882" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEl8nSFh79zj" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BE_zguU80daZ7Uc" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7dyK9Qwbij8" title="Useful life"><ix:nonNumeric contextRef="AsOf2024-06-30_us-gaap_PatentsMember" format="ixt-sec:duryear" id="Fact000884" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z96WPpRGp7ch" title="Net definite-life intangible assets at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_PatentsMember" id="Fact000886" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">290,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zDOWP0y1wTqb" title="Net definite-life intangible assets, Additions" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact000888" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5DYEh1SmK9l" title="Net definite-life intangible assets, Amortization" style="width: 9%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact000890" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQYZtKdmDtg2" title="Net definite-life intangible assets, Impairment" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact000892" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPKHgqYxtnv7" title="Net definite-life intangible assets, Translation adjustment" style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact000894" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,959</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0W2FcF7Dnoj" title="Net definite-life intangible assets at ending" style="width: 8%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_PatentsMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zBgHrcxmYJtd" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">251,260</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJm6WFyLE3xf" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000900" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvWdkHKVm7xk" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000902" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zZ4WN0DaFGT4" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000904" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zExdjQBCUmc2" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,622</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_znoeLMcAMwy5" title="Net definite-life intangible assets at ending" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000908" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">254,934</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_zFprgLQPC5Eg" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30" id="Fact000910" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zVzTCs5Srb6l" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-01to2024-06-30" id="Fact000912" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_zwPRsB9kBbWe" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2023-07-01to2024-06-30" id="Fact000914" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zyaOCZWWa8a8" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-07-01to2024-06-30" id="Fact000916" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zkvryP9DqIj4" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-01to2024-06-30" id="Fact000918" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,337</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zwajfl1cIqXk" title="Net definite-life intangible assets at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30" id="Fact000920" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,043</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets and Goodwill</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zlIfeJseg7x5" title="Total indefinite life intangible assets and goodwill at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_GoodwillMember" id="Fact000922" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zY6xVCLQ3dC3" title="Total indefinite life intangible assets and goodwill, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact000924" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,464,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_za115YJY9XE3" title="Total indefinite life intangible assets and goodwill, Amortization" style="text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact000926" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zka54eUJGBF9" title="Total indefinite life intangible assets and goodwill, Impairment" style="text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact000928" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zPmZDd8OfU2f" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact000930" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,878</ix:nonFraction></td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zg26Cl5CI21e" title="Total indefinite life intangible assets and goodwill at ending" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_GoodwillMember" id="Fact000932" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,330,161</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">IPR&amp;D</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLn2yjKUMK58" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zHyBYA6yg9da" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000936" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zqJR78VGTXu7" title="Total indefinite life intangible assets and goodwill, Amortization" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000938" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z3BpTO4IOjd6" title="Total indefinite life intangible assets and goodwill, Impairment" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000940" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">42,611,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziH1YYGLnT83" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000942" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zcxD7Crq1oEd" title="Total indefinite life intangible assets and goodwill at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000944" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets and Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_zO5NFDLW0qm8" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30" id="Fact000946" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,251,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_zTKCCd6mXxU8" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-01to2024-06-30" id="Fact000948" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,464,039</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zumaKkhNtit6" title="Total indefinite life intangible assets and goodwill, Amortization" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2023-07-01to2024-06-30" id="Fact000950" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zZxhATdqgWRe" title="Total indefinite life intangible assets and goodwill, Impairment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2023-07-01to2024-06-30" id="Fact000952" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">54,251,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zOEYGv6nCpli" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-01to2024-06-30" id="Fact000954" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,878</ix:nonFraction>)</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zpDO6SouziCc" title="Total indefinite life intangible assets and goodwill at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30" id="Fact000956" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,330,161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Period Change</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Effect of Currency Translation</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 15%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znm0KHNgwwpk" title="Useful life"><ix:nonNumeric contextRef="AsOf2024-06-30_us-gaap_PatentsMember" format="ixt-sec:duryear" id="Fact000958" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIE25F2BtUb" title="Net definite-life intangible assets at beginning" style="width: 13%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2022-06-30_us-gaap_PatentsMember" id="Fact000960" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279,257</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9QsOveXJTA6" title="Net definite-life intangible assets, Additions" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30_us-gaap_PatentsMember" id="Fact000962" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJeKX9RMA3Sj" title="Net definite-life intangible assets, Translation adjustment" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-07-012023-06-30_us-gaap_PatentsMember" id="Fact000964" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,679</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvoPlq3Zap8j" title="Net definite-life intangible assets at beginning" style="width: 13%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_PatentsMember" id="Fact000966" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">290,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zX09lanWwkO2" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2022-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000968" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">234,989</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zUVrP4CkYt2g" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000970" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,175</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zKedzq7HqHDh" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-07-012023-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000972" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,096</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zQiEWYbLuOW5" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000974" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">251,260</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630_zkLX76Nd92W9" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2022-06-30" id="Fact000976" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,268</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630_z5hlQtz3s8R3" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30" id="Fact000978" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,175</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630_z615P4r3zdwj" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-07-012023-06-30" id="Fact000980" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,583</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z4eTFgJ8uw5c" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30" id="Fact000982" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">License Agreement</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zpCS3SiQxZM" title="Total indefinite life intangible assets and goodwill at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2022-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000984" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,571,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zRWYFzXEmA0l" title="Total indefinite life intangible assets and goodwill, Additions" style="text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000986" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,960,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zTbpbsu4nJOa" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-07-012023-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000988" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zvtfob0kTZ85" title="Total indefinite life intangible assets and goodwill at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact000990" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z7qFqW4Pbkw5" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2022-06-30_us-gaap_GoodwillMember" id="Fact000992" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z74ldD7a5fB5" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30_us-gaap_GoodwillMember" id="Fact000994" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zm9JF2saKo32" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-07-012023-06-30_us-gaap_GoodwillMember" id="Fact000996" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zA4l0J03Jvs3" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_GoodwillMember" id="Fact000998" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630_zZix9ok7dt45" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2022-06-30" id="Fact001000" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,211,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20220701__20230630_zWaD10y60apk" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30" id="Fact001002" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,960,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630_zPcDEOjnNtD" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-07-012023-06-30" id="Fact001004" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z1QN35w9In11" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30" id="Fact001006" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,251,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_zkk9S4xIMC5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div id="xdx_23C_z6YZVCfGx308" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zXtgk2qR4F29" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_za5sD1W89Mbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Expected future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001009" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zXienn3ipfx5" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8BB_zShz1BCPmGof" style="display: none">Schedule of expected future amortization expense</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended&#160;June 30,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20240630_zsvcGDIsZ9U9" title="2025" style="width: 32%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-06-30" id="Fact001011" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,511</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20240630_zSrOJT6GdRVh" title="2026" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-06-30" id="Fact001013" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,511</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20240630_zqEzxGtJlZMb" title="2027" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-06-30" id="Fact001015" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,511</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20240630_z079g9uqL5f" title="2028" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-06-30" id="Fact001017" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,510</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #CCEEFF; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #CCEEFF">Total</span></td><td style="padding-bottom: 2.5pt; color: #CCEEFF; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zfcpDTyWqYdh" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact001019" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,043</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During February 2018, the Company
acquired IPR&amp;D related to a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale,
import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of
and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. The IPR&amp;D intangible
asset was classified as an indefinite life asset that was tested annually for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $159,464,039.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Impairment &#8211; <span style="background-color: white">On
March 1, 2024, the Company received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between
Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly owned subsidiary of the Company, dated
February 16, 2018. Due to the termination of the License Agreement, the Company recorded an impairment of $42,611,000 during the year
ended June 30, 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Following the fourth quarter of
each year, management performs its annual test of impairment of intangible assets by performing a assessment and determines if it is more
likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the year ended June 30,
2023, the results of the assessment indicated that the carrying value of the licenses acquired as an IPR&amp;D asset exceeded its fair
value, due to the changes in the projected economic benefits to be realized from these assets. Therefore, an impairment adjustment of
$<span id="xdx_903_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220701__20230630_zLKUqya1CBJ3" title="Impairment adjustment"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2022-07-012023-06-30" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,960,000</ix:nonFraction></span> was recorded for the year ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the year ended June 30,
2024, the results of the assessment indicated that the carrying value of the goodwill related to the RENB reporting unit exceeded its
fair value, due to the changes in the projected economic benefits to be realized from this reporting unit. Management concluded the significant
driver for the change in the economic benefits was due to the Company&#8217;s continued inability to raise capital for the further development
of the technologies within this reporting unit. Therefore, an impairment adjustment of $<span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_c20230701__20240630_zXUXxnf6sLS" title="Goodwill impairment adjustment"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-07-01to2024-06-30" id="Fact001023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></span> was recorded for the year ended June
30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001025" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zXbrV8Rn2e1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_82D_z27QhDto7etl">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b>Operating
Leases </b>&#8212; <span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20171112__20171113_zmhyhkwFTmj4" title="Lease premises, description"><ix:nonNumeric contextRef="From2017-11-122017-11-13" id="Fact001027" name="us-gaap:LesseeOperatingLeaseDescription">On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the &#8220;Landlord&#8221;) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20180618__20180619_zqJagRDgv5tg" title="Lease premises, description"><ix:nonNumeric contextRef="From2018-06-182018-06-19" id="Fact001029" name="us-gaap:LesseeOperatingLeaseDescription">On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.</ix:nonNumeric></span> Renovaro subleased the space as
of June 25, 2022 through April 30, 2023. (See subsection below &#8220;<i>Sublease Agreement</i>&#8221; for details.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_231_zrDZhdEYmUR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div id="xdx_23E_z2byRXqbSXRf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_z5to2eM8cbw6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zyHECBHeDyqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company identified and assessed
the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Expected lease term </i></b>&#8212;
The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company&#8217;s leases have a remaining lease term of 38 and 20 months. As of
June 30, 2024, the weighted-average remaining term is <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zqLQfwhuDwl4" title="Weighted-average remaining term"><ix:nonNumeric contextRef="AsOf2024-06-30" format="ixt-sec:duryear" id="Fact001033" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.54</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Incremental borrowing rate</i></b>
&#8212; The Company&#8217;s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of June 30, 2024, the weighted-average
discount rate is <span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zRNk7Yzwz3u8" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-06-30" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.14</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Lease and non-lease components</i></b>
&#8212; In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company&#8217;s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Below are the lease commitments for the next 5 years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001037" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHnI1BKjk2W9" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left"><span id="xdx_8B0_zI0dHC8GMQWj" style="display: none">Schedule of lease commitments</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ending June 30</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Expense</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; width: 55%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20240630_z91Jc5YnhIbl" title="2025" style="width: 32%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-06-30" id="Fact001039" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">554,453</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20240630_zsmiQQUwerna" title="2026" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-06-30" id="Fact001041" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">457,876</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20240630_zlzQZjSgi9h7" title="2027" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-06-30" id="Fact001043" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">334,788</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_c20240630_zfPOPFOpA5L8" title="Thereafter" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" contextRef="AsOf2024-06-30" id="Fact001045" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,830</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20240630_ziLYInVw9imf" title="Less imputed interest" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-06-30" id="Fact001047" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">91,005</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20240630_zt7k5GblH3Z4" title="Total" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-06-30" id="Fact001049" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,335,942</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A1_zXhrEROCZzyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Sublease Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_902_eus-gaap--LesseeFinanceSubleaseResidualValueGuaranteeDescription_c20220619__20220620_zJcESeUYkgOg" title="Sublease agreement description"><ix:nonNumeric contextRef="From2022-06-192022-06-20" id="Fact001051" name="us-gaap:LesseeFinanceSubleaseResidualValueGuaranteeDescription">On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the &#8220;Subtenant&#8221;), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In accordance with ASC Topic 842,
the Company treated the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease.
The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement
date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease was classified as an operating lease,
as it did not meet the criteria of a sales-type or direct financing lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23F_zdAiunmCAPs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div id="xdx_23F_zQ1ELFEdnhxk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zbJIeeWV6TS5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zY7qhGD9Nzui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
April 18, 2023, the Company entered into a sublease termination agreement with the Subtenant, whereby the Subtenant and the Company agreed
to terminate the sublease effective as of April 30, 2023. The Subtenant agreed to pay the Company $<span id="xdx_90C_eus-gaap--PaymentsForLeasingCosts_c20230417__20230418_zEmfToCM6E0j" title="Lease payment"><ix:nonFraction name="us-gaap:PaymentsForLeasingCosts" contextRef="From2023-04-172023-04-18" id="Fact001055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,460</ix:nonFraction></span>&#160;along with the security
deposit of $<span id="xdx_90C_eus-gaap--SecurityDeposit_iI_c20230418_ziBoBeUGwQRi" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-04-18" id="Fact001057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,540</ix:nonFraction></span>&#160;for a total termination fee of $<span id="xdx_902_eus-gaap--LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_iI_c20230418_z9bPmX0t24o5" title="Termination fee"><ix:nonFraction name="us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" contextRef="AsOf2023-04-18" id="Fact001059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>, to permit early termination of the sublease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recognized operating
income from the sublease on a straight-line basis in its statements of operations over the sublease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the year ended June 30,
2024 and 2023, the net operating lease expenses were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001061" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zClWMCshP0ll" summary="xdx: Disclosure - LEASES  (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zVDyewUsV1i4" style="display: none">Schedule of net operating lease expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20230701__20240630_z7Z8JeCBbNge" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220701__20230630_zaAsbDrXA7wa" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr id="xdx_404_eus-gaap--OperatingLeaseExpense_z8QC4eOSRgKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Lease Expense</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-07-01to2024-06-30" id="Fact001063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">383,549</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-07-012023-06-30" id="Fact001064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">322,447</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--SubleaseIncome_iN_di0_zjjQBthl57J7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-lease Income</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2023-07-01to2024-06-30" id="Fact001066" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2022-07-012023-06-30" id="Fact001067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,700</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_409_ecustom--OperatingLeaseRentExpenses_zU4fEdtwtDM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Net Lease Expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:OperatingLeaseRentExpenses" contextRef="From2023-07-01to2024-06-30" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">383,549</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="RENB:OperatingLeaseRentExpenses" contextRef="From2022-07-012023-06-30" id="Fact001070" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,253</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A6_zfFtkQQ3ZWKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lease expense charged&#160;to general
and administrative expenses for the years ended June 30, 2024 and 2023, amounted to $<span id="xdx_902_eus-gaap--LeaseCost_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqtDwp9XG5k7" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-07-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">383,549</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--LeaseCost_c20220701__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgHKCs3mzAF2" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-07-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">322,447</ix:nonFraction></span>, respectively. During the years
ended June 30, 2024 and 2023, the Company paid $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20230701__20240630_zI7A5sLbbQm2" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-07-01to2024-06-30" id="Fact001076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,983</ix:nonFraction></span>&#160;and $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20220701__20230630_zWYmGiyAW043" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-07-012023-06-30" id="Fact001078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,519</ix:nonFraction></span> under operating leases, respectively. The difference between
the operating lease expense for the year ended June 30, 2023 in the amount of $<span id="xdx_905_ecustom--OperatingLeaseExpenses_c20220701__20230630_zs7DsWAxctke" title="Operating lease expense"><ix:nonFraction name="RENB:OperatingLeaseExpenses" contextRef="From2022-07-012023-06-30" id="Fact001080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">322,447</ix:nonFraction></span> and the cash paid of $<span id="xdx_900_ecustom--CashPaidForTheTerminationOfLease_iI_c20230630_zDyL8t7GYUI7" title="Cash payments"><ix:nonFraction name="RENB:CashPaidForTheTerminationOfLease" contextRef="AsOf2023-06-30" id="Fact001082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439,519</ix:nonFraction></span>, is primarily made
up of the release of an accrual of $<span id="xdx_908_ecustom--AccrualPaymentsRelatedToTerminationOfLease_c20220701__20230630_znv95olzTyS8" title="Accrual payments related to the termination of lease"><ix:nonFraction name="RENB:AccrualPaymentsRelatedToTerminationOfLease" contextRef="From2022-07-012023-06-30" id="Fact001084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,242</ix:nonFraction></span> related to the termination of the Plaza Medical Office Building, LLC lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001086" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_ztOurOM8R2ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; <span id="xdx_82E_zWJtPRBWOp3b">DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>March 2024 Note &#8212;</i></b>
On March 14, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note in the amount
of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_znEreOjiWg1g" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-03-14_custom_MarchNote2024Member" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> (the &#8220;March 2024 Note&#8221;). The March 2024 Note had an interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zRrjeum5ZSuj" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-03-14_custom_MarchNote2024Member" id="Fact001090" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum and was due to mature on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20240313__20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_z38E3Pzd24xf" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-03-132024-03-14_custom_MarchNote2024Member" format="ixt:datemonthdayyearen" id="Fact001092" name="us-gaap:DebtInstrumentMaturityDate">March
15, 2025</ix:nonNumeric></span>. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the issue date prior to the maturity of the March 2024 Note. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The March 2024 Note was convertible at the option of the holder after a qualified offering.
If no qualified offering occurs prior to the maturity date, the March 2024 Note was to be repaid in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company sold
<span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zbZJpgBjjY93" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">344,966</ix:nonFraction></span> of the Company&#8217;s units, each such unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zIThcbEni5Zc" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member" id="Fact001096" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value
per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock (a &#8220;Unit&#8221;), to the holder
of the March 2024 Note in consideration for the total $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_z9AAEdhuCaWh" title="Sale of stock, consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member" id="Fact001098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,361</ix:nonFraction></span> in principal amount and interest accrued under the March 2024 Note. The
warrants are exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zP9r6wIEZMKg" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_MarchNote2024Member" id="Fact001100" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span> per share, payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In the year ended June 30, 2024,
the Company recorded interest expense of $<span id="xdx_908_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zWPXjcMYN8We" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_MarchNote2024Member" id="Fact001102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,361</ix:nonFraction>
</span>related to the March 2024 Note. The March 2024 Note balance at June 30, 2024 was zero <b style="display: none"><span id="xdx_905_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zcfvv3UMhxwg" title="Interest expense related to note balance"><ix:nonFraction name="RENB:InterestExpenseRelatedToNoteBalance" contextRef="From2023-07-012024-06-30_custom_MarchNote2024Member" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>The 2024 Notes &#8212;</i></b>
On January 11, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note (the &#8220;January
2024 Note I&#8221;) in the amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zG7dM5YCtCyb" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-11_custom_JanuaryNote2024Member" id="Fact001106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">460,000</ix:nonFraction></span>. The January 2024 Note I had an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zcWtBEbhmEl7" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-11_custom_JanuaryNote2024Member" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and was due to mature on
<span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20240110__20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zlJdzbZmYQK3" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-01-102024-01-11_custom_JanuaryNote2024Member" format="ixt:datemonthdayyearen" id="Fact001110" name="us-gaap:DebtInstrumentMaturityDate">January 11, 2025</ix:nonNumeric></span>. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year
following the issue date prior to the maturity of the notes. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The January 2024 Note I was convertible either at the option of the holder or automatically
upon maturity into shares of the Company&#8217;s Common Stock at the conversion price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z15aYoyYosHd" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-01-11_custom_JanuaryNote2024Member" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></span>. On January 12, 2024, the Company entered
into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zUekcdH8TOb8" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> (the
&#8220;January 2024 Note II&#8221;, and collectively with the January 2024 Note I, the &#8220;January 2024 Notes&#8221;). The Company
received a total of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zlVS57Qfh3n5" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member" id="Fact001116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> in gross proceeds.&#160;The January 2024 Note II bears an interest rate of <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zILBVqcMJW07" title="Bear interest percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and shall mature
on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRwwKnRyZ3Xe" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member" format="ixt:datemonthdayyearen" id="Fact001120" name="us-gaap:DebtInstrumentMaturityDate">December 29, 2024</ix:nonNumeric></span>. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each
year following the issue date prior to the maturity of the January 2024 Note II. The January 2024 Note II is convertible either at the
option of the holder or automatically upon maturity into shares of the Company&#8217;s Common Stock at the Note Conversion Price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zsPSPhg9COkl" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_237_zxhCRaKKXQkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div id="xdx_23D_zZMALrTcf2Bd" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zbBNwNyRigLg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zBqLc7cINVUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company sold
<span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDdKEEkV0yGg" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">325,508</ix:nonFraction></span> of the Company&#8217;s Units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zNsTgxBIiRI6" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value
per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, to the holder of the January 2024
Note I in consideration for the total $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zTll5SqOjwr7" title="Sale of stock, consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483,460</ix:nonFraction></span> in principal amount and interest accrued under the January 2024 Note I. The warrants are
exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zkGoAObVqdrl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_JanuaryNote2024Member" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span> per share, payable in cash. The January 2024
Notes principal balance at June 30, 2024, is $<span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zqDL8c4094tg" title="Principal outstanding balance"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-06-30_custom_JanuaryNote2024Member" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>December 2023 Notes &#8212;
</i></b>Between December 1, 2023, and December 29, 2023, the Company entered into Subscription Agreements with two investors to purchase
Convertible Promissory Notes for an aggregate principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zBDrc6MPnTw4" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-29_custom_DecemberNote2023Member" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">560,000</ix:nonFraction></span> (the &#8220;December Notes&#8221;). The Company received a
total of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zPlTycp5Xdya" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-12-012023-12-29_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member" id="Fact001138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">560,000</ix:nonFraction></span> in gross proceeds, consisting of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement1Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zqhikarnyqi7" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-12-012023-12-29_custom_PrivatePlacement1Member_custom_DecemberNote2023Member" id="Fact001140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">440,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement2Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zYHut2UtMQr9" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-12-012023-12-29_custom_PrivatePlacement2Member_custom_DecemberNote2023Member" id="Fact001142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> from the private placement prior to the end of the quarter ending
December 31, 2023, and $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20240130__20240131__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement3Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zgAUZi71WEf9" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-302024-01-31_custom_PrivatePlacement3Member_custom_DecemberNote2023Member" id="Fact001144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> received in January 2024.&#160;The December Notes bear an interest rate of <span id="xdx_902_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z3xnT4EyCOZh" title="Bear interest percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="AsOf2023-12-29_custom_DecemberNote2023Member" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and shall mature
one year after their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December Notes.
Notwithstanding the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis.
The December Notes are convertible into shares of the Company&#8217;s Common Stock in whole or in part at any time and from time to time,
after the original issue date and prior to the Maturity Date, at a conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zJCCP7ZLU7bi" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-29_custom_DecemberNote2023Member" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></span> per share. The December Notes will be accounted
for under ASC 470-20.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, in a private
placement the Company sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zncBlcuFNyr9" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member" id="Fact001150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,715</ix:nonFraction></span> Units to an investor who surrendered and terminated $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zVxlDSbpUNb1" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member" id="Fact001152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">440,000</ix:nonFraction></span> in aggregate principal amount and $<span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z7DOdIZxFOf2" title="Interest accrued"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member" id="Fact001154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,453</ix:nonFraction></span>
of interest accrued on the December Notes and paid in cash an aggregate amount of $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zdTdL0VUcoe6" title="Sale of stock, consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member" id="Fact001156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></span> to the Company in consideration for the Units,
each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zhGaOZoP782d" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share and (ii) one common stock
purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are exercisable for five years from the date of issuance
and have an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zBTzXUBEhmNf" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_DecemberNote2023Member" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span> per share, payable in cash. The December Notes principal balance at June 30, 2024, is $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zYuY6PBuEtt1" title="Principal outstanding balance"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-06-30_custom_DecemberNote2023Member" id="Fact001162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In the year ended June 30, 2024,
the Company has recorded interest expense of $<span id="xdx_909_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRCjcugYiKgh" title="Accrued interest expense"><span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zH4XMIkRRvog" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_JanuaryNote2024Member" id="Fact001164" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_DecemberNote2023Member" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,013</ix:nonFraction></ix:nonFraction></span></span> related to the January 2024 Notes and December 2023 Notes. The January 2024 Notes
and December 2023 Notes balance at June 30, 2024 was $<span id="xdx_902_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630_zqTv4FS1LN9a" title="Interest expense related to note balance"><ix:nonFraction name="RENB:InterestExpenseRelatedToNoteBalance" contextRef="From2023-07-01to2024-06-30" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></span> of which $<span id="xdx_900_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zT5acpvAkmWa" title="Interest expense related to note balance"><ix:nonFraction name="RENB:InterestExpenseRelatedToNoteBalance" contextRef="From2023-07-012024-06-30_custom_DecemberNote2023Member" id="Fact001170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> is related to the December 2023 Notes and $<span id="xdx_906_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRV4rHnAPg5c" title="Interest expense related to note balance"><ix:nonFraction name="RENB:InterestExpenseRelatedToNoteBalance" contextRef="From2023-07-012024-06-30_custom_JanuaryNote2024Member" id="Fact001172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> is
related to the January 2024 Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The 2023 Notes &#8212; </i></b>Between
September 5, 2023, and October 5, 2023, the Company entered into Subscription Agreements with five investors to purchase <span id="xdx_902_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zGXhzfXeVYOd" title="Original issue discount percentage"><ix:nonFraction name="RENB:OriginalIssueDiscountPromissoryNotePercentage" contextRef="AsOf2023-10-05_custom_Note2023Member" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% Original Issue
Discount Convertible Promissory Notes (the &#8220;2023 Notes&#8221;) for an aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zWbt2orNN3Cl" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-10-05_custom_Note2023Member" id="Fact001176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,105,263</ix:nonFraction></span>. The Company received
a total of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zKjJfGCthUa" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-09-052023-10-05_custom_Note2023Member" id="Fact001178" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> in gross proceeds from the private placement, after taking into account the <span id="xdx_90F_ecustom--DebtInstrumentOriginalIssueDiscount_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zFaYBLSPpv13" title="Original issue discount percentage"><ix:nonFraction name="RENB:DebtInstrumentOriginalIssueDiscount" contextRef="AsOf2023-10-05_custom_Note2023Member" id="Fact001180" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% original issue discount.&#160;The
discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zS3sUwPlRzFf" title="Discount accreted"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-10-05_custom_Note2023Member" id="Fact001182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,263</ix:nonFraction></span> was to be accreted over the life of the 2023 Notes. The 2023 Notes had an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_z7JpsOqsJWq1" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-10-05_custom_Note2023Member" id="Fact001184" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and were
due to mature on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zjlOUtzeLBjg" title="Maturity date"><ix:nonNumeric contextRef="From2023-09-052023-10-05_custom_Note2023Member" format="ixt:datemonthdayyearen" id="Fact001186" name="us-gaap:DebtInstrumentMaturityDate">September 5, 2024</ix:nonNumeric></span> (the &#8220;Maturity Date&#8221;). The Company was required to pay interest quarterly, in arrears,
in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest could accrue on the notes on a quarterly basis. The 2023 Notes were convertible
into shares of the Company&#8217;s Common Stock upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The 2023 Notes were subject to
mandatory conversion (&#8220;Mandatory Conversion&#8221;) in the event the Company closed an offering of its Common Stock and received
gross proceeds of not less than $<span id="xdx_90B_ecustom--CommonStockAndReceivedGrossProceeds_pp0p0_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zUXdxKUqGpLc" title="Common stock and received gross proceeds"><ix:nonFraction name="RENB:CommonStockAndReceivedGrossProceeds" contextRef="From2023-09-052023-10-05_custom_Note2023Member" id="Fact001188" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></span> (a &#8220;Qualified Offering&#8221;). The conversion price per share of Common Stock in the
case of a Mandatory Conversion was to be <span id="xdx_906_ecustom--OfferingPricePerSharePercentage_dp_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zfm3KMyQS5Ei" title="Offering price per share percentage"><ix:nonFraction name="RENB:OfferingPricePerSharePercentage" contextRef="From2023-09-052023-10-05_custom_Note2023Member" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95</ix:nonFraction></span>% of the offering price per share in the Qualified Offering, subject to a floor of $<span id="xdx_909_ecustom--DebtInstrumentsFloorPricePerShare_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zqDEAEufuJcg" title="Floor price per share"><ix:nonFraction name="RENB:DebtInstrumentsFloorPricePerShare" contextRef="AsOf2023-10-05_custom_Note2023Member" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span> per
share.&#160;In addition, if no Qualified Offering occurred prior to the Maturity Date, the 2023 Notes were to automatically convert into
shares of Common Stock on the Maturity Date at a conversion price per share equal to the closing sale price of the Common Stock on the
Maturity Date, subject to a floor of $<span id="xdx_900_ecustom--DebtInstrumentsFloorPricePerShare_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zXwaXT00AhN2" title="Floor price per share"><ix:nonFraction name="RENB:DebtInstrumentsFloorPricePerShare" contextRef="AsOf2023-10-05_custom_Note2023Member" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<ix:exclude><p id="xdx_23D_zyH8SGl1r0nl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zMziouqSNnH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div id="xdx_231_zeJe6AobIOfl" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_z6neH6TCPUG6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zKW0fFnMPiY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 11, 2024, the Company
entered into an amendment with one of the investors of the 2023 Notes whereas the conversion terms were amended to provide for optional
conversion at a conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240111__us-gaap--AwardDateAxis__custom--Note2023Member_znVOFdEFVWtb" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-01-11_custom_Note2023Member" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></span> per share. All other terms of the Promissory Note remained the same. The Company treated this
as a modification for accounting purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company
sold <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_z7usAFPfMSub"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_Note2023Member" id="Fact001200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,546,449</ix:nonFraction> </span>Units
to the holders of the 2023 Notes who surrendered and terminated $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zuxAOAQ9hmke"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,825</ix:nonFraction> </span>in
aggregate principal amount and interest accrued thereon of the 2023 Notes and paid in cash an aggregate amount of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zY6p69xrGXMc"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_Note2023Member" id="Fact001202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,575</ix:nonFraction> </span>(of
which $<span id="xdx_90F_eus-gaap--OtherNotesPayable_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zTQWpU6C4gR7"><ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member" id="Fact001203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,063</ix:nonFraction> </span>was
applied against the Company&#8217;s Promissory Notes), to the Company in consideration for the Units, each such Unit consisting of
(i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_z7FYUQoOXDFj"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member" id="Fact001204" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> </span>par
value per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are
exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--Note2023Member__srt--RangeAxis__srt--MinimumMember_zHw7RDMKS5kb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MinimumMember" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--Note2023Member__srt--RangeAxis__srt--MaximumMember_zBnU4maHJYN3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MaximumMember" id="Fact001206" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4765</ix:nonFraction> </span>per
share, payable in cash. The 2023 Notes principal balance at June 30, 2024, is zero <span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240614__us-gaap--AwardDateAxis__custom--Note2023Member_zadYXn9LQs5" title="Principal outstanding balance" style="display: none"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-06-14_custom_Note2023Member" id="Fact001208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span><b></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;For the year ended
June 30, 2024, discount amortization of $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zT2Kwalmf8f5" title="Debt amortization discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-012024-06-30_custom_Note2023Member" id="Fact001210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,567</ix:nonFraction>
</span>was charged to interest expense and $<span id="xdx_90A_eus-gaap--InterestIncomeExpenseAfterProvisionForLoanLoss_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zmyiWjDhFsjh" title="Discount amortization to other income and expense"><ix:nonFraction name="us-gaap:InterestIncomeExpenseAfterProvisionForLoanLoss" contextRef="From2023-07-012024-06-30_custom_Note2023Member" id="Fact001212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,696</ix:nonFraction>
</span>of discount amortization was charged to other income and expense due to the early termination of the notes, respectively. In the
year ended June 30, 2024, the Company recorded interest expense of $<span id="xdx_90C_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zOW3uHhkvnbd" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_Note2023Member" id="Fact001214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,614</ix:nonFraction></span> related to the 2023 Notes. The 2023 Notes balance, net of
discount at June 30, 2024 is zero <b style="display: none"><span id="xdx_905_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zvOZs0QDeTg7" title="Interest expense related to note balance"><ix:nonFraction name="RENB:InterestExpenseRelatedToNoteBalance" contextRef="From2023-07-012024-06-30_custom_Note2023Member" id="Fact001216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The Convertible Notes &#8212;
</i></b>On February 6, 2020, the Company issued two Convertible Notes (the &#8220;Convertible Notes&#8221;) to Paseco ApS (the &#8220;Holder&#8221;),
a Danish limited company and an existing stockholder of the Company, each with a face value amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200206__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_zNL4Iqq8QOY5" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-02-06_custom_ConvertibleNotesPayablesMember" id="Fact001218" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></span>, convertible into shares
of Common Stock. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023. Interest on the Convertible
Notes commenced accruing on the date of issuance at six percent (<span id="xdx_901_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200205__20200206__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_z88mGEiBFj5b" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-02-052020-02-06_custom_ConvertibleNotesPayablesMember" id="Fact001220" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%) per annum, computed on the basis of twelve 30-day months, and was
compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as
of such compound date. The interest was payable in cash on a semi-annual basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">The
conversion price was equal to $12.00&#160;per share of Common Stock. The Holder did not exercise its conversion feature that expired on
February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded
conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily
convertible into cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Effective December 30, 2022 (the
&#8220;Effective Date&#8221;), the Company amended and restated the Convertible Notes (the &#8220;Amended and Restated Secured Notes&#8221;).
Pursuant to the Amended and Restated Secured Notes, the due date was extended to <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zbSaZAfpZdoa" title="Maturity date"><ix:nonNumeric contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember" format="ixt:datemonthdayyearen" id="Fact001222" name="us-gaap:DebtInstrumentMaturityDate">February 28, 2024</ix:nonNumeric></span>. The Amended and Restated Secured Notes
were convertible by the Holder if the Company consummated a public offering or private placement of Common Stock or securities convertible
into Common Stock. The conversion price was to be the price being paid by the investors in such offering. The interest rate was increased
to twelve percent (<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zW3l8gv54ipd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%) per annum, which was prepaid by the Company in full on the date of amendment through the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_ziVjgvyAdWj" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001226" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">198,439</ix:nonFraction></span> shares
of the Company&#8217;s Common Stock: <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zDHmxxKeGdj4" title="Shares issued for accrued interest"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001228" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,419</ix:nonFraction></span> shares for accrued interest up to the Effective Date and <span id="xdx_901_ecustom--PrepaymentShares_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zLFtIxfT4c6f" title="Prepayment shares"><ix:nonFraction name="RENB:PrepaymentShares" contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,020</ix:nonFraction></span> shares related to the prepayment
of interest through the extension date of the Amended and Restated Secured Notes using the Common Stock closing market price on the Effective
Date, of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zeskKTPMIVH7" title="Stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></span>. The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the
&#8220;Security Agreement&#8221;). The Company evaluated the Amended and Restated Secured Notes and conversion feature to determine the
appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480 - Distinguishing Liabilities from Equity,
the Company determined that the Amended and Restated Secured Notes embody an obligation that may require the Company to settle with the
issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a fixed monetary amount
of $<span id="xdx_902_eus-gaap--ContractualObligation_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_znbRdp9YqTfa" title="Obligation value"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001234" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,200,000</ix:nonFraction></span> known at inception. Accordingly, the Company recorded the Amended and Restated Secured Notes as share settled debt. The
total value of the shares issued was $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zb7Iirudq5pj" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001236" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">204,392</ix:nonFraction></span> which included $<span id="xdx_90F_eus-gaap--PrepaidInterest_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zVa32eaFbIc" title="Prepaid interest"><ix:nonFraction name="us-gaap:PrepaidInterest" contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001238" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">174,090</ix:nonFraction></span> of prepaid interest and $<span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zP4wggekfhRd" title="Accrued interest amount"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001240" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,302</ix:nonFraction></span> for accrued interest as of December
30, 2022. On June 26, 2023, <span style="background-color: white">the Holder notified the Company that it wished to elect to exercise
its conversion right triggered by a private placement. Therefore, all outstanding $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20230625__20230626__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zydmnuHiR6ek" title="Stock issued for debt conversion"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-06-252023-06-26_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001242" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,200,000</ix:nonFraction></span> Amended and Restated Secured Notes were converted
into 2,264,150 shares of Common Stock and warrants to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230625__20230626__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zNo35IDjqls4" title="Stock issued for debt conversion, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-06-252023-06-26_us-gaap_WarrantMember_custom_AmendedAndRestatedSecuredNotesMember" id="Fact001244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,132,075</ix:nonFraction></span> shares of Common Stock. There were no Amended and Restated Secured
Notes outstanding after the foregoing conversion. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_232_zrBg3vuyj1D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div id="xdx_231_zUmvbWJC5XK3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zlILP7QuA5Qi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_z3Fp4fRDtApf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Notes Payable </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Bridge Loans &#8212; </i></b>Between
March 26, 2024 and June 4, 2024 the Company issued Paseco ApS promissory notes (the &#8220;Notes&#8221;) in the aggregate principal and
interest accrued amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20240326__20240604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zjGjqVJdo5Fb" title="Principal and interest accrued amount"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-03-262024-06-04_custom_TheNotesMember" id="Fact001248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,098,252</ix:nonFraction></span>. The Notes had an interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zceVXPNJudY7" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-06-04_custom_TheNotesMember" id="Fact001250" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum and were to mature between May 1, 2024, and August
1, 2024. The Notes were accounted for under ASC 470-20, and all proceeds received from the issuance was recognized as a liability on the
balance sheet. On June 14, 2024, the Company sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_znI3FhikuxQc" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-06-132024-06-14_custom_TheNotesMember" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,424,862</ix:nonFraction></span> Units at a price per Unit equal to $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zs7p5aUctQqi" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-06-14_custom_TheNotesMember" id="Fact001254" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span> to settle the bridge loan aggregate
amount of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_z30xhfD2iRh2" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-06-132024-06-14_custom_TheNotesMember" id="Fact001256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,098,252</ix:nonFraction></span>. As of June 30, 2024 the Notes balance is zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 5, 2024, the
Company entered into an agreement with RS Bio ApS, a Danish entity controlled by the Company&#8217;s Chairman, Rene Sindlev
(&#8220;RS Bio&#8221;) to issue a <span id="xdx_901_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zJpZ1yRAt5ji" title="Original issue discount promissory note percentage"><ix:nonFraction name="RENB:OriginalIssueDiscountPromissoryNotePercentage" contextRef="AsOf2024-02-05_custom_RSBioMember" id="Fact001258" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zbd3k9k9P9vc" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-02-05_custom_RSBioMember" id="Fact001260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,263</ix:nonFraction></span>.
The Company received $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfDebt_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zvREn5B0qmG1" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-02-042024-02-05_custom_RSBioMember" id="Fact001262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>
in gross proceeds after taking into account the <span id="xdx_90E_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zj82Hp9EAvfl" title="Gross proceeds original issue discount rate"><ix:nonFraction name="RENB:GrossProceedsDiscountPercentage" contextRef="AsOf2024-02-05_custom_RSBioMember" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
original issue discount. The note bears an interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zchMHdsRwFN3" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2024-02-042024-02-05_custom_RSBioMember" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%
per annum and matured on <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zMcqeKmWlsJa" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-02-042024-02-05_custom_RSBioMember" format="ixt:datemonthdayyearen" id="Fact001268" name="us-gaap:DebtInstrumentMaturityDate">March
1, 2024</ix:nonNumeric></span> and was extended to December 31, 2024. The obligations under this note are secured by the Amended
and Restated Security Agreement. The Company is required to pay interest on the maturity date. The note is accounted for under ASC
470-20, and all proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. For the
year ended June 30, 2024, discount amortization of $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zXmxZ1pp5oea" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_RSBioApSMember" id="Fact001270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,263</ix:nonFraction></span>
was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_90E_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zDhup9fSBzmi" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_RSBioApSMember" id="Fact001272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,316</ix:nonFraction></span>
of interest expense that is included in accrued expenses on the balance sheet. The note balance, net of discount at June 30, 2024
was $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zQD1XR0yIaga" title="Net of debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_RSBioApSMember" id="Fact001274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,263</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a <span id="xdx_903_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zNgqXKkLY9t2" title="Original issue discount promissory note percentage"><ix:nonFraction name="RENB:OriginalIssueDiscountPromissoryNotePercentage" contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact001276" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zprJ9yNX5ZI9" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact001278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,315</ix:nonFraction></span>
(the &#8220;January 2024 Note&#8221;). The Company received a total of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zlYx472HH0Tc" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact001280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> in gross proceeds after taking into account the <span id="xdx_90C_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zOaT0QXUFg2k" title="Gross proceeds original issue discount rate"><ix:nonFraction name="RENB:GrossProceedsDiscountPercentage" contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact001282" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% original
issue discount.&#160;The January 2024 Note bears an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zU2WDNKwwWnl" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact001284" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and matured on <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_znbqkgXK8jA4" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" format="ixt:datemonthdayyearen" id="Fact001286" name="us-gaap:DebtInstrumentMaturityDate">March 1, 2024</ix:nonNumeric></span> and was extended to December 31, 2024. The Company
is required to pay interest on the maturity date. The January 2024 Note will be accounted for under ASC 470-20, and all proceeds received
from the issuance will be recognized as a liability on the balance sheet net of discount. For the year ended June 30, 2024, discount amortization
of $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zMOD7WyFuTxh" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,315</ix:nonFraction></span> was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_905_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zXkp7b5ojcgi" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_JanuaryNote2024Member" id="Fact001290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,579</ix:nonFraction></span> of interest expense that is included in accrued
expenses on the balance sheet. The Note balance, net of discount at June 30, 2024 was $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zAwEZfPawyW7" title="Net of debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member" id="Fact001292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,315</ix:nonFraction></span>. In connection with the entry into the
January 2024 Note, the Company and Paseco ApS agreed to amend and restate a Security Agreement to add the Company&#8217;s obligations
under the November 2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 22, 2023, Renovaro
Cube entered into a loan agreement where the holder agreed to loan the Company up to &#163;500,000 (approximately $624,000 USD). The
note had a repayment date occurring the first business day after the first anniversary of the draw down of the loan. The first draw down
of &#163;250,000 occurred on November 27, 2023, and the second draw down of &#163;250,000 occurred on December 13, 2023. The Company
paid interest on the loan at the rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20231121__20231122__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z21yqa3vCc02" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2023-11-212023-11-22_custom_LoanAgreementMember_us-gaap_BridgeLoanMember" id="Fact001294" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
per annum. Interest was accrued quarterly in arrears on the last business day of March, June, September, and December and was payable
on the repayment date. On June 14, 2024 the Company sold <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdPDkHfWH8T1"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,708</ix:nonFraction>
</span>Units to the holder and terminated $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zOtixoiodQLg"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember" id="Fact001296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">665,387</ix:nonFraction>
</span>in aggregate principal amount and accrued interest and received in cash an aggregate amount of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zONqHSUkgIRh"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember" id="Fact001297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,400</ix:nonFraction>
</span>in consideration for the Units which was applied against the loan. For the year ended June 30, 2024, the Company recorded $<span id="xdx_903_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember_zRKoThO9EJL6" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_us-gaap_BridgeLoanMember_custom_LoanAgreementMember" id="Fact001299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,388</ix:nonFraction>
</span>of interest expense related to this loan. The total amount of the loan at June 30, 2024, is zero <b style="display: none"><span id="xdx_900_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember_zYQD5pRu7a3i" title="Interest expense related to note balance"><ix:nonFraction name="RENB:InterestExpenseRelatedToNoteBalance" contextRef="From2023-07-012024-06-30_us-gaap_BridgeLoanMember_custom_LoanAgreementMember" id="Fact001301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 3, 2023, the
Company entered into an agreement with RS Bio to issue a <span id="xdx_908_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zZWayyJt9D2b"><ix:nonFraction name="RENB:OriginalIssueDiscountPromissoryNotePercentage" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact001302" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
Original Issue Discount Promissory Note for the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zkFpdUV0hIua"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>
(the &#8220;November 2023 Note&#8221;). The Company received a total of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zaJWGPOfuhNj"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact001304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950,000</ix:nonFraction></span>
in gross proceeds after taking into account the <span id="xdx_901_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zect0el2ZFYb"><ix:nonFraction name="RENB:GrossProceedsDiscountPercentage" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
original issue discount.&#160;The discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zqKCsOO5C8Vl"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact001306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
will be accreted over the life of the Note. The November 2023 Note bears an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKhLsNSuUiqi"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact001307" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%
per annum and was due to mature on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zCRB9dwseT18"><ix:nonNumeric contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember" format="ixt:datemonthdayyearen" id="Fact001308" name="us-gaap:DebtInstrumentMaturityDate">January
1, 2024</ix:nonNumeric></span> (the &#8220;Maturity Date&#8221;). On January 1, 2024, the Company entered into an amendment with RS
Bio for the November 2023 Note to extend the maturity date to <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxF6zffsgI4h"><ix:nonNumeric contextRef="From2024-01-012024-01-02_custom_November2023NoteMember_custom_RSBioMember" format="ixt:datemonthdayyearen" id="Fact001309" name="us-gaap:DebtInstrumentMaturityDate">March
1, 2024</ix:nonNumeric></span> and  was extended to December 31, 2024. The Company is required to pay interest on the maturity
date. The November 2023 Note will be accounted for under ASC 470-20, and all proceeds received from the issuance will be recognized
as a liability on the balance sheet net of discount. On February 16, 2024, the Company received notice from the holder to exercise <span id="xdx_903_ecustom--ExerciseWarrants_iI_c20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_z4u4gDi1kBxl" title="Number of warrants exercised"><ix:nonFraction name="RENB:ExerciseWarrants" contextRef="AsOf2024-02-16_custom_November2023NoteMember" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,699</ix:nonFraction></span>
warrants outstanding at $<span id="xdx_903_ecustom--WarrantsOutstandingPerShare_c20240214__20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_zSuNlCLbsBHh" title="Warrant exercise price per share"><ix:nonFraction name="RENB:WarrantsOutstandingPerShare" contextRef="From2024-02-142024-02-16_custom_November2023NoteMember" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span>
per share and apply $<span id="xdx_906_ecustom--ExerciseWarrantsAmount_iI_c20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_z6yMtNpb0TM9" title="Exercise warrants amount"><ix:nonFraction name="RENB:ExerciseWarrantsAmount" contextRef="AsOf2024-02-16_custom_November2023NoteMember" id="Fact001315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>
of the note balance to the exercise price of the warrants. For the year ended June 30, 2024, discount amortization of $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_z8Tg8ixJkAu9"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-012024-06-30_custom_November2023NoteMember" id="Fact001316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_904_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_zet7t18EnN7i"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_November2023NoteMember" id="Fact001317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,083</ix:nonFraction></span>
of interest expense that is included in accrued expenses on the balance sheet. The November 2023 Note balance, net of discount at
June 30, 2024 is $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_zLPuGOUM4z48"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2024-06-30_custom_November2023NoteMember" id="Fact001318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><p id="xdx_234_zK5tavGelVHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zycXPLq5Mnih" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div id="xdx_236_zbugWn8OH5E" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_z3NN7DfdWOmh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zFCO5qH8GNza" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zoGUhnOaSSY5" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-03-30_custom_PromissoryNoteMember" id="Fact001323" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> (the &#8220;Promissory
Note&#8221;) to the Holder. The principal amount of the Promissory Note was originally payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zFZ2qNerVYw7" title="Maturity date"><ix:nonNumeric contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact001325" name="us-gaap:DebtInstrumentMaturityDate">November 30, 2021</ix:nonNumeric></span> (the &#8220;Maturity
Date&#8221;). The Promissory Note bore interest at a fixed rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zGZfb2eWWoi6" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum, computed based on the number of days between the Issuance
Date and the Maturity Date, and the interest was prepaid by the Company in full on the Issuance Date through the issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zdaKfHFOG1yk" title="Stock issued for debt conversion, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">188,485</ix:nonFraction></span> shares
of the Company&#8217;s Common Stock based on the closing market price on that date for a total value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3VBFVpr0KZ9" title="Stock issued for debt conversion"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" id="Fact001331" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">501,370</ix:nonFraction></span>. The Company evaluated
the Promissory Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds
received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount
of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zOA7lNduxW6a" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">493,192</ix:nonFraction></span>, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest
method. The discount of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zhMxnugQa1o" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" id="Fact001335" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">493,192</ix:nonFraction></span> will be accreted over the life of the Promissory Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 11, 2021, the Company
entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory
Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of <span id="xdx_90E_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3MeFF689GN8" title="Interest at the fixed rate"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2021-02-11_custom_PromissoryNoteMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum, which was
prepaid by the Company in full on the date of the amendment through the issuance of <span id="xdx_90F_eus-gaap--SharesIssued_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2021-02-11_custom_PromissoryNoteMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,054</ix:nonFraction></span> shares of the Company&#8217;s Common Stock
based on the closing market price on that date for a total value of $<span id="xdx_903_ecustom--MarketPrice_iI_pp0p0_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3Q5ZMzidku7" title="Market price"><ix:nonFraction name="RENB:MarketPrice" contextRef="AsOf2021-02-11_custom_PromissoryNoteMember" id="Fact001341" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">298,178</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On May 17, 2022, the Company entered
into a second amendment to the Promissory Note that extended the Maturity Date to <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220516__20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zoMCUly4hPGh" title="Maturity date"><ix:nonNumeric contextRef="From2022-05-162022-05-17_custom_PromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact001343" name="us-gaap:DebtInstrumentMaturityDate">November 30, 2023</ix:nonNumeric></span> and increased the interest rate from
<span id="xdx_903_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20220517__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zKpwnd8unzN6" title="Interest at the fixed rate"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2022-05-17_srt_MinimumMember_custom_PromissoryNoteMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% to <span id="xdx_905_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20220517__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zalunitf0fd4" title="Interest at the fixed rate"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2022-05-17_srt_MaximumMember_custom_PromissoryNoteMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year
of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022
until May 30, 2023 on the date of the amendment through the issuance of <span id="xdx_903_eus-gaap--SharesIssued_iI_c20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zh8eL3iAPes8" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2022-05-17_custom_PromissoryNoteMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,115</ix:nonFraction></span> shares of the Company&#8217;s Common Stock based on the
closing market price on that date for a total value of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220516__20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zyR6sGR2Vsv3" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-05-162022-05-17_custom_PromissoryNoteMember" id="Fact001351" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">299,178</ix:nonFraction></span>. All other accrued interest payable from May 30, 2023 to the Maturity
Date was required to be paid by the Company on May 30, 2023, at the option of the Holder in either (i) cash or (ii) shares of the Company&#8217;s
Common Stock, valued at the closing sale price of the Common Stock on the Nasdaq Capital Market on May 30, 2023. The Holder elected the
interest be paid in cash (the &#8220;Interest Payment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Effective December 30, 2022, the
Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company&#8217;s obligations under
the Promissory Note were secured by a Security Agreement. To secure the Company&#8217;s obligations under each of the Amended and Restated
Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted
a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of the Holder. Upon an Event of Default (as defined
in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession
of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 12, 2023, the Holder notified
the Company that it wanted to apply the Interest Payment due to it towards the Company&#8217;s next private placement. Therefore, on June
26, 2023, in conjunction with the Company&#8217;s private placement, the Company issued (i) <span id="xdx_908_eus-gaap--SharesIssued_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zD42HVxZjg9" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,588</ix:nonFraction></span> shares of its Common Stock, par value
$<span id="xdx_909_eus-gaap--SharePrice_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zM8sAl8ipnXi" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember" id="Fact001355" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share and (ii) warrants to purchase <span id="xdx_90E_ecustom--WarrantsPurchased_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGcva7fgxp6l" title="Warrants purchased"><ix:nonFraction name="RENB:WarrantsPurchased" contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember" id="Fact001357" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">283,794</ix:nonFraction></span> shares of Common Stock at a purchase price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYXqnayQkbx5" title="Warrant purchase price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> per share and applied the
Interest Payment of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHFfa8ACjsC5" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-06-252023-06-26_us-gaap_PrivatePlacementMember" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,822</ix:nonFraction></span> it owed to the Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_237_zFtUbZLFity" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div id="xdx_239_zaFxUpus3Gt2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_zgCk4eyJRzBf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zpLtShIUo5o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><p id="xdx_239_zZ0NbVX1BzU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 31, 2023, the Company and
the Holder agreed to amend the Promissory Note (the &#8220;Fourth Amendment&#8221;) to provide the Holder with limited conversion rights
in connection with the Company&#8217;s next private placement. Per the terms of the Fourth Amendment, the Holder could elect to convert
$2 million of the outstanding principal balance of the Promissory Note into the Units being offered in a private placement at the price
per Unit being paid by the investors in the private placement (the &#8220;Conversion Right&#8221;). On August 1, 2023, the Holder notified
the Company of its election to exercise the Conversion Right. As a result, $2 million of the outstanding principal balance of the Promissory
Note was converted into 280,505 Units at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible Preferred
Stock of the Company and (ii) Warrants to purchase an aggregate of 1,402,525 shares of Common Stock with an exercise price of $0.65 per
share. The Series A Convertible Preferred Stock acquired by the Holder was initially convertible into 2,805,050 shares of Common Stock.
A $3 million principal balance remained outstanding under the Promissory Note after the foregoing conversion. The Company concluded that
in accordance with ASC 470-20-40-4, the difference between the fair value of the Preferred Shares and warrants and the carrying value
of the portion of the Note being converted should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded
in Other Income/Loss in the Statement of Operations. On November 30, 2023, the Company and the Holder agreed to amend the Promissory Note
(the &#8220;Fifth Amendment&#8221;) such that the Company and the Holder extended the maturity of the original Promissory Note until February
29, 2024. In addition, all interest payable from November 30, 2023 to the Maturity Date was payable and is currently payable by the Company
as of November 30, 2023. On February 16, 2024, the Company received notice from the Holder to exercise 2,953,700 warrants outstanding
ranging from $0.53 to $0.65 per share and apply $1,750,000 of the note balance to the exercise price of the warrants. On February 29,
2024, the Company and the Holder agreed to amend the Promissory Note (the &#8220;Sixth Amendment&#8221;) to where the Company and the
Holder extended the maturity of the original Promissory Note until May 1, 2024. On May 1, 2024, the Company and the Holder agreed to amend
the Promissory Note (the &#8220;Seventh Amendment&#8221;) to extend the maturity of the original Promissory Note until August 1, 2024.
On June 14, 2024 the Holder requested the Company repay $<span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zp1Auc8DNYYd" title="Repayment on promissory note"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-06-132024-06-14_custom_PromissoryNoteMember" id="Fact001366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,503</ix:nonFraction></span> of the Promissory Note. The Company applied $<span id="xdx_904_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zdjWj96bwTyb" title="Repayment on promissory note"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreementsMember" id="Fact001368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,440</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreements1Member_zLwQk7yNLPef" title="Repayment on promissory note"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreements1Member" id="Fact001370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,063</ix:nonFraction></span> owed
to the Company pursuant to certain Subscription Agreements. As such, payment of the 2020 Note Repayment decreased the principal amount
by $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--LongtermDebtTypeAxis__custom--Note2020Member_zCkuYbPTKEge" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-06-14_custom_Note2020Member" id="Fact001372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,503</ix:nonFraction></span>. For the year ended June 30, 2024 and 2023, discount amortization of $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zs9XfinTrwJh" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember" id="Fact001374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,763</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20220701__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z9IObNqog49d" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-07-012023-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember" id="Fact001376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,621</ix:nonFraction></span> was charged to interest expense.
The Promissory Note balance, net of discount at June 30, 2024 is $<span id="xdx_907_ecustom--PromissoryNoteBalanceNetOfDiscount_iI_c20240630__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zsnCy1CMFHWh" title="Promissory note balance, net of discount"><ix:nonFraction name="RENB:PromissoryNoteBalanceNetOfDiscount" contextRef="AsOf2024-06-30_custom_PromissoryNoteMember" id="Fact001378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">824,418</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Finance Agreement </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 30, 2023, the Company
entered into a premium finance agreement (the &#8220;Agreement&#8221;) related to insurance,&#160;<span style="background-color: white">which
resulted in the recognition of a liability and prepaid expense with a principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20231130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z2w0HAneaCRd" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2023-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember" id="Fact001380" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">906,834</ix:nonFraction></span>&#160;at&#160;<span id="xdx_903_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20231130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zsqjdQeqoCe7" title="Rate of interest"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2023-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember" id="Fact001382" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.90</ix:nonFraction></span>% interest per annum,
which is reflected on the consolidated balance sheet under &#8220;other current liabilities&#8221; and &#8220;prepaid assets and other
assets&#8221;, respectively. The repayment of the Agreement will be made in nine equal monthly installments of $<span id="xdx_90A_ecustom--MonthlyInstallments_pp0p0_c20231129__20231130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zYRXt6AFLEC6" title="Monthly instalments amount"><ix:nonFraction name="RENB:MonthlyInstallments" contextRef="From2023-11-292023-11-30_custom_FinanceAgreementMember" id="Fact001384" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,127</ix:nonFraction></span>&#160;after a down
payment of $<span id="xdx_907_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20231129__20231130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zDtbJNOwXWl4" title="Down payment amount"><ix:nonFraction name="RENB:RepaymentOnFinanceAgreement" contextRef="From2023-11-292023-11-30_custom_FinanceAgreementMember" id="Fact001386" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">235,000</ix:nonFraction></span>.&#160;For the years ended June 30, 2024 and 2023 the Company made payments of $<span id="xdx_905_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zOUuyx8t33U1" title="Down payment amount"><ix:nonFraction name="RENB:RepaymentOnFinanceAgreement" contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember" id="Fact001388" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">870,073</ix:nonFraction></span>&#160;and $<span id="xdx_906_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20220701__20230630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zdUheJLEdgy6" title="Down payment amount"><ix:nonFraction name="RENB:RepaymentOnFinanceAgreement" contextRef="From2022-07-012023-06-30_custom_FinanceAgreementMember" id="Fact001390" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,121,767</ix:nonFraction></span>, respectively.
</span>The remaining balance at June 30, 2024 is $<span id="xdx_90A_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20240630_zzaO2CeeXcN8" title="Other current liabilities"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-06-30" id="Fact001392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,381</ix:nonFraction></span>; the amount is reflected in other current liabilities. <span style="background-color: white">For
the years ended June 30, 2024 and 2023 the Company recorded total interest expense in the amount of $<span id="xdx_905_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z2ZpR51JW4Og" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember" id="Fact001394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,128</ix:nonFraction></span> and $</span><span id="xdx_908_eus-gaap--InterestAndDebtExpense_c20220701__20230630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zitl49jOc7R" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2022-07-012023-06-30_custom_FinanceAgreementMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,180</ix:nonFraction></span><span style="background-color: white">&#160;related
to the Agreement. This amount is reflected in other income and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Total
interest expense recorded for the years ended June 30, 2024 and 2023, was $<span id="xdx_901_eus-gaap--InterestExpenseNonoperating_c20230701__20240630_zGSB71TNikb9" title="Total interest expense"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-07-01to2024-06-30" id="Fact001398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,011,322</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--InterestExpenseNonoperating_c20220701__20230630_zLTSFcUX6DOk" title="Total interest expense"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2022-07-012023-06-30" id="Fact001400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,344</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001402" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zseQf7biGuTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_821_zwu0sdUG06Ck">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company accounts for income
taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset
or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and
any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax
assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other future
events, the effects of which cannot be determined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024 and 2023, the Company had net operating loss carryforwards
of approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zjVGt9m2hH22" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember" id="Fact001404" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">489,177,759</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20230630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z6H9YnsH3ED1" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-06-30_custom_UnitedStatesTaxMember" id="Fact001406" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">476,965,239</ix:nonFraction></span>, respectively, giving rise to deferred tax assets of $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z2dZIMoIak0j" title="Deferred tax assets"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember" id="Fact001408" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,191,530</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20230630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zm7eh49aVwMl" title="Deferred tax assets"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2023-06-30_custom_UnitedStatesTaxMember" id="Fact001410" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,547,314</ix:nonFraction></span>, respectively.
The net operating loss carryforwards generated prior to January 1, 2018 expire over various dates from 2031 to 2038. All subsequent net
operating loss carryforwards are indefinite.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company files Danish and U.S.
income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2020 for the Danish tax returns
and 2021 for the U.S. tax returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zqGLcy6nkvVf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div id="xdx_231_z8BaU3bZKBp1" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zWSBJYch88Mg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zccooOhcpp17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The temporary differences, tax
credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001414" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ztWcSMWdxjSk" summary="xdx: Disclosure - INCOME TAXES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20240630_zrtimKmuCoh7" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_493_20230630_zsiS1GUd4u15" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
<tr id="xdx_40C_ecustom--DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_iI_pp0p0_maDTALNzwuT_zy85kfWMavXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of fixed assets</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" contextRef="AsOf2024-06-30" id="Fact001416" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,258</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" contextRef="AsOf2023-06-30" id="Fact001417" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,258</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_zHkoz6FQxJG3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of patents</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents" contextRef="AsOf2024-06-30" id="Fact001419" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,415</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents" contextRef="AsOf2023-06-30" id="Fact001420" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,415</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_zyKcZ9CDZlGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock/options compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:StockoptionsCompensation" contextRef="AsOf2024-06-30" id="Fact001422" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,672,252</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:StockoptionsCompensation" contextRef="AsOf2023-06-30" id="Fact001423" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,885,996</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_zZQ7YsxC6dyd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DepreciationAndAmortizations" contextRef="AsOf2024-06-30" id="Fact001425" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">188,422</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DepreciationAndAmortizations" contextRef="AsOf2023-06-30" id="Fact001426" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,059</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_zhXX7JcqYuFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-06-30" id="Fact001428" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,191,530</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-06-30" id="Fact001429" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,547,314</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPBUAL6t8tS3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ImpairmentExpense" contextRef="AsOf2024-06-30" id="Fact001431" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,188,497</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ImpairmentExpense" contextRef="AsOf2023-06-30" id="Fact001432" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zqRgsu6xVEva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationFairValue" contextRef="AsOf2024-06-30" id="Fact001434" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,410,678</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationFairValue" contextRef="AsOf2023-06-30" id="Fact001435" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zFEx1Nug8bV7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in tax rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ChangeInTaxRate" contextRef="AsOf2024-06-30" id="Fact001437" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ChangeInTaxRate" contextRef="AsOf2023-06-30" id="Fact001438" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_zsOa3FBgqbL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-06-30" id="Fact001440" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">168,668,052</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-06-30" id="Fact001441" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,602,042</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_d0_mtDTALNzwuT_zXlzkLjANGZf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Deferred Tax Assets (Liabilities)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-06-30" id="Fact001443" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-06-30" id="Fact001444" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A1_z5KNx5UUL8jb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In accordance with prevailing accounting
guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to
recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine
whether the tax position meets the more-likely-than-not condition for recognition, and the second step is to determine the amount to be
recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred
tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other
future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely
than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance
was recorded for all deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A reconciliation of income tax
expense at the federal statutory rate to income tax expense at the Company&#8217;s effective rate is as follows for the years ended June
30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001446" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zye7fHvoq3m9" summary="xdx: Disclosure - INCOME TAXES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zioNRtqge65g" style="display: none">Schedule of reconciliation of income tax expense</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_496_20230701__20240630_zSIkBTY8xu11" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_495_20220701__20230630_zs7bvbPUPSt4" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed tax at expected statutory rate</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2023-07-01to2024-06-30" id="Fact001448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,066,011</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2022-07-012023-06-30" id="Fact001449" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70,341,751</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zxqPCIjJ4Zm4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-US income taxed at different rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextRef="From2023-07-01to2024-06-30" id="Fact001451" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextRef="From2022-07-012023-06-30" id="Fact001452" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zT8grGiUTgcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible expenses / other items</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2023-07-01to2024-06-30" id="Fact001454" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2022-07-012023-06-30" id="Fact001455" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-07-01to2024-06-30" id="Fact001457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,066,011</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-07-012023-06-30" id="Fact001458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,341,751</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zDIinjTeozVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income Tax Expense (Benefit)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherTaxExpenseBenefit" contextRef="From2023-07-01to2024-06-30" id="Fact001460" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherTaxExpenseBenefit" contextRef="From2022-07-012023-06-30" id="Fact001461" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A7_z9e9taVSiNSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The components of income tax expense
(benefit) from continuing operations for the years ended June 30, 2024 and 2023 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001463" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z4CIuVvF8H48" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 30pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20230701__20240630_zr2YwIHX5iU6" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220701__20230630_zesYaS1viu83" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Income Tax Expense</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zl4O7PzwD6Gj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Danish income tax (benefit)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-07-01to2024-06-30" id="Fact001468" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-07-012023-06-30" id="Fact001469" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_zELkXbtmTxTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Current Tax Expense (Benefit)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-07-01to2024-06-30" id="Fact001471" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-07-012023-06-30" id="Fact001472" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred Income Tax Expense (Benefit)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationFixedAssets_i01_pp0p0_maDITEBzk3M_z85liOo5WeSb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess of tax over book depreciation of fixed assets</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExcessTaxBenefitOverDepreciationFixedAssets" contextRef="From2023-07-01to2024-06-30" id="Fact001477" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,258</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExcessTaxBenefitOverDepreciationFixedAssets" contextRef="From2022-07-012023-06-30" id="Fact001478" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,258</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationPatents_i01_pp0p0_maDITEBzk3M_z1yauBO3fNuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess of tax over book depreciation of patents</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExcessTaxBenefitOverDepreciationPatents" contextRef="From2023-07-01to2024-06-30" id="Fact001480" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,415</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExcessTaxBenefitOverDepreciationPatents" contextRef="From2022-07-012023-06-30" id="Fact001481" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,415</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_pp0p0_maDITEBzk3M_zG0AXNB2Sh1b" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock/options compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-07-01to2024-06-30" id="Fact001483" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,672,252</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2022-07-012023-06-30" id="Fact001484" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,885,996</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_i01_pp0p0_maDITEBzk3M_zK3c0RPowwug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="From2023-07-01to2024-06-30" id="Fact001486" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">188,422</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="From2022-07-012023-06-30" id="Fact001487" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,059</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--IncomeTaxExpenseBenefitOperatingLossCarryforwards_i01_pp0p0_maDITEBzk3M_zJa1QBHTfmG3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:IncomeTaxExpenseBenefitOperatingLossCarryforwards" contextRef="From2023-07-01to2024-06-30" id="Fact001489" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,191,530</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:IncomeTaxExpenseBenefitOperatingLossCarryforwards" contextRef="From2022-07-012023-06-30" id="Fact001490" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,547,314</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--IncomeTaxExpenseBenefitImpairmentExpense_i01_pp0p0_d0_maDITEBzk3M_z2jEHfKiLsj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IncomeTaxExpenseBenefitImpairmentExpense" contextRef="From2023-07-01to2024-06-30" id="Fact001492" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,188,497</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IncomeTaxExpenseBenefitImpairmentExpense" contextRef="From2022-07-012023-06-30" id="Fact001493" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--IncomeTaxExpenseBenefitContingentConsiderationFairValue_i01_pp0p0_d0_maDITEBzk3M_z8ygs5gtrVLi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;Contingent consideration fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IncomeTaxExpenseBenefitContingentConsiderationFairValue" contextRef="From2023-07-01to2024-06-30" id="Fact001495" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,410,678</ix:nonFraction>&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredIncomeTaxExpenseChangeInTaxRate_i01_pp0p0_d0_maDITEBzk3M_zM7EdBLlqlLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in tax rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:DeferredIncomeTaxExpenseChangeInTaxRate" contextRef="From2023-07-01to2024-06-30" id="Fact001498" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:DeferredIncomeTaxExpenseChangeInTaxRate" contextRef="From2022-07-012023-06-30" id="Fact001499" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0p0_di_msDITEBzk3M_z5Eh1OC24NW5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in the valuation allowance</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-07-01to2024-06-30" id="Fact001501" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">168,668,052</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-07-012023-06-30" id="Fact001502" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,602,042</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_zT3pXbVezUE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Deferred Tax Expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-07-01to2024-06-30" id="Fact001504" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-07-012023-06-30" id="Fact001505" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A2_zYNhkACAc4D" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Deferred income tax expense (benefit)
results primarily from the reversal of temporary timing differences between tax and financial statement income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_z3ioJeRX7DXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div id="xdx_231_zw02dxiipNw5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zEtNa5vwNnCa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_z0T6u3VkoNc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001509" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zETp2fzeaXG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_82D_zHs0CpSh7iw7">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Preferred Stock </b>&#8212;
The Company has <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zStdSSz8DFTi" title="Preferred stock shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3NJ2Wdgwjj6" title="Preferred stock shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001511" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span>
authorized shares of Preferred Stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zFUMv1LdNuA4" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001515" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001517" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
per share, <span id="xdx_900_ecustom--PreferredStockDesignatedShares_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXrqVFbmkix3" title="Preferred stock designated shares"><span id="xdx_902_ecustom--PreferredStockDesignatedShares_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAjcMhsCWXpi" title="Preferred stock designated shares"><ix:nonFraction name="RENB:PreferredStockDesignatedShares" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001519" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="RENB:PreferredStockDesignatedShares" contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span>
of which have been designated as Series A Convertible Preferred Stock. At June 30, 2024 and 2023, there were zero <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8VNXDieA7Rk" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLPe8T1l4DSl" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVp1TeIgJfRg" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zbuNJvtIQ4Ha" title="Preferred stock, shares outstanding" style="display: none"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001523" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001525" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001527" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001529" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of
Preferred Stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Voting &#8212; </b>Holders of
Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
holder&#8217;s shares of Preferred Stock could then be converted in accordance with conversion rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><b>Dividends &#8212; </b>The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Liquidation Rights &#8212;</b>
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all shares held by such holder. The Series A Preferred Stock is not participating preferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Conversion Rights &#8212; </b>On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a &#8220;Series A Election
Notice&#8221;) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
&#8220;Conversion Ratio&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Common Stock </b>&#8212;
The Company has <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zW3Y4NSXdBc4" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20230630_zIu7vIsRz4Mi" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact001531" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30" id="Fact001533" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares of Common Stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zdB9zWIA8U8f" title="Common stock, par value"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230630_zZsIFg9USyDb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact001535" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" id="Fact001537" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
per share. At June 30, 2024 and 2023, there were <span id="xdx_902_ecustom--CommonStockShareIssued_iI_c20240630_z4VLYJHgq7Rh" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_z18ifjdFevt4" title="Common stock, shares outstanding"><ix:nonFraction name="RENB:CommonStockShareIssued" contextRef="AsOf2024-06-30" id="Fact001539" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact001541" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,027,245</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_ecustom--CommonStockShareIssued_iI_c20230630_zhlGTy00WDDa" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230630_zcu4r5C51X4i" title="Common stock, shares outstanding"><ix:nonFraction name="RENB:CommonStockShareIssued" contextRef="AsOf2023-06-30" id="Fact001543" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" id="Fact001545" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,698,144</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, respectively. At June 30, 2024
the Company has <span id="xdx_90C_ecustom--CommonStockConvertibleSharesIssuable_iI_c20240630_zma3H2pxOvNg" title="Common stock, shares issuable"><ix:nonFraction name="RENB:CommonStockConvertibleSharesIssuable" contextRef="AsOf2024-06-30" id="Fact001547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,189,672</ix:nonFraction></span> shares issuable, which are included in shares outstanding, related to the contingent consideration settlement
(see Notes 3 and 12).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Voting &#8212; </b>Holders of
Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Dividends &#8212; </b>Holders
of Common Stock are entitled to receive ratably such dividends as the Company&#8217;s Board of Directors from time to time may declare
out of funds legally available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Liquidation Rights &#8212;</b>
In the event of any liquidation, dissolution or winding-up of the affairs of the Company, after payment of all debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any remaining assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Purchase Agreement with Lincoln
Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June
20, 2023, the Company entered into a purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park, pursuant to which
the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_ziTc8e9bO4w1" title="Obligation to purchase"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2023-06-20" id="Fact001549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span> of shares of Common Stock
over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the 2023 Purchase Agreement, the Company also entered
into a registration rights agreement with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration
rights related to the shares issued under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_23E_zPweiJkLAK4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div id="xdx_232_zdljoOmGkEr5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zBlGzllv4KT2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zN7xd1M7BPs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In consideration for entering into
the 2023 Purchase Agreement, the Company issued <span id="xdx_909_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zdBKGlQzvPT5" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-06-20_custom_PurchaseAgreementMember" id="Fact001553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">696,021</ix:nonFraction></span> shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June 30,
2024 and June 30, 2023 no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;<b>Preferred Stock Issuances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 1, 2023, the Company
closed a private placement of <span id="xdx_901_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20230729__20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zb7qp816ycJe" title="Closed private placement units"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement" contextRef="From2023-07-292023-08-01_custom_PreferredStockIssuancesMember" id="Fact001555" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,505</ix:nonFraction></span> units (the &#8220;<span style="text-decoration: underline">Units</span>&#8221;), each consisting of (i) one share of the Company&#8217;s
Series A Convertible Preferred Stock, (the &#8220;<span style="text-decoration: underline">Preferred Stock</span>&#8221;) and (ii) one Common Stock purchase warrant (each, a &#8220;<span style="text-decoration: underline">Warrant</span>&#8221;,
and together with the Units and the shares of Preferred Stock, the &#8220;<span style="text-decoration: underline">Securities</span>&#8221;) to purchase five shares of the Company&#8217;s
Common Stock, at a price per Unit equal to $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-01_custom_PreferredStockIssuancesMember" id="Fact001557" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.13</ix:nonFraction></span> for aggregate proceeds to the Company of $<span id="xdx_90D_eus-gaap--ProceedsFromRepaymentsOfDebt_c20230729__20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pp0p0" title="aggregate proceeds"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfDebt" contextRef="From2023-07-292023-08-01_custom_PreferredStockIssuancesMember" id="Fact001559" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> in cash. In addition, the Company
issued <span id="xdx_900_eus-gaap--SharesIssued_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-08-01_custom_PreferredStockIssuancesMember" id="Fact001561" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,505</ix:nonFraction></span> Units in connection with the conversion of $<span id="xdx_900_ecustom--ConversionOfPromissoryNote_iI_pp0p0_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_z4WWDvA5ypBl" title="Conversion of promissory note"><ix:nonFraction name="RENB:ConversionOfPromissoryNote" contextRef="AsOf2023-08-01_custom_PreferredStockIssuancesMember" id="Fact001563" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> of the Promissory Note (see Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company issued an
aggregate of <span id="xdx_909_ecustom--AggregatePreferredStockShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zxtlTqyw1Ms" title="Aggregate preferred stock shares"><ix:nonFraction name="RENB:AggregatePreferredStockShares" contextRef="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember" id="Fact001565" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">561,010</ix:nonFraction></span>
shares of Preferred Stock, which were initially&#160;convertible into an aggregate of <span id="xdx_90A_ecustom--AggregateCommonStockShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zLhOjKInR5D9" title="Aggregate common stock shares"><ix:nonFraction name="RENB:AggregateCommonStockShares" contextRef="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember" id="Fact001567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,610,100</ix:nonFraction></span>
shares of Common Stock. In connection with the private placement, the Company sold warrants to purchase an aggregate of <span id="xdx_90E_ecustom--WarrantsSold_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zWxUMCnQVRsh" title="Warrants sold"><ix:nonFraction name="RENB:WarrantsSold" contextRef="AsOf2024-06-30_custom_PreferredStockIssuancesMember" id="Fact001569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,805,050</ix:nonFraction></span>
shares of Common Stock. The warrants are exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zEfGcWA0w4y1" title="Exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember" id="Fact001571" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></span>
per share, payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 13, 2024 pursuant
to the acquisition of Renovaro Cube, the <span id="xdx_907_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zZRts06UIqG8"><ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="AsOf2024-02-13_custom_RenovaroCubeMember" id="Fact001572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">561,010</ix:nonFraction> </span>shares
of Preferred Stock were converted into an aggregate of <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zbnoxENVNuT9"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember" id="Fact001573" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,610,100</ix:nonFraction> </span>shares
of Common Stock. As of June 30, 2024 there were zero shares of Preferred Stock outstanding. The extinguishment loss of $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zdpKUxKkO8Tg" title="Extinguishment loss"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-07-012024-06-30_custom_RenovaroCubeMember" id="Fact001575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,018</ix:nonFraction></span> is
recorded in Other Income/Loss in the Statement of Operations (see Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><b>June
2024 Private Placement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">On
June 14, 2024, Renovaro Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
closed a private placement of <span id="xdx_908_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3OkmCfsC4i2" title="Closed private placement units"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement" contextRef="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember" id="Fact001577" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,315,215</ix:nonFraction></span>
of the Company&#8217;s units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_905_ecustom--ClosedSharesParValue_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXd1Tbwwrbk9" title="Closed shares, par value"><ix:nonFraction name="RENB:ClosedSharesParValue" contextRef="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember" id="Fact001579" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
par value per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain
investors (the &#8220;Private Placement&#8221;). The Warrants are exercisable for five years from the date of issuance and have an
exercise price of $1.4726 and $<span id="xdx_908_ecustom--ExercisePricePerShare_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z9VIBRpcDjEc" title="Exercise price per share"><ix:nonFraction name="RENB:ExercisePricePerShare" contextRef="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember" id="Fact001581" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4765</ix:nonFraction></span>
per share, payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The Private
Placement was completed pursuant to Regulation S promulgated under the Securities Act of 1933, as amended (&#8220;<span style="text-decoration: underline">Regulation S</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">In the Private Placement, the
Company sold <span style="background-color: white"><span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwg9J6Rs8KPh" title="Shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember" id="Fact001583" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,325,869</ix:nonFraction></span></span> Units at a price per Unit equal to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zT2s6IiUhV8f" title="Price per unit"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-06-30_us-gaap_PrivatePlacementMember" id="Fact001585" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction> </span>to a certain investor who
paid in cash and settlement of debt an aggregate amount of $<span style="background-color: white"><span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGec3ElNuo5b" title="Paid in cash and settlement of debt"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember" id="Fact001587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,425,075</ix:nonFraction></span></span> in consideration for
the Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">Additionally, the Company sold
<span style="background-color: white"><span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zyKRJPvjZERb" title="Shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember" id="Fact001589" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,671,631</ix:nonFraction></span></span> Units to certain investors who surrendered and terminated <span style="background-color: white">$<span id="xdx_90F_ecustom--PrincipalAmountAndInterestAccrued_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zxowiBxASdjj" title="Principal amount and interest accrued"><ix:nonFraction name="RENB:PrincipalAmountAndInterestAccrued" contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember" id="Fact001591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction>,<span style="background-color: white">955,033</span></span></span>
in aggregate principal amount and interest accrued thereon of certain convertible promissory notes issued by the Company in 2023 and 2024
and paid in cash an aggregate amount of $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zcNtVuvi8co4" title="Paid in cash and settlement of debt"><span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zEuc3KB1Yl06" title="Paid in cash and settlement of debt"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember" id="Fact001593" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-07-012023-06-30_us-gaap_InvestorMember" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,060</ix:nonFraction></ix:nonFraction></span></span> to the Company in consideration for the Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">Additionally,
the Company sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zSAS88AEcZWe" title="Shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-07-012023-06-30_custom_Investor1Member" id="Fact001597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,715</ix:nonFraction></span> Units to an investor who surrendered and terminated $<span style="background-color: white"><span id="xdx_90B_ecustom--PrincipalAmountAndInterestAccrued_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zIzvvrDIgZcc" title="Principal amount and interest accrued"><ix:nonFraction name="RENB:PrincipalAmountAndInterestAccrued" contextRef="From2022-07-012023-06-30_custom_Investor1Member" id="Fact001599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,453</ix:nonFraction></span></span> in
aggregate principal amount and interest accrued thereon of a convertible promissory note issued in 2023 and paid in cash an aggregate
amount of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zf3u1VH8Ruc1" title="Paid in cash and settlement of debt"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-07-012023-06-30_custom_Investor1Member" id="Fact001601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></span> to the Company in consideration for the Units.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">In relation to the June 14, 2024 Private Placement the Company recognized
a loss on the settlement of debt for $<span id="xdx_909_ecustom--SettlementOfDebt_c20230701__20240630_zinr59qD6xyg" title="Settlement of debt"><ix:nonFraction name="RENB:SettlementOfDebt" contextRef="From2023-07-01to2024-06-30" id="Fact001603" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,560</ix:nonFraction></span> which was recorded in other income (expense) in the statement of operations for the year
ended June 30, 2024.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_233_zAqVMCcxNy1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div id="xdx_231_zncZ2Xk5zml" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zQ9E0cVXSWi9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zSkVrNY2aTEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b>Common Stock Issuances </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On April 5, 2024, the Company issued&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z04ccZU16SHc" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember" id="Fact001607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,760</ix:nonFraction></span>&#160;shares
of common stock for consulting services valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zqlOgRSWx8S9" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember" id="Fact001609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,190</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 20, 2024, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zEO8isVpn10a" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-02-20_us-gaap_WarrantMember" id="Fact001611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,953,700</ix:nonFraction></span>
warrants outstanding were exercised at prices ranging from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zFglnvxhwkZ6" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001613" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zySnTpcRpjei" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></span> per share and the aggregate $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z3rdTeCL4Oj6" title="Warrants aggregate amount"><ix:nonNumeric contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember" id="Fact001617" name="us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized">1,750,000</ix:nonNumeric></span> of a promissory note
held by the holder was applied to the exercise price of the warrants (see Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 20, 2024, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zwVp5MBPbrNb" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember" id="Fact001619" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,699</ix:nonFraction></span> warrants
outstanding were exercised at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zKknGuiqGMVb" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember" id="Fact001621" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> per share valued at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_ztr69WMQxFGi" title="Warrants aggregate amount"><ix:nonNumeric contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember" id="Fact001623" name="us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized">250,000.</ix:nonNumeric></span> A promissory note held by the holder was applied to the exercise
price of the warrants in lieu of cash proceeds (see Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 15, 2024, the Company
issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240214__20240215_zJJJdyIV0aUa" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-02-142024-02-15" id="Fact001625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of Common Stock for consulting services valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240214__20240215__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zTvgBPEYBvQ5" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-02-142024-02-15_custom_CommonStockIssuancesMember" id="Fact001627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
February 15, 2024, the Company closed a private placement of <span id="xdx_906_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240214__20240215_zELhbbt0sBXf" title="Issuance of common stock under private placement"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering" contextRef="From2024-02-142024-02-15" id="Fact001629" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">344,827</ix:nonFraction></span> shares of Common Stock, $<span id="xdx_90C_ecustom--CommonStockParValuePrivatePlacement_c20240214__20240215_zt7gWnwyhYwe" title="Common stock par value under private placement"><ix:nonFraction name="RENB:CommonStockParValuePrivatePlacement" contextRef="From2024-02-142024-02-15" id="Fact001631" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value, at $2.90 per share for
aggregate proceeds to the Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20240214__20240215_zYVvf4r4eHj5" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-02-142024-02-15" id="Fact001633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
February 13, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zFr7sA8xCVJ2" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember" id="Fact001635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,834,183</ix:nonFraction> </span></span><span style="background-color: white">valued
at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zKYdZAjUfFx6" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember" id="Fact001637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction> </span></span><span style="background-color: white">(see
Note 12) shares of Common Stock pursuant to the Stock Purchase Agreement of Renovaro Cube.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On December 4, 2023, the Company
issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231203__20231204_zDJTTY1D8lXi" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-12-032023-12-04" id="Fact001639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,945</ix:nonFraction></span> shares of Common Stock pursuant to warrants exercised for cash proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231203__20231204_zqT6Xm3ZwREk" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-12-032023-12-04" id="Fact001641" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,865</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On October 23, 2023, the
Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--AdvisoryServicesMember_zD7HF5yEiyle" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-222023-10-23_custom_AdvisoryServicesMember" id="Fact001643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction> </span>shares
of Common Stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--AdvisoryServicesMember_z7fFKHzkMUVj" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-222023-10-23_custom_AdvisoryServicesMember" id="Fact001645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,760,000</ix:nonFraction></span> for advisory services to Avram Miller, a member of the Company&#8217;s board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Between July 28, 2023, and
September 28, 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230926__20230928__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zCfX0okrNho" title="Issuance of common stock shares"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230727__20230728__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zNOMtI5jRP6d" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-09-262023-09-28_custom_CommonStockIssuancesMember" id="Fact001647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-07-272023-07-28_custom_CommonStockIssuancesMember" id="Fact001649" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></ix:nonFraction></span></span>
shares of Common Stock for consulting services valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230926__20230928__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z3CExpf9h0El" title="Issuance of common stock shares, value"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230727__20230728__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zs1NwoOJLju2" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-09-262023-09-28_custom_CommonStockIssuancesMember" id="Fact001651" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-272023-07-28_custom_CommonStockIssuancesMember" id="Fact001653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,470,000</ix:nonFraction></ix:nonFraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
June 26, 2023, the Company issued <span id="xdx_90F_eus-gaap--SharesIssued_iI_c20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzbRvSYH6tc6" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-06-26_us-gaap_CommonStockMember" id="Fact001655" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,718,532</ix:nonFraction></span> shares of Common Stock and warrants to purchase <span id="xdx_90B_ecustom--NumberOfShareWarrantPurchase_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zdbvj5OJhHPk" title="Number of share warrant purchase"><ix:nonFraction name="RENB:NumberOfShareWarrantPurchase" contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember" id="Fact001657" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,359,266</ix:nonFraction></span> shares of common stock resulting
in proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCJupqgE204g" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember" id="Fact001659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,300,823</ix:nonFraction></span> </span>in a private placement offering and the reduction of notes payable of $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20230626_zjfTPiQltga2" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-06-26" id="Fact001661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000</ix:nonFraction></span>. The warrants were immediately
exercisable and had an exercise term of five years with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626_zt4sEvPNS7d9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-26" id="Fact001663" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> per share. The combined purchase price for one share
of Common Stock and one warrant was $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zj8aBvmCPna2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-26_custom_OneWarrantMember" id="Fact001665" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
June 26, 2023, the Company issued <span id="xdx_905_eus-gaap--SharesIssued_iI_c20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z18h64maPYzi" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-06-26_us-gaap_CommonStockMember" id="Fact001667" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,718,532</ix:nonFraction></span> shares of Common Stock and warrants to purchase <span id="xdx_90D_ecustom--NumberOfShareWarrantPurchase_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z3zaJoK17Lw9" title="Number of share warrant purchase"><ix:nonFraction name="RENB:NumberOfShareWarrantPurchase" contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember" id="Fact001669" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,359,266</ix:nonFraction></span> shares of common stock resulting
in proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zVyzK65EnJlk" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember" id="Fact001671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,300,823</ix:nonFraction></span> </span>in a private placement offering and the aforementioned reduction of notes payable of $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20230626_zm3n606Ystf3" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-06-26" id="Fact001673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000</ix:nonFraction></span>. The
warrants were immediately exercisable and had an exercise term of five years with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626_zcwPAnsgx8d2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-26" id="Fact001675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> per share. The combined purchase
price for one share of Common Stock and one warrant was $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zTLwurwLdDl2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-26_custom_OneWarrantMember" id="Fact001677" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On June 20, 2023, the Company issued
<span id="xdx_900_eus-gaap--SharesIssued_iI_c20230620__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LincolnParkMember_zrVyZWJRuNFe" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-06-20_us-gaap_CommonStockMember_custom_LincolnParkMember" id="Fact001679" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">696,021</ix:nonFraction></span> shares of Common Stock to Lincoln Park as a commitment fee as part of a purchase agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On April 27, 2023, there were <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20230426__20230427__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFZqj0mTzBjj" title="Converted shares of common stock, shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-04-262023-04-27_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
shares issued that immediately vested and were converted into shares of Common Stock in exchange for consulting services valued at $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20230426__20230427__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq2kP7sDkd1f" title="Converted shares of common stock, value"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-04-262023-04-27_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_237_z9jlKbJnQrHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div id="xdx_233_zkqcOJToVbl4" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zm4sFdlxwG25" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zmZ7MBueYsR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March 2023, the Company issued <span id="xdx_908_eus-gaap--SharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z5wLNaPT8bAb" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact001687" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,378,070</ix:nonFraction></span> shares of Common Stock and warrants
to purchase <span id="xdx_902_eus-gaap--SharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zjZpbhJPa08" title="Shares issued of common stock"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-03-31_us-gaap_WarrantMember" id="Fact001689" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189,036</ix:nonFraction></span> shares of Common Stock resulting in proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230330__20230331_ziH4PPABULee" title="Proceeds of private placement offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-03-302023-03-31" id="Fact001691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,711,000</ix:nonFraction></span> in a private placement offering. The Company effected
the issuances of the shares of Common Stock from March 13, 2023 to March 29, 2023. The purchase warrants were immediately exercisable
and had an exercise term of five years with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331_z6xDB24WUGhb" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31" id="Fact001693" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span> per share. The combined purchase price for one share of Common
Stock and one Purchase Warrant was $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zq6fJMg2Sib4" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_custom_OneWarrantMember" id="Fact001695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2023, there were <span id="xdx_902_eus-gaap--SharesIssued_iI_c20230210__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyjhN52b87l1" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-02-10_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001697" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> restricted share units issued that immediately vested and were converted into shares of Common
Stock in exchange for consulting services valued at $<span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_c20230209__20230210__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbLEbYyAA553" title="Converted shares of common stock, value"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-02-092023-02-10_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2022, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221229__20221230__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zpwFqwKBB5K3" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-12-292022-12-30_us-gaap_CommonStockMember" id="Fact001701" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">198,439</ix:nonFraction></span> shares of Common stock valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueOther_c20221229__20221230__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zDi5TgSvupN3" title="Shares issued of common stock, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-12-292022-12-30_us-gaap_CommonStockMember" id="Fact001703" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,392</ix:nonFraction></span> based on the closing price of the common stock
on that date, issued in lieu of prepaid interest related to the amended and restated secured notes (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, certain of our warrant holders exercised warrants to purchase&#160;<span id="xdx_901_ecustom--PurchaseSharesOfCommonStock_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zolmneUCAEG8" title="Purchase shares of common stock"><ix:nonFraction name="RENB:PurchaseSharesOfCommonStock" contextRef="AsOf2022-07-14_us-gaap_CommonStockMember" id="Fact001705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span>&#160;shares of Common Stock for total proceeds
to the Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z97ALMTfU8Qf" title="Total Proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-07-132022-07-14_us-gaap_CommonStockMember" id="Fact001707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,000</ix:nonFraction></span>, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences, based on the share price on that date of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20220714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroBioPharmaIncMember_z7WgnHhbH8ei" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-14_custom_RenovaroBioPharmaIncMember" id="Fact001709" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></span>. This non-cash earn-out distribution impacted stockholders&#8217;
equity in the amount of $<span id="xdx_901_ecustom--EarnOutDistribution_c20220713__20220714_zkVqTXgMf2Oj" title="Earn-out distribution"><ix:nonFraction name="RENB:EarnOutDistribution" contextRef="From2022-07-132022-07-14" id="Fact001711" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,762,500</ix:nonFraction></span>&#160;based on the share price on July 14, 2022, of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220714_zhX7gnAVdulf" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-07-14" id="Fact001713" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></span>.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, certain of our warrant holders exercised warrants to purchase&#160;<span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zq3Nf6dlObJ" title="Shares purchased"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember" id="Fact001715" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span>&#160;shares of Common Stock for total proceeds
to the Company of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zR7J4uOVUpNe" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember" id="Fact001717" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,625,000</ix:nonFraction></span>, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences. This non-cash earn-out distribution impacted stockholders&#8217; equity in the amount of $<span id="xdx_90C_eus-gaap--NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zPJOm6GrbwSd" title="Non cash earn out distribution"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember" id="Fact001719" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,762,500</ix:nonFraction></span>&#160;based
on the share price on July 14, 2022 of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zs9dyGuOOn4c" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-14_us-gaap_WarrantMember" id="Fact001721" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></span>. The Company recorded a loss on extinguishment of contingent consideration liability of
$<span id="xdx_90D_ecustom--ExtinguishmentOfContingentConsiderationLiability_c20230701__20240630_zesf902ZjZs7" title="Extinguishment of contingent consideration liability"><ix:nonFraction name="RENB:ExtinguishmentOfContingentConsiderationLiability" contextRef="From2023-07-01to2024-06-30" id="Fact001723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">419,182</ix:nonFraction></span>&#160;during the year ended June 30, 2024 which reflected the difference between the fair value of the shares and the contingent
consideration liability at the time of extinguishment. As of June 30, 2023, all outstanding warrants as of the date of acquisition of
Renovaro Biosciences (the &#8220;2017 Warrants&#8221;) were exercised and there is no further contingent consideration liability related
to the 2017 Warrants remaining as of June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition
of Renovaro Biopharma / Contingently issuable shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2018, the acquisition of Renovaro Biosciences was completed. As part of the acquisition, the stockholders of Renovaro Biosciences
received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise
or conversion of warrants, which were outstanding at closing. As of June 30, 2024, <span id="xdx_90E_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_iI_do_c20240630__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember_zT6rXsINFpc4" title="Common shares contingently issuable"><ix:nonFraction name="RENB:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" contextRef="AsOf2024-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember" id="Fact001725" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> further Contingent Shares are issuable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition
of Renovaro Denmark </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024 and 2023, the Company maintained a reserve of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240630_zJZ6NUz8lss9" title="Common stock reserved for issuance"><span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230630_zFAAoU6Igv42" title="Common stock reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-06-30" id="Fact001727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-06-30" id="Fact001729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,414</ix:nonFraction></ix:nonFraction></span></span> Escrow Shares, all of which are reflected as issued and outstanding
in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Renovaro Denmark held by non-consenting
shareholders of Renovaro Denmark on both June 30, 2024 and 2023, in accordance with Section 70 of the Danish Companies Act and the Articles
of Association of Renovaro Denmark. There have been <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DanDritDenmarkMember_zkJUEqgzjs73" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30_custom_DanDritDenmarkMember" id="Fact001731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,639</ix:nonFraction></span> shares of Common Stock issued to non-consenting shareholders of Renovaro
Denmark as of June 30, 2024. During the years ended June 30, 2024 and 2023, the Company did <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_do_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroDenmarkMember_zHVrgGiTrXP7" title="Common stock issued"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_do_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroDenmarkMember_zUezR2nR84ek" title="Common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_custom_RenovaroDenmarkMember" id="Fact001733" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30_custom_RenovaroDenmarkMember" id="Fact001735" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span>t issue any shares of Common Stock to such
non-consenting shareholders of Renovaro Denmark.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock
option is estimated on the date of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2024, the weighted-average
assumptions used to estimate the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zmBG13CRloF" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div id="xdx_23D_zYgXMuZjpS45" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_za1GYapvnAQc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zuURNQeCc9C2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001739" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ziYDjmukkW87" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B7_zZekknpnQxkf" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Inc.</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (in years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zxI0mQVwU0w8" title="Expected term (in years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember" format="ixt-sec:duryear" id="Fact001741" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span> &#8211; <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zTEAG4zVuCO" title="Expected term (in years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember" format="ixt-sec:duryear" id="Fact001743" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.5</ix:nonNumeric></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zil2MGMcU6S2" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember" id="Fact001745" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.33</ix:nonFraction></span>% &#8211; <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zLpHcN3GAqie" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember" id="Fact001747" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">114.88</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zSI9QmAnsQbf" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember" id="Fact001749" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.12</ix:nonFraction></span>%- <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBWEbywJ1kkh" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember" id="Fact001751" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.83</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 75%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td>
<td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230701__20240630__dei--LegalEntityAxis__custom--RenovaroMember_zbOyIYpfcVh1" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-07-012024-06-30_custom_RenovaroMember" id="Fact001753" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table></ix:nonNumeric>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recognized stock-based compensation expense related to all equity
instruments of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20240630_z37t2AO6EzHl" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-01to2024-06-30" id="Fact001755" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,673,129</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20230630_zkOiheIK0TCe" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012023-06-30" id="Fact001757" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,535,051</ix:nonFraction></span> for the years ended June 30, 2024 and 2023, respectively. At June 30, 2024, the Company had approximately
$<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20240630_z9yUHIT01Lsb" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-06-30" id="Fact001759" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,373</ix:nonFraction></span> of unrecognized compensation cost related to non-vested options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Plan Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 6, 2014, the Company&#8217;s
Board of Directors adopted the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), and the Company had reserved
<span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_znuUt4vLmYof" title="Common stock reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2014-02-06_custom_EquityIncentivePlan2014Member" id="Fact001761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,206,000</ix:nonFraction></span> shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 30, 2019, the Board
approved and on October 31, 2019, the Company&#8217;s stockholders adopted its 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Effective July 21, 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan replaced the 2019 Plan.
The 2023 Plan provides that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved and available for issuance
under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the
effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject
to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;The Company granted options
to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zyhteRw5pGm4" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_EmployeesMember" id="Fact001763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">369,500</ix:nonFraction></span> shares of Common Stock to employees with a three-year vesting period during the year June 30, 2024 under the 2019
and 2023 Plan. For the year ended June 30, 2023, the Company granted options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_z5kWUAuYYf1d" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_custom_EmployeesMember" id="Fact001765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">193,000</ix:nonFraction></span> shares to employees with a three-year
vesting period under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">During
the year ended June 30, 2024 and 2023, the Company granted options to purchase&#160;zero<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z54F7F7Ikx71" title="Option granted" style="display: none"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact001767" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zuZ0XgA4u6yi" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact001769" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">184,800</ix:nonFraction></span>, respectively, and zero<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zHcUIzLKVAx8" title="Shares forfeited" style="display: none"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact001771" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zxlTQir4CUn2" title="Shares forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact001773" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,960</ix:nonFraction></span>
forfeited shares of Common stock to employees with a&#160;six-month vesting period, respectively under the 2019 Plan. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">During
the year ended June 30, 2024 and 2023, the Company granted options to purchase zero<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDm9oK6Sx6R8" title="Option granted" style="display: none"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact001775" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDnZ1FvoSZp1" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact001777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,200</ix:nonFraction></span> issued and<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zwCDCtBIsTFl" title="Shares forfeited" style="display: none"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact001779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDLnAzVvdZka" title="Shares forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact001781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,640</ix:nonFraction></span> forfeited, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Employees1Member_zm7WBMgr0PHh" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_custom_Employees1Member" id="Fact001783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,000</ix:nonFraction></span>
shares of Common stock, respectively, to employees with a&#160;one-year vesting period,</span> respectively under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June 30,
2024 and 2023, the Company granted options to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardOneMember_zQEnwZH2bvk7" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" id="Fact001785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">424,412</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardOneMember_ziWKvO4mgHxj" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" id="Fact001787" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">355,359</ix:nonFraction></span> shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June
30, 2024 and 2023, the Company granted options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_zOoU06c85NJj" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" id="Fact001789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">329,729</ix:nonFraction></span>
and zero <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_z73JZCmMqLW6" title="Option granted" style="display: none"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" id="Fact001791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the
2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June 30,
2024, and 2023, the Company granted options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultingServicesMember_zN94ONxMQf14" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_ConsultingServicesMember" id="Fact001793" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultingServicesMember_zwSk6DOBDg28" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_custom_ConsultingServicesMember" id="Fact001795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_230_zG0pje1fK56i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div id="xdx_234_zb8scVHyKtx8" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zesohgJU4pfi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zE7vt97PYa74" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">All of the above options are exercisable
at the market price of the Company&#8217;s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931
eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing
price of the Company&#8217;s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $921,254 during the year ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;To date the Company has granted
options under the 2014, 2019 and 2023 Plans (&#8220;Plan Options&#8221;) to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zwp6P3jISZH9" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_PlanOptionsMember" id="Fact001799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,665,821</ix:nonFraction></span> shares of Common Stock. At June 30, 2024,
the Company has <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20230701__20240630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zaMI4uZNnEX2" title="Options available to be issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="From2023-07-012024-06-30_custom_PlanOptionsMember" id="Fact001801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,515,873</ix:nonFraction></span> options available to be issued under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">A summary of the Plan Options outstanding at June 30,
2024 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>


<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001803" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zT9pS2QOYL1g" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zcvOLyxfHAd1" style="display: none">Schedule of stock options outstanding</span></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Outstanding</span></td><td style="padding-bottom: 1pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ranges</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 10%; font-size: 11pt; text-align: right; text-indent: -10pt"/><td style="width: 1%; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoj3UP0Zi3ak" title="Exercise Prices, Lower"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001805" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.45</ix:nonFraction></span>&#8211;<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zL0sWyyJuEz4" title="Exercise Prices, Upper"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001807" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjlok0NFGud7" title="Number share option outstanding" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,244,987</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlGCuS8k9Mp7" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001811" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.38</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDpZZNCO6LRb" title="Options Outstanding, Weighted Average Exercise Price" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001813" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.89</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z22dzV2B8Kq2" title="Options Exercisable" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,817,105</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zxuFiyv6UiI9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001817" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.15</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zNTwhPrOcLm7" title="Options Exercisable, Weighted Average Exercise Price" style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001819" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.92</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zq9vHnGJWQV2" title="Exercise Prices, Lower"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001821" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></span>&#8211;<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zciuoVCxbwIc" title="Exercise Prices, Upper"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001823" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zBiexlnMnqN5" title="Number share option outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,634</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zOcUyvdWiRYe" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" id="Fact001827" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.48</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_znLyCeBR1gq" title="Options Outstanding, Weighted Average Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001829" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.33</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zG4XmsEVoZtd" title="Options Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001831" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,376</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zlLnBvEEgxHl" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" id="Fact001833" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.81</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z8XvPUv82eC3" title="Options Exercisable, Weighted Average Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001835" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.49</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zxgHQnjms6K9" title="Exercise Prices, Lower"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001837" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.51</ix:nonFraction></span>&#8211;<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z1iHs4UyFfn" title="Exercise Prices, Upper"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001839" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zJDB519dnxl5" title="Number share option outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001841" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,231</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z95XU05DBeYj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" id="Fact001843" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.66</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zqGoGpDbGFJg" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001845" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.63</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zd9mGZcrJfqc" title="Options Exercisable" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,585</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zYpGqlOd5Zdi" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" id="Fact001849" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.57</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zOBaby8lmIFi" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001851" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.61</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z0FnfEqDYY8c" title="Number share option outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,527,852</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zUtQF25tWt92" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001855" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.29</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2njRW3iJke7" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001857" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSLtYzFUsth9" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001859" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,064,066</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z56RVX2La7W6" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001861" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.03</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFXK6LhPxeE9" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001863" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.20</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of changes  are presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001865" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zB5GW3YRRQLc" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zw9nn7pGElIh" style="display: none">Schedule of stock option activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Remaining Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Intrinsic<br/> Value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zqOYtBsVQHrj" title="Options Outstanding at beginning of period" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_custom_EmployeeStockOptionsMember" id="Fact001867" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,401,211</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zuydU65POhs6" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_EmployeeStockOptionsMember" id="Fact001869" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zA0GqPCBt3ef" title="Weighted Average remaining life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_EmployeeStockOptionsMember" format="ixt-sec:duryear" id="Fact001871" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.82</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWtzNzpAK1hg" title="Weighted Average Intrinsic Value, Outstanding at beginning of period" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-06-30_custom_EmployeeStockOptionsMember" id="Fact001873" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zoHzvvRQOfGe" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001875" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,983,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zaqAJu6klj2j" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001877" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.94</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zY7qYMCgsDV" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001879" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zVSnrPz3OMOi" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001881" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zrixLPhkVI27" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001883" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_ztZA2pG3dtv4" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001885" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired/Canceled </span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zSpp8TEe05Zb" title="Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001887" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,856,931</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z6p89UjP9Uth" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" id="Fact001889" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.94</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z4j7YnkZlqd" title="Options Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001891" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,527,852</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zFd7mtnTwQe" title="Weighted Average Exercise Price, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001893" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjVPtAU0P3G3" title="Weighted Average remaining life"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" format="ixt-sec:duryear" id="Fact001895" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxhKc537x1n2" title="Weighted Average Intrinsic Value, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001897" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zTcizUH5ETt7" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,064,066</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhiWPKQHagb9" title="Weighted Average Exercise Price, Exercisable at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001901" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zffv5yDgJU66" title="Weighted Average Remaining Life, Exercisable"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" format="ixt-sec:duryear" id="Fact001903" name="RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1">7.05</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zp4eeIM2rhv" title="Weighted Average Intrinsic Value, Exercisable end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">525,943</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024, the Company had Plan Options to purchase 4,064,066 shares
of common stock that were exercisable. The total intrinsic value of options exercisable at June 30, 2024, was $<span>525,943</span>.
Intrinsic value is measured using the fair value at the date of exercise (for shares exercised) and at June 30, 2024 (for outstanding
options), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23A_zZ41dBFof0R5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div id="xdx_237_zKIZsLK09sUf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zFgqaTS59Phk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zLS0Xoeagllh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock Purchase Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of the status of the
Common Stock Purchase Warrants outstanding at June 30, 2024, is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001909" name="RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_z15TSkAxnsY5" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B9_zKDohMfsJ2Xf" style="display: none">Schedule of common stock purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zVP8y94nQXYk" title="Exercise Prices" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" id="Fact001911" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zK4rbHn9NDrg" title="Number share option outstanding" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" id="Fact001913" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,698</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zPGq0Ov22cbg" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001915" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.33</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z7hyH1ivX6yc" title="Options Exercisable" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" id="Fact001917" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,698</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zbFuATanrD0i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001919" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.33</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zb7LOW9sKtX" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" id="Fact001921" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zGRWikXfOpP8" title="Number share option outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" id="Fact001923" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">741,274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z5FKhhbk0KV4" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" id="Fact001925" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.07</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zz962SNTavV1" title="Options Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" id="Fact001927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">741,274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zXQZuEZjvPE7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" id="Fact001929" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.07</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDWgYmDaVoX7" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" id="Fact001931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zsmq8SZi4Zia" title="Number share option outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" id="Fact001933" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189,036</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDlwyhcY1gt5" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" id="Fact001935" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.73</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zHQpPrwjKjQi" title="Options Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" id="Fact001937" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189,036</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zscw9Uwubqhb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" id="Fact001939" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.73</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zTCr0coe40u2" title="Exercise Prices" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" id="Fact001941" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyqBq827QNRb" title="Number share option outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" id="Fact001943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">642,128</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zrwVmoHgrzhl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" format="ixt-sec:duryear" id="Fact001945" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.96</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zqbHHcTCLnba" title="Options Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" id="Fact001947" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">642,128</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z7uoQANbhZ7i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" format="ixt-sec:duryear" id="Fact001949" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.96</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"/><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zarw1JsAZnn2" title="Exercise Prices" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" id="Fact001951" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zxmv2q80PLIf" title="Number share option outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" id="Fact001953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,740</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zfX6NxHlPMfj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" format="ixt-sec:duryear" id="Fact001955" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.99</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"/><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zoOIOuAFfvfl" title="Options Exercisable" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" id="Fact001957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,740</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z1KgSx9mvVM9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" format="ixt-sec:duryear" id="Fact001959" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.99</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"/><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zsRMblqnRRyh" title="Number share option outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001961" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,094,876</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zy6LzXLVkzXa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" id="Fact001963" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.48</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zfj00j7Vcl66" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001965" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zpKbBGNg1hDh" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,094,876</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zibIj0t3A8Kg" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" id="Fact001969" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.48</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zRKHO2xYrCzh" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of the warrant activity is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001973" name="RENB:ScheduleOfWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_ztFOeXoPMG9e" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BE_zU6u061FCDDe" style="display: none">Schedule of warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining<br/> Life</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Outstanding at June 30, 2023</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zW15v1YzQH09" title="Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrant" contextRef="AsOf2023-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,548,302</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXAGuqsB02k3" title="Weighted average exercise price, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001977" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zszXr2mEb9t1" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_CommonStockPurchaseWarrantMember" format="ixt-sec:duryear" id="Fact001979" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.80</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkr824MJeNK6" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001981" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,497,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_ztJ9eeD9EDDf" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001983" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zp9CTBEdlPq8" title="Weighted Average remaining life, Granted"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" format="ixt-sec:duryear" id="Fact001985" name="RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">4.27</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zojIebZ8mG33" title="Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001987" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,344</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z4cmo8MvhJAd" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001989" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_znRVOnkAZAql" title="Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001991" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zJUKdMhvktH9" title="Weighted average exercise price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001993" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding and exercisable at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_ecustom--CommonStockPurchaseWarrant_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zQDiCVjl0PCf" title="Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrant" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001995" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,094,876</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z2x7roGAMXy8" title="Weighted average exercise price, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001997" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zzhIRpQ4RLQ4" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" format="ixt-sec:duryear" id="Fact001999" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.48</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024, the Company had <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zc1fvaxgrNVa" title="Common stock purchase warrants exercisable outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact002001" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,094,876</ix:nonFraction></span> exercisable Common Stock Purchase
Warrants outstanding. The total intrinsic value of warrants exercisable at June 30, 2024, was $<span><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zEDT93Jqtuta" title="Total intrinsic value of options exercisable"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact002003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,309,681</ix:nonFraction></span></span>.
Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at June 30, 2024 (for outstanding
warrants), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards (RSA)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The Company recognized stock-based
compensation expense related to RSAs of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOfIa2Z7Gytk" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember" id="Fact002005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,415,157</ix:nonFraction></span> for the year ended June 30, 2024. The restricted stock awards are related to&#160;a
grant of&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zSuE10NEYIWd" title="Number of shares grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember" id="Fact002007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares of restricted stock with a 3-year vesting period made to a director as consideration for advisory
services, with a total value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zIXReW7RcIU8" title="Number of value grant"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember" id="Fact002009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,760,000</ix:nonFraction></span>. At June 30, 2024, the Company had $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z7yYcpenajc2" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-06-30_custom_RestrictedStockAwardsMember" id="Fact002011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,344,843</ix:nonFraction></span> of unrecognized stock-based compensation expense
remaining to be amortized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">The Company recognized stock-based
compensation expense related to other RSAs of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHqKQfLzx4Yl" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_custom_RestrictedStockAwardsMember" id="Fact002013" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,000</ix:nonFraction></span> for the year ended June 30, 2023. These restricted stock awards are related to
a grant of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlcY1JKpLatl" title="Number of shares grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-07-012023-06-30_custom_RestrictedStockAwardsMember" id="Fact002015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>&#160;shares of restricted stock made to a consultant as consideration for consulting services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<ix:exclude><p id="xdx_23A_zXwqzwm2vAKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div id="xdx_230_zkhQv6DzDZng" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zIFbn9tMmFSc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z7sXM1Z4oz95" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002019" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zY5H7f9mPU1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 &#8212; <span id="xdx_82E_z3Ik7uUBKUB">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#8220;HBV License Agreement&#8221;) by and among the Company, G-Tech, and
G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute
(&#8220;SRI&#8221;) (collectively the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual, sublicensable, exclusive license
(the &#8220;HBV License&#8221;) for a treatment under development (the &#8220;Treatment&#8221;) aimed to treat Hepatitis B Virus (HBV)
infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24 month period, and provides for an up-front payment of $<span id="xdx_90B_eus-gaap--PaymentsForFees_pn5n6_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zGGTKxt471r8" title="Payment for license"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember" id="Fact002021" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a <span id="xdx_906_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zIQvxlumRys3" title="Royalty percentage"><ix:nonFraction name="RENB:RoyaltyPercentage" contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember" id="Fact002023" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>% royalty to G-Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $<span id="xdx_90B_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrn3UvWfov12" title="Payment for license"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember" id="Fact002025" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement in the years ended June 30, 2024, and 2023. The Company
has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section
below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#8220;License Development Agreement&#8221;), by and among the Company, G-Tech
and SRI (collectively, the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual sublicensable, exclusive license (the &#8220;Development
License&#8221;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating pan-coronavirus
or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza
(the &#8220;Prevention and Treatment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides
for an up-front payment of $<span id="xdx_90C_ecustom--UpfrontPayment_c20191114__20191115_z8Zm6ad6TGzh" title="Up-front payment"><ix:nonFraction name="RENB:UpfrontPayment" contextRef="From2019-11-142019-11-15" id="Fact002027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span> and a $<span id="xdx_907_ecustom--PaymentForExpenditures_c20191114__20191115_zUiWRwaZbnK6" title="Payment for expenditures"><ix:nonFraction name="RENB:PaymentForExpenditures" contextRef="From2019-11-142019-11-15" id="Fact002029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">760,000</ix:nonFraction></span> payment for expenditures to date prior to the effective date related to research
towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional payments
upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement, in each
case subject to the terms of the Development License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G-Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product candidates
that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license
(see Contingencies sub-section below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_239_zRZ239tWvb43" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div id="xdx_235_zc7TWVygKM56" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zTdzWrj0pD6c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zapTPeJsQTI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#8220;ALC License Agreement&#8221;) with Serhat
G&#252;mr&#252;kc&#252; and SRI (collectively, the &#8220;Licensors&#8221;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $<span id="xdx_905_ecustom--InitialPayment_c20210824__20210825_zHdfcMUBnwQh" title="Initial payment"><ix:nonFraction name="RENB:InitialPayment" contextRef="From2021-08-242021-08-25" id="Fact002033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span> and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $<span id="xdx_90C_ecustom--InitialPayment_c20210909__20210910_zllz47s6Fvme" title="Initial payment"><ix:nonFraction name="RENB:InitialPayment" contextRef="From2021-09-092021-09-10" id="Fact002035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">G-Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Shares held for non-consenting
shareholders</b> &#8211; The <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240630_zOeXKcJ2YHRe" title="Remaining shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-06-30" id="Fact002037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,414</ix:nonFraction></span> remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have been reflected
as issued and outstanding in the accompanying financial statements.&#160;There were zero shares of Common Stock issued to such&#160;non-consenting
stockholders during the years ended June 30, 2024 and 2023 (see Note 9.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Service Agreements</b> <i>&#8211;</i>The
Company maintains employment agreements with certain senior staff in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Securities Class Action Litigation</i>.
On July 26, 2022 and July 28, 2022, securities class action complaints (the
former, the &#8220;Chow Action&#8221; and the latter, the &#8220;Manici Action&#8221;) were filed by purported stockholders of the Company
in the United States District Court for the Central District of California against the Company and certain of the Company&#8217;s current
and former officers and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of
material fact in connection with the Company&#8217;s relationship with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The
complaints seek unspecified damages, interest, fees, and costs. On November 22, 2022, the Manici Action was voluntarily dismissed without
prejudice, but the Chow action remains pending.&#160;On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The
lead plaintiff filed an amended complaint on December 15, 2023. The Company has filed a motion to dismiss the amended complaint on March
15, 2024. The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, and the
parties have come to an agreement in principle to settle the class action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Federal Derivative Litigation</i>.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action
in the United States District Court for the Central District of California. On January 19, 2023, John Solak filed a substantially similar
shareholder derivative action in the United States District Court for the District of Delaware. Both derivative actions recite similar
underlying facts as those alleged in the Securities Class Action Litigation. The actions, filed on behalf of the Company, name Serhat
G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and former directors as defendants. The actions also name the Company
as a nominal defendant. The actions allege violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also set
out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiffs do
not quantify any alleged injury, but seek damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United
States District Court for the Central District of California stayed the Koenig matter pending resolution of the defendants&#8217; anticipated
motion to dismiss in the Securities Class Action Litigation. On April 4, 2023, the United States District Court for the District of Delaware
stayed the Solak matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation.
On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion to dismiss the
Securities Class Action Litigation. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings in
the Koenig matter is October 21, 2024. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings
in the Solak matter is October 22, 2024. The defendants have not yet responded to either complaint. The Company intends to contest these
matters but expresses no opinion as to the likelihood of favorable outcomes. Management is unable to determine the likelihood of a loss,
including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_236_zRZBlpnRGHXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div id="xdx_234_z6kARy17Xvc7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zgueadLbhny" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zGvPbILYJntc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>State Derivative Litigation</i>.
On October 20, 2022, Susan Midler filed a shareholder derivative action in
the Superior Court of California, Los Angeles County, reciting similar underlying facts as those alleged in the Securities Class Action
Litigation. The action, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current
and former directors as defendants. The action also names the Company as a nominal defendant. The action sets out claims for breaches
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the Court stayed the Midler matter
pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024,
the United States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class
Action Litigation. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings in the Midler matter
is October 23, 2024. The defendants have not yet responded to the complaint. The Company intends
to contest this matter but expresses no opinion as to the likelihood of a favorable outcome. Management is unable to determine the likelihood
of a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252;, William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio LLC (&#8220;G Tech&#8221;), SG &amp; AW Holdings,
LLC, and Seraph Research Institute (&#8220;SRI&#8221;) (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants
engaged in a &#8220;concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting
its Hepatitis B and SARS-CoV-2/influenza pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive
outcomes from various studies, and even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the
Company claims that it &#8220;paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221;
On April 21, 2023, defendants Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all,
of the Company&#8217;s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending
motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening
deadlines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including,
<i>inter alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License
Agreement, effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications,
effective as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently
scheduled to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while
pursuing its claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 1, 2021, the Company&#8217;s
former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District
of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and
Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company&#8217;s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Gr&#248;nfeldt-S&#248;rensen. On November 29, 2022,
the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24, 2023,
the court denied the motion for summary judgment. The court vacated the July 15, 2024 trial date and has yet to re-set the trial date.
The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (such trusts, collectively, the
&#8220;Trusts&#8221;) (collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery
of Delaware. In the Verified Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between
the Company, Weird Science, and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor
Rights Agreement required the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days
prior to filing a registration statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in
such registration statement. Plaintiffs alleged that the Company breached these registration rights by failing to provide the required
notice in connection with S-3 registration statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to
dismiss the Verified Complaint on September 15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_23E_zDsvLykYfiXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div id="xdx_231_zm0JrpFGTCT9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zFlwdCXyWCH2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zMEOse23UOQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023. The Court scheduled oral argument on the motions to dismiss for November 15, 2024. The Company denies Plaintiffs&#8217;
allegations and intends to vigorously defend against the claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 24, 2023, counsel on
behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company&#8217;s
books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167;&#160;220 (&#8220;Section 220&#8221;).
The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company takes
its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with
those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, Weird Science
and Wittekind sent the Company&#8217;s Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues
identified therein. On February 27, 2024, Weird Science and Wittekind sent the Company&#8217;s Board of Directors a supplemental letter
that expanded their demand for corrective actions to twenty-six issues. In response to these demand letters, the Board of Directors initially
formed a Special Committee (&#8220;Special Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained
Stradling Yocca Carlson &amp; Rauth LLP as its counsel to investigate the issues identified in the demand letters. The Special Committee&#8217;s
investigation is ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States
District Court for the Central District of California against certain officers, directors, and investors of the Company, as well as other
defendants, in connection with, <i>inter alia</i>, Weird Science and Wittekind&#8217;s demand for corrective action. Plaintiffs filed
an amended complaint on June 21, 2024. The First Amended Verified Stockholder Derivative Complaint (&#8220;Derivative Complaint&#8221;)
alleges, among other claims, violations of Section 13(d) and 14(a) and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934.
The Derivative Complaint also includes claims of breach of fiduciary duty, corporate waste, unjust enrichment, and contribution/indemnification.
Weird Science and Wittekind seek unspecified compensatory, exemplary, and punitive damages and certain injunctive relief. The Derivative
Complaint names the Company as a nominal defendant. On July 19, 2024, certain of the director defendants, who had agreed to waive service
of the summons and Derivative Complaint, filed a motion to dismiss the Derivative Complaint on a variety of procedural and substantive
grounds. A hearing on the motion dismiss was held on October 3, 2024 and the court subsequently took the motion under submission. The
director defendants deny the allegations in the Derivative Complaint and intend to vigorously defend against the claims asserted therein.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 21, 2024, the Company
filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002043" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcIyhkWtg4Ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 &#8212; <span id="xdx_82B_zXkV8j374a24">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024, the Company
has accrued $<span id="xdx_904_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_zBrDUJdrcso4" title="Accrued balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-07-012024-06-30_custom_MarkDybulMember" id="Fact002045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,402</ix:nonFraction></span> of compensation related expenses for the Company&#8217;s Chief Executive Officer, Mark Dybul, related to budget constraints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 16, 2024, the Company
received an exercise notice from RS Bio ApS (&#8220;RS Bio&#8221;) to exercise <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxelBOoSD492" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-02-16_custom_RSBioMember" id="Fact002047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,699</ix:nonFraction></span> warrants outstanding at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxFYilgpUBpl" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-16_custom_RSBioMember" id="Fact002049" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span>
per share. Mr. Rene Sindlev, the Chairman of the Company&#8217;s Board of Directors, holds the sole voting and disposition power of the
shares owned by RS Bio. RS Bio applied $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240214__20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z6iC2Jc8pjB7" title="Proceeds from notes payables"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-02-142024-02-16_custom_RSBioMember" id="Fact002051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> of one of its outstanding note payable balance to the exercise price (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a <span id="xdx_902_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zhEPEaQp7FTf" title="Original issue discount promissory note percentage"><ix:nonFraction name="RENB:OriginalIssueDiscountPromissoryNotePercentage" contextRef="AsOf2024-02-05_custom_RSBioMember" id="Fact002053" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zQNWH5831WJl" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-02-05_custom_RSBioMember" id="Fact002055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,263</ix:nonFraction></span>.
The Company received $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfDebt_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RsBioMember_zCChAn7V4Wl6" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-02-042024-02-05_custom_RSBioMember" id="Fact002057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in gross proceeds after taking into account the <span id="xdx_909_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RsBioMember_zI4CBiIK6Mb" title="Gross proceeds original issue discount rate"><ix:nonFraction name="RENB:GrossProceedsOriginalIssueDiscountRate" contextRef="AsOf2024-02-05_custom_RSBioMember" id="Fact002059" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% original issue discount. The Note bears an interest rate
of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z6FoWuOSRzjc" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-02-05_custom_RSBioMember" id="Fact002061" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and matured on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKtbh6YbJpbf" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-02-042024-02-05_custom_RSBioMember" format="ixt:datemonthdayyearen" id="Fact002063" name="us-gaap:DebtInstrumentMaturityDate">March 1, 2024</ix:nonNumeric></span> . The obligations under this Note are secured by the Amended and Restated Security Agreement
(see Note 7). The Company is required to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of
$<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zmMeRmSyfR19" title="Amortization discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-012024-06-30_custom_RSBioMember" id="Fact002065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,263</ix:nonFraction></span> was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_904_eus-gaap--InterestExpense_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zG9yUMYG52e9" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012024-06-30_custom_RSBioMember" id="Fact002067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,316</ix:nonFraction></span> of interest expense that is included in accrued
expenses on the balance sheet. The Note balance, net of discount at June 30, 2024 is $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKA1FKonUdE3" title="Note balance"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2024-06-30_custom_RSBioMember" id="Fact002069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,263</ix:nonFraction></span> (see Note 7.)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zzKEVq12oJ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div id="xdx_23C_zvHmnnK81We4" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zG5tk2dechJ5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zE1A8BkfAN98" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 2, 2024, the Company entered into an agreement with RS Bio to issue
a <span id="xdx_90B_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zfYE7otv7BQa" title="Original issue discount promissory note percentage"><ix:nonFraction name="RENB:OriginalIssueDiscountPromissoryNotePercentage" contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact002073" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zJmohid8rcag" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact002075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,315</ix:nonFraction></span> (the &#8220;January 2024 Note&#8221;). The Company
received a total of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z8WJQN2AvyJ6" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact002077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> in gross proceeds after taking into account the <span id="xdx_90F_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zAXbBFSDVRs" title="Gross proceeds original issue discount rate"><ix:nonFraction name="RENB:GrossProceedsOriginalIssueDiscountRate" contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact002079" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% original issue discount.&#160;The January 2024 Note bears
an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDS1ufUwWOIi" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" id="Fact002081" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and shall mature on <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zd9gR6h8tUw8" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember" format="ixt:datemonthdayyearen" id="Fact002083" name="us-gaap:DebtInstrumentMaturityDate">March 1, 2024</ix:nonNumeric></span> (the &#8220;Maturity Date&#8221;) is past due. The Company is required
to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zTestoiqexF3" title="Amortization discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-012024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member" id="Fact002085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,315</ix:nonFraction></span> was charged to interest expense.
As of June 30, 2024, the Company accrued $<span id="xdx_90D_eus-gaap--InterestExpense_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z5qqrIOAIdr2" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member" id="Fact002087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,579</ix:nonFraction></span> of interest expense that is included in accrued expenses on the balance sheet. The January
2024 Note balance, net of discount at June 30, 2024 is $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zZ46hv0blwZa" title="Note balance"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member" id="Fact002089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,315</ix:nonFraction></span> (see Note 7.) In connection with the entry into the January 2024 Note,
the Company and Paseco ApS agreed to amend and restate the Security Agreement (see Note 7) to add the Company&#8217;s obligations under
the November 2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 3, 2023, the Company entered into an agreement with RS Bio to
issue a <span id="xdx_90A_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_z5XBVS43U0dl" title="Original issue discount promissory note percentage"><ix:nonFraction name="RENB:OriginalIssueDiscountPromissoryNotePercentage" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact002091" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% Original Issue Discount Promissory Note for the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zHeOnXLQGWa3" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact002093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> (the &#8220;November 2023 Note&#8221;). The
Company received a total of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zxOP8jH5ZVai" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact002095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950,000</ix:nonFraction></span> in gross proceeds after taking into account the <span id="xdx_904_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_ztkv0e4nQLZg" title="Gross proceeds original issue discount rate"><ix:nonFraction name="RENB:GrossProceedsOriginalIssueDiscountRate" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact002097" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% original issue discount.&#160;The discount of
$<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zaKBj9H1pxM" title="Discount accreted"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact002099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> will be accreted over the life of the Note. The Note bears an interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zX0sZ9nPP2t5" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember" id="Fact002101" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum and shall mature on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zWI8zXEdLgbb" title="Debt maturity period"><ix:nonNumeric contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember" format="ixt:datemonthdayyearen" id="Fact002103" name="us-gaap:DebtInstrumentMaturityDate">January 1, 2024</ix:nonNumeric></span>
(the &#8220;Maturity Date&#8221;) is past due. The Company is required to pay interest on the maturity date (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
10, 2023, the Board of Directors of the Company (the &#8220;Board&#8221;) appointed Avram Miller to the Board, effective October 11, 2023,
to fill a vacancy. Mr. Miller will serve until the Company&#8217;s 2024 Annual Meeting of Stockholders subject to this re-election or
until his successor has been duly elected and qualified. In addition to Mr. Miller&#8217;s appointment to the Board, Mr. Miller, the co-founder
of Intel Capital, entered into an advisory agreement&#160;with the Company (the &#8220;Advisory Agreement&#8221;), pursuant to which Mr.
Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation, business
development, minority investments and licensing arrangements, among others. As compensation for these services, the Company will issue
Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will vest
in 2026, subject to Mr. Miller&#8217;s continued service through each applicable vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 1, 2023, RS Bio, purchased
in a Private Placement 70,126 of the Company&#8217;s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of
$500,000. <span style="background-color: white">The Board of Directors (excluding Mr. Sindlev) approved the participation of certain officers
and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement</span> (see Note
7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 1, 2023, Paseco ApS,
in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company&#8217;s Units at a price
per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company&#8217;s Units at a price per
Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS
was deemed to be an affiliate of the Company (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company currently has a consulting
agreement with Paseco ApS for business advisory services since December of 2019. For the years ended June 30, 2023 and 2024 the Company
issued zero and 1,000,000 restricted common shares, respectively, as payment for services rendered thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The information
set forth above in Note 7&#8212;Debt&#8212;Notes Payable&#8212;Promissory Note relating to the Promissory Note issued to Paseco ApS is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_23C_zWf5qWdBAId8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div id="xdx_237_zBY4XlX521za" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zY8QNGgWm5oj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zebMpdoghaYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002107" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_805_eus-gaap--BusinessCombinationDisclosureTextBlock_zI30BkyMafhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 12 &#8212; <span id="xdx_820_zP4MCwf0eON3">ACQUISITION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On September 28, 2023, the Company, entered into a Stock Purchase Agreement
(the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;) with GEDi Cube Intl Ltd., a private company formed
under the laws of England and Wales (&#8220;<span style="text-decoration: underline">GEDi Cube</span>&#8221;) to acquire 100% of the equity
interests of GEDi Cube from its equity holders (the &#8220;<span style="text-decoration: underline">Sellers</span>&#8221;). On September
28, 2023, the Board of Directors of the Company, and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and
on January 25, 2024, the shareholders of the Company approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement.
On February 13, 2024 (the &#8220;Closing Date&#8221;), the Company consummated the acquisition of GEDi Cube and the other transactions
contemplated by the Stock Purchase Agreement (collectively, the &#8220;Transaction&#8221;). As a result of the Transaction, GEDi Cube
became a wholly-owned subsidiary of the Company. The Company believes the acquisition will provide it with access to the nascent field
of artificial intelligence and machine learning driven diagnostics, which was the primary purpose for the acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a &#8220;GEDi Cube Share&#8221; and, collectively, the &#8220;GEDi Cube Shares&#8221;)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller&#8217;s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (&#8220;Common Stock&#8221;), which represents the 67,224,089
shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to
a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of
the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the &#8220;Closing
Consideration&#8221;) plus 5,610,100 shares of Common Stock representing the Seller&#8217;s Earnout Shares (defined below) resulting from
the automatic conversion of the Company&#8217;s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller&#8217;s
pro rata percentage of the shares of Common Stock (the &#8220;Earnout Shares&#8221; and, together with the Closing Consideration, the
&#8220;Exchange Consideration&#8221;) to be issued to the Sellers upon the exercise or conversion of any of the Company&#8217;s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the &#8220;Closing Derivative Securities&#8221;).
Each Seller&#8217;s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with the provisions of ASC 805-10 -&#160;<i>Business Combinations</i>. </span>As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The assets acquired and liabilities assumed were initially recognized provisionally
in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition date. The fair values as of the acquisition
date are based on information that existed as of the acquisition date. The Company completed its accounting for this acquisition during
the period ended June 30, 2024. As a result of the completion of the Company&#8217;s analysis, the amount of in-process research and development
was determined to have a value of nil. Accordingly, the amount of goodwill recognized was increased to include the previously recognized
amount of in-process research and development. There was no impact to the Company&#8217;s consolidated statement of operations as a result
of this change to the allocation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The acquisition-date fair value of the consideration transferred totaled approximately
$<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIyqwjvBZN39" title="Fair value of consideration transferred amount"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredOther1" contextRef="From2024-02-122024-02-13_custom_GEDiCubeMember" id="Fact002109" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">156.6</ix:nonFraction></span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002111" name="RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_zSVvaUuM9A34" summary="xdx: Disclosure - ACQUISITION (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8B5_z8PF5HteaUe9" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of acquisition
date fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_987_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zEyPw6ZlO64h" title="Common stock" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:BusinessCombinationContingentConsiderationCommonStock" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent consideration</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zjoz7V4huMji" title="Contingent consideration" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationAsset" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total consideration transferred</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_988_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zDGlty6NlcNl" title="Total consideration transferred" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2024-02-122024-02-13_custom_GEDiCubeMember" id="Fact002117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,559,131</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AA_zHcQhzufb7m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_232_zUFQbmldL5M3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div id="xdx_231_zWckuEfQroVc" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zZ0aVs96xUxg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zIGV2IqPznl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
<span style="background-color: white">fair value of the Company&#8217;s
common shares issued as consideration was based on the closing price of the Company&#8217;s common stock as of the Acquisition Date. The
fair value of the contingent consideration </span>was based on the Sellers&#8217; right to receive additional shares of common, pro rata,
upon the exercise or conversion of warrants, options and convertible notes payables outstanding as of the Closing Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002121" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zhQ1zpvhkhpd" summary="xdx: Disclosure - ACQUISITION (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td id="xdx_8BE_zxLldG2RVoqe" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of fair value of assets acquired and
liabilities assumed</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zq6XQ3FaWyjk" style="text-align: center">&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_zN7yl1t9V7j1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,851</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zPtCA0lnhfvl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid &amp; Other Assets</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,544</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zaLoQzJniMYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed Assets</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,243</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zpRE5TOLHeq1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,366</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zF7WS3oEDFUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Assets Acquired:</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">858,004</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_ztLBL5Vn73w9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts Payable</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583,577</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zc8gaUrUdn7a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued Expenses</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">722,508</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zZG1qV9C9zRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Lease liability</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,367</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zXWz0fg8LK64" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes Payable</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,460</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zxGOOPJ2KWs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Liabilities Assumed</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,762,913</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zKwI0eP5MbA4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Assets Acquired</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002143" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,904,909</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--Goodwill_iI_zHRyIik7FMrl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,464,040</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zHZX42cQ67G1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Consideration</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="AsOf2024-02-13_custom_GEDiCubeMember" id="Fact002147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,559,131</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A9_ze4tEVn648n8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected
to be deductible for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The Company
recognized approximately $<span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zz4VgQDDkHod" title="Acquisition related costs"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember" id="Fact002149" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#8220;selling, general and administrative expenses&#8221; in the accompanying condensed consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The amounts
of revenue and loss of GEDi Cube, included in the Company&#8217;s consolidated statements of operations from the Closing Date through
June 30, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002151" name="RENB:ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_zOmaFbuynzC6" summary="xdx: Disclosure - ACQUISITION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8B8_zeLWSDKMJN96" style="display: none; text-align: left; text-indent: -10pt; padding-left: 10pt">Schedule of consolidated
statements of operations</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zp4H0VijRbig" style="text-align: center">&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_z64I3QNoR8ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:BusinessAcquisitionsRevenue" contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember" id="Fact002153" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zcmIUGNg4Swa" style="vertical-align: bottom; background-color: White">
<td style="width: 70%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="RENB:BusinessAcquisitionsNetIncomeLoss" contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember" id="Fact002155" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,243,144</ix:nonFraction></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A2_zaCVFPNFr1Le" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the twelve-month
period ended June 30, 2024. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002157" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zBEzpRDzvu64" summary="xdx: Disclosure - ACQUISITION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BB_zKIHK0PZjQql" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of consolidated
    proforma information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zXDOVA9dTWZi" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_zEgo4gSzun87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember" id="Fact002159" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zyt8a5cHxpy" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember" id="Fact002161" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,571,822</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month
period ended June 30, 2023. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - ACQUISITION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_496_20220701__20230630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zNchmyR3IVbc" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_z3BVtj2Kxp55" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Revenues</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="From2022-07-012023-06-30_custom_GEDiCubeMember" id="Fact002163" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zdddk2sSnw8g" style="vertical-align: bottom; background-color: white">
    <td style="width: 71%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="From2022-07-012023-06-30_custom_GEDiCubeMember" id="Fact002165" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,490,305</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zfIhwl1NJQOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:exclude><p id="xdx_234_ziN40Xn7i6vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div id="xdx_23C_z7gY2Ut84Qdb" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zlq2KOQUIRU8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zN8WO0Z3NyUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002169" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zyP6YjorNxXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 &#8212; <span id="xdx_82A_zsAM44MFaptg">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Beginning with the year ended June 30, 2024, the Company has two reportable segments.
Prior to the year ended June 30, 2024, the Company had only a single reportable segment, the acquisition and integration of Renovaro Cube
resulted in the identification of a separate reportable segment by the Company's chief operating decision maker. These segments have different
strategic and economic goals and are managed separately because they require different technology and marketing strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; width: 14%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reportable
Segment</b></span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0pt; white-space: nowrap; width: 84%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
</b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENB</b></span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; white-space: nowrap; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
new immunotherapies to combat cancer &#160; &#160; &#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENC</b></span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection &#160; &#160;
&#160; &#160; &#160; &#160; &#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The Company&#8217;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2024, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002171" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zrJ4efp1h77l" summary="xdx: Disclosure - SEGMENT REPORTING (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BF_z7ruVRAAMsgj" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt">Schedule of segment operating loss and
    asset information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--US_ziXHlVMmCpw" title="Operating income loss" style="width: 12%; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2023-07-012024-06-30_country_US" id="Fact002173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,470,579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--US_zaUgX8WbupB4" title="Assets" style="width: 12%; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2024-06-30_country_US" id="Fact002175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,998,311</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Netherlands</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--NL_zJF1tuPNXmn3" title="Operating income loss" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2023-07-012024-06-30_country_NL" id="Fact002177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,168,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--NL_zDkx9RGnOlG9" title="Assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2024-06-30_country_NL" id="Fact002179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,131,139</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--SegmentOperatingLoss_c20230701__20240630_zcNVmfundOdg" title="Operating income loss" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2023-07-01to2024-06-30" id="Fact002181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,639,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--SegmentAsset_iI_c20240630_zspUhtBjXKE7" title="Assets" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2024-06-30" id="Fact002183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,129,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A8_zj0irXWiTU0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#8217;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#8217;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Information
regarding each reportable segment for the year ended June 30, 2024 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002185" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zjCE6BwO8uOb" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B2_zhAVSfsaNtQj" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of information regarding segment reporting</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_498_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKlTOHhxf1Ja" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_z4LV39ZVDDz8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_491_20230701__20240630_zTY8qzOyXrj7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zdUyiL5QHx4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2023-07-012024-06-30_custom_RENBMember" id="Fact002187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,449,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2023-07-012024-06-30_custom_RENCMember" id="Fact002188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,449</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2023-07-01to2024-06-30" id="Fact002189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,557,608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zuklrLSSTxF6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012024-06-30_custom_RENBMember" id="Fact002191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,651,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012024-06-30_custom_RENCMember" id="Fact002192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-01to2024-06-30" id="Fact002193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,708,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_d0_zZsHuqTePqke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-07-012024-06-30_custom_RENBMember" id="Fact002195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-07-012024-06-30_custom_RENCMember" id="Fact002196" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-07-01to2024-06-30" id="Fact002197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zUmYrLUFHhmc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-07-012024-06-30_custom_RENBMember" id="Fact002199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-07-012024-06-30_custom_RENCMember" id="Fact002200" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-07-01to2024-06-30" id="Fact002201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_z7toYdt2lMGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-012024-06-30_custom_RENBMember" id="Fact002203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-012024-06-30_custom_RENCMember" id="Fact002204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,409</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-01to2024-06-30" id="Fact002205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SegmentOperatingLoss_zt5FK0XzrPik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2023-07-012024-06-30_custom_RENBMember" id="Fact002207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,470,579</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2023-07-012024-06-30_custom_RENCMember" id="Fact002208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,168,716</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2023-07-01to2024-06-30" id="Fact002209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,639,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_z2BAWHwk3fze" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white; text-indent: 0.5in"><b><span style="text-decoration: underline">Geographic
information:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">RENB and RENC are managed on a worldwide basis but operate in offices located
in the United Stated and the Netherlands, respectively. The geographic information analyses the Company's operations and assets based
on the country in which each segment operates. In presenting this geographic information, segment operating results have been based on
the geographic location in which the services were provided to the segment and segment assets were based on the geographic location of
the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact002211" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zIepvWb50mCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 &#8212; <span id="xdx_823_zx0Wl5yWp3Rg">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">Related to the June 14, 2024, Private Placement, ranging from July 3, 2024, to
October 2, 2024, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240703__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbwEal5gqa2j" title="Sale of stock issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-07-032024-10-02_us-gaap_SubsequentEventMember" id="Fact002213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,525,316</ix:nonFraction></span> Units at a price per Unit equal to $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcRyQIjfQ571" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-10-02_us-gaap_SubsequentEventMember" id="Fact002215" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span> to a certain investor who paid in cash an aggregate
amount of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240703__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv5HXwphGswg" title="Sale of stock issued cash consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-07-032024-10-02_us-gaap_SubsequentEventMember" id="Fact002217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,246,181</ix:nonFraction></span> in consideration of the Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On August
1, 2024, the Company issued&#160;<span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesIssuedForConsultingServices_c20240731__20240801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWMrTRgQJoEe" title="Issuance of common stock shares"><ix:nonFraction name="RENB:StockIssuedDuringPeriodSharesIssuedForConsultingServices" contextRef="From2024-07-312024-08-01_us-gaap_SubsequentEventMember" id="Fact002219" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span>&#160;shares of common stock for consulting services valued at $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueIssuedForConsultingServices_c20240731__20240801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSk3Nizyiu1l" title="Common stock for consulting services value"><ix:nonFraction name="RENB:StockIssuedDuringPeriodValueIssuedForConsultingServices" contextRef="From2024-07-312024-08-01_us-gaap_SubsequentEventMember" id="Fact002221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,400,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, the Company
forfeited <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0fUnIDkavkk" title="Forfeited shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember" id="Fact002223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">833,333</ix:nonFraction></span> shares of Common Stock from the original <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zg9P0Cn5SV0e" title="Original shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember" id="Fact002225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Common Stock for advisory services granted to Avram Miller,
a member of the Company&#8217;s board of directors on October 11, 2023. As consideration for and subject to such forfeiture, the Company
granted to Mr. Miller, an option to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zl7AT3tBZE98" title="Option to purchase shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember" id="Fact002227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">978,261</ix:nonFraction></span> shares of Common Stock of the Company with a per-share exercise price equal to the
fair market value of a share of the Common Stock on the date thereof, $<span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7g2QBv79GJ5" title="Option to purchase shares of common stock par value"><ix:nonFraction name="RENB:StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember" id="Fact002229" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.69</ix:nonFraction></span>. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><p id="xdx_814_zJMXqdugIEQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_015"></span>Item 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_016"></span>Item 9A. Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our Principal Executive Officer
and Principal Financial Officer (the &#8220;Certifying Officers&#8221;) are responsible for establishing and maintaining disclosure controls
and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure that material
information is made known to the Certifying Officers, particularly during the period in which this Report was prepared.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Certifying Officers conducted
a review of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in the Exchange Act, Rules 13a-15(e) and
15-d-15(e)) as of the end of the period covered by this Annual Report (the &#8220;Evaluation Date&#8221;). Based upon that evaluation,
the Certifying Officers concluded that, as of June 30, 2024, our disclosure controls and procedures were not effective in ensuring that
the information we were required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended,
is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Management Annual Report on Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Management is responsible for establishing and maintaining adequate internal control
over financial reporting for the Company. Management used the &#8220;Internal Control over Financial Reporting Integrated Framework&#8221;
issued by the Committee of Sponsoring Organizations (&#8220;COSO-2013&#8221;) to conduct a review of the Company&#8217;s internal controls
over financial reporting. As of June 30, 2024, Management concluded that internal controls over financial reporting were not effective,
based on COSO&#8217;s framework. The deficiency is attributed to the Company not having adequate resources to address complex accounting
matters. This control deficiency will be monitored, and attention will be given to this matter as the Company grows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">This Annual Report does not include
an attestation report from the Company&#8217;s registered public accounting firm regarding internal controls over financial reporting.
Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting firm pursuant to the rules
of the SEC that permit the Company to provide only management&#8217;s report in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There were no changes in our internal
control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 116; Options: NewSection; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_017"></span>Item 9B. Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the Company&#8217;s fourth quarter, no director or officer&#160;<span id="xdx_907_eecd--Rule10b51ArrAdoptedFlag_dbF_c20240401__20240630_zVZTRVn1R7Qj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_905_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20240401__20240630_z9fyjn2oXxL4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-04-012024-06-30" format="ixt:booleanfalse" id="Fact002230" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-04-012024-06-30" format="ixt:booleanfalse" id="Fact002231" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>&#160;or&#160;<span id="xdx_909_eecd--Rule10b51ArrTrmntdFlag_dbF_c20240401__20240630_ze4NECYWm2O4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90D_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20240401__20240630_zQzdajOcllId" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-04-012024-06-30" format="ixt:booleanfalse" id="Fact002232" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-04-012024-06-30" format="ixt:booleanfalse" id="Fact002233" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span>&#160;a
Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_018"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_019"></span>Item 10. Directors, Executive Officers and
Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The information
required by this Item 10 will be included under the captions &#8220;Directors and Executive Officers&#8221;, &#8220;Information as to
Nominees and Other Directors&#8221;, &#8220;Information Regarding Meetings and Committees of the Board&#8221;, &#8220;Compliance with
Section 16(a) of the Exchange Act&#8221;, &#8220;Code of Ethics&#8221;, &#8220;Corporate Governance&#8221; and as otherwise set forth
in the Company&#8217;s Definitive Proxy Statement and is incorporated herein by reference or, alternatively will be included, by amendment
to this Form 10-K under cover of Form 10-K/A no later than 120-days after the end of our fiscal year covered by this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_020"></span>Item 11. Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The information
required by this Item 11 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_021"></span>Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white; color: #212529">The
information required by this Item 12 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_022"></span>Item 13. Certain Relationships and Related
Transactions and Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white; color: #212529">The
information required by this Item 13 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_023"></span>Item 14. Principal Accounting Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; color: #212529">The information required by this Item
14 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 117; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_024"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_025"></span>Item 15. Exhibits and Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 46%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated
    by Reference</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001762/e5071_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Purchase Agreement, dated as of September 28, 2023, by and among Renovaro Biosciences Inc., GEDi Cube Intl Ltd., Yalla Yalla Ltd., in its capacity as Sellers&#8217; Representative, and the Sellers party thereto</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001762/e5071_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed with the SEC on September 29, 2023&#160;</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/e5418_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second&#160;Amendment&#160;to&#160;Stock&#160;Purchase&#160;Agreement, dated February 13, 2024, by and among Renovaro Inc., GEDi Cube Intl Ltd., the sellers party thereto and Yalla Yalla Ltd </span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224000246/e5418_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed with the SEC on February 14, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001770/e5061_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation, as amended</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224000248/e5415_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
by reference to Exhibit 3.1 to the Company&#8217;s Form 10-Q filed with the SEC on February 14, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000259/e1349_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000259/e1349_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 16, 2019.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/e5418_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Rights Agreement, dated February 13, 2024, by and among Renovaro Inc.&#160;Gedi Cube Intl Ltd, and the shareholders of Gedi Cube Intl
Ltd named the Sellers named thereto</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1527728/000173112224000246/e5418_8-k.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to exhibit to the Company&#8217;s Form 8-K filed with the SEC on February 14, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note dated March 30, 2020 issued to Paseco ApS</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on March 31, 2020.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000271/e4443_ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.2 to Promissory Note, dated May 17, 2022</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000271/e4443_ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Form 10-K filed with the SEC on February 27, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.3 to Promissory Note, effective December 30, 2022</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on February 23, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 4 to Promissory Note, effective July 31, 2023</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on August 7, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Form 10-K filed with the SEC on September 30, 2020.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000552/e4510_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000552/e4510_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on April 3, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000552/e4510_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on August 7, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224001001/e5764_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224001001/e5764_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on June 21, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001841/e5116_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 5% Original Issue Discount Convertible Promissory Note</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001841/e5116_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on October 10, 2023</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 118; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 45%"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000112/e1702_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019 Equity Incentive Plan</span></a></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 46%"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000112/e1702_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on February 10, 2020.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223002120/e5207_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023 Equity Incentive Plan</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001993/e5171_ex10-12.htm"><span style="font: normal 10pt Times New Roman, Times, Serif">Incorporated herein by reference to Exhibit 10.12 to the Company&#8217;s Form 10-K/A filed with the SEC on October 30, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000085/e1694_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Work and License Agreement by and among G-Tech Bio, LLC, the Company and G Health Research Foundation</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000085/e1694_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on February 3, 2020.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note Purchase Agreement</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on March 31, 2020.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000021/e1105_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Office Lease by and between the Registrant and Century City Medical Plaza Land Co., Inc. dated June 19, 2018</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000021/e1105_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 25, 2018.</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 7%"><span style="font-size: 10pt">10.6</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 45%"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm"><span style="font-size: 10pt">Employment Agreement, dated August 11, 2021, by and between the Company and Dr. Mark Dybul</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 46%"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit to 10.1 the Company&#8217;s Current Report on Form 8-K/A, filed with the SEC on August 16, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm"><span style="font-size: 10pt">Amendment to Employment Agreement between Mark Dybul, M.D. and the Company, dated December 12, 2022</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit to 10.1 the Company&#8217;s Current Report on Form 8-K, filed with the SEC on December 16, 2022.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">10.10 </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="e5986_ex10-10.htm"><span style="font-size: 10pt">Security Agreement, effective December 30, 2022, by and between the Company and Paseco ApS</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on February 23, 2023.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-1.htm"><span style="font-size: 10pt">Purchase Agreement, dated June 20, 2023, by and between the Company and Lincoln Park Capital Fund, LLC</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on June 27, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-2.htm"><span style="font-size: 10pt">Registration Rights Agreement, dated June 20, 2023, by and between the Company and Lincoln Park Capital Fund, LLC</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-2.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on June 27, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/e5493_ex10-1.htm"><span style="font-size: 10pt">Consulting Agreement, dated March 11, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224000419/e5493_ex10-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on March 13, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex10-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001396/e4889_ex10-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on August 7, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/e5116_ex10-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001841/e5116_ex10-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on October 10, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224001001/e5764_ex10-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224001001/e5764_ex10-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on June 21, 2024</span></a></td></tr>
</table>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 119; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 7%"><span style="font-size: 10pt">21.1*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 92%"><a href="e5986_ex21-1.htm"><span style="font-size: 10pt">Subsidiaries of the Registrant</span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.1*&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="e5986_ex23-1.htm"><span style="font-size: 10pt">Consent of Sadler, Gibb &amp; Associates&#160;</span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">31.1* </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="e5986_ex31-1.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">31.2* </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="e5986_ex31-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">32.1** </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="e5986_ex32-1.htm"><span style="font-size: 10pt">Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="e5986_ex32-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Clawback Policy</span></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.INS </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Instance Document* </span></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.SCH </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema* </span></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.CAL </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase* </span></td>
    </tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.DEF </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase* </span></td>
    </tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.LAB </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase* </span></td>
    </tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.PRE </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase* </span></td>
    </tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) *</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 120; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_026"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements of
Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 10, 2024</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENOVARO INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark Dybul</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Dybul</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer) </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Simon Tarsh</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon Tarsh</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements of
the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Dr.
    Mark Dybul</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Mark Dybul</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer) </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Simon
    Tarsh</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial
    Officer</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon Tarsh</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and
    Accounting Officer)</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Ren&#233;
    Sindlev </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chairman
    of the Board</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ren&#233; Sindlev </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Gregg
    Alton</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 10, 2024</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregg Alton </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jayne McNicol </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Jayne McNicol </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;James
    Sapirstein </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Sapirstein </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Carol
    Brosgart </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carol Brosgart </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Ruud
    Hendriks </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ruud Hendriks</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Karen
    Brink</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Karen Brink </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Avram
    Miller</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    10, 2024</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avram Miller</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>













































































































































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>2
<FILENAME>e5986_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">EXHIBIT 10.10</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">AMENDED AND RESTATED SECURITY AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in">This Amended and
Restated Security Agreement, dated as of January 2, 2024 (the <B><I>&ldquo;<U>Agreement</U>&rdquo;</I></B>) is made by and among Renovaro
BioSciences Inc., a corporation duly organized and validly existing under the laws of Delaware (the <B><I>&ldquo;<U>Company</U>&rdquo;</I></B>)
and Paseco ApS, a limited company organized under the Kingdom of Denmark (<B>&ldquo;<I><U>Paseco</U></I>&rdquo;</B>), and RS Bio ApS (<B>&ldquo;<I><U>RS
Bio</U></I>,&rdquo; </B>and together with Paseco, the <B><I>&ldquo;<U>Secured Parties</U>&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><B>WHEREAS</B>,
effective December 30, 2022, Paseco and the Company entered into that certain Security Agreement (the <B>&ldquo;<I><U>Original Agreement</U></I>&rdquo;</B>)
to secure the obligations of the Company under certain promissory notes issued to Paseco (the <B>&ldquo;<I><U>Paseco Notes</U></I>&rdquo;</B>),
of which $3,000,000 in principal amount remains outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><B>WHEREAS</B>,
on each of November 3, 2023 and January 2, 2024, RS Bio received 5% Original Issue Discount Promissory Notes from the Company in an aggregate
principal amount of $1,526,315 (the <B>&ldquo;<I><U>RS Bio Notes</U></I>&rdquo;</B>, and together with the Paseco Notes, the <B>&ldquo;<I><U>Notes</U></I>&rdquo;</B>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none"><B>WHEREAS</B>,
the Company has requested that Paseco amend and restate the Original Agreement to provide for security of the RS Bio Notes and Paseco
has agreed to amend and restate the Original Agreement in accordance with Section 5.04 of the Original Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none"><B>NOW
THEREFORE</B>, in order to induce the Secured Parties to extend the loans evidenced by the Paseco Notes and RS Bio Notes, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company has agreed to pledge and grant
a continuing security interest in the Collateral (as hereinafter defined) as security for the Secured Obligations (as hereinafter defined).
Accordingly, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><B><I>Section
1. <U>Definitions</U>. </I></B>Each capitalized term used herein and not otherwise defined shall have the meaning assigned to such term
in the Note. In addition, as used herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I>&ldquo;Collateral&rdquo; </I></B>shall have the meaning
ascribed thereto in <U>Section 3</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="text-decoration: none"><B><I>&ldquo;Event
of Default&rdquo; </I></B>shall have the meaning ascribed thereto in Section 5 of the February Notes, as amended and restated, and as
set forth in Section 6 of the March Note, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="text-decoration: none"><B><I>&ldquo;Secured
Obligations&rdquo;</I></B> shall mean, collectively, the principal of and interest on the Paseco Notes and RS Bio Notes issued by the
Company and held by the Secured Parties, and all other amounts from time to time owing to the Secured Parties by the Company under this
Agreement, the Paseco Notes and the RS Bio Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="text-decoration: none"><B><I>&ldquo;Secured
Parties&rdquo; </I></B>shall have the meaning defined in the preamble to this Agreement; provided, that such term also shall include,
as to the benefits, rights and obligations herein, the successors and assigns of any Secured Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><B><I>&ldquo;Subsidiary&rdquo;
or &ldquo;Subsidiaries&rdquo; </I></B>of the Company shall mean any entity whose equity interests are owned entirely by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><FONT STYLE="text-decoration: none"><B><I>&ldquo;Transaction
Agreements&rdquo; </I></B>shall mean this Agreement, the Paseco Notes, the RS Bio Notes and all ancillary documents referred to in those
agreements, and each of those agreements as may be amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><FONT STYLE="text-decoration: none"><B><I>&ldquo;Uniform
Commercial Code&rdquo; </I></B>shall mean the Uniform Commercial Code as in effect in the State of Delaware from time to time;
provided, however, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection,
priority, or remedies with respect to the Secured Party&rsquo; lien on any Collateral is governed by the Uniform Commercial Code as
enacted and in effect in a jurisdiction other than the State of Delaware, the term &ldquo;Uniform Commercial Code&rdquo; shall mean
the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes <FONT STYLE="letter-spacing: 0.1pt">of </FONT>the
provisions thereof relating to such attachment, perfection, priority, or remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><B><I>Section
2. <U>Representations and Warranties of the Company</U></I></B>. The Company hereby represents, warrants, and covenants that: (a) the
Company owns or has good and marketable title to <FONT STYLE="letter-spacing: 0.05pt">the </FONT>Collateral and no other person or organization
can make any claim of ownership of any kind on the Collateral; (b) the Company has the full power, authority and legal right to grant
the security interest in the Collateral; (c) the Collateral is free from any and all claims, encumbrances, rights of setoff or any other
security interest or lien of any kind except for the security interest in favor of the Secured Party created by this Security Agreement
and (d) this Security Agreement creates in favor of the Secured Party a valid security interest in the Collateral, securing payment of
the Secured Obligations, and such security interest is first priority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><B><I>Section
3. <U>Collateral</U>. </I></B>As collateral security for the prompt payment in full when due (whether at stated maturity, by acceleration
or otherwise) of the Secured Obligations, the Company hereby acknowledges, agrees and confirms that (i) the Secured Parties shall continue
to have a security interest in and lien upon and, (ii) to the extent not otherwise previously granted to the Secured Parties, Company
hereby pledges, grants, assigns, hypothecates and transfers to the Secured Parties as hereinafter provided, a first priority security
interest in and lien upon all of the Company&rsquo;s wholly-owned assets, whether now existing or hereafter from time to time arising
or acquired, and including those set forth on <B><U>Annex 1</U></B> (all of the foregoing being collectively referred to herein as <B><I>&ldquo;Collateral&rdquo;</I></B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><B><I>Section
4. <U>Further Assurances; Remedies</U>. </I></B>In furtherance of the grant of the pledge and security interest pursuant to Section 3
hereof, the Company hereby agrees with the Secured Parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B>4.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Delivery
and Other Perfection</U></I>. </B>The Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; width: 1in; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; width: 0.25in; text-indent: 0pt"><B>a.</B></TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">give, execute, deliver, file and record any financing statement, notice, instrument,
document, agreement or other papers that may be necessary or desirable (in the reasonable judgment of the Secured Parties) to create,
preserve, maintain, perfect or validate any security interest previously granted or granted pursuant hereto or to enable the Secured Party
to exercise and enforce its rights hereunder with respect to such security interest, including, without limitation, upon the occurrence
and continuance of an Event of Default, causing any or all of the Collateral to be transferred of record into the name of the Secured
Party or its nominee;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; text-indent: 0pt"><B>b.</B></TD><TD STYLE="padding: 0pt; text-indent: 0pt">keep accurate books and records relating to the Collateral; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; text-indent: 0pt"><B>c.</B></TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">permit representatives of the Secured Parties, upon reasonable notice, at any time
during normal business hours to inspect and make abstracts from its books and records pertaining to the Collateral, and permit representatives
of the Secured Parties to be present at the Company&rsquo;s place of business to receive copies of all communications and remittances
relating to the Collateral, and forward copies of any notices or communications by the Company with respect to the Collateral, all in
such manner as the Secured Parties may reasonably require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Other
Financing Statements and Liens</U>. </I></B>Without the prior written consent of the Secured Parties, the Company shall not file or suffer
to be on file, or authorize or permit to be filed or to be on file, in any jurisdiction, any financing statement or like instrument with
respect to the Collateral in which the Secured Parties are not named as the only secured parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><B>4.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Events
of Default, etc.</U></I></B> Upon the occurrence and during the continuation of an Event of Default, the Secured Parties may exercise
any or all of the following rights and remedies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; width: 1in; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; width: 0.25in; text-indent: 0pt"><B>a.</B></TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">require the Company to (and, upon such request, the Company shall) assemble and make available to the
Secured Parties the Collateral and all books and records relating thereto at such place or places, reasonably requested by the Secured
Parties, whether at the Company&rsquo;s premises or elsewhere;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; text-indent: 0pt"><B>b.</B></TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">the Secured Parties may make any reasonable compromise or settlement deemed desirable
with respect to any of the Collateral and may extend the time of payment, arrange for payment in installments, or otherwise modify the
terms of, any of the Collateral;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; text-indent: 0pt"><B>c.</B></TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">the Secured Parties shall have all of the rights and remedies with respect to the Collateral of a secured
party under the Uniform Commercial Code (whether or not said Code is in effect in the jurisdiction where the rights and remedies are asserted)
and such additional rights and remedies to which a secured party is entitled under the laws in effect in any jurisdiction where any rights
and remedies hereunder may be asserted, including, without limitation, the right, to the maximum extent permitted by law, to exercise
all voting, consensual and other powers of ownership pertaining to the Collateral as if the Secured Parties were the only and absolute
owner thereof (and the Company agrees to take all such action as may be appropriate to give effect to such right);</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; text-indent: 0pt"><B>d.</B></TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">the Secured Parties in their discretion may, in its name or in the name of the
Company or otherwise, demand, sue for, collect or receive any money or property at any time payable or receivable on account of or in
exchange for any of the Collateral, but shall be under no obligation to do so; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; text-indent: 0pt"></TD><TD STYLE="padding: 0pt; text-indent: 0pt"><B>e.</B></TD><TD STYLE="padding: 0pt; text-align: justify; text-indent: 0pt">the Secured Parties may, upon ten (10) days&rsquo; prior written notice to the Company of the time and
place, with respect to the Collateral or any part thereof which shall then be or shall thereafter come into the possession, custody or
control of the Secured Parties, or any of its respective agents, sell, lease, assign or otherwise dispose of all or any of such Collateral,
at such place or places as the Secured Parties deem best, and for cash or on credit or for future delivery (without thereby assuming any
credit risk), at public or private sale, without demand of performance or notice of intention to effect any such disposition or of time
or place thereof (except such notice as is required above or by applicable statute and cannot be waived) and the Secured Parties or anyone
else may be the purchaser, lessee, assignee or recipient of any or all of the Collateral so disposed of at any public sale (or, to the
extent permitted by law, at any private sale), and thereafter hold the same absolutely, free from any claim or right of whatsoever kind,
including any right or equity of redemption (statutory or otherwise), of the Company, any such demand, notice or right and equity being
hereby expressly waived and released. The Secured Parties may, without notice or publication, adjourn any public or private sale or cause
the same to be adjourned from time to time by announcement at the time and place fixed for the sale, and such sale may be made at any
time or place to which the same may be so adjourned.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="text-decoration: none">The proceeds of each
collection, sale or other disposition under this Section 4.03, shall be applied in accordance with Section 4.06 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Deficiency</U>.</I></B>
If the proceeds of sale, collection or other realization of or upon the Collateral pursuant to <U>Section 4.03</U> hereof are insufficient
to cover the costs and expenses of such realization and the payment in full of the Secured Obligations, the Company shall remain liable
for any deficiency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Removals,
etc</U>.</I></B> Without at least thirty (30) days&rsquo; prior written notice to the Secured Parties or unless otherwise required by
law, the Company shall not (i) maintain any of its books or records with respect to the Collateral at any office or maintain its chief
executive office or its principal place of business at any place, or permit any Collateral to be located anywhere other than 2080 Century
Park E, Suite 906, Los Angeles, CA 90067; or (ii) change its corporate name, or the name under which it does business, from the name shown
on the signature page hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Application
of Proceeds</U>. </I></B>Except as otherwise herein expressly provided, the proceeds of any collection, sale or other realization of all
or any part of the Collateral pursuant hereto, and any other cash at the time held by the Secured Parties under this <U>Section 4</U>,
shall be applied by the Secured Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><B><U>First</U>,</B>
to the payment of the costs and expenses of such collection, sale or other realization, including reasonable out-of-pocket costs and expenses
of the Secured Parties and the fees and expenses of its agents and counsel, and all expenses, and advances made or incurred by the Secured
Parties in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><B><U>Next</U>,</B>
to the payment in full of the Secured Obligations in each case equally and ratably in accordance with the respective amounts thereof then
due and owing to the Secured Parties; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><B><U>Finally</U>,
</B>to the payment to the Company, or its successors or assigns, or as a court of competent jurisdiction may direct, of any surplus then
remaining.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .75in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As used in this <U>Section 4</U>, <B><I>&ldquo;proceeds&rdquo;
</I></B>of Collateral shall mean cash, securities and other property realized in respect of, and distributions in kind of, Collateral,
including any thereof received under any reorganization, liquidation or adjustment of debt of the Company or any issuer of or obligor
on any of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Attorney-in-Fact</U>.
</I></B>Without limiting any rights or powers granted by this Agreement to the Secured Parties while no Event of Default has occurred
and is continuing, upon the occurrence and during the continuance of any Event of Default, the Secured Parties is hereby appointed the
attorney-in-fact of the Company for the purpose of carrying out the provisions of this <U>Section 4</U> and taking any action and executing
any instruments which the Secured Parties may deem necessary or advisable to accomplish the purposes hereof, which appointment as attorney-in-fact
is irrevocable and coupled with an interest. Without limiting the generality of the foregoing, so long as the Secured Parties shall be
entitled under this <U>Section 4</U> to make collections in respect of the Collateral, the Secured Parties shall have the right and power
to receive, endorse and collect all checks made payable to the order of the Company representing any dividend, payment, or other distribution
in respect of the Collateral or any part thereof and to give full discharge for the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Perfection</U>.</I></B>
Prior to or concurrently with the execution and delivery of this Agreement, the Company shall file such financing statements and other
documents in such offices as may be necessary (including any such offices as the Secured Parties may request) to perfect or maintain the
security interests granted by <U>Section 3</U> of this Agreement; and without limiting the Company&rsquo;s obligations with respect to
perfection of the security interests, the Company hereby authorizes the Secured Parties to file all such financing statements and other
documents (and ratifies any previously filed financing statements and other documents filed by the Secured Parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Termination</U>.
</I></B>When all Secured Obligations shall have been paid in full under the Note, this Agreement shall terminate, and the Secured Parties
shall forthwith cause to be assigned, transferred and delivered, against receipt but without any recourse, warranty or representation
whatsoever, any remaining Collateral and money received in respect thereof, to or on the order of the Company. <FONT STYLE="letter-spacing: 0.05pt">The</FONT>
Secured Parties shall also execute and deliver to the Company upon such termination such Uniform Commercial Code termination statements
and such other documentation as shall be reasonably requested by the Company, at the Company&rsquo;s expense, to effect the termination
and release of the liens on the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Expenses</U>.
</I></B>The Company agrees to pay to the Secured Parties all out-of-pocket expenses (including reasonable expenses for legal services
of every kind) of, or incident to, the enforcement of any of the provisions of this <U>Section 4</U>, or performance by the Secured Parties
of any obligations of the Company in respect of the Collateral which the Company has failed or refused to perform upon reasonable notice,
or any actual or attempted sale, or any exchange, enforcement, collection, compromise or settlement in respect of any of the Collateral,
and for the care of the Collateral and defending or asserting rights and claims of the Secured Parties in respect thereof, by litigation
or otherwise, including expenses of insurance, and all such expenses shall be Secured Obligations to the Secured Parties secured under
<U>Section 3</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Further
Assurances</U>.</I></B> The Company agrees that, from time to time upon the written request of the Secured Parties, the Company will execute
and deliver such further documents and do such other acts and things as the Secured Parties may reasonably request in order fully to effect
the purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I>Section 5.&#9;<U>Miscellaneous</U>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>No
Waiver</U>. </I></B>No failure on the part of the Secured Parties or any of its agents to exercise, and no course of dealing with respect
to, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial
exercise by the Secured Parties or any of its agents of any right, power or remedy hereunder preclude any other or further exercise thereof
or the exercise of any other right, power or remedy. The remedies herein are cumulative and are not exclusive of any remedies provided
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Governing
Law</U>. </I></B>This Agreement shall be governed by, and construed in accordance with, the law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><B><I><U>Notices</U>. </I></B>All
notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and,
unless otherwise specified herein, shall be (a) personally served, (b) delivered by reputable international courier service with
charges prepaid, or (d) transmitted by hand delivery, telegram, or email (upon confirmation of receipt), addressed as set forth
below or to such other address as such party shall have specified most recently by written notice given in accordance herewith. Any
notice or other communication required or permitted to be given hereunder shall be deemed effective (i) upon hand delivery or
delivery by email (upon confirmation of receipt), or (ii) on the second business day following the date of mailing by reputable
international courier service. The addresses for such communications shall be for (i) the Company at 9480 NE 2nd Avenue, #73 Miami,
FL 33138, Telephone: (305) 918-1980, Email: <FONT STYLE="color: blue"><U>lpuche@renovarobio.com </U></FONT>with a copy to
clayton.parker@klgates.com, <FONT STYLE="letter-spacing: -0.1pt">(ii) </FONT>Paseco at
Vedbaek Strandvej 506, 2950 Vedbaek, Denmark and (iii) RS Bio at Stumpedyssevej 17, 2970 H&oslash;rsholm, Denmark, Email: <FONT STYLE="color: #0462C1">an@rsgroup.dk </FONT>with
a copy to <FONT STYLE="color: #0462C1">rsindlev@drsmood.com</FONT>. Any party hereto may from time to time change its address or
facsimile number for notices under this Section by written notice to the other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Waivers,
etc</U>. </I></B>The terms of this Agreement may be waived, altered or amended only by an instrument in writing duly executed by the Company
and the Secured Parties. Any such amendment or waiver shall be binding upon the Secured Parties and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Successors
and Assigns</U>. </I></B>This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of the
Company and the Secured Parties (provided, however, that the Company shall not assign or transfer its rights hereunder without the prior
written consent of the Secured Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Counterparts;
Execution; Additional Secured Party</U>. </I></B>This Agreement may be executed in any number of counterparts, all of which together shall
constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. In the
event that any signature is delivered by facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force
and effect as if such facsimile or &ldquo;.pdf&rdquo; signature page was an original thereof. In the event additional Secured Parties
become holders of the Paseco Notes or RS Bio Notes, such Secured Party will become a party to this Agreement by signing a counterpart
to this Agreement in a form reasonably acceptable to the Secured Parties, all of which together shall be considered one and the same instrument.
The Company shall provide a copy of each counterpart to this Agreement executed by a Secured Party to the Secured Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Severability</U>.
</I></B>If any provision hereof is invalid and unenforceable in any jurisdiction, then, to the fullest extent permitted by law, (i) the
other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in favor of the Secured
Parties in order to carry out the intentions of the parties hereto as nearly as may be possible and (ii) the invalidity or unenforceability
of any provision hereof in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><U>Entire
Agreement</U>. </I></B>This Agreement and the other Transaction Agreements contains the entire agreement and understanding by and between
the parties hereto with respect to the subject matter hereof and their resulting obligations to each other, as herein described; and it
amends, restates and supersedes all prior agreements and understandings between the parties to this Agreement relating to the subject
matter hereof. No change or modification of this Agreement shall be valid or binding unless the same is in writing and signed by the party
intended to be so bound. No waiver of any provision of this Agreement shall be valid unless the same is in writing and signed by the party
against whom such waiver is sought to be enforced. Moreover, no valid waiver of any provision of this Agreement, at any time, shall be
deemed to be a waiver of any other provision of this Agreement at such time, or shall be deemed to be a valid waiver of such provision
at any other time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[The remainder of this page intentionally left blank.]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: .5in"><FONT STYLE="text-decoration: none">IN
WITNESS WHEREOF, the parties hereto have caused this Security Agreement to be duly executed as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: .5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
<TD COLSPAN="2"><B>The &ldquo;Company&rdquo;:</B></TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2"><B>The &ldquo;Secured Parties&rdquo;:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD COLSPAN="2">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD COLSPAN="2"><B>RENOVARO BIOSCIENCES INC.</B></TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2"><B>PASECO APS</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 7%">&nbsp;</TD>
<TD STYLE="width: 42%">&nbsp;</TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="width: 7%">&nbsp;</TD>
<TD STYLE="width: 42%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Luisa Puche</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Ole Abildgaard</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>Name:</TD>
<TD>Luisa Puche</TD>
<TD>&nbsp;</TD>
<TD>Name:</TD>
<TD>Ole Abildgaard</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>Title:</TD>
<TD>Chief Financial Officer</TD>
<TD>&nbsp;</TD>
<TD>Title:</TD>
<TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2"><B>RS BIO APS</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Rene Sindlev</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Name:</TD>
<TD>Rene Sindlev</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Title:</TD>
<TD>Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNEX 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>All fixed assets located at:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="text-decoration: none">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2080
Century Park E, Suite 906, Los Angeles, CA 90067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 107pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in">&#9679;</TD>
<TD>The Intellectual property set forth below:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&#9679;</TD>
<TD><B>ALLOGENEIC T-CELL-BASED HIV VACCINE TO INDUCE CELLULAR AND HUMORAL IMMUNITY</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B>Inventor(s): Serhat Gumrukcu </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B>Assignee:
Renovaro Biopharma Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: black">
<TD STYLE="padding: 2pt; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Country</B></FONT></TD>
<TD STYLE="padding: 2pt; text-align: center; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Appl. No.</B></FONT></TD>
<TD STYLE="padding: 2pt; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Filing Date</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; width: 19%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Pub. No./ Pub. Date</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Patent No. / Issue Date</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Status</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border: black 1pt solid; padding: 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/904,319</FONT></TD>
<TD STYLE="border-top: black 1pt solid; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US2021/0030795 02/04/2021</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AU</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020294700</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BR</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120210252860</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CA</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3143599</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CN</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202080056674.7</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EP</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20826762.5</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP3982981<BR>
04/20/2022</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HK</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62022062396.6</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IL</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">288945</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202217000341</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JP</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-574918</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KR</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2022-7000923</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/11/2022</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MX</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2021/015643</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NZ</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">784083</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ZA</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021/10224</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/17/2020</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SG</B></FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11202113941W</FONT></TD>
<TD STYLE="border-right: black 1pt solid; padding: 2pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/15/2021</FONT></TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>METHODS AND COMPOSITIONS USING
RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY </B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>Inventor(s): Serhat Gumrukcu</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>Assignee: Renovaro Biopharma Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: black">
<TD STYLE="padding: 2pt; text-align: center; width: 10%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Country</B></FONT></TD>
<TD STYLE="padding: 2pt; text-align: center; width: 28%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Appl.
No.</B></FONT></TD>
<TD STYLE="padding: 2pt; text-align: center; width: 14%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Filing
Date</B></FONT></TD>
<TD STYLE="padding: 2pt; text-align: center; width: 19%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Pub.
No./ Pub. Date</B></FONT></TD>
<TD STYLE="padding: 2pt; text-align: center; width: 14%; text-indent: 0pt"><FONT STYLE="color: White"><B>Patent No./&#9;Issue Date</B></FONT></TD>
<TD STYLE="padding: 2pt; text-align: center; width: 15%; text-indent: 0pt"><FONT STYLE="color: White"><B>Status</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/511,413</FONT></TD>
    <TD STYLE="padding: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,413,338<BR>
08/16/2022</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AE</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P6000067/21</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AU</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019306504</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BH</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20210012</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BR</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112021000620 6</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CA</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3106403</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CN</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201980051688.7</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EA</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202190267</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EP</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19837951.3</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP3820486<BR>
05/19/2021</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GE</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201915555</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HK-CN</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021039668.0</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2021</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HK-EP</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62021042617.2</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/17/2021</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IL</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">280145</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202117004635</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JP</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-502920</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KR</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2021-700-3120</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MX</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2021/000421</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MY</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI2021000186</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/5/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NZ</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QA</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QA/202101/00027</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SA</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">521421034</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SG</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11202100315T</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UA</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a202100559</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VN</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-2021-00752</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2019</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ZA</B></FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021/00234</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2021</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021/00234<BR>
07/27/2022</FONT></TD>
    <TD STYLE="padding: 2pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0pt; border-bottom: Black 1pt solid; width: 40%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
ref.</B></FONT></TD>
    <TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; border-bottom: Black 1pt solid; width: 18%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicant</B></FONT></TD>
    <TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; border-bottom: Black 1pt solid; width: 10%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt; border-bottom: Black 1pt solid; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appl.
No.</B></FONT></TD>
    <TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt; border-bottom: Black 1pt solid; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pat.
No.</B></FONT></TD>
    <TD STYLE="padding: 0pt; width: 1%; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 0pt; width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protocol for generating dendritic</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2640836</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2640836</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GENER.
DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Zealand</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">569343</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">569343</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GEN. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200680045697.8</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200680045697.8</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GEN. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013203315</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013203315</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GENER. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switzerland</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06818153.6</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1971680</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GENER. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06818153.6</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">602006027671.0</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GENER. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denmark</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06818153.6</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1971680</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GENER. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spain</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06818153.6</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1971680</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GENER. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06818153.6</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1971680</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GENER. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Italy</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06818153.6</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1971680</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTOCOL FOR GEN. DENDRITIC CELLS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DanDrit Biotech A/S</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191782</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="text-align: center; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191782</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
<TD STYLE="padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT>10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>e5986_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>LIST OF SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a list of subsidiaries of the Company as of June 30, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsidiary
    Legal Name</U></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>State or
    Other Jurisdiction of Incorporation or Organization</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Biosciences, Inc.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Biosciences Denmark
    ApS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denmark</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Tecnologies, Inc.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEDi Cube Intl Ltd.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">England and Wales</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEDi Cube B.V.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grace Systems B.V.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>e5986_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hereby consent to the incorporation by reference
in the Registration Statements on Forms S-8 (No. 333-261628 and 333-275132) of our report dated October 10, 2024, relating to the consolidated
financial statements of Renovaro Inc., which appears in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Sadler, Gibb &amp; Associates,
    LLC</I></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Draper, UT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 10, 2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>e5986_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>I, Mark Dybul, certify that: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
    this Annual Report on Form 10-K of Renovaro Inc.; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
    the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
    </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
    in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
    and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is
    reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
    equivalent functions): </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 10, 2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark Dybul</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Dybul</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>e5986_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I,
Simon Tarsh, certify that: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
    this Annual Report on Form 10-K of Renovaro Inc.; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
    the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
    </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
    in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
    and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is
    reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
    equivalent functions): </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 10, 2024</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Simon Tarsh</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon Tarsh</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial
    Officer <BR>
    (Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>e5986_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Renovaro Inc.
(the &ldquo;Company&rdquo;) on Form 10-K for the year ending June 30, 2023 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
the undersigned, Mark Dybul, as Chief Executive Officer (Principal Executive Officer) of the Company, hereby certifies as of the date
hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies
    with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained
    in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 10, 2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark Dybul</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Dybul</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>e5986_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Renovaro Inc.
(the &ldquo;Company&rdquo;) on Form 10-K for the year ending June 30, 2024 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
the undersigned, Simon Tarsh, as Interim Chief Financial Officer (Principal Financial Officer) of the Company, hereby certifies as of
the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies
    with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained
    in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 10, 2024</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Simon Tarsh</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon Tarsh</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer <BR>
    (Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>renb-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaWBycPtxJFzWZkhv2p+fenaDy8i5an9WyGj+MgmgUAK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:RENB="http://renovarobio.com/20240630" elementFormDefault="qualified" targetNamespace="http://renovarobio.com/20240630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://renovarobio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
          <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
          <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity" id="ConsolidatedStatementOfStockholdersEquity">
          <link:definition>00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
          <link:definition>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>995613 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/GoingConcern" id="GoingConcern">
          <link:definition>995614 - Disclosure - GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>995615 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>995616 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
          <link:definition>995617 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Leases" id="Leases">
          <link:definition>995618 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Debt" id="Debt">
          <link:definition>995619 - Disclosure - DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>995620 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>995621 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>995622 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>995623 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Acquisition" id="Acquisition">
          <link:definition>995624 - Disclosure - ACQUISITION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>995625 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>995626 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>995627 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>995628 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>995629 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
          <link:definition>995630 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/LeasesTables" id="LeasesTables">
          <link:definition>995631 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>995632 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>995633 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionTables" id="AcquisitionTables">
          <link:definition>995634 - Disclosure - ACQUISITION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>995635 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>995636 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>995637 - Disclosure - GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
          <link:definition>995638 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
          <link:definition>995639 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
          <link:definition>995640 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
          <link:definition>995641 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>995642 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" id="IntangibleAssetsAndGoodwillDetails">
          <link:definition>995643 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" id="IntangibleAssetsAndGoodwillDetails1">
          <link:definition>995644 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" id="IntangibleAssetsAndGoodwillDetailsNarrative">
          <link:definition>995645 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/LeasesDetails" id="LeasesDetails">
          <link:definition>995646 - Disclosure - LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/LeasesDetails1" id="LeasesDetails1">
          <link:definition>995647 - Disclosure - LEASES  (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>995648 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>995649 - Disclosure - DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>995650 - Disclosure - INCOME TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>995651 - Disclosure - INCOME TAXES (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
          <link:definition>995652 - Disclosure - INCOME TAXES (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>995653 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
          <link:definition>995654 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
          <link:definition>995655 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
          <link:definition>995656 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
          <link:definition>995657 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
          <link:definition>995658 - Disclosure - STOCKHOLDERS' EQUITY (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>995659 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>995660 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>995661 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails" id="AcquisitionDetails">
          <link:definition>995662 - Disclosure - ACQUISITION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails1" id="AcquisitionDetails1">
          <link:definition>995663 - Disclosure - ACQUISITION (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails2" id="AcquisitionDetails2">
          <link:definition>995664 - Disclosure - ACQUISITION (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails3" id="AcquisitionDetails3">
          <link:definition>995665 - Disclosure - ACQUISITION (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetailsNarrative" id="AcquisitionDetailsNarrative">
          <link:definition>995666 - Disclosure - ACQUISITION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
          <link:definition>995667 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingDetails1" id="SegmentReportingDetails1">
          <link:definition>995668 - Disclosure - SEGMENT REPORTING (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>995669 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="RENB_RenovaroCubeMember" name="RenovaroCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EmployeesOfficersDirectorsAndConsultantsMember" name="EmployeesOfficersDirectorsAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BlackScholesOptionPricingModelMember" name="BlackScholesOptionPricingModelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InitialRecognitionMember" name="InitialRecognitionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LabEquipmentAndInstrumentsMember" name="LabEquipmentAndInstrumentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LessAccumulatedAmortizationMember" name="LessAccumulatedAmortizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MarchNote2024Member" name="MarchNote2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_JanuaryNote2024Member" name="JanuaryNote2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DecemberNote2023Member" name="DecemberNote2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PrivatePlacement1Member" name="PrivatePlacement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PrivatePlacement2Member" name="PrivatePlacement2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PrivatePlacement3Member" name="PrivatePlacement3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Note2023Member" name="Note2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConvertibleNotesPayablesMember" name="ConvertibleNotesPayablesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AmendedAndRestatedSecuredNotesMember" name="AmendedAndRestatedSecuredNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TheNotesMember" name="TheNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RSBioMember" name="RSBioMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RSBioApSMember" name="RSBioApSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AccruedExpensesMember" name="AccruedExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_November2023NoteMember" name="November2023NoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SubscriptionAgreementsMember" name="SubscriptionAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SubscriptionAgreements1Member" name="SubscriptionAgreements1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Note2020Member" name="Note2020Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_FinanceAgreementMember" name="FinanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnitedStatesTaxMember" name="UnitedStatesTaxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PreferredStockIssuancesMember" name="PreferredStockIssuancesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Investor1Member" name="Investor1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockIssuancesMember" name="CommonStockIssuancesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SingleRangeMember" name="SingleRangeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockPurchaseAgreementOfRenovaroCubeMember" name="StockPurchaseAgreementOfRenovaroCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AdvisoryServicesMember" name="AdvisoryServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OneWarrantMember" name="OneWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LincolnParkMember" name="LincolnParkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RenovaroBioPharmaIncMember" name="RenovaroBioPharmaIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EBIAndWeirdScienceLLCMember" name="EBIAndWeirdScienceLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AgreementAndPlanOfMergerAgreementAxisMember" name="AgreementAndPlanOfMergerAgreementAxisMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DanDritDenmarkMember" name="DanDritDenmarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RenovaroDenmarkMember" name="RenovaroDenmarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EquityIncentivePlan2014Member" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Employees1Member" name="Employees1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" name="BoardOfDirectorsAndScientificAdvisoryBoardOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" name="BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConsultingServicesMember" name="ConsultingServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PlanOptionsMember" name="PlanOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrantsMember" name="CommonStockPurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RenovaroMember" name="RenovaroMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange1Member" name="ExercisePriceRange1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange2Member" name="ExercisePriceRange2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange3Member" name="ExercisePriceRange3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EmployeeStockOptionsMember" name="EmployeeStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange4Member" name="ExercisePriceRange4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange5Member" name="ExercisePriceRange5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrantMember" name="CommonStockPurchaseWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GTechMember" name="GTechMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MarkDybulMember" name="MarkDybulMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GEDiCubeMember" name="GEDiCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RENBMember" name="RENBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RENCMember" name="RENCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationLiabilityCurrent" name="ContingentConsiderationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NotesPayableRelatedPartiesNetCurrent" name="NotesPayableRelatedPartiesNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ChangeInFairValueOfContingentConsideration" name="ChangeInFairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LossOnExtinguishmentOfContingentConsiderationLiability" name="LossOnExtinguishmentOfContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InterestIncomeAndOtherIncomeExpense" name="InterestIncomeAndOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" name="IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" name="IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedPursuantToWarrantsExercisedValue" name="StockIssuedPursuantToWarrantsExercisedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedPursuantToWarrantsExercisedShares" name="StockIssuedPursuantToWarrantsExercisedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EarnoutSharesIssuedValue" name="EarnoutSharesIssuedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EarnoutSharesIssuedShares" name="EarnoutSharesIssuedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesIssuedForInterestOnNotesPayableExtensionValue" name="SharesIssuedForInterestOnNotesPayableExtensionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesIssuedForInterestOnNotesPayableExtensionShares" name="SharesIssuedForInterestOnNotesPayableExtensionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" name="IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" name="IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRenderedValue" name="RestrictedSharesIssuedForServicesRenderedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRenderedShares" name="RestrictedSharesIssuedForServicesRenderedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" name="IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" name="IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesIssuableForSettlementOfContingentConsiderationValue" name="SharesIssuableForSettlementOfContingentConsiderationValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesIssuableForSettlementOfContingentConsideration" name="SharesIssuableForSettlementOfContingentConsideration" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" name="IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" name="IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" name="PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" name="PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" name="IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" name="IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities" name="LossOnExtinguishmentOfContingentConsiderationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LossOnExtinguishmentOfDebt" name="LossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NoncashStockbasedCompensationExpense" name="NoncashStockbasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NoncashRestrictedSharesIssuedForServicesRendered" name="NoncashRestrictedSharesIssuedForServicesRendered" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AmortizationOfDiscountOnNotePayable" name="AmortizationOfDiscountOnNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RepaymentsOfFinanceAgreement" name="RepaymentsOfFinanceAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CashPaidDuringYearForAbstract" name="CashPaidDuringYearForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" name="ContingentSharesIssuedPursuantToAcquisitionAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension" name="SharesInLieuOfInterestOnMillionNotesPayableExtension" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" name="FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" name="ConversionOfNotePayableForIssuanceOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" name="NotePayableSettledThroughNoncashExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" name="DebtDiscountRelatedToConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonSharesIssuedUponAcquisition" name="CommonSharesIssuedUponAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationIssuedUponAcquisition" name="ContingentConsiderationIssuedUponAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonSharesIssuedUponSettlementOfDebt" name="CommonSharesIssuedUponSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" name="EarnOutSharesIssuedInSettlementOfContingentLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OptionsIssuedInSettlementOfDebt" name="OptionsIssuedInSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SettlementOfNotesPayable" name="SettlementOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessPolicyTextBlock" name="BusinessPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InsuranceReceivablePolicy" name="InsuranceReceivablePolicy" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfWarrantsOutstandingTableTextBlock" name="ScheduleOfWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" name="ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" name="ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EscrowSharesRemaining" name="EscrowSharesRemaining" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionPercentage" name="BusinessAcquisitionPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InProcessResearchAndDevelopment" name="InProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationInAcquisition" name="ContingentConsiderationInAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SettlementsContingentSharesToBeIssued" name="SettlementsContingentSharesToBeIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NetDefinitelifeIntangibleAssets" name="NetDefinitelifeIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NetDefinitelifeIntangibleAssetsAmortization" name="NetDefinitelifeIntangibleAssetsAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" name="IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" name="IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OperatingLeaseRentExpenses" name="OperatingLeaseRentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OperatingLeaseExpenses" name="OperatingLeaseExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CashPaidForTheTerminationOfLease" name="CashPaidForTheTerminationOfLease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AccrualPaymentsRelatedToTerminationOfLease" name="AccrualPaymentsRelatedToTerminationOfLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InterestExpenseRelatedToNoteBalance" name="InterestExpenseRelatedToNoteBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OriginalIssueDiscountPromissoryNotePercentage" name="OriginalIssueDiscountPromissoryNotePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DebtInstrumentOriginalIssueDiscount" name="DebtInstrumentOriginalIssueDiscount" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockAndReceivedGrossProceeds" name="CommonStockAndReceivedGrossProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OfferingPricePerSharePercentage" name="OfferingPricePerSharePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DebtInstrumentsFloorPricePerShare" name="DebtInstrumentsFloorPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PrepaymentShares" name="PrepaymentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GrossProceedsDiscountPercentage" name="GrossProceedsDiscountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExerciseWarrants" name="ExerciseWarrants" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_WarrantsOutstandingPerShare" name="WarrantsOutstandingPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExerciseWarrantsAmount" name="ExerciseWarrantsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MarketPrice" name="MarketPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_WarrantsPurchased" name="WarrantsPurchased" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PromissoryNoteBalanceNetOfDiscount" name="PromissoryNoteBalanceNetOfDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MonthlyInstallments" name="MonthlyInstallments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RepaymentOnFinanceAgreement" name="RepaymentOnFinanceAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" name="DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" name="DeferredTaxAssetExcessTaxOverDepreciationPatents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockoptionsCompensation" name="StockoptionsCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DepreciationAndAmortizations" name="DepreciationAndAmortizations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ImpairmentExpense" name="ImpairmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationFairValue" name="ContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ChangeInTaxRate" name="ChangeInTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExcessTaxBenefitOverDepreciationFixedAssets" name="ExcessTaxBenefitOverDepreciationFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExcessTaxBenefitOverDepreciationPatents" name="ExcessTaxBenefitOverDepreciationPatents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards" name="IncomeTaxExpenseBenefitOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IncomeTaxExpenseBenefitImpairmentExpense" name="IncomeTaxExpenseBenefitImpairmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue" name="IncomeTaxExpenseBenefitContingentConsiderationFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DeferredIncomeTaxExpenseChangeInTaxRate" name="DeferredIncomeTaxExpenseChangeInTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePrices" name="ExercisePrices" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrant" name="CommonStockPurchaseWarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" name="CommonStockPurchaseWarrantsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PreferredStockDesignatedShares" name="PreferredStockDesignatedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockShareIssued" name="CommonStockShareIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockConvertibleSharesIssuable" name="CommonStockConvertibleSharesIssuable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConversionOfPromissoryNote" name="ConversionOfPromissoryNote" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AggregatePreferredStockShares" name="AggregatePreferredStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AggregateCommonStockShares" name="AggregateCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_WarrantsSold" name="WarrantsSold" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ClosedSharesParValue" name="ClosedSharesParValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePricePerShare" name="ExercisePricePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PrincipalAmountAndInterestAccrued" name="PrincipalAmountAndInterestAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SettlementOfDebt" name="SettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" name="IssuanceOfCommonStockUnderPrivatePlacementOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockParValuePrivatePlacement" name="CommonStockParValuePrivatePlacement" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NumberOfShareWarrantPurchase" name="NumberOfShareWarrantPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchaseSharesOfCommonStock" name="PurchaseSharesOfCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EarnOutDistribution" name="EarnOutDistribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExtinguishmentOfContingentConsiderationLiability" name="ExtinguishmentOfContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" name="BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UpfrontPayment" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PaymentForExpenditures" name="PaymentForExpenditures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InitialPayment" name="InitialPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GrossProceedsOriginalIssueDiscountRate" name="GrossProceedsOriginalIssueDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationContingentConsiderationCommonStock" name="BusinessCombinationContingentConsiderationCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionsRevenue" name="BusinessAcquisitionsRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionsNetIncomeLoss" name="BusinessAcquisitionsNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SegmentOperatingLoss" name="SegmentOperatingLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SegmentAsset" name="SegmentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices" name="StockIssuedDuringPeriodSharesIssuedForConsultingServices" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices" name="StockIssuedDuringPeriodValueIssuedForConsultingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" name="StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>renb-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://renovarobio.com/role/Cover" xlink:href="renb-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:href="renb-20240630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="renb-20240630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="renb-20240630.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/GoingConcern" xlink:href="renb-20240630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurements" xlink:href="renb-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipment" xlink:href="renb-20240630.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Leases" xlink:href="renb-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Debt" xlink:href="renb-20240630.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxes" xlink:href="renb-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquity" xlink:href="renb-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:href="renb-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/RelatedPartyTransactions" xlink:href="renb-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Acquisition" xlink:href="renb-20240630.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReporting" xlink:href="renb-20240630.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SubsequentEvents" xlink:href="renb-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:href="renb-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:href="renb-20240630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesTables" xlink:href="renb-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesTables" xlink:href="renb-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityTables" xlink:href="renb-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionTables" xlink:href="renb-20240630.xsd#AcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingTables" xlink:href="renb-20240630.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:href="renb-20240630.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:href="renb-20240630.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="renb-20240630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetails" xlink:href="renb-20240630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetails1" xlink:href="renb-20240630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:href="renb-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/DebtDetailsNarrative" xlink:href="renb-20240630.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails" xlink:href="renb-20240630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:href="renb-20240630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:href="renb-20240630.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:href="renb-20240630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails" xlink:href="renb-20240630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:href="renb-20240630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:href="renb-20240630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:href="renb-20240630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:href="renb-20240630.xsd#StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:href="renb-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="renb-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="renb-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails" xlink:href="renb-20240630.xsd#AcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails1" xlink:href="renb-20240630.xsd#AcquisitionDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails2" xlink:href="renb-20240630.xsd#AcquisitionDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails3" xlink:href="renb-20240630.xsd#AcquisitionDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetailsNarrative" xlink:href="renb-20240630.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingDetails" xlink:href="renb-20240630.xsd#SegmentReportingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingDetails1" xlink:href="renb-20240630.xsd#SegmentReportingDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:href="renb-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaapInsuranceSettlementsReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInsuranceSettlementsReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="loc_RENBContingentConsiderationLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RENBContingentConsiderationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="loc_RENBNotesPayableRelatedPartiesNetCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RENBNotesPayableRelatedPartiesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfContingentConsiderationLiability" xlink:label="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="loc_RENBInterestIncomeAndOtherIncomeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBInterestIncomeAndOtherIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities" xlink:label="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="loc_RENBLossOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBLossOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="loc_RENBNoncashStockbasedCompensationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBNoncashStockbasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:label="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="loc_RENBAmortizationOfDiscountOnNotePayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBAmortizationOfDiscountOnNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="loc_us-gaapPaymentsToAcquireNotesReceivable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireNotesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="loc_RENBRepaymentsOfFinanceAgreement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RENBRepaymentsOfFinanceAgreement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="995613 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="995614 - Disclosure - GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="995615 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipment" xlink:title="995616 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="995617 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Leases" xlink:title="995618 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="995619 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxes" xlink:title="995620 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="995621 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="995622 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="995623 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisition" xlink:title="995624 - Disclosure - ACQUISITION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="995625 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="995626 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995627 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="995628 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:title="995629 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="995630 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesTables" xlink:title="995631 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesTables" xlink:title="995632 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="995633 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionTables" xlink:title="995634 - Disclosure - ACQUISITION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="995635 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995636 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="995637 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="995638 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="995639 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="995640 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:title="995641 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="995642 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="995643 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="995644 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="995645 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails" xlink:title="995646 - Disclosure - LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails1" xlink:title="995647 - Disclosure - LEASES  (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:title="995648 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="995649 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails" xlink:title="995650 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:label="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationFixedAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationPatents" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockoptionsCompensation" xlink:label="loc_RENBStockoptionsCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_RENBStockoptionsCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DepreciationAndAmortizations" xlink:label="loc_RENBDepreciationAndAmortizations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_RENBDepreciationAndAmortizations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ImpairmentExpense" xlink:label="loc_RENBImpairmentExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_RENBImpairmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationFairValue" xlink:label="loc_RENBContingentConsiderationFairValue" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_RENBContingentConsiderationFairValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInTaxRate" xlink:label="loc_RENBChangeInTaxRate" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_RENBChangeInTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:title="995651 - Disclosure - INCOME TAXES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:title="995652 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:label="loc_RENBExcessTaxBenefitOverDepreciationFixedAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_RENBExcessTaxBenefitOverDepreciationFixedAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExcessTaxBenefitOverDepreciationPatents" xlink:label="loc_RENBExcessTaxBenefitOverDepreciationPatents" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_RENBExcessTaxBenefitOverDepreciationPatents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:label="loc_RENBIncomeTaxExpenseBenefitOperatingLossCarryforwards" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_RENBIncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitImpairmentExpense" xlink:label="loc_RENBIncomeTaxExpenseBenefitImpairmentExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_RENBIncomeTaxExpenseBenefitImpairmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue" xlink:label="loc_RENBIncomeTaxExpenseBenefitContingentConsiderationFairValue" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_RENBIncomeTaxExpenseBenefitContingentConsiderationFairValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredIncomeTaxExpenseChangeInTaxRate" xlink:label="loc_RENBDeferredIncomeTaxExpenseChangeInTaxRate" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_RENBDeferredIncomeTaxExpenseChangeInTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:title="995653 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="995654 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:title="995655 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:title="995656 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:title="995657 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:title="995658 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="995659 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995660 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995661 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails" xlink:title="995662 - Disclosure - ACQUISITION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails1" xlink:title="995663 - Disclosure - ACQUISITION (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails2" xlink:title="995664 - Disclosure - ACQUISITION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails3" xlink:title="995665 - Disclosure - ACQUISITION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetailsNarrative" xlink:title="995666 - Disclosure - ACQUISITION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="995667 - Disclosure - SEGMENT REPORTING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="995668 - Disclosure - SEGMENT REPORTING (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="995669 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>renb-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://renovarobio.com/role/Cover" xlink:href="renb-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:href="renb-20240630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="renb-20240630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="renb-20240630.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/GoingConcern" xlink:href="renb-20240630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurements" xlink:href="renb-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipment" xlink:href="renb-20240630.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Leases" xlink:href="renb-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Debt" xlink:href="renb-20240630.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxes" xlink:href="renb-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquity" xlink:href="renb-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:href="renb-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/RelatedPartyTransactions" xlink:href="renb-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Acquisition" xlink:href="renb-20240630.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReporting" xlink:href="renb-20240630.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SubsequentEvents" xlink:href="renb-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:href="renb-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:href="renb-20240630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesTables" xlink:href="renb-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesTables" xlink:href="renb-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityTables" xlink:href="renb-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionTables" xlink:href="renb-20240630.xsd#AcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingTables" xlink:href="renb-20240630.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:href="renb-20240630.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:href="renb-20240630.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="renb-20240630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetails" xlink:href="renb-20240630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetails1" xlink:href="renb-20240630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:href="renb-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/DebtDetailsNarrative" xlink:href="renb-20240630.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails" xlink:href="renb-20240630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:href="renb-20240630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:href="renb-20240630.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:href="renb-20240630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails" xlink:href="renb-20240630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:href="renb-20240630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:href="renb-20240630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:href="renb-20240630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:href="renb-20240630.xsd#StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:href="renb-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="renb-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="renb-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails" xlink:href="renb-20240630.xsd#AcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails1" xlink:href="renb-20240630.xsd#AcquisitionDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails2" xlink:href="renb-20240630.xsd#AcquisitionDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails3" xlink:href="renb-20240630.xsd#AcquisitionDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetailsNarrative" xlink:href="renb-20240630.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingDetails" xlink:href="renb-20240630.xsd#SegmentReportingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingDetails1" xlink:href="renb-20240630.xsd#SegmentReportingDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:href="renb-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedPursuantToWarrantsExercisedValue" xlink:label="loc_RENBStockIssuedPursuantToWarrantsExercisedValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedPursuantToWarrantsExercisedValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedPursuantToWarrantsExercisedShares" xlink:label="loc_RENBStockIssuedPursuantToWarrantsExercisedShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedPursuantToWarrantsExercisedShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnoutSharesIssuedValue" xlink:label="loc_RENBEarnoutSharesIssuedValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBEarnoutSharesIssuedValue_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnoutSharesIssuedShares" xlink:label="loc_RENBEarnoutSharesIssuedShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBEarnoutSharesIssuedShares_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuedForInterestOnNotesPayableExtensionValue" xlink:label="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionValue_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuedForInterestOnNotesPayableExtensionShares" xlink:label="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionShares_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedValue_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedShares_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsideration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsideration_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_70" xlink:type="arc" order="34" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="995613 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="995614 - Disclosure - GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="995615 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipment" xlink:title="995616 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="995617 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Leases" xlink:title="995618 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="995619 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxes" xlink:title="995620 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="995621 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="995622 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="995623 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisition" xlink:title="995624 - Disclosure - ACQUISITION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="995625 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="995626 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995627 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="995628 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:title="995629 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="995630 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesTables" xlink:title="995631 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesTables" xlink:title="995632 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="995633 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionTables" xlink:title="995634 - Disclosure - ACQUISITION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="995635 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995636 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:label="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EscrowSharesRemaining" xlink:label="loc_RENBEscrowSharesRemaining_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBEscrowSharesRemaining_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionPercentage" xlink:label="loc_RENBBusinessAcquisitionPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBBusinessAcquisitionPercentage_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InProcessResearchAndDevelopment" xlink:label="loc_RENBInProcessResearchAndDevelopment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBInProcessResearchAndDevelopment_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaapCommonStockOtherSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCommonStockOtherSharesOutstanding_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="995637 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="995638 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="loc_RENBBlackScholesOptionPricingModelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBBlackScholesOptionPricingModelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InitialRecognitionMember" xlink:label="loc_RENBInitialRecognitionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBInitialRecognitionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:label="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="995639 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationInAcquisition" xlink:label="loc_RENBContingentConsiderationInAcquisition_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_RENBContingentConsiderationInAcquisition_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementsContingentSharesToBeIssued" xlink:label="loc_RENBSettlementsContingentSharesToBeIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_RENBSettlementsContingentSharesToBeIssued_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="995640 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:title="995641 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LabEquipmentAndInstrumentsMember" xlink:label="loc_RENBLabEquipmentAndInstrumentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_RENBLabEquipmentAndInstrumentsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="995642 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="995643 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="loc_RENBLessAccumulatedAmortizationMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBLessAccumulatedAmortizationMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapGoodwillMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="loc_RENBNetDefinitelifeIntangibleAssetsAmortization_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssetsAmortization_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_260" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="995644 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="995645 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails" xlink:title="995646 - Disclosure - LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails1" xlink:title="995647 - Disclosure - LEASES  (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:title="995648 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription" xlink:label="loc_us-gaapLesseeFinanceSubleaseResidualValueGuaranteeDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceSubleaseResidualValueGuaranteeDescription_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForLeasingCosts_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="loc_us-gaapLiabilitiesSubjectToCompromiseEarlyContractTerminationFees_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesSubjectToCompromiseEarlyContractTerminationFees_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OperatingLeaseExpenses" xlink:label="loc_RENBOperatingLeaseExpenses_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBOperatingLeaseExpenses_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CashPaidForTheTerminationOfLease" xlink:label="loc_RENBCashPaidForTheTerminationOfLease_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBCashPaidForTheTerminationOfLease_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AccrualPaymentsRelatedToTerminationOfLease" xlink:label="loc_RENBAccrualPaymentsRelatedToTerminationOfLease_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBAccrualPaymentsRelatedToTerminationOfLease_120" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="995649 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarchNote2024Member" xlink:label="loc_RENBMarchNote2024Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBMarchNote2024Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DecemberNote2023Member" xlink:label="loc_RENBDecemberNote2023Member_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBDecemberNote2023Member_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Note2023Member" xlink:label="loc_RENBNote2023Member_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBNote2023Member_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_November2023NoteMember" xlink:label="loc_RENBNovember2023NoteMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBNovember2023NoteMember_590" xlink:type="arc" order="591" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement1Member" xlink:label="loc_RENBPrivatePlacement1Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPrivatePlacement1Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement2Member" xlink:label="loc_RENBPrivatePlacement2Member_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPrivatePlacement2Member_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement3Member" xlink:label="loc_RENBPrivatePlacement3Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPrivatePlacement3Member_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_310" xlink:type="arc" order="313" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_320" xlink:type="arc" order="323" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConvertibleNotesPayablesMember" xlink:label="loc_RENBConvertibleNotesPayablesMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBConvertibleNotesPayablesMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AmendedAndRestatedSecuredNotesMember" xlink:label="loc_RENBAmendedAndRestatedSecuredNotesMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBAmendedAndRestatedSecuredNotesMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_TheNotesMember" xlink:label="loc_RENBTheNotesMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBTheNotesMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioApSMember" xlink:label="loc_RENBRSBioApSMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBRSBioApSMember_470" xlink:type="arc" order="473" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LoanAgreementMember" xlink:label="loc_RENBLoanAgreementMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBLoanAgreementMember_550" xlink:type="arc" order="551" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PromissoryNoteMember" xlink:label="loc_RENBPromissoryNoteMember_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNoteMember_660" xlink:type="arc" order="661" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Note2020Member" xlink:label="loc_RENBNote2020Member_780" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBNote2020Member_780" xlink:type="arc" order="781" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AccruedExpensesMember" xlink:label="loc_RENBAccruedExpensesMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_RENBAccruedExpensesMember_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaapBridgeLoanMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapBridgeLoanMember_470" xlink:type="arc" order="472" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SubscriptionAgreementsMember" xlink:label="loc_RENBSubscriptionAgreementsMember_760" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSubscriptionAgreementsMember_760" xlink:type="arc" order="762" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SubscriptionAgreements1Member" xlink:label="loc_RENBSubscriptionAgreements1Member_770" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSubscriptionAgreements1Member_770" xlink:type="arc" order="772" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_FinanceAgreementMember" xlink:label="loc_RENBFinanceAgreementMember_820" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBFinanceAgreementMember_820" xlink:type="arc" order="822" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaapOtherCurrentLiabilitiesMember_820" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapOtherCurrentLiabilitiesMember_820" xlink:type="arc" order="821" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_890" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_890" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_890" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_890" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_890" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_890" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_890" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense_890" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InterestExpenseRelatedToNoteBalance" xlink:label="loc_RENBInterestExpenseRelatedToNoteBalance_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBInterestExpenseRelatedToNoteBalance_890" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_890" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_890" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_890" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_890" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_890" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OriginalIssueDiscountPromissoryNotePercentage" xlink:label="loc_RENBOriginalIssueDiscountPromissoryNotePercentage_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBOriginalIssueDiscountPromissoryNotePercentage_890" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtInstrumentOriginalIssueDiscount" xlink:label="loc_RENBDebtInstrumentOriginalIssueDiscount_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBDebtInstrumentOriginalIssueDiscount_890" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_890" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockAndReceivedGrossProceeds" xlink:label="loc_RENBCommonStockAndReceivedGrossProceeds_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBCommonStockAndReceivedGrossProceeds_890" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OfferingPricePerSharePercentage" xlink:label="loc_RENBOfferingPricePerSharePercentage_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBOfferingPricePerSharePercentage_890" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtInstrumentsFloorPricePerShare" xlink:label="loc_RENBDebtInstrumentsFloorPricePerShare_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBDebtInstrumentsFloorPricePerShare_890" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherNotesPayable_890" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_890" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss" xlink:label="loc_us-gaapInterestIncomeExpenseAfterProvisionForLoanLoss_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseAfterProvisionForLoanLoss_890" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_890" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_890" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_890" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrepaymentShares" xlink:label="loc_RENBPrepaymentShares_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBPrepaymentShares_890" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharePrice_890" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapContractualObligation_890" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_890" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInterest" xlink:label="loc_us-gaapPrepaidInterest_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrepaidInterest_890" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_890" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_890" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_890" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_890" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GrossProceedsDiscountPercentage" xlink:label="loc_RENBGrossProceedsDiscountPercentage_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBGrossProceedsDiscountPercentage_890" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_890" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExerciseWarrants" xlink:label="loc_RENBExerciseWarrants_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBExerciseWarrants_890" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsOutstandingPerShare" xlink:label="loc_RENBWarrantsOutstandingPerShare_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBWarrantsOutstandingPerShare_890" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExerciseWarrantsAmount" xlink:label="loc_RENBExerciseWarrantsAmount_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBExerciseWarrantsAmount_890" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_890" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate_890" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssued_890" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarketPrice" xlink:label="loc_RENBMarketPrice_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBMarketPrice_890" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsPurchased" xlink:label="loc_RENBWarrantsPurchased_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBWarrantsPurchased_890" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_890" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_890" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PromissoryNoteBalanceNetOfDiscount" xlink:label="loc_RENBPromissoryNoteBalanceNetOfDiscount_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBPromissoryNoteBalanceNetOfDiscount_890" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_890" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MonthlyInstallments" xlink:label="loc_RENBMonthlyInstallments_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBMonthlyInstallments_890" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RepaymentOnFinanceAgreement" xlink:label="loc_RENBRepaymentOnFinanceAgreement_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBRepaymentOnFinanceAgreement_890" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_890" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_890" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating_890" xlink:type="arc" order="52" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails" xlink:title="995650 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:title="995651 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:title="995652 - Disclosure - INCOME TAXES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:title="995653 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_UnitedStatesTaxMember" xlink:label="loc_RENBUnitedStatesTaxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RENBUnitedStatesTaxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="995654 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroMember" xlink:label="loc_RENBRenovaroMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_RENBRenovaroMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:title="995655 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:title="995656 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeeStockOptionsMember" xlink:label="loc_RENBEmployeeStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBEmployeeStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:title="995657 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="loc_RENBCommonStockPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange4Member" xlink:label="loc_RENBExercisePriceRange4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange5Member" xlink:label="loc_RENBExercisePriceRange5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePrices" xlink:label="loc_RENBExercisePrices_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBExercisePrices_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:title="995658 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantMember" xlink:label="loc_RENBCommonStockPurchaseWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="loc_RENBCommonStockPurchaseWarrant_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrant_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="995659 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_RENBSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockIssuancesMember" xlink:label="loc_RENBPreferredStockIssuancesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBPreferredStockIssuancesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockIssuancesMember" xlink:label="loc_RENBCommonStockIssuancesMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStockIssuancesMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AdvisoryServicesMember" xlink:label="loc_RENBAdvisoryServicesMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBAdvisoryServicesMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PurchaseAgreementMember" xlink:label="loc_RENBPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OneWarrantMember" xlink:label="loc_RENBOneWarrantMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBOneWarrantMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EBIAndWeirdScienceLLCMember" xlink:label="loc_RENBEBIAndWeirdScienceLLCMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBEBIAndWeirdScienceLLCMember_550" xlink:type="arc" order="551" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Investor1Member" xlink:label="loc_RENBInvestor1Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBInvestor1Member_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LincolnParkMember" xlink:label="loc_RENBLincolnParkMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBLincolnParkMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroBioPharmaIncMember" xlink:label="loc_RENBRenovaroBioPharmaIncMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBRenovaroBioPharmaIncMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DanDritDenmarkMember" xlink:label="loc_RENBDanDritDenmarkMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBDanDritDenmarkMember_560" xlink:type="arc" order="561" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroDenmarkMember" xlink:label="loc_RENBRenovaroDenmarkMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBRenovaroDenmarkMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeesMember" xlink:label="loc_RENBEmployeesMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployeesMember_610" xlink:type="arc" order="611" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Employees1Member" xlink:label="loc_RENBEmployees1Member_680" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployees1Member_680" xlink:type="arc" order="681" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" xlink:label="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardOneMember_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardOneMember_690" xlink:type="arc" order="691" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" xlink:label="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardTwoMember_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardTwoMember_710" xlink:type="arc" order="711" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConsultingServicesMember" xlink:label="loc_RENBConsultingServicesMember_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBConsultingServicesMember_730" xlink:type="arc" order="731" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SingleRangeMember" xlink:label="loc_RENBSingleRangeMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSingleRangeMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:label="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:label="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember_550" xlink:type="arc" order="552" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="loc_RENBRestrictedStockAwardsMember_770" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBRestrictedStockAwardsMember_770" xlink:type="arc" order="771" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EquityIncentivePlan2014Member" xlink:label="loc_RENBEquityIncentivePlan2014Member_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBEquityIncentivePlan2014Member_600" xlink:type="arc" order="601" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PlanOptionsMember" xlink:label="loc_RENBPlanOptionsMember_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBPlanOptionsMember_750" xlink:type="arc" order="751" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_630" xlink:type="arc" order="631" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_650" xlink:type="arc" order="651" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="loc_RENBCommonStockPurchaseWarrantsMember_760" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantsMember_760" xlink:type="arc" order="761" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_810" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_810" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockDesignatedShares" xlink:label="loc_RENBPreferredStockDesignatedShares_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPreferredStockDesignatedShares_810" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_810" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_810" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_810" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_810" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockShareIssued" xlink:label="loc_RENBCommonStockShareIssued_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockShareIssued_810" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_810" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockConvertibleSharesIssuable" xlink:label="loc_RENBCommonStockConvertibleSharesIssuable_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockConvertibleSharesIssuable_810" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPurchaseObligation_810" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued_810" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="loc_us-gaapPartnersCapitalAccountUnitsSoldInPrivatePlacement_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPartnersCapitalAccountUnitsSoldInPrivatePlacement_810" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfDebt_810" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConversionOfPromissoryNote" xlink:label="loc_RENBConversionOfPromissoryNote_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBConversionOfPromissoryNote_810" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AggregatePreferredStockShares" xlink:label="loc_RENBAggregatePreferredStockShares_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBAggregatePreferredStockShares_810" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AggregateCommonStockShares" xlink:label="loc_RENBAggregateCommonStockShares_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBAggregateCommonStockShares_810" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsSold" xlink:label="loc_RENBWarrantsSold_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBWarrantsSold_810" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_810" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable_810" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_810" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_810" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ClosedSharesParValue" xlink:label="loc_RENBClosedSharesParValue_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBClosedSharesParValue_810" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePricePerShare" xlink:label="loc_RENBExercisePricePerShare_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBExercisePricePerShare_810" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_810" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_810" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_810" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrincipalAmountAndInterestAccrued" xlink:label="loc_RENBPrincipalAmountAndInterestAccrued_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPrincipalAmountAndInterestAccrued_810" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementOfDebt" xlink:label="loc_RENBSettlementOfDebt_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBSettlementOfDebt_810" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_810" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_810" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_810" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_810" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized_810" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering_810" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockParValuePrivatePlacement" xlink:label="loc_RENBCommonStockParValuePrivatePlacement_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockParValuePrivatePlacement_810" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_810" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NumberOfShareWarrantPurchase" xlink:label="loc_RENBNumberOfShareWarrantPurchase_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBNumberOfShareWarrantPurchase_810" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNotesPayable_810" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_810" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_810" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_810" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_810" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PurchaseSharesOfCommonStock" xlink:label="loc_RENBPurchaseSharesOfCommonStock_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPurchaseSharesOfCommonStock_810" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_810" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_810" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnOutDistribution" xlink:label="loc_RENBEarnOutDistribution_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBEarnOutDistribution_810" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_810" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_810" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_810" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:label="loc_RENBExtinguishmentOfContingentConsiderationLiability_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBExtinguishmentOfContingentConsiderationLiability_810" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:label="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_810" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_810" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease_810" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_810" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_810" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_810" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_810" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_810" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_810" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_810" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_810" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_810" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_810" xlink:type="arc" order="62" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995660 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GTechMember" xlink:label="loc_RENBGTechMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGTechMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LicenseAgreementMember" xlink:label="loc_RENBLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBLicenseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RoyaltyPercentage" xlink:label="loc_RENBRoyaltyPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBRoyaltyPercentage_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_UpfrontPayment" xlink:label="loc_RENBUpfrontPayment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBUpfrontPayment_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PaymentForExpenditures" xlink:label="loc_RENBPaymentForExpenditures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBPaymentForExpenditures_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InitialPayment" xlink:label="loc_RENBInitialPayment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBInitialPayment_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995661 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarkDybulMember" xlink:label="loc_RENBMarkDybulMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBMarkDybulMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_November2023NoteMember" xlink:label="loc_RENBNovember2023NoteMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBNovember2023NoteMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OriginalIssueDiscountPromissoryNotePercentage" xlink:label="loc_RENBOriginalIssueDiscountPromissoryNotePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBOriginalIssueDiscountPromissoryNotePercentage_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GrossProceedsOriginalIssueDiscountRate" xlink:label="loc_RENBGrossProceedsOriginalIssueDiscountRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBGrossProceedsOriginalIssueDiscountRate_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_140" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails" xlink:title="995662 - Disclosure - ACQUISITION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails1" xlink:title="995663 - Disclosure - ACQUISITION (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapGoodwill_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails2" xlink:title="995664 - Disclosure - ACQUISITION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="loc_RENBBusinessAcquisitionsRevenue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsRevenue_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="loc_RENBBusinessAcquisitionsNetIncomeLoss_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsNetIncomeLoss_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails3" xlink:title="995665 - Disclosure - ACQUISITION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaRevenue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaRevenue_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetailsNarrative" xlink:title="995666 - Disclosure - ACQUISITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="995667 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="loc_countryNL_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentOperatingLoss_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentAsset" xlink:label="loc_RENBSegmentAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentAsset_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="995668 - Disclosure - SEGMENT REPORTING (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RENBMember" xlink:label="loc_RENBRENBMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENBMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RENCMember" xlink:label="loc_RENBRENCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENCMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBSegmentOperatingLoss_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="995669 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="loc_RENBRestrictedStockAwardsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBRestrictedStockAwardsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices" xlink:label="loc_RENBStockIssuedDuringPeriodSharesIssuedForConsultingServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesIssuedForConsultingServices_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices" xlink:label="loc_RENBStockIssuedDuringPeriodValueIssuedForConsultingServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodValueIssuedForConsultingServices_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" xlink:label="loc_RENBStockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="loc_RENBRestrictedStockAwardsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBRestrictedStockAwardsMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>renb-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroCubeMember" xlink:label="RENB_RenovaroCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroCubeMember" xlink:to="RENB_RenovaroCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroCubeMember_lbl" xml:lang="en-US">Renovaro Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:label="RENB_EmployeesOfficersDirectorsAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:to="RENB_EmployeesOfficersDirectorsAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EmployeesOfficersDirectorsAndConsultantsMember_lbl" xml:lang="en-US">Employees, Officers, Directors and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="RENB_BlackScholesOptionPricingModelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BlackScholesOptionPricingModelMember" xlink:to="RENB_BlackScholesOptionPricingModelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BlackScholesOptionPricingModelMember_lbl" xml:lang="en-US">Black Scholes Option Pricing Model [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InitialRecognitionMember" xlink:label="RENB_InitialRecognitionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InitialRecognitionMember" xlink:to="RENB_InitialRecognitionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InitialRecognitionMember_lbl" xml:lang="en-US">Initial Recognition [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LabEquipmentAndInstrumentsMember" xlink:label="RENB_LabEquipmentAndInstrumentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LabEquipmentAndInstrumentsMember" xlink:to="RENB_LabEquipmentAndInstrumentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LabEquipmentAndInstrumentsMember_lbl" xml:lang="en-US">Lab Equipment And Instruments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="RENB_LessAccumulatedAmortizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LessAccumulatedAmortizationMember" xlink:to="RENB_LessAccumulatedAmortizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LessAccumulatedAmortizationMember_lbl" xml:lang="en-US">Less Accumulated Amortization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillMember" xlink:label="us-gaap_GoodwillMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US">In Process Research and Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarchNote2024Member" xlink:label="RENB_MarchNote2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MarchNote2024Member" xlink:to="RENB_MarchNote2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MarchNote2024Member_lbl" xml:lang="en-US">March Note 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_JanuaryNote2024Member" xlink:label="RENB_JanuaryNote2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_JanuaryNote2024Member" xlink:to="RENB_JanuaryNote2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_JanuaryNote2024Member_lbl" xml:lang="en-US">January Note 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DecemberNote2023Member" xlink:label="RENB_DecemberNote2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DecemberNote2023Member" xlink:to="RENB_DecemberNote2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DecemberNote2023Member_lbl" xml:lang="en-US">December Note 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement1Member" xlink:label="RENB_PrivatePlacement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PrivatePlacement1Member" xlink:to="RENB_PrivatePlacement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PrivatePlacement1Member_lbl" xml:lang="en-US">Private Placement 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement2Member" xlink:label="RENB_PrivatePlacement2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PrivatePlacement2Member" xlink:to="RENB_PrivatePlacement2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PrivatePlacement2Member_lbl" xml:lang="en-US">Private Placement 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement3Member" xlink:label="RENB_PrivatePlacement3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PrivatePlacement3Member" xlink:to="RENB_PrivatePlacement3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PrivatePlacement3Member_lbl" xml:lang="en-US">Private Placement 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Note2023Member" xlink:label="RENB_Note2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Note2023Member" xlink:to="RENB_Note2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Note2023Member_lbl" xml:lang="en-US">Note 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConvertibleNotesPayablesMember" xlink:label="RENB_ConvertibleNotesPayablesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConvertibleNotesPayablesMember" xlink:to="RENB_ConvertibleNotesPayablesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConvertibleNotesPayablesMember_lbl" xml:lang="en-US">Convertible Notes Payables [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AmendedAndRestatedSecuredNotesMember" xlink:label="RENB_AmendedAndRestatedSecuredNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AmendedAndRestatedSecuredNotesMember" xlink:to="RENB_AmendedAndRestatedSecuredNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AmendedAndRestatedSecuredNotesMember_lbl" xml:lang="en-US">Amended And Restated Secured Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_TheNotesMember" xlink:label="RENB_TheNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TheNotesMember" xlink:to="RENB_TheNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TheNotesMember_lbl" xml:lang="en-US">The Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioMember" xlink:label="RENB_RSBioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RSBioMember" xlink:to="RENB_RSBioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RSBioMember_lbl" xml:lang="en-US">RS Bio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US">Interest Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoanMember_lbl" xml:lang="en-US">Bridge Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioApSMember" xlink:label="RENB_RSBioApSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RSBioApSMember" xlink:to="RENB_RSBioApSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RSBioApSMember_lbl" xml:lang="en-US">RS Bio ApS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AccruedExpensesMember" xlink:label="RENB_AccruedExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AccruedExpensesMember" xlink:to="RENB_AccruedExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AccruedExpensesMember_lbl" xml:lang="en-US">Accrued Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LoanAgreementMember" xlink:label="RENB_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LoanAgreementMember" xlink:to="RENB_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_November2023NoteMember" xlink:label="RENB_November2023NoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_November2023NoteMember" xlink:to="RENB_November2023NoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_November2023NoteMember_lbl" xml:lang="en-US">November 2023 Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PromissoryNoteMember" xlink:label="RENB_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PromissoryNoteMember" xlink:to="RENB_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SubscriptionAgreementsMember" xlink:label="RENB_SubscriptionAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SubscriptionAgreementsMember" xlink:to="RENB_SubscriptionAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SubscriptionAgreementsMember_lbl" xml:lang="en-US">Subscription Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SubscriptionAgreements1Member" xlink:label="RENB_SubscriptionAgreements1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SubscriptionAgreements1Member" xlink:to="RENB_SubscriptionAgreements1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SubscriptionAgreements1Member_lbl" xml:lang="en-US">Subscription Agreements 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Note2020Member" xlink:label="RENB_Note2020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Note2020Member" xlink:to="RENB_Note2020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Note2020Member_lbl" xml:lang="en-US">Note 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_FinanceAgreementMember" xlink:label="RENB_FinanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_FinanceAgreementMember" xlink:to="RENB_FinanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_FinanceAgreementMember_lbl" xml:lang="en-US">Finance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_UnitedStatesTaxMember" xlink:label="RENB_UnitedStatesTaxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnitedStatesTaxMember" xlink:to="RENB_UnitedStatesTaxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnitedStatesTaxMember_lbl" xml:lang="en-US">United States Tax [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SeriesAConvertiblePreferredStockMember" xlink:label="RENB_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SeriesAConvertiblePreferredStockMember" xlink:to="RENB_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PurchaseAgreementMember" xlink:label="RENB_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchaseAgreementMember" xlink:to="RENB_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockIssuancesMember" xlink:label="RENB_PreferredStockIssuancesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PreferredStockIssuancesMember" xlink:to="RENB_PreferredStockIssuancesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PreferredStockIssuancesMember_lbl" xml:lang="en-US">Preferred Stock Issuances [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Investor1Member" xlink:label="RENB_Investor1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Investor1Member" xlink:to="RENB_Investor1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Investor1Member_lbl" xml:lang="en-US">Investor 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockIssuancesMember" xlink:label="RENB_CommonStockIssuancesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockIssuancesMember" xlink:to="RENB_CommonStockIssuancesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockIssuancesMember_lbl" xml:lang="en-US">Common Stock Issuances [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SingleRangeMember" xlink:label="RENB_SingleRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SingleRangeMember" xlink:to="RENB_SingleRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SingleRangeMember_lbl" xml:lang="en-US">Single Range [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:label="RENB_StockPurchaseAgreementOfRenovaroCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:to="RENB_StockPurchaseAgreementOfRenovaroCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockPurchaseAgreementOfRenovaroCubeMember_lbl" xml:lang="en-US">Stock Purchase Agreement Of Renovaro Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AdvisoryServicesMember" xlink:label="RENB_AdvisoryServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AdvisoryServicesMember" xlink:to="RENB_AdvisoryServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AdvisoryServicesMember_lbl" xml:lang="en-US">Advisory Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OneWarrantMember" xlink:label="RENB_OneWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OneWarrantMember" xlink:to="RENB_OneWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OneWarrantMember_lbl" xml:lang="en-US">One Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LincolnParkMember" xlink:label="RENB_LincolnParkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LincolnParkMember" xlink:to="RENB_LincolnParkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LincolnParkMember_lbl" xml:lang="en-US">Lincoln Park [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroBioPharmaIncMember" xlink:label="RENB_RenovaroBioPharmaIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroBioPharmaIncMember" xlink:to="RENB_RenovaroBioPharmaIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroBioPharmaIncMember_lbl" xml:lang="en-US">Renovaro Bio Pharma Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EBIAndWeirdScienceLLCMember" xlink:label="RENB_EBIAndWeirdScienceLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EBIAndWeirdScienceLLCMember" xlink:to="RENB_EBIAndWeirdScienceLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EBIAndWeirdScienceLLCMember_lbl" xml:lang="en-US">EBI And Weird Science LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:label="RENB_AgreementAndPlanOfMergerAgreementAxisMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:to="RENB_AgreementAndPlanOfMergerAgreementAxisMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AgreementAndPlanOfMergerAgreementAxisMember_lbl" xml:lang="en-US">Agreement And Plan Of Merger Agreement Axis [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DanDritDenmarkMember" xlink:label="RENB_DanDritDenmarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DanDritDenmarkMember" xlink:to="RENB_DanDritDenmarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DanDritDenmarkMember_lbl" xml:lang="en-US">Dan Drit Denmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroDenmarkMember" xlink:label="RENB_RenovaroDenmarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroDenmarkMember" xlink:to="RENB_RenovaroDenmarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroDenmarkMember_lbl" xml:lang="en-US">Renovaro Denmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EquityIncentivePlan2014Member" xlink:label="RENB_EquityIncentivePlan2014Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EquityIncentivePlan2014Member" xlink:to="RENB_EquityIncentivePlan2014Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EquityIncentivePlan2014Member_lbl" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeesMember" xlink:label="RENB_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EmployeesMember" xlink:to="RENB_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Employees1Member" xlink:label="RENB_Employees1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Employees1Member" xlink:to="RENB_Employees1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Employees1Member_lbl" xml:lang="en-US">Employees 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" xlink:label="RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" xlink:to="RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember_lbl" xml:lang="en-US">Board Of Directors And Scientific Advisory Board One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" xlink:label="RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" xlink:to="RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_lbl" xml:lang="en-US">Board Of Directors And Scientific Advisory Board Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConsultingServicesMember" xlink:label="RENB_ConsultingServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConsultingServicesMember" xlink:to="RENB_ConsultingServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConsultingServicesMember_lbl" xml:lang="en-US">Consulting Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PlanOptionsMember" xlink:label="RENB_PlanOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PlanOptionsMember" xlink:to="RENB_PlanOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PlanOptionsMember_lbl" xml:lang="en-US">Plan Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="RENB_CommonStockPurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsMember" xlink:to="RENB_CommonStockPurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrantsMember_lbl" xml:lang="en-US">Common Stock Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="RENB_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedStockAwardsMember" xlink:to="RENB_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroMember" xlink:label="RENB_RenovaroMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroMember" xlink:to="RENB_RenovaroMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroMember_lbl" xml:lang="en-US">Renovaro [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange1Member" xlink:label="RENB_ExercisePriceRange1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange1Member" xlink:to="RENB_ExercisePriceRange1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange1Member_lbl" xml:lang="en-US">Exercise Price Range 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange2Member" xlink:label="RENB_ExercisePriceRange2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange2Member" xlink:to="RENB_ExercisePriceRange2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange2Member_lbl" xml:lang="en-US">Exercise Price Range 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange3Member" xlink:label="RENB_ExercisePriceRange3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange3Member" xlink:to="RENB_ExercisePriceRange3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange3Member_lbl" xml:lang="en-US">Exercise Price Range 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeeStockOptionsMember" xlink:label="RENB_EmployeeStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EmployeeStockOptionsMember" xlink:to="RENB_EmployeeStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EmployeeStockOptionsMember_lbl" xml:lang="en-US">Employee Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange4Member" xlink:label="RENB_ExercisePriceRange4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange4Member" xlink:to="RENB_ExercisePriceRange4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange4Member_lbl" xml:lang="en-US">Exercise Price Range 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange5Member" xlink:label="RENB_ExercisePriceRange5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange5Member" xlink:to="RENB_ExercisePriceRange5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange5Member_lbl" xml:lang="en-US">Exercise Price Range 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantMember" xlink:label="RENB_CommonStockPurchaseWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantMember" xlink:to="RENB_CommonStockPurchaseWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrantMember_lbl" xml:lang="en-US">Common Stock Purchase Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GTechMember" xlink:label="RENB_GTechMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GTechMember" xlink:to="RENB_GTechMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GTechMember_lbl" xml:lang="en-US">G Tech [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LicenseAgreementMember" xlink:label="RENB_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LicenseAgreementMember" xlink:to="RENB_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarkDybulMember" xlink:label="RENB_MarkDybulMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MarkDybulMember" xlink:to="RENB_MarkDybulMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MarkDybulMember_lbl" xml:lang="en-US">Mark Dybul [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="RENB_GEDiCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GEDiCubeMember" xlink:to="RENB_GEDiCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GEDiCubeMember_lbl" xml:lang="en-US">GEDi Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RENBMember" xlink:label="RENB_RENBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RENBMember" xlink:to="RENB_RENBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RENBMember_lbl" xml:lang="en-US">RENB [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RENCMember" xlink:label="RENB_RENCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RENCMember" xlink:to="RENB_RENCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RENCMember_lbl" xml:lang="en-US">RENC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xml:lang="en-US">Insurance receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaids and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Definite life intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite life intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; trade</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="RENB_ContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationLiabilityCurrent" xlink:to="RENB_ContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="RENB_NotesPayableRelatedPartiesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NotesPayableRelatedPartiesNetCurrent" xlink:to="RENB_NotesPayableRelatedPartiesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NotesPayableRelatedPartiesNetCurrent_lbl" xml:lang="en-US">Notes payable &#8211; related parties, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Non-Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 350,000,000 shares authorized, 155,027,245 shares issued and outstanding at June 30, 2024; 63,698,144 shares issued and outstanding at June 30, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Intangible asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="RENB_ChangeInFairValueOfContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInFairValueOfContingentConsideration" xlink:to="RENB_ChangeInFairValueOfContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ChangeInFairValueOfContingentConsideration_lbl" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfContingentConsiderationLiability" xlink:label="RENB_LossOnExtinguishmentOfContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfContingentConsiderationLiability" xlink:to="RENB_LossOnExtinguishmentOfContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LossOnExtinguishmentOfContingentConsiderationLiability_lbl" xml:lang="en-US">Loss on extinguishment of contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xml:lang="en-US">Gain (loss) on foreign currency transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="RENB_InterestIncomeAndOtherIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InterestIncomeAndOtherIncomeExpense" xlink:to="RENB_InterestIncomeAndOtherIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InterestIncomeAndOtherIncomeExpense_lbl" xml:lang="en-US">Interest income and other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation, net of taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_lbl" xml:lang="en-US">Issuance of preferred stock and warrants in private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_lbl" xml:lang="en-US">Issuance of preferred stock and warrants for conversion of Note Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedPursuantToWarrantsExercisedValue" xlink:label="RENB_StockIssuedPursuantToWarrantsExercisedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedPursuantToWarrantsExercisedValue" xlink:to="RENB_StockIssuedPursuantToWarrantsExercisedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedPursuantToWarrantsExercisedValue_lbl" xml:lang="en-US">Stock issued pursuant to warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedPursuantToWarrantsExercisedShares" xlink:label="RENB_StockIssuedPursuantToWarrantsExercisedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedPursuantToWarrantsExercisedShares" xlink:to="RENB_StockIssuedPursuantToWarrantsExercisedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedPursuantToWarrantsExercisedShares_lbl" xml:lang="en-US">Stock issued pursuant to warrants exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnoutSharesIssuedValue" xlink:label="RENB_EarnoutSharesIssuedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EarnoutSharesIssuedValue" xlink:to="RENB_EarnoutSharesIssuedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EarnoutSharesIssuedValue_lbl" xml:lang="en-US">Earn-out shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnoutSharesIssuedShares" xlink:label="RENB_EarnoutSharesIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EarnoutSharesIssuedShares" xlink:to="RENB_EarnoutSharesIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EarnoutSharesIssuedShares_lbl" xml:lang="en-US">Earn-out shares issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuedForInterestOnNotesPayableExtensionValue" xlink:label="RENB_SharesIssuedForInterestOnNotesPayableExtensionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesIssuedForInterestOnNotesPayableExtensionValue" xlink:to="RENB_SharesIssuedForInterestOnNotesPayableExtensionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesIssuedForInterestOnNotesPayableExtensionValue_lbl" xml:lang="en-US">Shares issued for interest on $1.2 million notes payable extension</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuedForInterestOnNotesPayableExtensionShares" xlink:label="RENB_SharesIssuedForInterestOnNotesPayableExtensionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesIssuedForInterestOnNotesPayableExtensionShares" xlink:to="RENB_SharesIssuedForInterestOnNotesPayableExtensionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesIssuedForInterestOnNotesPayableExtensionShares_lbl" xml:lang="en-US">Shares issued for interest on $1.2 million notes payable extension, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" xlink:to="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue_lbl" xml:lang="en-US">Issuance of common stock and warrants under private placement offering</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" xlink:to="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares_lbl" xml:lang="en-US">Issuance of common stock and warrants under private placement offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:to="RENB_RestrictedSharesIssuedForServicesRenderedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedValue_lbl" xml:lang="en-US">Restricted shares issued for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:to="RENB_RestrictedSharesIssuedForServicesRenderedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedShares_lbl" xml:lang="en-US">Restricted shares issued for services rendered, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:to="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_lbl" xml:lang="en-US">Issuance of common stock and warrants under private placement offering in settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:to="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_lbl" xml:lang="en-US">Issuance of common stock and warrants under private placement offering in settlement of debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsiderationValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:to="RENB_SharesIssuableForSettlementOfContingentConsiderationValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsiderationValue_lbl" xml:lang="en-US">Shares issuable for settlement of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:to="RENB_SharesIssuableForSettlementOfContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsideration_lbl" xml:lang="en-US">Shares issuable for settlement of contingent consideration, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:to="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube_lbl" xml:lang="en-US">Issuance of common stock pursuant to acquisition of GEDi Cube</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:to="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares_lbl" xml:lang="en-US">Issuance of common stock pursuant to acquisition of GEDi Cube, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:to="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_lbl" xml:lang="en-US">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:to="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_lbl" xml:lang="en-US">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of options for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_lbl" xml:lang="en-US">Issuance of preferred stock and warrants in private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_lbl" xml:lang="en-US">Issuance of preferred stock and warrants for conversion of Note Payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInFairValueOfContingentConsideration" xlink:to="RENB_ChangeInFairValueOfContingentConsideration_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_ChangeInFairValueOfContingentConsideration_2_lbl" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities" xlink:label="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities" xlink:to="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities_lbl" xml:lang="en-US">Loss on extinguishment of contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="RENB_LossOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfDebt" xlink:to="RENB_LossOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_LossOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="RENB_NoncashStockbasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NoncashStockbasedCompensationExpense" xlink:to="RENB_NoncashStockbasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NoncashStockbasedCompensationExpense_lbl" xml:lang="en-US">Non-cash stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:label="RENB_NoncashRestrictedSharesIssuedForServicesRendered" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:to="RENB_NoncashRestrictedSharesIssuedForServicesRendered_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NoncashRestrictedSharesIssuedForServicesRendered_lbl" xml:lang="en-US">Non-cash restricted shares issued for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="RENB_AmortizationOfDiscountOnNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AmortizationOfDiscountOnNotePayable" xlink:to="RENB_AmortizationOfDiscountOnNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AmortizationOfDiscountOnNotePayable_lbl" xml:lang="en-US">Amortization of discount on note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Insurance receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses/deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xml:lang="en-US">Notes receivable prior to acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash received from acquisition, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="RENB_RepaymentsOfFinanceAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentsOfFinanceAgreement" xlink:to="RENB_RepaymentsOfFinanceAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_RepaymentsOfFinanceAgreement_lbl" xml:lang="en-US">Repayments of finance agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">&#160;Effect of exchange rates on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH, BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CASH, END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CashPaidDuringYearForAbstract" xlink:label="RENB_CashPaidDuringYearForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CashPaidDuringYearForAbstract" xlink:to="RENB_CashPaidDuringYearForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US">Cash Paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:label="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:to="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement_lbl" xml:lang="en-US">Contingent Shares issued pursuant to Acquisition Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension" xlink:label="RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension" xlink:to="RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension_lbl" xml:lang="en-US">Shares in lieu of interest on $1.2 million notes payable extension</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:label="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:to="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_lbl" xml:lang="en-US">Finance agreement entered into in exchange for prepaid assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" xlink:label="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" xlink:to="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock_lbl" xml:lang="en-US">Conversion of note payable for issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" xlink:label="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" xlink:to="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants_lbl" xml:lang="en-US">Note payable settled through non-cash exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:label="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:to="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes_lbl" xml:lang="en-US">Debt discount related to notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonSharesIssuedUponAcquisition" xlink:label="RENB_CommonSharesIssuedUponAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonSharesIssuedUponAcquisition" xlink:to="RENB_CommonSharesIssuedUponAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonSharesIssuedUponAcquisition_lbl" xml:lang="en-US">Common shares issued upon acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationIssuedUponAcquisition" xlink:label="RENB_ContingentConsiderationIssuedUponAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationIssuedUponAcquisition" xlink:to="RENB_ContingentConsiderationIssuedUponAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationIssuedUponAcquisition_lbl" xml:lang="en-US">Contingent consideration issued upon acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonSharesIssuedUponSettlementOfDebt" xlink:label="RENB_CommonSharesIssuedUponSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonSharesIssuedUponSettlementOfDebt" xlink:to="RENB_CommonSharesIssuedUponSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonSharesIssuedUponSettlementOfDebt_lbl" xml:lang="en-US">Common shares issued upon settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" xlink:label="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" xlink:to="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability_lbl" xml:lang="en-US">Earn out shares issued in settlement of contingent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OptionsIssuedInSettlementOfDebt" xlink:label="RENB_OptionsIssuedInSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OptionsIssuedInSettlementOfDebt" xlink:to="RENB_OptionsIssuedInSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OptionsIssuedInSettlementOfDebt_lbl" xml:lang="en-US">Options issued in settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementOfNotesPayable" xlink:label="RENB_SettlementOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SettlementOfNotesPayable" xlink:to="RENB_SettlementOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SettlementOfNotesPayable_lbl" xml:lang="en-US">Settlement of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="RENB_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DisclosureLeasesAbstract" xlink:to="RENB_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">ACQUISITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessPolicyTextBlock" xlink:label="RENB_BusinessPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessPolicyTextBlock" xlink:to="RENB_BusinessPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessPolicyTextBlock_lbl" xml:lang="en-US">Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" xml:lang="en-US">Subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional Currency and Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InsuranceReceivablePolicy" xlink:label="RENB_InsuranceReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InsuranceReceivablePolicy" xlink:to="RENB_InsuranceReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InsuranceReceivablePolicy_lbl" xml:lang="en-US">Insurance Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Goodwill and Indefinite Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xml:lang="en-US">Schedule of key input to valuing the contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurement on recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of definite-life and indefinite-life intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of expected future amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of lease commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of net operating lease expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:label="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:to="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of common stock purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="RENB_ScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="RENB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:label="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:to="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_lbl" xml:lang="en-US">Schedule of acquisition date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of assets acquired and liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" xlink:label="RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" xlink:to="RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_lbl" xml:lang="en-US">Schedule of consolidated statements of operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Schedule of consolidated proforma information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment operating loss and asset information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of information regarding segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Restructuring Cost [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EscrowSharesRemaining" xlink:label="RENB_EscrowSharesRemaining" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EscrowSharesRemaining" xlink:to="RENB_EscrowSharesRemaining_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EscrowSharesRemaining_lbl" xml:lang="en-US">Escrow shares remaining</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionPercentage" xlink:label="RENB_BusinessAcquisitionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionPercentage" xlink:to="RENB_BusinessAcquisitionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionPercentage_lbl" xml:lang="en-US">Acquisition percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InProcessResearchAndDevelopment" xlink:label="RENB_InProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InProcessResearchAndDevelopment" xlink:to="RENB_InProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InProcessResearchAndDevelopment_lbl" xml:lang="en-US">In-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WorkingCapitalDeficit" xlink:label="RENB_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_WorkingCapitalDeficit" xlink:to="RENB_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:label="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:to="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_lbl" xml:lang="en-US">Discount Rate (Monte-Carlo model only)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Balance June 30, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationInAcquisition" xlink:label="RENB_ContingentConsiderationInAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationInAcquisition" xlink:to="RENB_ContingentConsiderationInAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationInAcquisition_lbl" xml:lang="en-US">Contingent consideration in Acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementsContingentSharesToBeIssued" xlink:label="RENB_SettlementsContingentSharesToBeIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SettlementsContingentSharesToBeIssued" xlink:to="RENB_SettlementsContingentSharesToBeIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SettlementsContingentSharesToBeIssued_lbl" xml:lang="en-US">Settlements: contingent shares to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Fair value adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xml:lang="en-US">Contingent Consideration Liability at June 30, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Contingent shares issuable in connection with the acquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xml:lang="en-US">Contingent consideration liability was recorded at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Net Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="RENB_NetDefinitelifeIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="RENB_NetDefinitelifeIntangibleAssets_lbl" xml:lang="en-US">Net definite-life intangible assets at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net definite-life intangible assets, Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="RENB_NetDefinitelifeIntangibleAssetsAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:to="RENB_NetDefinitelifeIntangibleAssetsAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NetDefinitelifeIntangibleAssetsAmortization_lbl" xml:lang="en-US">Net definite-life intangible assets, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Net definite-life intangible assets, Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:to="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Net definite-life intangible assets, Translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="RENB_NetDefinitelifeIntangibleAssets_2_lbl" xml:lang="en-US">Net definite-life intangible assets at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:to="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:to="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_2_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Definite-life intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Impairment adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Goodwill impairment adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sub-lease Income</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OperatingLeaseRentExpenses" xlink:label="RENB_OperatingLeaseRentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OperatingLeaseRentExpenses" xlink:to="RENB_OperatingLeaseRentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OperatingLeaseRentExpenses_lbl" xml:lang="en-US">Total Net Lease Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease premises, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription" xlink:label="us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription" xlink:to="us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription_lbl" xml:lang="en-US">Sublease agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="us-gaap_PaymentsForLeasingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLeasingCosts" xlink:to="us-gaap_PaymentsForLeasingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLeasingCosts_lbl" xml:lang="en-US">Lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xml:lang="en-US">Termination fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OperatingLeaseExpenses" xlink:label="RENB_OperatingLeaseExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OperatingLeaseExpenses" xlink:to="RENB_OperatingLeaseExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OperatingLeaseExpenses_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CashPaidForTheTerminationOfLease" xlink:label="RENB_CashPaidForTheTerminationOfLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CashPaidForTheTerminationOfLease" xlink:to="RENB_CashPaidForTheTerminationOfLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CashPaidForTheTerminationOfLease_lbl" xml:lang="en-US">Cash payments</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AccrualPaymentsRelatedToTerminationOfLease" xlink:label="RENB_AccrualPaymentsRelatedToTerminationOfLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AccrualPaymentsRelatedToTerminationOfLease" xlink:to="RENB_AccrualPaymentsRelatedToTerminationOfLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AccrualPaymentsRelatedToTerminationOfLease_lbl" xml:lang="en-US">Accrual payments related to the termination of lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Note interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Accrued interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InterestExpenseRelatedToNoteBalance" xlink:label="RENB_InterestExpenseRelatedToNoteBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InterestExpenseRelatedToNoteBalance" xlink:to="RENB_InterestExpenseRelatedToNoteBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InterestExpenseRelatedToNoteBalance_lbl" xml:lang="en-US">Interest expense related to note balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bear interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Principal outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest amount</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OriginalIssueDiscountPromissoryNotePercentage" xlink:label="RENB_OriginalIssueDiscountPromissoryNotePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OriginalIssueDiscountPromissoryNotePercentage" xlink:to="RENB_OriginalIssueDiscountPromissoryNotePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OriginalIssueDiscountPromissoryNotePercentage_lbl" xml:lang="en-US">Original issue discount promissory note percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtInstrumentOriginalIssueDiscount" xlink:label="RENB_DebtInstrumentOriginalIssueDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DebtInstrumentOriginalIssueDiscount" xlink:to="RENB_DebtInstrumentOriginalIssueDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DebtInstrumentOriginalIssueDiscount_lbl" xml:lang="en-US">Original issue discount percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Discount accreted</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockAndReceivedGrossProceeds" xlink:label="RENB_CommonStockAndReceivedGrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockAndReceivedGrossProceeds" xlink:to="RENB_CommonStockAndReceivedGrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockAndReceivedGrossProceeds_lbl" xml:lang="en-US">Common stock and received gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OfferingPricePerSharePercentage" xlink:label="RENB_OfferingPricePerSharePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OfferingPricePerSharePercentage" xlink:to="RENB_OfferingPricePerSharePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OfferingPricePerSharePercentage_lbl" xml:lang="en-US">Offering price per share percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtInstrumentsFloorPricePerShare" xlink:label="RENB_DebtInstrumentsFloorPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DebtInstrumentsFloorPricePerShare" xlink:to="RENB_DebtInstrumentsFloorPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DebtInstrumentsFloorPricePerShare_lbl" xml:lang="en-US">Floor price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="us-gaap_OtherNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Other Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss" xlink:label="us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss" xlink:to="us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss_lbl" xml:lang="en-US">Discount amortization to other income and expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued for accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrepaymentShares" xlink:label="RENB_PrepaymentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PrepaymentShares" xlink:to="RENB_PrepaymentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PrepaymentShares_lbl" xml:lang="en-US">Prepayment shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Obligation value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInterest" xlink:label="us-gaap_PrepaidInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInterest" xlink:to="us-gaap_PrepaidInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInterest_lbl" xml:lang="en-US">Prepaid interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Stock issued for debt conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Stock issued for debt conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Principal and interest accrued amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GrossProceedsDiscountPercentage" xlink:label="RENB_GrossProceedsDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GrossProceedsDiscountPercentage" xlink:to="RENB_GrossProceedsDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GrossProceedsDiscountPercentage_lbl" xml:lang="en-US">Gross proceeds original issue discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Net of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExerciseWarrants" xlink:label="RENB_ExerciseWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExerciseWarrants" xlink:to="RENB_ExerciseWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExerciseWarrants_lbl" xml:lang="en-US">Number of warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsOutstandingPerShare" xlink:label="RENB_WarrantsOutstandingPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_WarrantsOutstandingPerShare" xlink:to="RENB_WarrantsOutstandingPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_WarrantsOutstandingPerShare_lbl" xml:lang="en-US">Warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExerciseWarrantsAmount" xlink:label="RENB_ExerciseWarrantsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExerciseWarrantsAmount" xlink:to="RENB_ExerciseWarrantsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExerciseWarrantsAmount_lbl" xml:lang="en-US">Exercise warrants amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="us-gaap_DerivativeFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Rate of interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarketPrice" xlink:label="RENB_MarketPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MarketPrice" xlink:to="RENB_MarketPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MarketPrice_lbl" xml:lang="en-US">Market price</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsPurchased" xlink:label="RENB_WarrantsPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_WarrantsPurchased" xlink:to="RENB_WarrantsPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_WarrantsPurchased_lbl" xml:lang="en-US">Warrants purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment on promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PromissoryNoteBalanceNetOfDiscount" xlink:label="RENB_PromissoryNoteBalanceNetOfDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PromissoryNoteBalanceNetOfDiscount" xlink:to="RENB_PromissoryNoteBalanceNetOfDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PromissoryNoteBalanceNetOfDiscount_lbl" xml:lang="en-US">Promissory note balance, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MonthlyInstallments" xlink:label="RENB_MonthlyInstallments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MonthlyInstallments" xlink:to="RENB_MonthlyInstallments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MonthlyInstallments_lbl" xml:lang="en-US">Monthly instalments amount</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RepaymentOnFinanceAgreement" xlink:label="RENB_RepaymentOnFinanceAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentOnFinanceAgreement" xlink:to="RENB_RepaymentOnFinanceAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RepaymentOnFinanceAgreement_lbl" xml:lang="en-US">Down payment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Total interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:label="RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:to="RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_lbl" xml:lang="en-US">Excess of tax over book depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:to="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents_lbl" xml:lang="en-US">Excess of tax over book depreciation of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockoptionsCompensation" xlink:label="RENB_StockoptionsCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockoptionsCompensation" xlink:to="RENB_StockoptionsCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockoptionsCompensation_lbl" xml:lang="en-US">Stock/options compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DepreciationAndAmortizations" xlink:label="RENB_DepreciationAndAmortizations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DepreciationAndAmortizations" xlink:to="RENB_DepreciationAndAmortizations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_DepreciationAndAmortizations_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ImpairmentExpense" xlink:label="RENB_ImpairmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ImpairmentExpense" xlink:to="RENB_ImpairmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ImpairmentExpense_lbl" xml:lang="en-US">&#160;Impairment expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationFairValue" xlink:label="RENB_ContingentConsiderationFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationFairValue" xlink:to="RENB_ContingentConsiderationFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationFairValue_lbl" xml:lang="en-US">Contingent consideration fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInTaxRate" xlink:label="RENB_ChangeInTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInTaxRate" xlink:to="RENB_ChangeInTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ChangeInTaxRate_lbl" xml:lang="en-US">Change in tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total Deferred Tax Assets (Liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Computed tax at expected statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_lbl" xml:lang="en-US">Non-US income taxed at different rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible expenses / other items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="us-gaap_OtherTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTaxExpenseBenefit" xlink:to="us-gaap_OtherTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Danish income tax (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Current Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:label="RENB_ExcessTaxBenefitOverDepreciationFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:to="RENB_ExcessTaxBenefitOverDepreciationFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_ExcessTaxBenefitOverDepreciationFixedAssets_lbl" xml:lang="en-US">Excess of tax over book depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExcessTaxBenefitOverDepreciationPatents" xlink:label="RENB_ExcessTaxBenefitOverDepreciationPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExcessTaxBenefitOverDepreciationPatents" xlink:to="RENB_ExcessTaxBenefitOverDepreciationPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_ExcessTaxBenefitOverDepreciationPatents_lbl" xml:lang="en-US">Excess of tax over book depreciation of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock/options compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:label="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:to="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitImpairmentExpense" xlink:label="RENB_IncomeTaxExpenseBenefitImpairmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IncomeTaxExpenseBenefitImpairmentExpense" xlink:to="RENB_IncomeTaxExpenseBenefitImpairmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_IncomeTaxExpenseBenefitImpairmentExpense_lbl" xml:lang="en-US">&#160;Impairment expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue" xlink:label="RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue" xlink:to="RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue_lbl" xml:lang="en-US">&#160;Contingent consideration fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredIncomeTaxExpenseChangeInTaxRate" xlink:label="RENB_DeferredIncomeTaxExpenseChangeInTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DeferredIncomeTaxExpenseChangeInTaxRate" xlink:to="RENB_DeferredIncomeTaxExpenseChangeInTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_DeferredIncomeTaxExpenseChangeInTaxRate_lbl" xml:lang="en-US">Change in tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in the valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Deferred Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise Prices, Lower</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise Prices, Upper</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number share option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Contractual Life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted Average remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Intrinsic Value, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Weighted Average Intrinsic Value, Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:to="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Weighted Average Intrinsic Value, Exercisable end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePrices" xlink:label="RENB_ExercisePrices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePrices" xlink:to="RENB_ExercisePrices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePrices_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="RENB_CommonStockPurchaseWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrant" xlink:to="RENB_CommonStockPurchaseWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="RENB_CommonStockPurchaseWarrant_lbl" xml:lang="en-US">Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:to="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">Weighted Average remaining life, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average remaining life, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrant" xlink:to="RENB_CommonStockPurchaseWarrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="RENB_CommonStockPurchaseWarrant_2_lbl" xml:lang="en-US">Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:to="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockDesignatedShares" xlink:label="RENB_PreferredStockDesignatedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PreferredStockDesignatedShares" xlink:to="RENB_PreferredStockDesignatedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PreferredStockDesignatedShares_lbl" xml:lang="en-US">Preferred stock designated shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockShareIssued" xlink:label="RENB_CommonStockShareIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockShareIssued" xlink:to="RENB_CommonStockShareIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_CommonStockShareIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockConvertibleSharesIssuable" xlink:label="RENB_CommonStockConvertibleSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockConvertibleSharesIssuable" xlink:to="RENB_CommonStockConvertibleSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Common stock, shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Obligation to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_lbl" xml:lang="en-US">Closed private placement units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US">aggregate proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConversionOfPromissoryNote" xlink:label="RENB_ConversionOfPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConversionOfPromissoryNote" xlink:to="RENB_ConversionOfPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConversionOfPromissoryNote_lbl" xml:lang="en-US">Conversion of promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AggregatePreferredStockShares" xlink:label="RENB_AggregatePreferredStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AggregatePreferredStockShares" xlink:to="RENB_AggregatePreferredStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AggregatePreferredStockShares_lbl" xml:lang="en-US">Aggregate preferred stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AggregateCommonStockShares" xlink:label="RENB_AggregateCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AggregateCommonStockShares" xlink:to="RENB_AggregateCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AggregateCommonStockShares_lbl" xml:lang="en-US">Aggregate common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsSold" xlink:label="RENB_WarrantsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_WarrantsSold" xlink:to="RENB_WarrantsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_WarrantsSold_lbl" xml:lang="en-US">Warrants sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Extinguishment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ClosedSharesParValue" xlink:label="RENB_ClosedSharesParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ClosedSharesParValue" xlink:to="RENB_ClosedSharesParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ClosedSharesParValue_lbl" xml:lang="en-US">Closed shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePricePerShare" xlink:label="RENB_ExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePricePerShare" xlink:to="RENB_ExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Shares sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Price per unit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Paid in cash and settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrincipalAmountAndInterestAccrued" xlink:label="RENB_PrincipalAmountAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PrincipalAmountAndInterestAccrued" xlink:to="RENB_PrincipalAmountAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PrincipalAmountAndInterestAccrued_lbl" xml:lang="en-US">Principal amount and interest accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementOfDebt" xlink:label="RENB_SettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SettlementOfDebt" xlink:to="RENB_SettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SettlementOfDebt_lbl" xml:lang="en-US">Settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock shares, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Common stock purchase warrants exercisable outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:to="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl" xml:lang="en-US">Warrants aggregate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:to="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering_lbl" xml:lang="en-US">Issuance of common stock under private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockParValuePrivatePlacement" xlink:label="RENB_CommonStockParValuePrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockParValuePrivatePlacement" xlink:to="RENB_CommonStockParValuePrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockParValuePrivatePlacement_lbl" xml:lang="en-US">Common stock par value under private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3_lbl" xml:lang="en-US">Proceeds of private placement offering</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NumberOfShareWarrantPurchase" xlink:label="RENB_NumberOfShareWarrantPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NumberOfShareWarrantPurchase" xlink:to="RENB_NumberOfShareWarrantPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NumberOfShareWarrantPurchase_lbl" xml:lang="en-US">Number of share warrant purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted shares of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Converted shares of common stock, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Shares issued of common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PurchaseSharesOfCommonStock" xlink:label="RENB_PurchaseSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchaseSharesOfCommonStock" xlink:to="RENB_PurchaseSharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Purchase shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnOutDistribution" xlink:label="RENB_EarnOutDistribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EarnOutDistribution" xlink:to="RENB_EarnOutDistribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EarnOutDistribution_lbl" xml:lang="en-US">Earn-out distribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_lbl" xml:lang="en-US">Non cash earn out distribution</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:label="RENB_ExtinguishmentOfContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:to="RENB_ExtinguishmentOfContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExtinguishmentOfContingentConsiderationLiability_lbl" xml:lang="en-US">Extinguishment of contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:label="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:to="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US">Common shares contingently issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Options available to be issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Total intrinsic value of options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of shares grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Number of value grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment for license</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RoyaltyPercentage" xlink:label="RENB_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RoyaltyPercentage" xlink:to="RENB_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_UpfrontPayment" xlink:label="RENB_UpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UpfrontPayment" xlink:to="RENB_UpfrontPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UpfrontPayment_lbl" xml:lang="en-US">Up-front payment</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PaymentForExpenditures" xlink:label="RENB_PaymentForExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PaymentForExpenditures" xlink:to="RENB_PaymentForExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PaymentForExpenditures_lbl" xml:lang="en-US">Payment for expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InitialPayment" xlink:label="RENB_InitialPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InitialPayment" xlink:to="RENB_InitialPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InitialPayment_lbl" xml:lang="en-US">Initial payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Remaining shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Accrued balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payables</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GrossProceedsOriginalIssueDiscountRate" xlink:label="RENB_GrossProceedsOriginalIssueDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GrossProceedsOriginalIssueDiscountRate" xlink:to="RENB_GrossProceedsOriginalIssueDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_GrossProceedsOriginalIssueDiscountRate_lbl" xml:lang="en-US">Gross proceeds original issue discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_2_lbl" xml:lang="en-US">Debt maturity period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Note balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="RENB_BusinessCombinationContingentConsiderationCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:to="RENB_BusinessCombinationContingentConsiderationCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationContingentConsiderationCommonStock_lbl" xml:lang="en-US">Common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid &amp; Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease ROU</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total Assets Acquired:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total Liabilities Assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net Assets Acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="RENB_BusinessAcquisitionsRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsRevenue" xlink:to="RENB_BusinessAcquisitionsRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionsRevenue_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsNetIncomeLoss" xlink:to="RENB_BusinessAcquisitionsNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xml:lang="en-US">Fair value of consideration transferred amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Acquisition related costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentOperatingLoss" xlink:label="RENB_SegmentOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentOperatingLoss" xlink:to="RENB_SegmentOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SegmentOperatingLoss_lbl" xml:lang="en-US">Operating income loss</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentAsset" xlink:label="RENB_SegmentAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentAsset" xlink:to="RENB_SegmentAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SegmentAsset_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentOperatingLoss" xlink:to="RENB_SegmentOperatingLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_SegmentOperatingLoss_2_lbl" xml:lang="en-US">Segment operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xml:lang="en-US">Sale of stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_3_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of stock issued cash consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices" xlink:label="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices" xlink:to="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices_lbl" xml:lang="en-US">Issuance of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices" xlink:label="RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices" xlink:to="RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices_lbl" xml:lang="en-US">Common stock for consulting services value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Forfeited shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Original shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Option to purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" xlink:label="RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" xlink:to="RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue_lbl" xml:lang="en-US">Option to purchase shares of common stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities" xlink:to="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities_2_lbl" xml:lang="en-US">LossOnExtinguishmentOfContingentConsiderationLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfDebt" xlink:to="RENB_LossOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LossOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">LossOnExtinguishmentOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_2_lbl" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentsOfFinanceAgreement" xlink:to="RENB_RepaymentsOfFinanceAgreement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RepaymentsOfFinanceAgreement_2_lbl" xml:lang="en-US">RepaymentsOfFinanceAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NetDefinitelifeIntangibleAssets_3_lbl" xml:lang="en-US">NetDefinitelifeIntangibleAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_3_lbl" xml:lang="en-US">Other Indefinite-Lived Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_2_lbl" xml:lang="en-US">Sublease Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_2_lbl" xml:lang="en-US">Debt Instrument, Annual Principal Payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DepreciationAndAmortizations" xlink:to="RENB_DepreciationAndAmortizations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DepreciationAndAmortizations_2_lbl" xml:lang="en-US">DepreciationAndAmortizations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:to="RENB_ExcessTaxBenefitOverDepreciationFixedAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExcessTaxBenefitOverDepreciationFixedAssets_2_lbl" xml:lang="en-US">ExcessTaxBenefitOverDepreciationFixedAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExcessTaxBenefitOverDepreciationPatents" xlink:to="RENB_ExcessTaxBenefitOverDepreciationPatents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExcessTaxBenefitOverDepreciationPatents_2_lbl" xml:lang="en-US">ExcessTaxBenefitOverDepreciationPatents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:to="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards_2_lbl" xml:lang="en-US">IncomeTaxExpenseBenefitOperatingLossCarryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IncomeTaxExpenseBenefitImpairmentExpense" xlink:to="RENB_IncomeTaxExpenseBenefitImpairmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IncomeTaxExpenseBenefitImpairmentExpense_2_lbl" xml:lang="en-US">IncomeTaxExpenseBenefitImpairmentExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DeferredIncomeTaxExpenseChangeInTaxRate" xlink:to="RENB_DeferredIncomeTaxExpenseChangeInTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DeferredIncomeTaxExpenseChangeInTaxRate_2_lbl" xml:lang="en-US">DeferredIncomeTaxExpenseChangeInTaxRate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit) [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrant" xlink:to="RENB_CommonStockPurchaseWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrant_3_lbl" xml:lang="en-US">CommonStockPurchaseWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:to="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">CommonStockPurchaseWarrantsWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockShareIssued" xlink:to="RENB_CommonStockShareIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockShareIssued_2_lbl" xml:lang="en-US">CommonStockShareIssued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GrossProceedsOriginalIssueDiscountRate" xlink:to="RENB_GrossProceedsOriginalIssueDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GrossProceedsOriginalIssueDiscountRate_2_lbl" xml:lang="en-US">GrossProceedsOriginalIssueDiscountRate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_2_lbl" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsNetIncomeLoss" xlink:to="RENB_BusinessAcquisitionsNetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss_2_lbl" xml:lang="en-US">BusinessAcquisitionsNetIncomeLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_2_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices" xlink:to="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices_2_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuedForConsultingServices</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>renb-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://renovarobio.com/role/Cover" xlink:href="renb-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:href="renb-20240630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="renb-20240630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="renb-20240630.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="renb-20240630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/GoingConcern" xlink:href="renb-20240630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurements" xlink:href="renb-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipment" xlink:href="renb-20240630.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Leases" xlink:href="renb-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Debt" xlink:href="renb-20240630.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxes" xlink:href="renb-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquity" xlink:href="renb-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:href="renb-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/RelatedPartyTransactions" xlink:href="renb-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/Acquisition" xlink:href="renb-20240630.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReporting" xlink:href="renb-20240630.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SubsequentEvents" xlink:href="renb-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:href="renb-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:href="renb-20240630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesTables" xlink:href="renb-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesTables" xlink:href="renb-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityTables" xlink:href="renb-20240630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionTables" xlink:href="renb-20240630.xsd#AcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingTables" xlink:href="renb-20240630.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="renb-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:href="renb-20240630.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="renb-20240630.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:href="renb-20240630.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="renb-20240630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="renb-20240630.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetails" xlink:href="renb-20240630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetails1" xlink:href="renb-20240630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:href="renb-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/DebtDetailsNarrative" xlink:href="renb-20240630.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails" xlink:href="renb-20240630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:href="renb-20240630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:href="renb-20240630.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:href="renb-20240630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails" xlink:href="renb-20240630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:href="renb-20240630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:href="renb-20240630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:href="renb-20240630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:href="renb-20240630.xsd#StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:href="renb-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="renb-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="renb-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails" xlink:href="renb-20240630.xsd#AcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails1" xlink:href="renb-20240630.xsd#AcquisitionDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails2" xlink:href="renb-20240630.xsd#AcquisitionDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetails3" xlink:href="renb-20240630.xsd#AcquisitionDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/AcquisitionDetailsNarrative" xlink:href="renb-20240630.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingDetails" xlink:href="renb-20240630.xsd#SegmentReportingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SegmentReportingDetails1" xlink:href="renb-20240630.xsd#SegmentReportingDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:href="renb-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaapInsuranceSettlementsReceivableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInsuranceSettlementsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="loc_RENBContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_RENBContingentConsiderationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="loc_RENBNotesPayableRelatedPartiesNetCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_RENBNotesPayableRelatedPartiesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfContingentConsiderationLiability" xlink:label="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="loc_RENBInterestIncomeAndOtherIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBInterestIncomeAndOtherIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedPursuantToWarrantsExercisedValue" xlink:label="loc_RENBStockIssuedPursuantToWarrantsExercisedValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedPursuantToWarrantsExercisedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedPursuantToWarrantsExercisedShares" xlink:label="loc_RENBStockIssuedPursuantToWarrantsExercisedShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedPursuantToWarrantsExercisedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnoutSharesIssuedValue" xlink:label="loc_RENBEarnoutSharesIssuedValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBEarnoutSharesIssuedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnoutSharesIssuedShares" xlink:label="loc_RENBEarnoutSharesIssuedShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBEarnoutSharesIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuedForInterestOnNotesPayableExtensionValue" xlink:label="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuedForInterestOnNotesPayableExtensionShares" xlink:label="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuedForInterestOnNotesPayableExtensionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsideration" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities" xlink:label="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBLossOnExtinguishmentOfContingentConsiderationLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="loc_RENBLossOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBLossOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="loc_RENBNoncashStockbasedCompensationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBNoncashStockbasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:label="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="loc_RENBAmortizationOfDiscountOnNotePayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBAmortizationOfDiscountOnNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="loc_us-gaapPaymentsToAcquireNotesReceivable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireNotesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="loc_RENBRepaymentsOfFinanceAgreement" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_RENBRepaymentsOfFinanceAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CashPaidDuringYearForAbstract" xlink:label="loc_RENBCashPaidDuringYearForAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_RENBCashPaidDuringYearForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBCashPaidDuringYearForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBCashPaidDuringYearForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:label="loc_RENBContingentSharesIssuedPursuantToAcquisitionAgreement" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension" xlink:label="loc_RENBSharesInLieuOfInterestOnMillionNotesPayableExtension" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBSharesInLieuOfInterestOnMillionNotesPayableExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:label="loc_RENBFinanceAgreementEnteredIntoInExchangeForPrepaidAssets" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBFinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" xlink:label="loc_RENBConversionOfNotePayableForIssuanceOfPreferredStock" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBConversionOfNotePayableForIssuanceOfPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" xlink:label="loc_RENBNotePayableSettledThroughNoncashExerciseOfWarrants" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBNotePayableSettledThroughNoncashExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:label="loc_RENBDebtDiscountRelatedToConvertiblePromissoryNotes" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBDebtDiscountRelatedToConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonSharesIssuedUponAcquisition" xlink:label="loc_RENBCommonSharesIssuedUponAcquisition" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBCommonSharesIssuedUponAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationIssuedUponAcquisition" xlink:label="loc_RENBContingentConsiderationIssuedUponAcquisition" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBContingentConsiderationIssuedUponAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonSharesIssuedUponSettlementOfDebt" xlink:label="loc_RENBCommonSharesIssuedUponSettlementOfDebt" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBCommonSharesIssuedUponSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" xlink:label="loc_RENBEarnOutSharesIssuedInSettlementOfContingentLiability" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBEarnOutSharesIssuedInSettlementOfContingentLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OptionsIssuedInSettlementOfDebt" xlink:label="loc_RENBOptionsIssuedInSettlementOfDebt" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBOptionsIssuedInSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementOfNotesPayable" xlink:label="loc_RENBSettlementOfNotesPayable" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBSettlementOfNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="995613 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="995614 - Disclosure - GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="995615 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipment" xlink:title="995616 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="995617 - Disclosure - INTANGIBLE ASSETS AND GOODWILL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Leases" xlink:title="995618 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="995619 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxes" xlink:title="995620 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="995621 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="995622 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="995623 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisition" xlink:title="995624 - Disclosure - ACQUISITION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="995625 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="995626 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995627 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessPolicyTextBlock" xlink:label="loc_RENBBusinessPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBBusinessPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="loc_us-gaapConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InsuranceReceivablePolicy" xlink:label="loc_RENBInsuranceReceivablePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBInsuranceReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="995628 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaapFairValueConcentrationOfRiskTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueConcentrationOfRiskTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:title="995629 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="995630 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesTables" xlink:title="995631 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesTables" xlink:title="995632 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="995633 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_RENBScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_RENBScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_RENBScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_RENBScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionTables" xlink:title="995634 - Disclosure - ACQUISITION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:label="loc_RENBScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_RENBScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" xlink:label="loc_RENBScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_RENBScheduleOfConsolidatedStatementsOfOperationsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="995635 - Disclosure - SEGMENT REPORTING (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995636 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:label="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EscrowSharesRemaining" xlink:label="loc_RENBEscrowSharesRemaining" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBEscrowSharesRemaining" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionPercentage" xlink:label="loc_RENBBusinessAcquisitionPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBBusinessAcquisitionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InProcessResearchAndDevelopment" xlink:label="loc_RENBInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaapCommonStockOtherSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCommonStockOtherSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="995637 - Disclosure - GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WorkingCapitalDeficit" xlink:label="loc_RENBWorkingCapitalDeficit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_RENBWorkingCapitalDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="995638 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="loc_RENBBlackScholesOptionPricingModelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBBlackScholesOptionPricingModelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InitialRecognitionMember" xlink:label="loc_RENBInitialRecognitionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBInitialRecognitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:label="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="995639 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationInAcquisition" xlink:label="loc_RENBContingentConsiderationInAcquisition" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_RENBContingentConsiderationInAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementsContingentSharesToBeIssued" xlink:label="loc_RENBSettlementsContingentSharesToBeIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_RENBSettlementsContingentSharesToBeIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="995640 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:title="995641 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LabEquipmentAndInstrumentsMember" xlink:label="loc_RENBLabEquipmentAndInstrumentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_RENBLabEquipmentAndInstrumentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="995642 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="995643 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="loc_RENBLessAccumulatedAmortizationMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBLessAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapGoodwillMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="loc_RENBNetDefinitelifeIntangibleAssetsAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssetsAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="995644 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="995645 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails" xlink:title="995646 - Disclosure - LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="loc_RENBLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_RENBLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails1" xlink:title="995647 - Disclosure - LEASES  (Details 1)">
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OperatingLeaseRentExpenses" xlink:label="loc_RENBOperatingLeaseRentExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_RENBOperatingLeaseRentExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:title="995648 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription" xlink:label="loc_us-gaapLesseeFinanceSubleaseResidualValueGuaranteeDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceSubleaseResidualValueGuaranteeDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForLeasingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="loc_us-gaapLiabilitiesSubjectToCompromiseEarlyContractTerminationFees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OperatingLeaseExpenses" xlink:label="loc_RENBOperatingLeaseExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBOperatingLeaseExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CashPaidForTheTerminationOfLease" xlink:label="loc_RENBCashPaidForTheTerminationOfLease" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBCashPaidForTheTerminationOfLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AccrualPaymentsRelatedToTerminationOfLease" xlink:label="loc_RENBAccrualPaymentsRelatedToTerminationOfLease" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBAccrualPaymentsRelatedToTerminationOfLease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="995649 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarchNote2024Member" xlink:label="loc_RENBMarchNote2024Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBMarchNote2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DecemberNote2023Member" xlink:label="loc_RENBDecemberNote2023Member" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBDecemberNote2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Note2023Member" xlink:label="loc_RENBNote2023Member" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBNote2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_November2023NoteMember" xlink:label="loc_RENBNovember2023NoteMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBNovember2023NoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement1Member" xlink:label="loc_RENBPrivatePlacement1Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPrivatePlacement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement2Member" xlink:label="loc_RENBPrivatePlacement2Member" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPrivatePlacement2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrivatePlacement3Member" xlink:label="loc_RENBPrivatePlacement3Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPrivatePlacement3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConvertibleNotesPayablesMember" xlink:label="loc_RENBConvertibleNotesPayablesMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBConvertibleNotesPayablesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AmendedAndRestatedSecuredNotesMember" xlink:label="loc_RENBAmendedAndRestatedSecuredNotesMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBAmendedAndRestatedSecuredNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_TheNotesMember" xlink:label="loc_RENBTheNotesMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBTheNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioApSMember" xlink:label="loc_RENBRSBioApSMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBRSBioApSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LoanAgreementMember" xlink:label="loc_RENBLoanAgreementMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PromissoryNoteMember" xlink:label="loc_RENBPromissoryNoteMember" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Note2020Member" xlink:label="loc_RENBNote2020Member" />
      <link:presentationArc order="790" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBNote2020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AccruedExpensesMember" xlink:label="loc_RENBAccruedExpensesMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_RENBAccruedExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaapBridgeLoanMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapBridgeLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SubscriptionAgreementsMember" xlink:label="loc_RENBSubscriptionAgreementsMember" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSubscriptionAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SubscriptionAgreements1Member" xlink:label="loc_RENBSubscriptionAgreements1Member" />
      <link:presentationArc order="780" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSubscriptionAgreements1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_FinanceAgreementMember" xlink:label="loc_RENBFinanceAgreementMember" />
      <link:presentationArc order="830" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBFinanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="110" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaapOtherCurrentLiabilitiesMember" />
      <link:presentationArc order="830" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapOtherCurrentLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InterestExpenseRelatedToNoteBalance" xlink:label="loc_RENBInterestExpenseRelatedToNoteBalance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBInterestExpenseRelatedToNoteBalance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OriginalIssueDiscountPromissoryNotePercentage" xlink:label="loc_RENBOriginalIssueDiscountPromissoryNotePercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBOriginalIssueDiscountPromissoryNotePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtInstrumentOriginalIssueDiscount" xlink:label="loc_RENBDebtInstrumentOriginalIssueDiscount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBDebtInstrumentOriginalIssueDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockAndReceivedGrossProceeds" xlink:label="loc_RENBCommonStockAndReceivedGrossProceeds" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBCommonStockAndReceivedGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OfferingPricePerSharePercentage" xlink:label="loc_RENBOfferingPricePerSharePercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBOfferingPricePerSharePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DebtInstrumentsFloorPricePerShare" xlink:label="loc_RENBDebtInstrumentsFloorPricePerShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBDebtInstrumentsFloorPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss" xlink:label="loc_us-gaapInterestIncomeExpenseAfterProvisionForLoanLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseAfterProvisionForLoanLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrepaymentShares" xlink:label="loc_RENBPrepaymentShares" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBPrepaymentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInterest" xlink:label="loc_us-gaapPrepaidInterest" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrepaidInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GrossProceedsDiscountPercentage" xlink:label="loc_RENBGrossProceedsDiscountPercentage" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBGrossProceedsDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExerciseWarrants" xlink:label="loc_RENBExerciseWarrants" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBExerciseWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsOutstandingPerShare" xlink:label="loc_RENBWarrantsOutstandingPerShare" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBWarrantsOutstandingPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExerciseWarrantsAmount" xlink:label="loc_RENBExerciseWarrantsAmount" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBExerciseWarrantsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarketPrice" xlink:label="loc_RENBMarketPrice" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBMarketPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsPurchased" xlink:label="loc_RENBWarrantsPurchased" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBWarrantsPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PromissoryNoteBalanceNetOfDiscount" xlink:label="loc_RENBPromissoryNoteBalanceNetOfDiscount" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBPromissoryNoteBalanceNetOfDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MonthlyInstallments" xlink:label="loc_RENBMonthlyInstallments" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBMonthlyInstallments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RepaymentOnFinanceAgreement" xlink:label="loc_RENBRepaymentOnFinanceAgreement" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBRepaymentOnFinanceAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails" xlink:title="995650 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:label="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationFixedAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationPatents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockoptionsCompensation" xlink:label="loc_RENBStockoptionsCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBStockoptionsCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DepreciationAndAmortizations" xlink:label="loc_RENBDepreciationAndAmortizations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBDepreciationAndAmortizations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ImpairmentExpense" xlink:label="loc_RENBImpairmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBImpairmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ContingentConsiderationFairValue" xlink:label="loc_RENBContingentConsiderationFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBContingentConsiderationFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ChangeInTaxRate" xlink:label="loc_RENBChangeInTaxRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBChangeInTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:title="995651 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaapIncomeTaxReconciliationRepatriationOfForeignEarnings" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaapOtherTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOtherTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:title="995652 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:label="loc_RENBExcessTaxBenefitOverDepreciationFixedAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_RENBExcessTaxBenefitOverDepreciationFixedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExcessTaxBenefitOverDepreciationPatents" xlink:label="loc_RENBExcessTaxBenefitOverDepreciationPatents" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_RENBExcessTaxBenefitOverDepreciationPatents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:label="loc_RENBIncomeTaxExpenseBenefitOperatingLossCarryforwards" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_RENBIncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitImpairmentExpense" xlink:label="loc_RENBIncomeTaxExpenseBenefitImpairmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_RENBIncomeTaxExpenseBenefitImpairmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue" xlink:label="loc_RENBIncomeTaxExpenseBenefitContingentConsiderationFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_RENBIncomeTaxExpenseBenefitContingentConsiderationFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DeferredIncomeTaxExpenseChangeInTaxRate" xlink:label="loc_RENBDeferredIncomeTaxExpenseChangeInTaxRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_RENBDeferredIncomeTaxExpenseChangeInTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:title="995653 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_UnitedStatesTaxMember" xlink:label="loc_RENBUnitedStatesTaxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RENBUnitedStatesTaxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="995654 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroMember" xlink:label="loc_RENBRenovaroMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_RENBRenovaroMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:title="995655 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:title="995656 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeeStockOptionsMember" xlink:label="loc_RENBEmployeeStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBEmployeeStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:title="995657 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="loc_RENBCommonStockPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange4Member" xlink:label="loc_RENBExercisePriceRange4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePriceRange5Member" xlink:label="loc_RENBExercisePriceRange5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePrices" xlink:label="loc_RENBExercisePrices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBExercisePrices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:title="995658 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantMember" xlink:label="loc_RENBCommonStockPurchaseWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="loc_RENBCommonStockPurchaseWarrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="loc_RENBCommonStockPurchaseWarrant_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="995659 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_RENBSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockIssuancesMember" xlink:label="loc_RENBPreferredStockIssuancesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBPreferredStockIssuancesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockIssuancesMember" xlink:label="loc_RENBCommonStockIssuancesMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStockIssuancesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AdvisoryServicesMember" xlink:label="loc_RENBAdvisoryServicesMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBAdvisoryServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PurchaseAgreementMember" xlink:label="loc_RENBPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OneWarrantMember" xlink:label="loc_RENBOneWarrantMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBOneWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EBIAndWeirdScienceLLCMember" xlink:label="loc_RENBEBIAndWeirdScienceLLCMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBEBIAndWeirdScienceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Investor1Member" xlink:label="loc_RENBInvestor1Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBInvestor1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LincolnParkMember" xlink:label="loc_RENBLincolnParkMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBLincolnParkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroBioPharmaIncMember" xlink:label="loc_RENBRenovaroBioPharmaIncMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBRenovaroBioPharmaIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_DanDritDenmarkMember" xlink:label="loc_RENBDanDritDenmarkMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBDanDritDenmarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RenovaroDenmarkMember" xlink:label="loc_RENBRenovaroDenmarkMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBRenovaroDenmarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EmployeesMember" xlink:label="loc_RENBEmployeesMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_Employees1Member" xlink:label="loc_RENBEmployees1Member" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployees1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember" xlink:label="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardOneMember" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember" xlink:label="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardTwoMember" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBBoardOfDirectorsAndScientificAdvisoryBoardTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConsultingServicesMember" xlink:label="loc_RENBConsultingServicesMember" />
      <link:presentationArc order="740" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBConsultingServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SingleRangeMember" xlink:label="loc_RENBSingleRangeMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSingleRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:label="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:label="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="loc_RENBRestrictedStockAwardsMember" />
      <link:presentationArc order="780" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EquityIncentivePlan2014Member" xlink:label="loc_RENBEquityIncentivePlan2014Member" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBEquityIncentivePlan2014Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PlanOptionsMember" xlink:label="loc_RENBPlanOptionsMember" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBPlanOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="loc_RENBCommonStockPurchaseWarrantsMember" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PreferredStockDesignatedShares" xlink:label="loc_RENBPreferredStockDesignatedShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPreferredStockDesignatedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockShareIssued" xlink:label="loc_RENBCommonStockShareIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockShareIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockConvertibleSharesIssuable" xlink:label="loc_RENBCommonStockConvertibleSharesIssuable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockConvertibleSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="loc_us-gaapPartnersCapitalAccountUnitsSoldInPrivatePlacement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ConversionOfPromissoryNote" xlink:label="loc_RENBConversionOfPromissoryNote" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBConversionOfPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AggregatePreferredStockShares" xlink:label="loc_RENBAggregatePreferredStockShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBAggregatePreferredStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_AggregateCommonStockShares" xlink:label="loc_RENBAggregateCommonStockShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBAggregateCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_WarrantsSold" xlink:label="loc_RENBWarrantsSold" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBWarrantsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ClosedSharesParValue" xlink:label="loc_RENBClosedSharesParValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBClosedSharesParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExercisePricePerShare" xlink:label="loc_RENBExercisePricePerShare" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBExercisePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PrincipalAmountAndInterestAccrued" xlink:label="loc_RENBPrincipalAmountAndInterestAccrued" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPrincipalAmountAndInterestAccrued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SettlementOfDebt" xlink:label="loc_RENBSettlementOfDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_CommonStockParValuePrivatePlacement" xlink:label="loc_RENBCommonStockParValuePrivatePlacement" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockParValuePrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_NumberOfShareWarrantPurchase" xlink:label="loc_RENBNumberOfShareWarrantPurchase" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBNumberOfShareWarrantPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PurchaseSharesOfCommonStock" xlink:label="loc_RENBPurchaseSharesOfCommonStock" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPurchaseSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_EarnOutDistribution" xlink:label="loc_RENBEarnOutDistribution" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBEarnOutDistribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:label="loc_RENBExtinguishmentOfContingentConsiderationLiability" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBExtinguishmentOfContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:label="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995660 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GTechMember" xlink:label="loc_RENBGTechMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGTechMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_LicenseAgreementMember" xlink:label="loc_RENBLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RoyaltyPercentage" xlink:label="loc_RENBRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_UpfrontPayment" xlink:label="loc_RENBUpfrontPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBUpfrontPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_PaymentForExpenditures" xlink:label="loc_RENBPaymentForExpenditures" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBPaymentForExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_InitialPayment" xlink:label="loc_RENBInitialPayment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBInitialPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995661 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_MarkDybulMember" xlink:label="loc_RENBMarkDybulMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBMarkDybulMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_November2023NoteMember" xlink:label="loc_RENBNovember2023NoteMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBNovember2023NoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_OriginalIssueDiscountPromissoryNotePercentage" xlink:label="loc_RENBOriginalIssueDiscountPromissoryNotePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBOriginalIssueDiscountPromissoryNotePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GrossProceedsOriginalIssueDiscountRate" xlink:label="loc_RENBGrossProceedsOriginalIssueDiscountRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBGrossProceedsOriginalIssueDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails" xlink:title="995662 - Disclosure - ACQUISITION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails1" xlink:title="995663 - Disclosure - ACQUISITION (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails2" xlink:title="995664 - Disclosure - ACQUISITION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="loc_RENBBusinessAcquisitionsRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="loc_RENBBusinessAcquisitionsNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails3" xlink:title="995665 - Disclosure - ACQUISITION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetailsNarrative" xlink:title="995666 - Disclosure - ACQUISITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredOther1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredOther1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="995667 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentAsset" xlink:label="loc_RENBSegmentAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="995668 - Disclosure - SEGMENT REPORTING (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RENBMember" xlink:label="loc_RENBRENBMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RENCMember" xlink:label="loc_RENBRENCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBSegmentOperatingLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="995669 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="loc_RENBRestrictedStockAwardsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices" xlink:label="loc_RENBStockIssuedDuringPeriodSharesIssuedForConsultingServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesIssuedForConsultingServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices" xlink:label="loc_RENBStockIssuedDuringPeriodValueIssuedForConsultingServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodValueIssuedForConsultingServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20240630.xsd#RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" xlink:label="loc_RENBStockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M%%$TTK?=1%WO3^J1'_:,OY3]]_\ AKKX*_\ 14/"_P#X,8_\:/\ AKCX*_\
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M9-T2[\_WON-_M4>TE_,'L*?\IYS_ ,.]_@!_T(K?^#.X_P#BZ/\ AWO\ /\
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MIK.'1Y]4U6\O+A8K>RL;%Y96W)YJOM7_ )9;?FWO_<:CVD@]A3_E.+_X=Y_
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M(XY9[R*'3WE-C%$T2RRS[-RHO[V+_OK_ &7H]I+^8/84_P"4Y#_AWG\ ]O\
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MMJ.\Z2OYJHGS/]QUV-\JT =;H7P&\.^']3TK4A=ZMJ-]I+V_V";4+OS?L]O
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MS%KK<MV\$6EW"7[N\JK_ !2[/[OS?\!>@#W1])L?L_E-I]E]GW?<>VBV;O\
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M%,H /,IZ?>6C?_M4)]Y&V[Z .HHHHJ#4BF_U+_[M<S733?ZE_P#=KF4_\?\
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MY^2C_>_W*/O_ 'JU ?\ [/\ [/3/X?FH^_\ +MW_ .PE/_S\E #*?_Z'3/\
MOFCY?[ZT %'_ 'S1_N4_^+[WS_\ H- #/^^:?13/X: '_P"?NT4S_@*[*/X:
M '_\!IFUJ?L^:F?\!H ?\U,HVK_M44 /_B_^QIG_ (_1_P!]4?\  : '_-_%
MNH_X%3?E_P!FDH ?_P!]?-\]'_?5,H_[Y_[YH ?_ -]4?=IE'^[_ /$4 %'_
M *'1_P "_P#'J?\ Y^1J #_@-,HH_P _W* "C_/R4_\ OM3/]G_@'ST /H3Y
MV3^Y3/\ OJG_ 'V3_P <H ZBBBBH-2*;_4O_ +M<S'733?ZE_P#=KF:N)$A]
M)_WU_P!\TM%!(S_OJG_Y^2F?[VVGT )\W^U3:*-_^U0 _P#X'_%3/XTJO?ZE
M!IL6Z>58?[O\=<Y>>,Y7^6S@5$^;_74&?,==_G?0FW<BLRHORK]^O.;G6+RY
M;=+/(_S?WO\ XG_@=5T?]ZC,S.ZM_>_S_M_]\5?*1S&K\'_&=YX\\&W&JZ@T
M+W":KJ-I_HZ[4VP73Q)_XXE=M_%_?KP+X7>%;SP9X5EL=0:-[AM3O[K?"V]-
ML]P\J?\ CCUVL-Y<V?S+/(FW;N_S_P!]T2",O=/2/\_>H^]7&6?BZ^MO]>WG
M(OWM_P FW^_]VNATWQ#9W_[K_4R_<\EZ@OF-7^+^_P#QT?P[J9]?^ 4?[2M0
M:#_\_/3*/N_PT_\ V?F_X'0 RL_6_$^B^&XHI]:U?3]'BE;8LU]=);HS?W/F
M>M#_ #]VN,^,^B:?KGPM\6_VGI]IJ*6^CW\L7VN!)?*;[._S+O\ N-0*7PG8
M0O%-"DL3*\3*KJZ?Q+3_ /T.N:^%:?\ %K_!B[?^8%8?P_\ 3NE=10 4?-13
M/X?NM0,?_G[U'\5'\5,H /\ <I__ 'U3/]NG[/\ 9_\ LJ (;F%;RWF@E9=D
MJ[*;9W+7-NCLJ^:K;&_WE^_5C_@548?DU2[5=OS*LO\ P+YT_P#9:B7Q<P%O
M_P ?H_V*P_&7BRU\$Z*=2NH;BZ+3Q6MM9VL>Z6YGE;:L2_[3/_'6?X+^(0\4
MZA>Z9?Z5/X?UJUBBNVLKJ>*5)+>7=LEBEB.UU^5U_P!EJU%S'6?Y^[5*9XO[
M618FWR[=DZ)_"O\  _\ G^_5KSHG_P"6L?\ WTE5=-F6;S9_-7_2)=Z_-L^1
M?E2N>I\48DFA3/\ @--\Z+;_ *V-]W^U63XN\8:5X)\/W>O:K+(FFVOSSRV\
M#W&W=_L+\U;%FW_P#Y*97*:/\5_"&O6MW/!KUI;?999;>ZAOI4MY8&5]CHZ-
M\R_/4TWQ,\)P_P#,QZ:\7_+66&Y1TB79OWL_\*[: .E\RGUSEG\2/#5]IME?
M+KUE#%>6L5[ EW.D3^5+_JGV-_?H_P"%C>$/*\W_ (2?1?L^UGW?;HMB[73?
M_P!\[DH Z#^&C_@55--UC3];BEET_4+:_2*7RI7MY4EVR_W/]ZKWW_EH 9_W
MS11]]?O4?P?[% !1_P!\T_\ WFIG_ : #;\OW:/^^:/[U,N;F*SB\V>54B_O
MO0!A:WXGEL+]X(H(W1?[_P#WU6[#-YT22K]QEWUP6O>(=,O-4\UI?]'BVI+_
M  NV[_/_ (Y46K_$BYL;B^M]$L;2[MM+MHI)IKVY\O<K!3L7\&^_7!BL?0PM
M/FJ2_K^D<LJD8^](](^[7.:WXDETV_>"*)9MO_C]:L.L6TFEV^HLWDV]Q$LJ
M^:NU_F3?7%>(?$.GWFK/NE_=6^V*?_@5=?M8<G.7*7NG>PS>="DB_P 2[ZF_
M] KSS5/'MS:WAT_P[9V]S]CLOML\MU.L2;?[B_[7R_?KK=*\0V>I>'[+56VV
MUO=1*ZH_S_\  *Y:.-HXBM*A'XHA&I'FY2EK?B2?3;Q((HEV(OS.Z_>K;L[G
M[3:Q3_<W+OKRSQ;\5/"J:M>K/J6Q-+B5[S9_"K/_ .A5P/Q4_:>U_P -^+E\
M)?#?P_H^KS:=H'_"17USKU\EK$UO\^R*+YE^=MC?/]Q:]'EY@]I&)]+5A>(?
M$,^E77E1*OW=[/-6=\,?B38_$SX7^'O&<4,FG66L6:77V:7Y_*W?*Z?[7S;O
MF_BKG?&WQ.\-)JTMG+?*DNFVK75TG]R+[G^4HY0E*/*>EV%Y]LM8I_N;E^9'
M_AJ7_OC[M?./Q*_:3U71/$'AKPA\,-(TG6]2U+2KK7&N]>O/LMK%:P;_ )$_
MO,[JZ_['\=>H?!+XM0?&+X2Z)XU-C_9?VZ*7S[7S?-\B6)WB=5?^)=Z?*U'*
M7&I&7NG3>(=;ET?[.L47SM]YW_NU=T>__M6P2=MN_<VY$_AKA?&WQ&\/0ZE;
MZ4U\J7OE2W6Q_D_=+]]_]FO._B!^TE+H?_"O_#WPWT_3_$/B+QA++]FN-8NO
ML]E!%%M\UG_C9OG1=M'*1S<I]&?Q?W_]]J*\N_9U^,D_QL^';ZW?:5'HFJV=
M]<:7?VEO/]HA2>+[S12_=9?G6O3O]^H-HRY@_P _/3_XJ93_ .+^)_FH&=11
M114&I%-_J7_W:YFNFF_U+_[M<S5$2'_Q4RBG^93)&?Y^]1]/^!T?]\_[]% !
M6%K?BA;/?!;;9KA?D9_X%_\ LJ9XGU[[&OV:!OWNWYIO[O\ ]ELKDGW;GW??
M7Y-W_C__ -C5&$I#III+F7S69II?O_>_W/\ ["F_]]/_ )WT/_XY_N_^.?\
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MOG@9-Z2KY3M\O^]\U;GB3_D7-8^]_P @Z?\ ]%/7*? 3_DA/P\^7Y/[ L_\
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M(OD^]_%_'09RD8CNTS.S,SNW\?\ '_G_ -FH?^/_ ,>=/D_S_G_;H_\ '/\
M/W/\_P#V-'S)\R_P_P!Q?\_Y2J, ^XWW?G5?N)_[)_X_7E/QF^+O_"&+_8ND
M,KZVR[)9OO\ V5?_ (KYZZ[XB^,X/ ?A6[U-MKW'^JM8?[TO\'_?'R5\::QK
M$MS<7%Y<R_:;VXEW-O\ GW,S[*WIQYSGJ2Y?=);RYEU*X>YO))+FXE^=IIFW
MO7UQ\'->;Q!\.]*EGG\Z[MU:WEWMO?Y?\I7Q[>7\6FVKW-S+\D7SL]=[^QX^
MH:WXRUW5Y[F2VM/LO[BT_@E7?L?_ +XK:I'W3&G+WCZXFN8K:+S99XX4W+\\
MS;$_S_#_ +M?&_Q@\;+XG\87M\TK/9++]BL4?^ZM>L?M=7+7/@&WT6VN6AU"
M\GWJF[Y&BB_OU\@P^)+G4K6RTAHMFMK=+N>9?D^7Y_GJ*<?M!6J?9/H;X5_%
MV^\#7B6.HRM<Z%*WS0_\\/\ ;2OJ6VN8+RUBG@GCFMY5WQ3)_$G]_P#SM^Y7
MP59PSI_K[GSG;^Y$B5[W^SQ\162X_P"$5U"7]U+\]B[?P_\ 3+_V9:*D?M%T
M:GV3W_\ [ZW_ /?#_-_G_/\ "OWVV_\ ?7^?\_<H_AW?^@?Y_P [Z/N+_N_W
MUKE.LZCPEJK.KV<O^^O_ ,172_\  EKS2&9K.5)5^1XOG7?_ )_SOKTB&9;F
MW2=?N-0;Q'_[OWZYKXI/_P 6O\9?-L_XDM__ .D[UU'WJY?XJ?\ )+_&OWO^
M0%?_ /I.]2$OA#X7?\DM\&+_ -0*P^]_U[I72_(__P"U7-?"[Y/A?X*V_P#0
M"L/_ $G2NE_@^]5!'X1/X?\ XNGO]^FT^I- _P"^JBFFBMHGEE;9$OWGIW^?
MNU5_X^=2_P!BU_\ 1K?_ &'_ *'42ER@)ON[EOW2K9Q?[:;W;_@'\-']FQ3?
M-/+)>/\ ]-F^3_OC[M7O]^F5/LX_:%RC-L5M%_"D2K_=K(N=>E>7]Q\B?[OW
MJ37KS?+Y"_<7[W^U6.\RHN[=][[M=$23YG_;\U*SN;7PQ \%E-<*N]OM$[12
MJC;_ /@+)7U!X;UM4\#^'&ME5-UC;[5^;8J[/]KYJ\5_:B\*Z5KW@'1[S4[.
M.YN(M1\I7?\ A79OV5ZPLS?98F_Y9- NW^Y%\G_H-7+X3"/\21UNE:Q]IE2*
M7:DO]]/XJJ>'K"VO-&3S8E=_/G^?;_TU?^.N*\)?$CPKXVOY;;0/$&GZQ=VN
MUY4MY]^U=^S?_N_[:5V?@F\^V>'TWM^]6>5&W_WO->L91]WWC:)I?8YX?^/:
M\9$_YXW'[U/_ (JA+]D;RKE5A=ONS(WR/_\ 95>_\<3^_5'6+FQL--EGU.Y@
ML[)?];<7$J(B_P# VK'EY?A-"]3*KZ;,]S9JS-O=?D9T^XW^W_[-5AWV,BLR
MH[?P?<W?WZN,N:/, ?[R[Z?1L?\ N-_WS2;7_NM5@-_N?QT4_P";^+=_?H^[
M0 4?\"IG\.VG_>_O?]]4 9?B7Y?#>L?)L_T&Z_\ 13UROP!_Y(7\/?\ L 67
M_HI*ZKQ+_P BWK;?<_T&Z_\ 135ROP%_Y(7\//\ L 67_HI*K[)'VCNZ*?\
M[_\ X]6?K&J_V5:HVWSI6;8J;JDLYSQ/>7-MJGRRR(FWY=C5U=@[7-G%*R_.
MR+NKYL\0_M+13:EKMS!IZWB:2T44#[ODG9G='_W5KR+]H3XV:]KWC"WNI?$_
MBWP;X4;PS]M\-_\ "+6WF_;]6W_/%+\_S,CHB+$_RM\]:^SD<OM(Q/O6N/\
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M_P!>[UTM<U\5/E^%_C7^#;H5_P#P_P#3O+3B;2^$/A6FSX7^"E^5/^)%8?\
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M_P"!T_\ X$O_ 'U1O7^%E_[ZH$9GB3_D7-8_Z\;C_P!%/7*? /\ Y(5\//\
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MJ_Z;:JUU _\ N_?3_@?_ +)7CQ.BI'F/E+Q._P!FTE)8E;?;RJ\2(W]W_/\
MNUJI,LT22JRNLJ_*_P#>W57O$_T69E7>^W9]VFZ58?8(HHE;8FWYHOX%_P!R
MM3S3M?A=J7]F^/-'E_YZR_9_[_WDV5]2V$S312I+%Y*+*T2_[2[/\K_P#_@5
M?'6E7C6=_:7*[7>*59?[^[[E?8VFQSPM<2-+YT3-^X_V5V?<?_@;NW_Q-:4^
M;VD3OPQ:N?->)UBE\F5E;RO]EF_C_P" 5S/@_P !_$)[JXV_%9DVK_T+-K_\
M7_NUU/W%_B^[]]*ZCP9#L^UM_M>5]ZO4.^,32\-V&H:5H=O;:KK3:]J$6[S=
M0>U6W\W_ +9+\JUF?%)MOPO\9;6V;=%O_P"+_IU>NI_S]ZN7^*G_ "2_QK_!
M_P 2*_\ _2=Z#:7PGFWPW_9R^&EY\-_"4\_A&T>XET>SE9VGG3<[6Z?[=='_
M ,,R_##_ *$VU_[_ ,__ ,=KI?A=_P DM\$_]@*P_P#2=*Z;_/R4[R(C3CR_
M">8_\,R_"[_H3;3_ ,"9_P#X[1_PS3\,/^A-M?\ O_/_ /':]1IE%Y%^SC_*
M>9K^S+\,-W_(FVO_ (%3_P#QVJNE_LT?##[#%N\'VG\2_P#'S/\ W_\ KK7K
M._YO_'_O51TK_CPB7^ZS[?E_VWK'FES?$3RQ_E//?^&:/AA_T)]I_P"!,_\
M\=K)UK]G'X:0W$2Q^$;1/EW_ .OG_P#CM>S5S^O?\?D3_-LV_?K;FD5[./\
M*>3_ /#.OPWW(W_")VGR_P#3>X_^+H_X9U^&Z+M7PG:)_P!M[C_XNG?%'XQV
M?PW:*SBL_P"TM8E7S?L^[8D2_P"W7C]S^T=XVN6_=1:?;(W\'D;_ /Q^MH\Q
MSRE3B=!\>_@)X TWX:)>6?A>VAN/[15-Z3RM\NQ_[TM>L:'^S;\,+K0=/E;P
M=:.\MG$S/Y\_\2*W]^OG+XA?&_Q5XD^&6L6E]!I]REJBWN](-GS*_P#]E6GX
M _:N\8OX3TQHETVY2*!8MCP?=V_)]Y:.67*9QJT^8]5U7]FSP+<Q?\2K2H]$
MU6*=;BSU.%I97@N%?>C[)7VM_N/6GX5\)7FMZN_B7Q9>6.L:GY#:;:V]I:O;
MV\%OYN]W^^[;G=-W_?%:7PKUCQ+XG\,Q:KXAL;:S^U2[[6&WB?\ U7^W6QX;
M?_B4I\W_ "WN/_1KU'-]DVC&)TUAX8TA["W_ .)?'OV_WGI/$7@;2/$GAF^T
M&[@FAT^Z97E^RSO%+O5T='5OX6WHE:>E?)86_P#M5;CK$ZCR2X_9L\"WFJ:P
MTMI=_:[^V^:XEN79U9I=[.O_  )-U6-'_9Q\+V?@VS\/ZA/J6I16VG-I4MPE
MS]E>XM6E\WRG\K9_$S?]]/7I<*?\32X;^/R%_P#9ZM[_ )?O?]]UC$7,>6)^
MS-\.X8O*BT.2&+[-+9,B74OS6[;]\3_[/S_^@5UO@GX=:#X TNXT_0;'[':7
M3>;*F_[S;$3_ - 2NCH^]6PSS3_AFGX6NW_(BZ;]W_IK_P#%T?\ #,OPN_Z$
M73?]W=+_ /%UZ6FW^ZU"?]][:N\C/EB>:?\ #-/PK?\ YD72_F;_ *:__%T?
M\,T_"W;M;P/IO_?4O_Q=>E_[%/\ ]K[E%Y#Y8_RGD?B+]F_X8)H.JRKX*TU)
M5LYW5]TO_/)_]JM[X _\D+^'O_8 LO\ T4E=7XE_Y%O6/^O&Z_\ 13URGP#_
M .2%?#S_ + %E_Z*2CF]T7+RR]T[O_<I]'_?58/BW4I;"P1EEV;OGE=&J"I&
M5XJLV?646+;ON%V?/_WQ5/QI\9O OPA32K3QCXJTWP_=W47[J&[;YV1?X_E^
MZG\.[[M?+$WQ%\6>,/\ A.+ZQOIT6)8KB)$_Y96ZRO\ <_\ '*KW7PQ\:_&K
M5AXQ\.?\(OJ5[X@\/-X8U.W\4VWFI9^4S_O8&V-\C_Q)\N[Y*Z?9_P QQ>V_
ME/NB&:*YMXIXFCFBE595FA^=&6N/\3VRS:YMB;YY57=_L_Y^2LKP]X;_ .%/
M_"?PIX3BU"2\BT/3EM6NW^1Y?*B^=_\ 9KY7A\9^*/&&F^.-0MM1GAVM;W7R
M-L\JW5W3]U_=V5$8FM2IRGUIXR^-7@+X4W&E:9XN\6:7H-[>1*D%O<2;&9=V
MW?\ [*;OXVVUWB3)-&DL4JO%+$KJZ?<96_CKX.G^$'CCXT:E?^+?#DOA6_E\
M6^'DT#54\46OF_8/*=/WMO\ (^Y'_P">7R_-LKZYT3P\WPQ^&/AKPO:WTES%
MI-C;Z?\ :W^1V\I/OU$HQB7&I*18\6VV_6D5?];+%LV;:J>,_C'X'^#]OI4'
MC/Q1I^@W%TG[B&[;YV5/X]B_PI_?KY:F^)'BKQM>>.)]/OI]JP++!"DOSQ1+
M+\^S_:V54?X;^./C=JEOXX\.MX9U6_U30)?"NIV_BFU\V*UV[_\ 2(O]]'W.
MO\57[/\ F,O;?RGW19W4&H6L-S;21W-O<*KQ31-N2563Y'7;_#7+^,(?],MY
M5^=W78R5C^ _!C?!_P"#OA3P=!J#7[Z39Q6'V[;LW-_&Z_W?]FOF_4OB+XH\
M9^.O&%MI5Y(Z16%Q%:VZ-]SRG^=T_P!K[_ST1B5*IR_$?37BWXJ>$_@SH>F2
M^-_$MCH*7'[J#[6_SRLO]Q$^;:G_ ([77:3JMCKVDVFIZ9<P7^GW47FP7%NV
M])8OX'1Z^'[/PKXV^,>I>%?&WA^7P_K'B#2+&\\-W5CXL@W6[13J^RX5]C[6
M^=]_R?.OR5]-?!OX;S_ ?X%:%X1>^CO[O38F\^XMXMD7FRR[W\I?X57?M6B4
M>4*=24CK/&T/RV\O\?S)6=KWC_PU\'/"5OJ?C/7K30;)I_*B>[;9O9_GV(OW
MF:OGCQ/\1O$>O?&*]TC2KR3_ $6UN+*"%V^1I?*^_P#^RUQFG>'?&/Q;;P;K
MNE3Z7JOBCP'?2PQ:?XI7=:7D4^SYV^]LE1T^_P#[='LR/:>][I]N^&?$^D>-
MM!LM<T'4K;6-'O%WP7UI+OBE6M9/]FO)OV9?@Y??!'X8_P!@ZK?6-YJMYJ-U
MJ5S_ &9%Y5E;RRO_ *JW3^!$_P#BZ]6_]FK&1V1YN7W@_A_BV?\ ?%.3[]-_
MVZ>GW_[_ /L4#.HHHHJ#4BF_U+_[M<S733?ZE_\ =KF:N)$A],_NT^F;_P#@
M%!(;%_V?[M>;W]L]G=2Q?W6^_7I'\?\ MURGC.PV,EXO\7R-\F__ '*HSE'W
M3G?E?_<;^Y_G_<KY9_:'N?.^)$L3?<BM8D7_ +XKZF_W_P#T+_XK_8_S\]?+
M/[0D+0_$NX9OD26UMW7_ +X_^PK>G\1P5OA/,MGS(W\:_P#CNZG_ %_X!1_$
MJ[?GW5L:5X-U[6U_T'2+NY1OXT@?972<FIC_ / ?XON5ZW^SK"TVO:G+Y3.D
M5JL6]/X=S_\ V%<]9_ WQG>?-_9'DI]_?<2IL6O;OA+\*V\#:'J<&IRQS7=_
M\C)"S[(E^Y]__@?WZX\7'VM/EB:QIRYCK?\ 6*F[=_WS65XJU5=$\+ZG?,WW
M;9MN]OO,WR)_X_6E,C::UO T4DR,NQ;A%_B^Y\^W[O\ WPJ_^@UR_P 3M!OO
M$GA*XL;':]WN65H=VSS=J/\ )7S<?BY9&TCYHV;U3^Y3OO\ _ JT[_PKK6FL
MZWFE7D+KNW;XJS_)9XI9?*^1?G;_ &:Z>;E/-!(99MVU=[*N]G=MB;5_OU]D
M>'[9;;1[3:S3>:JR[W^^S/\ .[_Y_N5\4W\T4RHMGYF]E_>_[6Y_N5]O:5"T
M.FVD6WYU@B3^Y_ E=E&C+^+([,-$E^[_ '=_W_G_ ,_Y_P" 5WOANS^QZ2G]
M]F9ZX_2K!K^\A@_@^\SI_=V5Z&B(BHJK\GW%_P!FNL]*F'^?GKF?BE\GPL\9
M?]@._P#_ $E>NGY_\=KF?BA_R2_QGM_Z 5__ .D[U,3:7PA\+O\ DE_@S_L!
M6'R?]NZ5TM<U\*U_XM?X*VK_ ,P6P_A_Z=TKI?X?N[$_N4!'X0_S]VBC?_NT
M_P#BH&'\54=*_P"/!/\ :9O_ $-ZO)_!_!5'2OGTVW^]\R[U2H^V!>3;NK,T
MVY_M6P2>>*-WW,GS_P"_5N\F^S6MQ+N^959ZJ:*GV.UE@^;9;R[/_'$_^+J)
M2_>1%]H^-/CK<M>?%KQ+NV_+=>4O^RJI7#_\!_[X6O1OC]IK0_&+6X(OWSW3
M12[$;^)HDKG_  ]\-=9\56MQ=Z5';7EE:_+=7?GHD4'\?SLS_P!VN^/PGE2C
M+F,GPWI?]O:LFBK!]I_M16LO)?[DNY-B?^/UK>'OV8/&?PBOTU6^T]?$FA;O
M-ETRWE\U_E_YZ[?_ &2NR^!>K?#?0/'$1U+Q7::AK<(_T6&%6:U@?^\TNW_;
MKW;6_P!H'P3H]G+<Q:NNI7"_=M[179V;_?HE*1<:<>7FD>8ZE^UI>*L46E>%
MX+-XFV2I<2[]O^PB;$KOO@'\2[/XG>&[M9;&.SU.SGE:>W3YT97E?YTKY4\8
M>))_&'B74M9N8EAEO)?-V1+\B_P5[A^QMH,\-AX@UQE9+>67[+%\OWMLKN]$
MHQY2Z=24JA]$?;(H;RWLU9=\L3.O^ZM6*RID5_$<4_\ =7[+_P!])O\ _9$K
M5K@IRE+F.R)73=_:EQN_YY+_ .AO5NJ/_,6_WH/^^OGJW_%_]C5TBXCZ*91_
MGYZL84?YV4]/[JT?W: #RZ9_Z'_MT4__ - H R_$W_(LZQ_V#[K_ -%-7*_
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M,T/Q-+%+JNE07\L2[%>9?NUZQK&CKJMOM^Y*OW7KA+FWEMKAX)5V2K\G^?\
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M_P#'O\[*BG1ITO>C$.2!P]G\$_!UGJ45Y%I7SJRNN^5]BM\G\%=PGS[/X_\
M<7_/^=E&S?O^3Y_]W?\ [_\ G_\ 9KJ/#WAY=R7EXO\ MJE;<Q<8EWPWH_\
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M4LWB9WWZNLKI^Z@_NJOW=WWM]?3G@7QTOBWX;^&O%ES9R:5_:VG6^H?87^_
MS)OV5XU\+?@AH>O:)X?L_'_A#2]5U/2VE^R_VA EP\2[]Z?\!_V/N5[5XS3R
M=-MUBB7Y6_=(B_['R)_Z!1+E+I\WQ2/-_&'QR\+IJVJK+*SIHRQ?:D1=^[<^
MS8G^W\]>:?&;]J/Q'8^-E\.^ M7\+^'M/L/#+>)&U/Q3]R_7Y]EO%_=5=OSM
M_#NK"\*_!_7KFW\5RZ]8LDMY:_Z+^_\ G\_?O2N[^%'P6T7Q/X9T?2OB)X0T
M_5;C39[A[:'4X$E\I-^_Y/\ 9W_P5?+&)ES2D>Q?"?XD?\+&^$/A7QK?6/\
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MFVO0H?"5\S/N:--U,B,92,7Y=W^Q_"__  /_ ,>^^]2V=A/>2I%%$SNW\?\
MXY\S_P#?%=19^#[:%MTLK3-]_P"2MVWLXK-=L42PI]SY%HYB^4Q]'\,16VR>
M=?.N/[G\"UM_Y^[1_P"/_P"__!1_L?+_ +E0;#W^\_\ [.U,I]% QE<U\4OD
M^%OC7YO^8%?_ #_]N[UTO_?5>=_'SQQH?@OX7^(QKFIQZ>^HZ9?6=FK*S?:)
M6@;Y%V_Q5<?B,Y?";_PK_P"27^"OE_Y@5A_Z3I72I_GYJYGX8Q-#\,?!\<B[
M)5T6S1EV[=O^CI74_>J C\(S_@5%/_\ VU^>F?Y7YJ#0J7FW[59?>_UK?^@/
M5O\ S\]5;S_C^T__ *ZM_P"@/5JHC\4@*DWSZI;JK?=B9_\ V1*\_P#CEI":
MU\-_$^_S-]JL$Z>5_?B_O?[/S5Z'#NFU*[;^!5BB_P#0W_\ 9TK@?C#MF^$/
MBJ=GD19OWJ>4OW_WJJG_  '[M1#XC"7PGYD?%'2I;SQIM7SW\V*W\I$:I?AI
MI6M>'I=5EMHI;.]MXMRW;L]O,K+_ ,LG=?O;_P"X_P#<KUO2M*TK6/%MO;:U
M;?:=/9[5Y4A^_MWO]S_:KLKS08/ =UK$JK(FH:7JVRY7[\36_P ^S_T!Z]7F
M^R>/&G[W,8]M\5/&+VZ-_:&J>5+ L3)]NW_NO[E>*WFI:YX;\1OJ&KZ9<ZE<
M2W7FKJ,UUYOR['V)O_\ 'O\ @%?6MY<MKVI:AJNF^$]+U/P_HT4%E>;?OW2;
M/OH_][Y/X*R_%-WIOC*_T71M(TVR\%:%%=?+<:A%_I=TS(^_YF^9O[M1&1M*
M)\EWG@/5];;^U[&"2\TR\E=TN$^38W\:/O\ [CU] ?L6V&H>$OB#I]G%%'>2
MRW4L4_\ 'Y2[/GV?[E=&^I16?P1TS0_(5_M&M2W$'D_)Y2JB(_\ WV[UR/[.
M>O:E:_%FRL=#TNVU3599[VX7[==-;VZ?.Z)]U'9ON/5RES1(C'EE$^_K:%9K
M>]MMJ[?-E3_OKY__ &>K%@_G:?;LWWO*7=OKC/ ?Q.TCQ/8/?,W]FW$K-Y^G
MR_.\$L3^1*F]?O;'B?YJ2_\ B);Z#+HNDV-HVJWVHSW,4">>D$2) JM*[LWR
M_=9?EKQX^[(]B)V.K?\ (+O?^N358^__ '?^^J\7U+]J;P--->V:W-W]G^PM
M<?:/LS[_ /OC[VWROWN[^Y72Z)\>_"&O:;97-C<W<R737$2K]C=7_=1)++*_
M]U=DL3[_ /;2MOM&AZ']_P#A_AH_AW5Y3HW[47P_\0W%O'I^H7MW+.^R!([&
M7][_ 'U7_<5U9O[M;WPY^-/A;XJ7$T7AR>[O/*@6XDFELWB149F1/F;^_L>K
M [NDV_[+?]\TVB@!_P W]W?1\W]]J9_WS10 ?W_[]/\ ^ TS?_M4?]\_[E !
MO_WO]JJE_IL6I-;M*S;(FW[-WWJM_P"?NT_^*@#G_P#A#[;_ )ZLG\=6K?P]
M!9M;M$S?Z/O_ .!UI_P_Q4^@7*4;S35O+BWE9FV1?/L_@K-_X0^V3_EJW_ *
MZ#_@'R4R@#,L]!BL[BWEB9M\2LGR?<JQ>6$5_+;L^[]TV_8G\57OO4R@9A?\
M(?;.W^M_\=_[[JU:^'H+.2W:)FWQ;O\ @5:W^=^VF4"Y8E2_TV*_6)9?N++Y
MNQ/XJS7\'VSL[>:WS/\ P5N_=HH&95MX;@MO*96;?%+YO^]5W4K-=2M?*9MB
M-\^_[_W:L?\ ?-/_ (J ,&Y\*VTUP\K2,B;ON;?_ !RGP^%;:&)%5FW[M[.E
M;'W/[M% N6(?Q??^?=13Z*!C/X?XJ?\ \M4^6F4]/D9* .HHHHJ#4BF_U+_[
MM<S733?ZE_\ =KF?X:N)$@H_AH_S]ZGT$C/\_)3_ .*F?Y^]10 4?<_] ^>G
MTSY: "C^&GTR@!_]_P#^*H5_)E5F_A:F_+_LTG_?- '*?"WP3/\ #WPK-I%U
M=1W\KZC>7OFPJR)^_N'E1?F_N[]M=6_WOF_]!I_^?D6F?[E #_X:*/\ @-,H
M ?\ Y^>F?PT4_P#O[5H 9_\ %?WZ/^^:/]W_ -"H^[0 ?\ ^2GQTS_\ 9IWS
M?[5 #?O?PT__ +ZI/G_]FIM #Z9_WS1_MT^@"C<_\?NG_P"]+M_[XJW\O]^J
M]Q_Q_P!E_P!M?_0:-2D;[ ZQ??E_=*Z+_>_CK'FY>:1!529O[)EG5O\ 2+IM
MZ_\  ON?^R5RWQIO(-'^%6L0-J"Z5YL'V>!W^?S?]C_@:)MKL+E%^V64'S;%
M_>_]\_\ [=>1?M2^&-0U[PEIE]8QM<IIL[>?#%\_R,GW_P#QW_Q^BC'WC*?P
MGRIX5U)M%^(.GWRSM9_9_L\KS(N_;ME?_P"SKTY]*U/P]OTJ\73?$FC^,-TO
MDV[;Y9U^?9+O^\K??_X%OKR_1_#>I^(?%5I]A@\ZWEB6WN9O^?5=_P#K7_V?
MG_\ 0*]=UC2Y_@OXHUI;Y;R.5;'[+HNO;$\J+^^__H?^[OKTI'%'X#F=%L_#
MNM>']2OKW7DT%'W?V9H]NKROYOR['E;^[_!46M^5>6L4OB"*[\0^(M2^SO8_
MV?/O>UMXDW^:_P#P!/N4> +/4)O#+ZTNH>'X75FB6'68D\VZW?W-R?W'J[X*
MU'4O#OBJWFT&VT73;V6"6)4U6]5G9V7[B[O]G=3$/\6:5I&E?"WPY+I6H->/
MJE_<74Z7:[)8F5$39_G[WR5RG[.?A*S\2?$K3_/U"]T>X2>_BBN],NGM[AE9
MW_=(ZUO>+4BTKPEH6AK>6-Y=Q75U=726DOFO [;$2+>O^Y5?]DY[F/XI6_V:
MV6;_ (F-ZDKNO^JB_C>E]D/MQ/L[1]"L?!^FZ5INE0?8]-ME^RK$KO\ )N^;
M>S?Q-N_B;^)Z=J7A[3-<O/(U73[34HMRWL27<2/ME7Y-Z?\ CG_?=7M53=IM
MQM^^J[U_X#\])?NJ-:7GW-LNQO\ =?Y/_B*\J7Q'IF%J7P[\)_V3=K_PC.DH
MGS7#?Z#%][[^_P#WM]6W\!^&IK.*VE\/:6]O$WFK"]G$Z*S)LW[/]SY:U]21
M_L%WM7Y_*;_T"IH7_=)_NUM]HLY^'X=>%8;6*"+POHR6\3;UA2SBV+M_C^Y_
ML)6AI7AO2-!WKIFF6FF^;][[) D6[[[_ /L[_P#?=:'_ *'3_P#/R58!_G[U
M%,_S\E'^W0 4_P"7[GS4?^ATWG_QV@!WF4?Y^>C^+_[*F;-B_=_\=H ?_P"/
MTS_OJC_Q_P#V** !_D_A:GTS[G^Q1_X_0 ?+N^:A_P".G_\ ?5,_]#H ?_%3
M*?1_P&@!GET^.CYO[E,_WZ #Y?[]/_VOFHH_VO\ Q^@!G_?-%'W:* '_ ,6U
M:90_]W=OI_S?W=] !3*?LW4S^'^*@ IZ??3_ - IFS_9IR??3_?H ZFBBBH-
M2*;_ %+_ .[7,_\ ?-=--_J7_P!VN9C^[\M41(?_ !?W*/F3^]1_P'_ONF?[
M=,D/^!44_P#X%_X]3-_RT '_ 'SOHI]'_ J "F?[/^S1_G[U/_\ '* #^+^*
MC8VWYMW_  .F?[RT>70 _P"^],HH_BH /^^:/^^=]/\ ]BF?^S4 %/H_[ZH_
MB_\ L: &?=I_S)_MTS^&G_\ LU #**?3* '_ /CE,_@^]3Z.?_'J &?[E/\
MO?\ [-,W_P#?=&S_ (!_O4 5YO\ D*6GR_(L4K_^@?\ V=,N?GO]/5ON;F?9
M_>;91-\^J6G^S%*__H%37ELTT7[K:DL7SQ?W*YN7XB"'?_Q-(OX]L#_^AU>3
MY/FW5GVURMS>)+M9-T#;D_X'\]7?XMWRI5T_>*B9]YX=T^\TW4+-K2"%;R!K
M>?[/$BNR,FS[VRLK5;"S\/> TL;Z>2_TRU@BBGN+O]Z[1*Z;]_\ P"NE^?\
M^)IES;17D%Q!/%OMY5V2P_WE:M@/S,^/WQRU#6O'UZVBZ5::5IEO$L5G:>1\
MBKL^_M7Y:X+3_B+J]Y+::8\37^H74NRU\F#8C2K\]>@?M8?"R?X<>-KORY%N
M]'M[:*5;B3Y)MC?<5_[VW[M>D_LK_"6UUB/PY/X@?6/"?B';/JOA^X\E$\[;
M\DLRL^Y6959=T3I]VN[W8Q/%Y9SJ\IYII6L:A?K=07*VVE7MG+]GO+>97=XF
M_P#06^1TKZ/_ &5?A[%X;6W\6:GJ]C;I+%=>5;O+MEEW.^YW_N_+7OW@OX?Z
M3X-M+J*)O[1N]2N6O;_4[_RGGO+C_GJWR;?X/E5?NUH>&$@_L9/E@_U]Q_<_
MYZO7/*H=U.CRRYI%O_A(=(DWK_:=I_M?OTKSSXA?&SPY\-/"NB-J#SWB:INM
M8FT[8_E,J;G=_G6O3?+@=ONP?>_V*\Q^(5QX CMO#5OXS^Q);^?++:RW"O\
M>_C^[]Q7^7=N^6N"I\1U%74/VFO L/A=+NYO98;VXM8)GTIHF^T(L_\ $_\
M#M7^)_X-E2Z'^TY\/+S_ $677OL=\LOV=+=X)?-E7>J;D39]UF;Y:FF^&GPB
M_P!(G31?"_VAU5M_FQ?[L7\?W=U0^']$^$%G:Z%J%C!X;A:Z^S_8[A)TWSLW
M[V+^+_99EW_W*V^T6=%K?QH\%^&_._M77%LT@NI;)Y98)=GVB)-[Q;]FUG7;
M_P"RUFM^T5\.H;);R;Q/%!:M.EIYS02JGVA]S^5]S_6[5W,O\-6-<\!_#+6+
MK^T]5TW0+RXG9M06XNITV,S?*\J?-M_X'22>!?AD))=]AH._[3YDO^DI_P ?
M"HS?WOO[7?\ VME6!V7A[7K'Q5H=EJ^F3M<Z?>1++!*ZLGFK_?V-6A_WU69H
M<VE+916.CSVCVEE$L2PVDBLD2[/D3Y?N_+6A_P!\_P#?5 !_O?)13_XJ90 [
MYO\ :I8Z9_XY1_G90 ?PT^C^+[S4R@ _S_<H_O4?[]% !_L4?>HW_P"U\G^Q
M3Z #^Y_\53*/X?[E/_X%0 RGT?[/S4S_ ,?H /\ QRBG_=IGET /IG^?GH_B
MIZ;O]K^Y0 ?Y^[3*/OI1_P"AT 'R[J/\_P"_3_\ @7^[3/\ =W4 '_ :?_$G
M^]3/^!;*?_&E '44445!J13?ZE_]VN9^;;73S+NB=?\ 9KF*N)$@^7_<H_WM
MU/\ NTS_ #]Z@D/O_P# J/\ ;I_^?GIG_?- #Z9_#3Z/\_>H /\ @5'\7_V-
M,_AHH /^^:/]S_QVC^&B@!/X?_BZD^__  KLH^[OIE #_NTS^';1]Q*?_%0
MS_;I_P!S_P"SH_X#3* !/\_-13_^!-1_G?0 S^+_ .QH3[E'^S\WW?NT_P#V
MZ &?P_\ V5%/^[10 ?,E,_N;/^ TO\7_ ,12?]\T 5/^8MM_Z=?E_P"^Z?-?
MQVUQ%$RL[LZ_<_AW/]]Z9>?Z,T5S_!%\DO\ NM5?4H7^U/M^^T2^5_M-$^[9
M7-*4H\Q 6'R:S+M_Z:_^AI_\6]:?^ZU95F[/JCR+N2*7S=N_Y-WW/_LZV/\
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M]?G_ +]%=/M7^Z/RIODQ_P#/-?R% '-??_NT?]\_WJZ7R4_N+^5'DI_<7\J
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MH\E/[B_E0!S7_ EH^3_ONNE\E/[B_E1Y*?W%_*@#FOX:*Z7R4_N+^5'DQ_\
M/-?R% '-?+1_GY*Z3:O]T?E3O*3^XOY4KL#F7=7H_P"!?\ KI]J_W1^5-\E/
M[B_E3 YK_P ?I_S?WZZ':O\ ='Y4ODQ_\\U_(4 <[]ZM+3M.:-O-E7YOX5K1
1A55Z*!]!4M05'8****"S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /T9^*'Q
M.M/A;IFD7MY:27B:CJ<&EHD+*NQI=V'.?X?EK/;XU:=N_P"0?=?FM<A^US_R
M*?@KYF3_ (JVP^[]):YC2H?.U:TBV_>G5_NUKR^[<Y)5)<W*>T6'Q.T_4-<_
MLU;:97^959_XG_NUT_\ :T7_ #SD_*OB+3?VF?"$.K6MY+<ZAI7VBZ7[+-J%
MF]O%/_I'E;T?[K1>;\K/7U=;^//#5S"CKXATE':S74-GVZ+_ (]_^>OW_P#5
M?[?W:GE-8RD=?_:\?_/.3\J/[8C_ .><GY5S5CXHT75+RWM+'6=-O+JZB^T0
M6\-Y$[RQ?\]43^-?]JJO@SQAIGCS08M:TB61[*666W5IEV/NB=XG_P#'DI%\
MQU_]L1_\\Y/RH_MB/_GG)^59M'_ ?^ 4^4.8U/[6C_YYR?E3?[8C_P"><GY5
M0A_UR_[U0[?E^[2#F-7^V(_^><GY4[^UH_\ GG)^59'^U\M/^[0',:7]L1_\
M\Y/RH_MB/_GG)^596W^&C_:^6GRAS&O_ &M'_P \Y/RIO]L1_P#/.3\JS?NT
MS;_#1RAS&K_;$?\ SSD_*G?VM'_SSD_*LC_:^6G_ ':.4.8TO[8C_P"><GY4
M?VQ'_P \Y/RK*V_PT?[7RT<H<QK_ -K1_P#/.3\J;_;$?_/.3\JS?NTS;_#1
MRAS&K_;$?_/.3\J=_:T?_/.3\JR/]KY:?]VCE#F-+^V(_P#GG)^5']L1_P#/
M.3\JRMO\-'^U\M'*',:_]J1_-^[D_*F_VQ'_ ,\Y/RK-^7RI=R_^._=K/\0Z
M]9^%]!U/6M09DL;"UEO9V1=S^4B.S_[U'*',=%_;$?\ SSD_*C^V(_\ GG)^
M5>+:'^TIX'U36;+2+RZN_#>IW3[$M=>@^Q.F^+S49M_R_.C?+_WS7>77C?PY
M9_;?M/B#28?L$JQ7GG7T2_96;[B/_=9Z.4.8ZW^V(_\ GG)^5']L1_\ /.3\
MJY'4O&6AZ;9ZW=2ZG;3C1K5KO48;2=99K>)5W_.B_-]S=_O50^'_ ,3-#^)<
M.H2Z'+-,M@\"3^;!Y6UI8DG3_P <E2D',=[_ &Q'_P \Y/RH_MB/_GG)^59M
M'^=]/E#F-+^V(_\ GG)^5']L1_\ /.3\JS:*0<QI?VQ'_P \Y/RH_MB/_GG)
M^59O^=]% <QI?VQ'_P \Y/RH_MB/_GG)^59M'^=]/E#F-+^V(_\ GG)^5']L
M1_\ /.3\JS:*0<QI?VQ'_P \Y/RH_MB/_GG)^59O^=]% <QI?VQ'_P \Y/RH
M_MB/_GG)^59M'^=]/E#F-+^V(_\ GG)^5']L1_\ /.3\JS:*0<QI?VQ'_P \
MY/RH_MB/_GG)^59O^=]% <QI?VQ'_P \Y/RH_MB/_GG)^59M'^=]/E#F-+^V
M(_\ GG)^5.75(Y&5?+D^;VK+HA^>5-R[_F^Y2#F-3^UH_P#GG)^5-_MB/_GG
M)^597RUY_P".OCEX:^'/B6+1M934-_V6*]N;NTL7EM[."67RD>5T^XF^GRAS
M'J_]K1_\\Y/RIO\ ;$?_ #SD_*O.O"_Q@\%^+/"R^(;3Q#IT.F>9Y4LUU<Q1
M>1+OV[)=S_*_R/\ (U;$WC3PY9I?>?KVDP_8F6*ZW7T2^0S?<27^[O\ ]NCE
M#F.M_MB/_GG)^5._M:/_ )YR?E7F7BOXQ>%_!^O+I&IW,Z7;16MQ_H\'FIMN
MKCR(O_'_ /XJMSP9XPTSQYH,6M:5*SV4LLL2O-%L??%*\3_^/H]'*',=?_;$
M?_/.3\J/[8C_ .><GY5E?PT__OFH#F-3^UH_^><GY4W^V(_^><GY5FTS^&KY
M0YC5_MB/_GG)^5._M:/_ )YR?E67_P!\T4<H<QI?VQ'_ ,\Y/RH_MB/_ )YR
M?E65_#3_ /OFD',:G]K1_P#/.3\J;_;$?_/.3\JS:9M_AI\H<QT22;E5O[U2
M5!9_\>T7^[4]06>$?M=?\BKX)_[&VP_]!EKF-!?R=<M6V_\ +6NE_:\V_P#"
M(>#-W3_A*['_ -!EKDK:;[->)*OWXI5=:VC\)P5/XAXKH_P!\)V&@VEC!?6E
MSJ%GJ<5U>:@[)</+MNGE^SNC.ZQ+O?[E=%X)_9(B\36\5M?>,_MMKI%F]E:Z
M==Z9OB594=?FVRHS+\^[^]_MUY_H?PI\8Z5>6]S%I7V.XV_ZZ[6U1/\ C]>5
M/*\KYI5V?>>7YOX4KH]%TSXGVDBM;:EK>G!;5]^_4XO->\\K[RLOR^1YNW:G
M_CE(N,N4]P^'7[*EGX$^)&F>,Y_$<_B'4+6"))7U"U_?-*L7E;XF67:B[/X-
MC?[]>E_"[P3!\-_"L7AZ#4/M[Q3W%TSNNU_W]P\OW%_WZ\>USP[\9HI[2UT:
M34IH;6ZN&BU.YUA'\VU?[B.G\;+]Y7?_ -EI-2^&?Q4TOQ ][H>H7$KW7AZ"
MSGNKR[1KB745BF_>NS?>B1G^[_MK_"M2=)]&5GVWB'2M06X:VU.QN4M_]>\,
M\3^4W^W_ '*\P^$_A/Q[;^(+6]\5ZOK3Z?;V+B.UNYT4_:7E^Y*JO+YNQ<;7
M=_XJ\]L_@_XLD\(Z'9:?X0C\/:KH]M>17E]<O O]I^;/N2)-KON3_EKNE^[M
MH ^I/XJ)OO/O_P!JO +/0_BA!KS)<OKEQH\=_<-$RZC%%<.[;?(:5-^U;9.5
MV)][^Y4,/AKXOK;M-87FI6V7@M9X-;U.*=M\JLEU>Q.N_;%%\DL2?^.)0!]"
MR45\_>'? _Q4;Q!%'KGB+63IG]K;[F6WGBB26U_>['B=79MNWRMR;4KN/@^G
MBB2\\0R^(]1GO+2RO'TO3/._Y>((G9OM3KM^\V_;N_Z9?[5!)Z31_P!];Z9Y
M=/\ \_=H **-G^S_ ..T;/\ 9_\ ': #_OK?11_G[M'_  '_ ,=H */^^M]&
MS_9_\=H_S]V@ HH_X#_X[1L_V?\ QV@ _P"^M]%'^?NT;/\ 9_\ ': "C_OJ
MC9_G;1_%]W_QV@ _Y92_/\G\58GCK08_%7@GQ'HTEVMC;ZIIUU92W?W_ "EE
M1TW_ / -];:_ZK^+?_#_ -]UA>/]-N=;\!^(],L8O.O;S3+JW@AW;-S-$Z)_
M[)0!X[JG[,_@3Q3HNE6VB7^GV\,=M>64MPC_ -H/>2RVJ6_F^:[-\T6SY4_]
M!K U;]BI]5U;4]5N?'4]S>SK$EK-+IGSV?E/N1TVRHOFI]U7_P!KYM]5])^$
M_P 1M'^UW>B6+:5<-M>*74#9P7:LMEY3;5@_=)_=5OO?Q-6_%X%^*FI:@&?5
M_$.FZ.EQ%]EM_P"UXOM:6K77[U)W7?NE\K_>_A^?=04:?@W]E?3?!5YXWFAU
MQKM_$UC=67VN>V_TN#[3_K=\OF[6^9MZHJ+77?!_X46WPHM=>@@U7^U?MTMJ
MTO[I$\IH+2*#9_Y"W?\  Z\NF\._''4;RRA$FH6$*6:VEY?+J\3/<-O7]ZB?
M=BEV[]WR;J?K?PZ^*NC^(/%?_"/7=S_8NHZFMQ:_9[E/M#1;(EE9MTJ,TKHF
MU6WKMV-_$] 'TC,\4,3RRLJ1+\[.^W8O_ ZKV&I6>L6:7-C>6U_:MNVS6\J2
MI_WTM>2:7X)\;WG@SQO!KVIZAJFI7^D_8-,M[N>)8FW6NUG\I7VJWF_[5<G=
M?"CX@^ ;/2%\(2R3ZE?2VMWJMW:RQ:?:0-$D47E?95?YMZ;_ )OGW-_P"@#Z
M2_\ LOX:B2:*;?Y3*Z*VQMG_ (_7SAJ/@OXS6MA8P66OZM+"ZV\M\_VR*XNU
MN/*E1O*^>+]TK^4S)OV_[_SUM3?#[Q_#X16QT^]O].OGUK5+^>:QNHH'EWQ.
MUJS_ .]+L^6@#W5YHO-\KS5\UE9U3Y-_^_LIZ31/++$LL;RQ?>1&3>O^_7SW
M#\/?B9-XALOM.H:E]B65(I=32^B^UI:M+;O*BR_>V_)/5>T^'OQ7F:X:XU._
ML+AH&WW=I>112W4L5JRV_FO_ !?O=N[_ (%0!]%_Y^[3]G^S_P".UX)^S_XA
M\5:UX^\6Q^);S6)GCW>5;W"_Z)%^]_\ '7_V$^7;\U>][?X:"0_S]VC9_L_^
M.TS_ +YI] !L_P!G_P =H_S]VF?+MI__  %: #9_L_\ CM&S_9_\=HIGR[:
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MW:FJ"S_X]HO]VIZ@U/!OVN<?\(GX+W?=_P"$MT_/Y2UQO\7_  +?79_M=?\
M(J>"?^QML/\ T&6N,?[VW=6T?A.&I\18TK_D*6O_ %U3_P!#J*;_ %LJKM^=
MO^^O\[*L:.K/JUI\O_+7?_NU4?YY7^?[S?WJHR#^^WS?WZ]-^&GB'[3:OI4[
M+YMO\\7^TM>7_P"U_P #JW87T^E7\5S;-LN(F^6@<9<I] ;/O_[U7+?3&E^:
M7Y%;^'^*H_#K+J&FVU^8V0SHLBH_\"XK;K%G?'8JPV,$8X3_ +ZYI_V6!O\
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M=M/_ ,_Y_P#'J/\ /^?_ !Z@ _BIUON\Y=OWOEVTW^^M";?-^;Y$W?-0 /\
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M]ZC^-Z '_P#+3_/]^C_;H^X]'W: &)_X_3_\_=H_V?\ /\%,3;MH ?L_V?\
MQVC9_L_^.T;/]FF?[O\ Z#0 ?P)4L6[SEV_.RM_X]45/AV^8FYMB[E_BH /[
MW^?[]'_+/_/]RA]S_P!YZ/XMU  W\?WJ/[U,I_\ L4 '_H='^S_P"F?\L_\
M/]RG_P!Z@ _B_BIG]VG[/FV_P?\ V='^W0 S[M'\-/H_NT %,_AH^]0_SJ]
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M?_'Z/,_O??6GS)LV?=_W_N4R@ _V?^ 4?W/]ZBF?P_\ CE !_#13_O4?^.4
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M )YM_P!]4)]Y_P"#[W_ :=O7_GNU "[U3YO*;_@;4-_KG_WJ=O\ OMYLC_\
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M )%/P7_V-UA_[5KCN?\ QZMH_"<-3XA/]W_@%,_\?W?Q_P"?]RG_ ,*;MO\
MOT?^A;:HR,_Q%_R+FK?]><O_ * ]/T3_ ) FF?=_X]8O_0*9X@_Y .J_]>LO
M_H#T_07_ .)'IC?P?98O_0$H)^V7?^^J*9_#MI_^Q04'^]_Z%1_<W4?^.?[J
MTS^'Y: +TWSZ3:?W/-E1G_[XH3Y]&N-[?=G67_=^1TI[_/HR,O\ #=,G_CE,
ML/GM=0B_@\AG_P"^72H J4S^'YOGI_\ %1_%5@7=-WS6NH1;F?\ =>;L_P!W
M_P"PJE_M??JWH_[RZV_P-$WS[O\ 8>J/W_O?[*4 /_OK_P!]4?[E,I_^SO\
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M_P!1$K?(J_\ LU:WA[XBWVF[(+[_ $^T^YO=OWJ_\#K;E.;VAZVFW;]YM_\
ML41UGZ)KUCXALWELY5?Y?F1_OK_P#_?K0_O5!H/AA:9MJ_?K3M+%;?YF^:3U
MKQKQ-_;6@_'70]9M['Q5JVC+H=U#<VUFH>Q67>C1;4^7][]_YFJ+XD_\)"WC
M!FC6_=?E^R);;]FW_@/\5'Q!*7+[Q[IG'M17Y_?\%!F^)4=]X-^S2ZLGAW["
MOF?V7YNQK[^+S=G\7]ROHW]F3_A-/^&??#/_  F7VE]9\EO^/O?]H\CGRO-W
M_-OV_P!ZJE3]WF,XUG*I[/E/=6;%5[BW2Z7[VP_=W+7@?[7G_">?\,R^-/\
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MQKX%U#0KNWT;3M1N=-UJ]N;B9]0@A:Z@G$JI\Z1;_DW_ '9=U07OP#\9>*/
MNA>'-2M;"PBTN"]L'N+?579[A9[B*7S4=4_=-L1_^!4!RGTL\T2?ZV>%/FV?
M/*GWO[E2['_RU?,O_"A?']CJFN7MW-H?C*^NI9TL9M75?+M3NB,5Z\3(R^8R
MIL?;\W\2U]-P[O*A5MN_ROGV+0 S9_NT/#_WQ3ON1K_O-_#_ +M/^XTK?Q__
M &=!(UW_ +K[/F;[E,\YO[W^?DHWL^SYFHH -^]J9_#\S?\  Z?1_=_S_<H
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M\_[=6*"1GWJ?L;Y_EH_B^;_Q^IIYA!#-.4:01*S;%^=FV_-_WU\O_H- $/\
M%1L;;]UJ\[U#]H?P5I5G:WLM_<"WN+:TN@\5JS82>7RDW?W&_=ON3^%4W?PU
MK:E\8_#6CV%U?3W4WV>SU-M(=UB?_7JGFO\ [R[4^_05RG7;7_NT;'W?=_\
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MMG_?%,\0_P#(OZKM^Y]EE_\ 0*?HG_(#T_\ CW6L6[>O^Q027?N?P_[M,_\
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M_?KS3Q5\(O%VN3Z[_9^A^%]%M=>T!=(GM[2^94LG2665714M_P![OWK_ ':
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MBU_GY%I__?6S_P"SH_S_ +:T?[6WYZ"@_P!K_P#8IFW^'_T*G_<_] IO^?\
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M^*B@!>?_ !ZD_P!7\W]U:*$1=VW;_P  H /N?+_ O\%'\7WO_LJ8G^?EI_\
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M[:__ 'TG_P!G69J<IJOS^+?#G]S_ $K^/_8K=K"UC_D;O#/][_2O_0*VN_\
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MC4IRE+FB?+'_  V%X.AOOE\/ZM?KYMA+/J%W!:Q7%_Y#W#[Y8D^3Y?M"*O\
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M+=?^BDK=^7=_X_02%'S?)_NT1_>_VZ8G^W_L_?H*).?_ !VD_P K\U,^XO\
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MR=XFENHI4?[G\$22I_VUKZ>_X9=^$G_0B:7_ -\M_P#%T[_AEGX3?]"%I?\
MWR__ ,71[2(>SJ'RQ:?M@?#ZP^Q+'X%NTM;?48KA=+^RV?V>#;>O</<(_P!Y
MYW1TB97^2LK]C7Q)>>,OVJ-0UF]E\ZXO+.\EW[$3Y?DVI\ORK\NW[M?77_#+
MOPD_Z$/2_P#OT];7@_X(^ _ >K?VKX<\*V.E:GM\I+NW5]^W^-/OT>TB/V<N
M:/,<U^T:F_1M$7_IO*G_ (Y6/-\5/"[ZDFK_ -GZI<WK:!%I$MI<11>5^Z1/
MG1]^[^#^Y_'7L6M^&]*\3QQ1:K8QW\47SJDW\.ZLC_A5?A#_ *%ZT_\ 'ZQY
MC649<QSVO?&SP9?6=E*UG=W*7#7'FVZ6MNEQ9[;B*6*+^[MV(ZU5TK]H3P]8
M:M%>?V+?6SQ-O6:WBMWEV_:GN'B^;[JNCHK?Q?)75_\ "KO"&[_D 6W_  #?
M2?\ "J_""+M_L&T^7_?H]T7[P\W\,?&G2M$\*ZQI5SIEW<O=:C?WOV?;$]O+
MY\6Q$EW?,NS[WR5K/\<O#-XM[$VASPI=3MN2:"W\J7=Y6R65_O(T6Q]NSY?G
MKLO^%5^$/^@#;?\ C_R_YV57O/AUX+L/*\_0[2'S95MXMF_[S4>Z1RU#'\2?
M'CPFGB#6(K;3[O4K)HKRW2^AM;>*656?>B1/_#$G_?7^Q7GOQ1\<V/B32?"]
MGI\%LEW%;+=:K-;KL\^\V>4G_CJ+_L;GKV+_ (5=X3?_ )EZT^;^#YJ/^%7>
M$/\ H P?^/\ ^?XZ(RB.492.CTW;]@M/NO\ NHO^!5+_ '/_ $"A$6-4B7[B
M_(OS?)3_ /OKYJS.@T-!\0:AX;O/M-C.RO\ =9'^Y+_OUZKH?QBTV]C5=2C:
MPE_OK\T3?C7C7^?NT)_P*IY32-243Z3M_%FC7B;HM4M'7_KLM,O/&&B6"MYV
MJ6B;>J^<M?-NS?\ >^?_ (#3O]U:.0OVQZWX@^,UM#&\>D0M-+C_ (^+A=J+
M_P !^\U>6:EJMYK%XUS>2M-<-_&__H"54_SO_CI[_P ='*1*7,,^7[OR[/N5
MH>'_ #_[;TW[,RI=>>OE/+]S=_M52^_]VC0;RQU+4MK/)-;Q77E77DK\_P#M
MI5&8^XW?:I=_W_-^;_:;?3*?-M\U_*^YN;;\O^W47/\ X[0!\K?\%"_#-]JG
MPMT+5;:)GM]+OM]TB?PJZ;$?_OO_ -#KFOV;]'^!WC[P)X<\?:[%9^&=?^%D
M;76OZ5'LV>(8E^>UF^?[[>;L5O\ OC^Y7V1J6CZ?XAL+C2M3LX-2T^\5HI[2
MX7Y)5_VZ^6/'W_!,6QOM6EN_!WC#^RM/9G=;+5K9Y?*_W67YO^^JWC*/+RR.
M65.7-S1CS'Q5\5/B)K/QH^)6O>+-7WS:KK=XTJPKN^5?N11*O^PNU:_>3]G/
MP;?_  ^^!/@/PWJ2LNH:;H]K#.K_ ,#[!N3_ (#]W\*^.?V;_P!A3PG\#_$M
MMXH\2W7_  FNNVC;K:)H_L]I:M_?V_-N?Y?XOEK[:C^)EJHQ)93Q_P# MU9U
MI<WNQ.G"TY1YIR.WIK,(U+'I7"3?$Y#\L-BV_P#Z:.H_S]U_^^:YO5/%%_K/
MRW$GEQ;O]5"C;?O?_M5S<K/1YD;/CKX@2V5FZZ0Z[TE5))63<C?[*UQ\/Q4U
M--GFP6TVW[VQ71ZHZQ_R+[K_ 'I8O_0'_P _]]US7W_E_O5I$XY3D>D3?%1H
M?LGFZ8K[H%?Y):EA^*]F[;9=/G3_ ($E>;^(K^#3;>TGN6\F+R(D_P"^GV)4
M6S_9_P#':.4.:1ZQ#\4=%?[RW*?]LJMP_$7069%^V,GW?^63UXY_GY*9O^7_
M -"HY0]I(V+.99O%$4\7SHUSOB?_ ,?KTCP3XM7Q#9^1._\ Q,(E^;_IK_MU
MY;HZ?\3:T_ZZK_G_ ,<IVB?:_P"UK=M/W?;?-7RME 1D?3%K_J(O]VIJJ:=Y
MGV&W\W;YOE+NV?=_"K=8G>>7?'GX8ZK\5/"NFV>B7]EI^IZ?JMOJ4<FH1-+"
M3%N^5E5A_>KS#_A1?Q>_Z#_@G_P7WG_QZOIMI%1-S-M7_:H$B_-\R_+U_P!F
MJYC&5.,O>/F7_A1/Q=X_XJ#P4W][_B777S?^1:3_ (45\77^]K_@K_P7WG_Q
MZOIOSE_O#[NZE\Q/E^9?F^[1[0GV,3Y3\2?!'XL0Z!JKS^(/!7E+;2M(5TZZ
MW;=C?]-:?H/P1^+4NBZ>\>O>"O*:UBVE[&\9ON?]=:^C_&+J_@_6MK+\UC/M
M;=_TR:I?"S ^%M'P?^72#_T!:OVC%[&/,?//_"B?BYM_Y&#P5G^]_9UU_P#'
M:7_A1?Q=_P"AA\$_^"ZZ_P#CM?37G+\WS+\M)YBJ&W,OR_>J/:#]C$^9?^%%
M_%S_ *#W@G_P7WG_ ,=I?^%&?%__ *&#P5_X+KK_ ..U]-[U_O4GF)\OS+\W
MW:/:![&!\R?\*)^+O_0P>"O_  777_QVIK;X*_&&U9V7Q#X)^9'7_D'77\7_
M &UKZ469&52K+\WW:/.7^\/O;:/:A[&)\SQ_ _XO),C/K_@J9%_A>QO/F_\
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M%_\ Z&+P5_N_V==?_':^FO-16V[E_O4N]/[P_O4>T#V,3YD_X49\7MV?[?\
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M[Y_O?O:^M_-3Y/F7Y_N\]:Y7X@,&7PUM/_,:MOXO]ZK]HPE1B>(+\"OB\O\
MS,/@G_P777_QVC_A1/Q=X_XJ'P5\O_4.NO\ X[7TUO3^\/[M+YB_-\R_+4>T
M#V,#YD_X43\7?^A@\%?^"ZZ_^.T?\*-^+_\ T,'@G_P77G_QVOIOS$7=\R_+
M]ZEWK_>H]H'L8GS'_P *)^+O_0P^"MO_ &#;K_X[2_\ "B_B[_T,/@G_ ,%U
MU_\ ':^FO,3Y?F7YONTGG)\OS+\WW:/:![&)\R_\*)^+O_0P>"O_  777_QV
MC_A1/Q=_Z&#P5_X+KK_X[7TWO3^\/[M'G+\WS+\M'M!>Q@?,O_"C/B[_ -![
MP3_X+KK_ ..TG_"B_B_][_A(?!.__L&W7_QVOIOS$7=\R_+]ZEWK_>H]H/V,
M3YC_ .%%_%W=_P C!X*_\%UU_P#':QO GPC^+5M?:K<VFO>"M]MJ\N[SM.NF
M7<J)_P!-?NU]9^8GR_,OS?=KE/ 'R2>)<_Q:U.5_VOE2K]HP]C$\2D^"'Q@E
MD=_^$@\$_,V__D'WG_QZF_\ "BOB_P#]##X*_P#!==?_ !VOIKSE_O#[VV@S
M*JLS,ORU'M ]C ^9T^!OQ>1L_P!O^"O_  7WG_QZM,_"_P",;-_R'/ _WL_\
M>%W_ /'?]ZOH7SD^;YU^7[W^S1YRJVUF'W=U'M ]C$^>/^%5_&;;_P A[P/_
M ."ZZ^7_ ,BTO_"K?C'N8?VUX%V_W?[-NO\ X[_G"U]#><GR_,OS?=H69&52
MK+\WW:/:![&)\]?\*M^,V[/]O>!_O;MW]G77_P =H3X6_&1=G_$\\#_+_P!0
MZZ_^._Y_[YV?0OGQ_P!X==O6AID7<69?EH]H'L8GSG<?"?XPWUF]K)KO@M$9
MM_RV%U][:?\ IK_M?^.U3_X4;\6NG]O^#$_[<+K_ ..^RU],><GS?.OR_>_V
M:/-16V[E_O4>T#V,3Y-^('P?^*:^'4-SK7@X1K/:P+Y5G=?\_";?X_[U;;_
MSXL/_P QSP9_P*PNO_CM>S_%1E;P?C*MNO+/Y?[W^D15V'FK\OS#YJOVC%[&
M/,?-'_"C/BUM;_B?>#/_   NO_CM._X4;\6MW_(>\&?[WV"Z_P#CM?2GG1;5
M;>NUN.M'G1_WE^]MZ_Q>E1[0?L8GQ5]@^*FFZL\46H>"YIHI]B_Z#=;&9?\
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M^ /ACY/LYO[29/NW%O=NKJN9=R]?XEGE7\:/=)_>%:]_:$T"Q\.VFHSVM_\
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M+)MVQIMW,O7Y_N_*U+JG[//A/6-32\G2\++.ER(?M)\KS$\K:^W_ +8)5O\
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M;^\M','LY?S'SLOQ&^+%Y;&Z.G16$BQ2?Z.^D2O\T5JL^_[_ /RU;Y-O\/\
MO5-I/Q.^*&L:A-;2:=::7)/J$%J8WLY9WL8VE=-Y3Y-Z[=C;]U?1G-'-*X_9
MR_F/&O@WXB\5ZYXJU=_$]Q-"DNGVLL&F-8O%$K_,DLJNW]YE^[_M5[+MH!IU
'*YI&/*?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714235216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Oct. 03, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RENOVARO INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001527728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2559340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2080 Century Park East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">918-1980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RENB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,193,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,193,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">3627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Sadler, Gibb & Associates, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Draper, UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712453680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 220,467<span></span>
</td>
<td class="nump">$ 1,874,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance receivable</a></td>
<td class="nump">1,108,247<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaids and other assets</a></td>
<td class="nump">668,929<span></span>
</td>
<td class="nump">690,925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">1,997,643<span></span>
</td>
<td class="nump">2,565,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">482,121<span></span>
</td>
<td class="nump">508,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Definite life intangible assets, net</a></td>
<td class="nump">30,043<span></span>
</td>
<td class="nump">39,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite life intangible assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,611,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">159,330,161<span></span>
</td>
<td class="nump">11,640,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">19,849<span></span>
</td>
<td class="nump">21,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,269,633<span></span>
</td>
<td class="nump">913,985<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="nump">160,649,686<span></span>
</td>
<td class="nump">55,226,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">163,129,450<span></span>
</td>
<td class="nump">58,300,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable &#8211; trade</a></td>
<td class="nump">9,448,683<span></span>
</td>
<td class="nump">5,296,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,311,324<span></span>
</td>
<td class="nump">723,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">295,361<span></span>
</td>
<td class="nump">184,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability</a></td>
<td class="nump">12,310,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">493,553<span></span>
</td>
<td class="nump">193,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NotesPayableRelatedPartiesNetCurrent', window );">Notes payable &#8211; related parties, net</a></td>
<td class="nump">2,205,996<span></span>
</td>
<td class="nump">4,624,947<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">30,309,917<span></span>
</td>
<td class="nump">11,023,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">842,389<span></span>
</td>
<td class="nump">775,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-Current Liabilities</a></td>
<td class="nump">842,389<span></span>
</td>
<td class="nump">775,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">31,152,306<span></span>
</td>
<td class="nump">11,798,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 350,000,000 shares authorized, 155,027,245 shares issued and outstanding at June 30, 2024; 63,698,144 shares issued and outstanding at June 30, 2023</a></td>
<td class="nump">15,504<span></span>
</td>
<td class="nump">6,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">456,811,911<span></span>
</td>
<td class="nump">290,554,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(324,679,425)<span></span>
</td>
<td class="num">(244,029,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss)</a></td>
<td class="num">(170,846)<span></span>
</td>
<td class="num">(29,882)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">131,977,144<span></span>
</td>
<td class="nump">46,502,111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 163,129,450<span></span>
</td>
<td class="nump">$ 58,300,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NotesPayableRelatedPartiesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NotesPayableRelatedPartiesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712464992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">155,027,245<span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">155,027,245<span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451713350544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 24,557,608<span></span>
</td>
<td class="nump">$ 15,318,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,708,829<span></span>
</td>
<td class="nump">4,165,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="nump">42,611,000<span></span>
</td>
<td class="nump">18,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">11,640,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">121,859<span></span>
</td>
<td class="nump">113,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">81,639,296<span></span>
</td>
<td class="nump">38,556,891<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(81,639,296)<span></span>
</td>
<td class="num">(38,556,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">4,727,473<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(1,303,578)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LossOnExtinguishmentOfContingentConsiderationLiability', window );">Loss on extinguishment of contingent consideration liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(419,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,011,322)<span></span>
</td>
<td class="num">(580,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Gain (loss) on foreign currency transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestIncomeAndOtherIncomeExpense', window );">Interest income and other income (expense)</a></td>
<td class="num">(1,423,449)<span></span>
</td>
<td class="num">(126,620)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="nump">989,124<span></span>
</td>
<td class="num">(1,127,165)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (80,650,172)<span></span>
</td>
<td class="num">$ (39,684,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC NET LOSS PER COMMON SHARE</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED NET LOSS PER COMMON SHARE</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC</a></td>
<td class="nump">96,248,090<span></span>
</td>
<td class="nump">56,265,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED</a></td>
<td class="nump">96,248,090<span></span>
</td>
<td class="nump">56,265,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InterestIncomeAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InterestIncomeAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LossOnExtinguishmentOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LossOnExtinguishmentOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715885744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="num">$ (80,650,172)<span></span>
</td>
<td class="num">$ (39,684,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, net of taxes</a></td>
<td class="num">(140,964)<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (80,791,136)<span></span>
</td>
<td class="num">$ (39,683,502)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712724048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,302<span></span>
</td>
<td class="nump">$ 276,989,179<span></span>
</td>
<td class="num">$ (204,345,197)<span></span>
</td>
<td class="num">$ (30,436)<span></span>
</td>
<td class="nump">$ 72,618,848<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">53,007,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedPursuantToWarrantsExercisedValue', window );">Stock issued pursuant to warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">1,624,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedPursuantToWarrantsExercisedShares', window );">Stock issued pursuant to warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_EarnoutSharesIssuedValue', window );">Earn-out shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">2,762,375<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,762,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_EarnoutSharesIssuedShares', window );">Earn-out shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesIssuedForInterestOnNotesPayableExtensionValue', window );">Shares issued for interest on $1.2 million notes payable extension</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">204,372<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">204,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesIssuedForInterestOnNotesPayableExtensionShares', window );">Shares issued for interest on $1.2 million notes payable extension, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue', window );">Issuance of common stock and warrants under private placement offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">4,011,339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,011,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares', window );">Issuance of common stock and warrants under private placement offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,832,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedValue', window );">Restricted shares issued for services rendered</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">227,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedShares', window );">Restricted shares issued for services rendered, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">1,199,774<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,264,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted commitment shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,535,051<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,535,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,684,056)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,684,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,371<span></span>
</td>
<td class="nump">290,554,875<span></span>
</td>
<td class="num">(244,029,253)<span></span>
</td>
<td class="num">(29,882)<span></span>
</td>
<td class="nump">46,502,111<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement', window );">Issuance of preferred stock and warrants in private placement</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,999,972<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable', window );">Issuance of preferred stock and warrants for conversion of Note Payable</a></td>
<td class="nump">28<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,999,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedValue', window );">Restricted shares issued for services rendered</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">4,663,882<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,664,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedShares', window );">Restricted shares issued for services rendered, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,083,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">2,341,470<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,341,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue', window );">Issuance of common stock and warrants under private placement offering in settlement of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
<td class="nump">10,575,759<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,576,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares', window );">Issuance of common stock and warrants under private placement offering in settlement of debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,660,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesIssuableForSettlementOfContingentConsiderationValue', window );">Shares issuable for settlement of contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">3,519,808<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,520,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesIssuableForSettlementOfContingentConsideration', window );">Shares issuable for settlement of contingent consideration, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube', window );">Issuance of common stock pursuant to acquisition of GEDi Cube</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,083<span></span>
</td>
<td class="nump">135,994,548<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">136,001,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares', window );">Issuance of common stock pursuant to acquisition of GEDi Cube, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,834,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube', window );">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube</a></td>
<td class="num">$ (56)<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares', window );">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares</a></td>
<td class="num">(561,010)<span></span>
</td>
<td class="nump">5,610,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of options for services rendered</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">489,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,673,129<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,673,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(80,650,172)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(80,650,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(140,964)<span></span>
</td>
<td class="num">(140,964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares', window );">Issuance of preferred stock and warrants in private placement, shares</a></td>
<td class="nump">280,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares', window );">Issuance of preferred stock and warrants for conversion of Note Payable, shares</a></td>
<td class="nump">280,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,504<span></span>
</td>
<td class="nump">$ 456,811,911<span></span>
</td>
<td class="num">$ (324,679,425)<span></span>
</td>
<td class="num">$ (170,846)<span></span>
</td>
<td class="nump">$ 131,977,144<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">155,027,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_EarnoutSharesIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_EarnoutSharesIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_EarnoutSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_EarnoutSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRenderedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRenderedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesIssuableForSettlementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesIssuableForSettlementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesIssuableForSettlementOfContingentConsiderationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesIssuableForSettlementOfContingentConsiderationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesIssuedForInterestOnNotesPayableExtensionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesIssuedForInterestOnNotesPayableExtensionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesIssuedForInterestOnNotesPayableExtensionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesIssuedForInterestOnNotesPayableExtensionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedPursuantToWarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedPursuantToWarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedPursuantToWarrantsExercisedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedPursuantToWarrantsExercisedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712260992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,650,172)<span></span>
</td>
<td class="num">$ (39,684,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">121,859<span></span>
</td>
<td class="nump">113,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(4,727,473)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities', window );">Loss on extinguishment of contingent consideration liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">419,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">1,303,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NoncashStockbasedCompensationExpense', window );">Non-cash stock-based compensation expense</a></td>
<td class="nump">4,673,129<span></span>
</td>
<td class="nump">3,535,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NoncashRestrictedSharesIssuedForServicesRendered', window );">Non-cash restricted shares issued for services rendered</a></td>
<td class="nump">4,664,190<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="nump">42,611,000<span></span>
</td>
<td class="nump">18,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">11,640,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AmortizationOfDiscountOnNotePayable', window );">Amortization of discount on note payable</a></td>
<td class="nump">580,605<span></span>
</td>
<td class="nump">348,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Insurance receivable</a></td>
<td class="num">(1,108,247)<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses/deposits</a></td>
<td class="nump">1,082,267<span></span>
</td>
<td class="nump">1,070,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,057,282<span></span>
</td>
<td class="nump">3,894,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(54,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating leases, net</a></td>
<td class="nump">11,284<span></span>
</td>
<td class="num">(27,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">4,769,268<span></span>
</td>
<td class="num">(578,809)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(10,971,430)<span></span>
</td>
<td class="num">(11,774,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Notes receivable prior to acquisition</a></td>
<td class="num">(1,255,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash received from acquisition, net</a></td>
<td class="nump">65,851<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(70,430)<span></span>
</td>
<td class="num">(29,774)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(1,260,179)<span></span>
</td>
<td class="num">(29,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RepaymentsOfFinanceAgreement', window );">Repayments of finance agreement</a></td>
<td class="num">(870,073)<span></span>
</td>
<td class="num">(1,121,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">341,865<span></span>
</td>
<td class="nump">1,625,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placements</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">4,011,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of promissory notes</a></td>
<td class="nump">3,770,512<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable</a></td>
<td class="nump">4,275,151<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">10,517,455<span></span>
</td>
<td class="nump">4,515,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">&#160;Effect of exchange rates on cash</a></td>
<td class="nump">60,141<span></span>
</td>
<td class="num">(8,395)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="num">(1,654,013)<span></span>
</td>
<td class="num">(7,297,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, BEGINNING OF PERIOD</a></td>
<td class="nump">1,874,480<span></span>
</td>
<td class="nump">9,172,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, END OF PERIOD</a></td>
<td class="nump">220,467<span></span>
</td>
<td class="nump">1,874,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CashPaidDuringYearForAbstract', window );"><strong>Cash Paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">20,128<span></span>
</td>
<td class="nump">352,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement', window );">Contingent Shares issued pursuant to Acquisition Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,762,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension', window );">Shares in lieu of interest on $1.2 million notes payable extension</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">204,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets', window );">Finance agreement entered into in exchange for prepaid assets</a></td>
<td class="nump">906,834<span></span>
</td>
<td class="nump">1,139,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ConversionOfNotePayableForIssuanceOfPreferredStock', window );">Conversion of note payable for issuance of preferred stock</a></td>
<td class="nump">2,000,001<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NotePayableSettledThroughNoncashExerciseOfWarrants', window );">Note payable settled through non-cash exercise of warrants</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DebtDiscountRelatedToConvertiblePromissoryNotes', window );">Debt discount related to notes payable</a></td>
<td class="nump">339,342<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonSharesIssuedUponAcquisition', window );">Common shares issued upon acquisition</a></td>
<td class="nump">136,001,631<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationIssuedUponAcquisition', window );">Contingent consideration issued upon acquisition</a></td>
<td class="nump">20,557,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonSharesIssuedUponSettlementOfDebt', window );">Common shares issued upon settlement of debt</a></td>
<td class="nump">9,582,912<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_EarnOutSharesIssuedInSettlementOfContingentLiability', window );">Earn out shares issued in settlement of contingent liability</a></td>
<td class="nump">3,520,027<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OptionsIssuedInSettlementOfDebt', window );">Options issued in settlement of debt</a></td>
<td class="nump">489,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SettlementOfNotesPayable', window );">Settlement of notes payable</a></td>
<td class="nump">$ 418,503<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AmortizationOfDiscountOnNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AmortizationOfDiscountOnNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonSharesIssuedUponAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonSharesIssuedUponAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonSharesIssuedUponSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonSharesIssuedUponSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationIssuedUponAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationIssuedUponAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ConversionOfNotePayableForIssuanceOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ConversionOfNotePayableForIssuanceOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DebtDiscountRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DebtDiscountRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_EarnOutSharesIssuedInSettlementOfContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_EarnOutSharesIssuedInSettlementOfContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NoncashRestrictedSharesIssuedForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NoncashRestrictedSharesIssuedForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NoncashStockbasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NoncashStockbasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NotePayableSettledThroughNoncashExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NotePayableSettledThroughNoncashExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OptionsIssuedInSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OptionsIssuedInSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RepaymentsOfFinanceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RepaymentsOfFinanceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714801168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (80,650,172)<span></span>
</td>
<td class="num">$ (39,684,056)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715539472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714868128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zrXbEPrplcx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_821_zhGp3RGLfcJf">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_ecustom--BusinessPolicyTextBlock_zCtkBTkm4538" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_865_z82mb7XDjm1a"><b>Business
</b></span><b>&#8211; </b>On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;). In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven
healthcare technology company that, if it can generate sufficient funding, will also continue to engage in the research and development
of pharmaceutical and biological products for the treatment of cancer and HIV with the intent to manufacture said products. On February
13, 2024, Renovaro Inc. acquired GEDi Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly owned subsidiary
pursuant to a stock purchase agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTPoI30TunA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_860_zqUWD5Hf2rW1">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zsCwLpRfduMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_zEYwhzNWWX1c">Principles of Consolidation</span>
&#8211; </b>For the years ended June 30, 2024 and 2023, the consolidated financial statements include the accounts and operations of Renovaro,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_840_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zmOlpHsTOpk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86A_zu4Y3q9DW8Se">Subsidiaries</span> &#8211; </b>Renovaro
Biosciences Inc. (&#8220;Renovaro Biosciences&#8221;), formerly Renovaro Biopharma Inc., was incorporated on May 19, 2017 in Delaware
and is a 100% owned subsidiary of Renovaro. Renovaro Biosciences owns a perpetual, fully paid-up, royalty-free, sublicensable, and sole
and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize
certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV
in humans, and research and development exclusively relating to HIV in humans. As of June 30, 2024 and June 30, 2023, zero and 1,250,000
shares of Common Stock, respectively, remain contingently issuable in connection with the acquisition of Renovaro Biosciences in February
2018 (the &#8220;Contingent Shares&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences Denmark ApS
(&#8220;Renovaro Denmark&#8221;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Renovaro subject to 185,053 shares of Common Stock of Renovaro held in escrow according to Danish
law (the &#8220;Escrow Shares&#8221;). As of June 30, 2024, there are <span id="xdx_902_ecustom--EscrowSharesRemaining_iI_c20240630_zPTtScEVzM09" title="Escrow shares remaining">17,414</span> Escrow Shares remaining (see Note 9.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 13, 2024, the Company
acquired <span id="xdx_901_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zv8GMXEb4Xc6" title="Acquisition percentage">100</span>% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
12.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p id="xdx_842_eus-gaap--UseOfEstimates_zUyeFCYi1Mn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86B_zKw8wsgRetn9">Use of Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zd0IBDoDmAv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_868_zz0esm3S9tD1">Functional Currency and Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;). The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of
these financial statements. The Company&#8217;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates
and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years ended June 30,
2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&#8217;
equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than
the functional currency are included in the statement of operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYzze4EMsqLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zmDCKPeMM7Q9">Cash and Cash Equivalents</span> </b>&#8211;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zXAySCjPuzqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_866_zivhDldXlM9l">Concentration of Credit Risk</span>
&#8211;</b> Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2024, and June 30, 2023, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_845_ecustom--InsuranceReceivablePolicy_z2nHO3Uaz1ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86E_zGoifVogyvLa">Insurance Receivable</span> &#8211;</b>
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_znZFYJ0dR5y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zGm4454iLvN8">Property and Equipment</span> </b>-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 4.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zqm81xJWC1Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zZy77FcQIkK1">Intangible Assets</span> - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zPTsAxhA9Zj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zvWXMaDKdB6c">Goodwill</span></b> - Goodwill is not
amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z2t7migVRUw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_ztLtjS9Gnd9a">Impairment of Goodwill and Indefinite
Lived Intangible Assets</span></b> &#8211; We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For indefinite life intangible
assets, such as IPR&amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the
IPR&amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023.
During the year ended June 30, 2024, the Company recorded an impairment loss of $42,611,000 related to the termination of the license
agreement with Weird Science LLC (see Note 5.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The carrying value of
IPR&amp;D and goodwill at June 30, 2024, were&#160;zero <span id="xdx_903_ecustom--InProcessResearchAndDevelopment_iI_c20240630_zgdNmgs40Mq4" style="display: none" title="In-process research and development">0</span> and $<span id="xdx_902_eus-gaap--Goodwill_iI_c20240630_zzUVZLh5FIY9" title="Goodwill">159,330,161</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zH3L3Gq0MHVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_869_zCJyAq8yKG0k">Impairment of Long-Lived
Assets</span> - </b>Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. <span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zfZ0RQu56Byk" title="Impairment of assets"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20220701__20230630_zC6SBvTVoZp5" title="Impairment of assets">No</span></span> impairment
of these assets was recorded during the year ended June 30, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zDYiDHm5Uj2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_86E_zcQPMq32T4Xg">Leases</span> -</b> In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zS59JGeVGI0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_z2M4Fvb45Zy3">Research and Development Expenses</span>
&#8211; </b>The Company expenses research and development costs incurred in formulating,
improving, validating, and creating alternative or modified processes related to and expanding the use of the Company&#8217;s technologies.
Research and development expenses for the years ended June 30, 2024 and 2023 amounted to $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_z6mknozksDMg" title="Research and development expense">2,708,829</span>, and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220701__20230630_zTNam0i3PUge" title="Research and development expense">4,165,197</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p>

<p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zi8R7RVllzg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zYcYrZIRngO4">Income Taxes</span> </b>- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 8.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zIGW5pW0zBr" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zX0uNS8uJHd9">Loss Per Share</span></b> - The Company calculates earnings (loss) per share in accordance with FASB ASC
260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding
during each period. Diluted earnings per common share are based on shares outstanding (computed as for basic EPS) and potentially dilutive
common shares. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options
that have been granted but have not been exercised. The shares of Common Stock outstanding at June 30, 2024 and 2023 were <span id="xdx_906_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zw5OieCHee3g" title="Common stock outstanding">152,837,573</span>
and <span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20230630_ztcHsHRLkHg9" title="Common stock outstanding">63,698,144</span>, respectively. Because of the net loss for each of the years ended June 30, 2024 and June 30, 2023, dilutive shares for
both periods were excluded from the diluted EPS calculation, as the effect of these potential shares of Common Stock is anti-dilutive.
The Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zeRkKRein5I1" title="Anti-dilutive shares">17,146,315</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z4zWBToR9xad" title="Anti-dilutive shares">7,949,513</span> potential shares of Common Stock excluded from the diluted EPS calculation for the years ended
June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJ4GG127mXq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zd3ygNizXXM1">Fair Value of Financial Instruments</span>
</b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of June 30, 2024. <span style="background-color: white">Level
3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition
of Renovaro Cube </span>(see Note 3.) There were no Level 1, 2, or 3 assets, nor any Level 1, 2, or 3 liabilities measured at fair value
on a recurring basis as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z7LWcUyS4ke3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_861_zA8jExqaafKd">Stock-Based Compensation</span>
- </b>The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation
&#8211; Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2024 and 2023 were $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zYradUXtK5s1" title="Stock based compensation costs"><span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z3hq54z74ox6" title="Stock based compensation costs">4,673,129</span></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zBWxheZ7LN9k" title="Stock based compensation costs"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zZU080u0jNHd" title="Stock based compensation costs">3,535,051</span></span>, respectively<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the
fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqM3IawMsYyf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86E_z5NM0CWTk5cl">New Accounting Pronouncements Not Yet Adopted</span></b>
- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715754288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zhz44LYWtA0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8211; <span id="xdx_824_zOZIFnamK5Q3">GOING CONCERN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s consolidated financial statements are prepared using the
generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations,
has used cash in the Company&#8217;s continuing operations, and is dependent on additional financing to fund operations. The Company incurred
a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20240630_ztiR01iTTzzh" title="Net loss">80,650,172</span> and $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20220701__20230630_zL7xBOLeMhrl" title="Net loss">39,684,056</span> for the years ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the Company had
cash and cash equivalents of $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20240630_zeP5qrsfzeKd" title="Cash and cash equivalents">220,467</span> and an accumulated deficit of $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20240630_zhqkj7eOUeec" title="Accumulated deficit">324,679,425</span> and a working capital deficit of $<span id="xdx_90B_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20240630_zFKeA5k9g448" title="Working capital deficit">28,312,274</span>. These conditions
raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements
are issued. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of
recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Management has reduced overhead and administrative costs by streamlining the organization
to focus around the development and validation of its AI driven cancer diagnostics platform. The Company has tailored its workforce to
focus on these activities. In addition, the Company intends to attempt to secure additional required funding through equity or debt financing.
However, there can be no assurance that the Company will be able to obtain any sources of funding. Such additional funding may not be
available or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant
additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our cash resources will be depleted
and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business,
stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained.
If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that
could result in our stockholders losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Funding that we may receive during
the fiscal year 2025 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712422080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zI3QC9EPZfqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_82F_zDC0EoQw7qMl">FAIR VALUE MEASUREMENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company accounts for fair value
measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1. Observable inputs
    such as quoted prices in active markets for identical assets or liabilities; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2. Inputs, other
    than quoted prices in active markets, that are observable either directly or indirectly; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3. Unobservable inputs
    in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There were no Level 1, 2 or 3 assets,
nor any Level 1 or 2 liabilities as of June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Level 3 liabilities held as of
June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2014, acquisition of <span style="background-color: white">Renovaro
Cube, (the &#8220;Acquisition&#8221;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) <span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKJXXo440qFc" title="Contingent shares issuable in connection with the acquisition">70,834,183</span>
shares of Common Stock, and (ii) the right to receive contingent shares pro rata upon the exercise of convertible notes, options, and
warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_z4uD6XkDdoFg" title="Contingent consideration liability was recorded at fair value">20,557,500</span> at the time
of acquisition and is subsequently remeasured to fair value at the end of each reporting period. At June 30, 2024, there were <span id="xdx_902_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zLeqic9sL7Q9" title="Contingent shares issuable in connection with the acquisition">7,613,301</span>
contingent shares issuable in connection with the Acquisition of Renovaro Cube.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The fair value of the contingent consideration liability is estimated using
a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs to the model are all contractual or observable
with the exception being volatility, which is computed based on the volatility of the Company&#8217;s underlying stock. The key inputs
to valuing the contingent consideration liability as of June 30, 2024, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueConcentrationOfRiskTextBlock_zBnobOxz4Vtb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B4_zsouarOEXVRg" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Price</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zwBLymJsiZka" title="Stock Price">1.75</span></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5eprAWv41Jc" title="Exercise Price">0.46</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zhNeqFWgidrh" title="Exercise Price">8.23</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zP4z1pEBAC81" title="Volatility">109</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zxf5r3wVt0b1" title="Volatility">145</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Rate</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zs1GUyksvtoa" title="Risk Free Rate">4.24</span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ztV9JVnkrA8c" title="Risk Free Rate">5.21</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividends</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zmMHK42S0KH2" title="Expected Dividends">0</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount Rate (Monte-Carlo model only)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zz2SMfb5pTuc" title="Discount Rate (Monte-Carlo model only)">0</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB4swLUudTNa" title="Expected Term (years)">0.47</span> &#8211; <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zD1KKMlnrDpk" title="Expected Term (years)">9.50</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At initial recognition of the contingent consideration,
the inputs were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Price</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTF6VMTXIC1f" title="Stock Price">1.92</span></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zSTSaYAmurm8" title="Exercise Price">0.46</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zp3IzcJBaQYi" title="Exercise Price">4.50</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zFtT5leyyXs8" title="Volatility">107</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zR4EEyr6Y2mh" title="Volatility">133</span>% </span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Rate</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z9Y2yH7mPZj1" title="Risk Free Rate">4.22</span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zPhGt6Kakbgd" title="Risk Free Rate">5.14</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividends</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zXhsgKfhOyzd" title="Expected Dividends">0</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount Rate (Monte-Carlo model only)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zM7q92wv8mMa" title="Discount Rate (Monte-Carlo model only)">12</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z5r91EIdusQa" title="Expected Term (years)">0.56</span> &#8211; <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zesDQI8RTnPg" title="Expected Term (years)">9.88</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p id="xdx_8A9_zgey0t7etDXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise disclosed, the
fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following table sets forth
the Level 3 liability at June 30, 2024, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required,
this liability is classified based on the lowest level of input that is significant to the fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zbGfG4BLPOI2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BA_z44FWU30YTme" style="display: none">Schedule of fair value measurement on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuxz3uOoLx22" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z20nVmD6NU5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5VPw7GjbsG4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z8wJR90B47wi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ContingentConsiderationInAcquisition_d0_zauLxMdQZTY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Contingent consideration in Acquisition</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">20,557,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SettlementsContingentSharesToBeIssued_d0_znw14uWDtjk3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Settlements: contingent shares to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,520,027</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zDIZ8nQTLE5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Fair value adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,727,473</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zn6e3bHWfmch" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent Consideration Liability at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A8_z2d3TaRjobdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714583632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zNsmgqT8NJu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 - <span id="xdx_824_z9IzJrt77ZFd">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Property and equipment consisted of the following at
June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSqHudftYW62" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BB_zu3zrzDbwOw1" style="display: none">Schedule of property and equipment</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Useful Life</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2023</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment and instruments</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zFEWN9XGhgs" title="Useful Life">4</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zCo7vEy4AjXd" title="Useful Life">7</span></span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zxDQdmzWigt4" style="width: 11%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">639,998</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" style="width: 11%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">576,298</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0g8PGI59Hu9" title="Useful Life">10</span></span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzoMogLZBzs9" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224,629</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224,629</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture, fixtures, and equipment</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoX8NBYdyitg" title="Useful Life">4</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaetA179rV2g" title="Useful Life">7</span></span></td>
<td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFJoCWYliyi8" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,834</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,861</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zxdkYuKTIwUf" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,060,461</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20230630_pp0p0" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">973,788</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less accumulated depreciation</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_zBgNg0j2Pjz" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(578,340</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230630_z7O7Yv6Oclv5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(464,799</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Property and Equipment</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zi2dTaTT79C8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">482,121</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">508,989</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Depreciation expense amounted to
$<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20230701__20240630_zEh2v9Hx0Lfk" title="Depreciation expense">113,563</span> and $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220701__20230630_z45hClhsf17d" title="Depreciation expense">107,321</span> for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451816940864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zsPsp0Xq5LKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_82F_zdg85Ykbdnwd">INTANGIBLE ASSETS AND GOODWILL</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024 and 2023, definite-life
intangible assets, net of accumulated amortization, consisted of patents on the Company&#8217;s products and processes of $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zEZlixppQ8Xj" title="Definite-life intangible assets">30,043</span> and
$<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20230630_zb4u9PhxMBA4" title="Definite-life intangible assets">39,676</span>, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense
for the years ended June 30, 2024 and 2023 was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230701__20240630_zxorhqbGDqYe" title="Amortization expense">8,296</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220701__20230630_zNT5FqBGRNJ2" title="Amortization expense">6,175</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024 and 2023, indefinite
life intangible assets consisted of a license agreement classified as In-Process Research and Development (&#8220;IPR&amp;D&#8221;) intangible
assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024 and 2023, definite-life
and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEl8nSFh79zj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BE_zguU80daZ7Uc" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7dyK9Qwbij8" title="Useful life">20</span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z96WPpRGp7ch" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning">290,936</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zDOWP0y1wTqb" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5DYEh1SmK9l" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQYZtKdmDtg2" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPKHgqYxtnv7" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(5,959</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0W2FcF7Dnoj" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending">284,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zBgHrcxmYJtd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(251,260</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJm6WFyLE3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvWdkHKVm7xk" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zZ4WN0DaFGT4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zExdjQBCUmc2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">4,622</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_znoeLMcAMwy5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(254,934</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_zFprgLQPC5Eg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">39,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zVzTCs5Srb6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_zwPRsB9kBbWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zyaOCZWWa8a8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zkvryP9DqIj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(1,337</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zwajfl1cIqXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">30,043</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets and Goodwill</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zlIfeJseg7x5" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zY6xVCLQ3dC3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_za115YJY9XE3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zka54eUJGBF9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(11,640,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zPmZDd8OfU2f" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878</td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zg26Cl5CI21e" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">IPR&amp;D</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLn2yjKUMK58" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">42,611,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zHyBYA6yg9da" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zqJR78VGTXu7" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z3BpTO4IOjd6" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(42,611,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziH1YYGLnT83" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zcxD7Crq1oEd" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets and Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_zO5NFDLW0qm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_zTKCCd6mXxU8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zumaKkhNtit6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zZxhATdqgWRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zOEYGv6nCpli" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878)</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zpDO6SouziCc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Period Change</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Effect of Currency Translation</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 15%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znm0KHNgwwpk" title="Useful life">20</span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIE25F2BtUb" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning">279,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9QsOveXJTA6" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJeKX9RMA3Sj" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">11,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvoPlq3Zap8j" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning">290,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zX09lanWwkO2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(234,989</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zUVrP4CkYt2g" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">(6,175</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zKedzq7HqHDh" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(10,096</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zQiEWYbLuOW5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(251,260</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630_zkLX76Nd92W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">44,268</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630_z5hlQtz3s8R3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">(6,175</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630_z615P4r3zdwj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">1,583</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z4eTFgJ8uw5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">39,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">License Agreement</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zpCS3SiQxZM" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">61,571,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zRWYFzXEmA0l" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">(18,960,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zTbpbsu4nJOa" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zvtfob0kTZ85" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">42,611,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z7qFqW4Pbkw5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z74ldD7a5fB5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zm9JF2saKo32" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zA4l0J03Jvs3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630_zZix9ok7dt45" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">73,211,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20220701__20230630_zWaD10y60apk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">(18,960,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630_zPcDEOjnNtD" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z1QN35w9In11" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AE_zkk9S4xIMC5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Expected future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zXienn3ipfx5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8BB_zShz1BCPmGof" style="display: none">Schedule of expected future amortization expense</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended&#160;June 30,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20240630_zsvcGDIsZ9U9" style="width: 32%; text-align: right" title="2025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,511</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20240630_zSrOJT6GdRVh" style="text-align: right" title="2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,511</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20240630_zqEzxGtJlZMb" style="text-align: right" title="2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,511</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20240630_z079g9uqL5f" style="border-bottom: Black 1pt solid; text-align: right" title="2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,510</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #CCEEFF; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #CCEEFF">Total</span></td><td style="padding-bottom: 2.5pt; color: #CCEEFF; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zfcpDTyWqYdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,043</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During February 2018, the Company
acquired IPR&amp;D related to a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale,
import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of
and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. The IPR&amp;D intangible
asset was classified as an indefinite life asset that was tested annually for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $159,464,039.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Impairment &#8211; <span style="background-color: white">On
March 1, 2024, the Company received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between
Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly owned subsidiary of the Company, dated
February 16, 2018. Due to the termination of the License Agreement, the Company recorded an impairment of $42,611,000 during the year
ended June 30, 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Following the fourth quarter of
each year, management performs its annual test of impairment of intangible assets by performing a assessment and determines if it is more
likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the year ended June 30,
2023, the results of the assessment indicated that the carrying value of the licenses acquired as an IPR&amp;D asset exceeded its fair
value, due to the changes in the projected economic benefits to be realized from these assets. Therefore, an impairment adjustment of
$<span id="xdx_903_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220701__20230630_zLKUqya1CBJ3" title="Impairment adjustment">18,960,000</span> was recorded for the year ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the year ended June 30,
2024, the results of the assessment indicated that the carrying value of the goodwill related to the RENB reporting unit exceeded its
fair value, due to the changes in the projected economic benefits to be realized from this reporting unit. Management concluded the significant
driver for the change in the economic benefits was due to the Company&#8217;s continued inability to raise capital for the further development
of the technologies within this reporting unit. Therefore, an impairment adjustment of $<span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_c20230701__20240630_zXUXxnf6sLS" title="Goodwill impairment adjustment">11,640,000</span> was recorded for the year ended June
30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714162080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zXbrV8Rn2e1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_82D_z27QhDto7etl">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b>Operating
Leases </b>&#8212; <span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20171112__20171113_zmhyhkwFTmj4" title="Lease premises, description">On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the &#8220;Landlord&#8221;) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20180618__20180619_zqJagRDgv5tg" title="Lease premises, description">On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.</span> Renovaro subleased the space as
of June 25, 2022 through April 30, 2023. (See subsection below &#8220;<i>Sublease Agreement</i>&#8221; for details.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company identified and assessed
the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Expected lease term </i></b>&#8212;
The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company&#8217;s leases have a remaining lease term of 38 and 20 months. As of
June 30, 2024, the weighted-average remaining term is <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zqLQfwhuDwl4" title="Weighted-average remaining term">2.54</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Incremental borrowing rate</i></b>
&#8212; The Company&#8217;s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of June 30, 2024, the weighted-average
discount rate is <span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zRNk7Yzwz3u8" title="Weighted-average discount rate">5.14</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Lease and non-lease components</i></b>
&#8212; In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company&#8217;s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Below are the lease commitments for the next 5 years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHnI1BKjk2W9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left"><span id="xdx_8B0_zI0dHC8GMQWj" style="display: none">Schedule of lease commitments</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ending June 30</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Expense</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; width: 55%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20240630_z91Jc5YnhIbl" style="width: 32%; text-align: right" title="2025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">554,453</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20240630_zsmiQQUwerna" style="text-align: right" title="2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">457,876</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20240630_zlzQZjSgi9h7" style="text-align: right" title="2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">334,788</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_c20240630_zfPOPFOpA5L8" style="text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79,830</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20240630_ziLYInVw9imf" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(91,005</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20240630_zt7k5GblH3Z4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,335,942</span></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p id="xdx_8A1_zXhrEROCZzyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Sublease Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_902_eus-gaap--LesseeFinanceSubleaseResidualValueGuaranteeDescription_c20220619__20220620_zJcESeUYkgOg" title="Sublease agreement description">On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the &#8220;Subtenant&#8221;), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In accordance with ASC Topic 842,
the Company treated the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease.
The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement
date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease was classified as an operating lease,
as it did not meet the criteria of a sales-type or direct financing lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
April 18, 2023, the Company entered into a sublease termination agreement with the Subtenant, whereby the Subtenant and the Company agreed
to terminate the sublease effective as of April 30, 2023. The Subtenant agreed to pay the Company $<span id="xdx_90C_eus-gaap--PaymentsForLeasingCosts_c20230417__20230418_zEmfToCM6E0j" title="Lease payment">139,460</span>&#160;along with the security
deposit of $<span id="xdx_90C_eus-gaap--SecurityDeposit_iI_c20230418_ziBoBeUGwQRi" title="Security deposit">35,540</span>&#160;for a total termination fee of $<span id="xdx_902_eus-gaap--LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_iI_c20230418_z9bPmX0t24o5" title="Termination fee">175,000</span>, to permit early termination of the sublease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recognized operating
income from the sublease on a straight-line basis in its statements of operations over the sublease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the year ended June 30,
2024 and 2023, the net operating lease expenses were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zClWMCshP0ll" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES  (Details 1)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zVDyewUsV1i4" style="display: none">Schedule of net operating lease expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20230701__20240630_z7Z8JeCBbNge" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220701__20230630_zaAsbDrXA7wa" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr id="xdx_404_eus-gaap--OperatingLeaseExpense_z8QC4eOSRgKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Lease Expense</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">383,549</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">322,447</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--SubleaseIncome_iN_di0_zjjQBthl57J7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-lease Income</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(352,700</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_409_ecustom--OperatingLeaseRentExpenses_zU4fEdtwtDM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Net Lease Expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">383,549</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,253</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


<p id="xdx_8A6_zfFtkQQ3ZWKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lease expense charged&#160;to general
and administrative expenses for the years ended June 30, 2024 and 2023, amounted to $<span id="xdx_902_eus-gaap--LeaseCost_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqtDwp9XG5k7" title="Lease expense">383,549</span> and $<span id="xdx_904_eus-gaap--LeaseCost_c20220701__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgHKCs3mzAF2" title="Lease expense">322,447</span>, respectively. During the years
ended June 30, 2024 and 2023, the Company paid $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20230701__20240630_zI7A5sLbbQm2" title="Operating lease payments">380,983</span>&#160;and $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20220701__20230630_zWYmGiyAW043" title="Operating lease payments">439,519</span> under operating leases, respectively. The difference between
the operating lease expense for the year ended June 30, 2023 in the amount of $<span id="xdx_905_ecustom--OperatingLeaseExpenses_c20220701__20230630_zs7DsWAxctke" title="Operating lease expense">322,447</span> and the cash paid of $<span id="xdx_900_ecustom--CashPaidForTheTerminationOfLease_iI_c20230630_zDyL8t7GYUI7" title="Cash payments">439,519</span>, is primarily made
up of the release of an accrual of $<span id="xdx_908_ecustom--AccrualPaymentsRelatedToTerminationOfLease_c20220701__20230630_znv95olzTyS8" title="Accrual payments related to the termination of lease">77,242</span> related to the termination of the Plaza Medical Office Building, LLC lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451713908608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_ztOurOM8R2ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; <span id="xdx_82E_zWJtPRBWOp3b">DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>March 2024 Note &#8212;</i></b>
On March 14, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note in the amount
of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_znEreOjiWg1g" title="Principal amount">500,000</span> (the &#8220;March 2024 Note&#8221;). The March 2024 Note had an interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zRrjeum5ZSuj" title="Note interest rate">10</span>% per annum and was due to mature on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20240313__20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_z38E3Pzd24xf" title="Debt maturity period">March
15, 2025</span>. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the issue date prior to the maturity of the March 2024 Note. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The March 2024 Note was convertible at the option of the holder after a qualified offering.
If no qualified offering occurs prior to the maturity date, the March 2024 Note was to be repaid in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company sold
<span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zbZJpgBjjY93" title="Sale of stock, shares">344,966</span> of the Company&#8217;s units, each such unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zIThcbEni5Zc" title="Common stock, par value">0.0001</span> par value
per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock (a &#8220;Unit&#8221;), to the holder
of the March 2024 Note in consideration for the total $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_z9AAEdhuCaWh" title="Sale of stock, consideration">512,361</span> in principal amount and interest accrued under the March 2024 Note. The
warrants are exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zP9r6wIEZMKg" title="Exercise price">1.4726</span> per share, payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In the year ended June 30, 2024,
the Company recorded interest expense of $<span id="xdx_908_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zWPXjcMYN8We" title="Accrued interest expense">12,361
</span>related to the March 2024 Note. The March 2024 Note balance at June 30, 2024 was zero <b style="display: none"><span id="xdx_905_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zcfvv3UMhxwg" title="Interest expense related to note balance">0</span></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><i>The 2024 Notes &#8212;</i></b>
On January 11, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note (the &#8220;January
2024 Note I&#8221;) in the amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zG7dM5YCtCyb" title="Principal amount">460,000</span>. The January 2024 Note I had an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zcWtBEbhmEl7" title="Note interest rate">12</span>% per annum and was due to mature on
<span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20240110__20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zlJdzbZmYQK3" title="Debt maturity period">January 11, 2025</span>. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year
following the issue date prior to the maturity of the notes. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The January 2024 Note I was convertible either at the option of the holder or automatically
upon maturity into shares of the Company&#8217;s Common Stock at the conversion price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z15aYoyYosHd" title="Conversion price per share">3.38</span>. On January 12, 2024, the Company entered
into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zUekcdH8TOb8" title="Principal amount">125,000</span> (the
&#8220;January 2024 Note II&#8221;, and collectively with the January 2024 Note I, the &#8220;January 2024 Notes&#8221;). The Company
received a total of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zlVS57Qfh3n5" title="Gross proceeds">125,000</span> in gross proceeds.&#160;The January 2024 Note II bears an interest rate of <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zILBVqcMJW07" title="Bear interest percentage">12</span>% per annum and shall mature
on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRwwKnRyZ3Xe" title="Debt maturity period">December 29, 2024</span>. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each
year following the issue date prior to the maturity of the January 2024 Note II. The January 2024 Note II is convertible either at the
option of the holder or automatically upon maturity into shares of the Company&#8217;s Common Stock at the Note Conversion Price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zsPSPhg9COkl" title="Conversion price">3.38</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company sold
<span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDdKEEkV0yGg" title="Sale of stock, shares">325,508</span> of the Company&#8217;s Units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zNsTgxBIiRI6" title="Common stock, par value">0.0001</span> par value
per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, to the holder of the January 2024
Note I in consideration for the total $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zTll5SqOjwr7" title="Sale of stock, consideration">483,460</span> in principal amount and interest accrued under the January 2024 Note I. The warrants are
exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zkGoAObVqdrl" title="Exercise price">1.4726</span> per share, payable in cash. The January 2024
Notes principal balance at June 30, 2024, is $<span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zqDL8c4094tg" title="Principal outstanding balance">125,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>December 2023 Notes &#8212;
</i></b>Between December 1, 2023, and December 29, 2023, the Company entered into Subscription Agreements with two investors to purchase
Convertible Promissory Notes for an aggregate principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zBDrc6MPnTw4" title="Principal amount">560,000</span> (the &#8220;December Notes&#8221;). The Company received a
total of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zPlTycp5Xdya" title="Gross proceeds">560,000</span> in gross proceeds, consisting of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement1Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zqhikarnyqi7" title="Gross proceeds">440,000</span> and $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement2Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zYHut2UtMQr9" title="Gross proceeds">100,000</span> from the private placement prior to the end of the quarter ending
December 31, 2023, and $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20240130__20240131__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement3Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zgAUZi71WEf9" title="Gross proceeds">20,000</span> received in January 2024.&#160;The December Notes bear an interest rate of <span id="xdx_902_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z3xnT4EyCOZh" title="Bear interest percentage">12</span>% per annum and shall mature
one year after their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December Notes.
Notwithstanding the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis.
The December Notes are convertible into shares of the Company&#8217;s Common Stock in whole or in part at any time and from time to time,
after the original issue date and prior to the Maturity Date, at a conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zJCCP7ZLU7bi" title="Conversion price">3.38</span> per share. The December Notes will be accounted
for under ASC 470-20.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, in a private
placement the Company sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zncBlcuFNyr9" title="Sale of stock, shares">317,715</span> Units to an investor who surrendered and terminated $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zVxlDSbpUNb1" title="Principal amount">440,000</span> in aggregate principal amount and $<span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z7DOdIZxFOf2" title="Interest accrued">28,453</span>
of interest accrued on the December Notes and paid in cash an aggregate amount of $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zdTdL0VUcoe6" title="Sale of stock, consideration">66,000</span> to the Company in consideration for the Units,
each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zhGaOZoP782d" title="Common stock, par value">0.0001</span> par value per share and (ii) one common stock
purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are exercisable for five years from the date of issuance
and have an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zBTzXUBEhmNf" title="Exercise price">1.4726</span> per share, payable in cash. The December Notes principal balance at June 30, 2024, is $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zYuY6PBuEtt1" title="Principal outstanding balance">120,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In the year ended June 30, 2024,
the Company has recorded interest expense of $<span id="xdx_909_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRCjcugYiKgh" title="Accrued interest expense"><span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zH4XMIkRRvog" title="Accrued interest expense">67,013</span></span> related to the January 2024 Notes and December 2023 Notes. The January 2024 Notes
and December 2023 Notes balance at June 30, 2024 was $<span id="xdx_902_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630_zqTv4FS1LN9a" title="Interest expense related to note balance">245,000</span> of which $<span id="xdx_900_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zT5acpvAkmWa" title="Interest expense related to note balance">120,000</span> is related to the December 2023 Notes and $<span id="xdx_906_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRV4rHnAPg5c" title="Interest expense related to note balance">125,000</span> is
related to the January 2024 Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The 2023 Notes &#8212; </i></b>Between
September 5, 2023, and October 5, 2023, the Company entered into Subscription Agreements with five investors to purchase <span id="xdx_902_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zGXhzfXeVYOd" title="Original issue discount percentage">5</span>% Original Issue
Discount Convertible Promissory Notes (the &#8220;2023 Notes&#8221;) for an aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zWbt2orNN3Cl" title="Principal amount">2,105,263</span>. The Company received
a total of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zKjJfGCthUa" title="Gross proceeds">2,000,000</span> in gross proceeds from the private placement, after taking into account the <span id="xdx_90F_ecustom--DebtInstrumentOriginalIssueDiscount_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zFaYBLSPpv13" title="Original issue discount percentage">5</span>% original issue discount.&#160;The
discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zS3sUwPlRzFf" title="Discount accreted">105,263</span> was to be accreted over the life of the 2023 Notes. The 2023 Notes had an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_z7JpsOqsJWq1" title="Note interest rate">12</span>% per annum and were
due to mature on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zjlOUtzeLBjg" title="Maturity date">September 5, 2024</span> (the &#8220;Maturity Date&#8221;). The Company was required to pay interest quarterly, in arrears,
in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest could accrue on the notes on a quarterly basis. The 2023 Notes were convertible
into shares of the Company&#8217;s Common Stock upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The 2023 Notes were subject to
mandatory conversion (&#8220;Mandatory Conversion&#8221;) in the event the Company closed an offering of its Common Stock and received
gross proceeds of not less than $<span id="xdx_90B_ecustom--CommonStockAndReceivedGrossProceeds_pp0p0_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zUXdxKUqGpLc" title="Common stock and received gross proceeds">10,000,000</span> (a &#8220;Qualified Offering&#8221;). The conversion price per share of Common Stock in the
case of a Mandatory Conversion was to be <span id="xdx_906_ecustom--OfferingPricePerSharePercentage_dp_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zfm3KMyQS5Ei" title="Offering price per share percentage">95</span>% of the offering price per share in the Qualified Offering, subject to a floor of $<span id="xdx_909_ecustom--DebtInstrumentsFloorPricePerShare_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zqDEAEufuJcg" title="Floor price per share">4.50</span> per
share.&#160;In addition, if no Qualified Offering occurred prior to the Maturity Date, the 2023 Notes were to automatically convert into
shares of Common Stock on the Maturity Date at a conversion price per share equal to the closing sale price of the Common Stock on the
Maturity Date, subject to a floor of $<span id="xdx_900_ecustom--DebtInstrumentsFloorPricePerShare_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zXwaXT00AhN2" title="Floor price per share">4.50</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 11, 2024, the Company
entered into an amendment with one of the investors of the 2023 Notes whereas the conversion terms were amended to provide for optional
conversion at a conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240111__us-gaap--AwardDateAxis__custom--Note2023Member_znVOFdEFVWtb" title="Conversion price">3.38</span> per share. All other terms of the Promissory Note remained the same. The Company treated this
as a modification for accounting purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 14, 2024, the Company
sold <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_z7usAFPfMSub">1,546,449 </span>Units
to the holders of the 2023 Notes who surrendered and terminated $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zuxAOAQ9hmke">2,293,825 </span>in
aggregate principal amount and interest accrued thereon of the 2023 Notes and paid in cash an aggregate amount of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zY6p69xrGXMc">443,575 </span>(of
which $<span id="xdx_90F_eus-gaap--OtherNotesPayable_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zTQWpU6C4gR7">318,063 </span>was
applied against the Company&#8217;s Promissory Notes), to the Company in consideration for the Units, each such Unit consisting of
(i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_z7FYUQoOXDFj">0.0001 </span>par
value per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are
exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--Note2023Member__srt--RangeAxis__srt--MinimumMember_zHw7RDMKS5kb">1.4726</span>
and $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--Note2023Member__srt--RangeAxis__srt--MaximumMember_zBnU4maHJYN3">1.4765 </span>per
share, payable in cash. The 2023 Notes principal balance at June 30, 2024, is zero <span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240614__us-gaap--AwardDateAxis__custom--Note2023Member_zadYXn9LQs5" style="display: none" title="Principal outstanding balance">0</span><b></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;For the year ended
June 30, 2024, discount amortization of $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zT2Kwalmf8f5" title="Debt amortization discount">78,567
</span>was charged to interest expense and $<span id="xdx_90A_eus-gaap--InterestIncomeExpenseAfterProvisionForLoanLoss_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zmyiWjDhFsjh" title="Discount amortization to other income and expense">26,696
</span>of discount amortization was charged to other income and expense due to the early termination of the notes, respectively. In the
year ended June 30, 2024, the Company recorded interest expense of $<span id="xdx_90C_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zOW3uHhkvnbd" title="Accrued interest expense">189,614</span> related to the 2023 Notes. The 2023 Notes balance, net of
discount at June 30, 2024 is zero <b style="display: none"><span id="xdx_905_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zvOZs0QDeTg7" title="Interest expense related to note balance">0</span></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The Convertible Notes &#8212;
</i></b>On February 6, 2020, the Company issued two Convertible Notes (the &#8220;Convertible Notes&#8221;) to Paseco ApS (the &#8220;Holder&#8221;),
a Danish limited company and an existing stockholder of the Company, each with a face value amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200206__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_zNL4Iqq8QOY5" title="Principal amount">600,000</span>, convertible into shares
of Common Stock. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023. Interest on the Convertible
Notes commenced accruing on the date of issuance at six percent (<span id="xdx_901_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200205__20200206__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_z88mGEiBFj5b" title="Interest rate">6</span>%) per annum, computed on the basis of twelve 30-day months, and was
compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as
of such compound date. The interest was payable in cash on a semi-annual basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">The
conversion price was equal to $12.00&#160;per share of Common Stock. The Holder did not exercise its conversion feature that expired on
February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded
conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily
convertible into cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Effective December 30, 2022 (the
&#8220;Effective Date&#8221;), the Company amended and restated the Convertible Notes (the &#8220;Amended and Restated Secured Notes&#8221;).
Pursuant to the Amended and Restated Secured Notes, the due date was extended to <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zbSaZAfpZdoa" title="Maturity date">February 28, 2024</span>. The Amended and Restated Secured Notes
were convertible by the Holder if the Company consummated a public offering or private placement of Common Stock or securities convertible
into Common Stock. The conversion price was to be the price being paid by the investors in such offering. The interest rate was increased
to twelve percent (<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zW3l8gv54ipd" title="Interest rate">12</span>%) per annum, which was prepaid by the Company in full on the date of amendment through the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_ziVjgvyAdWj" title="Issuance of shares">198,439</span> shares
of the Company&#8217;s Common Stock: <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zDHmxxKeGdj4" title="Shares issued for accrued interest">29,419</span> shares for accrued interest up to the Effective Date and <span id="xdx_901_ecustom--PrepaymentShares_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zLFtIxfT4c6f" title="Prepayment shares">169,020</span> shares related to the prepayment
of interest through the extension date of the Amended and Restated Secured Notes using the Common Stock closing market price on the Effective
Date, of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zeskKTPMIVH7" title="Stock price">1.03</span>. The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the
&#8220;Security Agreement&#8221;). The Company evaluated the Amended and Restated Secured Notes and conversion feature to determine the
appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480 - Distinguishing Liabilities from Equity,
the Company determined that the Amended and Restated Secured Notes embody an obligation that may require the Company to settle with the
issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a fixed monetary amount
of $<span id="xdx_902_eus-gaap--ContractualObligation_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_znbRdp9YqTfa" title="Obligation value">1,200,000</span> known at inception. Accordingly, the Company recorded the Amended and Restated Secured Notes as share settled debt. The
total value of the shares issued was $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zb7Iirudq5pj" title="Number of shares issued, value">204,392</span> which included $<span id="xdx_90F_eus-gaap--PrepaidInterest_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zVa32eaFbIc" title="Prepaid interest">174,090</span> of prepaid interest and $<span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zP4wggekfhRd" title="Accrued interest amount">30,302</span> for accrued interest as of December
30, 2022. On June 26, 2023, <span style="background-color: white">the Holder notified the Company that it wished to elect to exercise
its conversion right triggered by a private placement. Therefore, all outstanding $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20230625__20230626__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zydmnuHiR6ek" title="Stock issued for debt conversion">1,200,000</span> Amended and Restated Secured Notes were converted
into 2,264,150 shares of Common Stock and warrants to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230625__20230626__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zNo35IDjqls4" title="Stock issued for debt conversion, shares">1,132,075</span> shares of Common Stock. There were no Amended and Restated Secured
Notes outstanding after the foregoing conversion. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Notes Payable </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Bridge Loans &#8212; </i></b>Between
March 26, 2024 and June 4, 2024 the Company issued Paseco ApS promissory notes (the &#8220;Notes&#8221;) in the aggregate principal and
interest accrued amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20240326__20240604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zjGjqVJdo5Fb" title="Principal and interest accrued amount">2,098,252</span>. The Notes had an interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zceVXPNJudY7" title="Note interest rate">10</span>% per annum and were to mature between May 1, 2024, and August
1, 2024. The Notes were accounted for under ASC 470-20, and all proceeds received from the issuance was recognized as a liability on the
balance sheet. On June 14, 2024, the Company sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_znI3FhikuxQc" title="Sale of stock, shares">1,424,862</span> Units at a price per Unit equal to $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zs7p5aUctQqi" title="Sale of stock, price per share">1.4726</span> to settle the bridge loan aggregate
amount of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_z30xhfD2iRh2" title="Sale of stock, value">2,098,252</span>. As of June 30, 2024 the Notes balance is zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 5, 2024, the
Company entered into an agreement with RS Bio ApS, a Danish entity controlled by the Company&#8217;s Chairman, Rene Sindlev
(&#8220;RS Bio&#8221;) to issue a <span id="xdx_901_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zJpZ1yRAt5ji" title="Original issue discount promissory note percentage">5</span>%
Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zbd3k9k9P9vc" title="Principal amount">105,263</span>.
The Company received $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfDebt_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zvREn5B0qmG1" title="Gross proceeds">100,000</span>
in gross proceeds after taking into account the <span id="xdx_90E_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zj82Hp9EAvfl" title="Gross proceeds original issue discount rate">5</span>%
original issue discount. The note bears an interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zchMHdsRwFN3" title="Interest rate">12</span>%
per annum and matured on <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zMcqeKmWlsJa" title="Debt maturity period">March
1, 2024</span> and was extended to December 31, 2024. The obligations under this note are secured by the Amended
and Restated Security Agreement. The Company is required to pay interest on the maturity date. The note is accounted for under ASC
470-20, and all proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. For the
year ended June 30, 2024, discount amortization of $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zXmxZ1pp5oea" title="Amortization of debt discount">5,263</span>
was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_90E_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zDhup9fSBzmi" title="Accrued interest expense">6,316</span>
of interest expense that is included in accrued expenses on the balance sheet. The note balance, net of discount at June 30, 2024
was $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zQD1XR0yIaga" title="Net of debt discount">105,263</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a <span id="xdx_903_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zNgqXKkLY9t2" title="Original issue discount promissory note percentage">5</span>% Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zprJ9yNX5ZI9" title="Principal amount">526,315</span>
(the &#8220;January 2024 Note&#8221;). The Company received a total of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zlYx472HH0Tc" title="Gross proceeds">500,000</span> in gross proceeds after taking into account the <span id="xdx_90C_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zOaT0QXUFg2k" title="Gross proceeds original issue discount rate">5</span>% original
issue discount.&#160;The January 2024 Note bears an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zU2WDNKwwWnl" title="Interest rate">12</span>% per annum and matured on <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_znbqkgXK8jA4" title="Debt maturity period">March 1, 2024</span> and was extended to December 31, 2024. The Company
is required to pay interest on the maturity date. The January 2024 Note will be accounted for under ASC 470-20, and all proceeds received
from the issuance will be recognized as a liability on the balance sheet net of discount. For the year ended June 30, 2024, discount amortization
of $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zMOD7WyFuTxh" title="Amortization of debt discount">26,315</span> was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_905_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zXkp7b5ojcgi" title="Accrued interest expense">31,579</span> of interest expense that is included in accrued
expenses on the balance sheet. The Note balance, net of discount at June 30, 2024 was $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zAwEZfPawyW7" title="Net of debt discount">526,315</span>. In connection with the entry into the
January 2024 Note, the Company and Paseco ApS agreed to amend and restate a Security Agreement to add the Company&#8217;s obligations
under the November 2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 22, 2023, Renovaro
Cube entered into a loan agreement where the holder agreed to loan the Company up to &#163;500,000 (approximately $624,000 USD). The
note had a repayment date occurring the first business day after the first anniversary of the draw down of the loan. The first draw down
of &#163;250,000 occurred on November 27, 2023, and the second draw down of &#163;250,000 occurred on December 13, 2023. The Company
paid interest on the loan at the rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20231121__20231122__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z21yqa3vCc02" title="Interest rate">10</span>%
per annum. Interest was accrued quarterly in arrears on the last business day of March, June, September, and December and was payable
on the repayment date. On June 14, 2024 the Company sold <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdPDkHfWH8T1">454,708
</span>Units to the holder and terminated $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zOtixoiodQLg">665,387
</span>in aggregate principal amount and accrued interest and received in cash an aggregate amount of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zONqHSUkgIRh">100,400
</span>in consideration for the Units which was applied against the loan. For the year ended June 30, 2024, the Company recorded $<span id="xdx_903_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember_zRKoThO9EJL6" title="Accrued interest expense">36,388
</span>of interest expense related to this loan. The total amount of the loan at June 30, 2024, is zero <b style="display: none"><span id="xdx_900_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember_zYQD5pRu7a3i" title="Interest expense related to note balance">0</span></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 3, 2023, the
Company entered into an agreement with RS Bio to issue a <span id="xdx_908_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zZWayyJt9D2b">5</span>%
Original Issue Discount Promissory Note for the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zkFpdUV0hIua">1,000,000</span>
(the &#8220;November 2023 Note&#8221;). The Company received a total of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zaJWGPOfuhNj">950,000</span>
in gross proceeds after taking into account the <span id="xdx_901_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zect0el2ZFYb">5</span>%
original issue discount.&#160;The discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zqKCsOO5C8Vl">50,000</span>
will be accreted over the life of the Note. The November 2023 Note bears an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKhLsNSuUiqi">12</span>%
per annum and was due to mature on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zCRB9dwseT18">January
1, 2024</span> (the &#8220;Maturity Date&#8221;). On January 1, 2024, the Company entered into an amendment with RS
Bio for the November 2023 Note to extend the maturity date to <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxF6zffsgI4h">March
1, 2024</span> and  was extended to December 31, 2024. The Company is required to pay interest on the maturity
date. The November 2023 Note will be accounted for under ASC 470-20, and all proceeds received from the issuance will be recognized
as a liability on the balance sheet net of discount. On February 16, 2024, the Company received notice from the holder to exercise <span id="xdx_903_ecustom--ExerciseWarrants_iI_c20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_z4u4gDi1kBxl" title="Number of warrants exercised">471,699</span>
warrants outstanding at $<span id="xdx_903_ecustom--WarrantsOutstandingPerShare_c20240214__20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_zSuNlCLbsBHh" title="Warrant exercise price per share">0.53</span>
per share and apply $<span id="xdx_906_ecustom--ExerciseWarrantsAmount_iI_c20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_z6yMtNpb0TM9" title="Exercise warrants amount">250,000</span>
of the note balance to the exercise price of the warrants. For the year ended June 30, 2024, discount amortization of $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_z8Tg8ixJkAu9">50,000</span>
was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_904_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_zet7t18EnN7i">69,083</span>
of interest expense that is included in accrued expenses on the balance sheet. The November 2023 Note balance, net of discount at
June 30, 2024 is $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_zLPuGOUM4z48">750,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zoGUhnOaSSY5" title="Principal amount">5,000,000</span> (the &#8220;Promissory
Note&#8221;) to the Holder. The principal amount of the Promissory Note was originally payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zFZ2qNerVYw7" title="Maturity date">November 30, 2021</span> (the &#8220;Maturity
Date&#8221;). The Promissory Note bore interest at a fixed rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zGZfb2eWWoi6" title="Interest rate">6</span>% per annum, computed based on the number of days between the Issuance
Date and the Maturity Date, and the interest was prepaid by the Company in full on the Issuance Date through the issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zdaKfHFOG1yk" title="Stock issued for debt conversion, shares">188,485</span> shares
of the Company&#8217;s Common Stock based on the closing market price on that date for a total value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3VBFVpr0KZ9" title="Stock issued for debt conversion">501,370</span>. The Company evaluated
the Promissory Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds
received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount
of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zOA7lNduxW6a" title="Issuance of common stock">493,192</span>, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest
method. The discount of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zhMxnugQa1o" title="Issuance of common stock">493,192</span> will be accreted over the life of the Promissory Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 11, 2021, the Company
entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory
Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of <span id="xdx_90E_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3MeFF689GN8" title="Interest at the fixed rate">6</span>% per annum, which was
prepaid by the Company in full on the date of the amendment through the issuance of <span id="xdx_90F_eus-gaap--SharesIssued_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_pdd" title="Number of shares issued">74,054</span> shares of the Company&#8217;s Common Stock
based on the closing market price on that date for a total value of $<span id="xdx_903_ecustom--MarketPrice_iI_pp0p0_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3Q5ZMzidku7" title="Market price">298,178</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On May 17, 2022, the Company entered
into a second amendment to the Promissory Note that extended the Maturity Date to <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220516__20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zoMCUly4hPGh" title="Maturity date">November 30, 2023</span> and increased the interest rate from
<span id="xdx_903_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20220517__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zKpwnd8unzN6" title="Interest at the fixed rate">6</span>% to <span id="xdx_905_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20220517__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zalunitf0fd4" title="Interest at the fixed rate">12</span>% per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year
of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022
until May 30, 2023 on the date of the amendment through the issuance of <span id="xdx_903_eus-gaap--SharesIssued_iI_c20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zh8eL3iAPes8" title="Number of shares issued">47,115</span> shares of the Company&#8217;s Common Stock based on the
closing market price on that date for a total value of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220516__20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zyR6sGR2Vsv3" title="Issuance of common stock">299,178</span>. All other accrued interest payable from May 30, 2023 to the Maturity
Date was required to be paid by the Company on May 30, 2023, at the option of the Holder in either (i) cash or (ii) shares of the Company&#8217;s
Common Stock, valued at the closing sale price of the Common Stock on the Nasdaq Capital Market on May 30, 2023. The Holder elected the
interest be paid in cash (the &#8220;Interest Payment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Effective December 30, 2022, the
Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company&#8217;s obligations under
the Promissory Note were secured by a Security Agreement. To secure the Company&#8217;s obligations under each of the Amended and Restated
Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted
a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of the Holder. Upon an Event of Default (as defined
in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession
of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 12, 2023, the Holder notified
the Company that it wanted to apply the Interest Payment due to it towards the Company&#8217;s next private placement. Therefore, on June
26, 2023, in conjunction with the Company&#8217;s private placement, the Company issued (i) <span id="xdx_908_eus-gaap--SharesIssued_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zD42HVxZjg9" title="Number of shares issued">567,588</span> shares of its Common Stock, par value
$<span id="xdx_909_eus-gaap--SharePrice_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zM8sAl8ipnXi" title="Share price">0.0001</span> per share and (ii) warrants to purchase <span id="xdx_90E_ecustom--WarrantsPurchased_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGcva7fgxp6l" title="Warrants purchased">283,794</span> shares of Common Stock at a purchase price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYXqnayQkbx5" title="Warrant purchase price">0.53</span> per share and applied the
Interest Payment of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHFfa8ACjsC5" title="Proceeds from private placement">300,822</span> it owed to the Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 31, 2023, the Company and
the Holder agreed to amend the Promissory Note (the &#8220;Fourth Amendment&#8221;) to provide the Holder with limited conversion rights
in connection with the Company&#8217;s next private placement. Per the terms of the Fourth Amendment, the Holder could elect to convert
$2 million of the outstanding principal balance of the Promissory Note into the Units being offered in a private placement at the price
per Unit being paid by the investors in the private placement (the &#8220;Conversion Right&#8221;). On August 1, 2023, the Holder notified
the Company of its election to exercise the Conversion Right. As a result, $2 million of the outstanding principal balance of the Promissory
Note was converted into 280,505 Units at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible Preferred
Stock of the Company and (ii) Warrants to purchase an aggregate of 1,402,525 shares of Common Stock with an exercise price of $0.65 per
share. The Series A Convertible Preferred Stock acquired by the Holder was initially convertible into 2,805,050 shares of Common Stock.
A $3 million principal balance remained outstanding under the Promissory Note after the foregoing conversion. The Company concluded that
in accordance with ASC 470-20-40-4, the difference between the fair value of the Preferred Shares and warrants and the carrying value
of the portion of the Note being converted should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded
in Other Income/Loss in the Statement of Operations. On November 30, 2023, the Company and the Holder agreed to amend the Promissory Note
(the &#8220;Fifth Amendment&#8221;) such that the Company and the Holder extended the maturity of the original Promissory Note until February
29, 2024. In addition, all interest payable from November 30, 2023 to the Maturity Date was payable and is currently payable by the Company
as of November 30, 2023. On February 16, 2024, the Company received notice from the Holder to exercise 2,953,700 warrants outstanding
ranging from $0.53 to $0.65 per share and apply $1,750,000 of the note balance to the exercise price of the warrants. On February 29,
2024, the Company and the Holder agreed to amend the Promissory Note (the &#8220;Sixth Amendment&#8221;) to where the Company and the
Holder extended the maturity of the original Promissory Note until May 1, 2024. On May 1, 2024, the Company and the Holder agreed to amend
the Promissory Note (the &#8220;Seventh Amendment&#8221;) to extend the maturity of the original Promissory Note until August 1, 2024.
On June 14, 2024 the Holder requested the Company repay $<span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zp1Auc8DNYYd" title="Repayment on promissory note">418,503</span> of the Promissory Note. The Company applied $<span id="xdx_904_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zdjWj96bwTyb" title="Repayment on promissory note">100,440</span> and $<span id="xdx_90A_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreements1Member_zLwQk7yNLPef" title="Repayment on promissory note">318,063</span> owed
to the Company pursuant to certain Subscription Agreements. As such, payment of the 2020 Note Repayment decreased the principal amount
by $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--LongtermDebtTypeAxis__custom--Note2020Member_zCkuYbPTKEge" title="Principal amount">418,503</span>. For the year ended June 30, 2024 and 2023, discount amortization of $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zs9XfinTrwJh" title="Amortization of debt discount">393,763</span> and $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20220701__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z9IObNqog49d" title="Amortization of debt discount">348,621</span> was charged to interest expense.
The Promissory Note balance, net of discount at June 30, 2024 is $<span id="xdx_907_ecustom--PromissoryNoteBalanceNetOfDiscount_iI_c20240630__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zsnCy1CMFHWh" title="Promissory note balance, net of discount">824,418</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Finance Agreement </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 30, 2023, the Company
entered into a premium finance agreement (the &#8220;Agreement&#8221;) related to insurance,&#160;<span style="background-color: white">which
resulted in the recognition of a liability and prepaid expense with a principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20231130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z2w0HAneaCRd" title="Principal amount">906,834</span>&#160;at&#160;<span id="xdx_903_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20231130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zsqjdQeqoCe7" title="Rate of interest">7.90</span>% interest per annum,
which is reflected on the consolidated balance sheet under &#8220;other current liabilities&#8221; and &#8220;prepaid assets and other
assets&#8221;, respectively. The repayment of the Agreement will be made in nine equal monthly installments of $<span id="xdx_90A_ecustom--MonthlyInstallments_pp0p0_c20231129__20231130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zYRXt6AFLEC6" title="Monthly instalments amount">77,127</span>&#160;after a down
payment of $<span id="xdx_907_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20231129__20231130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zDtbJNOwXWl4" title="Down payment amount">235,000</span>.&#160;For the years ended June 30, 2024 and 2023 the Company made payments of $<span id="xdx_905_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zOUuyx8t33U1" title="Down payment amount">870,073</span>&#160;and $<span id="xdx_906_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20220701__20230630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zdUheJLEdgy6" title="Down payment amount">1,121,767</span>, respectively.
</span>The remaining balance at June 30, 2024 is $<span id="xdx_90A_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20240630_zzaO2CeeXcN8" title="Other current liabilities">231,381</span>; the amount is reflected in other current liabilities. <span style="background-color: white">For
the years ended June 30, 2024 and 2023 the Company recorded total interest expense in the amount of $<span id="xdx_905_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z2ZpR51JW4Og" title="Accrued interest expense">20,128</span> and $</span><span id="xdx_908_eus-gaap--InterestAndDebtExpense_c20220701__20230630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zitl49jOc7R" title="Accrued interest expense">21,180</span><span style="background-color: white">&#160;related
to the Agreement. This amount is reflected in other income and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Total
interest expense recorded for the years ended June 30, 2024 and 2023, was $<span id="xdx_901_eus-gaap--InterestExpenseNonoperating_c20230701__20240630_zGSB71TNikb9" title="Total interest expense">1,011,322</span> and $<span id="xdx_908_eus-gaap--InterestExpenseNonoperating_c20220701__20230630_zLTSFcUX6DOk" title="Total interest expense">580,344</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715483168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zseQf7biGuTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_821_zwu0sdUG06Ck">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company accounts for income
taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset
or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and
any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax
assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other future
events, the effects of which cannot be determined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024 and 2023, the Company had net operating loss carryforwards
of approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zjVGt9m2hH22" title="Operating loss carryforwards">489,177,759</span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20230630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z6H9YnsH3ED1" title="Operating loss carryforwards">476,965,239</span>, respectively, giving rise to deferred tax assets of $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z2dZIMoIak0j" title="Deferred tax assets">144,191,530</span> and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20230630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zm7eh49aVwMl" title="Deferred tax assets">140,547,314</span>, respectively.
The net operating loss carryforwards generated prior to January 1, 2018 expire over various dates from 2031 to 2038. All subsequent net
operating loss carryforwards are indefinite.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company files Danish and U.S.
income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2020 for the Danish tax returns
and 2021 for the U.S. tax returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The temporary differences, tax
credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ztWcSMWdxjSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20240630_zrtimKmuCoh7" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_493_20230630_zsiS1GUd4u15" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
<tr id="xdx_40C_ecustom--DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_iI_pp0p0_maDTALNzwuT_zy85kfWMavXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of fixed assets</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">8,258</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">8,258</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_zHkoz6FQxJG3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of patents</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">8,415</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">8,415</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_zyKcZ9CDZlGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock/options compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">6,672,252</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3,885,996</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_zZQ7YsxC6dyd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">188,422</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">152,059</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_zhXX7JcqYuFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">144,191,530</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">140,547,314</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPBUAL6t8tS3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">16,188,497&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zqRgsu6xVEva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,410,678&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zFEx1Nug8bV7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in tax rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_zsOa3FBgqbL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(168,668,052</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(144,602,042</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_d0_mtDTALNzwuT_zXlzkLjANGZf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Deferred Tax Assets (Liabilities)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8A1_z5KNx5UUL8jb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In accordance with prevailing accounting
guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to
recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine
whether the tax position meets the more-likely-than-not condition for recognition, and the second step is to determine the amount to be
recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred
tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other
future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely
than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance
was recorded for all deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A reconciliation of income tax
expense at the federal statutory rate to income tax expense at the Company&#8217;s effective rate is as follows for the years ended June
30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zye7fHvoq3m9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zioNRtqge65g" style="display: none">Schedule of reconciliation of income tax expense</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_496_20230701__20240630_zSIkBTY8xu11" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_495_20220701__20230630_zs7bvbPUPSt4" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed tax at expected statutory rate</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,066,011</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(70,341,751</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zxqPCIjJ4Zm4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-US income taxed at different rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zT8grGiUTgcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible expenses / other items</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,066,011</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,341,751</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zDIinjTeozVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income Tax Expense (Benefit)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p id="xdx_8A7_z9e9taVSiNSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The components of income tax expense
(benefit) from continuing operations for the years ended June 30, 2024 and 2023 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z4CIuVvF8H48" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 30pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20230701__20240630_zr2YwIHX5iU6" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220701__20230630_zesYaS1viu83" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Income Tax Expense</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zl4O7PzwD6Gj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Danish income tax (benefit)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_zELkXbtmTxTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Current Tax Expense (Benefit)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred Income Tax Expense (Benefit)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationFixedAssets_i01_pp0p0_maDITEBzk3M_z85liOo5WeSb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess of tax over book depreciation of fixed assets</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,258</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,258</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationPatents_i01_pp0p0_maDITEBzk3M_z1yauBO3fNuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess of tax over book depreciation of patents</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,415</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,415</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_pp0p0_maDITEBzk3M_zG0AXNB2Sh1b" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock/options compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,672,252</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,885,996</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_i01_pp0p0_maDITEBzk3M_zK3c0RPowwug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,422</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,059</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--IncomeTaxExpenseBenefitOperatingLossCarryforwards_i01_pp0p0_maDITEBzk3M_zJa1QBHTfmG3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,191,530</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140,547,314</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--IncomeTaxExpenseBenefitImpairmentExpense_i01_pp0p0_d0_maDITEBzk3M_z2jEHfKiLsj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">16,188,497&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--IncomeTaxExpenseBenefitContingentConsiderationFairValue_i01_pp0p0_d0_maDITEBzk3M_z8ygs5gtrVLi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;Contingent consideration fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,410,678&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredIncomeTaxExpenseChangeInTaxRate_i01_pp0p0_d0_maDITEBzk3M_zM7EdBLlqlLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in tax rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0p0_di_msDITEBzk3M_z5Eh1OC24NW5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in the valuation allowance</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(168,668,052</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(144,602,042</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_zT3pXbVezUE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Deferred Tax Expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p id="xdx_8A2_zYNhkACAc4D" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Deferred income tax expense (benefit)
results primarily from the reversal of temporary timing differences between tax and financial statement income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715123792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zETp2fzeaXG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_82D_zHs0CpSh7iw7">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Preferred Stock </b>&#8212;
The Company has <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zStdSSz8DFTi" title="Preferred stock shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3NJ2Wdgwjj6" title="Preferred stock shares authorized">10,000,000</span></span>
authorized shares of Preferred Stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zFUMv1LdNuA4" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_pdd" title="Preferred stock, par value">0.0001</span></span>
per share, <span id="xdx_900_ecustom--PreferredStockDesignatedShares_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXrqVFbmkix3" title="Preferred stock designated shares"><span id="xdx_902_ecustom--PreferredStockDesignatedShares_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAjcMhsCWXpi" title="Preferred stock designated shares">1,000,000</span></span>
of which have been designated as Series A Convertible Preferred Stock. At June 30, 2024 and 2023, there were zero <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8VNXDieA7Rk" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLPe8T1l4DSl" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVp1TeIgJfRg" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zbuNJvtIQ4Ha" style="display: none" title="Preferred stock, shares outstanding">0</span></span></span></span> shares of
Preferred Stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Voting &#8212; </b>Holders of
Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
holder&#8217;s shares of Preferred Stock could then be converted in accordance with conversion rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><b>Dividends &#8212; </b>The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Liquidation Rights &#8212;</b>
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all shares held by such holder. The Series A Preferred Stock is not participating preferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Conversion Rights &#8212; </b>On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a &#8220;Series A Election
Notice&#8221;) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
&#8220;Conversion Ratio&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Common Stock </b>&#8212;
The Company has <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zW3Y4NSXdBc4" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20230630_zIu7vIsRz4Mi" title="Common stock, shares authorized">350,000,000</span></span> authorized shares of Common Stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zdB9zWIA8U8f" title="Common stock, par value"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230630_zZsIFg9USyDb" title="Common stock, par value">0.0001</span></span>
per share. At June 30, 2024 and 2023, there were <span id="xdx_902_ecustom--CommonStockShareIssued_iI_c20240630_z4VLYJHgq7Rh" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_z18ifjdFevt4" title="Common stock, shares outstanding">155,027,245</span></span> and <span id="xdx_90D_ecustom--CommonStockShareIssued_iI_c20230630_zhlGTy00WDDa" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230630_zcu4r5C51X4i" title="Common stock, shares outstanding">63,698,144</span></span> shares issued and outstanding, respectively. At June 30, 2024
the Company has <span id="xdx_90C_ecustom--CommonStockConvertibleSharesIssuable_iI_c20240630_zma3H2pxOvNg" title="Common stock, shares issuable">2,189,672</span> shares issuable, which are included in shares outstanding, related to the contingent consideration settlement
(see Notes 3 and 12).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Voting &#8212; </b>Holders of
Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Dividends &#8212; </b>Holders
of Common Stock are entitled to receive ratably such dividends as the Company&#8217;s Board of Directors from time to time may declare
out of funds legally available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Liquidation Rights &#8212;</b>
In the event of any liquidation, dissolution or winding-up of the affairs of the Company, after payment of all debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any remaining assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Purchase Agreement with Lincoln
Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June
20, 2023, the Company entered into a purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park, pursuant to which
the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_ziTc8e9bO4w1" title="Obligation to purchase">20,000,000</span> of shares of Common Stock
over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the 2023 Purchase Agreement, the Company also entered
into a registration rights agreement with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration
rights related to the shares issued under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In consideration for entering into
the 2023 Purchase Agreement, the Company issued <span id="xdx_909_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zdBKGlQzvPT5" title="Number of shares issued">696,021</span> shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June 30,
2024 and June 30, 2023 no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;<b>Preferred Stock Issuances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 1, 2023, the Company
closed a private placement of <span id="xdx_901_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20230729__20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zb7qp816ycJe" title="Closed private placement units">280,505</span> units (the &#8220;<span style="text-decoration: underline">Units</span>&#8221;), each consisting of (i) one share of the Company&#8217;s
Series A Convertible Preferred Stock, (the &#8220;<span style="text-decoration: underline">Preferred Stock</span>&#8221;) and (ii) one Common Stock purchase warrant (each, a &#8220;<span style="text-decoration: underline">Warrant</span>&#8221;,
and together with the Units and the shares of Preferred Stock, the &#8220;<span style="text-decoration: underline">Securities</span>&#8221;) to purchase five shares of the Company&#8217;s
Common Stock, at a price per Unit equal to $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pdd" title="Common stock, par value">7.13</span> for aggregate proceeds to the Company of $<span id="xdx_90D_eus-gaap--ProceedsFromRepaymentsOfDebt_c20230729__20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pp0p0" title="aggregate proceeds">2,000,000</span> in cash. In addition, the Company
issued <span id="xdx_900_eus-gaap--SharesIssued_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pdd" title="Number of shares issued">280,505</span> Units in connection with the conversion of $<span id="xdx_900_ecustom--ConversionOfPromissoryNote_iI_pp0p0_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_z4WWDvA5ypBl" title="Conversion of promissory note">2,000,000</span> of the Promissory Note (see Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company issued an
aggregate of <span id="xdx_909_ecustom--AggregatePreferredStockShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zxtlTqyw1Ms" title="Aggregate preferred stock shares">561,010</span>
shares of Preferred Stock, which were initially&#160;convertible into an aggregate of <span id="xdx_90A_ecustom--AggregateCommonStockShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zLhOjKInR5D9" title="Aggregate common stock shares">5,610,100</span>
shares of Common Stock. In connection with the private placement, the Company sold warrants to purchase an aggregate of <span id="xdx_90E_ecustom--WarrantsSold_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zWxUMCnQVRsh" title="Warrants sold">2,805,050</span>
shares of Common Stock. The warrants are exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zEfGcWA0w4y1" title="Exercise price">0.65</span>
per share, payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 13, 2024 pursuant
to the acquisition of Renovaro Cube, the <span id="xdx_907_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zZRts06UIqG8">561,010 </span>shares
of Preferred Stock were converted into an aggregate of <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zbnoxENVNuT9">5,610,100 </span>shares
of Common Stock. As of June 30, 2024 there were zero shares of Preferred Stock outstanding. The extinguishment loss of $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zdpKUxKkO8Tg" title="Extinguishment loss">120,018</span> is
recorded in Other Income/Loss in the Statement of Operations (see Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><b>June
2024 Private Placement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">On
June 14, 2024, Renovaro Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
closed a private placement of <span id="xdx_908_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3OkmCfsC4i2" title="Closed private placement units">5,315,215</span>
of the Company&#8217;s units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_905_ecustom--ClosedSharesParValue_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXd1Tbwwrbk9" title="Closed shares, par value">0.0001</span>
par value per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain
investors (the &#8220;Private Placement&#8221;). The Warrants are exercisable for five years from the date of issuance and have an
exercise price of $1.4726 and $<span id="xdx_908_ecustom--ExercisePricePerShare_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z9VIBRpcDjEc" title="Exercise price per share">1.4765</span>
per share, payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The Private
Placement was completed pursuant to Regulation S promulgated under the Securities Act of 1933, as amended (&#8220;<span style="text-decoration: underline">Regulation S</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">In the Private Placement, the
Company sold <span style="background-color: white"><span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwg9J6Rs8KPh" title="Shares sold">2,325,869</span></span> Units at a price per Unit equal to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zT2s6IiUhV8f" title="Price per unit">1.4726 </span>to a certain investor who
paid in cash and settlement of debt an aggregate amount of $<span style="background-color: white"><span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGec3ElNuo5b" title="Paid in cash and settlement of debt">3,425,075</span></span> in consideration for
the Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">Additionally, the Company sold
<span style="background-color: white"><span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zyKRJPvjZERb" title="Shares sold">2,671,631</span></span> Units to certain investors who surrendered and terminated <span style="background-color: white">$<span id="xdx_90F_ecustom--PrincipalAmountAndInterestAccrued_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zxowiBxASdjj" title="Principal amount and interest accrued">3,<span style="background-color: white">955,033</span></span></span>
in aggregate principal amount and interest accrued thereon of certain convertible promissory notes issued by the Company in 2023 and 2024
and paid in cash an aggregate amount of $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zcNtVuvi8co4" title="Paid in cash and settlement of debt"><span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zEuc3KB1Yl06" title="Paid in cash and settlement of debt">478,060</span></span> to the Company in consideration for the Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">Additionally,
the Company sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zSAS88AEcZWe" title="Shares sold">317,715</span> Units to an investor who surrendered and terminated $<span style="background-color: white"><span id="xdx_90B_ecustom--PrincipalAmountAndInterestAccrued_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zIzvvrDIgZcc" title="Principal amount and interest accrued">468,453</span></span> in
aggregate principal amount and interest accrued thereon of a convertible promissory note issued in 2023 and paid in cash an aggregate
amount of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zf3u1VH8Ruc1" title="Paid in cash and settlement of debt">66,000</span> to the Company in consideration for the Units.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white">In relation to the June 14, 2024 Private Placement the Company recognized
a loss on the settlement of debt for $<span id="xdx_909_ecustom--SettlementOfDebt_c20230701__20240630_zinr59qD6xyg" title="Settlement of debt">1,183,560</span> which was recorded in other income (expense) in the statement of operations for the year
ended June 30, 2024.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b>Common Stock Issuances </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On April 5, 2024, the Company issued&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z04ccZU16SHc" title="Issuance of common stock shares">33,760</span>&#160;shares
of common stock for consulting services valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zqlOgRSWx8S9" title="Common stock for consulting services value">94,190</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 20, 2024, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zEO8isVpn10a" title="Warrants outstanding">2,953,700</span>
warrants outstanding were exercised at prices ranging from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zFglnvxhwkZ6" title="Warrants exercised">0.53</span> to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zySnTpcRpjei" title="Warrants exercised">0.65</span> per share and the aggregate $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z3rdTeCL4Oj6" title="Warrants aggregate amount">1,750,000</span> of a promissory note
held by the holder was applied to the exercise price of the warrants (see Note 7).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 20, 2024, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zwVp5MBPbrNb" title="Warrants outstanding">471,699</span> warrants
outstanding were exercised at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zKknGuiqGMVb" title="Warrants exercised">0.53</span> per share valued at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_ztr69WMQxFGi" title="Warrants aggregate amount">250,000.</span> A promissory note held by the holder was applied to the exercise
price of the warrants in lieu of cash proceeds (see Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 15, 2024, the Company
issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240214__20240215_zJJJdyIV0aUa" title="Issuance of common stock shares">50,000</span> shares of Common Stock for consulting services valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240214__20240215__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zTvgBPEYBvQ5" title="Common stock for consulting services value">100,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
February 15, 2024, the Company closed a private placement of <span id="xdx_906_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240214__20240215_zELhbbt0sBXf" title="Issuance of common stock under private placement">344,827</span> shares of Common Stock, $<span id="xdx_90C_ecustom--CommonStockParValuePrivatePlacement_c20240214__20240215_zt7gWnwyhYwe" title="Common stock par value under private placement">0.0001</span> par value, at $2.90 per share for
aggregate proceeds to the Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20240214__20240215_zYVvf4r4eHj5" title="Proceeds from issuance of private placement">1,000,000</span> in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
February 13, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zFr7sA8xCVJ2" title="Issuance of common stock shares">70,834,183 </span></span><span style="background-color: white">valued
at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zKYdZAjUfFx6" title="Issuance of common stock shares, value">136,001,631 </span></span><span style="background-color: white">(see
Note 12) shares of Common Stock pursuant to the Stock Purchase Agreement of Renovaro Cube.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On December 4, 2023, the Company
issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231203__20231204_zDJTTY1D8lXi" title="Issuance of common stock shares">525,945</span> shares of Common Stock pursuant to warrants exercised for cash proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231203__20231204_zqT6Xm3ZwREk" title="Issuance of common stock shares, value">341,865</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On October 23, 2023, the
Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--AdvisoryServicesMember_zD7HF5yEiyle" title="Issuance of common stock shares">1,000,000 </span>shares
of Common Stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--AdvisoryServicesMember_z7fFKHzkMUVj" title="Issuance of common stock shares, value">2,760,000</span> for advisory services to Avram Miller, a member of the Company&#8217;s board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Between July 28, 2023, and
September 28, 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230926__20230928__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zCfX0okrNho" title="Issuance of common stock shares"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230727__20230728__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zNOMtI5jRP6d" title="Issuance of common stock shares">2,000,000</span></span>
shares of Common Stock for consulting services valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230926__20230928__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z3CExpf9h0El" title="Issuance of common stock shares, value"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230727__20230728__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zs1NwoOJLju2" title="Issuance of common stock shares, value">4,470,000</span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
June 26, 2023, the Company issued <span id="xdx_90F_eus-gaap--SharesIssued_iI_c20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzbRvSYH6tc6" title="Number of shares issued">4,718,532</span> shares of Common Stock and warrants to purchase <span id="xdx_90B_ecustom--NumberOfShareWarrantPurchase_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zdbvj5OJhHPk" title="Number of share warrant purchase">2,359,266</span> shares of common stock resulting
in proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCJupqgE204g" title="Proceeds from private placement">1,300,823</span> </span>in a private placement offering and the reduction of notes payable of $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20230626_zjfTPiQltga2" title="Notes payable">1,200,000</span>. The warrants were immediately
exercisable and had an exercise term of five years with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626_zt4sEvPNS7d9" title="Exercise price">0.53</span> per share. The combined purchase price for one share
of Common Stock and one warrant was $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zj8aBvmCPna2" title="Exercise price">0.53</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">On
June 26, 2023, the Company issued <span id="xdx_905_eus-gaap--SharesIssued_iI_c20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z18h64maPYzi" title="Number of shares issued">4,718,532</span> shares of Common Stock and warrants to purchase <span id="xdx_90D_ecustom--NumberOfShareWarrantPurchase_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z3zaJoK17Lw9" title="Number of share warrant purchase">2,359,266</span> shares of common stock resulting
in proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zVyzK65EnJlk" title="Proceeds from private placement">1,300,823</span> </span>in a private placement offering and the aforementioned reduction of notes payable of $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20230626_zm3n606Ystf3" title="Notes payable">1,200,000</span>. The
warrants were immediately exercisable and had an exercise term of five years with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626_zcwPAnsgx8d2" title="Exercise price">0.53</span> per share. The combined purchase
price for one share of Common Stock and one warrant was $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zTLwurwLdDl2" title="Exercise price">0.53</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On June 20, 2023, the Company issued
<span id="xdx_900_eus-gaap--SharesIssued_iI_c20230620__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LincolnParkMember_zrVyZWJRuNFe" title="Shares issued">696,021</span> shares of Common Stock to Lincoln Park as a commitment fee as part of a purchase agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On April 27, 2023, there were <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20230426__20230427__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFZqj0mTzBjj" title="Converted shares of common stock, shares">100,000</span>
shares issued that immediately vested and were converted into shares of Common Stock in exchange for consulting services valued at $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20230426__20230427__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq2kP7sDkd1f" title="Converted shares of common stock, value">120,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March 2023, the Company issued <span id="xdx_908_eus-gaap--SharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z5wLNaPT8bAb" title="Shares issued">2,378,070</span> shares of Common Stock and warrants
to purchase <span id="xdx_902_eus-gaap--SharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zjZpbhJPa08" title="Shares issued of common stock">1,189,036</span> shares of Common Stock resulting in proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230330__20230331_ziH4PPABULee" title="Proceeds of private placement offering">2,711,000</span> in a private placement offering. The Company effected
the issuances of the shares of Common Stock from March 13, 2023 to March 29, 2023. The purchase warrants were immediately exercisable
and had an exercise term of five years with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331_z6xDB24WUGhb" title="Exercise price">1.14</span> per share. The combined purchase price for one share of Common
Stock and one Purchase Warrant was $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zq6fJMg2Sib4" title="Exercise price">1.14</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2023, there were <span id="xdx_902_eus-gaap--SharesIssued_iI_c20230210__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyjhN52b87l1" title="Shares issued">100,000</span> restricted share units issued that immediately vested and were converted into shares of Common
Stock in exchange for consulting services valued at $<span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_c20230209__20230210__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbLEbYyAA553" title="Converted shares of common stock, value">108,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2022, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221229__20221230__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zpwFqwKBB5K3" title="Issuance of shares">198,439</span> shares of Common stock valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueOther_c20221229__20221230__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zDi5TgSvupN3" title="Shares issued of common stock, value">204,392</span> based on the closing price of the common stock
on that date, issued in lieu of prepaid interest related to the amended and restated secured notes (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, certain of our warrant holders exercised warrants to purchase&#160;<span id="xdx_901_ecustom--PurchaseSharesOfCommonStock_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zolmneUCAEG8" title="Purchase shares of common stock">1,250,000</span>&#160;shares of Common Stock for total proceeds
to the Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z97ALMTfU8Qf" title="Total Proceeds">1,625,000</span>, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences, based on the share price on that date of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20220714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroBioPharmaIncMember_z7WgnHhbH8ei" title="Share price">2.21</span>. This non-cash earn-out distribution impacted stockholders&#8217;
equity in the amount of $<span id="xdx_901_ecustom--EarnOutDistribution_c20220713__20220714_zkVqTXgMf2Oj" title="Earn-out distribution">2,762,500</span>&#160;based on the share price on July 14, 2022, of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220714_zhX7gnAVdulf" title="Share price">2.21</span>.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, certain of our warrant holders exercised warrants to purchase&#160;<span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zq3Nf6dlObJ" title="Shares purchased">1,250,000</span>&#160;shares of Common Stock for total proceeds
to the Company of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zR7J4uOVUpNe" title="Proceeds from common stock">1,625,000</span>, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences. This non-cash earn-out distribution impacted stockholders&#8217; equity in the amount of $<span id="xdx_90C_eus-gaap--NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zPJOm6GrbwSd" title="Non cash earn out distribution">2,762,500</span>&#160;based
on the share price on July 14, 2022 of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zs9dyGuOOn4c" title="Share price">2.21</span>. The Company recorded a loss on extinguishment of contingent consideration liability of
$<span id="xdx_90D_ecustom--ExtinguishmentOfContingentConsiderationLiability_c20230701__20240630_zesf902ZjZs7" title="Extinguishment of contingent consideration liability">419,182</span>&#160;during the year ended June 30, 2024 which reflected the difference between the fair value of the shares and the contingent
consideration liability at the time of extinguishment. As of June 30, 2023, all outstanding warrants as of the date of acquisition of
Renovaro Biosciences (the &#8220;2017 Warrants&#8221;) were exercised and there is no further contingent consideration liability related
to the 2017 Warrants remaining as of June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition
of Renovaro Biopharma / Contingently issuable shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2018, the acquisition of Renovaro Biosciences was completed. As part of the acquisition, the stockholders of Renovaro Biosciences
received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise
or conversion of warrants, which were outstanding at closing. As of June 30, 2024, <span id="xdx_90E_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_iI_do_c20240630__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember_zT6rXsINFpc4" title="Common shares contingently issuable">no</span> further Contingent Shares are issuable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition
of Renovaro Denmark </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024 and 2023, the Company maintained a reserve of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240630_zJZ6NUz8lss9" title="Common stock reserved for issuance"><span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230630_zFAAoU6Igv42" title="Common stock reserved for issuance">17,414</span></span> Escrow Shares, all of which are reflected as issued and outstanding
in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Renovaro Denmark held by non-consenting
shareholders of Renovaro Denmark on both June 30, 2024 and 2023, in accordance with Section 70 of the Danish Companies Act and the Articles
of Association of Renovaro Denmark. There have been <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DanDritDenmarkMember_zkJUEqgzjs73" title="Common stock, shares outstanding">167,639</span> shares of Common Stock issued to non-consenting shareholders of Renovaro
Denmark as of June 30, 2024. During the years ended June 30, 2024 and 2023, the Company did <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_do_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroDenmarkMember_zHVrgGiTrXP7" title="Common stock issued"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_do_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroDenmarkMember_zUezR2nR84ek" title="Common stock issued">no</span></span>t issue any shares of Common Stock to such
non-consenting shareholders of Renovaro Denmark.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock
option is estimated on the date of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2024, the weighted-average
assumptions used to estimate the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ziYDjmukkW87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B7_zZekknpnQxkf" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Inc.</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (in years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zxI0mQVwU0w8" title="Expected term (in years)">5.0</span> &#8211; <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zTEAG4zVuCO" title="Expected term (in years)">6.5</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zil2MGMcU6S2" title="Volatility">84.33</span>% &#8211; <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zLpHcN3GAqie" title="Volatility">114.88</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zSI9QmAnsQbf" title="Risk free interest rate">3.12</span>%- <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBWEbywJ1kkh" title="Risk free interest rate">4.83</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 75%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td>
<td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230701__20240630__dei--LegalEntityAxis__custom--RenovaroMember_zbOyIYpfcVh1" title="Dividend yield">0</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recognized stock-based compensation expense related to all equity
instruments of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20240630_z37t2AO6EzHl" title="Stock based compensation expense">4,673,129</span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20230630_zkOiheIK0TCe" title="Stock based compensation expense">3,535,051</span> for the years ended June 30, 2024 and 2023, respectively. At June 30, 2024, the Company had approximately
$<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20240630_z9yUHIT01Lsb" title="Unrecognized compensation cost">250,373</span> of unrecognized compensation cost related to non-vested options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Plan Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 6, 2014, the Company&#8217;s
Board of Directors adopted the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), and the Company had reserved
<span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_znuUt4vLmYof" title="Common stock reserved for issuance">1,206,000</span> shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 30, 2019, the Board
approved and on October 31, 2019, the Company&#8217;s stockholders adopted its 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Effective July 21, 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan replaced the 2019 Plan.
The 2023 Plan provides that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved and available for issuance
under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the
effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject
to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;The Company granted options
to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zyhteRw5pGm4" title="Option granted">369,500</span> shares of Common Stock to employees with a three-year vesting period during the year June 30, 2024 under the 2019
and 2023 Plan. For the year ended June 30, 2023, the Company granted options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_z5kWUAuYYf1d" title="Option granted">193,000</span> shares to employees with a three-year
vesting period under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">During
the year ended June 30, 2024 and 2023, the Company granted options to purchase&#160;zero<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z54F7F7Ikx71" style="display: none" title="Option granted">0</span> and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zuZ0XgA4u6yi" title="Option granted">184,800</span>, respectively, and zero<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zHcUIzLKVAx8" style="display: none" title="Shares forfeited">0</span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zxlTQir4CUn2" title="Shares forfeited">18,960</span>
forfeited shares of Common stock to employees with a&#160;six-month vesting period, respectively under the 2019 Plan. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">During
the year ended June 30, 2024 and 2023, the Company granted options to purchase zero<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDm9oK6Sx6R8" style="display: none" title="Option granted">0</span> and&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDnZ1FvoSZp1" title="Option granted">73,200</span> issued and<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zwCDCtBIsTFl" style="display: none" title="Shares forfeited">0</span> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDLnAzVvdZka" title="Shares forfeited">12,640</span> forfeited, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Employees1Member_zm7WBMgr0PHh" title="Option granted">65,000</span>
shares of Common stock, respectively, to employees with a&#160;one-year vesting period,</span> respectively under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June 30,
2024 and 2023, the Company granted options to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardOneMember_zQEnwZH2bvk7" title="Option granted">424,412</span> and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardOneMember_ziWKvO4mgHxj" title="Option granted">355,359</span> shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June
30, 2024 and 2023, the Company granted options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_zOoU06c85NJj" title="Option granted">329,729</span>
and zero <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_z73JZCmMqLW6" style="display: none" title="Option granted">0</span> shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the
2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the years ended June 30,
2024, and 2023, the Company granted options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultingServicesMember_zN94ONxMQf14" title="Option granted">10,000</span> and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultingServicesMember_zwSk6DOBDg28" title="Option granted">75,000</span> shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">All of the above options are exercisable
at the market price of the Company&#8217;s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931
eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing
price of the Company&#8217;s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $921,254 during the year ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;To date the Company has granted
options under the 2014, 2019 and 2023 Plans (&#8220;Plan Options&#8221;) to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zwp6P3jISZH9" title="Option granted">6,665,821</span> shares of Common Stock. At June 30, 2024,
the Company has <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20230701__20240630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zaMI4uZNnEX2" title="Options available to be issued">4,515,873</span> options available to be issued under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">A summary of the Plan Options outstanding at June 30,
2024 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>


<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zT9pS2QOYL1g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zcvOLyxfHAd1" style="display: none">Schedule of stock options outstanding</span></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Outstanding</span></td><td style="padding-bottom: 1pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ranges</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 10%; font-size: 11pt; text-align: right; text-indent: -10pt"></td><td style="width: 1%; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoj3UP0Zi3ak" title="Exercise Prices, Lower">0.45</span>&#8211;<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zL0sWyyJuEz4" title="Exercise Prices, Upper">4.50</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjlok0NFGud7" style="width: 9%; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,244,987</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlGCuS8k9Mp7" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">7.38</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDpZZNCO6LRb" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.89</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z22dzV2B8Kq2" style="width: 9%; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,817,105</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zxuFiyv6UiI9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">7.15</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zNTwhPrOcLm7" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zq9vHnGJWQV2" title="Exercise Prices, Lower">4.51</span>&#8211;<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zciuoVCxbwIc" title="Exercise Prices, Upper">6.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zBiexlnMnqN5" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">167,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zOcUyvdWiRYe" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">6.48</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_znLyCeBR1gq" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zG4XmsEVoZtd" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,376</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zlLnBvEEgxHl" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">5.81</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z8XvPUv82eC3" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zxgHQnjms6K9" title="Exercise Prices, Lower">6.51</span>&#8211;<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z1iHs4UyFfn" title="Exercise Prices, Upper">12.00</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zJDB519dnxl5" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,231</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z95XU05DBeYj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">4.66</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zqGoGpDbGFJg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.63</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zd9mGZcrJfqc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111,585</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zYpGqlOd5Zdi" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">4.57</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zOBaby8lmIFi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.61</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z0FnfEqDYY8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,527,852</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zUtQF25tWt92" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">7.29</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2njRW3iJke7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSLtYzFUsth9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,064,066</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z56RVX2La7W6" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">7.03</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFXK6LhPxeE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of changes  are presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zB5GW3YRRQLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zw9nn7pGElIh" style="display: none">Schedule of stock option activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Remaining Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Intrinsic<br/> Value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zqOYtBsVQHrj" style="width: 13%; text-align: right" title="Options Outstanding at beginning of period">4,401,211</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zuydU65POhs6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">4.78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zA0GqPCBt3ef" title="Weighted Average remaining life">7.82</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWtzNzpAK1hg" style="width: 13%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zoHzvvRQOfGe" style="text-align: right" title="Granted">4,983,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zaqAJu6klj2j" style="text-align: right" title="Weighted average exercise price, Granted">1.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zY7qYMCgsDV" style="text-align: right" title="Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zVSnrPz3OMOi" style="text-align: right" title="Weighted average exercise price, Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zrixLPhkVI27" style="text-align: right" title="Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_ztZA2pG3dtv4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired/Canceled </span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zSpp8TEe05Zb" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">(3,856,931</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z6p89UjP9Uth" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">4.94</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z4j7YnkZlqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period">5,527,852</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zFd7mtnTwQe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period">2.11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjVPtAU0P3G3" title="Weighted Average remaining life">7.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxhKc537x1n2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zTcizUH5ETt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">4,064,066</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhiWPKQHagb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period">2.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zffv5yDgJU66" title="Weighted Average Remaining Life, Exercisable">7.05</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zp4eeIM2rhv" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period">525,943</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024, the Company had Plan Options to purchase 4,064,066 shares
of common stock that were exercisable. The total intrinsic value of options exercisable at June 30, 2024, was $<span>525,943</span>.
Intrinsic value is measured using the fair value at the date of exercise (for shares exercised) and at June 30, 2024 (for outstanding
options), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock Purchase Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of the status of the
Common Stock Purchase Warrants outstanding at June 30, 2024, is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_z15TSkAxnsY5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B9_zKDohMfsJ2Xf" style="display: none">Schedule of common stock purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zVP8y94nQXYk" style="width: 9%; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.53</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zK4rbHn9NDrg" style="width: 9%; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">471,698</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zPGq0Ov22cbg" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">1.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z7hyH1ivX6yc" style="width: 9%; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">471,698</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zbFuATanrD0i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">1.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zb7LOW9sKtX" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zGRWikXfOpP8" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z5FKhhbk0KV4" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zz962SNTavV1" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zXQZuEZjvPE7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDWgYmDaVoX7" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zsmq8SZi4Zia" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,189,036</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDlwyhcY1gt5" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.73</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zHQpPrwjKjQi" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,189,036</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zscw9Uwubqhb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.73</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zTCr0coe40u2" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyqBq827QNRb" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">642,128</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zrwVmoHgrzhl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">4.96</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zqbHHcTCLnba" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">642,128</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z7uoQANbhZ7i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">4.96</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zarw1JsAZnn2" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zxmv2q80PLIf" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,740</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zfX6NxHlPMfj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">4.99</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zoOIOuAFfvfl" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,740</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z1KgSx9mvVM9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">4.99</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zsRMblqnRRyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,094,876</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zy6LzXLVkzXa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.48</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zfj00j7Vcl66" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zpKbBGNg1hDh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,094,876</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zibIj0t3A8Kg" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.48</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zRKHO2xYrCzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of the warrant activity is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_ztFOeXoPMG9e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BE_zU6u061FCDDe" style="display: none">Schedule of warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining<br/> Life</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Outstanding at June 30, 2023</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zW15v1YzQH09" style="width: 11%; text-align: right" title="Outstanding at beginning of period">3,548,302</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXAGuqsB02k3" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">0.73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zszXr2mEb9t1" title="Weighted Average remaining life, Outstanding">4.80</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkr824MJeNK6" style="text-align: right" title="Granted">3,497,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_ztJ9eeD9EDDf" style="text-align: right" title="Weighted average exercise price, Granted">0.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zp9CTBEdlPq8" title="Weighted Average remaining life, Granted">4.27</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zojIebZ8mG33" style="text-align: right" title="Exercised">(3,951,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z4cmo8MvhJAd" style="text-align: right" title="Weighted average exercise price, Exercised">0.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_znRVOnkAZAql" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zJUKdMhvktH9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding and exercisable at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_ecustom--CommonStockPurchaseWarrant_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zQDiCVjl0PCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period">3,094,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z2x7roGAMXy8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period">1.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zzhIRpQ4RLQ4" title="Weighted Average remaining life, Outstanding">3.48</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2024, the Company had <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zc1fvaxgrNVa" title="Common stock purchase warrants exercisable outstanding">3,094,876</span> exercisable Common Stock Purchase
Warrants outstanding. The total intrinsic value of warrants exercisable at June 30, 2024, was $<span><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zEDT93Jqtuta" title="Total intrinsic value of options exercisable">2,309,681</span></span>.
Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at June 30, 2024 (for outstanding
warrants), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards (RSA)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The Company recognized stock-based
compensation expense related to RSAs of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOfIa2Z7Gytk" title="Stock based compensation expense">1,415,157</span> for the year ended June 30, 2024. The restricted stock awards are related to&#160;a
grant of&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zSuE10NEYIWd" title="Number of shares grant">1,000,000</span>&#160;shares of restricted stock with a 3-year vesting period made to a director as consideration for advisory
services, with a total value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zIXReW7RcIU8" title="Number of value grant">2,760,000</span>. At June 30, 2024, the Company had $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z7yYcpenajc2" title="Unrecognized compensation cost">1,344,843</span> of unrecognized stock-based compensation expense
remaining to be amortized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">The Company recognized stock-based
compensation expense related to other RSAs of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHqKQfLzx4Yl" title="Stock based compensation expense">108,000</span> for the year ended June 30, 2023. These restricted stock awards are related to
a grant of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlcY1JKpLatl" title="Number of shares grant">100,000</span>&#160;shares of restricted stock made to a consultant as consideration for consulting services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714801168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zY5H7f9mPU1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 &#8212; <span id="xdx_82E_z3Ik7uUBKUB">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#8220;HBV License Agreement&#8221;) by and among the Company, G-Tech, and
G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute
(&#8220;SRI&#8221;) (collectively the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual, sublicensable, exclusive license
(the &#8220;HBV License&#8221;) for a treatment under development (the &#8220;Treatment&#8221;) aimed to treat Hepatitis B Virus (HBV)
infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24 month period, and provides for an up-front payment of $<span id="xdx_90B_eus-gaap--PaymentsForFees_pn5n6_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zGGTKxt471r8" title="Payment for license">1.2</span> million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a <span id="xdx_906_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zIQvxlumRys3" title="Royalty percentage">2</span>% royalty to G-Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $<span id="xdx_90B_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrn3UvWfov12" title="Payment for license">1.2</span> million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement in the years ended June 30, 2024, and 2023. The Company
has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section
below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#8220;License Development Agreement&#8221;), by and among the Company, G-Tech
and SRI (collectively, the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual sublicensable, exclusive license (the &#8220;Development
License&#8221;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating pan-coronavirus
or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza
(the &#8220;Prevention and Treatment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides
for an up-front payment of $<span id="xdx_90C_ecustom--UpfrontPayment_c20191114__20191115_z8Zm6ad6TGzh" title="Up-front payment">10,000,000</span> and a $<span id="xdx_907_ecustom--PaymentForExpenditures_c20191114__20191115_zUiWRwaZbnK6" title="Payment for expenditures">760,000</span> payment for expenditures to date prior to the effective date related to research
towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional payments
upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement, in each
case subject to the terms of the Development License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G-Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product candidates
that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license
(see Contingencies sub-section below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#8220;ALC License Agreement&#8221;) with Serhat
G&#252;mr&#252;kc&#252; and SRI (collectively, the &#8220;Licensors&#8221;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $<span id="xdx_905_ecustom--InitialPayment_c20210824__20210825_zHdfcMUBnwQh" title="Initial payment">600,000</span> and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $<span id="xdx_90C_ecustom--InitialPayment_c20210909__20210910_zllz47s6Fvme" title="Initial payment">600,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">G-Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Shares held for non-consenting
shareholders</b> &#8211; The <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240630_zOeXKcJ2YHRe" title="Remaining shares">17,414</span> remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have been reflected
as issued and outstanding in the accompanying financial statements.&#160;There were zero shares of Common Stock issued to such&#160;non-consenting
stockholders during the years ended June 30, 2024 and 2023 (see Note 9.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Service Agreements</b> <i>&#8211;</i>The
Company maintains employment agreements with certain senior staff in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Securities Class Action Litigation</i>.
On July 26, 2022 and July 28, 2022, securities class action complaints (the
former, the &#8220;Chow Action&#8221; and the latter, the &#8220;Manici Action&#8221;) were filed by purported stockholders of the Company
in the United States District Court for the Central District of California against the Company and certain of the Company&#8217;s current
and former officers and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of
material fact in connection with the Company&#8217;s relationship with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The
complaints seek unspecified damages, interest, fees, and costs. On November 22, 2022, the Manici Action was voluntarily dismissed without
prejudice, but the Chow action remains pending.&#160;On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The
lead plaintiff filed an amended complaint on December 15, 2023. The Company has filed a motion to dismiss the amended complaint on March
15, 2024. The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, and the
parties have come to an agreement in principle to settle the class action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Federal Derivative Litigation</i>.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action
in the United States District Court for the Central District of California. On January 19, 2023, John Solak filed a substantially similar
shareholder derivative action in the United States District Court for the District of Delaware. Both derivative actions recite similar
underlying facts as those alleged in the Securities Class Action Litigation. The actions, filed on behalf of the Company, name Serhat
G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and former directors as defendants. The actions also name the Company
as a nominal defendant. The actions allege violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also set
out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiffs do
not quantify any alleged injury, but seek damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United
States District Court for the Central District of California stayed the Koenig matter pending resolution of the defendants&#8217; anticipated
motion to dismiss in the Securities Class Action Litigation. On April 4, 2023, the United States District Court for the District of Delaware
stayed the Solak matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation.
On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion to dismiss the
Securities Class Action Litigation. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings in
the Koenig matter is October 21, 2024. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings
in the Solak matter is October 22, 2024. The defendants have not yet responded to either complaint. The Company intends to contest these
matters but expresses no opinion as to the likelihood of favorable outcomes. Management is unable to determine the likelihood of a loss,
including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>State Derivative Litigation</i>.
On October 20, 2022, Susan Midler filed a shareholder derivative action in
the Superior Court of California, Los Angeles County, reciting similar underlying facts as those alleged in the Securities Class Action
Litigation. The action, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current
and former directors as defendants. The action also names the Company as a nominal defendant. The action sets out claims for breaches
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the Court stayed the Midler matter
pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024,
the United States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class
Action Litigation. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings in the Midler matter
is October 23, 2024. The defendants have not yet responded to the complaint. The Company intends
to contest this matter but expresses no opinion as to the likelihood of a favorable outcome. Management is unable to determine the likelihood
of a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252;, William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio LLC (&#8220;G Tech&#8221;), SG &amp; AW Holdings,
LLC, and Seraph Research Institute (&#8220;SRI&#8221;) (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants
engaged in a &#8220;concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting
its Hepatitis B and SARS-CoV-2/influenza pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive
outcomes from various studies, and even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the
Company claims that it &#8220;paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221;
On April 21, 2023, defendants Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all,
of the Company&#8217;s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending
motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening
deadlines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including,
<i>inter alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License
Agreement, effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications,
effective as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently
scheduled to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while
pursuing its claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 1, 2021, the Company&#8217;s
former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District
of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and
Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company&#8217;s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Gr&#248;nfeldt-S&#248;rensen. On November 29, 2022,
the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24, 2023,
the court denied the motion for summary judgment. The court vacated the July 15, 2024 trial date and has yet to re-set the trial date.
The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (such trusts, collectively, the
&#8220;Trusts&#8221;) (collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery
of Delaware. In the Verified Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between
the Company, Weird Science, and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor
Rights Agreement required the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days
prior to filing a registration statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in
such registration statement. Plaintiffs alleged that the Company breached these registration rights by failing to provide the required
notice in connection with S-3 registration statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to
dismiss the Verified Complaint on September 15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023. The Court scheduled oral argument on the motions to dismiss for November 15, 2024. The Company denies Plaintiffs&#8217;
allegations and intends to vigorously defend against the claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 24, 2023, counsel on
behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company&#8217;s
books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167;&#160;220 (&#8220;Section 220&#8221;).
The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company takes
its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with
those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, Weird Science
and Wittekind sent the Company&#8217;s Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues
identified therein. On February 27, 2024, Weird Science and Wittekind sent the Company&#8217;s Board of Directors a supplemental letter
that expanded their demand for corrective actions to twenty-six issues. In response to these demand letters, the Board of Directors initially
formed a Special Committee (&#8220;Special Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained
Stradling Yocca Carlson &amp; Rauth LLP as its counsel to investigate the issues identified in the demand letters. The Special Committee&#8217;s
investigation is ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States
District Court for the Central District of California against certain officers, directors, and investors of the Company, as well as other
defendants, in connection with, <i>inter alia</i>, Weird Science and Wittekind&#8217;s demand for corrective action. Plaintiffs filed
an amended complaint on June 21, 2024. The First Amended Verified Stockholder Derivative Complaint (&#8220;Derivative Complaint&#8221;)
alleges, among other claims, violations of Section 13(d) and 14(a) and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934.
The Derivative Complaint also includes claims of breach of fiduciary duty, corporate waste, unjust enrichment, and contribution/indemnification.
Weird Science and Wittekind seek unspecified compensatory, exemplary, and punitive damages and certain injunctive relief. The Derivative
Complaint names the Company as a nominal defendant. On July 19, 2024, certain of the director defendants, who had agreed to waive service
of the summons and Derivative Complaint, filed a motion to dismiss the Derivative Complaint on a variety of procedural and substantive
grounds. A hearing on the motion dismiss was held on October 3, 2024 and the court subsequently took the motion under submission. The
director defendants deny the allegations in the Derivative Complaint and intend to vigorously defend against the claims asserted therein.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 21, 2024, the Company
filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451816934208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcIyhkWtg4Ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 &#8212; <span id="xdx_82B_zXkV8j374a24">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of June 30, 2024, the Company
has accrued $<span id="xdx_904_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_zBrDUJdrcso4" title="Accrued balance">220,402</span> of compensation related expenses for the Company&#8217;s Chief Executive Officer, Mark Dybul, related to budget constraints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 16, 2024, the Company
received an exercise notice from RS Bio ApS (&#8220;RS Bio&#8221;) to exercise <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxelBOoSD492" title="Warrant exercise price">471,699</span> warrants outstanding at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxFYilgpUBpl" title="Warrant exercise price per share">0.53</span>
per share. Mr. Rene Sindlev, the Chairman of the Company&#8217;s Board of Directors, holds the sole voting and disposition power of the
shares owned by RS Bio. RS Bio applied $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240214__20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z6iC2Jc8pjB7" title="Proceeds from notes payables">250,000</span> of one of its outstanding note payable balance to the exercise price (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a <span id="xdx_902_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zhEPEaQp7FTf" title="Original issue discount promissory note percentage">5</span>% Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zQNWH5831WJl" title="Principal amount">105,263</span>.
The Company received $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfDebt_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RsBioMember_zCChAn7V4Wl6" title="Gross proceeds">100,000</span> in gross proceeds after taking into account the <span id="xdx_909_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RsBioMember_zI4CBiIK6Mb" title="Gross proceeds original issue discount rate">5</span>% original issue discount. The Note bears an interest rate
of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z6FoWuOSRzjc" title="Interest rate">12</span>% per annum and matured on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKtbh6YbJpbf" title="Debt maturity period">March 1, 2024</span> . The obligations under this Note are secured by the Amended and Restated Security Agreement
(see Note 7). The Company is required to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of
$<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zmMeRmSyfR19" title="Amortization discount">5,263</span> was charged to interest expense. As of June 30, 2024, the Company accrued $<span id="xdx_904_eus-gaap--InterestExpense_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zG9yUMYG52e9" title="Interest expense">6,316</span> of interest expense that is included in accrued
expenses on the balance sheet. The Note balance, net of discount at June 30, 2024 is $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKA1FKonUdE3" title="Note balance">105,263</span> (see Note 7.)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 2, 2024, the Company entered into an agreement with RS Bio to issue
a <span id="xdx_90B_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zfYE7otv7BQa" title="Original issue discount promissory note percentage">5</span>% Original Issue Discount Secured Promissory Note for the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zJmohid8rcag" title="Principal amount">526,315</span> (the &#8220;January 2024 Note&#8221;). The Company
received a total of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z8WJQN2AvyJ6" title="Gross proceeds">500,000</span> in gross proceeds after taking into account the <span id="xdx_90F_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zAXbBFSDVRs" title="Gross proceeds original issue discount rate">5</span>% original issue discount.&#160;The January 2024 Note bears
an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDS1ufUwWOIi" title="Interest rate">12</span>% per annum and shall mature on <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zd9gR6h8tUw8" title="Debt maturity period">March 1, 2024</span> (the &#8220;Maturity Date&#8221;) is past due. The Company is required
to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zTestoiqexF3" title="Amortization discount">26,315</span> was charged to interest expense.
As of June 30, 2024, the Company accrued $<span id="xdx_90D_eus-gaap--InterestExpense_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z5qqrIOAIdr2" title="Interest expense">31,579</span> of interest expense that is included in accrued expenses on the balance sheet. The January
2024 Note balance, net of discount at June 30, 2024 is $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zZ46hv0blwZa" title="Note balance">526,315</span> (see Note 7.) In connection with the entry into the January 2024 Note,
the Company and Paseco ApS agreed to amend and restate the Security Agreement (see Note 7) to add the Company&#8217;s obligations under
the November 2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 3, 2023, the Company entered into an agreement with RS Bio to
issue a <span id="xdx_90A_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_z5XBVS43U0dl" title="Original issue discount promissory note percentage">5</span>% Original Issue Discount Promissory Note for the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zHeOnXLQGWa3" title="Principal amount">1,000,000</span> (the &#8220;November 2023 Note&#8221;). The
Company received a total of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zxOP8jH5ZVai" title="Gross proceeds">950,000</span> in gross proceeds after taking into account the <span id="xdx_904_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_ztkv0e4nQLZg" title="Gross proceeds original issue discount rate">5</span>% original issue discount.&#160;The discount of
$<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zaKBj9H1pxM" title="Discount accreted">50,000</span> will be accreted over the life of the Note. The Note bears an interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zX0sZ9nPP2t5" title="Interest rate">12</span>% per annum and shall mature on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zWI8zXEdLgbb" title="Debt maturity period">January 1, 2024</span>
(the &#8220;Maturity Date&#8221;) is past due. The Company is required to pay interest on the maturity date (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
10, 2023, the Board of Directors of the Company (the &#8220;Board&#8221;) appointed Avram Miller to the Board, effective October 11, 2023,
to fill a vacancy. Mr. Miller will serve until the Company&#8217;s 2024 Annual Meeting of Stockholders subject to this re-election or
until his successor has been duly elected and qualified. In addition to Mr. Miller&#8217;s appointment to the Board, Mr. Miller, the co-founder
of Intel Capital, entered into an advisory agreement&#160;with the Company (the &#8220;Advisory Agreement&#8221;), pursuant to which Mr.
Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation, business
development, minority investments and licensing arrangements, among others. As compensation for these services, the Company will issue
Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will vest
in 2026, subject to Mr. Miller&#8217;s continued service through each applicable vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 1, 2023, RS Bio, purchased
in a Private Placement 70,126 of the Company&#8217;s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of
$500,000. <span style="background-color: white">The Board of Directors (excluding Mr. Sindlev) approved the participation of certain officers
and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement</span> (see Note
7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 1, 2023, Paseco ApS,
in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company&#8217;s Units at a price
per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company&#8217;s Units at a price per
Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS
was deemed to be an affiliate of the Company (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company currently has a consulting
agreement with Paseco ApS for business advisory services since December of 2019. For the years ended June 30, 2023 and 2024 the Company
issued zero and 1,000,000 restricted common shares, respectively, as payment for services rendered thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The information
set forth above in Note 7&#8212;Debt&#8212;Notes Payable&#8212;Promissory Note relating to the Promissory Note issued to Paseco ApS is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715212784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION</a></td>
<td class="text"><p id="xdx_805_eus-gaap--BusinessCombinationDisclosureTextBlock_zI30BkyMafhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 12 &#8212; <span id="xdx_820_zP4MCwf0eON3">ACQUISITION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On September 28, 2023, the Company, entered into a Stock Purchase Agreement
(the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;) with GEDi Cube Intl Ltd., a private company formed
under the laws of England and Wales (&#8220;<span style="text-decoration: underline">GEDi Cube</span>&#8221;) to acquire 100% of the equity
interests of GEDi Cube from its equity holders (the &#8220;<span style="text-decoration: underline">Sellers</span>&#8221;). On September
28, 2023, the Board of Directors of the Company, and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and
on January 25, 2024, the shareholders of the Company approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement.
On February 13, 2024 (the &#8220;Closing Date&#8221;), the Company consummated the acquisition of GEDi Cube and the other transactions
contemplated by the Stock Purchase Agreement (collectively, the &#8220;Transaction&#8221;). As a result of the Transaction, GEDi Cube
became a wholly-owned subsidiary of the Company. The Company believes the acquisition will provide it with access to the nascent field
of artificial intelligence and machine learning driven diagnostics, which was the primary purpose for the acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a &#8220;GEDi Cube Share&#8221; and, collectively, the &#8220;GEDi Cube Shares&#8221;)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller&#8217;s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (&#8220;Common Stock&#8221;), which represents the 67,224,089
shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to
a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of
the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the &#8220;Closing
Consideration&#8221;) plus 5,610,100 shares of Common Stock representing the Seller&#8217;s Earnout Shares (defined below) resulting from
the automatic conversion of the Company&#8217;s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller&#8217;s
pro rata percentage of the shares of Common Stock (the &#8220;Earnout Shares&#8221; and, together with the Closing Consideration, the
&#8220;Exchange Consideration&#8221;) to be issued to the Sellers upon the exercise or conversion of any of the Company&#8217;s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the &#8220;Closing Derivative Securities&#8221;).
Each Seller&#8217;s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with the provisions of ASC 805-10 -&#160;<i>Business Combinations</i>. </span>As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The assets acquired and liabilities assumed were initially recognized provisionally
in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition date. The fair values as of the acquisition
date are based on information that existed as of the acquisition date. The Company completed its accounting for this acquisition during
the period ended June 30, 2024. As a result of the completion of the Company&#8217;s analysis, the amount of in-process research and development
was determined to have a value of nil. Accordingly, the amount of goodwill recognized was increased to include the previously recognized
amount of in-process research and development. There was no impact to the Company&#8217;s consolidated statement of operations as a result
of this change to the allocation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The acquisition-date fair value of the consideration transferred totaled approximately
$<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIyqwjvBZN39" title="Fair value of consideration transferred amount">156.6</span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_zSVvaUuM9A34" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8B5_z8PF5HteaUe9" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of acquisition
date fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_987_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zEyPw6ZlO64h" style="width: 18%; text-align: right" title="Common stock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,001,631</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent consideration</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zjoz7V4huMji" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,557,500</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total consideration transferred</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_988_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zDGlty6NlcNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,559,131</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p id="xdx_8AA_zHcQhzufb7m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
<span style="background-color: white">fair value of the Company&#8217;s
common shares issued as consideration was based on the closing price of the Company&#8217;s common stock as of the Acquisition Date. The
fair value of the contingent consideration </span>was based on the Sellers&#8217; right to receive additional shares of common, pro rata,
upon the exercise or conversion of warrants, options and convertible notes payables outstanding as of the Closing Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zhQ1zpvhkhpd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)">
<tr style="vertical-align: bottom">
<td id="xdx_8BE_zxLldG2RVoqe" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of fair value of assets acquired and
liabilities assumed</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zq6XQ3FaWyjk" style="text-align: center">&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_zN7yl1t9V7j1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,851</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zPtCA0lnhfvl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid &amp; Other Assets</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">151,544</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zaLoQzJniMYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed Assets</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,243</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zpRE5TOLHeq1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">624,366</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zF7WS3oEDFUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Assets Acquired:</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">858,004</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_ztLBL5Vn73w9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts Payable</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">583,577</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zc8gaUrUdn7a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued Expenses</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">722,508</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zZG1qV9C9zRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Lease liability</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">624,367</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zXWz0fg8LK64" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes Payable</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,832,460</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zxGOOPJ2KWs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Liabilities Assumed</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,762,913</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zKwI0eP5MbA4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Assets Acquired</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,904,909</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--Goodwill_iI_zHRyIik7FMrl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">159,464,040</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zHZX42cQ67G1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Consideration</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,559,131</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p id="xdx_8A9_ze4tEVn648n8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected
to be deductible for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The Company
recognized approximately $<span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zz4VgQDDkHod" title="Acquisition related costs">1.2</span> million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#8220;selling, general and administrative expenses&#8221; in the accompanying condensed consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The amounts
of revenue and loss of GEDi Cube, included in the Company&#8217;s consolidated statements of operations from the Closing Date through
June 30, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_zOmaFbuynzC6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8B8_zeLWSDKMJN96" style="display: none; text-align: left; text-indent: -10pt; padding-left: 10pt">Schedule of consolidated
statements of operations</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zp4H0VijRbig" style="text-align: center">&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_z64I3QNoR8ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zcmIUGNg4Swa" style="vertical-align: bottom; background-color: White">
<td style="width: 70%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,243,144</span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


<p id="xdx_8A2_zaCVFPNFr1Le" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the twelve-month
period ended June 30, 2024. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zBEzpRDzvu64" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BB_zKIHK0PZjQql" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of consolidated
    proforma information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zXDOVA9dTWZi" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_zEgo4gSzun87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zyt8a5cHxpy" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(83,571,822</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month
period ended June 30, 2023. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ACQUISITION (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_496_20220701__20230630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zNchmyR3IVbc" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_z3BVtj2Kxp55" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Revenues</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zdddk2sSnw8g" style="vertical-align: bottom; background-color: white">
    <td style="width: 71%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: right"><span style="font-size: 10pt">(42,490,305</span></td>
    <td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p id="xdx_8A0_zfIhwl1NJQOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715224128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zyP6YjorNxXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 &#8212; <span id="xdx_82A_zsAM44MFaptg">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Beginning with the year ended June 30, 2024, the Company has two reportable segments.
Prior to the year ended June 30, 2024, the Company had only a single reportable segment, the acquisition and integration of Renovaro Cube
resulted in the identification of a separate reportable segment by the Company's chief operating decision maker. These segments have different
strategic and economic goals and are managed separately because they require different technology and marketing strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; width: 14%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reportable
Segment</b></span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0pt; white-space: nowrap; width: 84%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
</b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENB</b></span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; white-space: nowrap; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
new immunotherapies to combat cancer &#160; &#160; &#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENC</b></span></td>
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection &#160; &#160;
&#160; &#160; &#160; &#160; &#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The Company&#8217;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2024, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zrJ4efp1h77l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BF_z7ruVRAAMsgj" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt">Schedule of segment operating loss and
    asset information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--US_ziXHlVMmCpw" style="width: 12%; text-align: right" title="Operating income loss">80,470,579</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--US_zaUgX8WbupB4" style="width: 12%; text-align: right" title="Assets">2,998,311</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Netherlands</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--NL_zJF1tuPNXmn3" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss">1,168,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--NL_zDkx9RGnOlG9" style="border-bottom: Black 1pt solid; text-align: right" title="Assets">160,131,139</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--SegmentOperatingLoss_c20230701__20240630_zcNVmfundOdg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss">81,639,296</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--SegmentAsset_iI_c20240630_zspUhtBjXKE7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets">163,129,450</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A8_zj0irXWiTU0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#8217;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#8217;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Information
regarding each reportable segment for the year ended June 30, 2024 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zjCE6BwO8uOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B2_zhAVSfsaNtQj" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of information regarding segment reporting</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_498_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKlTOHhxf1Ja" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_z4LV39ZVDDz8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_491_20230701__20240630_zTY8qzOyXrj7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zdUyiL5QHx4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">23,449,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,108,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">24,557,608</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zuklrLSSTxF6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,651,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,708,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_d0_zZsHuqTePqke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,611,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,611,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zUmYrLUFHhmc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_z7toYdt2lMGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,859</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SegmentOperatingLoss_zt5FK0XzrPik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">80,470,579</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,168,716</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">81,639,296</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_z2BAWHwk3fze" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white; text-indent: 0.5in"><b><span style="text-decoration: underline">Geographic
information:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">RENB and RENC are managed on a worldwide basis but operate in offices located
in the United Stated and the Netherlands, respectively. The geographic information analyses the Company's operations and assets based
on the country in which each segment operates. In presenting this geographic information, segment operating results have been based on
the geographic location in which the services were provided to the segment and segment assets were based on the geographic location of
the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715819328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zIepvWb50mCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 &#8212; <span id="xdx_823_zx0Wl5yWp3Rg">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">Related to the June 14, 2024, Private Placement, ranging from July 3, 2024, to
October 2, 2024, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240703__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbwEal5gqa2j" title="Sale of stock issued">1,525,316</span> Units at a price per Unit equal to $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcRyQIjfQ571" title="Sale of stock price per share">1.4726</span> to a certain investor who paid in cash an aggregate
amount of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240703__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv5HXwphGswg" title="Sale of stock issued cash consideration">2,246,181</span> in consideration of the Units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On August
1, 2024, the Company issued&#160;<span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesIssuedForConsultingServices_c20240731__20240801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWMrTRgQJoEe" title="Issuance of common stock shares">2,000,000</span>&#160;shares of common stock for consulting services valued at $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueIssuedForConsultingServices_c20240731__20240801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSk3Nizyiu1l" title="Common stock for consulting services value">1,400,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, the Company
forfeited <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0fUnIDkavkk" title="Forfeited shares of common stock">833,333</span> shares of Common Stock from the original <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zg9P0Cn5SV0e" title="Original shares of common stock">1,000,000</span> shares of Common Stock for advisory services granted to Avram Miller,
a member of the Company&#8217;s board of directors on October 11, 2023. As consideration for and subject to such forfeiture, the Company
granted to Mr. Miller, an option to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zl7AT3tBZE98" title="Option to purchase shares of common stock">978,261</span> shares of Common Stock of the Company with a per-share exercise price equal to the
fair market value of a share of the Common Stock on the date thereof, $<span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7g2QBv79GJ5" title="Option to purchase shares of common stock par value">0.69</span>. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712314208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessPolicyTextBlock', window );">Business</a></td>
<td class="text"><p id="xdx_840_ecustom--BusinessPolicyTextBlock_zCtkBTkm4538" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_865_z82mb7XDjm1a"><b>Business
</b></span><b>&#8211; </b>On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;). In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven
healthcare technology company that, if it can generate sufficient funding, will also continue to engage in the research and development
of pharmaceutical and biological products for the treatment of cancer and HIV with the intent to manufacture said products. On February
13, 2024, Renovaro Inc. acquired GEDi Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly owned subsidiary
pursuant to a stock purchase agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTPoI30TunA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_860_zqUWD5Hf2rW1">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zsCwLpRfduMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_zEYwhzNWWX1c">Principles of Consolidation</span>
&#8211; </b>For the years ended June 30, 2024 and 2023, the consolidated financial statements include the accounts and operations of Renovaro,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Subsidiaries</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zmOlpHsTOpk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86A_zu4Y3q9DW8Se">Subsidiaries</span> &#8211; </b>Renovaro
Biosciences Inc. (&#8220;Renovaro Biosciences&#8221;), formerly Renovaro Biopharma Inc., was incorporated on May 19, 2017 in Delaware
and is a 100% owned subsidiary of Renovaro. Renovaro Biosciences owns a perpetual, fully paid-up, royalty-free, sublicensable, and sole
and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize
certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV
in humans, and research and development exclusively relating to HIV in humans. As of June 30, 2024 and June 30, 2023, zero and 1,250,000
shares of Common Stock, respectively, remain contingently issuable in connection with the acquisition of Renovaro Biosciences in February
2018 (the &#8220;Contingent Shares&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences Denmark ApS
(&#8220;Renovaro Denmark&#8221;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Renovaro subject to 185,053 shares of Common Stock of Renovaro held in escrow according to Danish
law (the &#8220;Escrow Shares&#8221;). As of June 30, 2024, there are <span id="xdx_902_ecustom--EscrowSharesRemaining_iI_c20240630_zPTtScEVzM09" title="Escrow shares remaining">17,414</span> Escrow Shares remaining (see Note 9.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 13, 2024, the Company
acquired <span id="xdx_901_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zv8GMXEb4Xc6" title="Acquisition percentage">100</span>% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
12.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Accounting Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zUyeFCYi1Mn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86B_zKw8wsgRetn9">Use of Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency and Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zd0IBDoDmAv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_868_zz0esm3S9tD1">Functional Currency and Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;). The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of
these financial statements. The Company&#8217;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates
and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years ended June 30,
2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&#8217;
equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than
the functional currency are included in the statement of operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYzze4EMsqLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zmDCKPeMM7Q9">Cash and Cash Equivalents</span> </b>&#8211;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zXAySCjPuzqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_866_zivhDldXlM9l">Concentration of Credit Risk</span>
&#8211;</b> Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2024, and June 30, 2023, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InsuranceReceivablePolicy', window );">Insurance Receivable</a></td>
<td class="text"><p id="xdx_845_ecustom--InsuranceReceivablePolicy_z2nHO3Uaz1ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86E_zGoifVogyvLa">Insurance Receivable</span> &#8211;</b>
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_znZFYJ0dR5y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zGm4454iLvN8">Property and Equipment</span> </b>-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 4.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zqm81xJWC1Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zZy77FcQIkK1">Intangible Assets</span> - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zPTsAxhA9Zj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zvWXMaDKdB6c">Goodwill</span></b> - Goodwill is not
amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Goodwill and Indefinite Lived Intangible Assets</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z2t7migVRUw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_ztLtjS9Gnd9a">Impairment of Goodwill and Indefinite
Lived Intangible Assets</span></b> &#8211; We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For indefinite life intangible
assets, such as IPR&amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the
IPR&amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023.
During the year ended June 30, 2024, the Company recorded an impairment loss of $42,611,000 related to the termination of the license
agreement with Weird Science LLC (see Note 5.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The carrying value of
IPR&amp;D and goodwill at June 30, 2024, were&#160;zero <span id="xdx_903_ecustom--InProcessResearchAndDevelopment_iI_c20240630_zgdNmgs40Mq4" style="display: none" title="In-process research and development">0</span> and $<span id="xdx_902_eus-gaap--Goodwill_iI_c20240630_zzUVZLh5FIY9" title="Goodwill">159,330,161</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zH3L3Gq0MHVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_869_zCJyAq8yKG0k">Impairment of Long-Lived
Assets</span> - </b>Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. <span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zfZ0RQu56Byk" title="Impairment of assets"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20220701__20230630_zC6SBvTVoZp5" title="Impairment of assets">No</span></span> impairment
of these assets was recorded during the year ended June 30, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zDYiDHm5Uj2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_86E_zcQPMq32T4Xg">Leases</span> -</b> In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zS59JGeVGI0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_z2M4Fvb45Zy3">Research and Development Expenses</span>
&#8211; </b>The Company expenses research and development costs incurred in formulating,
improving, validating, and creating alternative or modified processes related to and expanding the use of the Company&#8217;s technologies.
Research and development expenses for the years ended June 30, 2024 and 2023 amounted to $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_z6mknozksDMg" title="Research and development expense">2,708,829</span>, and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220701__20230630_zTNam0i3PUge" title="Research and development expense">4,165,197</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zi8R7RVllzg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zYcYrZIRngO4">Income Taxes</span> </b>- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 8.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zIGW5pW0zBr" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zX0uNS8uJHd9">Loss Per Share</span></b> - The Company calculates earnings (loss) per share in accordance with FASB ASC
260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding
during each period. Diluted earnings per common share are based on shares outstanding (computed as for basic EPS) and potentially dilutive
common shares. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options
that have been granted but have not been exercised. The shares of Common Stock outstanding at June 30, 2024 and 2023 were <span id="xdx_906_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zw5OieCHee3g" title="Common stock outstanding">152,837,573</span>
and <span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20230630_ztcHsHRLkHg9" title="Common stock outstanding">63,698,144</span>, respectively. Because of the net loss for each of the years ended June 30, 2024 and June 30, 2023, dilutive shares for
both periods were excluded from the diluted EPS calculation, as the effect of these potential shares of Common Stock is anti-dilutive.
The Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zeRkKRein5I1" title="Anti-dilutive shares">17,146,315</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z4zWBToR9xad" title="Anti-dilutive shares">7,949,513</span> potential shares of Common Stock excluded from the diluted EPS calculation for the years ended
June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJ4GG127mXq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zd3ygNizXXM1">Fair Value of Financial Instruments</span>
</b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of June 30, 2024. <span style="background-color: white">Level
3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition
of Renovaro Cube </span>(see Note 3.) There were no Level 1, 2, or 3 assets, nor any Level 1, 2, or 3 liabilities measured at fair value
on a recurring basis as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z7LWcUyS4ke3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_861_zA8jExqaafKd">Stock-Based Compensation</span>
- </b>The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation
&#8211; Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2024 and 2023 were $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zYradUXtK5s1" title="Stock based compensation costs"><span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z3hq54z74ox6" title="Stock based compensation costs">4,673,129</span></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zBWxheZ7LN9k" title="Stock based compensation costs"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zZU080u0jNHd" title="Stock based compensation costs">3,535,051</span></span>, respectively<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the
fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqM3IawMsYyf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86E_z5NM0CWTk5cl">New Accounting Pronouncements Not Yet Adopted</span></b>
- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected to have a material
impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InsuranceReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InsuranceReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451816803456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of key input to valuing the contingent consideration liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueConcentrationOfRiskTextBlock_zBnobOxz4Vtb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B4_zsouarOEXVRg" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Price</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zwBLymJsiZka" title="Stock Price">1.75</span></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5eprAWv41Jc" title="Exercise Price">0.46</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zhNeqFWgidrh" title="Exercise Price">8.23</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zP4z1pEBAC81" title="Volatility">109</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zxf5r3wVt0b1" title="Volatility">145</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Rate</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zs1GUyksvtoa" title="Risk Free Rate">4.24</span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ztV9JVnkrA8c" title="Risk Free Rate">5.21</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividends</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zmMHK42S0KH2" title="Expected Dividends">0</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount Rate (Monte-Carlo model only)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zz2SMfb5pTuc" title="Discount Rate (Monte-Carlo model only)">0</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB4swLUudTNa" title="Expected Term (years)">0.47</span> &#8211; <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zD1KKMlnrDpk" title="Expected Term (years)">9.50</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At initial recognition of the contingent consideration,
the inputs were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Price</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTF6VMTXIC1f" title="Stock Price">1.92</span></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zSTSaYAmurm8" title="Exercise Price">0.46</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zp3IzcJBaQYi" title="Exercise Price">4.50</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zFtT5leyyXs8" title="Volatility">107</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zR4EEyr6Y2mh" title="Volatility">133</span>% </span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Rate</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z9Y2yH7mPZj1" title="Risk Free Rate">4.22</span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zPhGt6Kakbgd" title="Risk Free Rate">5.14</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividends</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zXhsgKfhOyzd" title="Expected Dividends">0</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount Rate (Monte-Carlo model only)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zM7q92wv8mMa" title="Discount Rate (Monte-Carlo model only)">12</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z5r91EIdusQa" title="Expected Term (years)">0.56</span> &#8211; <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zesDQI8RTnPg" title="Expected Term (years)">9.88</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value measurement on recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zbGfG4BLPOI2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BA_z44FWU30YTme" style="display: none">Schedule of fair value measurement on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuxz3uOoLx22" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z20nVmD6NU5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5VPw7GjbsG4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z8wJR90B47wi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ContingentConsiderationInAcquisition_d0_zauLxMdQZTY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Contingent consideration in Acquisition</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">20,557,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SettlementsContingentSharesToBeIssued_d0_znw14uWDtjk3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Settlements: contingent shares to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,520,027</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zDIZ8nQTLE5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Fair value adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,727,473</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zn6e3bHWfmch" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent Consideration Liability at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451818652912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSqHudftYW62" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BB_zu3zrzDbwOw1" style="display: none">Schedule of property and equipment</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Useful Life</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2023</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment and instruments</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zFEWN9XGhgs" title="Useful Life">4</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zCo7vEy4AjXd" title="Useful Life">7</span></span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zxDQdmzWigt4" style="width: 11%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">639,998</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" style="width: 11%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">576,298</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0g8PGI59Hu9" title="Useful Life">10</span></span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzoMogLZBzs9" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224,629</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224,629</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture, fixtures, and equipment</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoX8NBYdyitg" title="Useful Life">4</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaetA179rV2g" title="Useful Life">7</span></span></td>
<td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFJoCWYliyi8" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,834</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,861</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zxdkYuKTIwUf" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,060,461</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20230630_pp0p0" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">973,788</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less accumulated depreciation</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_zBgNg0j2Pjz" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(578,340</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230630_z7O7Yv6Oclv5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(464,799</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Property and Equipment</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zi2dTaTT79C8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">482,121</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">508,989</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715763360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of definite-life and indefinite-life intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEl8nSFh79zj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BE_zguU80daZ7Uc" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7dyK9Qwbij8" title="Useful life">20</span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z96WPpRGp7ch" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning">290,936</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zDOWP0y1wTqb" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5DYEh1SmK9l" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQYZtKdmDtg2" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPKHgqYxtnv7" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(5,959</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0W2FcF7Dnoj" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending">284,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zBgHrcxmYJtd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(251,260</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJm6WFyLE3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvWdkHKVm7xk" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zZ4WN0DaFGT4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zExdjQBCUmc2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">4,622</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_znoeLMcAMwy5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(254,934</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_zFprgLQPC5Eg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">39,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zVzTCs5Srb6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_zwPRsB9kBbWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zyaOCZWWa8a8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zkvryP9DqIj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(1,337</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zwajfl1cIqXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">30,043</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets and Goodwill</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zlIfeJseg7x5" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zY6xVCLQ3dC3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_za115YJY9XE3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zka54eUJGBF9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(11,640,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zPmZDd8OfU2f" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878</td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zg26Cl5CI21e" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">IPR&amp;D</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLn2yjKUMK58" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">42,611,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zHyBYA6yg9da" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zqJR78VGTXu7" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z3BpTO4IOjd6" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(42,611,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziH1YYGLnT83" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zcxD7Crq1oEd" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets and Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_zO5NFDLW0qm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_zTKCCd6mXxU8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zumaKkhNtit6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zZxhATdqgWRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zOEYGv6nCpli" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878)</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zpDO6SouziCc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Period Change</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Effect of Currency Translation</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 15%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znm0KHNgwwpk" title="Useful life">20</span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIE25F2BtUb" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning">279,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9QsOveXJTA6" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJeKX9RMA3Sj" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">11,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvoPlq3Zap8j" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning">290,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zX09lanWwkO2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(234,989</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zUVrP4CkYt2g" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">(6,175</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zKedzq7HqHDh" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(10,096</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zQiEWYbLuOW5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(251,260</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630_zkLX76Nd92W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">44,268</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630_z5hlQtz3s8R3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">(6,175</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630_z615P4r3zdwj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">1,583</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z4eTFgJ8uw5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">39,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">License Agreement</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zpCS3SiQxZM" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">61,571,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zRWYFzXEmA0l" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">(18,960,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zTbpbsu4nJOa" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zvtfob0kTZ85" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">42,611,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z7qFqW4Pbkw5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z74ldD7a5fB5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zm9JF2saKo32" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zA4l0J03Jvs3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630_zZix9ok7dt45" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">73,211,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20220701__20230630_zWaD10y60apk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">(18,960,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630_zPcDEOjnNtD" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z1QN35w9In11" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of expected future amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zXienn3ipfx5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8BB_zShz1BCPmGof" style="display: none">Schedule of expected future amortization expense</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended&#160;June 30,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20240630_zsvcGDIsZ9U9" style="width: 32%; text-align: right" title="2025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,511</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20240630_zSrOJT6GdRVh" style="text-align: right" title="2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,511</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20240630_zqEzxGtJlZMb" style="text-align: right" title="2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,511</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20240630_z079g9uqL5f" style="border-bottom: Black 1pt solid; text-align: right" title="2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,510</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #CCEEFF; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #CCEEFF">Total</span></td><td style="padding-bottom: 2.5pt; color: #CCEEFF; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zfcpDTyWqYdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,043</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451816977424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of lease commitments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHnI1BKjk2W9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left"><span id="xdx_8B0_zI0dHC8GMQWj" style="display: none">Schedule of lease commitments</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ending June 30</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Expense</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; width: 55%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20240630_z91Jc5YnhIbl" style="width: 32%; text-align: right" title="2025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">554,453</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20240630_zsmiQQUwerna" style="text-align: right" title="2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">457,876</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20240630_zlzQZjSgi9h7" style="text-align: right" title="2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">334,788</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_c20240630_zfPOPFOpA5L8" style="text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79,830</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20240630_ziLYInVw9imf" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(91,005</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20240630_zt7k5GblH3Z4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,335,942</span></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of net operating lease expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zClWMCshP0ll" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES  (Details 1)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zVDyewUsV1i4" style="display: none">Schedule of net operating lease expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20230701__20240630_z7Z8JeCBbNge" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220701__20230630_zaAsbDrXA7wa" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr id="xdx_404_eus-gaap--OperatingLeaseExpense_z8QC4eOSRgKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Lease Expense</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">383,549</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">322,447</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--SubleaseIncome_iN_di0_zjjQBthl57J7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-lease Income</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(352,700</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_409_ecustom--OperatingLeaseRentExpenses_zU4fEdtwtDM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Net Lease Expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">383,549</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,253</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451816781536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ztWcSMWdxjSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20240630_zrtimKmuCoh7" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_493_20230630_zsiS1GUd4u15" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
<tr id="xdx_40C_ecustom--DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_iI_pp0p0_maDTALNzwuT_zy85kfWMavXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of fixed assets</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">8,258</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">8,258</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_zHkoz6FQxJG3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of patents</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">8,415</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">8,415</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_zyKcZ9CDZlGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock/options compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">6,672,252</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3,885,996</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_zZQ7YsxC6dyd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">188,422</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">152,059</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_zhXX7JcqYuFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">144,191,530</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">140,547,314</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPBUAL6t8tS3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">16,188,497&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zqRgsu6xVEva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,410,678&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zFEx1Nug8bV7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in tax rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_zsOa3FBgqbL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(168,668,052</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(144,602,042</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_d0_mtDTALNzwuT_zXlzkLjANGZf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Deferred Tax Assets (Liabilities)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zye7fHvoq3m9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zioNRtqge65g" style="display: none">Schedule of reconciliation of income tax expense</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_496_20230701__20240630_zSIkBTY8xu11" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_495_20220701__20230630_zs7bvbPUPSt4" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed tax at expected statutory rate</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,066,011</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(70,341,751</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zxqPCIjJ4Zm4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-US income taxed at different rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zT8grGiUTgcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible expenses / other items</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,066,011</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,341,751</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zDIinjTeozVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income Tax Expense (Benefit)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z4CIuVvF8H48" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 30pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20230701__20240630_zr2YwIHX5iU6" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220701__20230630_zesYaS1viu83" style="text-align: center">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
<tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Income Tax Expense</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zl4O7PzwD6Gj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Danish income tax (benefit)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_zELkXbtmTxTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Current Tax Expense (Benefit)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred Income Tax Expense (Benefit)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationFixedAssets_i01_pp0p0_maDITEBzk3M_z85liOo5WeSb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess of tax over book depreciation of fixed assets</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,258</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,258</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationPatents_i01_pp0p0_maDITEBzk3M_z1yauBO3fNuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess of tax over book depreciation of patents</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,415</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,415</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_pp0p0_maDITEBzk3M_zG0AXNB2Sh1b" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock/options compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,672,252</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,885,996</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_i01_pp0p0_maDITEBzk3M_zK3c0RPowwug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,422</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,059</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--IncomeTaxExpenseBenefitOperatingLossCarryforwards_i01_pp0p0_maDITEBzk3M_zJa1QBHTfmG3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,191,530</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140,547,314</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--IncomeTaxExpenseBenefitImpairmentExpense_i01_pp0p0_d0_maDITEBzk3M_z2jEHfKiLsj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">16,188,497&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--IncomeTaxExpenseBenefitContingentConsiderationFairValue_i01_pp0p0_d0_maDITEBzk3M_z8ygs5gtrVLi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;Contingent consideration fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,410,678&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredIncomeTaxExpenseChangeInTaxRate_i01_pp0p0_d0_maDITEBzk3M_zM7EdBLlqlLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in tax rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0p0_di_msDITEBzk3M_z5Eh1OC24NW5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in the valuation allowance</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(168,668,052</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(144,602,042</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_zT3pXbVezUE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Deferred Tax Expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714188384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ziYDjmukkW87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B7_zZekknpnQxkf" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Inc.</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (in years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zxI0mQVwU0w8" title="Expected term (in years)">5.0</span> &#8211; <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zTEAG4zVuCO" title="Expected term (in years)">6.5</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zil2MGMcU6S2" title="Volatility">84.33</span>% &#8211; <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zLpHcN3GAqie" title="Volatility">114.88</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zSI9QmAnsQbf" title="Risk free interest rate">3.12</span>%- <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBWEbywJ1kkh" title="Risk free interest rate">4.83</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 75%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td>
<td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230701__20240630__dei--LegalEntityAxis__custom--RenovaroMember_zbOyIYpfcVh1" title="Dividend yield">0</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock options outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zT9pS2QOYL1g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zcvOLyxfHAd1" style="display: none">Schedule of stock options outstanding</span></td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Outstanding</span></td><td style="padding-bottom: 1pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ranges</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 10%; font-size: 11pt; text-align: right; text-indent: -10pt"></td><td style="width: 1%; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoj3UP0Zi3ak" title="Exercise Prices, Lower">0.45</span>&#8211;<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zL0sWyyJuEz4" title="Exercise Prices, Upper">4.50</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjlok0NFGud7" style="width: 9%; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,244,987</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlGCuS8k9Mp7" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">7.38</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDpZZNCO6LRb" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.89</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z22dzV2B8Kq2" style="width: 9%; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,817,105</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zxuFiyv6UiI9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">7.15</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zNTwhPrOcLm7" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zq9vHnGJWQV2" title="Exercise Prices, Lower">4.51</span>&#8211;<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zciuoVCxbwIc" title="Exercise Prices, Upper">6.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zBiexlnMnqN5" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">167,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zOcUyvdWiRYe" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">6.48</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_znLyCeBR1gq" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zG4XmsEVoZtd" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,376</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zlLnBvEEgxHl" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">5.81</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z8XvPUv82eC3" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zxgHQnjms6K9" title="Exercise Prices, Lower">6.51</span>&#8211;<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z1iHs4UyFfn" title="Exercise Prices, Upper">12.00</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zJDB519dnxl5" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,231</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z95XU05DBeYj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">4.66</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zqGoGpDbGFJg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.63</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zd9mGZcrJfqc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111,585</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zYpGqlOd5Zdi" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">4.57</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zOBaby8lmIFi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.61</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z0FnfEqDYY8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,527,852</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zUtQF25tWt92" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">7.29</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2njRW3iJke7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSLtYzFUsth9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,064,066</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z56RVX2La7W6" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">7.03</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFXK6LhPxeE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zB5GW3YRRQLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zw9nn7pGElIh" style="display: none">Schedule of stock option activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Remaining Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Intrinsic<br/> Value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zqOYtBsVQHrj" style="width: 13%; text-align: right" title="Options Outstanding at beginning of period">4,401,211</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zuydU65POhs6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">4.78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zA0GqPCBt3ef" title="Weighted Average remaining life">7.82</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWtzNzpAK1hg" style="width: 13%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zoHzvvRQOfGe" style="text-align: right" title="Granted">4,983,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zaqAJu6klj2j" style="text-align: right" title="Weighted average exercise price, Granted">1.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zY7qYMCgsDV" style="text-align: right" title="Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zVSnrPz3OMOi" style="text-align: right" title="Weighted average exercise price, Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zrixLPhkVI27" style="text-align: right" title="Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_ztZA2pG3dtv4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired/Canceled </span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zSpp8TEe05Zb" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">(3,856,931</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z6p89UjP9Uth" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">4.94</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z4j7YnkZlqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period">5,527,852</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zFd7mtnTwQe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period">2.11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjVPtAU0P3G3" title="Weighted Average remaining life">7.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxhKc537x1n2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zTcizUH5ETt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">4,064,066</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhiWPKQHagb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period">2.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zffv5yDgJU66" title="Weighted Average Remaining Life, Exercisable">7.05</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zp4eeIM2rhv" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period">525,943</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of common stock purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_z15TSkAxnsY5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B9_zKDohMfsJ2Xf" style="display: none">Schedule of common stock purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                            (years)</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zVP8y94nQXYk" style="width: 9%; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.53</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zK4rbHn9NDrg" style="width: 9%; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">471,698</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zPGq0Ov22cbg" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">1.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z7hyH1ivX6yc" style="width: 9%; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">471,698</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zbFuATanrD0i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">1.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zb7LOW9sKtX" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zGRWikXfOpP8" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z5FKhhbk0KV4" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zz962SNTavV1" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zXQZuEZjvPE7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDWgYmDaVoX7" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zsmq8SZi4Zia" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,189,036</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDlwyhcY1gt5" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.73</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zHQpPrwjKjQi" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,189,036</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zscw9Uwubqhb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.73</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zTCr0coe40u2" style="text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyqBq827QNRb" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">642,128</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zrwVmoHgrzhl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">4.96</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zqbHHcTCLnba" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">642,128</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z7uoQANbhZ7i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">4.96</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zarw1JsAZnn2" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zxmv2q80PLIf" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,740</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zfX6NxHlPMfj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">4.99</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zoOIOuAFfvfl" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,740</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z1KgSx9mvVM9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">4.99</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zsRMblqnRRyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,094,876</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zy6LzXLVkzXa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.48</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zfj00j7Vcl66" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zpKbBGNg1hDh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,094,876</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zibIj0t3A8Kg" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.48</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zRKHO2xYrCzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfWarrantsOutstandingTableTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_ztFOeXoPMG9e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BE_zU6u061FCDDe" style="display: none">Schedule of warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining<br/> Life</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Outstanding at June 30, 2023</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zW15v1YzQH09" style="width: 11%; text-align: right" title="Outstanding at beginning of period">3,548,302</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXAGuqsB02k3" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">0.73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zszXr2mEb9t1" title="Weighted Average remaining life, Outstanding">4.80</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkr824MJeNK6" style="text-align: right" title="Granted">3,497,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_ztJ9eeD9EDDf" style="text-align: right" title="Weighted average exercise price, Granted">0.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zp9CTBEdlPq8" title="Weighted Average remaining life, Granted">4.27</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zojIebZ8mG33" style="text-align: right" title="Exercised">(3,951,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z4cmo8MvhJAd" style="text-align: right" title="Weighted average exercise price, Exercised">0.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_znRVOnkAZAql" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zJUKdMhvktH9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding and exercisable at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_ecustom--CommonStockPurchaseWarrant_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zQDiCVjl0PCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period">3,094,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z2x7roGAMXy8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period">1.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zzhIRpQ4RLQ4" title="Weighted Average remaining life, Outstanding">3.48</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451716043696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock', window );">Schedule of acquisition date fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_zSVvaUuM9A34" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8B5_z8PF5HteaUe9" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of acquisition
date fair value</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_987_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zEyPw6ZlO64h" style="width: 18%; text-align: right" title="Common stock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,001,631</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent consideration</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zjoz7V4huMji" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,557,500</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total consideration transferred</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_988_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zDGlty6NlcNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,559,131</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of fair value of assets acquired and liabilities assumed</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zhQ1zpvhkhpd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)">
<tr style="vertical-align: bottom">
<td id="xdx_8BE_zxLldG2RVoqe" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of fair value of assets acquired and
liabilities assumed</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zq6XQ3FaWyjk" style="text-align: center">&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_zN7yl1t9V7j1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td>
<td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,851</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zPtCA0lnhfvl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid &amp; Other Assets</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">151,544</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zaLoQzJniMYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed Assets</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,243</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zpRE5TOLHeq1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">624,366</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zF7WS3oEDFUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Assets Acquired:</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">858,004</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_ztLBL5Vn73w9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts Payable</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">583,577</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zc8gaUrUdn7a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued Expenses</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">722,508</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zZG1qV9C9zRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Lease liability</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">624,367</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zXWz0fg8LK64" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes Payable</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,832,460</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zxGOOPJ2KWs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Liabilities Assumed</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,762,913</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zKwI0eP5MbA4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Assets Acquired</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,904,909</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--Goodwill_iI_zHRyIik7FMrl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">159,464,040</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zHZX42cQ67G1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Consideration</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,559,131</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock', window );">Schedule of consolidated statements of operations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_zOmaFbuynzC6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td id="xdx_8B8_zeLWSDKMJN96" style="display: none; text-align: left; text-indent: -10pt; padding-left: 10pt">Schedule of consolidated
statements of operations</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zp4H0VijRbig" style="text-align: center">&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_z64I3QNoR8ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zcmIUGNg4Swa" style="vertical-align: bottom; background-color: White">
<td style="width: 70%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
<td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,243,144</span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of consolidated proforma information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zBEzpRDzvu64" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BB_zKIHK0PZjQql" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of consolidated
    proforma information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zXDOVA9dTWZi" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_zEgo4gSzun87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zyt8a5cHxpy" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="width: 10%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(83,571,822</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month
period ended June 30, 2023. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ACQUISITION (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_496_20220701__20230630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zNchmyR3IVbc" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_z3BVtj2Kxp55" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Revenues</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zdddk2sSnw8g" style="vertical-align: bottom; background-color: white">
    <td style="width: 71%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; width: 17%; text-align: right"><span style="font-size: 10pt">(42,490,305</span></td>
    <td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451816840560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment operating loss and asset information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zrJ4efp1h77l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BF_z7ruVRAAMsgj" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt">Schedule of segment operating loss and
    asset information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--US_ziXHlVMmCpw" style="width: 12%; text-align: right" title="Operating income loss">80,470,579</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--US_zaUgX8WbupB4" style="width: 12%; text-align: right" title="Assets">2,998,311</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Netherlands</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--NL_zJF1tuPNXmn3" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss">1,168,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--NL_zDkx9RGnOlG9" style="border-bottom: Black 1pt solid; text-align: right" title="Assets">160,131,139</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--SegmentOperatingLoss_c20230701__20240630_zcNVmfundOdg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss">81,639,296</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--SegmentAsset_iI_c20240630_zspUhtBjXKE7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets">163,129,450</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of information regarding segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zjCE6BwO8uOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B2_zhAVSfsaNtQj" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of information regarding segment reporting</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_498_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKlTOHhxf1Ja" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_z4LV39ZVDDz8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_491_20230701__20240630_zTY8qzOyXrj7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zdUyiL5QHx4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">23,449,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,108,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">24,557,608</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zuklrLSSTxF6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,651,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,708,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_d0_zZsHuqTePqke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,611,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,611,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zUmYrLUFHhmc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_z7toYdt2lMGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,859</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SegmentOperatingLoss_zt5FK0XzrPik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">80,470,579</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,168,716</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">81,639,296</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451716610720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_EscrowSharesRemaining', window );">Escrow shares remaining</a></td>
<td class="nump">17,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">159,330,161<span></span>
</td>
<td class="nump">$ 11,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 2,708,829<span></span>
</td>
<td class="nump">$ 4,165,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">152,837,573<span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">17,146,315<span></span>
</td>
<td class="nump">7,949,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation costs</a></td>
<td class="nump">$ 4,673,129<span></span>
</td>
<td class="nump">$ 3,535,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember', window );">Options Held [Member] | Employees, Officers, Directors and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation costs</a></td>
<td class="nump">4,673,129<span></span>
</td>
<td class="nump">3,535,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees, Officers, Directors and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation costs</a></td>
<td class="nump">$ 4,673,129<span></span>
</td>
<td class="nump">$ 3,535,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember', window );">Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionPercentage', window );">Acquisition percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_EscrowSharesRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_EscrowSharesRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=RENB_EmployeesOfficersDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=RENB_EmployeesOfficersDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715214912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 80,650,172<span></span>
</td>
<td class="nump">$ 39,684,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">220,467<span></span>
</td>
<td class="nump">1,874,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">324,679,425<span></span>
</td>
<td class="nump">$ 244,029,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="nump">$ 28,312,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714775504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Black Scholes Option Pricing Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock Price</a></td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate', window );">Discount Rate (Monte-Carlo model only)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Black Scholes Option Pricing Model [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">109.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">4.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">5 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Black Scholes Option Pricing Model [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">145.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">5.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember', window );">Initial Recognition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock Price</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate', window );">Discount Rate (Monte-Carlo model only)</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember', window );">Initial Recognition [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">4.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">6 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember', window );">Initial Recognition [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">133.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">5.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">9 years 10 months 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715309696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationInAcquisition', window );">Contingent consideration in Acquisition</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SettlementsContingentSharesToBeIssued', window );">Settlements: contingent shares to be issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at June 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationInAcquisition', window );">Contingent consideration in Acquisition</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SettlementsContingentSharesToBeIssued', window );">Settlements: contingent shares to be issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at June 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationInAcquisition', window );">Contingent consideration in Acquisition</a></td>
<td class="nump">20,557,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SettlementsContingentSharesToBeIssued', window );">Settlements: contingent shares to be issued</a></td>
<td class="num">(3,520,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="num">(4,727,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at June 30, 2024</a></td>
<td class="nump">$ 12,310,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationInAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationInAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SettlementsContingentSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SettlementsContingentSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451713450336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative) - Renovaro Cube [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,613,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability was recorded at fair value</a></td>
<td class="nump">$ 20,557,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="nump">70,834,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714135376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 1,060,461<span></span>
</td>
<td class="nump">$ 973,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less Accumulated Depreciation</a></td>
<td class="num">(578,340)<span></span>
</td>
<td class="num">(464,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Property and Equipment</a></td>
<td class="nump">482,121<span></span>
</td>
<td class="nump">508,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=RENB_LabEquipmentAndInstrumentsMember', window );">Lab Equipment And Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 639,998<span></span>
</td>
<td class="nump">576,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 224,629<span></span>
</td>
<td class="nump">224,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 195,834<span></span>
</td>
<td class="nump">$ 172,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lab Equipment And Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lab Equipment And Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=RENB_LabEquipmentAndInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=RENB_LabEquipmentAndInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712239344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 113,563<span></span>
</td>
<td class="nump">$ 107,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451713784976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 39,676<span></span>
</td>
<td class="nump">$ 44,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(8,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="num">(1,337)<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">30,043<span></span>
</td>
<td class="nump">39,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">54,251,000<span></span>
</td>
<td class="nump">73,211,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="nump">159,464,039<span></span>
</td>
<td class="num">(18,960,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="num">(54,251,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="num">(133,878)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="nump">$ 159,330,161<span></span>
</td>
<td class="nump">54,251,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 290,936<span></span>
</td>
<td class="nump">279,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="num">(5,959)<span></span>
</td>
<td class="nump">11,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">284,977<span></span>
</td>
<td class="nump">290,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember', window );">Less Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="num">(251,260)<span></span>
</td>
<td class="num">(234,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(8,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="nump">4,622<span></span>
</td>
<td class="num">(10,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="num">(254,934)<span></span>
</td>
<td class="num">(251,260)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">11,640,000<span></span>
</td>
<td class="nump">11,640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="nump">159,464,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="num">(11,640,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="num">(133,878)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="nump">159,330,161<span></span>
</td>
<td class="nump">11,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">42,611,000<span></span>
</td>
<td class="nump">61,571,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,960,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="num">(42,611,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42,611,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NetDefinitelifeIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NetDefinitelifeIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NetDefinitelifeIntangibleAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NetDefinitelifeIntangibleAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments and purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from foreign currency translation and purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715805168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 7,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">7,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">7,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">7,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 30,043<span></span>
</td>
<td class="nump">$ 39,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715220576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Definite-life intangible assets</a></td>
<td class="nump">$ 30,043<span></span>
</td>
<td class="nump">$ 39,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">8,296<span></span>
</td>
<td class="nump">6,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment adjustment</a></td>
<td class="nump">42,611,000<span></span>
</td>
<td class="nump">18,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment adjustment</a></td>
<td class="nump">$ 11,640,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714871264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 554,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">457,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">334,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree', window );">Thereafter</a></td>
<td class="nump">79,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(91,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,335,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714144288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES  (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease Expense</a></td>
<td class="nump">$ 383,549<span></span>
</td>
<td class="nump">$ 322,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sub-lease Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OperatingLeaseRentExpenses', window );">Total Net Lease Expense</a></td>
<td class="nump">$ 383,549<span></span>
</td>
<td class="num">$ (30,253)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OperatingLeaseRentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OperatingLeaseRentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714101152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 18, 2023</div></th>
<th class="th"><div>Jun. 20, 2022</div></th>
<th class="th"><div>Jun. 19, 2018</div></th>
<th class="th"><div>Nov. 13, 2017</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease premises, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.<span></span>
</td>
<td class="text">On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the &#8220;Landlord&#8221;) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription', window );">Sublease agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the &#8220;Subtenant&#8221;), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCosts', window );">Lease payment</a></td>
<td class="nump">$ 139,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">35,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Termination fee</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,983<span></span>
</td>
<td class="nump">$ 439,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OperatingLeaseExpenses', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CashPaidForTheTerminationOfLease', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AccrualPaymentsRelatedToTerminationOfLease', window );">Accrual payments related to the termination of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,549<span></span>
</td>
<td class="nump">$ 322,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AccrualPaymentsRelatedToTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AccrualPaymentsRelatedToTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CashPaidForTheTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CashPaidForTheTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OperatingLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OperatingLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of residual value guarantee provided by sublessee on finance sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of early contract termination fees included in liabilities subject to compromise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451620977008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 12, 2024</div></th>
<th class="th"><div>Jan. 11, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 22, 2023</div></th>
<th class="th"><div>Nov. 03, 2023</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Feb. 06, 2020</div></th>
<th class="th"><div>Dec. 29, 2023</div></th>
<th class="th"><div>Oct. 05, 2023</div></th>
<th class="th"><div>Jun. 04, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestExpenseRelatedToNoteBalance', window );">Interest expense related to note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,770,512<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">4,011,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011,322<span></span>
</td>
<td class="nump">580,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember', window );">Finance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,128<span></span>
</td>
<td class="nump">21,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_MonthlyInstallments', window );">Monthly instalments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RepaymentOnFinanceAgreement', window );">Down payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870,073<span></span>
</td>
<td class="nump">1,121,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember', window );">Finance Agreement [Member] | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Rate of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember', window );">RS Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OriginalIssueDiscountPromissoryNotePercentage', window );">Original issue discount promissory note percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GrossProceedsDiscountPercentage', window );">Gross proceeds original issue discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_ConvertibleNotesPayablesMember', window );">Convertible Notes Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_AmendedAndRestatedSecuredNotesMember', window );">Amended And Restated Secured Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PrepaymentShares', window );">Prepayment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInterest', window );">Prepaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember', window );">The Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="nump">1,424,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 2,098,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal and interest accrued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,098,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_RSBioApSMember', window );">RS Bio ApS [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Net of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_RSBioApSMember', window );">RS Bio ApS [Member] | Interest Expense [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_RSBioApSMember', window );">RS Bio ApS [Member] | Accrued Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_LoanAgreementMember', window );">Loan Agreement [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestExpenseRelatedToNoteBalance', window );">Interest expense related to note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2023<span></span>
</td>
<td class="text">Nov. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued for debt conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299,178<span></span>
</td>
<td class="nump">$ 493,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Rate of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_MarketPrice', window );">Market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment on promissory note</a></td>
<td class="nump">$ 418,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PromissoryNoteBalanceNetOfDiscount', window );">Promissory note balance, net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember', window );">Promissory Note [Member] | Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment on promissory note</a></td>
<td class="nump">100,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember', window );">Promissory Note [Member] | Subscription Agreements 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment on promissory note</a></td>
<td class="nump">318,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember', window );">Promissory Note [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393,763<span></span>
</td>
<td class="nump">$ 348,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_Note2020Member', window );">Note 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">418,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Rate of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Rate of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,425,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_WarrantsPurchased', window );">Warrants purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Amended And Restated Secured Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued for debt conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,718,532<span></span>
</td>
<td class="nump">2,378,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 665,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="nump">454,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 100,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_MarchNote2024Member', window );">March Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestExpenseRelatedToNoteBalance', window );">Interest expense related to note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_MarchNote2024Member', window );">March Note 2024 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_MarchNote2024Member', window );">March Note 2024 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="nump">344,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 512,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 29,  2024<span></span>
</td>
<td class="text">Jan. 11,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestExpenseRelatedToNoteBalance', window );">Interest expense related to note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bear interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Net of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | Interest Expense [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | Accrued Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | RS Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OriginalIssueDiscountPromissoryNotePercentage', window );">Original issue discount promissory note percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GrossProceedsDiscountPercentage', window );">Gross proceeds original issue discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="nump">325,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 483,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestExpenseRelatedToNoteBalance', window );">Interest expense related to note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bear interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Private Placement 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Private Placement 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Private Placement 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="nump">317,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest amount</a></td>
<td class="nump">28,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_Note2023Member', window );">Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  05,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestExpenseRelatedToNoteBalance', window );">Interest expense related to note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OriginalIssueDiscountPromissoryNotePercentage', window );">Original issue discount promissory note percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DebtInstrumentOriginalIssueDiscount', window );">Original issue discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount accreted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockAndReceivedGrossProceeds', window );">Common stock and received gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OfferingPricePerSharePercentage', window );">Offering price per share percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DebtInstrumentsFloorPricePerShare', window );">Floor price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss', window );">Discount amortization to other income and expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_Note2023Member', window );">Note 2023 [Member] | Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_Note2023Member', window );">Note 2023 [Member] | Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price</a></td>
<td class="nump">$ 1.4765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_Note2023Member', window );">Note 2023 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 2,293,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="nump">1,546,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 443,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other Notes Payable</a></td>
<td class="nump">$ 318,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_November2023NoteMember', window );">November 2023 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Net of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExerciseWarrants', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_WarrantsOutstandingPerShare', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExerciseWarrantsAmount', window );">Exercise warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_November2023NoteMember', window );">November 2023 Note [Member] | RS Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OriginalIssueDiscountPromissoryNotePercentage', window );">Original issue discount promissory note percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount accreted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GrossProceedsDiscountPercentage', window );">Gross proceeds original issue discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockAndReceivedGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockAndReceivedGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DebtInstrumentOriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DebtInstrumentOriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DebtInstrumentsFloorPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DebtInstrumentsFloorPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExerciseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExerciseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExerciseWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExerciseWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_GrossProceedsDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_GrossProceedsDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InterestExpenseRelatedToNoteBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InterestExpenseRelatedToNoteBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_MarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_MarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_MonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_MonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OfferingPricePerSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OfferingPricePerSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OriginalIssueDiscountPromissoryNotePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OriginalIssueDiscountPromissoryNotePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PrepaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PrepaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PromissoryNoteBalanceNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PromissoryNoteBalanceNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RepaymentOnFinanceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RepaymentOnFinanceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_WarrantsOutstandingPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_WarrantsOutstandingPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_WarrantsPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_WarrantsPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income or expense, including any amortization and accretion (as applicable) of discounts and premiums, including consideration of the provisions for loan, lease, credit, and other related losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_ConvertibleNotesPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_ConvertibleNotesPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_AmendedAndRestatedSecuredNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_AmendedAndRestatedSecuredNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_RSBioApSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_RSBioApSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=RENB_AccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=RENB_AccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_SubscriptionAgreements1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_SubscriptionAgreements1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_Note2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_Note2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_MarchNote2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_MarchNote2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_DecemberNote2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PrivatePlacement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_PrivatePlacement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PrivatePlacement2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_PrivatePlacement2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PrivatePlacement3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_PrivatePlacement3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_Note2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_Note2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_November2023NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_November2023NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451621179840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets', window );">Excess of tax over book depreciation of fixed assets</a></td>
<td class="nump">$ 8,258<span></span>
</td>
<td class="nump">$ 8,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents', window );">Excess of tax over book depreciation of patents</a></td>
<td class="nump">8,415<span></span>
</td>
<td class="nump">8,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockoptionsCompensation', window );">Stock/options compensation</a></td>
<td class="nump">6,672,252<span></span>
</td>
<td class="nump">3,885,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DepreciationAndAmortizations', window );">Depreciation and amortization</a></td>
<td class="nump">188,422<span></span>
</td>
<td class="nump">152,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">144,191,530<span></span>
</td>
<td class="nump">140,547,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ImpairmentExpense', window );">&#160;Impairment expense</a></td>
<td class="nump">16,188,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationFairValue', window );">Contingent consideration fair value</a></td>
<td class="nump">1,410,678<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(168,668,052)<span></span>
</td>
<td class="num">(144,602,042)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total Deferred Tax Assets (Liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DepreciationAndAmortizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DepreciationAndAmortizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ImpairmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ImpairmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockoptionsCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockoptionsCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451817521936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Computed tax at expected statutory rate</a></td>
<td class="num">$ (24,066,011)<span></span>
</td>
<td class="num">$ (70,341,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Non-US income taxed at different rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses / other items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">24,066,011<span></span>
</td>
<td class="nump">70,341,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451716364352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Income Tax Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Danish income tax (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current Tax Expense (Benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Income Tax Expense (Benefit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExcessTaxBenefitOverDepreciationFixedAssets', window );">Excess of tax over book depreciation of fixed assets</a></td>
<td class="nump">8,258<span></span>
</td>
<td class="nump">8,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExcessTaxBenefitOverDepreciationPatents', window );">Excess of tax over book depreciation of patents</a></td>
<td class="nump">8,415<span></span>
</td>
<td class="nump">8,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock/options compensation</a></td>
<td class="nump">6,672,252<span></span>
</td>
<td class="nump">3,885,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">188,422<span></span>
</td>
<td class="nump">152,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">144,191,530<span></span>
</td>
<td class="nump">140,547,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IncomeTaxExpenseBenefitImpairmentExpense', window );">&#160;Impairment expense</a></td>
<td class="nump">16,188,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue', window );">&#160;Contingent consideration fair value</a></td>
<td class="nump">1,410,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DeferredIncomeTaxExpenseChangeInTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in the valuation allowance</a></td>
<td class="num">(168,668,052)<span></span>
</td>
<td class="num">(144,602,042)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred Tax Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DeferredIncomeTaxExpenseChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DeferredIncomeTaxExpenseChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExcessTaxBenefitOverDepreciationFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExcessTaxBenefitOverDepreciationFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExcessTaxBenefitOverDepreciationPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExcessTaxBenefitOverDepreciationPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IncomeTaxExpenseBenefitImpairmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IncomeTaxExpenseBenefitImpairmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451820492576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - United States Tax [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 489,177,759<span></span>
</td>
<td class="nump">$ 476,965,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets</a></td>
<td class="nump">$ 144,191,530<span></span>
</td>
<td class="nump">$ 140,547,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=RENB_UnitedStatesTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=RENB_UnitedStatesTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451715497824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Renovaro [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">84.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.12%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">114.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.83%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=RENB_RenovaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=RENB_RenovaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712227600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - Share-Based Payment Arrangement, Option [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="nump">5,527,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">4,064,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Prices, Lower</a></td>
<td class="nump">0.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices, Upper</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="nump">5,244,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">3,817,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Prices, Lower</a></td>
<td class="nump">4.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices, Upper</a></td>
<td class="nump">$ 6.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="nump">167,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">135,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Prices, Lower</a></td>
<td class="nump">6.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices, Upper</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="nump">115,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">111,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451716605536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) - Employee Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning of period</a></td>
<td class="nump">4,401,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average remaining life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Intrinsic Value, Outstanding at beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">4,983,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled/Expired</a></td>
<td class="num">(3,856,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at end of period</a></td>
<td class="nump">5,527,852<span></span>
</td>
<td class="nump">4,401,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at ending of period</a></td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Intrinsic Value, Outstanding at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">4,064,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at ending of period</a></td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">7 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Weighted Average Intrinsic Value, Exercisable end of period</a></td>
<td class="nump">$ 525,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_EmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_EmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451713523536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 3) - Common Stock Purchase Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">3,094,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">3,094,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">471,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">471,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">741,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">741,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">1,189,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">1,189,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Exercise Price Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">642,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">642,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Exercise Price Range 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">50,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">50,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714795568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 4) - Common Stock Purchase Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrant', window );">Outstanding at beginning of period</a></td>
<td class="nump">3,548,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of period</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average remaining life, Outstanding</a></td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,497,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted Average remaining life, Granted</a></td>
<td class="text">4 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(3,951,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled/Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrant', window );">Outstanding at end of period</a></td>
<td class="nump">3,094,876<span></span>
</td>
<td class="nump">3,548,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at ending of period</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockPurchaseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockPurchaseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451624568528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Apr. 05, 2024</div></th>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Dec. 04, 2023</div></th>
<th class="th"><div>Oct. 23, 2023</div></th>
<th class="th"><div>Sep. 28, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Jul. 28, 2023</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 10, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
<th class="th"><div>Feb. 06, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockShareIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,027,245<span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
<td class="nump">155,027,245<span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,027,245<span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
<td class="nump">155,027,245<span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockConvertibleSharesIssuable', window );">Common stock, shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Obligation to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,303,578)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SettlementOfDebt', window );">Settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering', window );">Issuance of common stock under private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockParValuePrivatePlacement', window );">Common stock par value under private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds of private placement offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">$ 4,011,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_EarnOutDistribution', window );">Earn-out distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,762,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExtinguishmentOfContingentConsiderationLiability', window );">Extinguishment of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,673,129<span></span>
</td>
<td class="nump">$ 3,535,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,673,129<span></span>
</td>
<td class="nump">$ 3,535,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock purchase warrants exercisable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,094,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,094,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total intrinsic value of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,309,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,309,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">184,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=RENB_EquityIncentivePlan2014Member', window );">Equity Incentive Plan 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=RENB_PlanOptionsMember', window );">Plan Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,665,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Options available to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,515,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Converted shares of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=RENB_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,344,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,344,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,415,157<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Number of value grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RENB_StockPurchaseAgreementOfRenovaroCubeMember', window );">Stock Purchase Agreement Of Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,834,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,001,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,671,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Paid in cash and settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478,060<span></span>
</td>
<td class="nump">$ 478,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PrincipalAmountAndInterestAccrued', window );">Principal amount and interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Investor1Member', window );">Investor 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Paid in cash and settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PrincipalAmountAndInterestAccrued', window );">Principal amount and interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_RenovaroBioPharmaIncMember', window );">Renovaro Bio Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_DanDritDenmarkMember', window );">Dan Drit Denmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_RenovaroDenmarkMember', window );">Renovaro Denmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,500<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Employees1Member', window );">Employees 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember', window );">Board Of Directors And Scientific Advisory Board One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,412<span></span>
</td>
<td class="nump">355,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember', window );">Board Of Directors And Scientific Advisory Board Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,729<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_ConsultingServicesMember', window );">Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember', window );">Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred Stock, Convertible, Shares Issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,610,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_EBIAndWeirdScienceLLCMember', window );">EBI And Weird Science LLC [Member] | Agreement And Plan Of Merger Agreement Axis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable', window );">Common shares contingently issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Closed private placement units</a></td>
<td class="nump">5,315,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ClosedSharesParValue', window );">Closed shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePricePerShare', window );">Exercise price per share</a></td>
<td class="nump">$ 1.4765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Paid in cash and settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,425,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds of private placement offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_OneWarrantMember', window );">One Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PreferredStockDesignatedShares', window );">Preferred stock designated shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_PreferredStockIssuancesMember', window );">Preferred Stock Issuances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Closed private placement units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ConversionOfPromissoryNote', window );">Conversion of promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AggregatePreferredStockShares', window );">Aggregate preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AggregateCommonStockShares', window );">Aggregate common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,610,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_WarrantsSold', window );">Warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,805,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,805,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember', window );">Common Stock Issuances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock purchase warrants exercisable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,953,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized', window );">Warrants aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1', window );">Non cash earn out distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,762,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Single Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock purchase warrants exercisable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized', window );">Warrants aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">250,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_AdvisoryServicesMember', window );">Advisory Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,718,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,378,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds of private placement offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NumberOfShareWarrantPurchase', window );">Number of share warrant purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,359,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PurchaseSharesOfCommonStock', window );">Purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AggregateCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AggregateCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AggregatePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AggregatePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ClosedSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ClosedSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockParValuePrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockParValuePrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ConversionOfPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ConversionOfPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_EarnOutDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_EarnOutDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExtinguishmentOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExtinguishmentOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NumberOfShareWarrantPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NumberOfShareWarrantPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PreferredStockDesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PreferredStockDesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PrincipalAmountAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PrincipalAmountAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_WarrantsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_WarrantsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of expense or revenue offset related to the warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=RENB_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=RENB_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=RENB_PlanOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=RENB_PlanOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_StockPurchaseAgreementOfRenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_StockPurchaseAgreementOfRenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Investor1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Investor1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_RenovaroBioPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_RenovaroBioPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_DanDritDenmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_DanDritDenmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_RenovaroDenmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_RenovaroDenmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Employees1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Employees1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_EBIAndWeirdScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_EBIAndWeirdScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_AgreementAndPlanOfMergerAgreementAxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_AgreementAndPlanOfMergerAgreementAxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_OneWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_OneWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_PreferredStockIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_PreferredStockIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_SingleRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_SingleRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_AdvisoryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_AdvisoryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451624959280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
<th class="th"><div>Aug. 25, 2021</div></th>
<th class="th"><div>Feb. 06, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Nov. 15, 2019</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UpfrontPayment', window );">Up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PaymentForExpenditures', window );">Payment for expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InitialPayment', window );">Initial payment</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Remaining shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember', window );">G Tech [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PaymentForExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PaymentForExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451713414224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 12, 2024</div></th>
<th class="th"><div>Jan. 11, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Nov. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,770,512<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 29,  2024<span></span>
</td>
<td class="text">Jan. 11,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_November2023NoteMember', window );">November 2023 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember', window );">Mark Dybul [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Accrued balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember', window );">RS Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant exercise price</a></td>
<td class="nump">471,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payables</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OriginalIssueDiscountPromissoryNotePercentage', window );">Original issue discount promissory note percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GrossProceedsOriginalIssueDiscountRate', window );">Gross proceeds original issue discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember', window );">RS Bio [Member] | January Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OriginalIssueDiscountPromissoryNotePercentage', window );">Original issue discount promissory note percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GrossProceedsOriginalIssueDiscountRate', window );">Gross proceeds original issue discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Note balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember', window );">RS Bio [Member] | November 2023 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OriginalIssueDiscountPromissoryNotePercentage', window );">Original issue discount promissory note percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GrossProceedsOriginalIssueDiscountRate', window );">Gross proceeds original issue discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount accreted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_GrossProceedsOriginalIssueDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_GrossProceedsOriginalIssueDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OriginalIssueDiscountPromissoryNotePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OriginalIssueDiscountPromissoryNotePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_November2023NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_November2023NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451818679040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITION (Details) - GEDi Cube [Member]<br></strong></div></th>
<th class="th">
<div>Feb. 13, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationContingentConsiderationCommonStock', window );">Common stock</a></td>
<td class="nump">$ 136,001,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Contingent consideration</a></td>
<td class="nump">20,557,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">$ 156,559,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationContingentConsiderationCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationContingentConsiderationCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451712212016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITION (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 159,330,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember', window );">GEDi Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid &amp; Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets', window );">Fixed Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets', window );">Operating lease ROU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total Assets Acquired:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,832,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,762,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,904,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,464,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,559,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714481360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details 2) - GEDi Cube [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsRevenue', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,243,144)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451827471936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details 3) - GEDi Cube [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (83,571,822)<span></span>
</td>
<td class="num">$ (42,490,305)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451713070384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details Narrative) - GEDi Cube [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of consideration transferred amount</a></td>
<td class="nump">$ 156.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451816919760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">$ 81,639,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">163,129,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">80,470,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">2,998,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">1,168,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">$ 160,131,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451714262256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 24,557,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,708,829<span></span>
</td>
<td class="nump">$ 4,165,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="nump">42,611,000<span></span>
</td>
<td class="nump">18,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment</a></td>
<td class="nump">11,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">121,859<span></span>
</td>
<td class="nump">$ 113,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">81,639,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember', window );">RENB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,449,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,651,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="nump">42,611,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment</a></td>
<td class="nump">11,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">118,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">80,470,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember', window );">RENC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,108,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">56,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">$ 1,168,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46451827416288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Oct. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,525,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,246,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices', window );">Common stock for consulting services value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Forfeited shares of common stock</a></td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Original shares of common stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Option to purchase shares of common stock</a></td>
<td class="nump">978,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue', window );">Option to purchase shares of common stock par value</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*N_%\V=>)^2I>+%(B^I_]%S;.@,4EX44V]H9$&R3;/\W^EXOQ($#=GL<2.U
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M>(062[A,Q[/E LT_H_GC^&FPG( !ZJ+GQ0A=_?JIIPEH5+IJJZ*!N[P!TM
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ME3KB=GELYFWJ<A2%_DL8A>)-F8W9PEBD43?IFMC#+FE(IM).W"Z>H$@41J6
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ML#B[W5(?I%H:P/]KQL3[@VR@/&[K_PM02P,$%     @ ((1*6:[X 'OD @
M  @  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RM5<ENVS 0_15"+8H4
M2*)=3E);@+<@+N(%49(>BAYH>6P)D4B7I)?\?4E*5FU7-GK(12*I>8_O<:B9
MYH:R-YX "+3-,\);1B+$\LXT>9Q CODU70*17^:4Y5C(*5N8?,D SS0HSTS'
ML@(SQRDQPJ9>F["P25<B2PE,&.*K/,?LO0,9W;0,V]@M/*6+1*@%,VPN\0(B
M$"_+"9,SLV*9I3D0GE*"&,Q;1MN^ZS94O YX36'#]\9(.9E2^J8F@UG+L)0@
MR" 6B@'+UQJZD&6*2,KX77(:U98*N#_>L=]K[]++%'/HTNQ'.A-)R[@QT SF
M>)6))[IY@-*/K_ABFG']1)LBU@\,%*^XH'D)E@KRE!1OO"W/80]@GP(X)< Y
M!G@G &X)<+710IFVU<,"ATU&-XBI:,FF!OIL-%JZ28G*8B28_)I*G B[XU$T
M?ASTVL_]'HJ>Y6O8'SU':'R/NN/AY*G_T!]%@]<^>AQ'$;I"+U$/77S^VC2%
MW%Q1F'&Y4:?8R#FQD>V@(24BX:A/9C [)#"EZDJZLY/><<XR?E^1:^1:E\BQ
M'*]&4/?_X>X9.6YUDJ[F<T_P#4A,<T"1P +D-1?H9WO*!9/W]%?=:15D7CV9
M^G?O^!+'T#+DS\F!K<$(OWRR ^M;G=,/(COP[56^O7/LX4B6FD?*>9W) NEK
MI*HGZ_#JQ@I\RVXX37.][Z FTKT-;CS+#ZK( WE^)<\_FY:Q2("A+LVE]415
MGS6@,E472G;M5?8_,CD?1';@/JC<!V>3(TN=+&1$5A+&@,3O2%Y(PC.L2N@E
M(C)U=(X$WD)M^@KN8#\IMF?=!MY1\OZ-\WVO/FV-2GCCK/##A)VZ7XVZ^]6X
MM6TW.))8$ZGNE^M;SI%0<Z^8YL 6NL=P%-,5$45QJE:K-M;6U?MHO2/;6]&-
M_M(4O7&(V2(E'&4PEY36=4/J8D6_*2:"+G7)GE(A&X >)K)% U,!\ON<4K&;
MJ VJIA_^ 5!+ P04    "  @A$I9O<7;PN4*  "\6   &    'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;+V<?7/;N!&'OPI'O6E[,Z>(>.%;:GLFD4B<VTOL
MQDD[G4[_H"789D.1.A*RDV]?D))%$0!AT=V[R\Q9M('?@MS%$GBXXME367VM
M'S@7SK=U7M3GDP<A-F]GLWKYP-=I_:;<\$+^Y:ZLUJF0A]7]K-Y4/%VUG=;Y
M#+NN/UNG63&Y.&M_=UU=G)5;D6<%OZZ<>KM>I]7W]SPOG\XG:/+\BT_9_8-H
M?C&[.-ND]_R&BR^;ZTH>S0XJJVS-BSHK"Z?B=^>3=^@MH[3IT+;X1\:?ZJ//
M3G,JMV7YM3FX7)U/W&9$/.=+T4BD\L<CG_,\;Y3D.'[=BTX.-IN.QY^?U9/V
MY.7)W*8UGY?Y/[.5>#B?A!-GQ>_2;2X^E4\_\_T)>8W>LLSK]O_.T[ZM.W&6
MVUJ4ZWUG.8)U5NQ^IM_V%^*H _8&.N!]!ZQVP ,=R+X#43H0?Z #W7>@JH5@
MH(.W[^"I%H8Z^/L.OM(!T8$.P;Y#T#IK=W5;URQ2D5Z<5>634S6MI5KSH?5O
MVUMZ)"N:4+P1E?QK)ON)B_G5QYNK7RX7[S['"^?FL_SQ(?[XV;E*Y,'5_&\_
M7_VRB#_=_,F)__[E\O._G*GSY6;A_/F''\]F0EIO-&;+O:7W.TMXP-*UC#%>
M57SEW(AR^=7Y]P>^ON75?PQ*<[O2O%RO912_*+.PR[Q;K;)F.J2Y<YUFJVE6
M./-TDPEY;!&-[:*?N)#S7YYDG%9%5MS7-JWDA0%>S2^==T)4V>U6I+<Y=T0I
MAUKQ0MA4F5WU<RG/L-]M)H/F$#GX$#FXU:$#.N_Y?58TIRA309X62_Z3\YCF
M6^ZDPOGKMGCC$/<G![L8FT+%*MVDW[?U)EWR\XG,KS6O'OGDPC$%RD[':W6:
MK/MXX1%76GP\#@.]$0[\*(Q0$/5;QGK+*78IH1Z*@G[3Q-"4R*9^OQG3FP78
M1V%(PT/#WM4GAZM/QE[]^D&&1GW2Y;=JC[C\.QV_?_G=P U5%[S"X!__@'SW
M+Z89""F60(HQ(+%>1-!#1%!K1.S285;76YE]-MNJWJ8R3\B,\916E?Q8._P;
MKY99S5>FD+"*CP@)J@4\PIX2#50+&^1C&@9*NQAH3 F0#C..VW-=USR7O8/G
M/"C//<]RDP>M1D9&\MS33[4]4U=Q):31&%(L@11C0&*]\/ /X>%;PZ-924SE
M+N(YP>\"Q10!5IT1<]@_80[[6H#(FRHFVAP&&E,"I,/,X_:&YG!P<%+P"B?9
MIJM5;^QT#4Z<KI!&8TBQ!%*, 8GU(B$\1$)HS^;' >#<E963%8++7PE';EI^
M0&^PW,?E>;,/+THA6V[2[^WBGG\3NRV^*5JL-D=,[5!?"ZLQ$NHS1"YL V5)
M%P.-* '28>9A1]@\KZ.#-Z/?V)NV'&"U/38'1'H.B$)Y!13W0MJ,(<422#$&
M)-8+&N1V5,6UALUEW2SBEMPI[YSE#E?4[2HO+5;=LFY;K'CE;*KL,17<V>1R
M/.MF<U_>W?%*[NV,D,5J>$0FV L=IP(:$B58]HV.@XJZ"!$UJF*H82500FQ@
MZ"$>R CH")FAW\&YMKQ@'\#8Q+!7\_N>QM13=^F@9F-0M014C4&I]2.H0V?(
MSLX^R?M'E2V%O*74V@VF,9<MY>\JWH20>:EO-S F#1CHF+HBV+?IW5MQ$(6N
MF@2 !I5 "3'CR,/!'3OJ\!NR\[=Q'K3.=4@"-4<ZDL.N82, :C4&54M U1B4
M6C]0.BJ'[%AN7A:/O&J?W+6WB^9(9,T*<5.5:QDT9?5]MW0T!@<4ED,ZE\/8
M5X/" +A0% 4!52<Z%)F#$F*FH2N!WW=@!^>0G<Z=[D#K+ >E<TC'<]*;%'G:
M- ?E<Z!J":@:@U+K1TG'Z) =TAVO":ONWM L#S/1KOLLL0'%[9 .[@(M(G0
M-E4;Q5 C2J"$&(!0W[,=V$-VLG>J9ZVS'Q3V(9WV^9'O8J2Z&I3V@:HEH&H,
M2JT?(AWQ0R\@OV;W-VTJ8MJXV/"B3L4 R+-+C9GL0$(+I),SXA'/]9":%:"0
M'Y00.V'H?9=VV _9N=]'+IR\K,VS^15LR>Q"(*$%E%",=(@X)9$?4M=3%HL)
ME$UVDLU^B4K'X;"=PR5EQ;/[PEEN*[D76WYW1)46=9[NRN!6_]W6;0HWEJA
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M7%!"S'2=6M\.I?$.<&$[X/K_'T;8#8S)YIXVTXD;JHE<AU_4]XEVZXNAAI5
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M72FS^/Z@>?GKX87%%_\#4$L#!!0    ( ""$2EFA_P]8Z0D  ,PK   8
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M4>S[S#7%%Y'<2'ZL8Y[-OT]7[VFUR(>VS!\UVZD5)/F2-[IF(-CJ*'&C;9E
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M.YLFHY.92--1,IV=BDDZ36:G[Y)I>B+2LV0R3I/T="J^2H/ISC*(.0)NDR%
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MMO(O3JGKLU"A"AA:Q[$U#J2(%'+:K@0[4\F:IX].S?&A86NMHBS$/BF EU!
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M>>@'P83>>X\6&T[0EW$\\<_'T:'1Z2@@VF*<EX+OL4#]6M[V^CT4_"[!;RL
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M4[OY8N-XL#TA3D%_C%.69"""EF0<B^\R,0BLYNTI5:E-;\[;D/469(OY%6P
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M0LC@#'#9E;(YW!H\TAJ4\NNF9/!RT>CLOP$R$6K@YCL5PI!6802E+Y#E.#?
M"7E'$)I%X*N-I]$0"<^;Z2K (LS%-X=S OK@&H"W;%3UIQQ%C]/1"-/+F^E@
M1HA^V3CXT]7'+V^OC\>_["XS()1/40#*Q3%PAQU"@/3=8\>ALK6D*.OYXC:^
MJ6_ ,=KU*RM7BBJ"GCO.E%\K54456$_!4'#4? ".K6:(]/%#<O_Q+W]E,X&
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M("F#0)34[//F04<D@7"V0S1TX9Y]A'0NS+B3(=&@*;\W,%#H8DXN B]PCS-
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M6R>.T]^B.,PD)"\=6D2#.Y46"H]R(:W:L[-X^A). OG-F-#BY5"AEU I=MO
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MUJ$!N#\WQJ<O](#V1T,O_@-02P,$%     @ ((1*69= S7#O!@  OA   !D
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MW=[D-+A&+F0FM./8MI2LRI'B<3B)HS".HGU!=Y6F_&UZK\/H#=<E*MHT"3O
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M!,<8H@-X?J\P#IL+,M#]BG3U;U!+ P04    "  @A$I9%LT$_OD&  "Q$
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MYJKJNM4&E5K9( 9%-#?U0GJ12YV#):';GA Z$Y.O8.^BW=*RJY6L.$A5I5:
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MPQ:" ]+A]P15C K<$GV_6;^JK;1L"69E?)0O6)2-$X@B]QM;"7$Q+7(0!@%
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M:+CG,'MUD:NE_;QIHO)<+>S/N>!(0+0 SZ=*Y=4%,:@_>#O[/U!+ P04
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M.U;A,?1TAL\K:TH@8DE*PY L1%45&B^\WDOV*-Q^LD?WZ/T$)NVI%7Q%4'1
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M;KJVYL.JLNZ4ILI2WU6_+JG11>TFD'VNZ AJ/YR#KG4>_0=02P,$%     @
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MT%E?-E.ZC:&R"VA^(:6Y[]@ ]?TN^@Y02P,$%     @ ((1*65I'_:AG!
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MD66UX&1>?*<8$<Y)6FS.,)I@*@/$\2DA_&TA/WV4G[IZ/P!02P,$%     @
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MO<XEBI+U?*@-+4K;8DNAL6'M-L.1"M(XX/U*"+TW3(!V2$=_ %!+ P04
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M(5?67F)95R9(!NL+,#U4@;&\>]16!5:8MBD2/(+U/-)/]1?OWRW2QW7H'!4
M@_4 TT?U%ZNVC5KF:!\E%RP(".L)J._J+U; D;+ZJS!LF=)$, _I9Q.J/:,2
M&8':JK\J4^WB0P3F$#WFS")PF\3S[)WRCL\)-YFO<@U7](D&\3J[%]I\JW?_
MVAS3E;?Z8 A*(JC/?$LZ*M248]%'V8<(VB+=[V3M/TTB5W4(,J%B)TMA:<*1
MU;[A079.Q?2Q2Z7-MT2WWU0*4NU=:7=;B6 CTCT;[<^W9/_Q&7U<A\Y104ZD
M#W+2YUNB.'C3-D?[J/H005FD#\IZ>;XE^WE+:U*7)2"*= ]1>S*M+>WC2$)D
M$^FF%WJ&.X<[0YHL\S.O*9C'FX@5)R:K;ZMSM=/\-&GC^PMX=EF<CA5NBL.Z
MG]R$KZ$I".B"NS1.+1Y64IQ_+2Y8O,Z/D#[&C,5A_G%%78\FF0'_?1''[/DB
MZZ ZA3SY'U!+ P04    "  @A$I9T+G2>XL"  #J!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6RME5U/VS 4AO^*E4T32!OY:A+&TDBE9:P3 T1A
M7$R[<)/3UL*)@^TV[-_/=D)46 BHVDWCC_.^YSFGB1U7C-^)%8!$#SDMQ-!:
M25D>V;9(5Y!C<<!**-3.@O$<2S7E2UN4''!F1#FU/<<)[1R3PDIBLW;)DYBM
M)24%7'(DUGF.^9]CH*P:6J[UN'!%EBNI%^PD+O$29B!ORDNN9G;KDI$<"D%8
M@3@LAM;(/1I'.MX$_"10B:TQTI7,&;O3DVDVM!P-!!12J1VP>FQ@#)1J(X5Q
MWWA:;4HMW!X_NG\UM:M:YEC F-%;DLG5T#JT4 8+O*;RBE7?H*DGT'XIH\+\
MHJJ.#7P+I6LA6=Z(%4%.BOJ)'YH^; G<P0L"KQ%X;Q7XC< WA=9DIJP)ECB)
M.:L0U]'*30],;XQ:54,*_2_.)%>[1.ED,CV_'IV?3H_/3M!H-CNYGJ'1^02=
M7EQ,;J=G9VAO A(3*I"[CSZAF]D$[;W?CVVI,FN]G399CNLLW@M9OJ^+ ^0[
M'Y'G>(,.^?CM<O^IW%;UMD5[;=&>\?-?\#ME+*L(I0@7&9H6$A=+,J> 1D*
M%&A"1$J96'- OT9S(;EZUWYW%5UG&71GT=_?D2AQ"D-+?6 "^ :LY,,[-W2^
M=+7@/YD]:8C?-L3O<T]47X.N FM58%3Z/-@D4>"ZL;W9!N^UWA%\T((/7@,/
MN\!K5=@/WFN](WC0@@>O@4==X,%;P'NM=P0/6_#P-?##+O"P"]QY!MYKO2-X
MU()'O>#73&+:11[]\Y+[CC/PGZ%W1'T.H["-JIGLK9-8WX(_,%^20B *"Z5S
M#B)EP.N;I9Y(5IK#><ZD.NK-<*4N8^ Z0.TO&)./$WW>M]=[\A=02P,$%
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M@\ WN7N02;G $N<99QWB>K5RTPU3JE&K<*31?\I*<C5+E$[F][?7J]L5NEJ
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MG5]V6.@O# A3H/<7G*O-Q!S0?;/2/U!+ P04    "  @A$I9>LB\IE (  "
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M!QLJAT(F*R/#4^"N' 5S+,!"?DL*6: <'T54%7WP6LB$%,KZ /U2X(J>X_6
M'9:@?VPTQVH"#:'.Q&K]U=CI31Q'/=8<2Z/O6 P5-@$C/.E@$P9%R0=YCW))
M=;HTQ?S29IM860*K]=IAU6N'K>GYIQZE2?03?B(<M@9@);6_@,S03FKJMZV
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M9K?ZU^O3YS^R R#V;LY_M#X/U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M(<TAS%^7T8\K[5<3':V<0S4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M9[GBQ+V_#8^.6V%<+_1;57D38>6.H$)7^K?T6[.Z_UI+SF:Q%C?KB@>Y?2+
M]N>AG,IR&LOI+&>PG,ER%LO9+.>PG,MR'LOY+!>P7,AR$<O%+)>P7,IR&<OE
M+%>P7,ER%<;UI@MR:[KPVN^#->M.V"X]E%-83F4YC>5TEC-8SF0YB^5LEG-8
MSF4YC^5\E@M8+F2YB.5BEDM8+F6YC.5REBM8KF2Y"N-Z,X-6+]_DG5Z^>G=X
M[-[]88)PO]HNWVS7%3NWSPC89CZ44UE.8SF=Y0R6,UG.8CF;Y1R6<UG.8SF?
MY0*6"UDN8KF8Y1*62UDN8[F<Y8H3U]XTF,C3T7!RL6G =O-17"_K6]U\^]?_
M\:;!CQO[U>.-_?_1AH+P#=P^22 YA>54EM-83F<Y@^5,EK-8SF8YA^5<EO-8
MSF>Y@.5"EHM8+F:YA.52ELM8+F>Y@N5*EJLPKC>5:+7^32;PA@+;_(=R"LNI
M+*>QG,YR!LN9+&>QG,UR#LNY+.>QG,]R <N%+!>Q7,QR"<NE+)>Q7,YR!<N5
M+%=A7&]FT"H(G(@+ G]]W#2[U;\6NT-%T,=V%MA60)136$YE.8WE=)8S6,YD
M.8OE;)9S6,YE.8_E?)8+6"YDN8CE8I9+6"YEN8SE<I8K3EQ[9^'ZQ@);"DAQ
MO<QOE0).Q*6 PHV%TP,"COL*VW=V$-CJ0)136$YE.8WE=)8S6,YD.8OE;)9S
M6,YE.8_E?)8+6"YDN8CE8I9+6"YEN8SE<I8K6*YDN0KC>G.&5A7A9 [O(+#%
MA"BGL)S*<AK+Z2QGL)S)<A;+V2SGL)S+<A[+^2P7L%S(<A'+Q2R7L%S*<AG+
MY2Q7L%S)<A7&]68&K?K"B;B^\*8G"HJMVV<%;'TARJDLI[&<SG(&RYDL9[&<
MS7(.R[DLY[&<SW(!RX4L%[%<S'()RZ4LE[%<SG+%B6MO'HSVI^EW%YL';'\A
MQ77C?MKJ+YR*^PN%FP=1+/VVVHBW#,3^S5, E%-83F4YC>5TEC-8SF0YB^5L
MEG-8SF4YC^5\E@M8+F2YB.5BEDM8+F6YC.5REBM8KF2Y"N-Z,X56Z>%TR&X9
M3-E^0Y136$YE.8WE=)8S6,YD.8OE;)9S6,YE.8_E?)8+6"YDN8CE8I9+6"YE
MN8SE<I8K6*YDN0KC>C,#N34S$/8DM9Z!L'A\\SX#L7'[;(#M-$0YE>4TEM-9
MSF YD^6L$]=^[N*UOA&;'==A.9?E/);S62Y@N9#E(I:+62YAN93E,I;+6:Y@
MN9+E*HSKY7RKK7 J;BMT%[OG9K7[2[I?[*Y?#R &;@]YMJ80Y526TUA.9SF#
MY4R6L][_@]M\DJ3!\&?I98OK^FD^6TV(<B[+>2SGLUS <B'+12P7LUS"<BG+
M92R7LUS!<B7+51C7B_]6@>'^M>BGJ-YLMEOIJ=DLZ_I^>SW_A<+M^4]R"LNI
M+*>QG,YR!LN9+&>=N,Y)_F!P\20RFQW783F7Y3R6\UDN8+F0Y2*6BUDN8;F4
MY3*6RUFN8+F2Y2J,ZZ5\JUMP*NPH^NPWJZ^K]>)!6FVWS_6/[J!#[C_N?VG3
M_"6M#]<*/M7-LE[O%E_?6 E@&P=13F$YE>4TEM-9SF YD^6L$W?7F@D,/@TN
M%_O9)D&4<UG.8SF?Y0*6"UDN8KF8Y1*62UDN8[F<Y0J6*UFNPKC>/*#5)#BE
MFP3%X.V1SS8)HIS*<AK+Z2QGL)S)<A;+V2SGL)S+<A[+^2P7L%S(<A'+Q2R7
ML%S*<AG+Y2Q7G+AWFP3182N,ZV5^JTEP*FX2_/$4HN;-#7ZV(!#E%)9364YC
M.9WE#)8S6<XZ<=W3^J%\<5K/%O^AG,MR'LOY+!>P7,AR$<O%+)>P7,IR&<OE
M+%>P7,ER%<;U(KY5_#<5%@CU-O&ES1NK_6]/ -@>0)136$YE.8WE=)8S6,YD
M.>O$O;NNS_;[H9S+<A[+^2P7L%S(<A'+Q2R7L%S*<AG+Y2Q7L%S)<A7&]28
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M#V]$_>PBZD?#^6 ZNHAZMAP0Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UC.9[F
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M+\5R9JLZ^5@K&6*3'<VW1N"Q(96N$XW.[XZ^W05>U_G:V)QAX@U%7L+*^NI
M6B-@&\2\<]NOADQ.X8ZZKCL(]PD3UIZU'"<I6J9F.K>W]2LWBJ,H=GH7@]$V
M""+'<P+O N_7)NH.MJGDD2N:DSED( 1V"MU-;^MN0:Y^9W3)<J882/.TX/7Z
M0B_#0R8-L7TTXNCY\AT5:X;7:@X9^CC7(W06S<C6+!2OZJEGR17.4/7C!L=<
M$-H OV><J^>%'J2ZP3GY#U!+ P04    "  @A$I9$H,V(?H"  !3"   &0
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M!.O5NC.>V8;P8GVD.V;5X)YEJG9[0>62<44R6&A)[Z2G>635PJH)BL)V@;E
MW5/L<*6[/DACH-\OA,"GB=F@_A\1_P502P,$%     @ ((1*69DYYO .!
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M3B29C#C; !X_K:S%!TFHR6@%SH_BMW(ON;KKJW%R<O_IYNR/CS=7YQ=W]V_
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M!TA]0Y3#G6E2@1(ZFNP=(\[O$-R12,&"9@HW6FS)5[ @3[!COLT<'#@ I -
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MCN)N,4_[R>F)9*NDA_O(I&1A<KBD9$9Y_("Z/V=,;D]B!WE7?_(_4$L#!!0
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M;*FF+HK8%-:2)B9J&^>"R:>QM!/C^<>;R9_O;SY<3>_F;]#TKT^SC_^@GZ]
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M2%X!4\XWF_EJMU6VZ_ON>T/EP/7!QY:]H)S!<B;+62QGLYS#<B[+>2SGLUS
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M:ZYJVNW%Z5ZXR9,$'6!F.TDK[8^?#90E*^$2Z5E?- ;\_=C !V-@L&?\N]@
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M>1J;;X;E^N5I-SS[3[+>6,[V24HHAMM0#+6A"+(TS\LDI!,I;_.F"&C'=XT
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M6H1J M5B2E.#5/<R;'TOX[IJT!IW63HW%FDA<V.9?$MN9K*Q55MQN^55N^%
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MNCPAJD6H)E MIC3U[K-U*\+1MR):=XKT3M=DH9J+:AZJ^:@6H%KH[%<C&C[
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MDUN9K9Y0_OPN38OOWZPF>$ZS+^O%'O\/4$L#!!0    ( ""$2EFU[\W>5 (
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MUX0K1&%EM$'GRIC(NC#K0(O2%<-2:%-:KKDQ;QE(.\&,KX30A\#65_,Z9O\
M4$L#!!0    ( ""$2EE*+2#A3 0  ,46   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;+6876_;-A2&_PJA#44+K)&H+\NI;<"QFRY#FF1)LUT4NZ"M
MXYBH)+HD%2?_?M1'94M6B!A@<I%(LM[WB$_(XU<<;1G_(=8 $CVE22;&UEK*
MS:EMB^4:4B).V 8R]<F*\91(=<H?;+'A0.)2E":VZSBAG1*:69-1>>V&3T8L
MEPG-X(8CD:<IX<]GD+#MV,+6KPNW]&$MBPOV9+0A#W '\GYSP]69W;C$-(5,
M4)8A#JNQ-<6G<QP5@O*.?RALQ=XQ*H:R8.Q'<7(1CRVG>")(8"D+"Z+^/,(,
MDJ1P4L_QLS:UFIJ%</_XE_MY.7@UF 41,&/)OS26Z[$562B&%<D3><NV?T(]
MH*#P6[)$E+_1MKK7\RVTS(5D:2U63Y#2K/I+GFH0>P+\DL"M!>YK!5XM\%XK
M\&N!7Y*IAE)RF!-))B/.MH@7=RNWXJ"$6:K5\&E6_-_O)%>?4J63D^GL[_N+
MNXMO%]=7Z/T<)*&)0/@#^HCN[^;H_>\?1K9498J;[65M>599NB]8_I5G)\AS
M_D"NX_H]\IE>?@Z+$X2]%^7SUU?WVG);L6D N0T@M_3S7O [RX6Z(@2:+G_F
M5-!RMGZ_5-?0A814_-<'J++T^RV+I7PJ-F0)8TNM50'\$:S)N]]PZ'SJPV72
M;&[(K(72:U!Z.O?)%\;B+4V2/F*5,BB51:]ZG.!@Z'D.#O'(?MS'H:UQ+(Z>
MLCCT'?735&T-U6^&ZNN'^GE.T2Q? /K^%=(%\-YIHO4X=IJ8-)L;,FNQ"QIV
M@?D5%YA$:=)L;LBLA3)L4(;::3@C8MU'2ZLZEE9XL(;"( HZRW9NJ&0+PZ#!
M,-!BN.&P(31&[TBZ^82NY1HXF@H!4O3!T7H="Z<R"UM]#0>^WZ%CJ&:+3M30
MB;1TSND3Q!H>6O6Q/*)#'J'K>QT<ADJV< P;'$,MCNL-<")I]H 24($2W5[?
M]U'1FAQ+97A I8 2AATLAFJVL&!GEQ0=+9AO3)*DGB=5;^80G_;F0ZW1L7!J
MMWTZ41 Y3G<-F:K:QK,7I+$6SW2Y9'FFT-R09[)(H!>,UN)H,/@ 3!!YP6#0
M!6.H:AO,+D!C;:@LP/!<=9C/3^IE54!OC]%;' W&/0 S<-W B;I@WB(-XUT<
MQOH\O.LTEV6G22A9T(3*YUY")G/OK'8[Z#@'4\=0U3:A78K&^AA]Q23H%Y31
M"%V[M;Z=(L_U0Z>+Y2WR,=X%9*P-C74GOJRG"U6(5%?.4XA[$1F-QK7;/B)O
M$+I#W/T*-U6VC6@7?+$^^5Z!['Y5]<(QFH1KMWTX']VAXP^=89?.6\1AO,O#
M6!^(=6_B>NG12/H"\-!7[]C^P:)ZBQ",=RD8ZV-PM:AF+!,T+OLRRWKQ&(W#
MM5M[WR,, K6>NB]0I@I7>.R]+<-B@_<KX0\T$RKSKI2]<S)0C\2K/=/J1+)-
MN8NX8%*RM#Q< U&DBAO4YRNF>G5]4FQ,-CO7D_\!4$L#!!0    ( ""$2EEU
M*\ G1P(  ! %   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;'U46Y/2
M,!3^*YGJ.+LS+BVAK Z6SG!9%4=6!-&''1]">Z"9S:6;I+#^>Y,4*BKPTN:<
MG.]RVIPD.ZD>=0%@T#-G0O>#PIBR%X8Z*X 3W9(E"+NSEHH38T.U"76I@.0>
MQ%F(H^@VY(2*($U\;J;21%:&40$SA73%.5&_AL#DKA^T@T-B3C>%<8DP34JR
M@06893E3-@H;EIQR$)I*@12L^\&@W1MV7;TO^$YAIX_6R'6RDO+1!9.\'T3.
M$##(C&,@]K6%$3#FB*R-ISUGT$@ZX/'ZP/[>]VY[61$-(\E^T-P4_>!M@')8
MDXJ9N=Q]A'T_WF FF?9/M*MKXVZ LDH;R?=@ZX!34;_)\_X[' $P/@/ >P#V
MOFLA[W),#$D3)7=(N6K+YA:^58^VYJAP/V5AE-VE%F?2P>CK<K*8?)M\N4=7
M8S"$,HWP-;I!'^[&%(VJ%:"'*? 5J)]):*RBPX79GGU8L^,S[&V,IE*80J,[
MD4/^-T%HK39^\<'O$%]D_%2)%NI$KQ&.<(R6BS&Z>GE]@;?3?(>.Y^V<X1U6
MVF:T1H/LJ:*:^B/S\-GFT,0 UR>;KRGCTY1NG'JZ)!GT SLO&M06@O35B_9M
M].Z"X;@Q'%]B3^>P!5&!/N6K1G8]TDWE-HV2<'M"K-N(=2^*W=O;@4E]4JS[
MG]A-&\>==AS_HQD>G5(.:N-G4:-,5L+4![;)-N,^J$_YG_+ZKI@2M:%"(P9K
M"XU:;ZR\JN>O#HPL_9E?26,GR"\+>V6!<@5V?RVE.01.H+D$T]]02P,$%
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MH @69)/(*=M=0Q%04_.%+!'9$^WRN:Z:'&Z$9&D!5@[2F.9O\E@LQ!' MD\
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M\_S*D7<D6V?'_#V3*O59<Z6N:<#U!/5]P9C<=[1 >?'S_P)02P,$%     @
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M^U-*]HC*TL)-GBB82BW"CS/YWI><BJ>QT'%_^7R[7'Q]7GSY%RV^B?T2O0^
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M5[LL&ZFR()\6Z?+XPN?Q9=7K?P%02P,$%     @ ((1*61[?F5X< @  /2<
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M<' N>&UL4$L! A0#%     @ ((1*6<^R,_[O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ((1*69E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  @A$I9'Q3MT+<'   K,P  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ((1*6;#$HGLW
M!P  HAT  !@              ("!^P\  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( ""$2ED= +:A[0(  .<)   8              "
M@6@7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  @A$I9
M4*V_[50%  !Z$P  &               @(&+&@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ ((1*6:[X 'OD @    @  !@
M     ("!%2   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M ""$2EF]Q=O"Y0H  +Q8   8              " @2\C  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  @A$I9H?\/6.D)  #,*P  &
M            @(%*+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ ((1*639OI39. @  HP4  !@              ("!:3@  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ""$2EF%>5PM0P(  ) &
M   8              " @>TZ  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  @A$I9Z&JZIJ *  !N&@  &0              @(%F/0
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ""$2ED:-ZRN
M% 8  &0-   9              " @3U(  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ ((1*62UY1B@<"   \A,  !D
M ("!B$X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  @
MA$I93O#')R0#  "U!@  &0              @(';5@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ""$2ED[5XXSP@@  .06   9
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M970Q."YX;6Q02P$"% ,4    "  @A$I9C%9SW*X2  ! -   &0
M    @($ D0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M ""$2EF70,UP[P8  +X0   9              " @>6C  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ ((1*64-UDPVR"0  41H  !D
M             ("!"ZL  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  @A$I9%LT$_OD&  "Q$   &0              @('TM   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ""$2EG(;(^5J0(
M -,%   9              " @22\  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ ((1*60>0^G@>#   _"8  !D              ("!
M!+\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  @A$I9
M"]=K@0P$  #W"0  &0              @(%9RP  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( ""$2EF!?N>DZP(  "H&   9
M      " @9S/  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ ((1*64]\.=%%!   8@L  !D              ("!OM(  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  @A$I9,<'/7-0"  "F!@
M&0              @($ZUP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( ""$2EDW06C3100  *,,   9              " @47:  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ((1*68R*,UXT
M!0  E \  !D              ("!P=X  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  @A$I9/A;Y&'P$  !&"P  &0
M@($LY   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ""$
M2EG O-.R7@,  -@'   9              " @=_H  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ ((1*68UU7OH.!0  >!D  !D
M         ("!=.P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    "  @A$I9QS?E(O@"  #K!P  &0              @(&Y\0  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ""$2EG&/,^^RP0  !P8
M   9              " @>CT  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ ((1*61 728G1 P  E!   !D              ("!ZOD
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  @A$I9QA'=
MR1D#  #K"0  &0              @('R_0  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( ""$2EE:1_VH9P0  /8:   9
M  " @4(! 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M((1*67(MMZEN @  L 4  !D              ("!X 4! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  @A$I9$V4<;;,&  "1+   &0
M            @(&%" $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( ""$2EG0N=)[BP(  .H'   9              " @6\/ 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ((1*63C (DSM @
MQ <  !D              ("!,1(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  @A$I9WRP+B4T"   7!@  &0              @(%5
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ""$2EEX
MK9W6@0(  +\&   9              " @=D7 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ ((1*67K(O*90"   @"@  !D
M     ("!D1H! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ""$2EDLHZ/;@0(  .,%   9              "
M@;J& 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ((1*
M60_QC/W' @  50@  !D              ("!<HD! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    "  @A$I9T]QE-_ $  #C&P  &0
M        @(%PC $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( ""$2EF%R_+NE@0  (P5   9              " @9>1 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ ((1*6?=;:S Z!0  X1\
M !D              ("!9)8! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    "  @A$I9-JR=G> #  "##P  &0              @('5FP$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ""$2EG5X8S.
M@CH  ,SR!  9              " @>R? 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ ((1*6=MW/VD*!   BAH  !D
M ("!I=H! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  @
MA$I91><#YQT,  !KKP  &0              @('FW@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ""$2EFU[\W>5 (  "D%   9
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M970V,RYX;6Q02P$"% ,4    "  @A$I9'6.54P #   $"@  &0
M    @(%6^@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M ""$2EFV.D[\B00  %(7   9              " @8W] 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ ((1*64I.\'?Z P  UQ(  !D
M             ("!30(" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    "  @A$I9D.;M)CX#  #N$P  #0              @ %^!@( >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ""$2EF7BKL<P    !,"   +
M      "  ><) @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ""$2EFV=+S1]@0
M # K   /              "  = * @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  @A$I9'M^97AP"   ])P  &@              @ 'S#P( >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  @A$I9I7\.<>X!  "0
M)@  $P              @ %'$@( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    2@!* #T4  !F% (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>315</ContextCount>
  <ElementCount>473</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995613 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995614 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/GoingConcern</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995615 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995616 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995617 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995618 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995619 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995620 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995621 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995622 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995623 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995624 - Disclosure - ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Acquisition</Role>
      <ShortName>ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995625 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995626 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995627 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995628 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995629 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/PropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995630 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995631 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995632 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995633 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995634 - Disclosure - ACQUISITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionTables</Role>
      <ShortName>ACQUISITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Acquisition</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995635 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReporting</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995636 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995637 - Disclosure - GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/GoingConcern</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995638 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995639 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995640 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995641 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995642 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995643 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995644 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995645 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995646 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/LeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995647 - Disclosure - LEASES  (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/LeasesDetails1</Role>
      <ShortName>LEASES  (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/LeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995648 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/LeasesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995649 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Debt</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995650 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995651 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995652 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995653 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995654 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995655 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995656 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995657 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995658 - Disclosure - STOCKHOLDERS' EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails4</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995659 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/StockholdersEquityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995660 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995661 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995662 - Disclosure - ACQUISITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails</Role>
      <ShortName>ACQUISITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995663 - Disclosure - ACQUISITION (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails1</Role>
      <ShortName>ACQUISITION (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995664 - Disclosure - ACQUISITION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails2</Role>
      <ShortName>ACQUISITION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995665 - Disclosure - ACQUISITION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails3</Role>
      <ShortName>ACQUISITION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995666 - Disclosure - ACQUISITION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetailsNarrative</Role>
      <ShortName>ACQUISITION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995667 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReportingTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>995668 - Disclosure - SEGMENT REPORTING (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingDetails1</Role>
      <ShortName>SEGMENT REPORTING (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReportingTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="e5986_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>995669 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SubsequentEvents</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="e5986_10-k.htm">e5986_10-k.htm</File>
    <File>renb-20240630.xsd</File>
    <File>renb-20240630_cal.xml</File>
    <File>renb-20240630_def.xml</File>
    <File>renb-20240630_lab.xml</File>
    <File>renb-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="870">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e5986_10-k.htm": {
   "nsprefix": "RENB",
   "nsuri": "http://renovarobio.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "e5986_10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "renb-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "renb-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "renb-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "renb-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "renb-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 334,
   "keyCustom": 139,
   "axisStandard": 28,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 65,
   "hidden": {
    "total": 84,
    "http://fasb.org/us-gaap/2024": 41,
    "http://renovarobio.com/20240630": 39,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 315,
   "entityCount": 1,
   "segmentCount": 97,
   "elementCount": 799,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 870,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://renovarobio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://renovarobio.com/role/ConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:InsuranceSettlementsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995613 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://renovarobio.com/role/GoingConcern",
     "longName": "995614 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://renovarobio.com/role/FairValueMeasurements",
     "longName": "995615 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://renovarobio.com/role/PropertyAndEquipment",
     "longName": "995616 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwill",
     "longName": "995617 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://renovarobio.com/role/Leases",
     "longName": "995618 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://renovarobio.com/role/Debt",
     "longName": "995619 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://renovarobio.com/role/IncomeTaxes",
     "longName": "995620 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://renovarobio.com/role/StockholdersEquity",
     "longName": "995621 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://renovarobio.com/role/CommitmentsAndContingencies",
     "longName": "995622 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://renovarobio.com/role/RelatedPartyTransactions",
     "longName": "995623 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://renovarobio.com/role/Acquisition",
     "longName": "995624 - Disclosure - ACQUISITION",
     "shortName": "ACQUISITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://renovarobio.com/role/SegmentReporting",
     "longName": "995625 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://renovarobio.com/role/SubsequentEvents",
     "longName": "995626 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995627 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "RENB:BusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "RENB:BusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsTables",
     "longName": "995628 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:FairValueConcentrationOfRiskTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:FairValueConcentrationOfRiskTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://renovarobio.com/role/PropertyAndEquipmentTables",
     "longName": "995629 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables",
     "longName": "995630 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://renovarobio.com/role/LeasesTables",
     "longName": "995631 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://renovarobio.com/role/IncomeTaxesTables",
     "longName": "995632 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://renovarobio.com/role/StockholdersEquityTables",
     "longName": "995633 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://renovarobio.com/role/AcquisitionTables",
     "longName": "995634 - Disclosure - ACQUISITION (Tables)",
     "shortName": "ACQUISITION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://renovarobio.com/role/SegmentReportingTables",
     "longName": "995635 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "995636 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "RENB:EscrowSharesRemaining",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "RENB:EscrowSharesRemaining",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://renovarobio.com/role/GoingConcernDetailsNarrative",
     "longName": "995637 - Disclosure - GOING CONCERN (Details Narrative)",
     "shortName": "GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "RENB:WorkingCapitalDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetails",
     "longName": "995638 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_BlackScholesOptionPricingModelMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_BlackScholesOptionPricingModelMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetails1",
     "longName": "995639 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
     "longName": "995640 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_RenovaroCubeMember",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_RenovaroCubeMember",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://renovarobio.com/role/PropertyAndEquipmentDetails",
     "longName": "995641 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "995642 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
     "longName": "995643 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "RENB:NetDefinitelifeIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-30",
      "name": "RENB:NetDefinitelifeIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1",
     "longName": "995644 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
     "longName": "995645 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://renovarobio.com/role/LeasesDetails",
     "longName": "995646 - Disclosure - LEASES (Details)",
     "shortName": "LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://renovarobio.com/role/LeasesDetails1",
     "longName": "995647 - Disclosure - LEASES  (Details 1)",
     "shortName": "LEASES  (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://renovarobio.com/role/LeasesDetailsNarrative",
     "longName": "995648 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2018-06-182018-06-19",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2018-06-182018-06-19",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://renovarobio.com/role/DebtDetailsNarrative",
     "longName": "995649 - Disclosure - DEBT (Details Narrative)",
     "shortName": "DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "RENB:InterestExpenseRelatedToNoteBalance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetails",
     "longName": "995650 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetails1",
     "longName": "995651 - Disclosure - INCOME TAXES (Details 1)",
     "shortName": "INCOME TAXES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetails2",
     "longName": "995652 - Disclosure - INCOME TAXES (Details 2)",
     "shortName": "INCOME TAXES (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetailsNarrative",
     "longName": "995653 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_UnitedStatesTaxMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_UnitedStatesTaxMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails",
     "longName": "995654 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_RenovaroMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_RenovaroMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails1",
     "longName": "995655 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails2",
     "longName": "995656 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_custom_EmployeeStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_EmployeeStockOptionsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails3",
     "longName": "995657 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails4",
     "longName": "995658 - Disclosure - STOCKHOLDERS' EQUITY (Details 4)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_custom_CommonStockPurchaseWarrantMember",
      "name": "RENB:CommonStockPurchaseWarrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
     "longName": "995659 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-20",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995660 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2019-11-142019-11-15",
      "name": "RENB:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2019-11-142019-11-15",
      "name": "RENB:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "995661 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-26",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_MarkDybulMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://renovarobio.com/role/AcquisitionDetails",
     "longName": "995662 - Disclosure - ACQUISITION (Details)",
     "shortName": "ACQUISITION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-13_custom_GEDiCubeMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-13_custom_GEDiCubeMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://renovarobio.com/role/AcquisitionDetails1",
     "longName": "995663 - Disclosure - ACQUISITION (Details 1)",
     "shortName": "ACQUISITION (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-13_custom_GEDiCubeMember",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://renovarobio.com/role/AcquisitionDetails2",
     "longName": "995664 - Disclosure - ACQUISITION (Details 2)",
     "shortName": "ACQUISITION (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_GEDiCubeMember",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_GEDiCubeMember",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://renovarobio.com/role/AcquisitionDetails3",
     "longName": "995665 - Disclosure - ACQUISITION (Details 3)",
     "shortName": "ACQUISITION (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_GEDiCubeMember",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_GEDiCubeMember",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://renovarobio.com/role/AcquisitionDetailsNarrative",
     "longName": "995666 - Disclosure - ACQUISITION (Details Narrative)",
     "shortName": "ACQUISITION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-02-122024-02-13_custom_GEDiCubeMember",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredOther1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-122024-02-13_custom_GEDiCubeMember",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredOther1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://renovarobio.com/role/SegmentReportingDetails",
     "longName": "995667 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "RENB:SegmentOperatingLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "RENB:SegmentAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://renovarobio.com/role/SegmentReportingDetails1",
     "longName": "995668 - Disclosure - SEGMENT REPORTING (Details 1)",
     "shortName": "SEGMENT REPORTING (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://renovarobio.com/role/SubsequentEventsDetailsNarrative",
     "longName": "995669 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2024-07-032024-10-02_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-032024-10-02_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5986_10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable \u2013 trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r86"
     ]
    },
    "RENB_AccrualPaymentsRelatedToTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AccrualPaymentsRelatedToTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual payments related to the termination of lease"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AccruedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AccruedExpensesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Accumulated Depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r173",
      "r603"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r102",
      "r181",
      "r598",
      "r630",
      "r631"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16",
      "r24",
      "r480",
      "r483",
      "r537",
      "r626",
      "r627",
      "r922",
      "r923",
      "r924",
      "r936",
      "r937",
      "r938",
      "r939"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r801",
      "r1076"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r936",
      "r937",
      "r938",
      "r939",
      "r1012",
      "r1079"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AdvisoryServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AdvisoryServicesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AggregateCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AggregateCommonStockShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate common stock shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AggregatePreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AggregatePreferredStockShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate preferred stock shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r853",
      "r863",
      "r889"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r856",
      "r866",
      "r892"
     ]
    },
    "RENB_AgreementAndPlanOfMergerAgreementAxisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AgreementAndPlanOfMergerAgreementAxisMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement And Plan Of Merger Agreement Axis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r884",
      "r893",
      "r897",
      "r905"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r423"
     ]
    },
    "RENB_AmendedAndRestatedSecuredNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AmendedAndRestatedSecuredNotesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended And Restated Secured Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "verboseLabel": "Amortization discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r107",
      "r360",
      "r1022"
     ]
    },
    "RENB_AmortizationOfDiscountOnNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "AmortizationOfDiscountOnNotePayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of discount on note payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r289",
      "r296",
      "r775"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of assets",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r154",
      "r176",
      "r202",
      "r231",
      "r239",
      "r258",
      "r262",
      "r271",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r473",
      "r477",
      "r501",
      "r594",
      "r681",
      "r767",
      "r768",
      "r801",
      "r823",
      "r972",
      "r973",
      "r1032"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r182",
      "r202",
      "r271",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r473",
      "r477",
      "r501",
      "r801",
      "r972",
      "r973",
      "r1032"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r837",
      "r849"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r837",
      "r849"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r837",
      "r849"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r313",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BlackScholesOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BlackScholesOptionPricingModelMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black Scholes Option Pricing Model [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BoardOfDirectorsAndScientificAdvisoryBoardOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BoardOfDirectorsAndScientificAdvisoryBoardOneMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors And Scientific Advisory Board One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BoardOfDirectorsAndScientificAdvisoryBoardTwoMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors And Scientific Advisory Board Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BridgeLoanMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge Loan [Member]",
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r466",
      "r786",
      "r787"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r466",
      "r786",
      "r787"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent shares issuable in connection with the acquisition",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "RENB_BusinessAcquisitionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessAcquisitionPercentage",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of consolidated proforma information",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915"
     ]
    },
    "RENB_BusinessAcquisitionsNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessAcquisitionsNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "BusinessAcquisitionsNetIncomeLoss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465"
     ]
    },
    "RENB_BusinessAcquisitionsRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessAcquisitionsRevenue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition related costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total consideration transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r14"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of consideration transferred amount",
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationAsset",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration",
        "documentation": "Amount of asset recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r138",
      "r468"
     ]
    },
    "RENB_BusinessCombinationContingentConsiderationCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessCombinationContingentConsiderationCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance June 30, 2023",
        "periodEndLabel": "Contingent Consideration Liability at June 30, 2024",
        "label": "Contingent consideration liability was recorded at fair value",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r138",
      "r468",
      "r492",
      "r493",
      "r494"
     ]
    },
    "RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares contingently issuable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Acquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACQUISITION",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r467"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Assets Acquired:",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease ROU"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid &amp; Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities Assumed",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Assets Acquired",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Consideration",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "RENB_BusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "BusinessPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash received from acquisition, net",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r171",
      "r756"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH, END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r110",
      "r199"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r110"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CashPaidDuringYearForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CashPaidDuringYearForAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CashPaidForTheTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CashPaidForTheTerminationOfLease",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payments"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ChangeInFairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ChangeInFairValueOfContingentConsideration",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of contingent consideration",
        "negatedLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ChangeInTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r178",
      "r179",
      "r180",
      "r202",
      "r222",
      "r223",
      "r225",
      "r227",
      "r233",
      "r234",
      "r271",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r368",
      "r369",
      "r373",
      "r376",
      "r383",
      "r501",
      "r635",
      "r636",
      "r637",
      "r638",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r669",
      "r691",
      "r714",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r913",
      "r931",
      "r940"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r233",
      "r368",
      "r369",
      "r371",
      "r373",
      "r376",
      "r381",
      "r383",
      "r635",
      "r636",
      "r637",
      "r638",
      "r781",
      "r913",
      "r931"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant purchase price",
        "verboseLabel": "Exercise price",
        "terseLabel": "Warrant exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExpenseOrRevenueRecognized",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants aggregate amount",
        "documentation": "Description of expense or revenue offset related to the warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchase warrants exercisable outstanding",
        "verboseLabel": "Warrant exercise price",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ClosedSharesParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ClosedSharesParValue",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closed shares, par value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r321",
      "r322",
      "r741",
      "r966",
      "r971"
     ]
    },
    "RENB_CommonSharesIssuedUponAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonSharesIssuedUponAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued upon acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonSharesIssuedUponSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonSharesIssuedUponSettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued upon settlement of debt"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockAndReceivedGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockAndReceivedGrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and received gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for issuance",
        "verboseLabel": "Remaining shares",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "RENB_CommonStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockConvertibleSharesIssuable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issuable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockIssuancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockIssuancesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuances [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r814",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r936",
      "r937",
      "r939",
      "r1012",
      "r1075",
      "r1079"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock outstanding",
        "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "RENB_CommonStockParValuePrivatePlacement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockParValuePrivatePlacement",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock par value under private placement"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockPurchaseWarrant",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period",
        "periodEndLabel": "Outstanding at end of period",
        "label": "CommonStockPurchaseWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockPurchaseWarrantMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Purchase Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockPurchaseWarrantsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Purchase Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockPurchaseWarrantsWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of period",
        "periodEndLabel": "Weighted average exercise price, Outstanding at ending of period",
        "label": "CommonStockPurchaseWarrantsWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockShareIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "CommonStockShareIssued",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued",
        "label": "CommonStockShareIssued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r669"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r96",
      "r669",
      "r687",
      "r1079",
      "r1081"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001, 350,000,000 shares authorized, 155,027,245 shares issued and outstanding at June 30, 2024; 63,698,144 shares issued and outstanding at June 30, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r597",
      "r801"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive Loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r184",
      "r186",
      "r191",
      "r590",
      "r608",
      "r609"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r158"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r758"
     ]
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "RENB_ConsultingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ConsultingServicesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentConsiderationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ContingentConsiderationFairValue",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration fair value"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentConsiderationInAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ContingentConsiderationInAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration in Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentConsiderationIssuedUponAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ContingentConsiderationIssuedUponAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration issued upon acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ContingentSharesIssuedPursuantToAcquisitionAgreement",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Shares issued pursuant to Acquisition Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation value",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "RENB_ConversionOfNotePayableForIssuanceOfPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ConversionOfNotePayableForIssuanceOfPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of note payable for issuance of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ConversionOfPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ConversionOfPromissoryNote",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of promissory note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted shares of common stock, value",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted shares of common stock, shares",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r147",
      "r1041"
     ]
    },
    "RENB_ConvertibleNotesPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ConvertibleNotesPayablesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Tax Expense (Benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r934"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Danish income tax (benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r934",
      "r1011"
     ]
    },
    "RENB_DanDritDenmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DanDritDenmarkMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dan Drit Denmark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options available to be issued",
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r200",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r327",
      "r328",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r354",
      "r361",
      "r362",
      "r364",
      "r519"
     ]
    },
    "RENB_DebtDiscountRelatedToConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DebtDiscountRelatedToConvertiblePromissoryNotes",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount related to notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal amount",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal outstanding balance",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r147",
      "r365"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r341"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r519",
      "r520",
      "r777",
      "r778",
      "r799"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r357",
      "r1021"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note interest rate",
        "verboseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r340"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r799",
      "r932",
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "verboseLabel": "Debt maturity period",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r776",
      "r1015",
      "r1016"
     ]
    },
    "RENB_DebtInstrumentOriginalIssueDiscount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DebtInstrumentOriginalIssueDiscount",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal and interest accrued amount",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r83"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r55",
      "r58",
      "r82",
      "r125",
      "r126",
      "r205",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r799",
      "r932",
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount accreted",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1020",
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note balance",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r366",
      "r518",
      "r519",
      "r520",
      "r777",
      "r778",
      "r799"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1020",
      "r1021",
      "r1023"
     ]
    },
    "RENB_DebtInstrumentsFloorPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DebtInstrumentsFloorPricePerShare",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor price per share"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_DecemberNote2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DecemberNote2023Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Note 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred Tax Expense",
        "label": "Deferred Income Tax Expense (Benefit) [Default Label]",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r164",
      "r934"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_DeferredIncomeTaxExpenseChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DeferredIncomeTaxExpenseChangeInTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in tax rate",
        "label": "DeferredIncomeTaxExpenseChangeInTaxRate"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DeferredTaxAssetExcessTaxOverDepreciationFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess of tax over book depreciation of fixed assets"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DeferredTaxAssetExcessTaxOverDepreciationPatents",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess of tax over book depreciation of patents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred Tax Assets (Liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits and other assets",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47"
     ]
    },
    "RENB_DepreciationAndAmortizations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DepreciationAndAmortizations",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "DepreciationAndAmortizations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r231",
      "r244",
      "r262",
      "r767",
      "r768"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate of interest",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r837",
      "r849"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r837",
      "r849",
      "r885"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "RENB_EBIAndWeirdScienceLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EBIAndWeirdScienceLLCMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EBI And Weird Science LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EarnOutDistribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EarnOutDistribution",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-out distribution"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EarnOutSharesIssuedInSettlementOfContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EarnOutSharesIssuedInSettlementOfContingentLiability",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn out shares issued in settlement of contingent liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC NET LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r220",
      "r222",
      "r225",
      "r226",
      "r227",
      "r230",
      "r462",
      "r470",
      "r487",
      "r488",
      "r591",
      "r610",
      "r760"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DILUTED NET LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r222",
      "r225",
      "r226",
      "r227",
      "r230",
      "r462",
      "r470",
      "r487",
      "r488",
      "r591",
      "r610",
      "r760"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r229"
     ]
    },
    "RENB_EarnoutSharesIssuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EarnoutSharesIssuedShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-out shares issued, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EarnoutSharesIssuedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EarnoutSharesIssuedValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-out shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rates on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r789"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r789"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EmployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EmployeeStockOptionsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Employees1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "Employees1Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EmployeesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EmployeesOfficersDirectorsAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EmployeesOfficersDirectorsAndConsultantsMember",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees, Officers, Directors and Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r166",
      "r188",
      "r189",
      "r190",
      "r206",
      "r207",
      "r208",
      "r210",
      "r215",
      "r217",
      "r219",
      "r232",
      "r272",
      "r273",
      "r305",
      "r385",
      "r453",
      "r454",
      "r459",
      "r460",
      "r461",
      "r463",
      "r469",
      "r470",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r521",
      "r523",
      "r537",
      "r607",
      "r626",
      "r627",
      "r628",
      "r645",
      "r714"
     ]
    },
    "RENB_EquityIncentivePlan2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EquityIncentivePlan2014Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan 2014 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r853",
      "r863",
      "r889"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r860",
      "r886"
     ]
    },
    "RENB_EscrowSharesRemaining": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "EscrowSharesRemaining",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow shares remaining"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExcessTaxBenefitOverDepreciationFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExcessTaxBenefitOverDepreciationFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Excess of tax over book depreciation of fixed assets",
        "label": "ExcessTaxBenefitOverDepreciationFixedAssets"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExcessTaxBenefitOverDepreciationPatents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExcessTaxBenefitOverDepreciationPatents",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Excess of tax over book depreciation of patents",
        "label": "ExcessTaxBenefitOverDepreciationPatents"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "RENB_ExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExercisePricePerShare",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price per share"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExercisePriceRange1Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExercisePriceRange2Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExercisePriceRange3Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExercisePriceRange4Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExercisePriceRange5Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePrices": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExercisePrices",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExerciseWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExerciseWarrants",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExerciseWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExerciseWarrantsAmount",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise warrants amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExtinguishmentOfContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ExtinguishmentOfContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r498",
      "r792"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r498",
      "r792"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493",
      "r494",
      "r795"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493",
      "r494",
      "r795"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r498",
      "r500",
      "r547",
      "r548",
      "r549",
      "r777",
      "r778",
      "r783",
      "r784",
      "r785",
      "r792",
      "r795"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of key input to valuing the contingent consideration liability",
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r144",
      "r145"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r392",
      "r491",
      "r498",
      "r547",
      "r783",
      "r784",
      "r785",
      "r792"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r392",
      "r491",
      "r492",
      "r498",
      "r548",
      "r777",
      "r778",
      "r783",
      "r784",
      "r785",
      "r792"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r549",
      "r777",
      "r778",
      "r783",
      "r784",
      "r785",
      "r792",
      "r795"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r498",
      "r500",
      "r547",
      "r548",
      "r549",
      "r777",
      "r778",
      "r783",
      "r784",
      "r785",
      "r792",
      "r795"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "FinanceAgreementEnteredIntoInExchangeForPrepaidAssets",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance agreement entered into in exchange for prepaid assets"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_FinanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "FinanceAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r754",
      "r775"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r754",
      "r775"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r754",
      "r775"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r754",
      "r775"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r299",
      "r300",
      "r557",
      "r558",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r295",
      "r299",
      "r300",
      "r303",
      "r557",
      "r754",
      "r775"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r299",
      "r300",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Definite life intangible assets, net",
        "verboseLabel": "Total",
        "terseLabel": "Definite-life intangible assets",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r960"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Additions",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Translation adjustment",
        "documentation": "Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments and purchase accounting adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r507",
      "r711"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on foreign currency transactions",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r821",
      "r1018",
      "r1019",
      "r1078"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional Currency and Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r893"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r893"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r893"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r893"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r893"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GEDiCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "GEDiCubeMember",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEDi Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GTechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "GTechMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "G Tech [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "verboseLabel": "Extinguishment loss",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r50",
      "r51"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r693"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r275",
      "r589",
      "r768",
      "r774",
      "r793",
      "r801",
      "r950",
      "r951"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill impairment",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r952"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment",
        "verboseLabel": "Goodwill impairment adjustment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r276",
      "r282",
      "r286",
      "r774",
      "r793"
     ]
    },
    "us-gaap_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Member]",
        "documentation": "Asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GrossProceedsDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "GrossProceedsDiscountPercentage",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds original issue discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GrossProceedsOriginalIssueDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "GrossProceedsOriginalIssueDiscountRate",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds original issue discount rate",
        "label": "GrossProceedsOriginalIssueDiscountRate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r837",
      "r849"
     ]
    },
    "RENB_ImpairmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ImpairmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset impairment",
        "verboseLabel": "Impairment adjustment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r289",
      "r302"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Impairment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r930",
      "r965"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Goodwill and Indefinite Lived Intangible Assets",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r119"
     ]
    },
    "RENB_InProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "InProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r960",
      "r962",
      "r963",
      "r964"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r313",
      "r316",
      "r495",
      "r496",
      "r499",
      "r623",
      "r625",
      "r698",
      "r754",
      "r794",
      "r1046"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r316",
      "r495",
      "r496",
      "r499",
      "r623",
      "r625",
      "r698",
      "r754",
      "r794",
      "r1046"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r431",
      "r432",
      "r441",
      "r449",
      "r789",
      "r1008"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r431",
      "r432",
      "r441",
      "r449",
      "r789",
      "r1008"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r427",
      "r431",
      "r438",
      "r439",
      "r440",
      "r442",
      "r447",
      "r455",
      "r456",
      "r457",
      "r458",
      "r640",
      "r789"
     ]
    },
    "RENB_IncomeTaxExpenseBenefitContingentConsiderationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IncomeTaxExpenseBenefitContingentConsiderationFairValue",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration fair value"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IncomeTaxExpenseBenefitImpairmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IncomeTaxExpenseBenefitImpairmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment expense",
        "label": "IncomeTaxExpenseBenefitImpairmentExpense"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IncomeTaxExpenseBenefitOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IncomeTaxExpenseBenefitOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "IncomeTaxExpenseBenefitOperatingLossCarryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r429",
      "r430",
      "r442",
      "r443",
      "r446",
      "r451",
      "r634"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r789",
      "r1004"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computed tax at expected statutory rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r431",
      "r434",
      "r789"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses / other items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r1004"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible depreciation and amortization."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1006"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock/options compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r1004",
      "r1006"
     ]
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-US income taxed at different rates",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r198",
      "r448",
      "r449"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance receivable",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, net",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r929"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses/deposits",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IndefiniteLifeIntangibleAssetsAndGoodwillAmortization",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IndefiniteLifeIntangibleAssetsAndGoodwillImpairment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite life intangible assets, net",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r298",
      "r775"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Additions",
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Translation adjustment",
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from foreign currency translation and purchase accounting adjustments."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r884",
      "r893",
      "r897",
      "r905"
     ]
    },
    "RENB_InitialPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "InitialPayment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial payment"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_InitialRecognitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "InitialRecognitionMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Recognition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r908"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r908"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r908"
     ]
    },
    "RENB_InsuranceReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "InsuranceReceivablePolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceSettlementsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance receivable",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS AND GOODWILL",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r301",
      "r304",
      "r753",
      "r754"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r557",
      "r759",
      "r952"
     ]
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r239",
      "r243",
      "r249",
      "r262",
      "r517",
      "r767",
      "r768"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Total interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r926"
     ]
    },
    "RENB_InterestExpenseRelatedToNoteBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "InterestExpenseRelatedToNoteBalance",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense related to note balance"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_InterestIncomeAndOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "InterestIncomeAndOtherIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income and other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseAfterProvisionForLoanLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount amortization to other income and expense",
        "documentation": "Amount of interest income or expense, including any amortization and accretion (as applicable) of discounts and premiums, including consideration of the provisions for loan, lease, credit, and other related losses."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r196",
      "r197"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest amount",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "RENB_Investor1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "Investor1Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028"
     ]
    },
    "RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants under private placement offering in settlement of debt, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants under private placement offering in settlement of debt"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants under private placement offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants under private placement offering"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfCommonStockPursuantToAcquisitionOfGediCube",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to acquisition of GEDi Cube"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to acquisition of GEDi Cube, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfCommonStockUnderPrivatePlacementOffering",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under private placement"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants for conversion of Note Payable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants for conversion of Note Payable, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfPreferredStockAndWarrantsInPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants in private placement"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants in private placement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_JanuaryNote2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "JanuaryNote2024Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Note 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LabEquipmentAndInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LabEquipmentAndInstrumentsMember",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment And Instruments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r800"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of net operating lease expenses",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r536"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LessAccumulatedAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LessAccumulatedAmortizationMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Accumulated Amortization [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceSubleaseResidualValueGuaranteeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceSubleaseResidualValueGuaranteeDescription",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease agreement description",
        "documentation": "Description of terms and conditions of residual value guarantee provided by sublessee on finance sublease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease premises, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of lease commitments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r87",
      "r88",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r202",
      "r271",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r474",
      "r477",
      "r478",
      "r501",
      "r668",
      "r761",
      "r823",
      "r972",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r148",
      "r600",
      "r801",
      "r933",
      "r947",
      "r1017"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r170",
      "r202",
      "r271",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r474",
      "r477",
      "r478",
      "r501",
      "r801",
      "r972",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r91",
      "r92",
      "r93",
      "r94",
      "r202",
      "r271",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r474",
      "r477",
      "r478",
      "r501",
      "r972",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination fee",
        "documentation": "The amount of early contract termination fees included in liabilities subject to compromise."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "RENB_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LincolnParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LincolnParkMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bear interest percentage",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r967",
      "r968",
      "r969"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r49",
      "r967",
      "r968",
      "r969"
     ]
    },
    "RENB_LossOnExtinguishmentOfContingentConsiderationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LossOnExtinguishmentOfContingentConsiderationLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on extinguishment of contingent consideration liability",
        "label": "LossOnExtinguishmentOfContingentConsiderationLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LossOnExtinguishmentOfContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LossOnExtinguishmentOfContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LossOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "LossOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on extinguishment of debt",
        "label": "LossOnExtinguishmentOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_MarchNote2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "MarchNote2024Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March Note 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_MarkDybulMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "MarkDybulMember",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mark Dybul [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_MarketPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "MarketPrice",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r394",
      "r424",
      "r494",
      "r552",
      "r622",
      "r624",
      "r632",
      "r660",
      "r661",
      "r722",
      "r724",
      "r726",
      "r727",
      "r732",
      "r751",
      "r752",
      "r772",
      "r781",
      "r788",
      "r795",
      "r796",
      "r797",
      "r798",
      "r810",
      "r974",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493",
      "r494",
      "r795"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493",
      "r494",
      "r795"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r394",
      "r424",
      "r494",
      "r552",
      "r622",
      "r624",
      "r632",
      "r660",
      "r661",
      "r722",
      "r724",
      "r726",
      "r727",
      "r732",
      "r751",
      "r752",
      "r772",
      "r781",
      "r788",
      "r795",
      "r796",
      "r797",
      "r810",
      "r974",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "RENB_MonthlyInstallments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "MonthlyInstallments",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly instalments amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "NL",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NetDefinitelifeIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "NetDefinitelifeIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Net definite-life intangible assets at beginning",
        "periodEndLabel": "Net definite-life intangible assets at ending",
        "label": "NetDefinitelifeIntangibleAssets"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NetDefinitelifeIntangibleAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "NetDefinitelifeIntangibleAssetsAmortization",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r112",
      "r150",
      "r168",
      "r183",
      "r185",
      "r190",
      "r202",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r224",
      "r271",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r462",
      "r470",
      "r488",
      "r501",
      "r606",
      "r690",
      "r712",
      "r713",
      "r821",
      "r972"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non cash earn out distribution",
        "documentation": "The amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "RENB_NoncashRestrictedSharesIssuedForServicesRendered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "NoncashRestrictedSharesIssuedForServicesRendered",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash restricted shares issued for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NoncashStockbasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "NoncashStockbasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash stock-based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income (Expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Note2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "Note2020Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Note2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "Note2023Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NotePayableSettledThroughNoncashExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "NotePayableSettledThroughNoncashExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable settled through non-cash exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r147",
      "r1041",
      "r1042"
     ]
    },
    "RENB_NotesPayableRelatedPartiesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "NotesPayableRelatedPartiesNetCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable \u2013 related parties, net"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_November2023NoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "November2023NoteMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2023 Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NumberOfShareWarrantPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "NumberOfShareWarrantPurchase",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share warrant purchase"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_OfferingPricePerSharePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "OfferingPricePerSharePercentage",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per share percentage"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_OneWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "OneWarrantMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses [Default Label]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r762",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "RENB_OperatingLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "OperatingLeaseExpenses",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r532"
     ]
    },
    "RENB_OperatingLeaseRentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "OperatingLeaseRentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Net Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r800"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r800"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r76",
      "r77",
      "r142"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Equity [Table]",
        "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as equity. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r76",
      "r77",
      "r142"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionMember",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r677",
      "r682",
      "r701",
      "r707",
      "r729",
      "r730",
      "r731",
      "r813",
      "r814"
     ]
    },
    "RENB_OptionsIssuedInSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "OptionsIssuedInSettlementOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued in settlement of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r140"
     ]
    },
    "RENB_OriginalIssueDiscountPromissoryNotePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "OriginalIssueDiscountPromissoryNotePercentage",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount promissory note percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation, net of taxes",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r506",
      "r514"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r1077"
     ]
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total indefinite life intangible assets and goodwill at beginning",
        "periodEndLabel": "Total indefinite life intangible assets and goodwill at ending",
        "label": "Other Indefinite-Lived Intangible Assets",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r962"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r801"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Notes Payable",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r147",
      "r1041"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaids and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r948"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_OtherTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of other income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r1003",
      "r1010"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r855",
      "r865",
      "r891"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r868",
      "r894"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r868",
      "r894"
     ]
    },
    "us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnersCapitalAccountUnitsSoldInPrivatePlacement",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closed private placement units",
        "documentation": "The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r953",
      "r954",
      "r955",
      "r956",
      "r958",
      "r960",
      "r963",
      "r964"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r872"
     ]
    },
    "RENB_PaymentForExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PaymentForExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for license",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsForLeasingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLeasingCosts",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease payment",
        "documentation": "Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes receivable prior to acquisition",
        "label": "Payments to Acquire Notes Receivable",
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "RENB_PlanOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PlanOptionsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock converted to common stock pursuant to acquisition of GEDi Cube"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "RENB_PreferredStockDesignatedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PreferredStockDesignatedShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock designated shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PreferredStockIssuancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PreferredStockIssuancesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Issuances [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r820",
      "r1075",
      "r1079"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r368"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r669"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r368"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r669",
      "r687",
      "r1079",
      "r1081"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r596",
      "r801"
     ]
    },
    "us-gaap_PrepaidInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInterest",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid interest",
        "documentation": "Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r773",
      "r948"
     ]
    },
    "RENB_PrepaymentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PrepaymentShares",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PrincipalAmountAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PrincipalAmountAndInterestAccrued",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount and interest accrued"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PrivatePlacement1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PrivatePlacement1Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PrivatePlacement2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PrivatePlacement2Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PrivatePlacement3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PrivatePlacement3Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible notes payable",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock",
        "verboseLabel": "Proceeds from common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of promissory notes",
        "verboseLabel": "Gross proceeds",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placements",
        "verboseLabel": "Proceeds from private placement",
        "terseLabel": "Proceeds of private placement offering",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payables",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aggregate proceeds",
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r183",
      "r185",
      "r194",
      "r202",
      "r209",
      "r215",
      "r218",
      "r219",
      "r271",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r462",
      "r470",
      "r472",
      "r475",
      "r476",
      "r488",
      "r501",
      "r592",
      "r605",
      "r644",
      "r690",
      "r712",
      "r713",
      "r790",
      "r791",
      "r822",
      "r924",
      "r972"
     ]
    },
    "RENB_PromissoryNoteBalanceNetOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PromissoryNoteBalanceNetOfDiscount",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note balance, net of discount"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r536"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r159",
      "r162",
      "r163"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r172",
      "r604"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Net Property and Equipment",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r536",
      "r593",
      "r604",
      "r801"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r159",
      "r162",
      "r602"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r536"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation to purchase",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PurchaseSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "PurchaseSharesOfCommonStock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "RENB_RENBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RENBMember",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RENB [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RENCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RENCMember",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RENC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RSBioApSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RSBioApSMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RS Bio ApS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RSBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RSBioMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RS Bio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r386",
      "r394",
      "r417",
      "r418",
      "r419",
      "r424",
      "r494",
      "r550",
      "r551",
      "r552",
      "r622",
      "r624",
      "r632",
      "r660",
      "r661",
      "r722",
      "r724",
      "r726",
      "r727",
      "r732",
      "r751",
      "r752",
      "r772",
      "r781",
      "r788",
      "r795",
      "r796",
      "r797",
      "r798",
      "r810",
      "r815",
      "r970",
      "r974",
      "r1015",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r386",
      "r394",
      "r417",
      "r418",
      "r419",
      "r424",
      "r494",
      "r550",
      "r551",
      "r552",
      "r622",
      "r624",
      "r632",
      "r660",
      "r661",
      "r722",
      "r724",
      "r726",
      "r727",
      "r732",
      "r751",
      "r752",
      "r772",
      "r781",
      "r788",
      "r795",
      "r796",
      "r797",
      "r798",
      "r810",
      "r815",
      "r970",
      "r974",
      "r1015",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information regarding segment reporting",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r839",
      "r850",
      "r860",
      "r886"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r393",
      "r541",
      "r542",
      "r595",
      "r601",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r686",
      "r688",
      "r721"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued balance",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r541"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r1030"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r694",
      "r695",
      "r698"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r393",
      "r541",
      "r542",
      "r595",
      "r601",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r686",
      "r688",
      "r721",
      "r1030"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r641",
      "r642",
      "r643",
      "r696",
      "r697",
      "r698",
      "r718",
      "r720"
     ]
    },
    "RENB_RenovaroBioPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RenovaroBioPharmaIncMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro Bio Pharma Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RenovaroCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RenovaroCubeMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RenovaroDenmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RenovaroDenmarkMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro Denmark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RenovaroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RenovaroMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RepaymentOnFinanceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RepaymentOnFinanceAgreement",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Down payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RepaymentsOfFinanceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RepaymentsOfFinanceAgreement",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of finance agreement",
        "label": "RepaymentsOfFinanceAgreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment on promissory note",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r754",
      "r767",
      "r1040"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r861",
      "r887"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r852",
      "r862",
      "r888"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r869",
      "r895"
     ]
    },
    "RENB_RestrictedSharesIssuedForServicesRenderedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RestrictedSharesIssuedForServicesRenderedShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RestrictedSharesIssuedForServicesRenderedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RestrictedSharesIssuedForServicesRenderedValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r127",
      "r599",
      "r629",
      "r631",
      "r639",
      "r670",
      "r801"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r206",
      "r207",
      "r208",
      "r210",
      "r215",
      "r217",
      "r219",
      "r272",
      "r273",
      "r305",
      "r453",
      "r454",
      "r459",
      "r460",
      "r461",
      "r463",
      "r469",
      "r470",
      "r479",
      "r481",
      "r482",
      "r484",
      "r486",
      "r521",
      "r523",
      "r626",
      "r628",
      "r645",
      "r1079"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, value",
        "verboseLabel": "Paid in cash and settlement of debt",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock issued cash consideration",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, shares",
        "verboseLabel": "Shares sold",
        "terseLabel": "Sale of stock issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, price per share",
        "verboseLabel": "Price per unit",
        "terseLabel": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of acquisition date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r466"
     ]
    },
    "RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of common stock purchase warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "RENB_ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of consolidated statements of operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r59",
      "r60",
      "r61",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r789",
      "r1004"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurement on recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r295",
      "r299",
      "r300",
      "r303",
      "r557",
      "r754",
      "r775"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of definite-life and indefinite-life intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r959"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r536"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of assets acquired and liabilities assumed",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r694",
      "r695",
      "r698"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r103"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment operating loss and asset information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock options outstanding",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r131"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r130"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r123",
      "r125",
      "r126",
      "r127",
      "r178",
      "r179",
      "r180",
      "r233",
      "r368",
      "r369",
      "r371",
      "r373",
      "r376",
      "r381",
      "r383",
      "r635",
      "r636",
      "r637",
      "r638",
      "r781",
      "r913",
      "r931"
     ]
    },
    "RENB_ScheduleOfWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ScheduleOfWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expected future amortization expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r961"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "RENB_SegmentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SegmentAsset",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r231",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r269",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r303",
      "r317",
      "r320",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r764",
      "r767",
      "r768",
      "r774",
      "r812",
      "r1043",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "auth_ref": [
      "r267",
      "r268",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r657",
      "r658",
      "r659",
      "r723",
      "r725",
      "r728",
      "r733",
      "r740",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r755",
      "r782",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r811",
      "r815",
      "r976",
      "r1043",
      "r1047",
      "r1048",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "RENB_SegmentOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SegmentOperatingLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income loss",
        "verboseLabel": "Segment operating loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r252",
      "r254",
      "r255",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r763",
      "r765",
      "r766",
      "r767",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of debt"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SettlementOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SettlementOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SettlementsContingentSharesToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SettlementsContingentSharesToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlements: contingent shares to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "verboseLabel": "Stock based compensation costs",
        "terseLabel": "Stock based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount Rate (Monte-Carlo model only)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Dividends",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Free Rate",
        "verboseLabel": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable at ending of period",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/Expired",
        "label": "Cancelled/Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Shares forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "verboseLabel": "Number of shares grant",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Intrinsic Value, Outstanding at beginning of period",
        "periodEndLabel": "Weighted Average Intrinsic Value, Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number share option outstanding",
        "periodStartLabel": "Options Outstanding at beginning of period",
        "periodEndLabel": "Options Outstanding at end of period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning of period",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at ending of period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices, Lower",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices, Upper",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Term (years)",
        "verboseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Intrinsic Value, Exercisable end of period",
        "verboseLabel": "Total intrinsic value of options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable, Weighted Average Remaining Contractual Life (years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average remaining life, Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding, Weighted Average Remaining Contractual Life (years)",
        "verboseLabel": "Weighted Average remaining life",
        "terseLabel": "Weighted Average remaining life, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "RENB_SharesInLieuOfInterestOnMillionNotesPayableExtension": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SharesInLieuOfInterestOnMillionNotesPayableExtension",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares in lieu of interest on $1.2 million notes payable extension"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharesIssuableForSettlementOfContingentConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SharesIssuableForSettlementOfContingentConsideration",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable for settlement of contingent consideration, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharesIssuableForSettlementOfContingentConsiderationValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SharesIssuableForSettlementOfContingentConsiderationValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable for settlement of contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "RENB_SharesIssuedForInterestOnNotesPayableExtensionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SharesIssuedForInterestOnNotesPayableExtensionShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for interest on $1.2 million notes payable extension, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharesIssuedForInterestOnNotesPayableExtensionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SharesIssuedForInterestOnNotesPayableExtensionValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for interest on $1.2 million notes payable extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r967",
      "r968",
      "r969"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r967",
      "r968",
      "r969"
     ]
    },
    "RENB_SingleRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SingleRangeMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Single Range [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r167",
      "r231",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r269",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r303",
      "r307",
      "r317",
      "r320",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r764",
      "r767",
      "r768",
      "r774",
      "r812",
      "r1043",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r178",
      "r179",
      "r180",
      "r202",
      "r222",
      "r223",
      "r225",
      "r227",
      "r233",
      "r234",
      "r271",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r368",
      "r369",
      "r373",
      "r376",
      "r383",
      "r501",
      "r635",
      "r636",
      "r637",
      "r638",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r669",
      "r691",
      "r714",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r913",
      "r931",
      "r940"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r96",
      "r99",
      "r100",
      "r166",
      "r188",
      "r189",
      "r190",
      "r206",
      "r207",
      "r208",
      "r210",
      "r215",
      "r217",
      "r219",
      "r232",
      "r272",
      "r273",
      "r305",
      "r385",
      "r453",
      "r454",
      "r459",
      "r460",
      "r461",
      "r463",
      "r469",
      "r470",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r521",
      "r523",
      "r537",
      "r607",
      "r626",
      "r627",
      "r628",
      "r645",
      "r714"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r657",
      "r658",
      "r659",
      "r723",
      "r725",
      "r728",
      "r733",
      "r740",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r755",
      "r782",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r811",
      "r815",
      "r976",
      "r1043",
      "r1047",
      "r1048",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/LeasesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r232",
      "r523",
      "r556",
      "r633",
      "r656",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r692",
      "r693",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r816"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/LeasesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r232",
      "r270",
      "r523",
      "r556",
      "r633",
      "r656",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r692",
      "r693",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r816"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r854",
      "r864",
      "r890"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes, shares",
        "verboseLabel": "Stock issued for debt conversion, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r55",
      "r96",
      "r99",
      "r127",
      "r355"
     ]
    },
    "RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockIssuedDuringPeriodSharesIssuedForConsultingServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesIssuedForConsultingServices",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock shares",
        "label": "StockIssuedDuringPeriodSharesIssuedForConsultingServices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r127",
      "r635",
      "r714",
      "r735"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for accrued interest",
        "verboseLabel": "Issuance of shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued",
        "documentation": "The increase (decrease) during the period in the number of shares issued."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted commitment shares, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r127"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original shares of common stock",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r127"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to purchase shares of common stock",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to purchase shares of common stock par value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited shares of common stock",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "negatedLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r127",
      "r403"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes",
        "verboseLabel": "Stock issued for debt conversion",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r96",
      "r99",
      "r100",
      "r127"
     ]
    },
    "RENB_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockIssuedDuringPeriodValueIssuedForConsultingServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockIssuedDuringPeriodValueIssuedForConsultingServices",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock for consulting services value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock shares, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r127",
      "r645",
      "r714",
      "r735",
      "r822"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of options for services rendered",
        "verboseLabel": "Shares issued of common stock, value",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted commitment shares",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r127"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of value grant",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r127"
     ]
    },
    "RENB_StockIssuedPursuantToWarrantsExercisedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockIssuedPursuantToWarrantsExercisedShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued pursuant to warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockIssuedPursuantToWarrantsExercisedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockIssuedPursuantToWarrantsExercisedValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued pursuant to warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockPurchaseAgreementOfRenovaroCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockPurchaseAgreementOfRenovaroCubeMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Purchase Agreement Of Renovaro Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares purchased",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r127",
      "r638",
      "r714",
      "r737"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99",
      "r100",
      "r116",
      "r671",
      "r687",
      "r715",
      "r716",
      "r801",
      "r823",
      "r933",
      "r947",
      "r1017",
      "r1079"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r201",
      "r367",
      "r369",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r385",
      "r485",
      "r717",
      "r719",
      "r739"
     ]
    },
    "RENB_StockoptionsCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "StockoptionsCompensation",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock/options compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sub-lease Income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r800"
     ]
    },
    "RENB_SubscriptionAgreements1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SubscriptionAgreements1Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "SubscriptionAgreementsMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r545"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r545"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r545"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r545"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r545"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r546"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://renovarobio.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "RENB_TheNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "TheNotesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1029"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "RENB_UnitedStatesTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "UnitedStatesTaxMember",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States Tax [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Up-front payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r156",
      "r157",
      "r160",
      "r161"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in the valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "RENB_WarrantsOutstandingPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "WarrantsOutstandingPerShare",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price per share"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_WarrantsPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "WarrantsPurchased",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchased"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_WarrantsSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "WarrantsSold",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r227"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r227"
     ]
    },
    "RENB_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20240630",
     "localname": "WorkingCapitalDeficit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital deficit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-7"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-22"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001731122-24-001578-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-24-001578-xbrl.zip
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M4\]1;/4;:!S!=<#O86G7KMUAJ Q==0%UX+B7AG>-P\W:U(QHV'B9_%[YMEZ
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MV4Z,*CJ E]M3HM&L-8\5@#^Q#NU+;GX+QJCE03A_EVL"L83 ,IVP\ *992.
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MQ+.M.SYSS_8Z;(N*TC[:+N[HML_8!&XU]6!69B_DG_S:?+V$.\M4#+&0_=A
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M7WF4)6X=U _5@1GG#&>W+[?UK*0<G:9""%;Y$Q[Y@@<=?=!.^0S%GJ4\!W_
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M%N>0I:<3"#KRV5G?[,&$:I(@6<QE'B^<)X]XH6 ]RD72)\!U.Y%K+W.]D\I
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MK+YPWRQN16>C-@MDSMG((D'Z5>=<4A#Z-L):AMXH<]IV$9$ Z;@DX)* ETO
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MZ:&4Z=7*U.>_RNS O%4N^'75^N7\$[?.8K#B+[S(M;Y$3I5L;6$IJJP4U66
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M4:Q[3@W.:6/'?LS^RL]D_*&E& =@C+),#E,ETV_-L\:;[LK>H2Y&DO# D3X
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M!UL@=<3$*8P3 -/#B=L1LBI5J-#W0U%<(Z(<V\@G[L1@Y:\8'HNVFU?H )'
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M1OJ)M$]UJTA85JZD3>U9,-7+<4W:]E>A;6^=EP,1+\^LT$5H%>Y-3.35]G7
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MB(I!877ED1MH  2_ %/N5V$VYG<5P+![:W_!:!'#8/CE-?Z!6[&0B>_J"S)
M <G,AV276;*3><9+)5!%ND8'KI>E[+EFB)C/LYI9$X^)T43!3W$6X-369=NQ
MC <2FRQD9TA4^SNB4*LWL,GWFY3\R'Y IW:+75A[4_#]_EX5?)\<"KZ'/L'/
MT^;Q4BDBP1[>%1$:L";*4M1,5@K70",V)'9CISJBADL,#YSUJ9N\\8BO;*"6
M5/"%*,LVX)2,&"&9]O'OY,VUXHZ1D*/X1-S'31Y6$OGN+*ID-G7EORNI?K]B
M[2=L?%H494\)@&7/].@%*L3V[+51TONH*=IWULOU;TN4'Y#$+#HGP/E&BOT]
MS@H<EM.?6TZ_"QVRED1"]DA31G-/[1N(BKU=6R;6ZZVRP+9(=<S%.7GW$(@P
M@:>_ GC1AL<YD )[[R/4)-4):3%*7']./JV#N7YF<Y4@80=VWAA,%E%+!]\5
M3*M :=U>DA++HD&M^:;N2,)"&9TZ@^[DD)EW5&&QB#C&T67KC4KW1=V7"]RB
MX?<+[F->]B6I=B/%L' :\Z^"PK5>!!MQ9G](M,[)65HA-"P)>^MF:R)9HM$4
M_EL2S!,]2KH+]:+1QJY,F*%E;.8H@M=18>T_K&Q7G1=-7>$Q<%A07^Z"^I$H
MF*>74^N:<V6Q5J,R\/E!!'FPDB_=2F#.2W*]<VU1!:MP#6Y2X"8VVJ8:V'EG
MVKSC_$ZDHCY>CY=2L"3"WN1,#1-O4CO47W=8K.[$!V/\<HWQJ2:^9ABB8>W-
MVD8^;VKXU3N'Q%8-&!$8DO-RM*J/P7H8*>IA<#WM9-G &TH?:%/Y+\]/Q)Z_
MPE.7#^8.'&'V UA@ R(]L.Q_P:\6]9JM^%>B;2MSS-CA=?_ID--FFTFQ@#HV
M0EF6>GN/J$L4CG3^ WC-P2N8L;I'(^EF5/.E9SE98ZYND7,V[N>Z6@CW*+8*
M<N-,C:+*K&+<=W[(IQHX:A7&+R3X$Z.>2(WAL("^W 7TC*4N<A72)=*T?.;7
M"-B^V+S9RZE*-BR^U5X<5;J"$4NQ:1Q$C+EG05;0+*S28NYL,RC,(].C4^)Y
ME F/@[[_CN58#W0N'V6D<J?'U[[3E>;\D5?\>)9>_L<GJ L]?[^A.G7'LNFF
M^9.XIL2,A>8/%>=I)%0Z-+\<\_NY"F[KF \4"_&RF?MU(:H&#^IJ3J1&>":)
M&!+\^ZN,BME'AB#M2%VN<&D:"CGJ];*[H"Y+_1,7##_52S-&_Z=O\3&+;FQ'
MU,&^_5MZNEW/ZI)&^/V3O_/HV)YXS/%>1M@:*IFUN'2+%CN'D>'1'=7+(]BS
MCN#PEZ@=U;.HPI\^>/KS2U;9>GGZ*L3D7_G8"?951*NQ$Q*$KV@T V4K#L"M
MEIGV,7,BN&@6E(K#CS[8- 6\MH+0FI(Q8\H)40[#Y&_18?;V*_4+J.Y/UAKV
M5:Z.XV"0TD&*\M1V(RGG+3T)COVB-AUD))WYM]N;]1NWNN\>?Q*KBPR._Y\&
M_++3&<&^/-P)$!XFB<S0&L6YTJU)0>4IQ5P%=?"QB>&'C=680YT_06T?%'2]
M>@^?7:2_YE4-$\GS_E8!-%JSR"LK\ 9V-O<B2[@-.=QC^,XM<[L*7Q >=_C]
M2;VV6YFDNVXDV&).>Q-!LCQ&Q?$QQ66C12#P,;Q-%B+(AC3!3,*HE./T9([U
M)HX'"KD-81R16Z@[V_JC!<M6%4+-";<#VP"8QH::V2-:H<#0."\9Y$T.9+0#
M8;^]RGWF8/<$@B)C<]Q:KW!&Y4S:]+0GNP6-!LY)V5A)5#&H^X:B@-?DT4Q$
M)$E$D55T  @O,I<Z^$N-FSM< TV]S<ON"[/ESW;,\O^G)Y)J'QV,6S]#_N3E
M9/14.-WDFP)YKWD-,'<P%U_;HC-A_F\9Q+/><!N4G!*KOZB;<G',^("IJ.&V
MPH8H>+@,6?+#O4*6?'U EGPF>J'9/U[U3?H2)K1$$EW$!Z B%KBZVQO27[XE
MUO&.SB#<!^!XA /,<5L190CKI(:'UD3B<8JO0 K?6SP$87M98AO5AJX242,*
MFK:C4IU'(6<$Y= >+',,>QQ&^+MD5YSOET]BBH:)M'<\VM_1983=L*;*'5&H
M^\8"'G$&O]YL"7%+NA,0'.3-.SDO\4?8C^>-ZV [OL#QMD3WE>2MP@N].H&G
MVRTJ/#7E :V.P+NJOBC=8B7L<EY8#P.7(SQ8MVF^:IR3CF-/N,\E5TQ2EL6Z
M4 @SW'_)4&I*^R3VJZBY2H :IM];(KF.^7.(B,POP_R3.VO^$L=\'"O1K.++
MM@](K[$]3GXG!AU"/1-"%S$,)/9#E8M23YK"+J6-+"6Y"$\](>//\Z)DD":"
MGSF&=^Z=Z(G12'RO""I5RP5:%$80\X&3F0-3Y%>H"QZYF:<O"3(\>4N<$0Q%
M=LT<T]?QVIAI@R.GQALDR<,".(X %R)$4CG:14*)1E9NS S*"Z:[:&OFEG7O
MW1QB;,1?+8IV7M:MX@KR%EWBD.27-6\,+^TW2%.,7BF<:$:ON"#%8=49YM%I
MAR9XY-J&>9?[?.BX.6E%_^&+.W->5>E)OX(/I(^^S=+'#Q\_5D7VUV]?P;'2
M]A#'_'9\>ISRZ93^6A^GCQYE7S]ZDCUY\GWZ(WQ>"E&_@ -<B_/[%%L$6FE3
M_(WVL3=.MGVXR#,(S:DK+7V*66<Z0IXR6A%"&_"<MU+1RC +U7&U%3MXUN8>
M<WL/IA&6EET!/F+B'O;10N FF+WH*R?-(RW)-N<+["[&G#[C2W18E Q7]C?\
MTQDRF>'! N=$0FNWJ)3V14Y<6=%M"@;SYOFO/QX]>_KHT=]2LH[B'__D+"F1
MSJSK!>?D3LJ2V>+FHU<"Y]IK'R&^%L C/N7/"GM+WKAUT:IXWRFZS.G;?HWK
MG:K,C\ 7US(@07)>YP1(I7O0&\+>!3Y&_)V4#U-#TO L1X\>_^__/?4XR<T\
M3AH]SDF07'\9,@<T8)KJ"[C4-MW"X2D$=T\Y_Y34%Y50\8T=H<PW:9D]+Z<L
MPW_U,"^/OL$E\.B'+_X0@E7_7[@4'GU':_XA'!KZNKJB \](UW28T>3M$<[D
MT8]4>/WIY;\AM)O/B=JOQBGJ(=3!#Y"F&-K43VB*.'VXZL M\BOZMU.\YZ._
M/GSXY.%W/WR3GCR*DHBRI%5I#):[=)'AD3=WFZY-\.-DE3_]&ZSR.+V .43?
M=Q&90OJ1IG *]W"4%WK\/;V>1S=H#U>=59^[,>3/W&Q'ZH!.S)?5T<\<PBQ"
MWO:F3LJ=-[ZQI312 )27-OO'6PI%3BD4X7/(BC'_"P*+HY_JBYM^T$^T8UPO
M^>/[PG+9E)4 ?A0R)'(&<M)R8^)9']NUU$I(?%(VJO/ _BA&.\+67H@;<^5/
M%F^9SJ;,PD4%K^78_TWD&+M99L\/>5LW.$5D=KBGP8&+SWICMO6%[C_7X,]'
M:\T[K6-BL0C<F+F^XG/'K,!*JB'TDZ$;0#(=:),G+X^P6]+9-GB/,V6W%'P4
M1%0+03I2X@;9;=LKSU5V.%&/DW^Y;:K#J9O6U_;_V4 $GJ4O(#"KZK5D+UY=
MO"O@)3DLOS*&D?Q=;E=8D$Q&Y:7\@O8@-6KGY?8_;MAGSOU Y"$F?KC'Z>_$
MTL-=/N%=4/M1&FJ\*#:H+?SFE5AQBG@N#'4%S4C7NG+I3V=$.+ ,99;(*SSR
M%[4*!)Z1QVLW<DXG")UR-8>(V@>DVA%I!F?6]+H>K^EB80.N2&5<K2I=#+[/
MZ8W1[X7Z?LR,8.F,-I*B$@+QW).RA(3-,7C4V"$F-;*FOEA 8$;5!AB"&[S4
M_]&F\&O)U9B$GVTTL'4V$5D(#?9*%;+ YOG6<8ETZ]^>=](*=)J2'#FV6]BD
M2[*O!;7%C^4K.U:0U?;?7MIJF#T[3V=@(/C5)J\X0>4!_E(8X4P951AO9CO_
M/*0@']F7"][W?:J>?'.HGGP>=V*WS_Y/)$+C2.B-)ZVX>R[[]5\G93)>/#N!
MQSTOX :$KL:#ZCPO$R9VT(>_DY[C]6]JIC[O(>9N&'X1H<>34X28X0XNDK9N
M@7Y1QM S*5O4N%\3F8W6E"I)1C-T'*\*MV=P1NG94?#KZQJSW/19"-JK5<N9
M2-WX,UM@RI+.41L95EBJ?IE3FUPV1-YF['><XRCA-'0E?6,#&R6ARG'H-78F
M9\1XV2R.WCFWX<\T];H6'9<%P55;^CV>S-K"G>$Y"*]7+08>@##\@D%J'%;(
M9(SH3NH?P)70IC>NHDDVO8&#O"?_4;-O*G3%Y12A8 G>YW%ZPH@K@8_XOR7X
M.5%:(+H<9DDT/7E-L'@ZD*EQ3P]^QK=@3H90TQ1C85HU;A'G+X<\G;FZOA),
ME?KK#"#3Q\AP9WH3U+KP5[@FU3+ "6GZ56NZ$EZPX:4OZGJ1I<_@KY)S;M>.
MW$)PG!Z\>/;TY"L%VR2O$9,S3W\BHAM<*03LH ^^_NDT?+ 8<-59\IX5K9%I
M0T7_*.X=GK!/_#%I\Z5#;1"'8FHY*G$%PQQ8HS?&R )#><?;*$7@Z'3.[W2@
M^P'YRYG4!,A2U-H8"C:'-0G1'$THW.F("F5K(WIX''])%H?4.=%I53-ONWZ!
M^]7,Z2H(:!^#"9)=+F>64I;/$^DT+%FL<O:%L6)<#2M\\#\U!#9!HW1"+-[Y
M'PB?))OA_&=32<);U=)X[VB='ZY0I2$[X&Q==+AS4V<OUK5%5O+EK\^4J5&7
MVQIK0,-=(66GBH4F1^M_3C KN"H/""X:=.!R(3(C':YVWA04XR12;\8\3XVI
M07])9I4H5E(%AHT-$8-NXVC>8:M@C# ;NQS7/]9YL_!]4"_?_.C;H.AAJ,QJ
MGVCC089)H'+#=NIYS3$&A=!A^F%;NA>KR09!)Q[(2^^032AADY%L!C$>F-E"
MHY?^ "7F(&2 9@$"\O.!(+SITK*DTM%R(XH'V&,Y>2?M.K@ 6-=*ETLP);J,
MX8JOTYKVAVB=LXWRP4)8R58.Z%:YLWT_&ER9GA)V]#8.1&533SBA$NB'13?3
MTV5F1+6'3@Y3W*4L@^01+\.55-"J[*N+O('H%[<9YC^!L<P(U$X[#"'J$<>*
M256/25%:S7N]\ZN;D1A/:^)05F,I)CR/M-MNI#[KCP1/NDNFT$Y-W<=9*VR=
MBV(!7SA.GPZ]*MQO8>M%"'-3$%.BX;[FOZLV%YD%;<[BC37VJ/),:XD]U<2&
MQS<60N#P?<Q^3KZIFO([>#*@G)UW[,&C&[^?:$C)U-<R^V;4SXOZ9!GJQ8ZP
MLQ<V_!/64Y.73192+?XJ! #!/TWHWJ[!!>6#G$&4<IS^AJ 7PY'/6K@[EG"(
M-%B-DM+'/%I-\S& G!<Q)B0]'^ZFWLC0=0[0 &&:< [!Q_,/,SD9Y@F'CS5\
MI"^]K'V-I-JC>Y54^_:05-NW ^S$XG*]AZZ\M+#*D\'&1HZ!B+1[K6,/V"DI
M_D<J++>PQZ%$.EHT6$&H?+3,B1"K)D"&Z;XQ+2H(.F0]RD3TJTKNE-&N%=R&
M%JJ!$&-^Y:8A@L?-#$5X%Q#1$H)P67">@%QRPRV<18I9OC-H4;LVJ6I8>_!S
M"Q$1[7%-08A:WD[U@>LF'-HF)3%%% <?7?:-!-#.T(.-/-'C]#D6]L YPVF9
M2&^0/XNDN.24( UO+EN_"R1U11O3)!%6V;\&29LA2AAS2RR[PM4D^'O=MS#!
M?86U<*IQP_Q#5(F/ +$5$0C72DCLR:!,DUN4\#',R**Q@5KN<$Q@STE3S.7L
MK(3Y0?THC!C]P]0-W6?1Y!=YF0R<&G]6R?%GSNU 2%V<%_RR&XJ'X67GU?S&
MH+][[[^>(O002[H3KB22+GM&179I")J8F72B#_N)E)EDT3G56:+Y[0BG,Y^M
M@LWD-44UC\8?,?.<&(LUN3C*VKUMF,@.Q]8$KT5#H0UGV@S&&)^409P14MYD
M!*/UB1O"O3"%M[QTYA)RUCZR,8ZJ3Z3Z#1AFAMMFNQ'E6J0^,TC.<V)>>-;(
M_\8_].) 1MZS#6JICQ*V4YC'A!2C9M@X3M.'R37AI:M0*9V,0@K$Q^F+:^U/
M!"R.=B9L-:BV?'%SSDQLY(D_;X;''FXO^1)WU)#]1Q-5H\XK<[!1"9I!P-RC
MB=_^HT<D1K0YT3KP/Z)372XTW94E-B?,U7]J[ECV+0<$FGNBMXG!J?$",K.E
M2GXNC-O0W)W5)2SQ"X%OE*0,&4!0F-: [8 .AW"]=K@IA\^WKO@/JE5B5TG'
M!R#%)OC4/GDAN 9/RM=$!1!X_C_Z2A]WB:T^_JE;M)=5*"MIBP(WO6@RCPHJ
MJ[I1DJ%FXH" H4A/*Y4[P$NL,* VL^0PHRJ-"?SV97X09I;DO@F'$^FP^[$$
M#9YUMDLI,Z9LU$U,HI5Q0RSWA(Y3WIZE2]1PNXD-ZX,:,F]XW_J(>U\CV'I\
MKX*M[^YAL/71-GMSEOO],5K,PP_*$U#A_Q7MUC]Y[8ODY_PB=*_(P1J $&T,
M"/CL@[Z%?,I)B<V.JS/JW.L;A,HADK%.,2CCO=76GZ/0@6"^>.I2&686A[0A
M0C/2(]8'H=RIV=5G6PLYL.<*HGVQD6>,6FA]?LS[/'^ 1]$N--0I*JF!7?@4
MY:!K=;I"O0.ID 2D0ESS'8 &X'!TBG;F^BV=LG&F&O\^*WPGJW_')!)J@O_)
M#&@R\?H4#QD[A@:T,7B#%NLM ;UIA*5?/77,G(V1^"]4 9*.0OZA6"2GRKZB
M1;JGOYQJD4Z#$J1X;VW:-DYO/D.&MDY[#J6 +_TEX"F%.[CCU3'G'EYATIWB
MCI<5-2?638+]2O#87_$G"#/PW+R@$^,"<G,(MI%@X1A&J.U*IUR&A=U!&I6R
M"([ G0'#O[Z:S_N-U,D2N0(-GY]DZL;/ Y\Q-TLI8OB$7!^=NA,X!YK*;=M4
M'LY  X:3:Q<,7@2]J01QKK*LA>>90/.>JS)0^=N9IR+@>^+/8UMN#;Z%0U6A
M&(-9^"O2I6B5<(6U+2ZSY2@5*&5 C X2%D'@=V)W TQ=^(;O$#E<T9-]B[(N
M>TJFIX1V#Z_)^/CPMA@?[3:/D>;1NV+^;H:.H02L1F(R-UDD_B,G$E&-JB5L
M,ERJK%F.S*A)M-R?W'GM(<ROP=24O#21Y(6;U F0S9'1ENNX-?FF\Z+CE"-5
MDG&#)\DNN0G]&P+:OG*ZK+$8TQ!^"3MGJ%F.PEJ(EL](JX/^FC%I<2;7IG[K
MA>3@"L23I(%+J^7Q$! $!MD( ;S4@NF!PR=]"S\<@^M9WR#T@NMLN7_9=O')
M&K7+?G*#_WLZ26MY3=N<LL/+;/-2_.A-W?^V;?X%F"><(F5>P'2?S#LU=YB2
MLV)6=#O\#VO<?/J+=5/\'^Q;*@ZT;U*7!].M=>JB<3D"(F$:!B::F[Q?]"6%
M\#RH):\'/9+-T8)R+BI+X*-V[<S@#I;NK'%,WM>*<H%^VW=:+/(UG%&HA #N
M"J<#PL4\!(4'2$/ZN_57Y$P>O$5LO5AC^2!7T3\:I.<!P0>A)\UD.7$&EG!3
M_]T7:9>O4^K_@.E<9IYK):>SJ2\HE3!S9WFY5"\F.G%SY#CD%<]WKX.7R>\'
M%[M4@M 8>"@PD1F6'RAKQBX 51.T),W/.AH?JVJB=)L4\?FI,0(6Z@_>-KC8
ML&,-WP@U[>%LO-%]0O<(?^JA]2END;<'X?D0_L7YF5L[AJB025%NU81<,W <
MEX7WR= LX>QDHN.RE1"*$[.V"]-<89U3&G*:@_MP#GSX.2!QP4O4!Z4,Q&ND
M69+.+&I0F!.@0W^%FQNLZ$<__/ M[>@_O7Q]<J*'!F]"K?362X0;RC$.^W<A
MTBCFD2 T$A5)$MN2#/%E6C"O1L>R:8IS03>%SE]Q) S,]> FW+B;\/ILVV+R
MNTI?\U'<IJ=]U5*+I_$:?%%<I]QT2W 1DL#UF3">,Y*=D@YM1(B.-/]EX9A*
M2"J1>85U;.XP@+@^PC73;L%GZ$;'%Z)3I<*B 2"4C5L/])%\O=(8)9C7TE%8
M[8MACCI:5U8ZCVYQ(0)@ LQ6M3I6ZH4?2-*>&]3]'<W@+K^IM @H#2XS2\)K
M0KZ(=@?1^Q1AXY6L/Y: Z.I,^Y-[E6G__JYGV@\.TJ?9(4/:2S.^X"&EN ?"
M+D.;D&*[Q0G.9UB5U4V5$TW:=*47LSD(NG2(/%KVP'BOQ60W]G.1WX1X&M?$
MM6V"7YA[I0HCQ[P6;:.C(-\&[#-N"8']%#[P($3F!D=1D*IX$ZJ31_!I:GV1
MO,!7?Y?'"IZC!VY<HGTX+.$//HL9#7CDK0_ASNL2791F:S$*J(^.C4XN@!G@
MF'#8X#[\&/T#T^-]N<J%361'_A_>!>W;%T7K/)(I'#J2#R)4[1KSL['[.M[A
MI;7**#9*=D6@#;M?()ZD@_,U')8W=SA>YZ@B/UX!7 ;#P2>4?0)^DP%FP?X<
M,SN*HP?#&+MT&')[5$_1S/LU D/FG RNZ$N\*IAD@=,0O/)HZ/ U2\1]D6];
MOQRTNJ1*+5JOQW 74P)D*W..1HSAP(>PG>/XLX6SGTF/G:E4+?2@0?KZGMK%
M$I)=3\_!:_/=)?+^:1^C22:J_*V\^;!V-("D;&.HO7&R$+<DRB]L=?F84I//
MQ]@\?#+)C4KY&]J.1GB.3%,]'CMBP2"<W  ;Q#8R7>JTP'LIK,6(C P,'8:"
M2R A:_/M,FJO(:VL2R!>0%*6B/&C%!<SKP@MAED9('-&GQBI<XN6BS99A(M)
M&)C#NSI!;@RHYD/0-^BD5P5_-D8,^;8K18M%V"-.?25,MT&^&3Y/S3[]U@)S
MPIDR#=S1?^(#^ZF##:[OM,2#YT(V!%3!^04CI^FEWR,U/NY7A9+=2N%)F&GH
MEV8'"5">]&:@/ .[2090'FP40^7 *XO4/+!<!C!=3*.&KI4X *;(-=ZT,^R5
MKM!>+7R3&%TMURO<I 6O5 ]Y2UE,GL&7W^7Q"[AV:)Z94A='HK$E E-YAK+$
M]W+[O;%R%W8.,ZX$A4(P^H=!X'FP*8H-5F[%A@V7S]GVA+Q0_3"86"H\4[Z:
MD/2DV&L7_KB;7^Q)KUYN_?61Z?N,#49%3O%WAJ^GR=']F><4"-]1"_AX),_3
MF@7FZ<V\48\9Y_/^879VD2KX;2+A;<)79*YY*JXF&4(R=AD[E8I<^/HA"J@T
MYN_>A>0()0E>;"3,3I2Z@QV-UDE!W+4M5['F9W"BDFJ8]UM1K@]A"85W9C5W
MQ9W!FK+DM@OY3()D 4=\A"")FT"QO=P9>O0!>F/S8;ZT.H#*4-\>_%MN4/CF
M?=L->IR>HF\F3P?N54(N4SI7.\;3V9.H18.@EAV%$R--/*F"(L2*>T18PQN\
M=.PPW&H:<(T<9.17ZZRC1R*PGB.]6L)$&\,^1=/ /3$[8= :9=7$/;(NN)B5
M5UKIQLB8KQXS#V"14:)UBWPW<"33N:]OXCA]P4T\L(-7CH<2*HC.]ELSJPD)
M^OBQ\C/:5TO=1O2*\I;:%G#'3R0:Y(D2<<EVQ_6HF\E<\8YNP]>_I9^!@1/B
M>,DF5R]9N]BB=1;6EZ0*< =HS2:0$C,W.=,5YJP#RUV<N6"]IL1L:;CDN559
MT1<-A4!]*S&WY1BEK8>,0F0/A%D@7T#0SSIHYK0Q/,:LXL/%]8BT-/$A%7QX
M57-0HX"0@H8!VX,)C?M*XNQNRZX)D6D+*B^^/8%@6G%SRFW8)N(=709"4)<S
MQST+^CQV*KUUJ^J1%X!@CD1D0[2,@>L-PD/E#<WMF<S>/KU#10XP2R,&:LD,
M5MD01H#=C%I@ZIRNP"4U[\4,Y8'UZ(,B!0D R,TC?'^67.93$>T@YVPB=:X)
M&:_,.VCT"N#53<0B7_SF<(VBQ=?WJFCQPUTO6MP-"_WX*")T D ,@2[4O0P>
M?B&2U<</'SW,R(\D_+-KJ6LS>37+UZR@2-0CL!EB&0,;&5\+EX5!*Q-8 7.R
M"]KXG^*+/9F'5G)!.CQ54.%SA0K[;_%6C,(AL'N6A?QQWF%K&8XP?8"MZ^R[
M2[;2"Q>,;QR Y^Q_FF9&]D^HAQZO<9%'*)FBE1V<"Q&#XRHO$WM2^1+,%%F'
MP*/#Z8Z'-!U+<N<=A14F+YIZF9B20W19FB=!S)+<TU9SE &RCZ6ID/!W%;8-
M<V;*9$<GH[_8S\@7:$2A<*'8(J00!O\EX7>)_7H^AZ;3,_4,XM4)(A CN'6_
M9A))?!H%F\(@9N0T@#- %YAMQW"&68/#J&#SY6CF[P8"(;;"B2"]&!%!4]RS
MP7O -?W]HI VBE+-54<%GY!V1F-(\N )K?(-]_CW 0:?"0[7AT1"O$7B2^1P
M4OED4\-J0W5G:A[1B^ 3HZ^WJHD\6U1)Z3V8)EMZ)1+;8088M@%JQ6?P%[@E
M1,H9FFV+)AXR:?@N&( ?'!COZ]H7X".PNN^4W<;?>";Q$@2:_,P>4OP:7AGO
M=L_^[FDQ2?P.Y:J.%H[R>\Q]0=P)2T=^_V"U#(RA$79-_.'B#")JY"*0[8'>
M":6A SD=CU1V"1."(PO/N.ZH:^.+=^1."W13$#OK*GBYOC33L(I#,G.N"JVX
MW#Y7$9$:)\\U\)-*LM0,<\F/2AU^8EO@O?*">]#GG=S2AR(A.Q]N0!MQCJ!Y
M+V&X>\_A@C(%$Q#.4!3D<\<00,@>QM$$/:,G+63>TWJ#*ZZEMQ/?)?%W06$:
M>FL(J0X[<;Z"][/B\%%2UVW8Z1IGRM=UR*5)^DKTA\TG5*# YYCU.HG_[G$:
M9<UI[EKJ7Z SB)X/5O[J#((9N'I4(X0%@H#2+84SNN0KKN$J\L$NO-9UNA')
M'E$TR9 6I=53F,>!$1BSF>G#Q$945"2#YX),",T$> @EIGO$(^GJ'>RLM+5A
M8BJAZCILT=1#SF^7LC\B'IXI.XV@$WB[1S"9T.)$*N/VN5//YA4*B31?I$XP
MWCB2^$AEI2,K;A[E_8Y)!4MJC=+8.,D&QL$OMURB*G6<-Q6E]***6&X36^@P
M+U.I18;[[.B=!<N6K$YX&_%3SIDGKZ!"EC_%LHB!)JD#LL 7-@GQ+N]<< V\
M%5*F92!H&,WQ&AZ>:0X830\6AJ]EGK><O49+$E@S?!ZB=CSV1-RT\[7D(84U
MM6?VY3O-(2&A'@_H=Q*YQ)21<#:!G6/IR)80R23 S<%3FY@H)76JFTJ\.=W-
M ^9#6L)5$W/ ?"4MJ\DE1.,$V(KJ>;SHI'?*,YH$[#JFXU%9^QU7W,2;:;,A
MHV_4PAOHE2E_%W,S]DP2ROR_(6-)O\=_@W6"C7&E_BS_3]XLL ^W;J(^WO '
M"4OF<==EDR^*6I8OJ:1AJTW""%>J7N!756,&6SQQ6?4M&Q,\9B6>+Y6@,3>E
MS<H<6A E^["=)[Q7@5%1%4%JZ+0LL$[/5IJ8NBOA36((@+)R\,I 4Y_/>TP!
M$G\9K1.WN!>L/ZK3DJ!.B_>7_V?QCY.7F&\X(I3<8DI-**@6"3&G*A=YJG1L
M^_*MPYDIX>#63PV1175>E[CC2#D.R9826]@R4BT0OJ$'?EHONPN*T?&G7^1S
MSP@OGCXXS7]Y)DW5?ISDHRDJ;DA2I'WH2"!E:>,9BA$,?M9SP<I7DMB7(\8@
M)'ZGI45]W'$+-3*_GWPU!!L^[U&A+*_PM(3/#)XBD#RD#WYY]N8K;HTV'<A!
M9UO?7YX2UWQ?TKJ;8L'+%V>L*BIB:4VE(!E<W@M8[8'?'\][E2[@J),8CH1%
M_#A%/2A7.HW5N837%*NZP=M[AJ!SN,)"@5=;1*0+AB]C\2.%]SV@/2&>%^H;
MH7?USV>OWWS%VYB,*5%'@ Y).F?U?#?53:OV1*L;"YVOL< J?'#PQ7,'MD$W
M9>)!(L/#9S#2X]['%S4G850M*M6!-4.7JJHIW^:,K"C6]%)793V+J,:\^, _
M2;2+W+Q\4RQ0D1JG-N;?2KW $EUM2NP+C#;6LVK<FA(RIJ.O#@<.N"E.D;3F
M/K-:J:^K_+Q8*9/PD-E*H;-!-@G<1H'KLBZ[+B2:)@[H\RXN::V=4-/B[N':
MSM@CH@8GRM7W85\6,1@I1#^MFZ;?=,EK/?<QG+M_^>!7!E)GZ"#$7[4L@53,
MCU]>&KT\0EJ]>/KZ1'.@ZX*58KOB".*S&=%>RL]SO@#NQQ,>'E9,^Y(C7?++
MD^"76TH7.2Z%^!WNG*Z8)X,Y4[F;FO-K7O)%-#96Q;EV2 L.@33UZ&ZT2E?D
MU%1;BC ]4!N672&<)L@!4&XM(P!E0&M):=$Q9E'LRR7G3^BP6)9<&_*_S04
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MA$?F_2@T[\!AG C3(P;K2+SIKFY9I]S-,'86,"6F]=R"?+Z 7-G6/2%W<B0
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MWRR;&D6,I%F7NA_AM$9UH:&N(WO(C%48I\;8PCQ^C+3-?7(V2Y'(U[9Q>A6
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MR:?1_YJ1^PA/A6V@;4>1/C>81'R5S!<$@2<9TX#@UG(FR?J_;.TG'C,YF-?
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MVH_T:U;Z+77F8KVO5+\J'X<S;G6$5B^\C_KY'5*9<Q@U'&UH"E@XK#1J"$5
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M-IVKOZ<SB%%6#28]CN9P(C5_2ZD;;.AU)4_[F9/##*<070.JF6*>HUA19/!
M\O8G+R51_]58%":=./K"BD0.WQ2VW@*K\TXWWR7Z^'I )KE?!Z.5'/BWW^$.
MV<5E-UG8+O7G-#Z33]DH,B3*3DGR>_HKB3:61<J\G][UV#EE-Q:3W(@!39G.
ME$[0GS()VN"9NQ;.?\H_&8^WJ/B5/'[XZ$F6G%$.:J?U',>SG,(VML0/(FK$
M&X7/,MH.;#_\!S5)>KV%WWR%R4=X;=*0Q2[!HLA750WO<MYBA1*&]3WS-_O*
M<R0"-,#%D N@SD_(O7%,,^DSID/QQ8EQG+Q$=K0.+?AXQ])HSZB:-CHX>9V1
M]XJJ%JVZ*Q9H%?"9(X9K7&#GA9*%FW/3UE>".NEV(+X2M#[D3*7N&ROP875&
M:^)A9-F'<ALE+&=;MA+CI/,O_!&"DS5M@_YTD8G+%XL&G\TH4(X&%@6=L>(D
M>TP8>KGF$QXY'[:0]VM;F3J7>&6K68(%&JF5F/)/>XRZ43&( >OFBY]'$>X+
MG*%_0B3CDM-MV[EUFSZ8WE/P9*7R9]U\1?,'?B\,HRBW0;7+3 8K<16$-% )
M0-Y!GX30>;P1)E,;8<&>^V C3'=OA!]@/^$IS. EJ)M2>HKO<T9M:EC-&6B6
MA=,F5(^-NLPH" ]-PM$N6&LL1>_ '%RAC"1^^)#4#@DT:468(ZG,87,^TPT_
M>GT$A??]^9=Z3]=512IQY#NOIF?+2-@/AV9Z!(<22<FR+LOZ0K6H)PDW1T\7
M<B338S&/A%:R+'LL!'9NT.='OL1_0ZC>8=MIK?^D8:.X'(X7_RL(.0:3\5)G
MW:*CKC[B?YGS"LX<'O;TV*8[_(0" /N%4'FCEM*I?P67OO/8_]V//6B_=L3X
MM&(7IOUT G)I(41OV#92=)^3^/1S3,E-.!%7%_L>W:MBW[>'8M^?MNE/S_*[
M<R3P!S9' HUL6I@(_9<R X]9?_BZ7W^_>7\I.] $#U'@]/WZTW'Z3M[W(VZ5
M=Y1:AQ=ZAK!"A3UB3-GBF5MR-A^VUQ8ST>4NYC0_P ]^61_*Q_11%_ET(]V;
MF?38I93;PZYT?@]3N:]36:!TE-?6$#[D-B(OT>+#>4[(<Z'G:7N2GKH^73XU
M?4DH<["'?;4'9AALX[C4<V(;B3++B<51:T>3"S]ZM"0I#^6$>\O;08@MXI'M
M,)AMX5[N8!_[:A_8ZM?N5I.AFH'P!G@VIKX[JQO9"2C_/"]=+N*/T]1IQ*G3
M$BL/-4@=MHX[8!JAZ-M>@U2OJ)9-#C]C2J:9D*4YS/E=F'-1O\95K5UK*CO?
M2M]W\"0FP?C7ENHX3/9M3S:7&;UH5B84KUO#X^GE6Q:]$T@5'@DJWE(/./>N
MP9-]F/;;GG8FTVL#%35)]2)V4FH23#XMT>#T(L=085F716W+(-,?Y=L1V2VS
M)8Z5?PZVLJ^V@KY@@7C.:-L?GO0:.S+E".<2%KOS" /F(9+&$QVYG;*C,3?3
MP6#VU6"PX(PMY +/A/F<%95'#<+1@NA$Y9@(<$JQD37%JO#=F6,%=&ZTTF]?
MQE]_F/K;GGKNXPL@4B-YZ1OMMMK=%[3L)UBI;*SP^=GDKT#(W'@KQ"?$[@R1
M&XK:H KYU7 -H2*H';=/"$2,^G'Q'52PO5/#-O^H%T=(W'+9NBZ9KFZ+>*A)
M/@4&RYW]1%[31>'%9$VWT=Y]1RJQD3$$'L#=B W1#),%&V28],TGT9N/SV,!
MEY#DP  8LCL+<)S^?@:QQS"/")Y &W^QW"HD!KYN<94ZB.<].INP-?U6*1\&
M_ L-_E]@7HMZS9"FQU\/@"6[^G"*;M37L0 O)^YJ0T5E<5N8A9OT&80T;AK6
M$5#^?#GFDM[0! RPT#P;,D?<+BQ]<2^X!QUQ^1F1;23% $="F& 9=WAQ=F&;
M $_!2(7AU%[C4PU1.)&<Q6S0)12:VI+1-B!NH4K4[%C).][9E,%Z3NV==BOF
MF)RY_+S@[B <A )D88WMQR(]E+GWO\PM0M)4)-'2V;! 9J(C4U7;B>^*$("!
M7X!<GS53ZJ@]#WM6N9X34.LN%S9]/"]Q^1Y"HWTU)"RU4-]9T .U^V&D@QC*
M,)FIKF2:.V&I'?<>53NXN>LZ91>2[XXUF_B+\3XOQGW(RNRM)?G*# ?)?.91
MSLZ4:#*B6:9*[Q(\CV9"5'.0R<$VXKSLD+R:.5<RF]V%6TE+Y3A)(P1,MK<]
M^!Y#!,&A%G0WK"QL4Z(A++)D>!3-"*/?]NN88(A?0.O*)7A +=B4 *B9BEX^
MV[D51Z/<JI:VW-"0V=8UR3LRN5=7:(J(KV;4@@2UG6_K9LJ2?)X@F<!$[HK7
MS >N 6=]?*_@K-_==3CKKMF_3\[W9-AB//(]VH/BDV[@+6'9H50.FJI'.O6^
MX5AYQ!@XZ)(_8SH)#7C%#V_A<.0V1ME_O-(BM<V 59YI]PU^@S"NK,9A_'GD
MZBSFW(JOA9&=@0-1G//NRMEO<M0N[PHY')Q[?G#F\[/"G;,@F@AU$EN,,,4T
MKEC/^J9EYN'&S>M51=&CY'R\PH4_$E,Z3%DLI5GEE<=>>>;72P]&YHV]Q.-G
M1^T U=ACD^+V9]X%MQ-(3K^)^/TEZE 4R@_4DSYL'WL^UY5;U8CA9G&1<PB^
M*-M*$L&8I:VV,>@F"W*6!KD3263"F5D+A\<XITM.8S9QNI(F3^&):^3\L1<^
M&-&^&E$X@SAM#KO$HMYXNG 3REV=I81@CZ58.)V L7P/)];V,/O[.OMF'7ML
MEWK0G$'&GW9,NT*[J,EC$M+%VLOV?,$6?B9I;_(%Z0XT#G[DM_JNJB^.SNH+
M 9"BVXN?PB/KL(/LK0T%6F8!=.SP,4FJ>.D:)I]N**E8R 'AB9:Q/GK [^SW
MA$L_)^T9,,FZ7W!')_XTT=/Y^=$Y47GU\=?'W]Q-1$9$?1(4M"U)/)?,1Q"*
MRP_K775T3WF@2I>DKHBR -M:Q):\LD>!S7T((O!2VN(!_'9\BJJ -9/&/6OZ
M57JR0)$2$EI'W^(!?DSHZEX\.U&^NBR&:?R"G@3R,J4GR'"W3>S7GO\R^%KX
M-#%_1DEB=E#>A/8EOJ"GS/OEIS?^:L$WMNU.JM!)'"XERJ>C,#H%Q%E:@;-;
M7Q#,G17B%!&-^H!IWPKSJY"(REY'/*9;+M!MO!+?N.LRT^*N]ZQ]%3F9_#AS
M2TIDW[@C_I=V:FS 7(ZT;)B) +T,+**;# ),.U$C"K5((HR%E;DWX+YV-U!D
M0 AIX%T,]+,T':+Q;DKI*O<.4^,_B._R9MDCOS#<%T,!GPLNZ,)-XJBF]P@+
M$ J:0F&621N0B'>$\9.##"<]PPCG9WW+0;4H"17I87,H W(.,+Z=8WD;D2<E
MBF#:&;1-S^&PZF\(H9BE]XH9C.M]R6>K]V6":SD3XD O$91=FO \3MY>\3Q7
M![WV%6'0K/+5*/B9SUD5QK^' YSL ">[YJU(''L ZO('=-\QVG% KX#=]A O
MPP+L>"59#FD#."-D6*]$S4K2NG$P$W"0%^Y"U^<?==_ "7N(OO?63*Y$PQI[
MX$Z;*VV(RXV%E00PU-_(LG](\MTE$R%-MIF?["O.LPF3:?-UO!?IC@&A87ET
M43?E(J1X?,2SJ3>]ZFSG[8ZMZ& U^VPUZ-N  U"))WD;2"YV3'U;YVC;07NE
MG>S*C,?!U.Z4J6DH<SEB 2TD "%2^2UE#,Z%R=7#*"Z!S$2Q:]K.ZPT[7(%"
M5U1-T-DOBW=!&)-%*1<%V&Z/@Y4+1H_3V/-XDV^O,1#13:0;:7-*42U+AM%-
M+1NY!&HQ%JT*>2!H!&GY=W4:7;(V/@,D\LF]@D1^?X!$WOT \@Y!(@G.V+A6
MY1K\UL+T+!9A. 'U8E>N-?!\W+30KZ,&P%E3YTAOO%UOP-IRTO;R_EXF+?W8
M,BR=D@02\2/@VD+I<DSN2G8:'OM(VHN+5C/6)"JP.N,?EQ"(NJ,-_!V[#L0#
M93E \#BKD#Q4)X'TU!>>B9SJ) <O8)^] "43U+:X,1PM%A5Q7#IIY>-D=I:@
M$'[GD4D'/_ N6,!D"C:H+1M%LDF+<*TB5]$Y"K(^W@E<'*9_7Z<_TDC'H^,2
M[)%1A9V K![@(WL\S11A=; N5]W9[GS4)0R2TBQQ@)1\6'506"62ZY0$4?1E
M'HYC9*X@X48(25NI*VS.MBUJ$%;IJH< M"3@1=P\O(-!FI>I2P)FV6NB-'*;
M#RI.J#N)NG+D G@$ZY1VS,L ';#YI\0'TE?V#]H#AS G>4/]M%NO,#OY;HJV
M[1DBXX7I<*Y0J5,=5M0D=>BX)*$D^\YMXV8.4:/)VP"U><W,('@JGFI7T=N\
M?9>^X%Y?CAPE3R8H;3T1@_).VRE@(]#\)*AV-V^<J_1X1?7C[HP(^L;:28(D
M0>174Q#A[]@"QI."\4+1&K86IA':NLX3_21*]),9$\2ATKL(;_D ]!B-17A@
MLA']RW32"6W!"%-1L%ANQ4K6*K/70+"%YF8:N<-R!I^\;DD&9_?BY<->+)K4
MN2B40ZUEOWA,O\H'E>2IO"EAXJ"+BOP%:;$*F3*;CTNFK\E[#+$FK*3K73*
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M0,P@$(-#V!;\%#BVJ\*TIYI+'B<GRF8:WTKO(Y2D[%W)OB51E/./OJS+LKY
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MOGQC/"BD/J-ST"0.?8RLGT>;_RSXP3NQ0<>G,4:KKI6%<IWIS)CJL42$%/]
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MQ!.DI>2"QKCVVKPB,#&!QUPXGF1CHZ1@*Y27B4XE1[@$JV\[GQI&<DNJ)OI
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MA!;="DB+GCM=.AO'U=1UMQ'_O!)U' VS/!&R[OBS]!4=9>,K$^'L80]@877
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MN$8F)1<"$2I:7[K'J !5'@>&5<@/+=W.5+XDUT<8(PE21G<A=QOR8H#('X@
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M_U"0 9"!L"^=_!K(900!,HA)1@.91D+RET"%35O6G34=L8HU)SU:VY@$T+O
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MLM >*N-1WR/V_DG .>]JL$OC'0Y#W"$9"D9W4MN64G J98CMK5*L=USC0[!
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M=CV>O/[?UNOX\&=H>@SV3=<_\5DI&DG7#YN2.U?<17]9E%4%Z/$C6Z73YG\
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MDK?'Q?C^-PV1Q+[28"F/R*#K80<:4G0N4R93PJDDXK14(E3B]PLW$OB*U_F
M0NZ(2!4@D+RJ/@ I_(>=N!NLU8MH$Q(?.9BA;1":R*QUZ45!%-=>TY+I^'=\
M8+PF+18"%-P@8&]:(OT6UMVA5\+VF&0T)WE,]SLDOMG-+E!WEER_YL/Z(E[X
M]*8+3X36*4KV]8$@/6?I3Q<E..I3=Y+.80M^II=)1M^#$C\.YSE2[*V;$<R%
MTJB[C<.I]B #2I3RM5#B#FTW8-[=YWX<W#\\^^03)K:G<;X*R*$7ZSX3?FW[
MI(0'ORK2JMP2Q^_6PIEM2B!=@Y=<00@K4%43.@FO8A])O+#N:R@;X2GFJ3!(
M"C,ZB3)[L%4)_JY?0\O#4S8YC.#FKVD(75%5\J^99W??##AK-V"EO=_F[ 9?
MR3;NIX*OC+(FLO6-)\!.+/,U_=03SV^( 9^@:Y9%>%60=)=N?;X8F H9D[N#
MGA<GDCF+W#$A_&73Q^(9.!DD!T#/2?0YAG=1<?&WH:!Q.Q:TF\PKR8]$2Y=X
M[O+ITED#3-V[&40QT)VK<FOL.6K_@K-,JH?BK4R@VYXJ$1,Q?_K-6X8Y)F1*
MKBY*.O?T.?=][FB=R]<X3[0^[S+V0MQ[;&$%64,5-NF;EVY(]8!1_GMPKD;1
MLAR!VWBD"-#+.)C&:TSAY86K6 QJPN%_ED[<M%=YN\K=[SSYX6U5'-@2NMU]
M!0OB_LN\GMBC?/G@YMDT>Q'Z"$/>$-\U$X+*=? ]F9D$"^&V;Z%M'9=EI\(?
M2]\/%>BNB%8NGO,ZWA$EMEC@R>;/4BVF@^M>=A?X/2&N)RNIWAP+)8!P:5-V
MZZJ!#'4ZF;R^;2HF-S4Z\$$\A16EY7CBLEU[HO%7.W=9NU7_T6^>E[R':3#_
M:.HG;B\6%7Q--Z/?NKW0TN[&_E,H2)^_ 5+^TDT#T$M E+"F)^UC9[85#9NC
M\K3A2X@NGMG985M5O"UV^SXAV13>W7Y^\>O8,4#CN_@L=[_6ZS4A@H1A5FA'
MX0$LO.&&7C=IY;:[>VFW@=V]>6!CN3@3F-=D>298D8"V UXI?F4]::H. O6:
M>-^PN:;#QA_*11HCR!30K?Q20,KD?LT==#XM>@B]W%M:U)=EVY">N ]L@J -
M0ANF^$\-$U\+Q-N.R-^K(I?U,AY7<948%EUZK-F>C=O1Y_'[VR>9HJ2Y-^3:
M<D]RARN'Q6!E&Q>283/S8ZXT[BEB:X(/0+H'JD\HB_8Z#R0%HTCO!^\VP,+-
M\AQK4[D[L(F_O0WNB^XJL\+5P3@4F&EFE1C;G9G%V\$6=,V.Q>XOV7LEU5ZX
M#D&))^&0 6(]SN/D"\R]$)UN<7.-/=V4R,_0A_*>MFX(4HSO0@(PVG[+BDM\
MIWEU*FFWY\-RX!.77"]28S?;LO;,K%3-@]]T-\ ;?_ZH\,;/[SO>^,'M4(JF
M_E9P<L?=$9LFQ1T1;H9DGQ_8V78V(>\N8'#*#>G8R>E7SKK.)A*P3%U1D!_$
MEVCF/^@L;ENLN8$@D[@\8V=AQ5&NV]SX'^@-1B)S"73'Z&(>Q_"/)J;2R+=V
M3EM+.DXYXE_T6^;E)KG!$E&0%)R D'EH"_9,JTHO$'%_BIQH6+JP6+[WB]=+
M:%#)V0G]7XD\1:^'2,#GNNTPEZ0ZLD46-P;^,9G?D0___J'3_2TO(F-HR(OL
MD%IS@4XR-\EHU2/6'$YFM"YL<J;!?L1&)#9/1ZW#SC7IR47"B8543)77)I&E
M,H7&T]V4U4#(/(DJ*:$F\=*5L&?.INW83[J-W/3=7.Z?5+&,8Z:(H-1/=Z+'
M3@]3712;(($F)Y[#2,[&$/M#A7!C$X5=SC5M\[(K]"!3R(=HAC.8)BC*=TC9
MD/<7@;<@J!@2N>X+J=2( ^J,4L/ 38[:^=0VTZ1U4U-3.KO1K=MJRI2>2Y)4
MMGQ-7BQ")AHF%$_;'13P2&M2<W><W>8LK\R$/RSCT:>CT3S1*E1X)=C)\X+<
M;)\E<L%[NRZ5$3)D_1L6*<><7.6M>Q.$K:0"BS [G!;)%],*JP(9$V%17L.]
M(4T ?Z'EI24&/&[C-X8<CPBG4OW\1,^D'FO?\'*6OJ(,/QD3_')>=<W,$]+Q
M$XJW94>!N3W"_(8N9C8=-7RB8<\3MD,9I$&W!4EJRF^XE;TL7>"%]%91ETW+
MB3[I-#3Y]JFTVS]O:+#D-Y%79-SP2Z+D[0O,=YH/[MM:YT?3Q7F.Y9(G/5E1
M9!B>E[OEW'3^ZUQ@V!P*O$C=U$_TKVZZ6H9"^8*1FU!L@K-4[#=]"9GL'U_]
M"P/<APR#9$'Y5>0+(TL_V;Q<2EF> #8/85W]<HJ"I$2&]4Q$>"I3A%(LHGU8
M&K\9G3E#8CC9-.N! WA,Z-?.=%PA;^C^0Z=*9K<OGR"#B!RE3'"4#T-BR3V4
M-7[M8<>W#=1B3SO#O0E2?'SH[>>2*RV2K8JZ<'<%%3*:^:L6XU*17J0:=GMF
MR9Y\F%Q)MXO6!??][YI+OD4T Q?R$H_F;H8 Z4O<;KB0>SH3WWD-;SB^B1:<
M_G: 9'&4R+?;0UTIRB:5/=]\FW*[!;"!-3US%"K:#<$=2%Q<*5N(SSP(,5-2
MM.DH0<P?0?9I,+METY#%;E+=)]@D_63%L^O762Y5=ASU3& KG[0P;X3M/FEA
MWK&6A#W\1SX*?VO<A8M#]+5>XIXY"9Y9.NSQYV=/LZ=/Z?\-#H,]&P3P'4=6
M[+;5REQZW/<!"0MRM:SH#'_?F993\](CZGHX=:W< TN!NCGN/*(]<3?Z9;Y&
MD41HE21%-S4B-LTRPJRXB DB[^X:1\#I8P>6&7'6($/@7+BK"DA)>(!79:@;
M4?6?/(D501@J@=H*)B!WKD3KPCB$ @1R(=B28KSPMQ"KN,\3ZJF!^U$$OX$$
MY=W[(NK^]]"TP^ZT@4\&Z(Y.W\DJ1<X\C:,KBC<D6]_  >D$_K-ONKQR,1\5
MX6 4BH)2.H QV@"0\S'H<X%#8FDA$9X4E:2H\LZF/?KH@3P*^]"=FX-41TV0
MFC4 *T#L$ H"*;?Z7')F2$H!704(2U0N9]XZJ0?L--E"Q75&SX:O%(E$GA#^
MHF,=.:>3<#)O=W'Z'J=YDSJVV@O8G?6P&UBAD<;B?!O"B4F<!2^I6"&?7357
M9/K&R&WK E$%TD=Q46856=2^XL0P^4^H/;B SIL]ZT%IH$@_U,HK'AX,HZ\0
M6-MYEG[P;J>[F4=[4?OYWW(;6%JAO<#9_%7C5A:A\+8=6(*/68@E8XDRRGO*
M6N+W=SE=D+,9N&3IP;L"L'^?#)[S^:\N&D*0 AT,=B(M?.7[/>0#=6>.GA1E
M5!]V)C5"0:\"<@635OJ4JHMIW+G3Q*G'Y3+<ET.@5W(>GS_]6+>43[3^E[3K
MO@P9VO3O")D"9C,DWT%Z6[E_,;L-,+]&JXL^MRH)V%V!ES[G7(_[IZL+KA&Z
M'\%FN2U54ANDQFIHL3N:GC]+_T7EG#A/G*<FOTPU&_?T+.KF*^IS% ^H.FJ
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MX;F=\G-E"7?D]R.*3>A^6O1,*3LCBY"'9']BFG)&LZS%U#YX'*8F#2N-,X!
MA[@4:3^L!==O#9I@P[22S EZ5BC4XH_\DJ[(15VOJ6QZ1Z0%#?$*5R%40I&F
M=]%\W]K5)M*!2&W:OP^\PO<YRATC@F@$;LR5\!K^(F0.$ELC;)Y6"!FI\I%4
M[@\'*TTO8Y!/BA>/#G3N4'EAR@X*//!?B9B QY((W=6 V))703PD%8A&1U4=
M"(%&VA!&D4H^<[H4DU9*F\LN\D_X#)80[WB:N#?GB=+S:+#TJ>GME!^*?Q&/
M--HDT&PX4$H$/[.;9NDX^IIDP&<'XX%PR4!1%U_.@B]D5P(60-+Q% ]8U7D-
MBL=+:6:P;GDL#*=GK^3<=%$QE^,$='UMH+P9J2?7_9>>M/7IJD_C,QI5+Y+1
M;+:W;/.;1%@N@J"D_R,]W]NPS;\F9PCUA$BG+,BM4I(^>9]"[P ;@;,QP8'G
M/*I$_<7\BF:FQRB":MNM9$RB1A0*2&)QR!-/Q"HJ<! "6 XPSQ2H>33D^A5T
M._J2;TF$##&^%N (BNV@VJK^N'V\?5V*!U7JOX&.$6+!44T$JY%5L6#VYOV$
M1LC";8]Q-COPQG%@A6KL ?2RJ$C+/R7Y_#^R;;U%K[@KJN"D2BHCUA*="B1E
M"4'&L&/ 5F2A81D-^-LBFH&T3^$4+=J,$B7)+Q@+IE:=])2"_CP'1GG=-"B7
MGTK#T<%B1\@R%>HB3!%$3)M*PXM$Q@![@+GP"^\-F)ZEN0K#&(;*! =YH+01
M?R1^]DS630IG)\2_*/JPEZ1KT8HE8=?=HWR-) ;IDG$50. ?LH^\BV.#@7J^
M)KD,M9CBJ&[:/61K4C6"-*,6JI()Y#^D343W[AGW3C2AR!4!60>VK8N_*@BI
M/W"?>U>G,T8#>1N/P2CTWZ!KV.S^"G;6:##=.N:?,A33O#E=2=43&_1<'JW8
MQ)" ,R\N4%G]-1N<:0A.PZZE0 TZ"%P_18@RM"&J07-0,RUD9W:&$/(J:^V5
M[%;\Q9QUR.(R_ ;.CI7W0065LK*)S4S1AH6B!R@4PS_D)VUAT0!^17_(+J[2
MVL?2/?@UA&HZ+Y.RZ@738:SKE%/AU%C=/!AMLUCLA_3-?)L7 Z"><D8^Q>#\
M^<?,]U;TPOJ+#F(8/AT>^IR "1ID\/OQ# OU3W!HFOLKGO65T/459D_QP+-X
M5/R,M+).KH"=3RD477R0_X+LJBG^.P_\4O1$EO/2A_.J,(OXD*Y341^4#/]O
MO+?$]@<<Q;B*X&66A@!VLRO/*J(Z4**W\,S +)61X?V2$A,Y"#X;U2(1MD5'
M\($8U>0?L36JK6+A*7B6PK<(0M3:'H.@3&<3TA,OC!A4Y:-U2&JGWT_%)(ZT
M<I?X>_DLK[1,-7':"BZE_HOD)4U4'5+J0Z[I+5==R[@+'+3XPQ$8!-C*A0%?
M'9A7I=]3ZAV9^HT:@E_EWH0"DFP*<+@X$P_@9)#R//"$7B2PE@@!Z09LV(M5
M4"^-,:]+8'/B3A(X->>*)*@4&NP>/<S]XNVEB8,ZE8U'"?<$K(5AE*@!7FJD
MKY[U[>D)N<6BZ..M1L7Z<K<QDHJJ_I MAAJ=GZ9:$3BVW9H+GM"6>F9RQ<&"
M=N&L+ "^)2< ,4HWQ2&Y9BT+5%6$CZJJHOU457&G-+TVLZ<<Z@.9!0[2C)&*
M,<@O9Y^6_0Y#GI;T?%444-I1KW=VM=(3"AU^%WBFD":GUA4^,3TU"N^RQZL;
MBLPZ U-;EC1O@"-M9FBV86H%/0ER@$4<V1.=E52:$/6G$H">YEK(?AY&5376
M36%)TY,-_/@;(MM'F4@#%;U8R\55P0$=V/0XDAD8(.TFP#0[WO$6_R/-IUO*
MF]*-+U2F( 9X 5MEX_A*)5*P*<96(95-'YZX*;MYI"MTA]'IH8-Q*1X6D.[,
MA,45Z0"S! "OL! -U<TCELMD6YI4*KMR\(ZHZ_;RT-<QY5W("!(%18\9?5_P
MZX',QYXN32J8NX;? _^5@"4TX\0BWH'Q1ZQ70!<B5N K[%$0TKW,:Y&_DL*#
MA._O" :>INF77,!>HZ&<6_;U'CU#.1\4A!53QJX?,HP'WQ'=JO PG5Z6$XOK
M-26QR(WGMXF2(5>HIKQ8AT$H$Z8"5-= N!?.$+_&9H-I] 4_.\V]]'242+KG
M0+FQ7CS=A"D_(M>470IJO)YJVQ?-UIAJF+)8P!66GQ78M2H@S:YDFU^*X2:]
MCEOFI0U4JUZA ZE9C"A8W.%S,8"#@!PSF+$+D"IJF%_$-'2D!X2 RF0J1K2]
ME&)IE_"JJRT<DEVF-]1F<<+A,XT<T/GQ'7B%'= H"]*^A%9$VR%BC+_!EP>\
ME$1ND=1">6_&=O+DF]@.F1)JP F3>QZ+!WG\JKQROC7#(V, 5L)=<[4$20N%
MW"_%0O$O2NS@?&[8!>:]\5ATC#_5Y^J)^*A0;^779(@6/HYY7NF G,W_IOU^
MY.]&V0@C2IP-/(IF<,/OWGT@%'[JDV6A37(4;1X&9<8=NR2,QZ6%=,[B>"I6
MI*Y4/Y8*;',)./^X5>@UT466!YXL'IS/3;?=-*GL(5U!S(FH0!-O(*PJ.<:\
M6*5LV*]L%NL40^!0>X$OL^B>SJ+/.1-%??-DPK;#(ZEH>^9Z5[/1Q[,]%N7(
M'&MH K-@O>S1N/ZH9(*H+8-S,I  9!V.U;/H29T;-EX,N&51-R]B%S]B IQN
MM>!7@?A77WXLVNK)BW&U,S)G.S=!5=X*G9T7AD0RK\E1 B9>1CG"P<_&R!X^
M)HKZYWK4JEG5_7.AHGO[&J5B=_-[2[E45IZU5!,RYRA4K?MU[:<*<$-K^4()
MON0>BQDNSS&H.>!:!C)X+R-<@9SY)+Z+^2CIS+C6J1+9GKN6VKDWK!PFBS/F
M8E YZDM@_JN>:/@2B[(<6^[/8Q[2:GENZF6R#1^[]661M!!S*@/!:31\/(6*
MIC1V*?UB/DY6>9P*C E17UT^0?0!KTI),V4LRUU[=M:,C==%W4&=3Y=&T8^G
MS=:IV^[,2;3DIE6OX3$Y(N*E.M!J9]%D3DX^52&(E!,T%W%V1@5].()%C<D0
MJR"*NTSU)!*L*\VQW+,X8^W-["*;?>G/5/BI;R=8%/>;9<'R2V;D21?_BC'C
M%%$"24TU250E'(E@RHR"P*"\MLX1RE/4"JLQ,$8:C$L=R8H#N6NWPQ.8ZY1K
M&MFC$T<2Z:@6D ME0K" %D2G8 ^#B_1@&C(SA+R4$E8QH):!R!"Y65^BM^F+
M38IRM+^!!BA)(T)K9<U U]2GV@A$&)LD6=2_\I4WK:T#H\9./U8&PW1-GBI[
M'247"9?Z8;O.=):-BU76-$*)=RPF.='IN$B/3Y6)596;&)UI%AL81RO3+Y8\
MU@T@#U24.."YNC8\%Q@@?V"WR7$T1/T#QBCRIAB0NFD@78OWE+Q/":9G!$8-
M4.=];#&NG)+MRBLY[KFG[OG#SM&)?W"PINMTO_YFK[B\O;!FDW%KFZJCN$I'
M):79V"<?!7UFD"/[*+"N N](E!^;GL0?HN$>1<L!^N69_T$@'Y)OQ=\UL]PW
M<J1JS[=PIN+,#FB66*2:/-]JU#?$,1=G1V=UG[=<.4O.W" .049_BPUK[WV4
M#Z*_P3&?X"@J261L&)-+0*-N57W&_OM7PK^\CS)GJ5?N$'T4O O;3$.7*FRU
M W!T@UY8ESH> QW&B7L4!.,"] +<?:]3@B'DL+UJ:I[!I8QGE)W"Z=+FAY,<
M'*8X$I%,O$[XC?XL/\@_5U4N:',(9]MZ#CJ'&(4_C<<Q>,D8@4LOQQ*:XY+Z
MS:6]EL4,?Y9@$4F&@P,(..D4BUC2+U*Z<*B!O-?X=AM>-A4 H_ZH2C4Z3Z4:
MMS;3["C&^P3[=L22Y^.82[VH5TKK\OML[-+MW9*VE%V4+9>\9T'.)]!H!)UV
MC?_-TM'C7H(+*K!#3<L!XS&ZP^3S<K M9]!KFN_RO-<$Y5%[\!+2S.Z%KJ.5
M.K)5"VJU6H4B7>1 PQH]09SHO3M2'G<NR&V^=7Z?.?I].KZ73JN\(6RN&<0T
M#^'^7L*)9<DR6 W7?U']E,_MZ]C='N7G_D!N&3T'S/I:)BZ%JR3BC8Y[B\?Q
MTZY<#].SB>(\CCF"-YO.,C%,2,+\8\>6_(Z&_DAXI+$,-"9Y/XL)D\:</*T;
M6#@_+E,*Q;(!,83:?#S&'H5C),JL-2[U4'4%(B) HGQ+J@9GD![$;!) 1WHU
M%Y&><'"?6< .5X1VN**][?^_B)Z!=5;_W^;QB&,#=7L#'1/!1I$(1@]GE"FB
MJ]X91Z.K/"'QK)M$=R4Y>-S3I\ U#GGH!MS]YIW(4DAJ)^?FK-F!/I1TZ&$\
MI8HU#*"15)T%Z'K"MSC%&'LT$"D93IW*P+C]4-V]H-N-9+L]B!^"9/(8)LUH
M=% =&_$HCR\QP\:R)\D%/!#E9.0<-1G!AS\#"]/8/;V 1(>3 B&]'(=!B&&2
M0C C34#L\$V<;+8U2M,O!;1[QON@#!-LB*:VX_9F8Y&T0J4O9IMS7$">)XJ4
M03(<,G84 >1C/1%G>+!0SD3M8F&9QW-6LHW)CWLLFO"(7LUR!-NXQZPVKS=D
M[0.5/.KH9JZDO&.&+=.4U<0,>C)(,(&?5_2:6\W+.*9HV_X1 7S$1,@W\2"A
M7QV,IZ-M_]UTL*WF+2 FS^C*P^#30+_V2GTG\%]M_YL__B;#\8_'5^#G7N3T
M:YE^I'$?45^THZ6FXR%1U,R1.0_H+LOS@![0YA2AFG278)',:0(ROW\^AA>?
M74D0!F&#,KH &X/C&!O3D1"&,T8'0LU]RB6/ 5NK7^-1.@$E\!5['*A'/3V+
MQW'2I\GD##<4,W9=!H8AH_]-0-"FB,(US=(Q50E<7&#)0D[4J4I#<W^28@VT
MJO;T1_#Q+40H09S 43*,M_ W8'*BQ/=I-&DNJNX0:$FC,F)Q)L+V\2>%&C2?
MCMH+0\-H>(._&,NB;%1=E'&&?X*JXEEBC'*2^V]G<!'> 2X^'5 D&$[YRO\W
MX:^\>'OP[Y?JZPBI5$#+2DDO =OEB820?+._E_B*V9V\2$-EJ=TR/T^&%?@#
MV.=)??+#%)2K-"7@A?U801**NY/. OZJ\'I%)*1&'S2SW-7FUCIH.?40O2 @
MPC+,18WM@VS,O:NY#'[B9XUQ4^25QJ=3:;N-S[;5N.0Q-E01-V<"'D@^)T/H
MN)D8@AM["+#:%Q"9)I@GS^_%-X( 0$@X3H]0A@=K,9##+RB=1@7SKLI9>,//
M\*G]&?8_;/O["%D'T@I8@M#\9WV46,,96IP>+)KJX:SWF>_"Q2_P&N(X$!SH
MJ)\!+R+JAY@5'8GU:HA3^2+A/A.+;7N?8C(Y^01/Z6-#+I.Y ]5Z0_'T/2U/
MUF=#PN/E8F\NR[PT]!H/)V^Z MY4QS8@:%LL<8QQQ%,_-H5L450CY<%*J8*7
M% O^@@,>.3$"? ]! ; =A**\E=#11B0]\)_7MFNU6HAX-1SMI9G8_ #5W(_/
MY*]Y'("7@QU]<'0RT92E?@>?WN(QV@0]JQ9CQK7$F$M=TBM*T3DX]8F?RGP?
M?\-183E'L+!2#>M!<4!WKFOMY(Q,#'9'LOB8A[>/Y0.0G41)[O-PN]FIM^E3
M].]V2V\[P-@8O0T]YB@_7V,PZ8[PNQ;5D]>G6QN/*MW:?;SIULVF5!02'X3D
M_* D)Q:O4V5FC%6R9L/H47PVXZX,_YC<BMGHC(P378]C5&?I+HN&.7M1-8>8
M3[/ZWAUUIUYIF4*&JR9V$$\(L2;'F/6S9,*!/84!\P*_$&BLXF/S8R78&2/R
M3[!:^]_.D]-DZH6U[1";Q1D1!>-TT_31B#91%>ZX#%,K@Y :^(V@U^@%]5Z/
M-&SND_W&J@-T!.EA+%^.J"U/:A+$HRMI,RH XO&#PEPF=Q*S/T*U\.1"N$'J
MZXLN$-B;%%0KZ-;"H!;61=B6LAJ1PC=#PJ+5;?N68U"Y?ZZY(H.D4:O.P/OU
MH%&'=[=[%9EBA\$0>)0>YG/0Q@.!%JJM"5#^O%C C7MM!$UX9ZW3,DYE(,Y-
M6D1T?+#9-5K!FT:BQV9#C8%RBW==L"07(>,03A5.MM5VDK&_+!DCU7KE^U%T
M[2;C>E#KM8.P&U:2,:_NT<@A,S5LM. CQB.'TJ::591U6]9T>'AG OM ]^X1
M8@I-+-E'#>-6$SICT@>W)J7PCT*QYU  Y=>$99_$Q?90@6YJ:S%SM@2[O.#7
M'J@&4^$;R/X>0]>BJ$"/6:@V@FV=$&:>1"?S>)P-]4^?7E'7I-^KU7$)IB)F
MS\%M%%Q$ ]E]!KSE  @=IVP)7,*JL,@S,_PQ,*OX,6IN@/V  J9)PHCR_%DD
M>WE/: 'W$SYB?$,T "]_RC//*)XBOIE2OJEP3$)L3F:G\)"J%I?2YN\Q6Y%/
M_P9;T3'O"R*),YV.W#'L=HV)W[N*)*PUP@<:PY75=:5JN2-226/TJWVV=@O&
M J5_0$Q,J(I%V\T1& X7$PV5?AF+N0HRGN<5XHS4@$L@ ]QIEHUEAHF&YF!C
MU53T[((/-4J^1S+LC6UK:J!#[&-G6SX4#?0XOR8!-V[$_#*895+8C#&E//*P
M:Y41E$]%!I,B[66KB.+F ZWHZ!]8I +6#ITB*;9Z+6BV.P%IOGY_=B&&;'!X
MGY5? Y[6[O30NN$UIU-8A[E*^E08A"TPNVIM'4*%>T(8]($8R<.:0)PGA7K4
M:0I(]AD&DVBAV&TXRZH^3)7R6>QI0(M4I^9U*I[!$#$,;'R;Y%P>Z]*#W,\B
M#*L8PY?]03I#<^"4AH%@XH+V>F7%=S4!>(( B/PPR$3D%PVG@K8&$NW"2<VH
M.MAL91&\),F+Z;OB QZI@@$RJ"@:T--12/+*<4E<1"5@^F6W!_4$((Z8V"[1
M#0Z]4MWQ!OT*5F,S*7=\UBL0,_$5!H9%4D@9!F):"RMHF@8E*QJN[B1@_)1H
M,?>@=96'58# SS/,?2*=G&-!#C'CX"(9"_Q0&FB?,R8I]H!$%R/&>J:KSLZB
ML92%R)R<L2,=7,K3X9-!6B4#17J(+K5SX _ 0HC',A$Z2**S,;PQZ>=H[TPQ
M8F!;,[ANH"?0\+&H)$BS+_"Q?JS7D,JZ%Y3$7Q,NIC$J?@KER-KHQ:XYT!PT
MI2:F9*HAB13NK<@IJ\J)F,MU"47 3D"]32\Q<1)PFS]N$G,H8-JABLHH+"Q1
MLM1\(<J_G"+,.D]1X[0UYZQ$'A3A,G@-VV!28T;7D)=B<92U2:?TI*]P7CRR
M+:OX/:(:16#A$NH^IJE9,@<R<D.3<M#"YJT:0AEVD:OI[WU2LT(F8"H;:)MD
M"%* 7N,@$;,'<7N8QC-:E."B,"OF"5DH=J_.WGA*\=AGH@: E TJ'ITXEF<*
M2H8B<2+?)]9[JI%U<46ZKLIC!O$)OCWG@E)#=8DB%'H&3;>[$@%^]0BVJ',I
MF_&<<752W0>B>8!]8')B9AD[VOB&\V3"1:\>#8M24PC)N@8/^$(EU.4#[>\&
M&D69$Y@.,C'J(L3)2RW$F?K9D(L#^'QI*K72FM995!PF@:R<1N,OV6PR[5^A
M*SD53@(J6&H>HT%F8Q(W0K,4Z:A()-Z(@4.Y5"(CUXY=PB0300*!3@EVR)/>
MN?,]O!95.-(<9\N!T!&D73Q,<JR\Q!DZ2)2<B9>3=MB:1'(B _L*_BQ2C%2>
MS?:/"55(>&.&O4+\#HJ"+#Q1YCW&D 85 XG)=Y10Q,2<9>+;67A&',(?!)P+
MZ,.^@+?)V/?'T2(TE,DH,S(>@EI@@'H0#LP3D)0\2^ATEM!H-KE2HR"=RJOO
MAI(WL\FR^:BR?KW'F_6[_:*0_>./[TZ._</7_N&'_:.=DX/#]\>;5UI,:_UO
M16R$2R,S/1ZX(HC2N-? *'9O F/WD#M+TVT\MJ6HO@NK5,3L; ZNQE,*9%A!
MIMQYDA$/2&D4'7JC,0#$-ZP!M1:A***'@.XP!1MF ZS.PJ@""1Z*R"P:%9 ]
M"SA1!3Y\Q*T+=R?\^82Q.G:"EN3X[)_/:L_H9]!*??GSTLL2HAI'OD23'(24
M_->O8.D.IN?XE-I/SU#2_&.:R>=3I!HTK]P%RZYG0AY-!_)S8JDDO=1_JF6X
M=09;M@4V'?QF/)A4PF6,>._X]M' ^J!:!FP&=?8_GW6>57[3C4/S6M#F?XDV
M]Y$VY1H6?=,\>!M\TL_3;../]5=?O$NII[#P[7DGX+0#0FT'+'@74B;<C]4>
MC/OHSL<_O]B+^5\O'_9]-]9]@BCZ[\U*&_=CI<_OQS)_6HY57)G'[.ST1;W6
M#.J-;E!OM5XNQ4[7+',4#Z=N_A(]IV *[0M;9ZZZ<*@(?'85GYJ?HT%5BWS0
M]<"GQ=R#Q?P(]7_BO/L2)"_,O&;MIT5I74[9*"<LBOL4SV[\Y)8C]J="QP(<
M@DN9I86/BP.O-X-6JQ.T:]VJ+SI?X[ZG.UA_V H:83<(>QNR_KD/KMI$#Z1O
M+VB&M7N\A_9RB[]KS;48ZR)6!(THYHXME2*\82E8#SJU;M"M]S9$*C>#L-T"
M'NMLR'I>A%B9&33:):8O/_3E3:^ET5I@$6L@]^55U6(T?C">1N,S*LZ@"@L_
MN9A$278+9-ZL!^TP1%BL#:$K4"2]=FV#%E1O!.W61IU0?0%JOQ^R_4V:#BC7
M?FOT#K3>;FX2><$'6^&FF/X;=SKA(BO98,&^AV7I..5!XAQ%%SC7D[/%Q9TM
M',Q8,("QZ+DO\QPE@\*@VRK91HX=++Z,^[3]L!$T>^W'NOTNF'VE(.)CV7S)
M %]PX_=#(Y]@A;=?'1J\AQ?6!:5&[9"/EE^!7%K@JW5[X6,]@68CJ'7K0;-6
M,IT?RPF$8?WN!-?RYM7*68UWA\?'_NNCPS^L:IR;#3]42YB[B(54,OL=+*::
M[VY_,0X.V% M/3<1OD%9GZ?%W(O%W!/)?4C%_0=CZ@=[(0S/FQ8*]_YRGQ9S
M$V1_"Y[6+L]#QL[E*)'(930F!-MES@3.@8:;N.E$0-"I=X)FI^37/\5%-^]P
M[GM8]!W64J>(:X>D/DOR<S7)(3Z]Z13 BS!HU!I!J[,!F<N-HO)-.I@7"Y'X
M.G*ZMR#JJ\F]2MBK9K2K1T6 S; 7A-T%W+2;)K^%%W)+C'E;S'"#!0YQAK#D
MHJWFYB59+01I5M\ 4GK1ZM:"1K-4'GXGT9A:T-L$Z=Y9X#3NAVA_@V@#+[ W
M##&&:585?,,G\!M$R#?Q#AZ5*$<.7*!V[L:#?HLMXTF,+R?&]23?1,1KXD*\
MYAZF2%X(P,GFJG4-]WOS]7;0KI<(]%%L'5,WKEK?1[!Y$)#EUK6'6-(P-[I\
M#R^NUP479>6KN_?Y;&#:L-[!HOA'R+3U( S;0;W[: OP7H3=DANSZ+W?G7WU
ME-=]6LQ#2'"MG.)]OW_B8X'.=:Q;WVZM(GOH:P3@.HH7:FQ<\BFJWJ<6M%NU
M(.Q<6U)%SUI)^VSX$31Z0;O;#&JM:XLJ-^X(EE!"UY]#LQ;TVFU4QX_Z',+:
MM?7@E?LOZ..?"3;H";)H$[%6W$1X!Y!%C84AB];WI(<*AO,$?O0$?O0$?K1A
M*WV8X$>WP"J;IS<V\4EWYCJ:T#VKNY'QU,>:FB*/W 'VS1Q?<.Y[2D;_7:R]
MVHG;_+4KQZL4_[WUM;MU]76@266/Z:;!>FZ]EA]'5&3Q>3S.$;A=YEZ0<Y_*
M^I\6<]^BGHM1/B_UM:@#VI5U0"=8!\2S-@*"D\;Q$]&W>]U8_2(D(;QJ"O(^
M)^!:K4><>&V&02M<.?UVG[=>;P6MYLH)YZ?$X[U2-$^+V3@5O+(]:ENB+M_Q
MGN7?P.WL],(@;-R_O--:4Y"-H%5[O%E8L+_"6B=H-ZZU1C;N"-:;?5Q]_YN4
M??SA^3[_2'X[$A-L_O%S\MM]'M;S*:;IN!$.;-X28WD"^D'.4/-.$YP->#X&
MQ7)V)08#3W%\),_;F<8C> T-OA)#0\_C:#0][^-SC2_VY1!T.;MXC#,XQ=!S
MG+\CAP+1*US3C;T\P;?@?]$8:7J4&(N(4X7[R03' ,=1-N89=%?ZF3QI$6?_
M8,@DFM!097."'!["!'ZD.4$TD#/[$JM9=GDTBN]PQ,_&S'=K/:;Y;NW:TWRW
MVY2I+CB\^RU=#_5 >]B5FG4FQIMYUX\W\R]QXMASC7Q%?WFNP:<"G$*),SE!
M\HZN\*<)CJ4<"\F%PI*2[31!7L-$H>P+P_I/-#[-&\'.L-T(VZ2SY'0V3;-<
MCJA3#\!YKY5;J9IDUPQX!\4GX<_C=+PE)M%+6&ZO",M-R];0T/Z+/([]]Z"/
M_)9<X&LUMNU8C6U[&52_[:P,ADQOT:"\//ZSL.*SRM$6^C#P,6K  <\%QGG%
M\/LA;NOT2LS?UD_-*E#WU3,]6IK$@%]F@.##UE75DT;TT2T^15!0Z7,](H3Y
M3(_<6(K/% T$P&=>N\9LMC0Y)3F.H(;#2497/$*:+UX^!Z<3:KI&8(/9B-8S
MC 4Q-H-VNPG+KP5>U.]G,YQC*)]N/! /Z<W^7N+OSG#^>/_O69(G<M N")]Z
MT.FT K#DSW"^MTGM(5 EN,CM,!#SG5-C4+;]T2Y(GE:C&7C&0JT/M.$I/3QI
M;7I9?T?0C$ZC)F;Z&CS"6PT;0;=6#YQL%UE,ATP$7Z1%>OPT/@KK@1T0NLUV
MY\%S4M7@CR7X*"@SDASKP7RDIFK,9R-]2[;4@_<W6C]M>R?+2L]*%H(%UH K
M>JT.$\1H%('IRKH-"0B84SV$[X2FN^_N_7%(%+-[=&AQT"#)Y?SU@6NBM)LJ
MQY9((+ZX0+\X%VH/3K!=E\.MBSQ#FJ'1 *KO->\ID2K#S]4TB,GK^VW]8?V,
MLWL[?[G$A%O_,LJ]YZ(-D=E)-^6]7$HOJ7XV,O^Z78=>LM8+;_8'LUBSD">4
M15^!JN%/-K :_;T*;T=\([I(9\+L4IA?(#K.$^!E6#Y0NIS6BY]&?8!,QGH!
MU"4>.O*YE_+CLO@B2LCGOQ[H1RZAVF UU<9H+H*6>)9G;$=A.]%-)>5&?D$"
M4L)Q(_P]YU]=*';_&7:)^=.6Q4W,\ER7J7GLJ*G2KX49%6TZN0YB$-7Z0EQ;
M:SBX5GT!%Z$5'O"N5W3CX)$.QZLT#ZG@> 7+^E!^T8?R5O*A;,^IOR26HRU@
M\+6>>))A7"QE4-QG1GV7@%T_0!%(%DPT2:8TOCQ/9UD?8RWWEW%E2/D\00\$
MH]9 _6C@Y\,D'M#(^;[8+^Y]I$XBB^%?F9CU/CW/TMG9N3^<C0?D1J$"@@?V
MOYRG(Z"IG+D 8\%(6?C4W?3B NCL&#]$C[Z,LBR"AP6"A$!)B+GRX[-MKRKT
MC:%J?&PN ]:H[O+9!"?+TWM$Y 6(FQ]\R1P#1B:-HH=/2_-SD4BW5Q'I%JKQ
MXSC!15$XA:+Q/\.G]F<9+&+;W\<(?S+$%6#,/)_U@7;RX0Q3 ;@Y?,Z<EQLO
M]N@@KW\G^A1H2V.8_VP6X?'&&%&*0*U*FT *;/=;250)=J:DP45T)>[@-/;@
M8\.$\E'WE+L7?^5.CLD2)+A3N 4@%:!J.K?S."*2_[__IUNOUWY]D^(/N^FX
M'V<\4.F/:!R=$9_@1\+.K[GW810!.=(WPE\5\Y2B?X543CX[S:>8K0%>Y+0.
MW0A=T3C&I0T&%'N OR,CYECD<*ZB>+ G?WH9C^"1P'C3\YST[&E\E8Z9FE]$
M+RO%>."_.'UIAT^ K_)T/(Y'\+?^2WK'!,3AN5"5*![$5]F>PQ@':02Q(./I
MM!+02>CR">5#C*!28*RWHZ]1,I+&*'R&TU0DADJ;)Y.6*?^4=/0,/K0-GI(G
M/XCK@F\!*>."9U.RVV%M'*NA:,S9#-S4-+M"?NC#"<-#:>ML;@L^9B2UZ0CM
MXZ_I"%DTS92!/YO"BXEK3F/]@7XZ&PT\\7+X9C0<HD3"38\L73-4(=I)RH$E
MQ859E.0D1<[%;;/5#X1.@2GZ7T%9D]GI*.DS8R=?,=/'(I//V<,CQ!/-6.KF
M,6P)WH7T=4R/EV*8N5\<*5\&"G0XQCXF%NDG,-LO<HS>^2AE1B.^?MP96!XC
M/ Q8':]=*I;+\WA,% P*ATX&W@./8:??>4AG67H)I#U!/M+/5V<%$IWO6$2\
MT"WBW2IE\. %U@(IR?:C2DF&3RG)S:+0'6+)@M9#H;G+]0Z@_L /!*6*P60*
M\Z$#139<FGUA 4\"A.)Y+^K=H!'6@WJG^1+DO97O 9^EVVD&S6YMWF/(YWG1
M!?>F$[1[#7I*88$-5D162!R?QB&)=@O\U;#A)05/4B8*^FD^M:40?Q$Q3\&K
MPG>@C8&F;#\&.8WB%!Z$!EI:RBV$6)P8M&LRJC^)KM@6AS^R) 1C]2R+8^5B
M=CO@7V*T2$=4_X%M>8K*2Z60EUS,JUU)J5FGB%B&_T"_M='M!*UZUPSJ2C4#
M KK/+D+@"1TJ]!1N%!9RQ4%;Z?+&W^*LG[ !(?T!.,&,WGD>_^-G7.]O:'HD
MZ> AB7 9#]IG5;S&<-#<U\E-K>UM1;$^-\4_]E_'IQGX)5=^V'(( *\/9BZ:
M=F5Z @+AM3>:S:!;[_ /^3EP/'& Z5T&_O/:=JU6"_E#0/T<_PC00GE>W^[5
MD*!\^C(9PM$9\,T9O4_0K(P%2<G$#(C1'?@//U:*@L582F?C>W.S\=N"Y&_Y
M:M9&[$O2P\[L##[@AX%(B2U)#/5N+6C56OS##/SBW'^!CQ"^F74UM  0Y"F+
MXE_8I0.A!K>#+G4N3EYX:2\#/X[ZG"M.<O+Y@0A>) BJ' O:$2%\L6#E[>&9
MP&'MH%=(9>@HUS]D\3 FMT[0Z$H++3REL&02JR\2L<8^LP1%9;2G)J2L_P)W
M!QRQ]!(^\0/L5P=<")*>Q12YIPR@C%5H::_9M70:JQS&L?);BN> &DEN>(@Q
M4_UFUX69)T5"@F@.;$44$[@%=&Z!3]&RZ&R'#:8WM^3P'9*C[I0<Z)SZVCG%
M[(C\4@+N:SQPT#B?)V= QS&!>.O#[A.YY=)@*+Q5[/T#*&-X/#JY)(X6%U_>
M;8NOFQ!+M@0Z,2Z*SYQB!/)2/2EG6FU$[:X5E4Z)BF6<($-+,6&;B[_4-T1!
M,D;SSGB/DF=@WX580&^]R:.PO:90HAO7_7\0<O*#E).V=0U.W,#_)(TLDT6<
M:ZD'W5HKJ+6N60L>H7HH"D5ATI$QBRQ"_,?9(96F'/"+Z,S1<-5US-%8VX3,
M@TC*M>VV8 "EN,&^9&/2O[^*N'*1:T\[BAOR]\79KC?_>$.V9971L ?>TL4I
M$$+38398LK-5;P6]9JM(P58J K@ B7"*U*!<$$F#'"@E\E("GHI)FN!AMELK
MTYQWTS1W]SY_;;N5C&VCOZZ\_GK0:S6"3JWFJ2-/9U.,=I.[21)4WP%H9)(%
MX"AC$E;FFT LM!JDE%$^&#:]M#>T4 /CO=/B;"O&D?$RI19$Q]0[CT$VBH0G
M9[ H/QQ-)J-$%_Z5)1/^5NW@QP60=Z/$L,AUK5'RN&^^V0F#=J_G+WCO=,>>
MOEIRY/@O=;[0;3"T"]?IK^4Z,360Q#/*FIL"P+M!17/?>%[*_CT:DG?3,8Q;
MV(OILKVGV-P'86:0MU#_]?9V>'N9 [K"/R@-2!4[1+5JOWRK'K S?R1LNF*W
M%,Z/!\*X]8]GIWD_2ZCYS-]184FR5:F$1U1 8XTV*FSXBNTMVUZ*50Q'X=\6
M^S:6&UW8@G0'V4@M[@^#S;0247>6"9LTK/U$JB0:CV<7HE AEU'=BXC2>ZDX
M"T^$L5K\"GD6^ 65IT1#.[K2[P%/,H-_8F$3[ J$#9K&@;1B U\4Z@V3##X\
MB,B#I$B$^*+ZF<KRANEHE%Z"[/2H@HB.<L#^J(@C<UG@%#WE*RGC"F>QC?^-
M5Z,$,3WLXB(>)/"LT15-D3K#3#>YQ_C7="(CTUK(!FJ7(JW'E?2\I803ZI0]
MU(< -G">Y.X;NJ2HOB:*.6_VHR$>#3UXE& E"]9#Q1F5DAQ@'9?C+W[:[X/Q
M5W%4>(J!Z[1H7?#ITYBB\,E WMU#BD]7V=Z4''%* (_\2PS/]MKMBDB+3S$Z
M$5FC3#;^8H48FV^';$2\%Q,='I>ZV<;@@C$QTR>&3V]-8>_G;#"JQ5B^PPL5
M/L/ C(X<3E//H$TWT\DZ=EV"IRIS:#S,\U98#QKMD$HO@%RQ97<DRX'MBEG1
MKZ)K5/2K/.;O$].PN2DO/=QN=NIM??2!KUUTCTRH%XN93LIRZMRNY;2(KEQH
M [=KNF]RR4'G494<U)]*#C:,0LFT1>FGY&[NLFS_%8TY+1G>OFUK6K!B'9[6
M$@<JJ>%H"&D+#Q@W*+=@?+7:QJTO8N-ZA5.Y,RO74U:NOXR52[45&V+;NFZG
M:-_&"27/YIFYF'*: >]'4Z[<]F83^(S:.!'HW%Q7H0Q[6DP<:6W>V&YTMWV3
M-^IS>,.C5[LY(U^9-2C%-K:R; 5#B.R.>DNY@I[-2.9Y2TX*1)O@:"1;3'0*
MQ?$U*S=9^GMN.YG2%N:"'LI>LS5GKA/;.S)L09$1I6V6C!5T<@">!MIEBS$R
MW/YH)'@8F[Y4L+S>X^NSF3BY!1[V;$]U*1YVG4<E1QW@=BHYREN(H_RU<!2M
M9U>SU0>;K1ZZ83C74:1$I-= Y,I:M^I0/Q8=Q8_K=A0YE.S=BJ,82/*V/4*3
MA#VA%*[S"IO=1@!Z?Q6OT,$Q9<_0NVW/D(/K18[VV%336SR-1ORF:;&"%'A>
MB=9E0_-+.)@/F%UE#%]J"NS1M$QE3]K*K^+I91P;6D55;B$%%'5-8XX9;9H*
M7M%4F%ZFRE:P2Q7F6 OY@N9"JUV.',N5>]4ZW7?J=/FPDDX/"L+J>=/H]GP>
MBNBUXJA2C9MGJ<486QY8:$CE&K,UJ\Z\85W%\SJ_0"TZ&5O\99@<Z@E\B&AL
MF+:&MYBM05*3%#V'8F&I268T\I+,R"VA88?NA<+=BXJ!>VE3W8:IXB]@JG@5
MIHI]CNOW.Z@91WD=7OF5<]R/P@>IC:E8D;2$E4,M42FV F78K(SUY50V!UQ"
M?4C4R53L3@HT9<#W$A!2"(JH#Q>_9!&]11.B+J_25=&*W+EC:IHCQ)X^"@)1
MV,&Z<>=XUV]V:EOUVB,TS)!=I/3Q=(5MJ7"L$7:"3M@2%9U<P*;<.2 &L-*P
M+6Y $IX*,.+L JX8CUK)OF2N<&:YA?T8#4SQE2P9P<1%6D:R,;(PM@8PY'Z[
M36LHU&=6VEML@7HW;H$NDJKP?M@"75,*P/M10\_)G(M;>;4EK3SOR<ISQT(+
M!IY?,/"\XW@RY2MJF6;%87^:6K]<R+XKA8*(U-P&7NLG_U JAP-4#MX> D8A
M$\^U_4QC0N]/!4\7,PWK05AK!?5VPVWY>:;EI\JKR[;?'+-.*<'H"\,(4*<7
M[P^_ -LOZD:Q?6VQ>?)7HIN,5FQDI5%>QBAWTZ]"W8Z2H1)/^G!XDP8Q+!$N
MA@]XI9J((M$TES3Q5@DI>S=BXU6%H\S#*]AWW@_;=^6XLHAASS'LC-NCXCG#
MJO.6M>HH\D7K['./.POUR/]3E4X<RM*)%Y@OB(?).$9( 3C)EQA)4T^P[OK!
M6U4+Y$&[CRH/VGC*@VY:LYU+6.2ST[\(&"?UX#4#AKXP/*P72G++/^J0=C$M
MB6 \MML@^_?&1L$56)+38L2<NIF%@BWH44+@FOJC.$?((7@2]DY+M:N+;\KR
MR58O):=1F]S%BAX!4]<7H":1[]J[H6M[J+!9MJI=%M\A3JB\RL"X 7C5<)2F
M&<>*MEO4H^JQ0\L$8W6+)533YA#,0G;/=Z6G#F+ )5B)$*%*R$;QW)VVODO<
M5SCJ^CQ4,QWE'H%*<-V$<&058CM>Y!7V<<WQB7C (^FEG5O#X-DU#$!*8(T.
M=-T">ISBW+5=7C)Z$+D%@1"*66/"@&$RHN=*4(#T*_C59'NSZ1.-/.-;\P,Z
MQ@7Z.Z.1P(3D-U7T,C*X92R:36$EMG4YA:437L%YDGO8#N!?I .<SJ$=?V&*
M$Q?/LDFZ)AR[>T$^\Q-V?ABTFFU$X-0A(&W%6K3B25J9'Q2J!_5>(^C66PN$
MA4JQ("2&6-O2!HG*>)!W73RHV43TT9;_ K$GJ''S.2*8UX0O)9M%HC.@J7SJ
M-)^+7NC+H!Q>\N:%EVX^P:G9R+O!!.=2X27O1_.(G$*!?YM=7Q6A)H,R2F$F
MSQEF^AYGZ0TR_1UQ.+]4S8*EX]? OE[A&%2$ ?@%O,GO"J;M>:<;M-H=KETZ
MQV$8 F=?\*?$[.58;CMH]Z@6W/V\PD-(PGL"4!D?(!]F0.K BL$TD6+$\*;)
M4;:18ZE1VM[G//2A#%$&!K$6-IX%0-SM!>VP69P%,">:(HA,#=?59U"@.DET
MFQO7W'C]I6.;Y0:N8@[;[$MLTPW47!W$E(0N/\V,:)7^:@)0? #9V4_]G<FQ
M]9VWI"]5JX 7@2D[3D!-C9(+PO44P[\8^1>EH- '!KIJ014(+<)%=OXPZHLV
M22OYP4Y34)7V*[9%,S6;O9FN@.G4>>"REI0U\97$#"P<>@/94T@-X488CQ(V
M!&HI#!V(L!CIQ7&%ZICZ>?(-]0'&-_P7[9]>ZJ!E0,<ZF^HL$L70: \,D=FH
M;6',D)$R UD3B] @$^1!^"+]":<2R#@CQFC-.".X32!D0-30)_$-6'XC0V+&
M^>'-@D4K;1G\>386.2QY(L;)1W0[9"3(Y=#V);BU^ H!6A?*:BAPF,<7R18>
M VD^#!T^"I&PD##%</IBGRPY*GC>&A<FK&]+V [EN+NM))8 H X&%-Q09@X:
MU<9+AC''U0F]%S01Q<3+;!3:/DZ,G"^\',23*?)F0MB=H.>(9TADZ/0WF]IX
MB!Q4H%?#<ZX4%-(TP@> 5+HXC0<#DE;N!7-I"$.'>J?)$(S)R)I4<([8>(.T
M/R,?]$6R'6\';GE"N'RT"CQ2?.0 DTD#U8,7#1(=KM""#1E J,#'I KW"345
MC6U=&L2&1MVJD#8^9^1C;$THG7F!JCJ5A'6-7MPQOG8DOT9H3?"_=H65]\&
MW\!'7/]=7N) YFN(#;]-5=1!8PYTS8+GZY_K%1,H$D% ,&QB*5TQ@^:"0<D5
MXJX*PV7EW%\Y>I89V+OEU$U9=#AE$+.!4#'PN].81_,D"@)!1W2 >TF/J.98
M6X5D\D E\/. BIU80RK-&M9MU2I0CVB>0FR^UZBQ&,XPA&.K;AV"DKC%,A47
MB=033A-K-GJ&C7)=$NL7K#ULAO(K,JA#>E9M<S:1U&8S 1%'V.X%8!+*!Q3L
M_8D"WK1*5,P-$#'2'<F-+D;7_BR7Z4B+2F2$5."W"V]X;*_?XX H.\DUD;].
M@2;/-/"H>26Z*GB!A7&R0/R*AKT(LH5_JO8G4[8<RS^KQ+\[WVMIJT56(@8\
ME51."CJ!G4+B!$;MAY.B2]4Q/8H TFK9.!.G: 45U8X8G\VE++LU?\O?8[L<
M!]W@H]^)J3G(R:3D&-DS\,Q35XO4NG6178,43P<T!$O?*#^ <,$Y86Y=+]KU
M\70ZBE5KBV?R500. AP.RCC@X%/V*)C@ X[Q<O8[!=<51:DUL<A80Y*+@P2V
M&*3HDA,N.EF=P^0;&\W\" .Z(0SJ(H7S99Q>4AS8&%2\0R<.1XJ)?J=_OBBM
MY")6Q2?!(R9XBB=7<5B[$NPN?#^:4%.O-8-&KR[D&RQQ-,-7/@\[31R)AM^<
M* 0 8WK1<]"WC5K=+7L88UC5&TO5S)U6&!6HMV5MS6)VJ:&AP#:2AIM!"D@G
M"8;Y\W.68_%(Y$RDZ>D53$\:8@[,DIR=Q8KE2^J,CC*C1&U _HSILQB7O*B
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M3E$K>OVU@')F^2A>*6AD^BB]U@WZ* :J@_=<O,BP\N= .FB,]_+NE@I+E5"
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MF&;'9;$C\T<Z, MN8=DI!&FCZZZ=-=2>4:8LGES;KK>2\;.??ZO\TZI%RGA
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M%JJA?;6GVJ -=!5CB4E;:W>4:F<RNGJ\/=-?Y48UB3=Y>7KA-*2RGW, *W+
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MY?#0O/L-L_;&7;G9@!:(GTE%3>OVM%4[JY6;I)+F@&D8;]T< 0?#@D?J<((
M%P6??*LWVM46TVXP[<LJ4VG46XVKVEFY777+B<I73*N-/X!2I"T"@0JV^GB(
M'^U%5D^0V9-&(/:,,9H2L[E/4Z6,#>-1TI0)\3A77!:.?SF53,4DR54F]+$@
M'XU-14.F>887,!2B<Y<UN=PCH6 L)V[PPST%F6V\R5,5<K& /!TEMA@81K+1
M=3L3XU>W>F.,U-Z;%WU-)F>[!#DP3[>U#<;#(7*J+-^9#"Y&0O/BJM_[WL<F
M9_.B7*_])NTP;/JYOBXW'Z!FK56[J-?.:Y5RO<V4*Y7&;9W4K=U@=*L0ZB+8
MN";\VC0N%3[YM4'GDLAEO,]! 9'S[)@Y#W0F%>OIM/TT%'-"<96["Y+7'[RJ
MTG^?LD\$*D."-YK/=2;%[+!;^'7V9\A+! ><S6;HW=!KZE(-E,<X@3]M:,PY
MZAICR7AG>(%E (HLZ891H9H40S.194:Q3 Q_8Z1#;VX"0SK4IHDT_44R=.94
MT4V,T%ALFDQ-ZWV&3!KWC_!!YB]8.<M]=3XEO_)?6:R@0=[-(\+K&LRK8@W(
M:N:X:RJR(AD*0 KV9#]O;\U]W/[X%=F?,+KA?#8V[<_^_HSWP)3'CQBD&<";
M>*>L:GIOH&" +SSES!_;OB44$Q31<NU$-I07I&4&2%*M00\45 OU!AJV9!_Q
M1NQO6P/)8AFECW?$]/!SCTA#9$_FN-\'QH'-TCZV@#$G83'(5)7!YH9NNWO'
M"+:%M$=0%Q2-G!18DV3T!@38,GI!JCX"%3<#J<@#"5LQ/30FYC;Y1E>!_9!?
M1]BJ&?<P8""#&5YE8;W'<AW,D,]JD&<N:W?T]N!+H''3:D2,[^,^IK\Q/JD)
MU0S."S\S/O3+>.@7P!H:.H8TZ8OJF<)4QEV$/[=4Y@J;2K#J-*HPTVA&GG'0
M ",;O@?F=:"KZCNCOVJ0?^T\_9[Q5U%*-#$;*BLQ>IB^HHW/1$=;GQA=1.<!
M=OA/@!]^6S][+$V+6ENR3<FM]\4,T]\/)MH+.I/VC5X3N/98*Z\D_&(PT.X,
M#^4ZD^?;^[/<93]KW/.?OI&] Y+[!;O-2!F;C1+FZJ=S4K,#(9FEQB60)IBL
MADQJ @CI2"Z<8!(G?F*DXE=1Z@>,Q7]'(XMZA8',;C4%?FO!2TV@Y3+!!<FE
M@MO/K<_,1;E\XU  (9H^1G_]U:2<80Q+P*<&>ARK=""\;2,SY/$6EG\&*<4G
M7W/*4^#(D#4'+A9GN5:UXG+<M:N;>T,G>7Z:3@+JX&+J\&N4BQ[K3,S*Z]6H
MV9?'U\K.: +K%=6'U\&D?G__B^_!2#L7*S&*!/9O4T;&KV"<VS(#FFN96"3)
M&%F_CS7$"!QE]P2C/($<A6B@M3@BW[:IA:*E/K*34,C.'.[/9APA$<[S,5)C
MBQ'+SR%>P8"U2.'MB2N(#4DSJ8^.+N.N.9!>$--%2&.0J@SQ5GUDV?/#Y9@)
M05A(""T?E!M& _0[VNN#7&7%=]=5S/. P5 :F%7 PRDFZ?L[DV%#'5V:[<;H
MB=\9:94[D['X(#R7SNZ++?3IF_\T4U*&T)*#TID9/7-&Y?%]P]-\P%>-#$P"
M_J]1W8^\!BN2$J$O1P&6H?;\6L*F00F(E2\ >I\A57K% H[2%2A3/,?]=T:5
M\M/@YW 5&3\"CV.R'2%K+*EXAV.@4"AX/!F/6,;0W[&._'[2QWH7"^_&=X<P
M-7951(T&?+UT'^@-,P43Z]7,JVZH\JN"&03],E&%'>67=31?EAF;\$JDXE4)
M(>-7R2R^V"=D?S"49/RCWN\CTA40JZZPJC+$H+$HOP%T>X5*'\PKAE#U@=%@
M@C)8';8DA?J<517UX&B@\^)S6N\ P1[^&,M9PA@-:01BU5&ML?* ;0- ;=93
ML_%9AYC%Z'9>)08L7OX?W7G^W3L]!AZ\"2OB&;S.8(Q1UV1MT1ZN_@>>)340
MI!VB3I1Y]QV80Q*F.LNY_9]@%@XA$/(YSV9SI+@G8R>H$&%!LLU(Q1L+.QHA
MZ/&#5X;?A@ S+UU%?:?5DE!K1?^@(1K-<4T,7U*I']L".*;X+ R,P47FKX A
M.=5,90]4E^TL&0JK,Z3A5STQY5%KQE9W_AC"34)M8]^[,(F?29IB#ES+FMQB
M"*LI8Y57Q:B#D8GCP3K,>,Z)+.% V#H,49J)48J,(170&%5DQ=4#)'JUGM+J
MEEP'/0"NF3E]8GAG!EOA7=0#=T $=@<?_X&19IB,^"+,_1.8<"H(/#5 *M$?
MP&&HO]J'M*F1 C"#.6\ @:OTJU/(&T:LY+ 0"\/_!N50R=]5A;Z0OJ])2!)O
MH*/4.CUX"9<7L(ETT[9:O>K=Y)K#UB*6JH"L]D;L4QK.DXMSPL+6BMX[.Q^U
M7T"M?NX+PM+U/GV#L9I\6,\ *G<#D/4.Q/QE(L200M#2Y[^/G4LL]0YF7*J9
MQBE^UF?JRPB_P=(2[.E'!+@ECVSTRO)"I^-Y#F:?*[\I9J?CO-BA'/#O7*-A
M%QF=R4OQXOI7M2O^ZN5=Y/2WPQJY*R_$S85[GH>CV1.\?[JYSNS>IK W:G4/
MP5ZL?\-!3K(^1+X9&P@FQ(;5#1 <_F^ N\!&"&>00/*.52<*[I>B;/#K'LNC
MIM-)&-/S\U"7.#)\=I?4@>%!U!H9^>V(+#"ORS>U>5^_O;[[LRV]GX1S?3N:
MVM^BZ'QN7G3>.Y+0F>3&QFA\66_WA/RGCQ:WY[E8@?L W)Z;/>%GXPY5SCWO
MRNY"^HMPQ(_#?&?2S$G]L=A[NBOFMX/#_E,$=[EI_T)AQM%V"Z7U5;Q7\->8
M4XX"_SR#X!<[D]MW=%YY4/AKK;!IJ'&?<XH6:O*?=B8_7HNOYF,365KIT[=;
MVB?"\XXS[HX=;QI8_B<DDD0]RZX1.,^EC*$.DD7!QB;1CD.<Q^%>9@,186Y"
MQ 9CY="-WSRA#'*V17U@V#(;VEG*$*EB)#K#EP::P$*&18;43P9*.&E?1!YU
MJA#<H)[L=G<UIPH6PI_*2'0=<.LX B@4%"2J.+LA>(98V6/[,.AM!'X"TS\+
M@#Y#X$/F&V+)2>UX*CO!N3]6Y8RL4/< A BM@8XOTX$3?J*%,43I*ST()WG@
M\[LO^Y)B,"_ X<E&1CJ$S(@+$LM3Q7!"; K6.K1'*%.W0<)./9VQP>"#7; 4
MTRW]8%VH^-:&R<OXYHESPL0T:&,224S>F"6\94=E8<91>8Y9/-Y096P86&2\
MMWU^WK(FDU_M6,AB=W[5QW,2O[,SD;G:Z9E^-BR_[,XA6>Q,)APRAT*K9)WQ
M6":/-;)YC)'.D0C^V,?,N!_Z3N884,"V'.<E,*^^]ZZ>\YA?/W6L;84&I6R/
MP0]#Q\S+]6^>_?@1"&-9@1=G0E],-%G[K=4Q_L!Y6?6VZ9G,O@@>V77AJ^EC
M NZ+[?>0J-@9UHGIQ!#JNL-JF$[8>88DEX;GDX8NU)54XLPP!PA9OJ &I ;8
MD'4Z!)*59;(R_@+EA)1%G2#J!_5-4">N4<SY'7X79'=17R^]8#;RB*:GLX.K
M4L),!8-G:HC*=)PG0^U&)]#SV8\NS",VK&T>KYO.MF2G-9H=<!D/QW23)'@/
MH1F,%I0Y$B\L^<A  ^B'^8*(7VE(W(8D@H^-%\P)31O<&<KK[%W8IM_,+JA4
M,\"[2[A[X/!,7QV#.* "D')_?Y@(DYGN"PA)/HPGN\4OUS+6'** \]M"P@TG
MN0A$3NS%N:@/#9[<'*/>?9"I,), :(_KFAY%'#WL&N7YSN1A,D%B]=I\OAKL
MC">?=2;#L\J/&W1]7?A9LD<7 :*2'WR[#V&\&7]>@J,1F(0C#)3' =8(506_
M0"8590'A[^2\R'96 D1'(07 -OD-;.</,2 &)N1:8=W1!$41\UG: <W;U#%C
M92$D] DF+R7.IF(^53!=*A;\-(6+I6! <]Y3G<FO\GNK\N=F/'GN[@P#\YV)
M\C(X4^5?ZG5))0T_O T3CS;9, ,[GDH! %QDSETYZ,<PPF!=C1>CHNLT]^&L
M13+:O-6HA4"7P[SYB2*U:2>BF0-/=F+&Z<K?#*RK6&/R!I9Y'2@0"03I1J&%
M>3M"5)GP3 09"W]3(50Q-HAT'AGZBR+;).%FU:E8"N(G_F#J,&7%CE 15SLQ
M4NA;B%3+@(-_CG,^))3FAP,F1:AG(;+;(!$65U#I&JUE">9"^"RX+E(5+/[-
M@-]6<=^GF[3IF>FS5@"TY,WFN.?!])AIN11("ZXY=]Y$/819&30("\M+\/78
MFOM(9Y+5+AO"K33A46]G-%SM3"YTI7^G/[Z_7$DPPLG!:F^_4RD'0+L! 6*@
MGHYQ9$*,6.=QPWT<M!%3Q_1F.5(#L!5F:9(G7Q!)SB06OFEY>@O1G\&R?[3C
M@D"=H&=C<NN2Z"]6J.F70<>4"-[;.6R&\VTK\("?<DAJ+-TDV,>V*CO&\#)(
M4A!Z4\CD&3^=VYGYP?1=.(,A@TK]3LG"?RC0\1X-V%B7I R2(+N.*)%I6*>G
MA&0[1"2B;4(2P;O;=I"<RK7?>\178XPEU::Z+1'=\5)X<<:1>&-G9-Q@V\O"
MRB"H4B0E(KJY'_45G8GV^_SA.R<W<^^[RV[-8AXP%,6<J%R]U(N0R6>GI)"<
M3F?K?C7R)!/X#G*^0VP48I/(($:!H#\S5; KL6 FCCR@S:'T!_\7&S7H%>,Q
MS2I'%L3I/04 P0P#*GK')NJ/5<P*7BB;&/F6S@27QI>L6"391K;S6;#Q9W,>
MTKVHBXCK3I5Z3O\$XT7IH=!-DD1UVI2?Y,F YXU:H5@#-AZI=+2-YHS?X&+.
MG&5IMS-BA(XMFZ6%6/^.B\!F&##*"JJ63[ -C6S& 1R%0,/U(\[ !?\UX[@!
M*?LSZ+P ,$/[^MB _>(CV::X%[ 6=QF2VSA]S_CW:J[7E#;/QVJH8J$K#$8Y
M5)B?!8>8+GZV,WD>%OFW[_<5_KNT,XH^[4Q^OQ<*Y[V?M:<?/)EMZCB*R_;$
M"$K,)XR=I9[Q:Y1='0MI&?7)X6@MA>;^JBI]-.MY/OK$J+/%Y\]0>0TD-I*L
M&8^>IX0#"U@"R[!,)L]6\H6$6OA!6<+*!W.JX_^Y#LSS<NO4\6!F0K]?T66B
MTUO^%/URRTW19]KZ").?D,-6Q[_*MPM=EVDM$<8%DDW+A*"4\NVS_V,G2F,@
M6T="<L85"C<$2+;*YV?;?L,MJ ]"Y0W-*J%B 50UE53T4XCCQ?NVQB<CD":*
M1HPW\-?97Z%:']:],L3U"W$,UC'7)*J0.OD\_CV-_)L-%P# ]!=?*FDX, 2_
M\80FM4TQ^DR0T2M&&*OO(XI6H7\BPI$B'_%'O^*?WFUN;T>BO.B8-!JI-@(<
M/>W6EG&OC!-\<U*#W8HNJIX\NOCOI#41[VW73@8" =\%MRX <S[9+V6BF1#"
MQT0)9/B9N9K>FHV/!B@;)@G)SD3OX).9(]F> 8H)[H&(0YV4')H6$*JFC8GW
MA6S<%W74''<$0ZPLK,0!PI+D9.+SH]YP&F]6C-YXB+4<.^%6!GR;"7!.;1,C
M+G4;.J[PGF08A,JIE73$SH;BC#O;X;O8A)C6/!8;(Z)/9XG^$DCA-,MO@W+I
M]Y_2SI27\\[DY?[7M73V0S[-]SZYPL=73X[U%E<D48]5QF.MW3&1 0C02W*T
M;A\*NZ@M^1UN*Z&S@Z.9 $I[84+(S</0>0=/N(O=<P@A^-0QH_N,G[SF7E+#
M.%-,;!)):J-_I6N/1,.F.%LCK!K#)QR9%],%[]?EU[]:9Y*U"D/E\:YY^[HS
M^BET)M:5]:=5NM#D$KCT CDC 57.$XP9<N8PK<XC.B=J?T^E!*$K5S+Z"<P*
M0W\5:DM8SXVG8Y6'? :.:/V5/&)',/$C)GHD[R+?^,PTQJ U6Y("DW5\2UG(
M<=*]Z.H+HJ:VY :=IW)9).*="^P*9NMAP>L*&?)EUHZSP@?. 3\SY][+#-2'
M^AW3+LU1P$< M_>$+-)(2NDI(_"7OT(R$! ]O,'.V!])[U1[\+)ZH(+(3@^8
MWI]=2]4E(3<L?)VQ)* I0URC3ZIUB3L%XN:D/ FV<4*?P%J>H>-C@].RU@_P
MJD5<)T,C'R;QA'I Q+?GZ/*D=Y9W#\1+28JAP)\)3YMXQ?U+]#WK3"[EI\N\
MU.__'&\K=KM"HF\^4J+OA7K3^'YS^W[.%S]>HB^?,-$7L\FR\?:]V!6O;G_+
MAY7H^_V2>[BN7I:TXI]=)_INA[C/%YI/KMN31E-,IG;3_+_2</3UC"6&MF;K
M?(XOU;5AL'WUBCQOP1R-C+S==@+/X7W0D04B0*R;]45YH/.*<*9+7TPL_B"C
M_<SXR^-#JN.=HOBPUV;<T]L!;+M]C?_U;0A$ XH'P\F.GR:,N^.7_X<OLJ4\
MJ=Z<3NT*V^/GS-G2+XGQ-B!FV3S/DPWXYG(Y97ZV"3YE4F8\RY=8U/=(P7?8
MH@6)S-55Q><*SQU_[58[#&]\.!/T=UC3M_6*$8?NFI3T3I=W"?[(]XVA Q$T
M[1)C;(">>07&4\6#CW)]^&B*W/6SZ-9GU;23$7W%W#)EE_UAQ6BD2N]?8-[B
MXA*N)?N*7FA82CSA<&YI%CG>?T+J,&>L^2GP36[O?E\-<N>U!Z_VTOGJ/&A,
M>QEBG#SQC P^5V(%C$U\/FP$%8$!F_%7@!^Q 5R:\?=$,DG7;.'.F+"7PI5P
M\<Q=7]X];56YF+5D2YU)Y?M[^;GX_N.">YJV9.$<)^0@F;"@%OFS2JS::?5@
M-"=X35C+<B^^@5X4]#KK6'+<1YEX[B/;7)[R<])N#K:* *XCR!CI(B>[!/)9
M/C.5P#NI:4T*4!C+4!X?\58D>[=.YC!+W&-P"G@?M*>A,O1+(,\+$S!6@TVZ
M<=B<8]L24]>OO7P-/"?),-\8^8\-WW3\Y)F>2J(6-#?T$2MDT/Y--\RO=I:S
M9:>L>[8M?-7S"MBI;=3=[N6@#A0L<6C5J9/\9N"/0;_!+_*-.QE[+\E,)R79
MJ093IR-] ^R]T;0ER5?=Y"EQ1%H.\8(8ID_0,H-X^.P[@Q8BL"69T" 8\GT_
MV-3W#+4WJ.*HD;^3'*30 -"Q*RA-!\-)89*O2HQD$I-D27(M8X D5N>'&%/'
M$,+HOMLU )">[ZF!BPC+5AY]@-9\'I;^F/0F]#E:G,RU#,UJ=IHODK5=9)AU
MM82L[/>P1%V>G5*+:1@2<C;=%#QO)W1)_!ME"W/VXV&PLZ$%-M!GVREHYW3[
MT9EXNB"J:M)21" !.R[E52M,E;/0K!J[!(\2$SXE-H;F79SAWYA* V\FW0XT
M["%OI!O1=/PJS((,LD\O"XA&YYP/@*]WG59^#I+1^@YDP]F.C+GM,_%)@$E(
ME%@5P]>MQK<Y\'TMT.$(%#UA5B'7:'9DG6AT E?@^$['T^WZO[GFSW$N?_K^
MY*G& 5%(]S[=^Y4T6XBX:-9=5*"+5O*MTY?VG?Y[E%NVZ$+E,GS99-,I2L'>
M""<FZH'J^0KYETA;J'>N;9-+1C^42HFW6-=#-.)P%=G1=#Q>D'%&%SAX#&UT
M7&MZN;$N G41H_UH]6V,X-/Z]A7F(0A=$55GL5J=]U'2@J<ZD[,'Y>QRF+O]
MDT4[UIZKG4GOY\WULY!MB[\>/WVC&W:59!+2J?D3#C)NP@'-_BF*V:!W)I!6
M [Q0(>&+GHIQSDLG(F4&5":[A<J0IT R7?3^R=A#4E)7!]L*J^.F?R MU/#F
MR*MHR@+-"\4*:A]OAW)T^EW:ZLG)Y:#^)))DBE5(KT]CP%,TFM+FO*;,&="
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MSW2B#%4EJ*(5Z,M*N%BP\QM6LKP&_C0MVIEL'?;E0!8G3=V%4!DD^FH(FL-
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MT,GX\'V;]8K='/_P3#L9U\K]2_E[IA6>WX]U:KO2?>^GQ3DUNV#-K)%H:<.
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MQS>7I^RF%W:)&5;.P PKYI@2'_-T;<^RVOIU##^(52I%5JG^ZU:@@<[ KM-
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MKRN[4:GDZT^-(7,[.JLH":72,^*UZT;_R[*2QTK^#Y-';X&L&WY8S#@WK8T
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MR6/-C3IX5Y@0-U=%>WDV5^X;E$B!8?BGTZ?*8V-EB20E(Y(%,U*M5Y82N9F
M\(8$L9)"$-UX^P:UXIO %Z2[T^.C9F5%&21D)1+FNE*L5)8"F&ED=Y6K^I^,
MA9&+?TOO1I%O4$BO1L]UL=SNW[']%85T2;HB>2XBN_7,4)2Y5/'D,%'FN%RY
M5$XCQVM1K6QBWV:=M;U!41VPQ9K"UUHL(ZWLVP3R%YMS;!+)6A:.#; D.2Z?
M8XJD1E.[&X,DAA?M+@"KXH7WN&:WM%/AAY9JM7"P.S@ 3>SIWV"?W'.5G;V>
MW5V<\>4U1"4R!_)G%K6(M3R!,Y]%?U8V5P164AP+:5]A^DQ&T9$UN:,QS\7)
M[.BI6IP-*J*0>=PD^\JO#<15TAR8[:"=]N6@[';8)N8Y>3^]*97OCSN/D](Z
MHCF9'96-17O2G)/-L!+NZSDI[FI4*>81X8[&G7:AU7X5B]D'FS(N$%M_,"K%
M^2ADZ=AG;X'M4DU]8YU!K^W>-/()\_1T?*YVRJOF#39=?;RU:%F:L[:=8IQ]
MN8N2^_B-G3@\O<]ZJ::_,UI#S#I MSL^?A;BO[/\%?O7(@;+5SK@X1]:P9P\
MRA]9Q]SF+YOU\X?\^VACP;T5JZ]6C>\%3G,&G!H\.#9\.GMQ?\JN2FM$-,T[
M9[6:6!P]?MZM)H6;*GO./)H67E=5R*#W>!) TOY*:'.MP;+Y9"2<O0TO@72N
MZJ-G6"&]R4A6N(SRV^%PW!_1+*PK/C5__AQ6.^+[X.%FM;1ZAL73&PP>18AD
MEOR*Z[C@=ZDF=:TA(;+9V7@Z_BBJM;$B;R%2LVJ=]6:B-1'"G24U11B,*9Z
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MF)17X]HM=RM??SY?['6[K2#8- 6I53D#*%01.!BE>%7RV6H)DCS6LJ68WI*
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MP3$3>CT=NIGPJB[E<^5\WFM8H<\--46$H64=B@VLJG:CI-"UG9@RLH<.%RZ
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MA@$'I^D.;1LN)T4GAK)Y$<)/@34D#X&6?[W@RS7=IQ?P YR/$4FD ^6N.4J
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M0EK(O+N0-?#!*_"YIJ:#3?4 B-M]-$T7SXS6LCX[+YNEXZ>[EGL9U_"[HL\
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M5=IWYEPZ/WIU@X\7WI9]<:CD8M^$23CDR%VGPSCD@KY*&(=<4OQR"IIG:J,
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M#V9W2]7$@39-D5=J96-5Q%5%H374U@#ONB4DP99*NC024!0'_M$ J^*/R)E
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M5F:'-*:2H$*I)'R>9C(:B=J:F!F"(M=^X"8GP[</M2ON!"-#I 2E[P-4KN2
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MJ&S?2O,O*]SWVH1.#V)O*VB<8K(P PPIE+?@7#J-1BWGDH+.I>U)$-0,:M\
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M#_6='=72-R81]'I;DPH.P?C@HPZ.7N:2>G5CO _$,N]T7P*+8"P+LW^!]%.
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MER12PYFG6V8(<VX CT3T_GH'=H,S-BV; UQPC!S$PU-)>6V+ZOQ^^)4=1&>
M(&$> O'3/(;(C$A$1\I:N7I1B\L*LB89>V96)'#"23V;JBU3*[#F$W??K$O)
M[LC^:Y'] MU93I8%V&RBCU&23LM:;,=:Y65>$VN&<'\K7=T6W['V8VDSV]<V
MA@NBLZH*;!$*KS0O_30;G7[A1B=(FI(R@7UF)FR=-54KV<1VC-*CPZH=LY'*
MGE/SA9H[RFQT<T?#/O%6WS:TO1(@=V\'&]K;D?K-+W.N<3JY_SBJGL#RFM2M
M'<PV39UQ3>VR?J/A<E;/[Z"$ S24PAY>0L=#,[170V.>IJ<GC[QT5][87@TN
MM%=#U)^$6_I#FE3C2S-WO1K;4#6^Z]78$<L7:3'8]6H4=) 1O1J>60BVR=*8
M:+!P+<)&:=@F:,NV0.L=W8#NRXMTL)J &#8 %ISD2HKB\5D1P5C9+D==K"^_
M:9O^PEO[=O<9)A$K08F(!JS#*:$JD&O!U( $K&H7/FCCM-T\F&M5^64N<ZW*
M]7QZ6#Y^76+"/HU75-QIFB.[7;$+.V:Q2TGF"I1N1C8R$>UGS!4L"[!T8Y..
M.R[X=ERP*'50^VX\$*9LF<3N!]2R;3<DITO--B_>'CO&J/W9SJ)FMR8OCW$^
M+<]CEY[_ZGG*>(;(IGHKJ^U;VB7L=XRP%D98H'TKJ^V+V@@V2!AD+ZAT_,OA
MM>RB,KLHV^X^BS+\J1 L_DU./-";DGBP8?[35.E^4<+ZEMRTN\^OM>DPZ>@:
M(-C\[(JZ#KC<Y.T6$'/N8<1'TJ?8P_T@KD3$2#A$X9$W]O)E7N5EJ:7R#Z*K
M-G-968AU I7AHT(%CD HJF"+8%OJ&X1\=V9R@[_V)835@LYLA_"T>H2GF!EH
M*:@]8_PC14=@E/<'C8;@/,<U7VLBVMJ1\W:1\Z(H1@%3O;>$F'-JR6O!@ 78
M41J2G@F3@Q;;OYJL*(&PGI1]4@4YQJ>ULSHW1E"8])M-YU4+F+-8)3F:WU#4
MC1UM;BQM+E!@U0)F2&XR989I+38;0MGM4-#$ T$7>["?"/P&?;*AZD:44CNF
MZH]7!\SMD%Z^V[=J379KJ-VW?]0Q[H/KNDYD)Q@V +(B'0%GU&IL?ME1)LL5
M!MAL8=-G-^66=P2\G02\2/5Q^<F7):M5GJS5RAM*OF'JKYI-_;D-CKK2JX]4
MH,CP:,@H_7?.=JF;:W4ZG:P(SG--==ANYPWV>PNNL]D)DPT5)C'TG%$=E@L8
MQUX%QC2S4X8[^BV<?A=IPP+"\C3/D!1?VU#J#=.%32> &5'[8%8\*(,+5=<;
M@J;-P"E-!:T7&<H\$^@_!R?M_NB8_7)>WY5H6/ GRH"0P9$07?>9[*3%RH)"
MJ>DUHU9+,XPE2BYP'$G7:))GJ0V5#3M:W0):7:#!:@4$V6F.(GFN0K(TMZ&4
M&A'07*#%3D=C0=+@V'IKW(*O9=:EOYC7YDG_7+K07VN;Y[7A W&VXPR&SHW5
M$\,CJ2D[<-[9A&^-*8"DRR3R*FJ5 $6O'@]I]6>\2&BP2VE#R(?7Y'!V>2%G
MX]K< 3B%!@28ZYGUN4?@:" Z<1RC5V<#G1\8VOV%M"&&*CX-9TL8-,_:$]$'
MFR(^X*XVC!0774)&[N<+X'Z2HRFR7 D6F&P2\Q?%+BYW+JJDW<+RMD?)1K+'
M9:79.[B0W^6++UV2@@^$D!14DA(V1W9G&"_-,$Y(I1GEQVI!'G8>VXXP$YE<
MJ\5=6+][YIX_%)P8X1\J89UP?034"2HML>>Y2B\CW:6@^.:0;C48[NJ!WQ#[
M;2E::2@BFT_8C29:T<I6/5 Z+4]DTH8\54"E&UVNDF7P'RI%O<K*<5]VX%\[
MUDBACWFJB" 3QY%EBB$I;EL8(\)]3-H2'0!#<NGE-CM^[-R+\[MFY>N#(=G=
MT#$ K%$WOH-^R;*N%9<D+&"$C,HXV33<+X7^LN.$97%"X?2[2&,FFYN;GGI7
M3+:)Y@[%#QYB7N9/5\.W>J/>Y0X+F#L4,ZNF@/$XWJ>O=.R.K2>#HX8<V-Z2
M)NH3V=")L0;(2 ,WB(</01]8$X$-H0.-"YL'Q=%8U01M1AC2"%;B]*0^>+P(
M[$.=Z(C&5!1Q.!=6H_8E!1B.$OBF#C$T4=84+V)_K8.'Q,^N/.F);GIBV.;+
MG)74,_'FL7+XV"U\D%4D'2 BMU;D6]__M[=''$FBW/N7N!8&0 ;=BN\3>-9P
M1> ]*,4#?B;V]GZ7"/!__^M)'ZX]T2_S*<7T/B5I?#5U0C7APL[Q._!.\'2>
M,N1[\Q?6%_#:,]R=^URLV1SNEU$A+T-R^VC/?1;6*?Q'M&=CL/^Z)G2D[G_$
M%1"_^*2N5'@D#._^UC_6U^"?\,F#TPH]MX.7>=.X$OB/Z972$)QSTT3A;:\C
M @D,WC-&-Y+RK&PB\=*E>RGN)<.]X.5&$\G8NW"J79ZP]V_J59=>#1&[=^%=
MI5]\%SSSBZ=J@9E?L#=LJ,J O/7F^T0R9E>J(3ISL]JB,^'+I4Q@.[DSO2OI
M,P"1M,=,?RX*C\=,GK,&B^G\OFJUFT2-,%4T@16KO4+F\&5^HE.-\>VP(DTK
M/W[?MEN-\Y/6Q6'SYA9]I_(?T?QS=]I^LG5JIP@]LY8Q>> XKC5+;:'[(.!V
MS+,IP2EZL ]'4&;$4-!]9U6C:-=MVL]!CT%]/'I]8@Q5#9B%O1?I]*5KC_-Z
M<=& J:\:LJ#KK3[Z<OU3TE]>K#0OW!UX5$-5D(<-;!;OJR[%44?47N:W1N_V
M=EX]/&I+/X#2-.#A.9O3T>9TM"Q"L-=E&5;.GFJ;M"?VZHQYZ VFKZ_E5'N*
M-9?C=^6UENM@_8Z,,-?_DFSY7AE")PW.GEX=N<QIO+P-W5+2[LCP+=$425'H
M/R%^0I3;B_ZGY%RV=?W 9/1Q,@D4IUE+0_SEIW(FDLJO!:VE(1+N(:OG6M30
M@E= [4=WEQ_T1>]J4N>BJ-VUJ2#K-M)OJFL/ZEO&CL:]7K*-I"#NJ*TLC<B3
MEBAYB1RXP==9>#?5]M@"MI>T*29Z>]0^8&$Z-0^/10TS+QG0JY13Y.3=P:&H
M YT.#P>_? 5,^:B]WQ]U1F_2)QNI@GKVLDQQ%.1-)NV6EL>5\_IK]W*H-QX>
MQ]&60MB6HFLIXK>T--9,VKB11J5FW4\!O,CD,Q'HS.H4*,_I4.H.@9'[(1(=
M&%IQW3\P?/%NB#KAVH]?W^X3=2-B,C0)PSN:2$SA?\%08H#CH_4QWMVIKD]6
M8G%6[Z\>#R6Q7KEYBU9=ILTAH44%>;VZ8#.MB:$;X&PD9;""'5U<B]4V+7.'
MM_+"':G.RH+;JJ>ZHR7*K_LQW19/!V?]FT'F.V+3W]$2=]297)U]&*=_N!,A
MU1U93G)/TL>R,/N7 $R>TIYRW]VR!#63SU%(OYV6^XR6M*=L=F'V/<5<41&Z
M)YL=N+PK*F)/^>R#1'HTG:;U_H_CNY;\42@LMI "=?'[&K,9*XO'W:NH\=H.
M3_[3^7V"8Z3PG&Q#Q']@X"AE&9@N!' K1I(![19#)3Y40R1P3258#O@M>(HF
MOD\D^$55\WX8?!E^O@>_T)FAC-30?C., X[ ']#;H,%DN&*#\)KL!8#M0 &.
M'FD,!8, 9 =($SX#/EXGP/L%&?T5V%GX5X!*T0.=CSIA#?>+"4D!W\.VFC[I
M#DMX@69<5H\.A@ .F\@]^ X%KK&+V0CEZ@BAVU6U'JR\(J:2,33_J$,V1NEG
M_2N3';M?X4W*.Y0^)/#;GNXAOO90+%GWC.]X+,R(GOU9<$K.J4>2)[[SGP@]
M!QC4>U)_S[Z#/4/=PY>,4P)$1] E_1>D$$A89H&P#B1J"4HS:(\[KP=B!CQ9
MGH%523WO8DP*=8AG"FZ?A%]'C^TC"G(_"ACGBY^R3URI)17:\ZZO.MP7^+[?
M2UCUQ:Y'BEU(0,CT<$'W#6(BPJZ)Z/PNG>([%3]@IAH<$B2N#U6>* ;,> -A
M("G./V7G620X<UT'?\$HNAI@6*08B,F8\,HDTB^_@D0:4#I(.KC43;A,LV]Y
M8ECOQ##WA%\J?@B2#&LLD'@#"S<TJ8-7#AXC@2_HK@P86<+Y3G06@,50$M]>
MP$CHB5B@1@IE*+,U4= QO##XH 0$Z50!GQQ*8^R JGT2\1\J)(6,U17TH4L>
MPZT,!IHX (9]R77L9A097A18CGF20Q$(5/!.Q$5X3?L$S!A%"@%)!_:Y 0.?
MAM25QAAA9&Q]Z"M+68LM&HYJ\7(%$K4MI00(1>@#-8WN AP^.G1H#$'U1"+:
MP$<=*VTQV:!@!JHK@:^"5S75H+)7"%$6L9GZ4T +8*C_[&<US;^5KH ATA71
MG^G_?EGT81$W^*<IP!%-P'5#NH4(138!>GCI=K&2"*&H$E+XD&8MNEQL(PC0
MZP76K0&-&T5$CQQ-9$,:RS.X$J^A8:X+,[9C%T #")S43YKZ1?P$WRB9Y^2^
M0<@;UOE\#^IUG7*:/#'OGD"+'I(@H3I_8)^XJ]O'WD'720>92_!&!.+2N<UT
MK\8QCOGII/)QJM_,N4LIQ:OCYRM&OSS.1?=Z=.PRDZAI5QA:.,GF"W6P?.:D
M*!&:%'73;&Q&E HGE&3IT'GOH#9_.*U7[ZK]"())F+=,\6J35I_UTZ-![>YV
M=MA)\.JD%) ES>BCA&4G#K.N-IQNUY\'3)I B$FM^5DX+&TPY^XOGLY.!N^5
MFV&\<(N*'=?B9&ID<'].5Z7^:^](_# 6R'-O%#XZ2Q6^VQ04NHS\6:0T31B3
M]2Z1RYD2XWF28BHDPX6A]R\0IX#V_#=_F)343-DTE(_;,XIZ.#P4LI':04I2
M,]_;G7 :W^#I1VZ!_EX"J86*%VZ9&8#4I!:^Q'P!_3)+EFM5DN;"8-7B*<U#
M _Z8+PF<6GT,?9(/49X%963)6&!\-D)IUA5(=](+T%GW":V1P)XPX\_6Q]5@
M,07#[R<EH\@%I! .^7(6#$E7:Q"</^I^_%LCS<@K#)1)"JH^1N&Y("_!2Y,%
MPPH"(\<J'/!)%PUPIC#84?JIBR)QA>+!+*("FOD6;E5\Q-_KVFK>6)2JX)@]
MBC") HR*P[O GC2P?C41AK9A0!+]$:< @'_=<:+^@IDDZ'NC4>8%F_YRR8X8
M@,_U)/!80X4?@K?44U%4!T4;( _B: .,#TR UPT]=ASC-^.XH4_Z#M<<'EXW
M;[H4"&+X;AH<E @D($1O JPX"\2N=7=TQLZ''*B"A@CAT#IIL]M(&N%P(OS?
M$8SGBUT9O+)D!C7[$_A061R@T+H=R/P.UY0A<IT@0+WG!*B%/@2Y\T>+23/N
M9T5^S5AK3^P8.%\A2T)'DB5# CLLQ86!IU(P9HVE@D4[)B=Z(M+F5C1Q)$@*
MY'H<T_X.-_X_Z??U1.L"VT$DZ@--Q/US*!5X ;OH9*4$_,LWHB&,)4.0@;8L
MJN=C@T\F#+=@BO&$6@JRP$H,ML"P<VJ;8*C;#-D%2+F,K9,5[).%X50K[ R_
M3P1/WXXZNV^!@+= PB?"<#A2,<@>\5B 4)CI(N  E..#%B7\G/<)\$_NW\!P
ML=H!)V)9+-:B29A7 O\.!(LJ[NHI\\,M_ 0T+.74Q(TP71(&&))2NUL5:YT6
M-Z5M0]+YBONM"ZM) B^,-O(9O\E8 -8W$Q>BPX9C9'"^A 9BP@MCRWO@M^!V
M89C>$H81Y+ /ZRZ[$TT#/P/YA8@"T1D45(C08K[L)4^P.=6B43.Y (3> (I"
M?!$XY>\BUR0D2$@&_@8F'TV%>ME+8[BT %C\0+YZWE@RW^BSF+U.$>!"\]RB
MCF@S9$/2#N#KJ2B=O5W4S[G^*IHG8U:<JS687MP:S+S,>_*KVAH=OS6U;]@:
M7,[8&LR_S _DX[DL?W#G;6:[6H.O*I\]^K)R<*U7UDS=T3W#J[%;@+GL WB&
MCJI;=)<2BVY3%,9%HR,*L1E/V?*D ]8C"=KL%NBWT+)E:R7V0JPZY=[!^;'\
M9_YQW>9M)7[EST?;L<Q8+9ZLJ)6Q"T CUN15[WR^,&.Y5B8I)BR%X:O7]'H<
M/@,+55C!>:$CR4 :M"^B(D04MK.,QB_O6!Q.-*O88"8*P$\3X8 G.W99LO,[
M[F@F2RAJTE-&N2"@+=S&P7KM@F6CN9A/#_:LGYH%,GJQ?MG::0AX6O7) 'R
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MD%IV* 3]:[]TZGNFI!,C48#8HCUBHD,-!3?8%R3-_ !X.OQ-3S#0 NQ6DY^
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M<=C9T6[DM-W,YYV=S8<Z9M$)+C&M\V*$2RBYDE+.*>5JIMA# D4B1 48#6&
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M_X[\.= /E\.81SM1&7\UJZ\;G^'! 3H7BHV[X8_'/\/';N&A\:TU1\LET6,
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M3/;MM,9=S%SOFI:%6T4?..!:5=;5 7%2+D"D2("H%C)SYBS7=1,?HUH!YGB
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M@6Q9B58D(AEU_M?\S D4< L=@E*D)9D\J\6@TF7FF@OO9D9*X-"% T%7-25
M!.C@N( <:*1H#HAL\O\&&>:O@4_&''-K+VMXBCV;@&0:$"&%)ZG)&? 98C''
M\%V;-'[$LFT)BR[ZH/P56.9=@<B2?<.B$ 4T.,)G:?0LSK$I[05QTR/G -J1
M7<.-&?&['>>1OYJ;\4&2E Q<T$]<?:+:IF;&K__ V!/SW8)B"DHGFCU!E63
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M843=[M$HDED5/@O-D<GEP(.X^R+%G]ETG'N/=Q5"7=]+]'C&9X3VD]A7)#"
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MI1DS<X@Y?8!'4_83Y2.KG$;[Y!0&L;75 90.LI+#%JM"P(TE59(F!APWUCR
MJF)):%+S9*(>!A(U<CRQX4$L59=J:;BV%M(/4)1A/@AMX!B;YKPU+.F(N!^2
M@B=FLD3;E/DF>>+;'\ !"@=Q[]>H3*!CTB@+ UNT]4Q7U09R:/2FZ@718P-_
M593]%R;86F;79$F%6!;D]UT[F<_-Q]'@CAD(&'324(]!E2%KF-@B5,#%R$
M;1#HB7'BJ-!D(YD([Q9XVH=-FUK0^Y#_F=9IM+B5KV[E%=\1NQ@:GJ;V8$]
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M1D$6)I=55N^&.S]+/ZP?Y8(R5%]?665USK+*^MWP9^W[Z6'[MEMV?C^CLDK
M;J-YTM.==D?]J3XQ=F?76ZZXM[>2KR9]@SM<!(.@;)HV<=?);;W%)(/I'G W
M/"KF=^X')VJKHRT=_$*;[T)FF^_\W?"\=++[V,H;9Z?%=Y\;N]^OCRZ/L+'W
M<OMZ9R\Q./C5O69F'V,TO[A02TEX2GJRF)M./N=JO]@[1G!<Q2Q<6I".T^\(
M.?YE*6T6(,V[SZ//X4<1>BS9 (C]/5/>[3=Q@*=OR<>^OIUC!@/I[EHPK)+F
M>4E!0QQ#MM1',D7W[;:E\AR]6Q5'\KR?=:7A$I(+I)@[N;?A^/+_!$8!S4
MO9-[NFD9T3:H0RD:/NPR.?![S@7$2P.=2%YB833_(#Q=*7ZZ$WW(N=!%V PN
M!5P$INLF=M*W5=OL\@&#H@]B]&CQD9(CU'K'NF\*P[-&'!*Q!YL\I2.X*'+F
M[3+]G:&HZ"!-7\^V%&NS'<S $<]@UV*3;\5(1]S52+9.MZORV3,,%WA[W1B@
M GCR:;'"  2)^#K.G/"CEDU9=":_!Q*V(K-$6*P0$HN0(&$#X^7"=;EH@5+3
MT$ RP-6/< K68(LU L890*9.<Z3BAQ(/\C1QT,<#G\,DPB#FBC:Y&:B2TSXX
M&5OU-#*K4+:C+QWM])9)@^F0?BS@<.&XJ:ZJ=0#K90OL/YL\H, $T.MOJFW;
M 1ZH><%(E4?NFP(VT<7UTUA@+\JG$Y:YB8KZ$Z_EG-./%*029R D6<8!:@CD
MDJS^X!% C!0'5,SC,V+38LX/1]BF1#04]J9FN<W$]C)>+[]'ESE*"4X=$252
M5VY.(6PH:B9))6[RPOEP)O9BYQ/;$)\8QI&7GJV+L ]=I;[%+$>>JR>_-S]D
M0LSKA_>'#C*@'<Q 4(4$6KR9<H^Y-PQIIIK/U8JEG%(K"@PQ<&BPR$9/=>4'
M-(SD_^2W\_F\$G5=SXWXL@(&*+#4B $&(XMZ\!X*Y>"ME6JN ,P\7ZM+&2PY
MX\RS#K!KVGU,5_\ =EP7V(@9^F9&F;UK// IMZ&M+H6.*)0"JN>9+&02.E@%
M/DAK>M^<\TVQ8"JB7#@%S6F))03QJ!V&+T<C?#D*Z>BCH5=$>UQET_ ?,<PI
M!+82T;P/:2),V@58  ]F^D,T']D"$)=S%26?4V*!L=BFPY,.9G@E<'0?>#&<
M*"<2^7U07@!2P7G\P,4/WHMZ#T%$[8,1"$O1N$_;X_(RS46,S V>VH ?R/UM
M8@#LG)PL+D.G'% 5D%4+R-AY#.>,32(M*8.TQB@5(F#CFX[Q$]]I&R3FH_ N
M7TSL%(C52,'C G:2?E#,_1RAG,@!^SV>1Q&V=:=IFR)<N6\\#;S1I%+)8R4?
M".WW0J0RB!X!QP-]$E66#ZS<"UM-)H94C))QFCH53?V[#%\93=;>5Z=F@_CP
M=,AAWDD80L#+Z.O@GBB28/<#!W.2V4NAN!&01Z8)YY$4FN9!&8R/YJR2R-!
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MK960K2E*9;6"HOR/?.::;1/'&1]AZ8:\9WK4=A]'4M.A8__B1-#[I<N5-1S
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M1[/\-'C&.XD,1'D[IM'A1*D[1=/VF3>W-$)93>_ -XI8)D6DSPMZ LZ-F0W
MOK%T=";./>I/S8FV;8$G&4RDI&,3,-NR@:) #.ZJ/=,'R_D H$OQOTV2<?-"
M:DV.4@;VI1?0OE%N@G+3\\<V Q\SFPN*FQ"G;<E9T[9>$1%/!;0UR=\W(EZQ
M6SU)S>D)/D^ F#AHK:3\_^U=67.C6+)^[U_AF!MWHOMJIA"K('IZ(M"" (%
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M1L1&SB"3E[DQ]7U4UYW5"''-I>NN7')/>I%F[Z? 9F@.G5!::LN\3GP_R$:
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MIJ,6A"1T63?6D%9Z]1Q*<0VMFRF6_7%[$@.,V&H._[IY&/SW_P%02P,$%
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M(MACRS(W,U$KBH#2F+!',A@POE?(:>&CF:R"+P1 ?#8*VV0/!DXZPOGD".3
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MQGZV:'(!>*\/899L. 7@O0#@Y5T0MDZDP->&U?':L,UFO4"] F:6;#@%ZKT
MZN7=4[9.I&#<7@;:;5&.JH"9)1M.@7HO@7J_KS?J79RJ<@7UO46*%:S8+'>W
M"L!;O>$4@/<"@)=W/>0ZD0) 72'9O79D6;+A%$#W D#WOVN>L_N_;=)F:Z3/
M-HK,W5>/,DLVG +T7@#TKM8<]'8:]6U,NBB**[]Z?%FRX11P]Q)PEW,W\#J1
M@BXVVJSO= O$>^T0LV3#*1#O!1#OZYH+>!8#WL[.(F!0X-U: LR2#:? NQ?
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M>\^=57_1.F_]G?S2G?7)-C?6K]DXOVK'JL\P]-E%<YBASSQ^ E!+ P04
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M!E6_VUBOAX.V>$MDA>H<_BB[D/:@-BA@7UT$00K,)=25XB%!YLF.NZ@-'H$
MSP*9*FWFV;Z] ;EQ+--4B*_D'IY"/4'M@8225L@.L(DH;RB5P#?M=.2LDE<'
M7S*)A=""PBSQ[<'![MM>X_8 :_,A>,-;B:T(=2V$2P"5-L1I?]V7 K 29K&)
M/C\QFPI^0PFRJW-M=FQK=7N,79R-/0NQ^9Z;.YY8$MUX@($&%[DV-L(]BNZ\
MPL<X0!0U>-5EZ086,%D<<XVEVQ7E2?C2\\37$_U^@%FVU;3_CFV^%G+L4",&
M5H%#8<,WD)RH/.TM<%]U*:I,)BJ:",I3$WZ=_Z1%YV%?Q.-(S01:IR/E CV_
M0RU@@6=G\D7V_8 VWBWWH3W[:[R3U?R.4B:!H+$'_R53O?V.<.W)00?N=L0N
MD5MY<*C]>I4UZHWWKX&3[AU"'OZRF<//]YN:^+"^YHDW&B9.9T=?-<*]EQN\
M^R\WK$Z3/;-7^O'UJT#&>JCBS0A0K3V2(F3=6^%GM'/-+EVYO5F+K'W5.WUW
M8(9TX,'2=S>Y]M4D'P]>V'CNJUP'ZWR3ZWO>U/J_C%&8@5Z:HY?EW-MS])+=
M/U!+ P04    "  @A$I9:7:B=!<(  !7-@  $    &4U.3@V7V5X,S$M,BYH
M=&WM6U%3XS80?N],_X.:F79@QCE"N.L#Y)@)(?0RI203TD[O4;'E1,6V<I*=
M7/KK^ZUD)PXD=S 7CD#A ; EK5;K_;[=E>S&A\$?EZ<__M#XT&Z>XR^CG\:@
M,[ALGS8.W%^T'N3-C;/N^4=V/?AXV7Y?"562'K/#VB1E QD+PZ[$C/55S!//
MW?#8M= RK& @AO:*<3'7(YD<LUH%4_1<XT_5*KN0(@J.63^+1+7'1X)5JZ>-
M\\Y?J^.JJ9I@UOHD/6'YG:%*4Q4?LR.Z-Y-!.B:U:C]75H:3NE4C_Q5HI(Y#
MI0.AG;BSB/LW##*949$,%HV%9-=^6+173G])AF9RTCB _-/\=VD)!RMKV+CZ
M0DCO5I?[&K8PP*HI7XZ8$Y:*SVF51W*$2RU'XQ22ST[;G\=R*%-V=/BFWC@X
M>\3)MOB$5N7[(DF%MJMIM?N#SD6GU1QTNE>L>\%Z_<Y5J]-K7K*+SE43_^*_
M[@5ZM/N-LSXTZ?W9O_ZS>35@@RZ[;K?LN*-:G<8./K39=;-_UKQJ7U>[?U^V
M/[)F:T M]5KML8RU6,Q%%TJ5X1;R6$;SXZ_)+4,3:BSM3@*WYI);TPX/K>/]
M^,.UC%7"!ER;L0<;Z%2&<Y:..51SAMZJ]KMFA/6/:- \NVRS5OOR\KK7;'6N
M?GM?J57L=:]Y?EY</W@%)5)?<+.OHHA/#!0J_JO8 -88](L)IO10?!X5C@JN
MK^1!KC$XWZ(Q#M^PA24&Y\LI6*M+AKAZ7ZDO5EU&SC^9(:_9YG/IL#&?"J;%
M5(J9")PJZ5@:UDR2C$>L+R9*IPRN>Z%TC%'5WYD*<3M14ZX5ZR3^FY.5Y>!7
M_\E,>\O/-EGW46=\4@/4=\>WSK@1 7E./'=JW"1J%HE@)#SG8MKY5J @-E$I
MD)FD7":,)W.6):G.!#,I3T6,B$%.Q\%-"!T2;AER'[<T4S$B>ZI<OSL=$N$+
M8[B>4Y>8WXC"OTN"#1H":(1Y(PKC-!%U\*7VLQC=$LB .B 1-AM+?\Q,1K^6
MXV="BUP(K2*6)A(\D,D(1)2.L4HS$;[5DN1.H)_*@>8K^ 5L-)R7#?(*I]V!
MT]%S@9-@H4S@J^3[2]_T@"6,0;,NM<LD!)?S5$*83/PH"R 8_E_R00\ DCJ:
MLPG<E^!'L(RB);YRKS9+1"WE \>!).D>=<LB8 2@4O!\.Z>Q2OG<C%D8J9DI
M$*?%2)I4<\S&Z:93'JIZ)>"80J,[*I_D#V=77.=_CYVWNX.=P8I[_:+-ITR=
MY+[KT)%GY,3:*@PE+O?,OG7 #N-:6'^'Z\IA),@EF0#(AI$T8QI!W6)$+HI>
M=!U(XT?*9!A',4VKR/G\1"M?!+AMV!Y</!# 3)%TP9G;G_TQ3T:"-1$N:%/
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M+N[1J2O:+3-[S-$,2V>_NP<D8N&F^RW!^Y, <3QFNA981D4]0BYDNU9_8L/
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M87H)8[:L*Z67WLYURKR<^Y[+M]>\63L,C;Y4U9>I^>VJOH3]!U!+ P04
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M74>;?<#:MZOP&F^J1QH[6D$+\52_:VSNX1LI5_5P#OAI@'2+^A[UECHG9RN
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MN;!,O*YE_\1Z @/-X[GP1@7PT.U-%+P.GUS<DW"2'MT-967.1J+GQB=L.YC
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M"D/N Y@NV?H'@N##3:>EI59OJ8>=+4Y/0IIT6:,8#XB>C< ^BQD?&[EYIO<
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MA]&$% SM.\VSA/K3D8+LE,,-3!)G9_(D1S[)@[KX&NO!MNF,V,^:4/XNB]C
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M[,<8 *D0:AR/H&NUF/O=2NZ;%8RM!,7!$ZGC8+%_,.C V'7$)T[E_5..>5+
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M"Y H$ W'F5&IFGJ,[G)\IRXH.]ZM.Y-B]6.%YD-G>9&%/=^%-)KXX7$N6;C
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MNBF9=!5P\?NXK=P$]#LPRRL_+G_Y']ZPD *YZ]O0)($&ZX@N<@!\U?Z#C1*
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MZS&)3]XG!];^W5<FC*%Z =VU:U$MX4+"H88P#G/<PB@PI://JC/\[YJRE??
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MPRN@!7@QPJJ*.*0BC!_,#%?QZ4EWNQ4@UCD 0'?J2%Q-<,80.@4;J*$S.Y?
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MQK:'CQ/ZVKJ.AC]V\DYAR)'-"QF6R.OR<?BN:0OC!?&Z?6F/PXN<2+I^2O$
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MBPJ>, 5XU@&&5DSY" 1:2)A5<UX#7N;@0\X4O]4FS?(C2WM8<DCNIZ7!NV>
M*"4DB>#RCG^V_]'*:&"JR-58 WDKMI N,QPAP!H/R35T$4 Z8(.C)@R\D^2+
M FQ# )U30^_>,D@:?<T'TU7=^D-L9[8"YBCQA=#[_]@W^0\E@?36?'.G 9_K
M6>#Q%:F?^,?[5]VBYN.Z \YKC 1OI]ZU46IDPEWR<C7$)X0%.O]G_+D!8!*.
M"V[J)2UH<!VP)JI<BD8IVV=2FO-:I%&L9;"8D5K44,@_WER[J+DR#8OO*P(8
M' H#\G0AG_/;L-YSO3[ZV/'J)$\FBK"];I>BM]LM5#N6")*9O=;"J$"#&6Z4
MTXPC$^7W@8X"[V;X%1=[UZ1A1_:U-:'PM;RVZ57FGZHZ-N=YIYUN_KH(YVF]
M#J-K23ZQ5V2.RTW;1LJ9KQ,<_#+19N')H3.QU(+>G,;*(NLE\N/V[I?ZCG,C
MR]L"A0X;XP['V[WO6:<J028[89GWHQOKGT7'Q8E6>SF(G)U\E7?$V7!=RO;<
MUH*FV!V.D5T,2;EL[FYV>W\FRM$3DN0M7M2;AX)>1^_.1+B_P@PQ_2ACPPWL
M(?E8(3.B^1R+KF+P2FW>XN8M10%)@1%SP\\[2W=+:*@G5C@>H60T(E@M[5')
MV:WIN;?2D41 8'*SQ3Q,ENOD'C2ES R,Y<CS-Q0Y38#%#X#//E%Y9J2A%DNY
MJ;=.Y (*ISD<!7GDQ)V]WA1>.;.K 'F%1+S:_VO864HZ4"=KCI.NLCT4Z%/X
M"_9W_C-PRMSNF: ^&=46I,+@GKK,J^%JR /M['F B9LGSRD=]HV(Z*M5CGAO
M.[7.*# _TN/Y\U&S_,J[9]PFY>\=J:9-;2HA&G_\ 5D%GW[K;C+5C<(\KM/M
M5W(@!M>4_G:.OH9VMJW*<T%7?RGRQW1\6*GE1]<>+'>RELITI"C/WHHJS$?I
M,VX.Z1,1 \*<NK)CE!,C[B'\X@YW:M1@@SYEQ%,U[4^1%P\VRAU<6(;!4UE;
MR<5U<6KH7I!FI&5L. 419RB=W!3DC[&'R2L<@[)&,]RYPLIWH0)6+;K;MFBY
M9\[3'4]YP?BJ"!J#)!][I#CU@608";]8:UC?:2X6"8O'?<J1S,.U>XN%$Z*F
MKD>WQ;W<M$\I#J-FP:"SK (02H0&' :9JXP,:T30VQ_A9A.Z!ZD>AQ&GB286
M&Q;!T4D#0$MLA/1='80D "5,D/4M[ZFAOEQ:I1K"EE[4E<&R:&. @1IMHP"M
M4.4GK].E<(T:*C^"C'+%%@#UI(X[EU#J#5 ^NL,*/T9"FR=A?B@V"GR@L1$P
MJ1]^+$ &E8;H&/MR'*DO!0%L9L $::Q R^#Q9*K7&RZ;.N#DX>#%M[+C]0
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M#]"VUYL$OP\P_KSE9H65#N1]/NC)#9^U5Z=5'M$Z&9Q[4'M6YP(8)W$T2T"
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M3$G?-^/^.J@41(#[I3L^_-X_[I*]C:7-:7WK;E #97N41+F#!ZE#];KI.N*
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MWMIOM03MGR]6DA2,V4OK<PODGI@ )\I'@'+I#^+W4;![OR$J1X@0GB[W'V;
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MA<$_+[-&RJ(LC2(3[-%^-Q$"Z6=P7U4^P<_$L@+4)E,[\?(3PJ_RRZMG;9'
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M+2F($M=#1Z7N+L*=3;$1%$^V^VQ&I]?@3*JGX1DM#G_"(';BC#=@"K+.EA3
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MG'"FVH>D=A4[BFZ  O]<N'1F.,TG"9KN]2A8O+[IM?I?;\&A4G#SYA."UI:
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M@=[DDLC./Y=J$/5U5OCWP>#04(?;,_D.@4]50=2F6<GAE@K%1,7K(T,GE:B
M0'>@II0(QHSC,^LIJXF'A'WQZDFAG NV:'M:WY)+.9::/M'EF&[@=&M79Q!4
M41]!Y!I=%W.K<\ \LOJ@'V,7-0ZR2N2>QU./BVR*2ZTT#ANZ;]K76%RWP/K
M'KIQ9)WE1CEVD]M@H)<N/ 1W#'A_$:@M[OCF._T&1<;$21D)&)6Q+ZD.]>.'
M)7%4@IKTD&V5T.EID=_.K=F5Y:.!?^HFSM#X7(.S6=X#]''""-3[6@J(W<#N
MT.!+&XY3/1TI_*"0M,F[U@/$LJGL427*$8'#$NXDK%5JJ:](M[".;"B=<9MX
MX!I@/YMQ;<9\ U1<E*U$A0K-F!D2F]J'"PLG YY9_E$C_/9QR=DDW])/@^WZ
MLM(_.+N/8"2=!B<^O^]M7/T:7+7<CDYTT[L7XO9*)^9 2+5_X)X@)8J>Z+!(
M[+T;@>631GFJNHM^\.,QQ!+,F(LP,+S9'BV7]_Q3AGQ\M_W"!2#Z#JR&C;MQ
M>#U>*DY1M4G\MW]L VZM@H(==Q0X*Y+KT"O?U+[!<BN9_\*U&/C4W+?D,X'W
M8)CU=W=J')$.(*[ST9\O![AYJI?Z5KMW8YO)HE6]$0"3^KF<&#WD%^W;H409
M5P'J$ +.Y#GHS^^"I>IOEQ0:\+'HRT!W.7YES9>*W'Z!@MN$@U2U.ZH*H69
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MZ=RR[:13=X!6=7.J+HN RQ8[MZ^#?B5> U:KYCB,:'0!(]J<&LAV?L(E:VI
M]:J"D#51L7OG)=T+!RSY4))(C@3')]USPQ0U^!-WN\7U;VJF+36[PEQR<PR<
M8F)^P@=5\S^1YX"4RTH45_,,$*)^;\,(U!1%/)IKF1(8FDF4<"]G7+%O((C
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M]E-PK71F#*,C31G%_Z[71\25<Z7Q+@V$S,!Z-R<9>%-;BN6X]65O/=U6M^L
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MT'VD&MY,<PHKZ%AHGGG5_2BJ:#>ML.;KGJH9CSU<C3_DSS[5*5$K?K-8)@>
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M2GJS]CU7D L;([>^5EFA)W(K3FH':BM1TY<$SA XH-(N(W/1SCT$<5+C)5@
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MJG6KS!@MR".I'.REZCE>*OLAO+?BJ")"203EGZC0^MG^^8IO+-40:7]E(Q:
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MY?4(8N+==W6?T@.0:-P"-?ZU'K ;ZSQG4&0ZEA-^R(A&KVGW#1$:NSS;IH5
MAFC$*P!LL $N>@>\.F6W>94HR.LH7K.(MZLWB=>*YPY6#%[:Q)75#B4;Z@&K
MAJ7(?^@O*[B'[*]>PQ_?"T^F.)5$O/'0K8_LZ(,TAK0)*&G_F(S#LMT/KN07
MLE+&_^#J : ]+2C-+J6[?-3<NV((E3"_OFV9I^&RSB)O@>%9TW=/,18:1^T7
M]_WIT1*WRK%/H&RTL>R89Z\01]#- ?PQ;_'*75S9ZNTT32,P0BOP80BIMJ#I
MVL%]QD$CY@T/#J4_B,CS]BO5?9KS$2PD=^:C1^1S+4&>&>"OIS] 4(KCM_4
MUW!^44!;X6#@;3G-T/@,8V,#)J]3W@E=_?*HXNG&07R\'H JSVRJ[\@Y_:.
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M>ML$SSHFHH4C*L2OGQ(&BR/6UYCK9/PG3./_@R#=R\7$JOO"FOPH]VH BHL
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MT?5XV-'F<QIX4ZAN=7WP>30>MT@)D1J#P4I\@_BW1/^_8_M_#+:JG;=+^GF
M'F*K%/Z2Z./W;!\/AM>MS2FS.? 3+8SG1)VS#ZK[NW=9M"E]_6[866B_M)I=
MTN^B5$#MF#]$H<NBD WL_^>_W_6ZW__0AO?5X?UF@_W0"X69%8(#&LTA9Q\&
MEA%(H-1C48*1<C=:1%$\G7DAFJ 1W7#2AG.E0,V037,K4P/<U(5G.,0P,ZEN
M8:D$1(5X?#8<A_F6J48]V<5,F\RU?IO4+L=',\%RD?"E$239!Q(H%()MK0^V
M:SZB_=YVNWA.02MJFV9HZWK4,L4S"OM4 H!"@#T?WH8YX]EPJL^HC6IA$,,0
M/!#T>P#2#A_WR8["4PD8"B'U_/YZ#M,X16+X<YOA.'ZZ]PAIWQKIWUXA(C\@
M_=OY+GESNUY>,QVY,!YL5):4C DD$"W$^(+49.>[J,T6JWHYRBQ4)>422!4R
M!?Q\90O408G++%[59-6P77$2#F5)S!8^V6QF%JG<$PE0"OF'*+/9=GZM!%Q^
MK+"/)6 H)!BRR;@6C"99N2PFPE(): J)!7&&K@6J5H8ABU#QL00T9=F&%HOZ
M:8?<D.&72:!2G8)HL7FA('B ? /;9&)X=&OP(SH@&"XT)8%\(>MQ4% <<]!)
M66C516Z?%%\+2BDDP"UD/'+[J%JX#D]FQ#U8DLU(*"3@DD]GQ(VV<#6#JUN-
M5U<&L$)6HPJP3K>%K!EDC&64(ZV&\'4APU$)86LL&V83<[:RC$ "MD(.1)1/
M;"WE(5@QHTZ*4@*]0NJD KUVS!V8&,X-/0DZ"0P+.9:JU' [$H^ 8%<60AG_
MY74A&2.)8>O&'(8B8U;K5)! M9#,D46UM;+2ZS<Y@YI_)(%0(>F2K."T-K)>
M_W<Y $A9OD)F)$:@-7'U06"LF:!, A3!D8W60-4^QL%'AELB@0OWF$>+2M.5
M9\89+SRO1N1-Z4&0=AIIA$=7!(C,A/*FD)#@(M+.*O4PZ8DPZ<E@4K%#(\&D
MUV)2!Y-"\"(FD,"(DT;@8=3.,8TVU.2F&G&Q!$Z%5 'O:S;MS',(2MT*F*3F
MH>).CC*<VOFH$5*]"J2D9J?B>9-2I-I9J@E25Q5(7<D@54@6E"-UU2+5 *G7
M%4B]ED&JD$$H1^IUBU0#I!@'4(). KE"CJ%LRV[K%1[GH#T?T#H5JI%]6\A5
ME![$;\&M!:[H^#T?66EJ"5@+"0_QX?T6TZ;;[7/Q&^>Y!$Z%)$ANPWT;KS6
MHRO"0R9">UO(>/  :0.S>I#T1)#(A&)ORP^EM!%8(TBN1)#(Q%QO"WD,+B1M
MJ%4+$L8=*".0@*B0P.!"U$[Y#4YUY?.V@D()B(J9B^*YKM8%: I/MQ0?*6>@
MF+ 0 M2Z!'6^ R3(551124!6S%2PWPGZTQL_^@^]?&R&EIWPTK(//I!].B.8
M7AMW%C];>VCYZ0S0?#A/KJ;Z)XC]ZGEC)R3T#267EH7(LST5OSAIPO#,0BN%
M2]6@D7!G.T;D(F$^:<#'/JT^S;RF0]\#UOGBB)+;QD-=R:$*LE]0Y#%M_R5D
M!06M*RNCTR\D<7__EI>0&T977;GS _*%Q!ZD+RE*_?$B?R4<_,U>&_<1!(>I
MK^,4KJ KNV<PNB%Q[)IA4R55Z%_G2;US^NB\VSN_ZKYZ)M:>TSI,[+NA'A-)
MO09,"&X[Y+V?B,CICU"99%\JN#6Q]*7<.A?(]DGRI#$+=)B0PWD(FZG%1/5]
MC")VJFJ&?Y-&2K"_1E)*"1)R^J.6\+E6PD\&>+LZ+\Y62?YHI@+[*SGET$_H
M(^3I+9U-7]M ]8HO%^I=?#]GE&(?3J[_.8L]U'[P@.[0YH'>A4D9I!EX3@FV
M;?IMC4]GOA=0TTRO:OT )AN[UB*<6:P@NC;NK!/--.F-HQ\L=V-@9^2C#:4$
MV<#!!:,>4.I;SPVVG\ZBYC"0E+$\A+G+W2%$].42F\@C ^PATW>]> V(!#;8
M7Y_DQ:E=2P51KVW#_#(WUS!S$GU+JT\];$+@=N=:R,X+*$FK@E@C.H,;]@R9
M[BJ:S/.BE)2KP#XXF^F94E">$<SW7G@3+*-R$G1*B(,(T4PSV 3ADINVH;F!
MZ'LNC#P2A"H(= ?.YGKB^H@:P+P(_"(5F/Z'X02&M^.S+2I4@?$!,D-V8N:N
M\IP+2U5@'0SD(VCR%"QG6-+-\RXN5I'Y7CGS/:69ORIG7BVUX6NZDAH.CLTC
M#:B!#\H?F1J[\-MH>=8KJ50018,_+9AU'&N&B!_>H8G,P$-6R')>($E:%<1:
MK!%'@,)3%5B=S:^QRP0)N4?*,*EMYQP^LT]58!5\*7BY-7S>(H<45%A0J +C
M8]=PM)6'PL>,C\@M4H'IB?L8LD-M-!U;K/46E*K ^M1S-Y@0-_( V:F26Z8"
MVW0)R_1P&(NF.L&H>06-NF)T9>10RV.,/91+KM]RJ12K-]BA*72!D1&6JL#Z
MO8.3^[W)PGC.<RXJ5('Q.;P.$2WC#$X]M$2>1QEVS2^,PLM2JR#:-("PWR B
M?1(7*\%\KE]'A 14^0D[#903J2#("%2%^*['F,[B8Q68I4<+7*>LRTLI5!!A
MCIV5C6:&LV)\!EZ!$@S3OBP,1GTI7J2H54,%$37K$5-G#<SG(RZHE+!4!=9U
M!WVFFX18Z\EYK@*[8^R8KNU,#8^9N7@%*C"<Z"Q$JM.UX6V,D6/RE^2X%"J(
M,+P>:8[U&6'/FIL8@44<C_O,.EPIB0I"I&8$^)S:AJ,O[Y"W0M[^^3-FQVVM
M*BH(.3"<@8?] 7(VA0$B*%.![60$</D6%:K >'3<%,8K/,6/-+/M]"Z[S#)/
M%9$2@B3KZ(+E=369[0JX5<OGO'8-S]*7V9T)H8WTZ3T:B6\0$3F,(]2LZK<E
M].+);2ITMJH*0L<;3L /YSN")>4JL!_.<6&NBPU#.04J,)R)U9)H(?99Q4&=
MD% %@>BZEH=-/P[XM2=0<L).AV4D:@@13=C\:5PI5H?/R#,Q071/510YLU-*
M"8&: O2J!%!KRT"1OZLJ =1:BT^<CG T<JUG*842(A2ZF/5@2PC4%.!-E0!O
ME!) /#_)SF-*B7.[0.8ZSWG^D0I,CD$5'.'B@;!4!=;O( X>[!X"9J]P\;$*
MS-X.![B8XBT\58%5^@_CM62?*,)BO\"B6IFV](--/HUWL(6\^-2<\8!M[._Z
M@>=!828HDB2O%"XZH^4G10^&39=O/IV9'K*PGX@<%8(=1;[A[8ZT I_LKLM\
MX0@C,D$^(ZTDK:JB]M=T\APYZ?5G^E* 7PIOG1HUU/?KRCUV"=&=X3/E.\!D
M':U'5:GN?OM4P]K*]L?(\9$'D6CT\67-L71_C;SHKWASVWXA6(9474GC16!]
MF5^,I\L=<0IAY+ [FU/9&U;^EGOCQO6B[2,$&M>7U.#%]JY&KY0VHFSOI+L&
MP*@''A727[B)2$D,8H56,+?4+5WE&Y=\OC8\>E=X'='3.K5=FXB"A/6/$60:
MGN,&?L1/Q'8.R9)R96'C\)S'J(S@U(!DF0)[D<PSNI/UL6#2A1D&FLZ/ND95
ME86QGCC,*&Q6]]3@[^>03$XD,X'<.^!/L3.KOH39!ERNG"X<I25E5>,@Z?*:
M<IRF3JTXF?63O.8G2W(S>LC(8XQ[[5K-%<)"#R^H#]*"Y+&O7^W4.&>\BT%
M-7 :OCO$)W$N]&6BNQR?1*Z6L@-?($F$3^T.**EV:J /,DLC9XY\WXZ?T?OI
MCC<WB-M65FF.+.\1YX^2QD^M@'N+2-D(;>*>4T&21^"-UF] 655J(M0A':*
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M'CZI0>\-DC4GAB0,-3TA@S-*)11%')IX:GSMX7-DMCG1+S3!K8HT5E=9$"P
ME.D\A\3IW2$.UKTH&!?)5 N"5%9-LB/4N!U'(NK 1^I>SL*ZH#%IDB+L^3QO
MMO7"L1?,!U'/>PHRC['C2B707;P05@N'99.T,T$=L1&8.UX2P<0CM7U_M5SE
MB6\?+ (_8&1?(K2ZZQO".A,7A$GJ*Z',*V9[EUH6Q^O0U9;PY<5=S+PULZ8K
M-Y'N:HCX8JPG(I.T7$K>T)TB$AD2GU)WWB'*&SV?_692<QG^>/?ZT=C\=%SE
M<@C_K>,, ?E.X[T#!6?B!PJL[_?F^T=[!R,X]QWO,73.8F@Z@W_<.B/(C'MM
MN6-G8L\&<(">LQ*[6L.F!9CQ\DX8JJE;+[_@/H3KR)XO@RA(L^(8SP87G0,N
MH6XO2-5&M:]/3 (F!:\)2 %$@HYX],$S"..\>X2K,@Z9;K<NJC A[DU2UV#Y
MY 5)<<'X(:W/<M/H?K4356<MZ9BDWBVV-T;*5]_3VY^KXW6_UPD[3":_)FFF
M#^!KB1]XQ<%D]+F6X@I!>XD.V18W"M+U)$:M^Z5-5&LRLC!)ASO^WMXK!=*J
M\F!C$A&< ]IF%:9+7"$=;1H9Q5&\SQ(W\V"0--I@] BC!QA$NYL5T2=)B&TV
MM!XCB0ETFQ57#7O=1M*2,<D'W'A!E*)U U(W<M8(]BI('XN<H?SQ D*PY9/J
MSGN%%2G.4N,JI"PXA +'P&MMHRR^NI/I3G2E%N)A$C-I4<)<'20@W;YXE:7
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M-8G-[/*%.:D9=)N@H%+*.44-":E/Z7B@V-4W86I3BFX-JDM=K:V)V]<*+B?
MCR,?IDPYXE&, OS*ST\/;P20W[=^5;T^OQ>G#+_2T/2FE/SDPDBCLOU&C:;6
MMY::FM^4&J4RLS'BLTT4[J2*E<57A:7G,:5>*1$K:DM+FR*%*YG"Y*84. ]7
MF\:Z)P51S7)H[=E,J9(>KDMSBJ<TGL2*JL+4IA1;)50G*1F3DB:\ME@M/VZ9
M@&%\Q;I93'XF4\JS<HE078F97ZME-:Q=$-IB2570MAK7\ ,[C/XUK F6^@GE
MMKHOJ?")]7+\- P7O_+B.94#8@T=/W'*YZ"KBX,S$@=8-ZP !V>Z.#@G<8#U
MR IP<*Z+ Z8OPIIG62?PVO9,C-L"!'B[Q'IMF;<'M,\>[48!$=ZP?3_Z#0/M
M,U8Z1$D/)9?89N#>*<IV@@>.E!0U+K&(38*J/$[@8$D!XI)].K6MD("#)<6"
M2RP>$\&J]OXX6.;BPT(P$71K^5OE*#!CR>&1%S\+W%+61@9-7'UXM*6B5I^K
M5>X$$3$7/,96[PBA&\WF70;]ACYL#'_R?U!+ P04    "  @A$I9H<9=1I]&
M  !VXP0 %0   ')E;F(M,C R-# V,S!?9&5F+GAM;.U]47/CN+'N^ZVZ_\%W
M3M6IY&%VQO9X/+/)WE.R+3LZQY842=Y-[HN*)B&968GPDI3'SJ^_ $E))(4&
M0 HD %MYV(QM .SNKP%T-QJ-O_[7RW)Q](S"R,?!+Q^.?_K\X0@%+O;\8/[+
MA_OQQ\[XLM?[<!3%3N Y"QR@7SX$^,-__=___;^.R/_^^G\^?CRZ]M'"^_GH
M"KL?>\$,_^6H[RS1ST<W*$"A$^/P+T>_.HL5_0V^]A<H/+K$RZ<%BA'Y0_KA
MGX_.?CKYXAQ]_"@Q[J\H\'!X/^IMQGV,XZ?HYT^??OSX\5. GYT?./P]^LG%
M2[D!Q[$3KZ+-:)]?/F?_2[O_=>$'O_],__/@1.B(R"N(?GZ)_%\^T.]FG_UQ
M^A,.YY]./G\^_O2/N]NQ^XB6SD<_H')ST8=U+SH*J]_Q]^_?/R5_73?=:?GR
M$"[6WSC]M"9G,S+YJQ=O.N0;GWU*_YAOZG.&SA$=^3]'"2>WV'7B1$.$%!V!
M+>A/']?-/M)??3P^^7AZ_--+Y'U8XY0(.\0+-$*S(_K_!.C-5T-$X0WQ@X\I
MO)_HWS]=8J*^A-BDYV.(9K]\(.T>R =.OGS^>OJ9#O\?A4;QZQ-1X\BG6OCA
MZ-,^GPXBO/ ])T;>A;.@4AL_(A1'8G($'9LG<>B0]O$CBGW76=2FESE*(\33
M68J6Y&/18#9XHBL+T<=*@N:/T#C1=-4+T2,*(O\9W>*H-NW@0,VR,)B-8^S^
M_H@7'EFUNW^L_/BU%@N\@9I'P8D>KQ?X1WWIEP=01O(@G#N!_^]$+3N!-UXM
MET[X2J3ESP-_1B98$'=<%Z^"F&S.0T*;ZR,A&WL-JHRU&TQ&)Q)U41B(*&:U
M54;(M>.'R3Y_AYQH%::@BBCB=E)&VC#$9%&*7PE*=$X\T:^(*./U4498+R#V
MP-Q_6*!.%)$UGWSL!F/OA[\0[AL27961>4O $<^'8BME'[]"#T*P\FT4@D/^
MB2;.BYAU1E-E9%3?&EK9 Y9+/TYF*U$\LJ30-8YX-Q++ID17962.T()N,L24
MBE\GH1-$CBMEVXCZ*2.PXQ)\(I\.+J*)T52=CJ$Y!62$GG!(X1!J&-!>'4&K
MAPC]L2+?Z#[+["-0>[T61*.61&,6!7-/GCADIZFWG1>[-KJIRU$I[MG&!B]'
MJ_0 BC=[.>I8;9O8?V5E!71H<"^6HTS4KXG]1(XRL$-C>XNDQ+B]]"[K5RAV
M_$74=T(:Z'A&C2SOT$<:<1RK<B33M]G]*/MJK0VIU+<50H_WH?2X55*EM:#2
M((WN^Y+:(-&U#3*E!5QEC#9,%DDQRX_0(M'""5AAB!;)EM:5&D,I-ADEM8/9
MN!E2A)BS6S=#C#22_%Y*XVI52>/U:<+NEUYPH!X-$B6QH(!=&B3KI#I9)RV0
M56$=$W9MT)V35#AAQ^9)%*J?N&?S1 J54=RS>2)/:Q-YVAZ17VH3^:4](J4G
MN?P(;9Q85*6^QE"-GVA4Y:'J.$U$J"076[A'@T0)EU=.EP;)$BZHG"X-DB5<
M0CE=&B1+>C9(=&TL'BIK<O"[-4V>V-P0]&OL:+#RWB/9OP[!259FA-R?YOCY
M$W*]+!3T_'3E1^X"TR#9;W[\V/&\1-><118Y*Z&_SKK=&8XR0O^1<)2&B.3'
M5LI0$H_?A^K" $I)ZWC_6D7I]CS!-*,/D=UM]X2]&KG"0=6Q0"2S6CCAK1_%
MT<5K]P6Y*ZJ7EV2_GN/PM387DN,VPLC>>LX92ZGRJ)B0C1)8QHT8G8-@45\K
MQ$,V-3GW)1L82AVYO<#SGWUOY2SVHQ481PFAG1].Z$W(2'M1R!Q%X4(0.O36
M2X?LL,11VA_\PG@-*L U#N<X(!U<>L=A)Y&G L7@2.J(':SBY"H1$8P"@KFC
MJ2,Z4;SHDI@O:(+O@B>?&C/[J3$TFLIU(?(]%#*T^N*5S/4]U@GVN%%<&%<=
M(U=HYJP6Y>RZ"A27!^"1YH3NFCI6XS(%C'M.Z^M6](+36?+]1S)$Z*X>T$?/
MIX)*[+'L0SOLTU'\(/Y$FG[*VGQB#M \W9N/??3PTO$K$KW;NP6*DR]]7*+E
M [WM58G<8M?F:75H"GP5"I,.S=,5X+A3E;1UGU9U,IW5M95RW;U(,_FU'R2N
MZ2WYL4 W>HE1X*'-"D<'K' S,?9CVCZ[6GI\])'>0UW1!9G\,VO9*"VB&X<%
M^DX(49M;3Y3 07\\N.U==2;=JZ.+SFVG?]D]&O^MVYV,]9#-OGA8X.%4GH>C
M/Q7&^W-K/ GN)!;X^<+C9SPA_W?7[1->!M='@V%WU)GT2 ,MG, W% L,G<DS
M=#FX&XZZ?^OVQ[U?NT>W@[$&QKCW%@N,?95BC/(UG@PN_^=O@]NK[FC\G\X3
MCOYRU/W[?6_RS_6%Z#5["^P6>%K0&]DXY!A%,R=Z2!;!5?1Q[CA/F65$#*'U
M;[8F4O:+Z89H(D/4(__<(+=P'M B^>PT:\QJ^TDOU85P'8?BK%V9VJT*=<(U
MW=G.(;D]I]O5SRX.8J)TW47R-;+EI6'G-66S$"^%HLS$AKD<Y&5+"/EPA$.B
MF[]\./Z\I84Z&MXO'^)PQ6"Y98#224.7!^)GTI/)%U]&P]C=E,+'M+%%<!51
M *#B\<Q 3A=&)3*O,J,=P@9HKA2371="! A7UEB& 0B7D\\V S,]9I"O"INU
M);WOXK<O> F3$'ZGVO ;DF%0&%)#@E@/=YF#"<'':CU5#E[1V06 X<\0+$6V
M<<L<38O!@104.TT;F$7*@6 3#<*@#8?M"?#0\;U><.D\^3$]#N9CPNTV92W2
MAN$C9@#<@;1A-:+)!P'RNDX8^,$\$H'$;C]E+<&&H<.A'-Q8]$TAUUTM5TF&
MW"!^1&'!ZTXSE(7327:(Z1?SP:O&#(3G%VUXPM$%EFM4;CL]UX-0!=^52;)Q
M%L+XT0E1E#M:Y*!0;FH^"$R*P2VG)@:,3-YN_V+:BZ(5C> .9D5SL1-XO]'$
M-F+S]X)AZ#\39H8+QT5YOR$G?3I8K;',A6<_EL"]J77\KC%9=H.LGNA@UL>$
M5.<5",M),@V/:3V> M; /4HMK@E5E%KD#5<A)3J>X#6)W1<4NGZ$O.02-8!B
MA1',QJPJ(Q!"9SH02A?WO2!*AW@+&.4X@4#ZJA8DZC3@59Q^.*6/-V>@YF8+
MGTLU).CSQ@7-57VPO76BEE#J;XI7GMS7R6[5"V)$?HX' =VKHFRSZM(#5KJ%
M<?>(ZB.9C4]=AB#DONM$CK]WU!CJ+6$G,>U8H6$UMG8NHINS'.\#\MFR,S"8
M$3.3.'6\:;C_P&8CJX@_Y1'S)G#F3EH%([]AI&6FM.+PQX@L,*'OQNMM?+/Z
MC%'X[+LH&M$LI9!O-58;Q&P :_ "8J4XU"%-&G<*5ASEC: E,[6:BV!<K>CT
M'I))CE.]67N$@]EZ81![R!*#F U6#5Y K)J+9>1)2[5F7["@4:Q$B\L,")?B
MJ,9>NVPO&*,X7F2_HX6Y&C--@4^9#7QC'(/:H3@4HYB!Y@Q:Z%OO2C]D=N;&
MXD?4HTZLA2U-FZI$,4VXI]<*D_L/<E&DBN.9#?1^;(%@-A92DJ=2(8YO#T+^
MZ7L;(:7M"4JNO-!@=H,\_W+U4&FG%@QE-GJU.0+1:R-0)""P^G8J->#;0U)B
M8SQ1' TJY@2D60#$MT[J]NPW.16,;#;"JA@$H58<3%) +W<F*QO_S<,N,\_K
MAJ;4Y'\",9LDH560#LKK:BZRE3@ 0:L;HVH4M'QJ5Z:NM/3]&+FD9>PSY[.$
M.(3#6@VV''>@(M2-?C6E".F*HUX3),>U516JL ?J0MU85Z.+0NX8)0GFT&I0
M-V&N1D*UQ0 <SE;D);@" :\;NVIV\JM#7#">K9#+L 5B7C?$I>:>R(43(8]5
M:16X+++3WGS,8+(A3/3=M>ZC.+WH=<N=7H5FQB.P2RTH>&V7IJYQB/QY<+DB
M_EG@YHOUWQ!14,(OT(RTF3@O,"P5!C$>M*J\@)":< =+,HY8>41S453!& BI
M2=>R]H56-++U$$LQ"$*="R;]]5.)=T+9[QIJLSG1X_4"_P!JLIU7J,G6&?_M
MZ/IV\%NSM=AJ/4Q;8N[[][.OQ[0>X/89 O+#8'33Z??^7U(H[ZC3)_S=W]UU
M1O],"K/U;OJ]Z]YEIS\YZEQ>#N[[DU[_YFA(9''9ZS;+<?[A6A8C7\J,W PH
M;02JR^ZHWRAIS-=4632>E6F\[O1&1[]V;N^[1W?=SOA^E"I2H]2RGB9E$?NU
M3.QP1"LH3OZ9: 4MR#>DQ#9**^=I3!;)YV62>_U)IW_3N[CM'G7&8UK3DM)^
M,QA<_=:[O6V4]/0M2!:5W\I4WA+H&YX]--&%1<OW,BU7W8NF(=V\$L@@Z.3S
M+H27@[ONT:3SCX9%)*QCF=!W7*:O4*SR/[Z=')]OJE4V6XP3?,F,1?9)F6PB
MU+O>)-VVZ)P@ZR1=R[O]QA=RZ/TR%MD[N].H>YMLNL,.78@FHTY_W+ELOJ9K
M[MR,1>;.WM.Y)!HP[E'"FM79TM--+.)V-IUQ]R:IM#KJ#@<C"GJS))8>;6*1
MN+/5C.\OQF0242J[OS:^(]8RICA&U<G./K2'477TI_67FBW S#1BDEJ>3!9W
M-C' E#GZ4SI&L\2S;!J8]IU-CVW9M$,ZQ\0!.3AE[)(\0Z<=3E*+!R9Z9^M,
M[9ZVQ+PQ.V *=W;)O/'1#IV[5@A,[L[N"-LB[1"?VR9AJGF;94LR+NV:,*WB
MO;,=BFOM4.#SB#D&=W;>O7:J[(M'FT_^64_%]N34;.7&R7':)8YB(C/R.Q0^
MHUMQ#7>YWIK.U]Q'Y*T6:# K4)E0F)C5E-Y(5/*]RB#&U(.O FKYN*ZZU(PO
M'W^QB@C7491;<_F%X\$.^DK&UX %R_$$@F@27/2?(4*BXN427?54F!=)7XP5
M4P(FU9EO$C:3Z\\KAK:9*O1@F8+4@J*YS6"MW_3R?KFAKF+F\G,#"\D'ESY]
M-9G7;Y3R-ZA2,XNW)2;#ZBK)-I2E57P.<]MFZ+S2WR5,;3D+O.'""?K.4K@0
M-O,U/5L>&UF9Y# UTC5I;[1?BTS>@75IFJ$/Q@R>*&NBTOWY5M,S34DV34Y_
MS&<7PNU,XS,9A03F>R+\:#2^%[^6P>DV_?KFD17S#T']52W441CG8"8_;2$F
M/TPG-)8XF/4"SW_VO96S $P\TA9H:J.9!W,#+IQ:0?G-CQ\3IN@Y^Z/_-,'=
M(/;C5W#/93$H&J1E@TR( 0<K.7DT;FL9"*.1%E%S4+<:E^@NGQ;X%:%H,)OY
M+@JC*^+?NZ1WEL$3$>'0Y%INS*+:(*W;0'O,-KP7DZ#EH_BJ0#<B<OBQOIQ%
M&6 _AI.PP6I+5$Z/]5+G_$3 !21TQ1.'$1T;DFV>K!7.'*KWP>UC'082W*@^
M\8#N503#$+N$%$HV^<XCX> */:,%+B02E^],\'M9AX<4/\:%_<JIT[MNU[J%
M58 P:6_'$*\2!*?97;WED^.'5$4NR7HZYY4X8+>W$1@>)Q!,VNK-L"=T]X6Z
M^YR4"FXW&T&38 @TN71AERMYE%3'J?!HH;"KC1A*,@5&DK0ME<0]\/S%BF:0
M;<N:=%_<Q<I#WC61$(V_K6(GK6.U?I=VF''86=)$.,[*JF)X&_5!(>.0SNBK
M+J.F\(2%J/(X@6#*U81I^09N_AJG3(+JSE6*PK5.9LIIZ[<D,AI8Y,M?D\@&
MT90QN^%K<PGAUG<>_$6R0F2\>H-@1%>-+$K>QT&X_I&HGQ_1_HGN39#[&/A_
MK%"TH[N,^A:-?UE3\8]F^!*D]C;[56-R@=M2UW+]DA8P-3[Q.+?R]0)B+8@3
MN^ >V@[_6D$22TI!=>BN$8A%^3F\/GIRM80"%^-C;O*56HB,//93#6.KAWT7
M"\?]?>P^$EE$:9K.,/1=LG3<80\MN$=\,EVG>MP4B3F"JS/2VM$%$8ZS(&LZ
MGJ=RXL( -=>5?51-]ESJP8A/J[E#(YHV!><+Y?[\+LR$(LOM'![)( 1.DC7!
MZP;M)P#MR@NS26MI_U8H3B-W9'F1MYE%+)#Z'1'9<K7DR;W0I/4[0("R8@YY
MX([9Z@)^Y[P()9MO,F5--[V2W2$/7"FT.6-)?)<:3KP;W9LVTV/6[&K!/-$4
MDBES#N%G[BT9*&<\+]#5,C&?-\^>RJA#(]]\E^K5H"2-"_TH9O@)T3L,OV*:
M_4FP>ATY<7MZR_KX08$;$FD[#HLN31[YT>_7(4(]8BF'*(I;U&/6IP]:W(A
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MH%:41R7HIB=53D;R4EB9FPC7!%PF)[DIAM30%+8;%*#06= ;/=Z2B#V*4T.
MOH\=1'!IGG5BBTQW7==2Y:88KLD0A.57;0LJS0A#:/"4U!4,YK=I;"YR0_\)
M"'YE/04=M27M2-LG4@Q @&F;>T5Z?T/^_)$F\CV3W\[1"%$)K?^8/%//.7FH
M.)+YB-;CR#@;A\L&=<EH?&5$9#(DEB#W-FK5D2R'&.0(-(STKKK7?N $+AJO
MB'5.N!FAR/=6SB)Y5NIFY80.,3ZJ+,95QS,?[GWX NTF?9G_KTDP]!J'5'NS
MZL"\F@'L#N;#QB4<PD5;WL>8/E?GQZ]7Z E'/F<Y+34T'P<FP9#\M250Y!X
M)%/\7\B-)_@2TVH\2S]"72=<O-(JV*%#_D"V[:PP]C5"G*E3?TSS4=V7-] )
MT5J$BJX0O TN:V(!/$52(6EK2V\IFE#KI5K6B%RW-Q\''MT0*(KS38HD9.$
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M 1\UD!BY[:J"K=64X$L</*,PIH4_:3Y7-'1>Z;R'7QE,KI!Q.TU/-85J!+,
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MZ86@V94?(I?TB3I!&M*(_9GOKI.*TD8!/Z!68Z3IU^\F0U.;(Q"][]K0F_S
MBM#;C#0]-WJQJLT1A-ZYZ@7MDOC+Q ?W@[E47B+4?'JNZ0A;#@<^V:"P:Y]8
MLQW^*(QSSC[Y:>OHDQ^FO#>PR=]->+6Z0ERS2#%H\K0N8%"]UP2O&[0<E&3*
M"[-):RG(J%"<1H81Y47>9EA0(/4[(K+E:LF3>Z')]*3M)V0!;<4\^D"-/FEU
M";YS7H3"S3>9GK2][8F%NTL?*%S%^UN%@#:MK#N8Y0H%\ _]@.8V[(-\#D K
M71<P^=H-Q%KMX\#9_B9_R"(ZBJ@\D)Y#0#XN>#^66MJG+8#7R/V_>15H]V8Q
M<6\6B&^5)3=PR^VF)YH27^I.*"QD!IQY9XJ/9@JUJS=)ZX.9= Z8_ #3$TV1
M*A4P5>02Q$]U]&I#"V&,/MH]F-VA<(["[>_)8L"_JBD_@K8,,P4(5F83=/EK
M3\']=S]:>8HN]WQKL]3,(BN3R:!-I0/!>F%;SE+UHS<HA'?7&OF:'CN5C:RJ
M:FQBZ9IDQ-JO12:;P[HTS=#4NQ&*XM!WXZQ@RCU!*!J-[T7^$;?;]%23)=?H
M"E'.K10*  1;M9%7HB7AA6_4<7I,SW7='VP!/"G>0;-"W^7#-5=\PZ[8RB*[
MCL6>045[9;=2,TPIIC#9\C;7!JHG<I/MCLJPM!I<2\OZ]@*7)F\\TYOOP<GG
MXR_\+#!>G^E738FXX@U @F[PW$)U'FX2:GCBAZ23NA'E=M-S3;$6L7P!6L%M
M5=^%O5^)*> '<_ZN6FADT:;*8&Y7^-\UBUZTOI>:Z=E169)DRMK<_;2.N$W>
M32M"8JCS#;@\B3M#W!XRY7D9P7R_B37(]*NF-$;V_) *NL!\@)NTOKP/,0^\
M)&%I06RS:;]JL@+4 %KB P14GX50[7'S:L^[Y_M;9%=4?.^=427#1#!I^$BT
M.\KVUV.E5,1%'M1=T9ADV;0#JLFV4 O MQJ+X+R:+KB\(>@W/==T:[7B[))[
M03[/$^A;U[[6JJ!V9+X0?_IF96<5/^+0_S?O:4]^O^DW TJ$WPI>())A 4),
M7\2U0/30"0=A\O2(]ZNS6*$A"A,^9'&#^EN('Y\5T,II\A6/*Q3Y\X!2E"H7
M%#3D=C(;"EGZ08/$C'F4DIJ^X5MMS4O[F V2)/F@X6 21H-5',5.X!&OMAI0
MN8[6HK7# P29MAIL.4-(WI;@=+("*B']$$S:'GG/VZN530B)SK;!5L]XJ'L]
M2NQ0)1\'MZ.2QY%K;+;<172#[I$!TZ3"[L/K939 T@Q 2-7-_1'/B-Q+?5O+
M!7@SMZ1G8%>SP:C&A7$GQ^LXR.!AX<^3(P6.O;;3UFQH!&2;%U*7\V^L\VCD
M?1A][[O1FC !"J-+Y\F/G47'=?$JB)-$Y#%>>+V@_(H)9YI4'<H*$&MR!2*M
M,:2 782\Z)I(8X2>TLQG(H4K], #E=/+#OR$#(!0U8TLP%6DR!9)#VL&,T+5
MTH]H8:L^CF$C >I@MN1E: >%7C<V %Y=G8=H3N<G(V !R)W;QWS12Y /2K^N
MRR^2_H[-+A+]3@>+Y [0#@I=L:.^/MJCVQ,@YGP3\P6[2RTH2FV^>$9C]P6%
MKA^1J>>[J!>X(2(&.+R[\GJ9C8LT R!4^B[B%);%*IX[,_9MJ?]>AQ<02VUN
M?-[,V#DW.N8%P7C]K$!.A@7P7%.;JW]#I!#=XBA"T2#HOM#TSY4?/::%3OBN
MB+"K%;!)<@$BI[JT[0)'Z[-PXNHFQPN0.\)H:K;(^52#(E9<_:BP.7+.KY);
M9:RVY@N90S8H96WG]ODG9E>4?_)#;NGL!;E:/YQH9(51S :P-D,@M-K.]W,\
MB&;;+M<6S3DIXD%XM)WKY^BEQ<9]0DYR+C%"+O*?D3>H//7$P]@&I"Q'(+J*
MHPE$L0+7?W(6G24-?'<"LA+$B"P+<<=U0S@#0-C/;& JL  B43<8 5511'&\
M0%Q+.:DB6&IFOIS9%(-BU18X2#A)=\.K%=&-.5EO?>SE=\EK'*X?3^"L7Y7&
M,1N_/5@" =8630"X2'R&_?%E#V,SO#R.('3UW9/.&,Y"EH-PY,\?8[F4*4%/
M*S"48P*$35N& I/N@L.Y^6.4_37B1?[J#&<OP'*<@:AKRU8 F*$7P!'Y"3VC
M8(6(>8SG@2![N]I -B/-YPG$6'&:0W)D$%!ERYV#W@?D6^5,F<%LAD+VPIL\
MTUMY(+/!VX<G$#S%Z1+%I/,TV5R< %:^8PKT-!\>:29 /+3%5O)Y3ELMJY"]
M)]7?; AKL ("J3B,4@BI9@OW.D$7F%&\+F;C($<]*'IM21PT/2T:.J_\X_]\
M*[-Q  D&1:\MM@*<9F<)"77.\K==K0!)D@L0.7-2,-)H:2WDREWM1([-!83<
M%WW7+GA!NT'\R"TO)NQK!7:R;(#@Z2L2QPG)U<-NV]5FZ,I<@,@ISO)8VS:9
MZN3].^B$#.YA-@!2Q(-RUUBO@>46\''B>A36 %:-"Q Y?6D=5,F2""9G4=NT
ML0*+,KF@T!7?R.@Z83!8Q5<^?;[B804D6B0Y7;LMS98LEVA0OMH>D<V?C<HF
M*T%=S 9&CGH0(7T/L5&N1N@IV^H8%J+ QN+VM0,S239 \+0%%/HX<)WH<1#2
M"[S9#QWWCY4?I=)-[_%&:885C8PD?PRY_FK],:T >U_V0"6H&YL $ZJ+6?/$
MTZ:_0(G/O4V>N_6=!W_AQZ_0!E=Q&+,QK,\1!!NK*/@^L%VL(D)\%!&#\\$/
M$DHN<43(7*M1EU"[+C:[SK3+]@N:>\>OJ*)H=/-!5LHHB+V^=(]<39FTY$*Z
MSXQ0A,+G)-'H>A6OTM),U(/AA1<K#F4V^/MQ!2*M+<6#&WM+_[V^2GJ%1#=I
M:PQF!=JU^0+QUA9_Z2R2<;/+6#M/.F3Y*S#$<OVM0+4**R"0VL(QW>73 K\B
ME"5\LGGHT^./B+"8/HTYP62ARO^=[EE]'/\3Q3)97(U]T@IU:9A[4,/T7102
MO>(*/>*:O1AWDR0Y]H)T@10$5)1]QPI=:H)E4('T!M?VX)(843/D4RNJ!2UB
M?.Q=J!+(-ZA/VD*!]%K2]IQ_<[3?"Z(X7%&^MHG5&7/"$A2UA[1"-_;D#M0
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MNVMLGVWT'?5T&^5Y6F:LJK;317(.]]+E,%L;Z;P0#!(HD/%;Z+7H:;__T?,
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M:$JQZ*M1<+CC9 "\M?6DD ;"% .(_&94M_MHM. $P9*T[?SRM?V+?4Z]T "
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MWDI/.^A57#'(%'S-(YT\"#89@NQSBJEU)]=,$5%-G]6,VL7MY2%>1\AQ9"P
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M0W@YR7-<Y!H&]H5<<DT,L,VJK@08_@AA<?W4P\-T^0"$!=5BI!$9.%GWG)#
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MV5EQG @VQ,5>>IB-"3!4'89;Q=ORF-FJ;0=]&Q,;O_-.97XZ9CQO\ST1-IL
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MPE]C]TVYK35X%KPW]8(OM]4^NKTZ:*(=^211GJ?9:YD##[51E./4B5N%L5$
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M0[Q+\^CXJMTC]L[B<-9"#T8O+ AHC94 QPEBI%Q(6TE!#EUIXRDSV0OY,OH
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MU!3?-M5V6H?;SJ5.26XS53 QOAU>KE#WY\7B=DIKG4YNT?7LX>IV_O#Y?OI
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M *;S& 2[SU8J?@B<=HT9[[SM=8UD@O!*[Z(RW]OJJW@<QH3@%2-71QX,WPQ
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M8H?NJP;,?;>M;@9#[U%B.\ S9W WQX4=\$(W5\2:ZO=U%H9#=8VE;;7<W1S
MTC@N4\+-T&YWX"ZS=B[5EW(H]ZLG7W0UW0):5_,+9$E@"T!S6:]4+A8\UQ(-
MSSRIW[O)R0=)HX1OV;,=(38RO=)!2[4<X<JYV)*.GRK-4H\;&Y3AR1]RW\DX
M,^VKZJKV%;M(4&4U2K@ E%,)@08MEI+;YM_69_F92M]+'D$I=U_\N>$%'2.P
M#Q< JZM@P1CPSZ@\YJ0\W_5:GYT:NH&46(?;[>\EVE>4+#H@6:@T<#K5R$OR
M+YZJ*.Z:K?N+EQSOR7&O,H^5"9Z5W"$/9E@29],7!@_DZC9M/D4^H%HR;--
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M(T,'BO23502;ISF,F5M:5'J)<A[/>4];G.6&CME'?0:W^:>CT."^/[4FHQL
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M&&R16@!,DNPG2[96=WE6-@"6&H-V:#/!RW:8FGW:AA\U J#83^XHL&:X,K)
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MC'=1A4@JJQPS#7]7KO%W0-;$=Q[]@(I,$KKORZ-[GJ*  I^P/6#ZIMYDP5O
M>Q/@=,)U<4*?4RL=!A^5R.K@/3/0E@$A@;:>IY0Q[LG<>6/N9I9(0^W0E5;"
M>ZX CGH$%\<>GN*,SO -V:0LB:K@/6MP D=R^=$9RDTK'7Z$%?!>.6C+CD+V
M4[FA;3WF@'_WP\?O<M 7H^G-K[=1?CF'?HA%M/@>B<L(F:(?;V(&6'5P;;PW
M#[3IT)++DG%#>_E"XI1YNJ912G:SL.0,7U0![Y6$MN-&(3LZ-\=;><# XKH
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MP@,WI?NKX(T%=*N YI8%X]U]0(8>WA))>X8]WRC0'K%>**<686$P\-W'4F@
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M>52#"64E,"5&W!+ZE !10$_R<?06-X>;0\[4:C'XJSTH3B)^IQN(XS[MU^(
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MVK)Z,GSH"G#K)$_LY(G^P0Z;7YR S1SPA156'2U14NM95@<6?!+9?;<P+9*
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M0APD";UYX(20E\_-?,T.'>#J;WTI,B(_]M3Y,W,LJ]\1KA5##\8PJ/DUVKD
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MF@;);RIF>IL'Y@Y";T$2=J3EY?>PB)=W14H!K"J4"&-['3@1.E@8HF/U1-3
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MGO(^<.EM5YN4]?)0;BQQP\C%-F13SF)_XX=.D+MZ=F_Q'E]5D[JD\R?']-J
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M9D1=(C^CEE2P^4Q''%NHDNJ=[&[.XCSF/6Y8(,<Q>K>KGDGL1RR38IR>YW7
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M3A-,K>MJY6_8?Q[I%^B__/]02P$"% ,4    "  @A$I93LD/H'*3 P D'A\
M#@              @ $     934Y.#9?,3 M:RYH=&U02P$"% ,4    "  @
MA$I9H "Q7J\O  !DT@$ $0              @ &>DP, 934Y.#9?97@Q,"TQ
M,"YH=&U02P$"% ,4    "  @A$I9LC/$2\ "  #Z$   $
M@ %\PP, 934Y.#9?97@R,2TQ+FAT;5!+ 0(4 Q0    ( ""$2EEM\ OXX0(
M ((,   0              "  6K& P!E-3DX-E]E>#(S+3$N:'1M4$L! A0#
M%     @ ((1*60A@]>L,"   :S<  !               ( !><D# &4U.3@V
M7V5X,S$M,2YH=&U02P$"% ,4    "  @A$I9:7:B=!<(  !7-@  $
M        @ &ST0, 934Y.#9?97@S,2TR+FAT;5!+ 0(4 Q0    ( ""$2ED!
M7<)^800   07   0              "  ?C9 P!E-3DX-E]E>#,R+3$N:'1M
M4$L! A0#%     @ ((1*64D0PM-<!   BQ4  !               ( !A]X#
M &4U.3@V7V5X,S(M,BYH=&U02P$"% ,4    "  @A$I99+A@G5:7  "+HP
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M+3(P,C0P-C,P7V1E9BYX;6Q02P$"% ,4    "  @A$I9WG6,^)J1  !"?@@
M%0              @ %M@P4 <F5N8BTR,#(T,#8S,%]L86(N>&UL4$L! A0#
M%     @ ((1*63X2[G&%;   _&(' !4              ( !.A4& ')E;F(M
F,C R-# V,S!?<')E+GAM;%!+!08     #P / + #  #R@08    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>e5986_10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:RENB="http://renovarobio.com/20240630"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="renb-20240630.xsd" xlink:type="simple"/>
    <context id="From2023-07-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-10-03</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-13_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2017-11-122017-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2017-11-12</startDate>
            <endDate>2017-11-13</endDate>
        </period>
    </context>
    <context id="From2018-06-182018-06-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2018-06-18</startDate>
            <endDate>2018-06-19</endDate>
        </period>
    </context>
    <context id="From2022-06-192022-06-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2022-06-19</startDate>
            <endDate>2022-06-20</endDate>
        </period>
    </context>
    <context id="From2023-04-172023-04-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-04-18</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-14_custom_MarchNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-14_custom_MarchNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_MarchNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_MarchNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:MarchNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-11_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-11</instant>
        </period>
    </context>
    <context id="From2024-01-102024-01-11_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-10</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-01-092024-01-12_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-09</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-29_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="From2023-12-012023-12-29_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="From2023-12-012023-12-29_custom_PrivatePlacement1Member_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PrivatePlacement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="From2023-12-012023-12-29_custom_PrivatePlacement2Member_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PrivatePlacement2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="From2024-01-302024-01-31_custom_PrivatePlacement3Member_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PrivatePlacement3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-30</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-05_custom_Note2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-05</instant>
        </period>
    </context>
    <context id="From2023-09-052023-10-05_custom_Note2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-05</startDate>
            <endDate>2023-10-05</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-11_custom_Note2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-11</instant>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_Note2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_custom_Note2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_Note2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:Note2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-06_custom_ConvertibleNotesPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="From2020-02-052020-02-06_custom_ConvertibleNotesPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-05</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-29</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="From2023-06-252023-06-26_custom_AmendedAndRestatedSecuredNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-25</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="From2023-06-252023-06-26_us-gaap_WarrantMember_custom_AmendedAndRestatedSecuredNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:AmendedAndRestatedSecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-25</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="From2024-03-262024-06-04_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-06-04</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-04_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-04</instant>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-02-05_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="From2024-02-042024-02-05_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-04</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_RSBioApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:RSBioApSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_RSBioApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">RENB:AccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:RSBioApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_RSBioApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:RSBioApSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">RENB:AccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-11-212023-11-22_custom_LoanAgreementMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-21</startDate>
            <endDate>2023-11-22</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_BridgeLoanMember_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-02_custom_November2023NoteMember_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-16_custom_November2023NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-16_custom_November2023NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_November2023NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_November2023NoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:November2023NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="From2020-03-292020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-11_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="From2022-05-162022-05-17_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-17_srt_MinimumMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="AsOf2022-05-17_srt_MaximumMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="AsOf2022-05-17_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="AsOf2023-06-26_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="From2023-06-252023-06-26_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-25</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreements1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SubscriptionAgreements1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_custom_Note2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:Note2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2023-11-292023-11-30_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-29</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_UnitedStatesTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_UnitedStatesTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="From2023-07-292023-08-01_custom_PreferredStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-29</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-01_custom_PreferredStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PreferredStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:PreferredStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_Investor1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:Investor1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-042024-04-05_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-20_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="From2024-02-192024-02-20_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-19</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-19</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="From2024-02-142024-02-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="From2024-02-142024-02-15_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:StockPurchaseAgreementOfRenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="From2023-12-032023-12-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-12-03</startDate>
            <endDate>2023-12-04</endDate>
        </period>
    </context>
    <context id="From2023-10-222023-10-23_custom_AdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:AdvisoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-22</startDate>
            <endDate>2023-10-23</endDate>
        </period>
    </context>
    <context id="From2023-09-262023-09-28_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-28</endDate>
        </period>
    </context>
    <context id="From2023-07-272023-07-28_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-26_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="From2023-06-252023-06-26_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-25</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="AsOf2023-06-26_custom_OneWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:OneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20_us-gaap_CommonStockMember_custom_LincolnParkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="From2023-04-262023-04-27_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-03-302023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_OneWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:OneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-02-10_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="From2023-02-092023-02-10_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-10</endDate>
        </period>
    </context>
    <context id="From2022-12-292022-12-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-29</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="From2022-07-132022-07-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-14_custom_RenovaroBioPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RenovaroBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="From2022-07-132022-07-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="From2022-07-132022-07-14_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-14_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DanDritDenmarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:DanDritDenmarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RenovaroDenmarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RenovaroDenmarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_RenovaroDenmarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:RenovaroDenmarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2014-02-06_custom_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-06</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_Employees1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:Employees1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:BoardOfDirectorsAndScientificAdvisoryBoardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_ConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_ConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PlanOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:PlanOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-05</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="From2019-11-142019-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2019-11-14</startDate>
            <endDate>2019-11-15</endDate>
        </period>
    </context>
    <context id="From2021-08-242021-08-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2021-08-24</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="From2021-09-092021-09-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2021-09-09</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_MarkDybulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:MarkDybulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-16_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-16_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RENBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RENCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-032024-10-02_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-03</startDate>
            <endDate>2024-10-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-02_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-02</instant>
        </period>
    </context>
    <context id="From2024-07-312024-08-01_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-22</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-07-01to2024-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2023-07-01to2024-06-30" id="Fact000004">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-07-01to2024-06-30" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-07-01to2024-06-30" id="Fact000006">0001527728</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="Shares"
      xsi:nil="true"/>
    <RENB:StockIssuedPursuantToWarrantsExercisedValue
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedPursuantToWarrantsExercisedValue
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedPursuantToWarrantsExercisedValue
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:EarnoutSharesIssuedValue
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:EarnoutSharesIssuedValue
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:EarnoutSharesIssuedValue
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuedForInterestOnNotesPayableExtensionValue
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuedForInterestOnNotesPayableExtensionValue
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuedForInterestOnNotesPayableExtensionValue
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="Shares"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0492"
      unitRef="Shares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-07-01to2024-06-30" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-07-01to2024-06-30" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-07-01to2024-06-30" id="Fact000015">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-07-01to2024-06-30" id="Fact000017">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-07-01to2024-06-30" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-07-01to2024-06-30" id="Fact000020">001-38758</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-07-01to2024-06-30" id="Fact000022">RENOVARO INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-07-01to2024-06-30" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-07-01to2024-06-30" id="Fact000024">45-2559340</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-07-01to2024-06-30" id="Fact000025">2080 Century Park East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-07-01to2024-06-30" id="Fact000026">Suite 906</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-07-01to2024-06-30" id="Fact000027">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-07-01to2024-06-30" id="Fact000028">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-07-01to2024-06-30" id="Fact000029">90067</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-07-01to2024-06-30" id="Fact000030">305</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-07-01to2024-06-30" id="Fact000031">918-1980</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-07-01to2024-06-30" id="Fact000032">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-07-01to2024-06-30" id="Fact000033">RENB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-07-01to2024-06-30" id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-07-01to2024-06-30" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-07-01to2024-06-30" id="Fact000036">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-07-01to2024-06-30" id="Fact000037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-07-01to2024-06-30" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-07-01to2024-06-30" id="Fact000040">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-07-01to2024-06-30" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-07-01to2024-06-30" id="Fact000044">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-07-01to2024-06-30" id="Fact000045">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-07-01to2024-06-30" id="Fact000046">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-07-01to2024-06-30" id="Fact000047">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">57193356</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-10-03"
      decimals="INF"
      id="Fact000050"
      unitRef="Shares">156193912</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2023-07-01to2024-06-30" id="Fact000051">3627</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-07-01to2024-06-30" id="Fact000052">Sadler, Gibb &amp; Associates, LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-07-01to2024-06-30" id="Fact000053">Draper, UT</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">220467</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000062"
      unitRef="USD">1874480</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000064"
      unitRef="USD">1108247</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000065"
      unitRef="USD">0</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000067"
      unitRef="USD">668929</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000068"
      unitRef="USD">690925</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">1997643</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">2565405</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">482121</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">508989</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">30043</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">39676</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000083"
      unitRef="USD">42611000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">159330161</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">11640000</us-gaap:Goodwill>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000088"
      unitRef="USD">19849</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000089"
      unitRef="USD">21741</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">1269633</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000092"
      unitRef="USD">913985</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000094"
      unitRef="USD">160649686</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000095"
      unitRef="USD">55226402</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000097"
      unitRef="USD">163129450</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000098"
      unitRef="USD">58300796</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">9448683</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000107"
      unitRef="USD">5296823</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000109"
      unitRef="USD">5311324</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000110"
      unitRef="USD">723173</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000112"
      unitRef="USD">295361</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000113"
      unitRef="USD">184733</us-gaap:OtherLiabilitiesCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000115"
      unitRef="USD">12310000</RENB:ContingentConsiderationLiabilityCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000116"
      unitRef="USD">0</RENB:ContingentConsiderationLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000118"
      unitRef="USD">245000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000119"
      unitRef="USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000121"
      unitRef="USD">493553</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000122"
      unitRef="USD">193422</us-gaap:OperatingLeaseLiabilityCurrent>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000124"
      unitRef="USD">2205996</RENB:NotesPayableRelatedPartiesNetCurrent>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000125"
      unitRef="USD">4624947</RENB:NotesPayableRelatedPartiesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000127"
      unitRef="USD">30309917</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000128"
      unitRef="USD">11023098</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000133"
      unitRef="USD">842389</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000134"
      unitRef="USD">775587</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000136"
      unitRef="USD">842389</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000137"
      unitRef="USD">775587</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000139"
      unitRef="USD">31152306</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000140"
      unitRef="USD">11798685</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000148"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000150"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000152"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000154"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000156"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000145"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000146"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000167"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000169"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000175"
      unitRef="Shares">155027245</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000177"
      unitRef="Shares">155027245</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000179"
      unitRef="Shares">63698144</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">63698144</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">15504</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000165"
      unitRef="USD">6371</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">456811911</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">290554875</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-324679425</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-244029253</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-170846</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-29882</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">131977144</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">46502111</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">163129450</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">58300796</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">24557608</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">15318198</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">2708829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">4165197</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">42611000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000208"
      unitRef="USD">18960000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">11640000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000213"
      unitRef="USD">121859</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000214"
      unitRef="USD">113496</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">81639296</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000217"
      unitRef="USD">38556891</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-81639296</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-38556891</us-gaap:OperatingIncomeLoss>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">4727473</RENB:ChangeInFairValueOfContingentConsideration>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">0</RENB:ChangeInFairValueOfContingentConsideration>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000228"
      unitRef="USD">-1303578</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <RENB:LossOnExtinguishmentOfContingentConsiderationLiability
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000231"
      unitRef="USD">0</RENB:LossOnExtinguishmentOfContingentConsiderationLiability>
    <RENB:LossOnExtinguishmentOfContingentConsiderationLiability
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-419182</RENB:LossOnExtinguishmentOfContingentConsiderationLiability>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000234"
      unitRef="USD">1011322</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">580344</us-gaap:InterestExpenseNonoperating>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000237"
      unitRef="USD">0</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-1019</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <RENB:InterestIncomeAndOtherIncomeExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-1423449</RENB:InterestIncomeAndOtherIncomeExpense>
    <RENB:InterestIncomeAndOtherIncomeExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-126620</RENB:InterestIncomeAndOtherIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000243"
      unitRef="USD">989124</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000244"
      unitRef="USD">-1127165</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-80650172</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-39684056</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000249"
      unitRef="USDPShares">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000251"
      unitRef="USDPShares">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000253"
      unitRef="USDPShares">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000255"
      unitRef="USDPShares">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000257"
      unitRef="Shares">96248090</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000259"
      unitRef="Shares">96248090</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000261"
      unitRef="Shares">56265362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000263"
      unitRef="Shares">56265362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-80650172</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-39684056</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000271"
      unitRef="USD">140964</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000272"
      unitRef="USD">-554</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000274"
      unitRef="USD">-80791136</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-39683502</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000286"
      unitRef="Shares">53007082</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">5302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">276989179</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-204345197</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-30436</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30"
      decimals="0"
      id="Fact000282"
      unitRef="USD">72618848</us-gaap:StockholdersEquity>
    <RENB:StockIssuedPursuantToWarrantsExercisedShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">1250000</RENB:StockIssuedPursuantToWarrantsExercisedShares>
    <RENB:StockIssuedPursuantToWarrantsExercisedValue
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000289"
      unitRef="USD">125</RENB:StockIssuedPursuantToWarrantsExercisedValue>
    <RENB:StockIssuedPursuantToWarrantsExercisedValue
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000290"
      unitRef="USD">1624875</RENB:StockIssuedPursuantToWarrantsExercisedValue>
    <RENB:StockIssuedPursuantToWarrantsExercisedValue
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000293"
      unitRef="USD">1625000</RENB:StockIssuedPursuantToWarrantsExercisedValue>
    <RENB:EarnoutSharesIssuedShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000304"
      unitRef="Shares">1250000</RENB:EarnoutSharesIssuedShares>
    <RENB:EarnoutSharesIssuedValue
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000298"
      unitRef="USD">125</RENB:EarnoutSharesIssuedValue>
    <RENB:EarnoutSharesIssuedValue
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">2762375</RENB:EarnoutSharesIssuedValue>
    <RENB:EarnoutSharesIssuedValue
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000302"
      unitRef="USD">2762500</RENB:EarnoutSharesIssuedValue>
    <RENB:SharesIssuedForInterestOnNotesPayableExtensionShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000313"
      unitRef="Shares">198439</RENB:SharesIssuedForInterestOnNotesPayableExtensionShares>
    <RENB:SharesIssuedForInterestOnNotesPayableExtensionValue
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">20</RENB:SharesIssuedForInterestOnNotesPayableExtensionValue>
    <RENB:SharesIssuedForInterestOnNotesPayableExtensionValue
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000308"
      unitRef="USD">204372</RENB:SharesIssuedForInterestOnNotesPayableExtensionValue>
    <RENB:SharesIssuedForInterestOnNotesPayableExtensionValue
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000311"
      unitRef="USD">204392</RENB:SharesIssuedForInterestOnNotesPayableExtensionValue>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">4832452</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingShares>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">483</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">4011339</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000320"
      unitRef="USD">4011822</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000331"
      unitRef="Shares">200000</RENB:RestrictedSharesIssuedForServicesRenderedShares>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">20</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">227980</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000329"
      unitRef="USD">228000</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">2264150</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">226</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">1199774</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000338"
      unitRef="USD">1200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">696021</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000343"
      unitRef="USD">70</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">-70</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">3535051</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000356"
      unitRef="USD">3535051</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-39684056</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-39684056</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">554</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000370"
      unitRef="USD">554</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000381"
      unitRef="Shares">63698144</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">6371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">290554875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-244029253</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">-29882</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000377"
      unitRef="USD">46502111</us-gaap:StockholdersEquity>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">280505</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">28</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">1999972</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000388"
      unitRef="USD">2000000</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">280505</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">28</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">1999973</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000397"
      unitRef="USD">2000001</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable>
    <RENB:RestrictedSharesIssuedForServicesRenderedShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">3083760</RENB:RestrictedSharesIssuedForServicesRenderedShares>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">308</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">4663882</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000406"
      unitRef="USD">4664190</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000417"
      unitRef="Shares">3951344</RENB:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000411"
      unitRef="USD">396</RENB:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000412"
      unitRef="USD">2341470</RENB:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000415"
      unitRef="USD">2341866</RENB:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000426"
      unitRef="Shares">5660042</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000420"
      unitRef="USD">566</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000421"
      unitRef="USD">10575759</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000424"
      unitRef="USD">10576106</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue>
    <RENB:SharesIssuableForSettlementOfContingentConsideration
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000435"
      unitRef="Shares">2189672</RENB:SharesIssuableForSettlementOfContingentConsideration>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">219</RENB:SharesIssuableForSettlementOfContingentConsiderationValue>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">3519808</RENB:SharesIssuableForSettlementOfContingentConsiderationValue>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000433"
      unitRef="USD">3520027</RENB:SharesIssuableForSettlementOfContingentConsiderationValue>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000444"
      unitRef="Shares">70834183</RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCubeShares>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000438"
      unitRef="USD">7083</RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">135994548</RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000442"
      unitRef="USD">136001631</RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000453"
      unitRef="Shares">-561010</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">-56</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000455"
      unitRef="Shares">5610100</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000447"
      unitRef="USD">561</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-505</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">489000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000462"
      unitRef="USD">489000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">4673129</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000469"
      unitRef="USD">4673129</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">-80650172</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-80650172</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">-140964</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000483"
      unitRef="USD">-140964</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">155027245</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">15504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000487"
      unitRef="USD">456811911</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000488"
      unitRef="USD">-324679425</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000489"
      unitRef="USD">-170846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000490"
      unitRef="USD">131977144</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000499"
      unitRef="USD">-80650172</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000500"
      unitRef="USD">-39684056</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000505"
      unitRef="USD">121859</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000506"
      unitRef="USD">113496</us-gaap:DepreciationAndAmortization>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000508"
      unitRef="USD">4727473</RENB:ChangeInFairValueOfContingentConsideration>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000509"
      unitRef="USD">-0</RENB:ChangeInFairValueOfContingentConsideration>
    <RENB:LossOnExtinguishmentOfContingentConsiderationLiabilities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000511"
      unitRef="USD">-0</RENB:LossOnExtinguishmentOfContingentConsiderationLiabilities>
    <RENB:LossOnExtinguishmentOfContingentConsiderationLiabilities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">-419182</RENB:LossOnExtinguishmentOfContingentConsiderationLiabilities>
    <RENB:LossOnExtinguishmentOfDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000514"
      unitRef="USD">-1303578</RENB:LossOnExtinguishmentOfDebt>
    <RENB:NoncashStockbasedCompensationExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000517"
      unitRef="USD">4673129</RENB:NoncashStockbasedCompensationExpense>
    <RENB:NoncashStockbasedCompensationExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000518"
      unitRef="USD">3535051</RENB:NoncashStockbasedCompensationExpense>
    <RENB:NoncashRestrictedSharesIssuedForServicesRendered
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000520"
      unitRef="USD">4664190</RENB:NoncashRestrictedSharesIssuedForServicesRendered>
    <RENB:NoncashRestrictedSharesIssuedForServicesRendered
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000521"
      unitRef="USD">228000</RENB:NoncashRestrictedSharesIssuedForServicesRendered>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000523"
      unitRef="USD">42611000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000524"
      unitRef="USD">18960000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000526"
      unitRef="USD">11640000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000527"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000529"
      unitRef="USD">580605</RENB:AmortizationOfDiscountOnNotePayable>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000530"
      unitRef="USD">348621</RENB:AmortizationOfDiscountOnNotePayable>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000535"
      unitRef="USD">1108247</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000536"
      unitRef="USD">-46</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000538"
      unitRef="USD">-1082267</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000539"
      unitRef="USD">-1070249</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000541"
      unitRef="USD">4057282</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000542"
      unitRef="USD">3894955</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000544"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000545"
      unitRef="USD">-54060</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000547"
      unitRef="USD">11284</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000548"
      unitRef="USD">-27224</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000550"
      unitRef="USD">4769268</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000551"
      unitRef="USD">-578809</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000553"
      unitRef="USD">-10971430</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000554"
      unitRef="USD">-11774549</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">1255600</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000560"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000562"
      unitRef="USD">65851</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000563"
      unitRef="USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000565"
      unitRef="USD">70430</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000566"
      unitRef="USD">29774</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000568"
      unitRef="USD">-1260179</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000569"
      unitRef="USD">-29774</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <RENB:RepaymentsOfFinanceAgreement
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000574"
      unitRef="USD">870073</RENB:RepaymentsOfFinanceAgreement>
    <RENB:RepaymentsOfFinanceAgreement
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000575"
      unitRef="USD">1121767</RENB:RepaymentsOfFinanceAgreement>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000577"
      unitRef="USD">341865</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000578"
      unitRef="USD">1625000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000580"
      unitRef="USD">3000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000581"
      unitRef="USD">4011823</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">3770512</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000584"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000586"
      unitRef="USD">4275151</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000587"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000589"
      unitRef="USD">10517455</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000590"
      unitRef="USD">4515056</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000592"
      unitRef="USD">60141</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000593"
      unitRef="USD">-8395</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000595"
      unitRef="USD">-1654013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000596"
      unitRef="USD">-7297662</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000598"
      unitRef="USD">1874480</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-06-30"
      decimals="0"
      id="Fact000599"
      unitRef="USD">9172142</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000601"
      unitRef="USD">220467</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000602"
      unitRef="USD">1874480</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">20128</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000611"
      unitRef="USD">352334</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000613"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000614"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000619"
      unitRef="USD">0</RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement>
    <RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000620"
      unitRef="USD">2762500</RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement>
    <RENB:SharesInLieuOfInterestOnMillionNotesPayableExtension
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000622"
      unitRef="USD">0</RENB:SharesInLieuOfInterestOnMillionNotesPayableExtension>
    <RENB:SharesInLieuOfInterestOnMillionNotesPayableExtension
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000623"
      unitRef="USD">204392</RENB:SharesInLieuOfInterestOnMillionNotesPayableExtension>
    <RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000625"
      unitRef="USD">906834</RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets>
    <RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000626"
      unitRef="USD">1139875</RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets>
    <RENB:ConversionOfNotePayableForIssuanceOfPreferredStock
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000628"
      unitRef="USD">2000001</RENB:ConversionOfNotePayableForIssuanceOfPreferredStock>
    <RENB:ConversionOfNotePayableForIssuanceOfPreferredStock
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000629"
      unitRef="USD">0</RENB:ConversionOfNotePayableForIssuanceOfPreferredStock>
    <RENB:NotePayableSettledThroughNoncashExerciseOfWarrants
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000631"
      unitRef="USD">2000000</RENB:NotePayableSettledThroughNoncashExerciseOfWarrants>
    <RENB:NotePayableSettledThroughNoncashExerciseOfWarrants
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000632"
      unitRef="USD">0</RENB:NotePayableSettledThroughNoncashExerciseOfWarrants>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000634"
      unitRef="USD">339342</RENB:DebtDiscountRelatedToConvertiblePromissoryNotes>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000635"
      unitRef="USD">0</RENB:DebtDiscountRelatedToConvertiblePromissoryNotes>
    <RENB:CommonSharesIssuedUponAcquisition
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000637"
      unitRef="USD">136001631</RENB:CommonSharesIssuedUponAcquisition>
    <RENB:CommonSharesIssuedUponAcquisition
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000638"
      unitRef="USD">0</RENB:CommonSharesIssuedUponAcquisition>
    <RENB:ContingentConsiderationIssuedUponAcquisition
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000640"
      unitRef="USD">20557500</RENB:ContingentConsiderationIssuedUponAcquisition>
    <RENB:ContingentConsiderationIssuedUponAcquisition
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000641"
      unitRef="USD">0</RENB:ContingentConsiderationIssuedUponAcquisition>
    <RENB:CommonSharesIssuedUponSettlementOfDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000643"
      unitRef="USD">9582912</RENB:CommonSharesIssuedUponSettlementOfDebt>
    <RENB:CommonSharesIssuedUponSettlementOfDebt
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000644"
      unitRef="USD">0</RENB:CommonSharesIssuedUponSettlementOfDebt>
    <RENB:EarnOutSharesIssuedInSettlementOfContingentLiability
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000646"
      unitRef="USD">3520027</RENB:EarnOutSharesIssuedInSettlementOfContingentLiability>
    <RENB:EarnOutSharesIssuedInSettlementOfContingentLiability
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000647"
      unitRef="USD">0</RENB:EarnOutSharesIssuedInSettlementOfContingentLiability>
    <RENB:OptionsIssuedInSettlementOfDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000649"
      unitRef="USD">489000</RENB:OptionsIssuedInSettlementOfDebt>
    <RENB:OptionsIssuedInSettlementOfDebt
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000650"
      unitRef="USD">0</RENB:OptionsIssuedInSettlementOfDebt>
    <RENB:SettlementOfNotesPayable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000652"
      unitRef="USD">418503</RENB:SettlementOfNotesPayable>
    <RENB:SettlementOfNotesPayable
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000653"
      unitRef="USD">0</RENB:SettlementOfNotesPayable>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000655">&lt;p id="xdx_803_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zrXbEPrplcx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_821_zhGp3RGLfcJf"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--BusinessPolicyTextBlock_zCtkBTkm4538" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_865_z82mb7XDjm1a"&gt;&lt;b&gt;Business
&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&#x2013; &lt;/b&gt;On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;, &#x201c;we&#x201d; or &#x201c;us&#x201d;). In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven
healthcare technology company that, if it can generate sufficient funding, will also continue to engage in the research and development
of pharmaceutical and biological products for the treatment of cancer and HIV with the intent to manufacture said products. On February
13, 2024, Renovaro Inc. acquired GEDi Cube Intl Ltd and its subsidiaries (&#x201c;Renovaro Cube&#x201d;), as a wholly owned subsidiary
pursuant to a stock purchase agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTPoI30TunA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zqUWD5Hf2rW1"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zsCwLpRfduMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zEYwhzNWWX1c"&gt;Principles of Consolidation&lt;/span&gt;
&#x2013; &lt;/b&gt;For the years ended June 30, 2024 and 2023, the consolidated financial statements include the accounts and operations of Renovaro,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zmOlpHsTOpk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zu4Y3q9DW8Se"&gt;Subsidiaries&lt;/span&gt; &#x2013; &lt;/b&gt;Renovaro
Biosciences Inc. (&#x201c;Renovaro Biosciences&#x201d;), formerly Renovaro Biopharma Inc., was incorporated on May 19, 2017 in Delaware
and is a 100% owned subsidiary of Renovaro. Renovaro Biosciences owns a perpetual, fully paid-up, royalty-free, sublicensable, and sole
and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize
certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV
in humans, and research and development exclusively relating to HIV in humans. As of June 30, 2024 and June 30, 2023, zero and 1,250,000
shares of Common Stock, respectively, remain contingently issuable in connection with the acquisition of Renovaro Biosciences in February
2018 (the &#x201c;Contingent Shares&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Renovaro Biosciences Denmark ApS
(&#x201c;Renovaro Denmark&#x201d;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Renovaro subject to 185,053 shares of Common Stock of Renovaro held in escrow according to Danish
law (the &#x201c;Escrow Shares&#x201d;). As of June 30, 2024, there are &lt;span id="xdx_902_ecustom--EscrowSharesRemaining_iI_c20240630_zPTtScEVzM09" title="Escrow shares remaining"&gt;17,414&lt;/span&gt; Escrow Shares remaining (see Note 9.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 13, 2024, the Company
acquired &lt;span id="xdx_901_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zv8GMXEb4Xc6" title="Acquisition percentage"&gt;100&lt;/span&gt;% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
12.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zUyeFCYi1Mn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86B_zKw8wsgRetn9"&gt;Use of Accounting Estimates&lt;/span&gt;
&lt;/b&gt;- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zd0IBDoDmAv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zz0esm3S9tD1"&gt;Functional Currency and Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Denmark is the Danish Kroner (&#x201c;DKK&#x201d;) and the functional
currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;). The Company&#x2019;s reporting currency is the U.S. Dollar for the purpose of
these financial statements. The Company&#x2019;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates
and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years ended June 30,
2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&#x2019;
equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than
the functional currency are included in the statement of operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYzze4EMsqLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zmDCKPeMM7Q9"&gt;Cash and Cash Equivalents&lt;/span&gt; &lt;/b&gt;&#x2013;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zXAySCjPuzqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zivhDldXlM9l"&gt;Concentration of Credit Risk&lt;/span&gt;
&#x2013;&lt;/b&gt; Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2024, and June 30, 2023, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--InsuranceReceivablePolicy_z2nHO3Uaz1ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zGoifVogyvLa"&gt;Insurance Receivable&lt;/span&gt; &#x2013;&lt;/b&gt;
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_znZFYJ0dR5y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zGm4454iLvN8"&gt;Property and Equipment&lt;/span&gt; &lt;/b&gt;-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 4.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zqm81xJWC1Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zZy77FcQIkK1"&gt;Intangible Assets&lt;/span&gt; - &lt;/b&gt;The
Company has both definite and indefinite life intangible assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 350, &lt;i&gt;Goodwill and Other Intangible Assets&lt;/i&gt;. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zPTsAxhA9Zj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zvWXMaDKdB6c"&gt;Goodwill&lt;/span&gt;&lt;/b&gt; - Goodwill is not
amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z2t7migVRUw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_ztLtjS9Gnd9a"&gt;Impairment of Goodwill and Indefinite
Lived Intangible Assets&lt;/span&gt;&lt;/b&gt; &#x2013; We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;For indefinite life intangible
assets, such as IPR&amp;amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the
IPR&amp;amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023.
During the year ended June 30, 2024, the Company recorded an impairment loss of $42,611,000 related to the termination of the license
agreement with Weird Science LLC (see Note 5.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The carrying value of
IPR&amp;amp;D and goodwill at June 30, 2024, were&#160;zero &lt;span id="xdx_903_ecustom--InProcessResearchAndDevelopment_iI_c20240630_zgdNmgs40Mq4" style="display: none" title="In-process research and development"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--Goodwill_iI_c20240630_zzUVZLh5FIY9" title="Goodwill"&gt;159,330,161&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zH3L3Gq0MHVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_869_zCJyAq8yKG0k"&gt;Impairment of Long-Lived
Assets&lt;/span&gt; - &lt;/b&gt;Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. &lt;span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zfZ0RQu56Byk" title="Impairment of assets"&gt;&lt;span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20220701__20230630_zC6SBvTVoZp5" title="Impairment of assets"&gt;No&lt;/span&gt;&lt;/span&gt; impairment
of these assets was recorded during the year ended June 30, 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zDYiDHm5Uj2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_86E_zcQPMq32T4Xg"&gt;Leases&lt;/span&gt; -&lt;/b&gt; In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zS59JGeVGI0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z2M4Fvb45Zy3"&gt;Research and Development Expenses&lt;/span&gt;
&#x2013; &lt;/b&gt;The Company expenses research and development costs incurred in formulating,
improving, validating, and creating alternative or modified processes related to and expanding the use of the Company&#x2019;s technologies.
Research and development expenses for the years ended June 30, 2024 and 2023 amounted to $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_z6mknozksDMg" title="Research and development expense"&gt;2,708,829&lt;/span&gt;, and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220701__20230630_zTNam0i3PUge" title="Research and development expense"&gt;4,165,197&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zi8R7RVllzg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zYcYrZIRngO4"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 8.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zIGW5pW0zBr" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zX0uNS8uJHd9"&gt;Loss Per Share&lt;/span&gt;&lt;/b&gt; - The Company calculates earnings (loss) per share in accordance with FASB ASC
260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding
during each period. Diluted earnings per common share are based on shares outstanding (computed as for basic EPS) and potentially dilutive
common shares. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options
that have been granted but have not been exercised. The shares of Common Stock outstanding at June 30, 2024 and 2023 were &lt;span id="xdx_906_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zw5OieCHee3g" title="Common stock outstanding"&gt;152,837,573&lt;/span&gt;
and &lt;span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20230630_ztcHsHRLkHg9" title="Common stock outstanding"&gt;63,698,144&lt;/span&gt;, respectively. Because of the net loss for each of the years ended June 30, 2024 and June 30, 2023, dilutive shares for
both periods were excluded from the diluted EPS calculation, as the effect of these potential shares of Common Stock is anti-dilutive.
The Company had &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zeRkKRein5I1" title="Anti-dilutive shares"&gt;17,146,315&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z4zWBToR9xad" title="Anti-dilutive shares"&gt;7,949,513&lt;/span&gt; potential shares of Common Stock excluded from the diluted EPS calculation for the years ended
June 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJ4GG127mXq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zd3ygNizXXM1"&gt;Fair Value of Financial Instruments&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#x201c;Fair Value Measurements&#x201d;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of June 30, 2024. &lt;span style="background-color: white"&gt;Level
3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition
of Renovaro Cube &lt;/span&gt;(see Note 3.) There were no Level 1, 2, or 3 assets, nor any Level 1, 2, or 3 liabilities measured at fair value
on a recurring basis as of June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z7LWcUyS4ke3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_861_zA8jExqaafKd"&gt;Stock-Based Compensation&lt;/span&gt;
- &lt;/b&gt;The Company has granted stock options, restricted share units (&#x201c;RSUs&#x201d;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of &lt;b&gt;&lt;i&gt;FASB ASC Topic 718, Compensation
&#x2013; Stock Compensation&lt;/i&gt;&lt;/b&gt;. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2024 and 2023 were $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zYradUXtK5s1" title="Stock based compensation costs"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z3hq54z74ox6" title="Stock based compensation costs"&gt;4,673,129&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zBWxheZ7LN9k" title="Stock based compensation costs"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zZU080u0jNHd" title="Stock based compensation costs"&gt;3,535,051&lt;/span&gt;&lt;/span&gt;, respectively&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company records stock-based
compensation for services received from non-employees in accordance with &lt;b&gt;&lt;i&gt;ASC 718, Compensation&#x2014;Stock Compensation Non-Employees&lt;/i&gt;&lt;/b&gt;.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the
fair value of the equity instruments issued and are recognized over the consultants&#x2019; required service period, which is generally
the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#x201c;simplified method&#x201d; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#x2019;s vesting term plus the original contractual term divided
by two.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqM3IawMsYyf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z5NM0CWTk5cl"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;
- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected to have a material
impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <RENB:BusinessPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000657">&lt;p id="xdx_840_ecustom--BusinessPolicyTextBlock_zCtkBTkm4538" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_865_z82mb7XDjm1a"&gt;&lt;b&gt;Business
&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&#x2013; &lt;/b&gt;On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;, &#x201c;we&#x201d; or &#x201c;us&#x201d;). In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven
healthcare technology company that, if it can generate sufficient funding, will also continue to engage in the research and development
of pharmaceutical and biological products for the treatment of cancer and HIV with the intent to manufacture said products. On February
13, 2024, Renovaro Inc. acquired GEDi Cube Intl Ltd and its subsidiaries (&#x201c;Renovaro Cube&#x201d;), as a wholly owned subsidiary
pursuant to a stock purchase agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</RENB:BusinessPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000659">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTPoI30TunA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zqUWD5Hf2rW1"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000661">&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zsCwLpRfduMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zEYwhzNWWX1c"&gt;Principles of Consolidation&lt;/span&gt;
&#x2013; &lt;/b&gt;For the years ended June 30, 2024 and 2023, the consolidated financial statements include the accounts and operations of Renovaro,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="From2023-07-01to2024-06-30" id="Fact000663">&lt;p id="xdx_840_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zmOlpHsTOpk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zu4Y3q9DW8Se"&gt;Subsidiaries&lt;/span&gt; &#x2013; &lt;/b&gt;Renovaro
Biosciences Inc. (&#x201c;Renovaro Biosciences&#x201d;), formerly Renovaro Biopharma Inc., was incorporated on May 19, 2017 in Delaware
and is a 100% owned subsidiary of Renovaro. Renovaro Biosciences owns a perpetual, fully paid-up, royalty-free, sublicensable, and sole
and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize
certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV
in humans, and research and development exclusively relating to HIV in humans. As of June 30, 2024 and June 30, 2023, zero and 1,250,000
shares of Common Stock, respectively, remain contingently issuable in connection with the acquisition of Renovaro Biosciences in February
2018 (the &#x201c;Contingent Shares&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Renovaro Biosciences Denmark ApS
(&#x201c;Renovaro Denmark&#x201d;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Renovaro subject to 185,053 shares of Common Stock of Renovaro held in escrow according to Danish
law (the &#x201c;Escrow Shares&#x201d;). As of June 30, 2024, there are &lt;span id="xdx_902_ecustom--EscrowSharesRemaining_iI_c20240630_zPTtScEVzM09" title="Escrow shares remaining"&gt;17,414&lt;/span&gt; Escrow Shares remaining (see Note 9.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 13, 2024, the Company
acquired &lt;span id="xdx_901_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zv8GMXEb4Xc6" title="Acquisition percentage"&gt;100&lt;/span&gt;% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
12.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <RENB:EscrowSharesRemaining
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">17414</RENB:EscrowSharesRemaining>
    <RENB:BusinessAcquisitionPercentage
      contextRef="AsOf2024-02-13_custom_RenovaroCubeMember"
      decimals="INF"
      id="Fact000667"
      unitRef="Pure">1</RENB:BusinessAcquisitionPercentage>
    <us-gaap:UseOfEstimates contextRef="From2023-07-01to2024-06-30" id="Fact000671">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zUyeFCYi1Mn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86B_zKw8wsgRetn9"&gt;Use of Accounting Estimates&lt;/span&gt;
&lt;/b&gt;- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000673">&lt;p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zd0IBDoDmAv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zz0esm3S9tD1"&gt;Functional Currency and Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Denmark is the Danish Kroner (&#x201c;DKK&#x201d;) and the functional
currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;). The Company&#x2019;s reporting currency is the U.S. Dollar for the purpose of
these financial statements. The Company&#x2019;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates
and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years ended June 30,
2024, and 2023. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&#x2019;
equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than
the functional currency are included in the statement of operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000675">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYzze4EMsqLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zmDCKPeMM7Q9"&gt;Cash and Cash Equivalents&lt;/span&gt; &lt;/b&gt;&#x2013;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-07-01to2024-06-30" id="Fact000677">&lt;p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zXAySCjPuzqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zivhDldXlM9l"&gt;Concentration of Credit Risk&lt;/span&gt;
&#x2013;&lt;/b&gt; Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2024, and June 30, 2023, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <RENB:InsuranceReceivablePolicy contextRef="From2023-07-01to2024-06-30" id="Fact000679">&lt;p id="xdx_845_ecustom--InsuranceReceivablePolicy_z2nHO3Uaz1ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zGoifVogyvLa"&gt;Insurance Receivable&lt;/span&gt; &#x2013;&lt;/b&gt;
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</RENB:InsuranceReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000681">&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_znZFYJ0dR5y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zGm4454iLvN8"&gt;Property and Equipment&lt;/span&gt; &lt;/b&gt;-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 4.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-07-01to2024-06-30" id="Fact000683">&lt;p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zqm81xJWC1Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zZy77FcQIkK1"&gt;Intangible Assets&lt;/span&gt; - &lt;/b&gt;The
Company has both definite and indefinite life intangible assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 350, &lt;i&gt;Goodwill and Other Intangible Assets&lt;/i&gt;. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000685">&lt;p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zPTsAxhA9Zj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zvWXMaDKdB6c"&gt;Goodwill&lt;/span&gt;&lt;/b&gt; - Goodwill is not
amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000687">&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z2t7migVRUw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_ztLtjS9Gnd9a"&gt;Impairment of Goodwill and Indefinite
Lived Intangible Assets&lt;/span&gt;&lt;/b&gt; &#x2013; We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;For indefinite life intangible
assets, such as IPR&amp;amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the
IPR&amp;amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023.
During the year ended June 30, 2024, the Company recorded an impairment loss of $42,611,000 related to the termination of the license
agreement with Weird Science LLC (see Note 5.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The carrying value of
IPR&amp;amp;D and goodwill at June 30, 2024, were&#160;zero &lt;span id="xdx_903_ecustom--InProcessResearchAndDevelopment_iI_c20240630_zgdNmgs40Mq4" style="display: none" title="In-process research and development"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--Goodwill_iI_c20240630_zzUVZLh5FIY9" title="Goodwill"&gt;159,330,161&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <RENB:InProcessResearchAndDevelopment
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000691"
      unitRef="USD">0</RENB:InProcessResearchAndDevelopment>
    <us-gaap:Goodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000693"
      unitRef="USD">159330161</us-gaap:Goodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000695">&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zH3L3Gq0MHVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_869_zCJyAq8yKG0k"&gt;Impairment of Long-Lived
Assets&lt;/span&gt; - &lt;/b&gt;Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. &lt;span id="xdx_902_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zfZ0RQu56Byk" title="Impairment of assets"&gt;&lt;span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20220701__20230630_zC6SBvTVoZp5" title="Impairment of assets"&gt;No&lt;/span&gt;&lt;/span&gt; impairment
of these assets was recorded during the year ended June 30, 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000697"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000699"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000701">&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zDYiDHm5Uj2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_86E_zcQPMq32T4Xg"&gt;Leases&lt;/span&gt; -&lt;/b&gt; In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-07-01to2024-06-30" id="Fact000703">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zS59JGeVGI0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z2M4Fvb45Zy3"&gt;Research and Development Expenses&lt;/span&gt;
&#x2013; &lt;/b&gt;The Company expenses research and development costs incurred in formulating,
improving, validating, and creating alternative or modified processes related to and expanding the use of the Company&#x2019;s technologies.
Research and development expenses for the years ended June 30, 2024 and 2023 amounted to $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_z6mknozksDMg" title="Research and development expense"&gt;2,708,829&lt;/span&gt;, and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220701__20230630_zTNam0i3PUge" title="Research and development expense"&gt;4,165,197&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000705"
      unitRef="USD">2708829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000707"
      unitRef="USD">4165197</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000709">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zi8R7RVllzg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zYcYrZIRngO4"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 8.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000713">&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zIGW5pW0zBr" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zX0uNS8uJHd9"&gt;Loss Per Share&lt;/span&gt;&lt;/b&gt; - The Company calculates earnings (loss) per share in accordance with FASB ASC
260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding
during each period. Diluted earnings per common share are based on shares outstanding (computed as for basic EPS) and potentially dilutive
common shares. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options
that have been granted but have not been exercised. The shares of Common Stock outstanding at June 30, 2024 and 2023 were &lt;span id="xdx_906_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zw5OieCHee3g" title="Common stock outstanding"&gt;152,837,573&lt;/span&gt;
and &lt;span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20230630_ztcHsHRLkHg9" title="Common stock outstanding"&gt;63,698,144&lt;/span&gt;, respectively. Because of the net loss for each of the years ended June 30, 2024 and June 30, 2023, dilutive shares for
both periods were excluded from the diluted EPS calculation, as the effect of these potential shares of Common Stock is anti-dilutive.
The Company had &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zeRkKRein5I1" title="Anti-dilutive shares"&gt;17,146,315&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z4zWBToR9xad" title="Anti-dilutive shares"&gt;7,949,513&lt;/span&gt; potential shares of Common Stock excluded from the diluted EPS calculation for the years ended
June 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000715"
      unitRef="Shares">152837573</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">63698144</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">17146315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">7949513</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-07-01to2024-06-30" id="Fact000723">&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJ4GG127mXq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zd3ygNizXXM1"&gt;Fair Value of Financial Instruments&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#x201c;Fair Value Measurements&#x201d;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell
an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 1, 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of June 30, 2024. &lt;span style="background-color: white"&gt;Level
3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition
of Renovaro Cube &lt;/span&gt;(see Note 3.) There were no Level 1, 2, or 3 assets, nor any Level 1, 2, or 3 liabilities measured at fair value
on a recurring basis as of June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000725">&lt;p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z7LWcUyS4ke3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;b&gt;&lt;span id="xdx_861_zA8jExqaafKd"&gt;Stock-Based Compensation&lt;/span&gt;
- &lt;/b&gt;The Company has granted stock options, restricted share units (&#x201c;RSUs&#x201d;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of &lt;b&gt;&lt;i&gt;FASB ASC Topic 718, Compensation
&#x2013; Stock Compensation&lt;/i&gt;&lt;/b&gt;. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2024 and 2023 were $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zYradUXtK5s1" title="Stock based compensation costs"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z3hq54z74ox6" title="Stock based compensation costs"&gt;4,673,129&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zBWxheZ7LN9k" title="Stock based compensation costs"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zZU080u0jNHd" title="Stock based compensation costs"&gt;3,535,051&lt;/span&gt;&lt;/span&gt;, respectively&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company records stock-based
compensation for services received from non-employees in accordance with &lt;b&gt;&lt;i&gt;ASC 718, Compensation&#x2014;Stock Compensation Non-Employees&lt;/i&gt;&lt;/b&gt;.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the
fair value of the equity instruments issued and are recognized over the consultants&#x2019; required service period, which is generally
the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#x201c;simplified method&#x201d; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#x2019;s vesting term plus the original contractual term divided
by two.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember"
      decimals="0"
      id="Fact000727"
      unitRef="USD">4673129</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember"
      decimals="0"
      id="Fact000729"
      unitRef="USD">4673129</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_OptionMember_custom_EmployeesOfficersDirectorsAndConsultantsMember"
      decimals="0"
      id="Fact000731"
      unitRef="USD">3535051</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember"
      decimals="0"
      id="Fact000733"
      unitRef="USD">3535051</us-gaap:ShareBasedCompensation>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000735">&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqM3IawMsYyf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z5NM0CWTk5cl"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;
- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected to have a material
impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000739">&lt;p id="xdx_808_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zhz44LYWtA0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span id="xdx_824_zOZIFnamK5Q3"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company&#x2019;s consolidated financial statements are prepared using the
generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations,
has used cash in the Company&#x2019;s continuing operations, and is dependent on additional financing to fund operations. The Company incurred
a net loss of $&lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20240630_ztiR01iTTzzh" title="Net loss"&gt;80,650,172&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20220701__20230630_zL7xBOLeMhrl" title="Net loss"&gt;39,684,056&lt;/span&gt; for the years ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the Company had
cash and cash equivalents of $&lt;span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20240630_zeP5qrsfzeKd" title="Cash and cash equivalents"&gt;220,467&lt;/span&gt; and an accumulated deficit of $&lt;span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20240630_zhqkj7eOUeec" title="Accumulated deficit"&gt;324,679,425&lt;/span&gt; and a working capital deficit of $&lt;span id="xdx_90B_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20240630_zFKeA5k9g448" title="Working capital deficit"&gt;28,312,274&lt;/span&gt;. These conditions
raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements
are issued. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of
recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Management has reduced overhead and administrative costs by streamlining the organization
to focus around the development and validation of its AI driven cancer diagnostics platform. The Company has tailored its workforce to
focus on these activities. In addition, the Company intends to attempt to secure additional required funding through equity or debt financing.
However, there can be no assurance that the Company will be able to obtain any sources of funding. Such additional funding may not be
available or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant
additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our cash resources will be depleted
and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business,
stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained.
If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that
could result in our stockholders losing some or all of their investment in us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Funding that we may receive during
the fiscal year 2025 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000741"
      unitRef="USD">-80650172</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000743"
      unitRef="USD">-39684056</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000745"
      unitRef="USD">220467</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000747"
      unitRef="USD">-324679425</us-gaap:RetainedEarningsAccumulatedDeficit>
    <RENB:WorkingCapitalDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000749"
      unitRef="USD">28312274</RENB:WorkingCapitalDeficit>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000751">&lt;p id="xdx_80F_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zI3QC9EPZfqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_82F_zDC0EoQw7qMl"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company accounts for fair value
measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#x201c;Fair Value Measurements&#x201d;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1. Observable inputs
    such as quoted prices in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2. Inputs, other
    than quoted prices in active markets, that are observable either directly or indirectly; and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3. Unobservable inputs
    in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;There were no Level 1, 2 or 3 assets,
nor any Level 1 or 2 liabilities as of June 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Level 3 liabilities held as of
June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2014, acquisition of &lt;span style="background-color: white"&gt;Renovaro
Cube, (the &#x201c;Acquisition&#x201d;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) &lt;span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKJXXo440qFc" title="Contingent shares issuable in connection with the acquisition"&gt;70,834,183&lt;/span&gt;
shares of Common Stock, and (ii) the right to receive contingent shares pro rata upon the exercise of convertible notes, options, and
warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $&lt;span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_z4uD6XkDdoFg" title="Contingent consideration liability was recorded at fair value"&gt;20,557,500&lt;/span&gt; at the time
of acquisition and is subsequently remeasured to fair value at the end of each reporting period. At June 30, 2024, there were &lt;span id="xdx_902_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zLeqic9sL7Q9" title="Contingent shares issuable in connection with the acquisition"&gt;7,613,301&lt;/span&gt;
contingent shares issuable in connection with the Acquisition of Renovaro Cube.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The fair value of the contingent consideration liability is estimated using
a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs to the model are all contractual or observable
with the exception being volatility, which is computed based on the volatility of the Company&#x2019;s underlying stock. The key inputs
to valuing the contingent consideration liability as of June 30, 2024, were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueConcentrationOfRiskTextBlock_zBnobOxz4Vtb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zsouarOEXVRg" style="display: none"&gt;Schedule of key input to valuing the
contingent consideration liability&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zwBLymJsiZka" title="Stock Price"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5eprAWv41Jc" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zhNeqFWgidrh" title="Exercise Price"&gt;8.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zP4z1pEBAC81" title="Volatility"&gt;109&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zxf5r3wVt0b1" title="Volatility"&gt;145&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zs1GUyksvtoa" title="Risk Free Rate"&gt;4.24&lt;/span&gt;% - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ztV9JVnkrA8c" title="Risk Free Rate"&gt;5.21&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Dividends&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zmMHK42S0KH2" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zz2SMfb5pTuc" title="Discount Rate (Monte-Carlo model only)"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Term (years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB4swLUudTNa" title="Expected Term (years)"&gt;0.47&lt;/span&gt; &#x2013; &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zD1KKMlnrDpk" title="Expected Term (years)"&gt;9.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At initial recognition of the contingent consideration,
the inputs were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTF6VMTXIC1f" title="Stock Price"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zSTSaYAmurm8" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zp3IzcJBaQYi" title="Exercise Price"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zFtT5leyyXs8" title="Volatility"&gt;107&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zR4EEyr6Y2mh" title="Volatility"&gt;133&lt;/span&gt;% &lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z9Y2yH7mPZj1" title="Risk Free Rate"&gt;4.22&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zPhGt6Kakbgd" title="Risk Free Rate"&gt;5.14&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Dividends&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zXhsgKfhOyzd" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zM7q92wv8mMa" title="Discount Rate (Monte-Carlo model only)"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Term (years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z5r91EIdusQa" title="Expected Term (years)"&gt;0.56&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zesDQI8RTnPg" title="Expected Term (years)"&gt;9.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A9_zgey0t7etDXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Unless otherwise disclosed, the
fair value of the Company&#x2019;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The following table sets forth
the Level 3 liability at June 30, 2024, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required,
this liability is classified based on the lowest level of input that is significant to the fair value measurement:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zbGfG4BLPOI2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_z44FWU30YTme" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuxz3uOoLx22" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z20nVmD6NU5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5VPw7GjbsG4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z8wJR90B47wi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Balance June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ContingentConsiderationInAcquisition_d0_zauLxMdQZTY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Contingent consideration in Acquisition&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;20,557,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--SettlementsContingentSharesToBeIssued_d0_znw14uWDtjk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Settlements: contingent shares to be issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,520,027&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zDIZ8nQTLE5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Fair value adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,727,473&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zn6e3bHWfmch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent Consideration Liability at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,310,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A8_z2d3TaRjobdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000753"
      unitRef="Shares">70834183</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-02-13_custom_RenovaroCubeMember"
      decimals="0"
      id="Fact000755"
      unitRef="USD">20557500</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2023-07-012024-06-30_custom_RenovaroCubeMember"
      decimals="INF"
      id="Fact000757"
      unitRef="Shares">7613301</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000761">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueConcentrationOfRiskTextBlock_zBnobOxz4Vtb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zsouarOEXVRg" style="display: none"&gt;Schedule of key input to valuing the
contingent consideration liability&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zwBLymJsiZka" title="Stock Price"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z5eprAWv41Jc" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zhNeqFWgidrh" title="Exercise Price"&gt;8.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zP4z1pEBAC81" title="Volatility"&gt;109&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zxf5r3wVt0b1" title="Volatility"&gt;145&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zs1GUyksvtoa" title="Risk Free Rate"&gt;4.24&lt;/span&gt;% - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ztV9JVnkrA8c" title="Risk Free Rate"&gt;5.21&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Dividends&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zmMHK42S0KH2" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zz2SMfb5pTuc" title="Discount Rate (Monte-Carlo model only)"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Term (years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB4swLUudTNa" title="Expected Term (years)"&gt;0.47&lt;/span&gt; &#x2013; &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zD1KKMlnrDpk" title="Expected Term (years)"&gt;9.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At initial recognition of the contingent consideration,
the inputs were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pip0_c20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTF6VMTXIC1f" title="Stock Price"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zSTSaYAmurm8" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zp3IzcJBaQYi" title="Exercise Price"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zFtT5leyyXs8" title="Volatility"&gt;107&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zR4EEyr6Y2mh" title="Volatility"&gt;133&lt;/span&gt;% &lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z9Y2yH7mPZj1" title="Risk Free Rate"&gt;4.22&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zPhGt6Kakbgd" title="Risk Free Rate"&gt;5.14&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Dividends&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zXhsgKfhOyzd" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20230701__20240630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zM7q92wv8mMa" title="Discount Rate (Monte-Carlo model only)"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected Term (years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z5r91EIdusQa" title="Expected Term (years)"&gt;0.56&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zesDQI8RTnPg" title="Expected Term (years)"&gt;9.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000763"
      unitRef="USDPShares">1.75</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000767"
      unitRef="USDPShares">8.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Pure">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000771"
      unitRef="Pure">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000773"
      unitRef="Pure">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000775"
      unitRef="Pure">0.0521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-07-012024-06-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate
      contextRef="From2023-07-012024-06-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Pure">0</RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000781">P0Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000783">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000785"
      unitRef="USDPShares">1.92</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000787"
      unitRef="USDPShares">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000789"
      unitRef="USDPShares">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Pure">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Pure">0.0514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-07-012024-06-30_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate
      contextRef="From2023-07-012024-06-30_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000801"
      unitRef="Pure">0.12</RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      id="Fact000803">P0Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      id="Fact000805">P9Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000807">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zbGfG4BLPOI2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_z44FWU30YTme" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuxz3uOoLx22" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z20nVmD6NU5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230701__20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5VPw7GjbsG4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z8wJR90B47wi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Balance June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ContingentConsiderationInAcquisition_d0_zauLxMdQZTY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Contingent consideration in Acquisition&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;20,557,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--SettlementsContingentSharesToBeIssued_d0_znw14uWDtjk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Settlements: contingent shares to be issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,520,027&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zDIZ8nQTLE5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Fair value adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,727,473&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zn6e3bHWfmch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent Consideration Liability at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,310,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000809"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000810"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000811"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <RENB:ContingentConsiderationInAcquisition
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000813"
      unitRef="USD">0</RENB:ContingentConsiderationInAcquisition>
    <RENB:ContingentConsiderationInAcquisition
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000814"
      unitRef="USD">0</RENB:ContingentConsiderationInAcquisition>
    <RENB:ContingentConsiderationInAcquisition
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000815"
      unitRef="USD">20557500</RENB:ContingentConsiderationInAcquisition>
    <RENB:SettlementsContingentSharesToBeIssued
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000817"
      unitRef="USD">0</RENB:SettlementsContingentSharesToBeIssued>
    <RENB:SettlementsContingentSharesToBeIssued
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000818"
      unitRef="USD">0</RENB:SettlementsContingentSharesToBeIssued>
    <RENB:SettlementsContingentSharesToBeIssued
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000819"
      unitRef="USD">-3520027</RENB:SettlementsContingentSharesToBeIssued>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000821"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000822"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-07-012024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000823"
      unitRef="USD">-4727473</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000825"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000826"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000827"
      unitRef="USD">12310000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000830">&lt;p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zNsmgqT8NJu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 - &lt;span id="xdx_824_z9IzJrt77ZFd"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;Property and equipment consisted of the following at
June 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSqHudftYW62" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_zu3zrzDbwOw1" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab equipment and instruments&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zFEWN9XGhgs" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zCo7vEy4AjXd" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zxDQdmzWigt4" style="width: 11%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;639,998&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" style="width: 11%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;576,298&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0g8PGI59Hu9" title="Useful Life"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzoMogLZBzs9" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;224,629&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;224,629&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoX8NBYdyitg" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaetA179rV2g" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFJoCWYliyi8" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195,834&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,861&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zxdkYuKTIwUf" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,060,461&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20230630_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;973,788&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_zBgNg0j2Pjz" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(578,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230630_z7O7Yv6Oclv5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(464,799&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net Property and Equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zi2dTaTT79C8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;482,121&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;508,989&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Depreciation expense amounted to
$&lt;span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20230701__20240630_zEh2v9Hx0Lfk" title="Depreciation expense"&gt;113,563&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220701__20230630_z45hClhsf17d" title="Depreciation expense"&gt;107,321&lt;/span&gt; for the years ended June 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000832">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSqHudftYW62" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BB_zu3zrzDbwOw1" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab equipment and instruments&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zFEWN9XGhgs" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zCo7vEy4AjXd" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zxDQdmzWigt4" style="width: 11%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;639,998&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" style="width: 11%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;576,298&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0g8PGI59Hu9" title="Useful Life"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzoMogLZBzs9" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;224,629&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;224,629&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoX8NBYdyitg" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zaetA179rV2g" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFJoCWYliyi8" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195,834&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,861&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zxdkYuKTIwUf" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,060,461&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20230630_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;973,788&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_zBgNg0j2Pjz" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(578,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230630_z7O7Yv6Oclv5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(464,799&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net Property and Equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zi2dTaTT79C8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;482,121&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;508,989&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember"
      id="Fact000834">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember"
      id="Fact000836">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember"
      decimals="0"
      id="Fact000838"
      unitRef="USD">639998</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-06-30_custom_LabEquipmentAndInstrumentsMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">576298</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember"
      id="Fact000842">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000844"
      unitRef="USD">224629</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000846"
      unitRef="USD">224629</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember"
      id="Fact000848">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember"
      id="Fact000850">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">195834</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-06-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000854"
      unitRef="USD">172861</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000856"
      unitRef="USD">1060461</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000858"
      unitRef="USD">973788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000860"
      unitRef="USD">578340</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000862"
      unitRef="USD">464799</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000864"
      unitRef="USD">482121</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000866"
      unitRef="USD">508989</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000868"
      unitRef="USD">113563</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000870"
      unitRef="USD">107321</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000872">&lt;p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zsPsp0Xq5LKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_82F_zdg85Ykbdnwd"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;At June 30, 2024 and 2023, definite-life
intangible assets, net of accumulated amortization, consisted of patents on the Company&#x2019;s products and processes of $&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zEZlixppQ8Xj" title="Definite-life intangible assets"&gt;30,043&lt;/span&gt; and
$&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20230630_zb4u9PhxMBA4" title="Definite-life intangible assets"&gt;39,676&lt;/span&gt;, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense
for the years ended June 30, 2024 and 2023 was $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230701__20240630_zxorhqbGDqYe" title="Amortization expense"&gt;8,296&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220701__20230630_zNT5FqBGRNJ2" title="Amortization expense"&gt;6,175&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;At June 30, 2024 and 2023, indefinite
life intangible assets consisted of a license agreement classified as In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) intangible
assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;At June 30, 2024 and 2023, definite-life
and indefinite-life intangible assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEl8nSFh79zj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zguU80daZ7Uc" style="display: none"&gt;Schedule of definite-life
and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7dyK9Qwbij8" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z96WPpRGp7ch" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;290,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zDOWP0y1wTqb" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5DYEh1SmK9l" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQYZtKdmDtg2" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPKHgqYxtnv7" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(5,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0W2FcF7Dnoj" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;284,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zBgHrcxmYJtd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(251,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJm6WFyLE3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvWdkHKVm7xk" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zZ4WN0DaFGT4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zExdjQBCUmc2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;4,622&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_znoeLMcAMwy5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_zFprgLQPC5Eg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;39,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zVzTCs5Srb6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_zwPRsB9kBbWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zyaOCZWWa8a8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zkvryP9DqIj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(1,337&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zwajfl1cIqXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zlIfeJseg7x5" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zY6xVCLQ3dC3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_za115YJY9XE3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zka54eUJGBF9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zPmZDd8OfU2f" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zg26Cl5CI21e" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;IPR&amp;amp;D&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLn2yjKUMK58" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zHyBYA6yg9da" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zqJR78VGTXu7" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z3BpTO4IOjd6" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziH1YYGLnT83" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zcxD7Crq1oEd" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_zO5NFDLW0qm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_zTKCCd6mXxU8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zumaKkhNtit6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zZxhATdqgWRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zOEYGv6nCpli" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zpDO6SouziCc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Period Change&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Effect of Currency Translation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 15%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znm0KHNgwwpk" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIE25F2BtUb" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;279,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9QsOveXJTA6" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJeKX9RMA3Sj" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;11,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvoPlq3Zap8j" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;290,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zX09lanWwkO2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(234,989&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zUVrP4CkYt2g" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;(6,175&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zKedzq7HqHDh" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(10,096&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zQiEWYbLuOW5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(251,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630_zkLX76Nd92W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;44,268&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630_z5hlQtz3s8R3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;(6,175&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630_z615P4r3zdwj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;1,583&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z4eTFgJ8uw5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;39,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Indefinite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;License Agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zpCS3SiQxZM" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;61,571,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zRWYFzXEmA0l" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;(18,960,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zTbpbsu4nJOa" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zvtfob0kTZ85" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;42,611,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z7qFqW4Pbkw5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z74ldD7a5fB5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zm9JF2saKo32" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zA4l0J03Jvs3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Indefinite Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630_zZix9ok7dt45" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;73,211,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20220701__20230630_zWaD10y60apk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;(18,960,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630_zPcDEOjnNtD" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z1QN35w9In11" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zkk9S4xIMC5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Expected future amortization expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zXienn3ipfx5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span id="xdx_8BB_zShz1BCPmGof" style="display: none"&gt;Schedule of expected future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years
    ended&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; width: 55%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20240630_zsvcGDIsZ9U9" style="width: 32%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,511&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20240630_zSrOJT6GdRVh" style="text-align: right" title="2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,511&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20240630_zqEzxGtJlZMb" style="text-align: right" title="2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,511&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20240630_z079g9uqL5f" style="border-bottom: Black 1pt solid; text-align: right" title="2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,510&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: #CCEEFF; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #CCEEFF"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: #CCEEFF; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zfcpDTyWqYdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,043&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During February 2018, the Company
acquired IPR&amp;amp;D related to a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale,
import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of
and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. The IPR&amp;amp;D intangible
asset was classified as an indefinite life asset that was tested annually for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $159,464,039.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Impairment &#x2013; &lt;span style="background-color: white"&gt;On
March 1, 2024, the Company received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between
Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly owned subsidiary of the Company, dated
February 16, 2018. Due to the termination of the License Agreement, the Company recorded an impairment of $42,611,000 during the year
ended June 30, 2024. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Following the fourth quarter of
each year, management performs its annual test of impairment of intangible assets by performing a assessment and determines if it is more
likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the year ended June 30,
2023, the results of the assessment indicated that the carrying value of the licenses acquired as an IPR&amp;amp;D asset exceeded its fair
value, due to the changes in the projected economic benefits to be realized from these assets. Therefore, an impairment adjustment of
$&lt;span id="xdx_903_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220701__20230630_zLKUqya1CBJ3" title="Impairment adjustment"&gt;18,960,000&lt;/span&gt; was recorded for the year ended June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the year ended June 30,
2024, the results of the assessment indicated that the carrying value of the goodwill related to the RENB reporting unit exceeded its
fair value, due to the changes in the projected economic benefits to be realized from this reporting unit. Management concluded the significant
driver for the change in the economic benefits was due to the Company&#x2019;s continued inability to raise capital for the further development
of the technologies within this reporting unit. Therefore, an impairment adjustment of $&lt;span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_c20230701__20240630_zXUXxnf6sLS" title="Goodwill impairment adjustment"&gt;11,640,000&lt;/span&gt; was recorded for the year ended June
30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000874"
      unitRef="USD">30043</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000876"
      unitRef="USD">39676</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000878"
      unitRef="USD">8296</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000880"
      unitRef="USD">6175</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000882">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEl8nSFh79zj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zguU80daZ7Uc" style="display: none"&gt;Schedule of definite-life
and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7dyK9Qwbij8" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z96WPpRGp7ch" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;290,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zDOWP0y1wTqb" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5DYEh1SmK9l" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQYZtKdmDtg2" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPKHgqYxtnv7" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(5,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0W2FcF7Dnoj" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;284,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zBgHrcxmYJtd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(251,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJm6WFyLE3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvWdkHKVm7xk" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zZ4WN0DaFGT4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zExdjQBCUmc2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;4,622&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_znoeLMcAMwy5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_zFprgLQPC5Eg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;39,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zVzTCs5Srb6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_zwPRsB9kBbWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zyaOCZWWa8a8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zkvryP9DqIj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(1,337&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zwajfl1cIqXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zlIfeJseg7x5" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zY6xVCLQ3dC3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_za115YJY9XE3" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zka54eUJGBF9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zPmZDd8OfU2f" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zg26Cl5CI21e" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;IPR&amp;amp;D&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zLn2yjKUMK58" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zHyBYA6yg9da" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zqJR78VGTXu7" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z3BpTO4IOjd6" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziH1YYGLnT83" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zcxD7Crq1oEd" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_zO5NFDLW0qm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_zTKCCd6mXxU8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zumaKkhNtit6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zZxhATdqgWRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zOEYGv6nCpli" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zpDO6SouziCc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Period Change&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Effect of Currency Translation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 15%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znm0KHNgwwpk" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIE25F2BtUb" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;279,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9QsOveXJTA6" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJeKX9RMA3Sj" style="width: 13%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;11,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvoPlq3Zap8j" style="width: 13%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;290,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zX09lanWwkO2" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(234,989&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zUVrP4CkYt2g" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;(6,175&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zKedzq7HqHDh" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(10,096&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zQiEWYbLuOW5" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(251,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20220701__20230630_zkLX76Nd92W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;44,268&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630_z5hlQtz3s8R3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;(6,175&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20220701__20230630_z615P4r3zdwj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;1,583&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z4eTFgJ8uw5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;39,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Indefinite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;License Agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zpCS3SiQxZM" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;61,571,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zRWYFzXEmA0l" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;(18,960,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zTbpbsu4nJOa" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zvtfob0kTZ85" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;42,611,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z7qFqW4Pbkw5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z74ldD7a5fB5" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zm9JF2saKo32" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zA4l0J03Jvs3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Indefinite Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20220701__20230630_zZix9ok7dt45" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;73,211,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20220701__20230630_zWaD10y60apk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;(18,960,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20220701__20230630_zPcDEOjnNtD" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z1QN35w9In11" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-06-30_us-gaap_PatentsMember"
      id="Fact000884">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">290936</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000888"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000890"
      unitRef="USD">0</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000894"
      unitRef="USD">-5959</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">284977</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">-251260</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000900"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000902"
      unitRef="USD">-8296</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000904"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">4622</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000908"
      unitRef="USD">-254934</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000910"
      unitRef="USD">39676</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000912"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000914"
      unitRef="USD">-8296</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000916"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000918"
      unitRef="USD">-1337</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000920"
      unitRef="USD">30043</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000922"
      unitRef="USD">11640000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000924"
      unitRef="USD">159464039</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000926"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">-11640000</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000930"
      unitRef="USD">-133878</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">42611000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000938"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000940"
      unitRef="USD">-42611000</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000944"
      unitRef="USD">0</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000946"
      unitRef="USD">54251000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000948"
      unitRef="USD">159464039</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000950"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000952"
      unitRef="USD">-54251000</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000954"
      unitRef="USD">-133878</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000956"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-06-30_us-gaap_PatentsMember"
      id="Fact000958">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2022-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000960"
      unitRef="USD">279257</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-07-012023-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">11679</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000966"
      unitRef="USD">290936</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2022-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000968"
      unitRef="USD">-234989</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">-6175</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-07-012023-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">-10096</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">-251260</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2022-06-30"
      decimals="0"
      id="Fact000976"
      unitRef="USD">44268</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000978"
      unitRef="USD">-6175</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000980"
      unitRef="USD">1583</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000982"
      unitRef="USD">39676</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2022-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000984"
      unitRef="USD">61571000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000986"
      unitRef="USD">-18960000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-07-012023-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000988"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000990"
      unitRef="USD">42611000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2022-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000992"
      unitRef="USD">11640000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000994"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-07-012023-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000996"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000998"
      unitRef="USD">11640000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2022-06-30"
      decimals="0"
      id="Fact001000"
      unitRef="USD">73211000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001002"
      unitRef="USD">-18960000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001004"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001006"
      unitRef="USD">54251000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001009">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zXienn3ipfx5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span id="xdx_8BB_zShz1BCPmGof" style="display: none"&gt;Schedule of expected future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years
    ended&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; width: 55%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20240630_zsvcGDIsZ9U9" style="width: 32%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,511&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20240630_zSrOJT6GdRVh" style="text-align: right" title="2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,511&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20240630_zqEzxGtJlZMb" style="text-align: right" title="2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,511&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20240630_z079g9uqL5f" style="border-bottom: Black 1pt solid; text-align: right" title="2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,510&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: #CCEEFF; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #CCEEFF"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: #CCEEFF; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20240630_zfcpDTyWqYdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,043&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001011"
      unitRef="USD">7511</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001013"
      unitRef="USD">7511</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001015"
      unitRef="USD">7511</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001017"
      unitRef="USD">7510</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001019"
      unitRef="USD">30043</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001021"
      unitRef="USD">18960000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001023"
      unitRef="USD">11640000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001025">&lt;p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zXbrV8Rn2e1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_82D_z27QhDto7etl"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;b&gt;Operating
Leases &lt;/b&gt;&#x2014; &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20171112__20171113_zmhyhkwFTmj4" title="Lease premises, description"&gt;On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the &#x201c;Landlord&#x201d;) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20180618__20180619_zqJagRDgv5tg" title="Lease premises, description"&gt;On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.&lt;/span&gt; Renovaro subleased the space as
of June 25, 2022 through April 30, 2023. (See subsection below &#x201c;&lt;i&gt;Sublease Agreement&lt;/i&gt;&#x201d; for details.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company identified and assessed
the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Expected lease term &lt;/i&gt;&lt;/b&gt;&#x2014;
The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company&#x2019;s leases have a remaining lease term of 38 and 20 months. As of
June 30, 2024, the weighted-average remaining term is &lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zqLQfwhuDwl4" title="Weighted-average remaining term"&gt;2.54&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Incremental borrowing rate&lt;/i&gt;&lt;/b&gt;
&#x2014; The Company&#x2019;s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of June 30, 2024, the weighted-average
discount rate is &lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zRNk7Yzwz3u8" title="Weighted-average discount rate"&gt;5.14&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Lease and non-lease components&lt;/i&gt;&lt;/b&gt;
&#x2014; In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company&#x2019;s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;Below are the lease commitments for the next 5 years:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHnI1BKjk2W9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left"&gt;&lt;span id="xdx_8B0_zI0dHC8GMQWj" style="display: none"&gt;Schedule of lease commitments&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years Ending June 30&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; width: 55%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20240630_z91Jc5YnhIbl" style="width: 32%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;554,453&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20240630_zsmiQQUwerna" style="text-align: right" title="2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;457,876&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20240630_zlzQZjSgi9h7" style="text-align: right" title="2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;334,788&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_c20240630_zfPOPFOpA5L8" style="text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;79,830&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20240630_ziLYInVw9imf" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(91,005&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20240630_zt7k5GblH3Z4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,335,942&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zXhrEROCZzyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Sublease Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_902_eus-gaap--LesseeFinanceSubleaseResidualValueGuaranteeDescription_c20220619__20220620_zJcESeUYkgOg" title="Sublease agreement description"&gt;On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the &#x201c;Subtenant&#x201d;), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;In accordance with ASC Topic 842,
the Company treated the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease.
The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement
date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease was classified as an operating lease,
as it did not meet the criteria of a sales-type or direct financing lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;On
April 18, 2023, the Company entered into a sublease termination agreement with the Subtenant, whereby the Subtenant and the Company agreed
to terminate the sublease effective as of April 30, 2023. The Subtenant agreed to pay the Company $&lt;span id="xdx_90C_eus-gaap--PaymentsForLeasingCosts_c20230417__20230418_zEmfToCM6E0j" title="Lease payment"&gt;139,460&lt;/span&gt;&#160;along with the security
deposit of $&lt;span id="xdx_90C_eus-gaap--SecurityDeposit_iI_c20230418_ziBoBeUGwQRi" title="Security deposit"&gt;35,540&lt;/span&gt;&#160;for a total termination fee of $&lt;span id="xdx_902_eus-gaap--LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_iI_c20230418_z9bPmX0t24o5" title="Termination fee"&gt;175,000&lt;/span&gt;, to permit early termination of the sublease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company recognized operating
income from the sublease on a straight-line basis in its statements of operations over the sublease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the year ended June 30,
2024 and 2023, the net operating lease expenses were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zClWMCshP0ll" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES  (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zVDyewUsV1i4" style="display: none"&gt;Schedule of net operating lease expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20230701__20240630_z7Z8JeCBbNge" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20220701__20230630_zaAsbDrXA7wa" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OperatingLeaseExpense_z8QC4eOSRgKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating Lease Expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;383,549&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;322,447&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--SubleaseIncome_iN_di0_zjjQBthl57J7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sub-lease Income&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(352,700&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--OperatingLeaseRentExpenses_zU4fEdtwtDM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Net Lease Expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;383,549&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(30,253&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A6_zfFtkQQ3ZWKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Lease expense charged&#160;to general
and administrative expenses for the years ended June 30, 2024 and 2023, amounted to $&lt;span id="xdx_902_eus-gaap--LeaseCost_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqtDwp9XG5k7" title="Lease expense"&gt;383,549&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--LeaseCost_c20220701__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgHKCs3mzAF2" title="Lease expense"&gt;322,447&lt;/span&gt;, respectively. During the years
ended June 30, 2024 and 2023, the Company paid $&lt;span id="xdx_907_eus-gaap--OperatingLeasePayments_c20230701__20240630_zI7A5sLbbQm2" title="Operating lease payments"&gt;380,983&lt;/span&gt;&#160;and $&lt;span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20220701__20230630_zWYmGiyAW043" title="Operating lease payments"&gt;439,519&lt;/span&gt; under operating leases, respectively. The difference between
the operating lease expense for the year ended June 30, 2023 in the amount of $&lt;span id="xdx_905_ecustom--OperatingLeaseExpenses_c20220701__20230630_zs7DsWAxctke" title="Operating lease expense"&gt;322,447&lt;/span&gt; and the cash paid of $&lt;span id="xdx_900_ecustom--CashPaidForTheTerminationOfLease_iI_c20230630_zDyL8t7GYUI7" title="Cash payments"&gt;439,519&lt;/span&gt;, is primarily made
up of the release of an accrual of $&lt;span id="xdx_908_ecustom--AccrualPaymentsRelatedToTerminationOfLease_c20220701__20230630_znv95olzTyS8" title="Accrual payments related to the termination of lease"&gt;77,242&lt;/span&gt; related to the termination of the Plaza Medical Office Building, LLC lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2017-11-122017-11-13" id="Fact001027">On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the &#x201c;Landlord&#x201d;) pursuant
to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year
and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease
was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold
improvements that was not utilized.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2018-06-182018-06-19" id="Fact001029">On June 19, 2018, Renovaro entered
into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which
the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original
Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for
a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186
per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-06-30" id="Fact001033">P2Y6M14D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001035"
      unitRef="Pure">0.0514</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001037">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHnI1BKjk2W9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left"&gt;&lt;span id="xdx_8B0_zI0dHC8GMQWj" style="display: none"&gt;Schedule of lease commitments&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years Ending June 30&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; width: 55%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20240630_z91Jc5YnhIbl" style="width: 32%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;554,453&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20240630_zsmiQQUwerna" style="text-align: right" title="2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;457,876&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20240630_zlzQZjSgi9h7" style="text-align: right" title="2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;334,788&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_c20240630_zfPOPFOpA5L8" style="text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;79,830&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20240630_ziLYInVw9imf" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(91,005&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20240630_zt7k5GblH3Z4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,335,942&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001039"
      unitRef="USD">554453</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001041"
      unitRef="USD">457876</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001043"
      unitRef="USD">334788</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <RENB:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001045"
      unitRef="USD">79830</RENB:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001047"
      unitRef="USD">91005</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001049"
      unitRef="USD">1335942</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeFinanceSubleaseResidualValueGuaranteeDescription contextRef="From2022-06-192022-06-20" id="Fact001051">On June 20, 2022, the Company entered
into a sublease Agreement with One Health Labs (the &#x201c;Subtenant&#x201d;), whereby the Subtenant agreed to lease 3,554 square feet
of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to
renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility
fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received
a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease
payment began on August 1, 2022.</us-gaap:LesseeFinanceSubleaseResidualValueGuaranteeDescription>
    <us-gaap:PaymentsForLeasingCosts
      contextRef="From2023-04-172023-04-18"
      decimals="0"
      id="Fact001055"
      unitRef="USD">139460</us-gaap:PaymentsForLeasingCosts>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-04-18"
      decimals="0"
      id="Fact001057"
      unitRef="USD">35540</us-gaap:SecurityDeposit>
    <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees
      contextRef="AsOf2023-04-18"
      decimals="0"
      id="Fact001059"
      unitRef="USD">175000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001061">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zClWMCshP0ll" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES  (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zVDyewUsV1i4" style="display: none"&gt;Schedule of net operating lease expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20230701__20240630_z7Z8JeCBbNge" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20220701__20230630_zaAsbDrXA7wa" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OperatingLeaseExpense_z8QC4eOSRgKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating Lease Expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;383,549&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;322,447&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--SubleaseIncome_iN_di0_zjjQBthl57J7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sub-lease Income&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(352,700&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--OperatingLeaseRentExpenses_zU4fEdtwtDM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Net Lease Expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;383,549&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(30,253&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001063"
      unitRef="USD">383549</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001064"
      unitRef="USD">322447</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001066"
      unitRef="USD">-0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001067"
      unitRef="USD">352700</us-gaap:SubleaseIncome>
    <RENB:OperatingLeaseRentExpenses
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001069"
      unitRef="USD">383549</RENB:OperatingLeaseRentExpenses>
    <RENB:OperatingLeaseRentExpenses
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001070"
      unitRef="USD">-30253</RENB:OperatingLeaseRentExpenses>
    <us-gaap:LeaseCost
      contextRef="From2023-07-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001072"
      unitRef="USD">383549</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-07-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001074"
      unitRef="USD">322447</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001076"
      unitRef="USD">380983</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001078"
      unitRef="USD">439519</us-gaap:OperatingLeasePayments>
    <RENB:OperatingLeaseExpenses
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001080"
      unitRef="USD">322447</RENB:OperatingLeaseExpenses>
    <RENB:CashPaidForTheTerminationOfLease
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001082"
      unitRef="USD">439519</RENB:CashPaidForTheTerminationOfLease>
    <RENB:AccrualPaymentsRelatedToTerminationOfLease
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001084"
      unitRef="USD">77242</RENB:AccrualPaymentsRelatedToTerminationOfLease>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001086">&lt;p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_ztOurOM8R2ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_82E_zWJtPRBWOp3b"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Convertible Notes Payable &#x2014;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;March 2024 Note &#x2014;&lt;/i&gt;&lt;/b&gt;
On March 14, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note in the amount
of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_znEreOjiWg1g" title="Principal amount"&gt;500,000&lt;/span&gt; (the &#x201c;March 2024 Note&#x201d;). The March 2024 Note had an interest rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zRrjeum5ZSuj" title="Note interest rate"&gt;10&lt;/span&gt;% per annum and was due to mature on &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20240313__20240314__us-gaap--AwardDateAxis__custom--MarchNote2024Member_z38E3Pzd24xf" title="Debt maturity period"&gt;March
15, 2025&lt;/span&gt;. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following
the issue date prior to the maturity of the March 2024 Note. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The March 2024 Note was convertible at the option of the holder after a qualified offering.
If no qualified offering occurs prior to the maturity date, the March 2024 Note was to be repaid in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On June 14, 2024, the Company sold
&lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zbZJpgBjjY93" title="Sale of stock, shares"&gt;344,966&lt;/span&gt; of the Company&#x2019;s units, each such unit consisting of (i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zIThcbEni5Zc" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value
per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock (a &#x201c;Unit&#x201d;), to the holder
of the March 2024 Note in consideration for the total $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_z9AAEdhuCaWh" title="Sale of stock, consideration"&gt;512,361&lt;/span&gt; in principal amount and interest accrued under the March 2024 Note. The
warrants are exercisable for five years from the date of issuance and have an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zP9r6wIEZMKg" title="Exercise price"&gt;1.4726&lt;/span&gt; per share, payable in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;In the year ended June 30, 2024,
the Company recorded interest expense of $&lt;span id="xdx_908_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zWPXjcMYN8We" title="Accrued interest expense"&gt;12,361
&lt;/span&gt;related to the March 2024 Note. The March 2024 Note balance at June 30, 2024 was zero &lt;b style="display: none"&gt;&lt;span id="xdx_905_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--MarchNote2024Member_zcfvv3UMhxwg" title="Interest expense related to note balance"&gt;0&lt;/span&gt;&lt;/b&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;The 2024 Notes &#x2014;&lt;/i&gt;&lt;/b&gt;
On January 11, 2024, the Company entered into a Subscription Agreement with an investor to issue a Convertible Promissory Note (the &#x201c;January
2024 Note I&#x201d;) in the amount of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zG7dM5YCtCyb" title="Principal amount"&gt;460,000&lt;/span&gt;. The January 2024 Note I had an interest rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zcWtBEbhmEl7" title="Note interest rate"&gt;12&lt;/span&gt;% per annum and was due to mature on
&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20240110__20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zlJdzbZmYQK3" title="Debt maturity period"&gt;January 11, 2025&lt;/span&gt;. The Company was required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year
following the issue date prior to the maturity of the notes. Notwithstanding the immediately foregoing, at the option of the holder, interest
could accrue on this note on a quarterly basis. The January 2024 Note I was convertible either at the option of the holder or automatically
upon maturity into shares of the Company&#x2019;s Common Stock at the conversion price of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240111__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z15aYoyYosHd" title="Conversion price per share"&gt;3.38&lt;/span&gt;. On January 12, 2024, the Company entered
into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate principal amount of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zUekcdH8TOb8" title="Principal amount"&gt;125,000&lt;/span&gt; (the
&#x201c;January 2024 Note II&#x201d;, and collectively with the January 2024 Note I, the &#x201c;January 2024 Notes&#x201d;). The Company
received a total of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zlVS57Qfh3n5" title="Gross proceeds"&gt;125,000&lt;/span&gt; in gross proceeds.&#160;The January 2024 Note II bears an interest rate of &lt;span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zILBVqcMJW07" title="Bear interest percentage"&gt;12&lt;/span&gt;% per annum and shall mature
on &lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRwwKnRyZ3Xe" title="Debt maturity period"&gt;December 29, 2024&lt;/span&gt;. The Company is required to pay interest quarterly, in arrears, in cash, on the first day of each quarter of each
year following the issue date prior to the maturity of the January 2024 Note II. The January 2024 Note II is convertible either at the
option of the holder or automatically upon maturity into shares of the Company&#x2019;s Common Stock at the Note Conversion Price of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zsPSPhg9COkl" title="Conversion price"&gt;3.38&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On June 14, 2024, the Company sold
&lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDdKEEkV0yGg" title="Sale of stock, shares"&gt;325,508&lt;/span&gt; of the Company&#x2019;s Units, each such Unit consisting of (i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zNsTgxBIiRI6" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value
per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, to the holder of the January 2024
Note I in consideration for the total $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zTll5SqOjwr7" title="Sale of stock, consideration"&gt;483,460&lt;/span&gt; in principal amount and interest accrued under the January 2024 Note I. The warrants are
exercisable for five years from the date of issuance and have an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zkGoAObVqdrl" title="Exercise price"&gt;1.4726&lt;/span&gt; per share, payable in cash. The January 2024
Notes principal balance at June 30, 2024, is $&lt;span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zqDL8c4094tg" title="Principal outstanding balance"&gt;125,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;December 2023 Notes &#x2014;
&lt;/i&gt;&lt;/b&gt;Between December 1, 2023, and December 29, 2023, the Company entered into Subscription Agreements with two investors to purchase
Convertible Promissory Notes for an aggregate principal amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zBDrc6MPnTw4" title="Principal amount"&gt;560,000&lt;/span&gt; (the &#x201c;December Notes&#x201d;). The Company received a
total of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zPlTycp5Xdya" title="Gross proceeds"&gt;560,000&lt;/span&gt; in gross proceeds, consisting of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement1Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zqhikarnyqi7" title="Gross proceeds"&gt;440,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20231201__20231229__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement2Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zYHut2UtMQr9" title="Gross proceeds"&gt;100,000&lt;/span&gt; from the private placement prior to the end of the quarter ending
December 31, 2023, and $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20240130__20240131__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacement3Member__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zgAUZi71WEf9" title="Gross proceeds"&gt;20,000&lt;/span&gt; received in January 2024.&#160;The December Notes bear an interest rate of &lt;span id="xdx_902_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z3xnT4EyCOZh" title="Bear interest percentage"&gt;12&lt;/span&gt;% per annum and shall mature
one year after their respective dates of issuance (the &#x201c;Maturity Date&#x201d;). The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December Notes.
Notwithstanding the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis.
The December Notes are convertible into shares of the Company&#x2019;s Common Stock in whole or in part at any time and from time to time,
after the original issue date and prior to the Maturity Date, at a conversion price of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231229__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zJCCP7ZLU7bi" title="Conversion price"&gt;3.38&lt;/span&gt; per share. The December Notes will be accounted
for under ASC 470-20.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On June 14, 2024, in a private
placement the Company sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zncBlcuFNyr9" title="Sale of stock, shares"&gt;317,715&lt;/span&gt; Units to an investor who surrendered and terminated $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zVxlDSbpUNb1" title="Principal amount"&gt;440,000&lt;/span&gt; in aggregate principal amount and $&lt;span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z7DOdIZxFOf2" title="Interest accrued"&gt;28,453&lt;/span&gt;
of interest accrued on the December Notes and paid in cash an aggregate amount of $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zdTdL0VUcoe6" title="Sale of stock, consideration"&gt;66,000&lt;/span&gt; to the Company in consideration for the Units,
each such Unit consisting of (i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zhGaOZoP782d" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value per share and (ii) one common stock
purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are exercisable for five years from the date of issuance
and have an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zBTzXUBEhmNf" title="Exercise price"&gt;1.4726&lt;/span&gt; per share, payable in cash. The December Notes principal balance at June 30, 2024, is $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zYuY6PBuEtt1" title="Principal outstanding balance"&gt;120,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;In the year ended June 30, 2024,
the Company has recorded interest expense of $&lt;span id="xdx_909_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRCjcugYiKgh" title="Accrued interest expense"&gt;&lt;span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zH4XMIkRRvog" title="Accrued interest expense"&gt;67,013&lt;/span&gt;&lt;/span&gt; related to the January 2024 Notes and December 2023 Notes. The January 2024 Notes
and December 2023 Notes balance at June 30, 2024 was $&lt;span id="xdx_902_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630_zqTv4FS1LN9a" title="Interest expense related to note balance"&gt;245,000&lt;/span&gt; of which $&lt;span id="xdx_900_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zT5acpvAkmWa" title="Interest expense related to note balance"&gt;120,000&lt;/span&gt; is related to the December 2023 Notes and $&lt;span id="xdx_906_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zRV4rHnAPg5c" title="Interest expense related to note balance"&gt;125,000&lt;/span&gt; is
related to the January 2024 Notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;The 2023 Notes &#x2014; &lt;/i&gt;&lt;/b&gt;Between
September 5, 2023, and October 5, 2023, the Company entered into Subscription Agreements with five investors to purchase &lt;span id="xdx_902_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zGXhzfXeVYOd" title="Original issue discount percentage"&gt;5&lt;/span&gt;% Original Issue
Discount Convertible Promissory Notes (the &#x201c;2023 Notes&#x201d;) for an aggregate principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zWbt2orNN3Cl" title="Principal amount"&gt;2,105,263&lt;/span&gt;. The Company received
a total of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zKjJfGCthUa" title="Gross proceeds"&gt;2,000,000&lt;/span&gt; in gross proceeds from the private placement, after taking into account the &lt;span id="xdx_90F_ecustom--DebtInstrumentOriginalIssueDiscount_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zFaYBLSPpv13" title="Original issue discount percentage"&gt;5&lt;/span&gt;% original issue discount.&#160;The
discount of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zS3sUwPlRzFf" title="Discount accreted"&gt;105,263&lt;/span&gt; was to be accreted over the life of the 2023 Notes. The 2023 Notes had an interest rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_z7JpsOqsJWq1" title="Note interest rate"&gt;12&lt;/span&gt;% per annum and were
due to mature on &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zjlOUtzeLBjg" title="Maturity date"&gt;September 5, 2024&lt;/span&gt; (the &#x201c;Maturity Date&#x201d;). The Company was required to pay interest quarterly, in arrears,
in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest could accrue on the notes on a quarterly basis. The 2023 Notes were convertible
into shares of the Company&#x2019;s Common Stock upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The 2023 Notes were subject to
mandatory conversion (&#x201c;Mandatory Conversion&#x201d;) in the event the Company closed an offering of its Common Stock and received
gross proceeds of not less than $&lt;span id="xdx_90B_ecustom--CommonStockAndReceivedGrossProceeds_pp0p0_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zUXdxKUqGpLc" title="Common stock and received gross proceeds"&gt;10,000,000&lt;/span&gt; (a &#x201c;Qualified Offering&#x201d;). The conversion price per share of Common Stock in the
case of a Mandatory Conversion was to be &lt;span id="xdx_906_ecustom--OfferingPricePerSharePercentage_dp_c20230905__20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zfm3KMyQS5Ei" title="Offering price per share percentage"&gt;95&lt;/span&gt;% of the offering price per share in the Qualified Offering, subject to a floor of $&lt;span id="xdx_909_ecustom--DebtInstrumentsFloorPricePerShare_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zqDEAEufuJcg" title="Floor price per share"&gt;4.50&lt;/span&gt; per
share.&#160;In addition, if no Qualified Offering occurred prior to the Maturity Date, the 2023 Notes were to automatically convert into
shares of Common Stock on the Maturity Date at a conversion price per share equal to the closing sale price of the Common Stock on the
Maturity Date, subject to a floor of $&lt;span id="xdx_900_ecustom--DebtInstrumentsFloorPricePerShare_iI_c20231005__us-gaap--AwardDateAxis__custom--Note2023Member_zXwaXT00AhN2" title="Floor price per share"&gt;4.50&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 11, 2024, the Company
entered into an amendment with one of the investors of the 2023 Notes whereas the conversion terms were amended to provide for optional
conversion at a conversion price of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240111__us-gaap--AwardDateAxis__custom--Note2023Member_znVOFdEFVWtb" title="Conversion price"&gt;3.38&lt;/span&gt; per share. All other terms of the Promissory Note remained the same. The Company treated this
as a modification for accounting purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On June 14, 2024, the Company
sold &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_z7usAFPfMSub"&gt;1,546,449 &lt;/span&gt;Units
to the holders of the 2023 Notes who surrendered and terminated $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zuxAOAQ9hmke"&gt;2,293,825 &lt;/span&gt;in
aggregate principal amount and interest accrued thereon of the 2023 Notes and paid in cash an aggregate amount of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zY6p69xrGXMc"&gt;443,575 &lt;/span&gt;(of
which $&lt;span id="xdx_90F_eus-gaap--OtherNotesPayable_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_zTQWpU6C4gR7"&gt;318,063 &lt;/span&gt;was
applied against the Company&#x2019;s Promissory Notes), to the Company in consideration for the Units, each such Unit consisting of
(i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--Note2023Member_z7FYUQoOXDFj"&gt;0.0001 &lt;/span&gt;par
value per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock. The warrants are
exercisable for five years from the date of issuance and have an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--Note2023Member__srt--RangeAxis__srt--MinimumMember_zHw7RDMKS5kb"&gt;1.4726&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--Note2023Member__srt--RangeAxis__srt--MaximumMember_zBnU4maHJYN3"&gt;1.4765 &lt;/span&gt;per
share, payable in cash. The 2023 Notes principal balance at June 30, 2024, is zero &lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240614__us-gaap--AwardDateAxis__custom--Note2023Member_zadYXn9LQs5" style="display: none" title="Principal outstanding balance"&gt;0&lt;/span&gt;&lt;b&gt;&lt;/b&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;For the year ended
June 30, 2024, discount amortization of $&lt;span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zT2Kwalmf8f5" title="Debt amortization discount"&gt;78,567
&lt;/span&gt;was charged to interest expense and $&lt;span id="xdx_90A_eus-gaap--InterestIncomeExpenseAfterProvisionForLoanLoss_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zmyiWjDhFsjh" title="Discount amortization to other income and expense"&gt;26,696
&lt;/span&gt;of discount amortization was charged to other income and expense due to the early termination of the notes, respectively. In the
year ended June 30, 2024, the Company recorded interest expense of $&lt;span id="xdx_90C_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zOW3uHhkvnbd" title="Accrued interest expense"&gt;189,614&lt;/span&gt; related to the 2023 Notes. The 2023 Notes balance, net of
discount at June 30, 2024 is zero &lt;b style="display: none"&gt;&lt;span id="xdx_905_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--AwardDateAxis__custom--Note2023Member_zvOZs0QDeTg7" title="Interest expense related to note balance"&gt;0&lt;/span&gt;&lt;/b&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;The Convertible Notes &#x2014;
&lt;/i&gt;&lt;/b&gt;On February 6, 2020, the Company issued two Convertible Notes (the &#x201c;Convertible Notes&#x201d;) to Paseco ApS (the &#x201c;Holder&#x201d;),
a Danish limited company and an existing stockholder of the Company, each with a face value amount of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200206__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_zNL4Iqq8QOY5" title="Principal amount"&gt;600,000&lt;/span&gt;, convertible into shares
of Common Stock. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023. Interest on the Convertible
Notes commenced accruing on the date of issuance at six percent (&lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200205__20200206__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_z88mGEiBFj5b" title="Interest rate"&gt;6&lt;/span&gt;%) per annum, computed on the basis of twelve 30-day months, and was
compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as
of such compound date. The interest was payable in cash on a semi-annual basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;The
conversion price was equal to $12.00&#160;per share of Common Stock. The Holder did not exercise its conversion feature that expired on
February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded
conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily
convertible into cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Effective December 30, 2022 (the
&#x201c;Effective Date&#x201d;), the Company amended and restated the Convertible Notes (the &#x201c;Amended and Restated Secured Notes&#x201d;).
Pursuant to the Amended and Restated Secured Notes, the due date was extended to &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zbSaZAfpZdoa" title="Maturity date"&gt;February 28, 2024&lt;/span&gt;. The Amended and Restated Secured Notes
were convertible by the Holder if the Company consummated a public offering or private placement of Common Stock or securities convertible
into Common Stock. The conversion price was to be the price being paid by the investors in such offering. The interest rate was increased
to twelve percent (&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zW3l8gv54ipd" title="Interest rate"&gt;12&lt;/span&gt;%) per annum, which was prepaid by the Company in full on the date of amendment through the issuance of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_ziVjgvyAdWj" title="Issuance of shares"&gt;198,439&lt;/span&gt; shares
of the Company&#x2019;s Common Stock: &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zDHmxxKeGdj4" title="Shares issued for accrued interest"&gt;29,419&lt;/span&gt; shares for accrued interest up to the Effective Date and &lt;span id="xdx_901_ecustom--PrepaymentShares_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zLFtIxfT4c6f" title="Prepayment shares"&gt;169,020&lt;/span&gt; shares related to the prepayment
of interest through the extension date of the Amended and Restated Secured Notes using the Common Stock closing market price on the Effective
Date, of $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zeskKTPMIVH7" title="Stock price"&gt;1.03&lt;/span&gt;. The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the
&#x201c;Security Agreement&#x201d;). The Company evaluated the Amended and Restated Secured Notes and conversion feature to determine the
appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480 - Distinguishing Liabilities from Equity,
the Company determined that the Amended and Restated Secured Notes embody an obligation that may require the Company to settle with the
issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a fixed monetary amount
of $&lt;span id="xdx_902_eus-gaap--ContractualObligation_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_znbRdp9YqTfa" title="Obligation value"&gt;1,200,000&lt;/span&gt; known at inception. Accordingly, the Company recorded the Amended and Restated Secured Notes as share settled debt. The
total value of the shares issued was $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20221229__20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zb7Iirudq5pj" title="Number of shares issued, value"&gt;204,392&lt;/span&gt; which included $&lt;span id="xdx_90F_eus-gaap--PrepaidInterest_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zVa32eaFbIc" title="Prepaid interest"&gt;174,090&lt;/span&gt; of prepaid interest and $&lt;span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221230__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zP4wggekfhRd" title="Accrued interest amount"&gt;30,302&lt;/span&gt; for accrued interest as of December
30, 2022. On June 26, 2023, &lt;span style="background-color: white"&gt;the Holder notified the Company that it wished to elect to exercise
its conversion right triggered by a private placement. Therefore, all outstanding $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20230625__20230626__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zydmnuHiR6ek" title="Stock issued for debt conversion"&gt;1,200,000&lt;/span&gt; Amended and Restated Secured Notes were converted
into 2,264,150 shares of Common Stock and warrants to purchase &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230625__20230626__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__custom--AmendedAndRestatedSecuredNotesMember_zNo35IDjqls4" title="Stock issued for debt conversion, shares"&gt;1,132,075&lt;/span&gt; shares of Common Stock. There were no Amended and Restated Secured
Notes outstanding after the foregoing conversion. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Notes Payable &lt;/b&gt;&#x2014;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Bridge Loans &#x2014; &lt;/i&gt;&lt;/b&gt;Between
March 26, 2024 and June 4, 2024 the Company issued Paseco ApS promissory notes (the &#x201c;Notes&#x201d;) in the aggregate principal and
interest accrued amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20240326__20240604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zjGjqVJdo5Fb" title="Principal and interest accrued amount"&gt;2,098,252&lt;/span&gt;. The Notes had an interest rate of &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zceVXPNJudY7" title="Note interest rate"&gt;10&lt;/span&gt;% per annum and were to mature between May 1, 2024, and August
1, 2024. The Notes were accounted for under ASC 470-20, and all proceeds received from the issuance was recognized as a liability on the
balance sheet. On June 14, 2024, the Company sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_znI3FhikuxQc" title="Sale of stock, shares"&gt;1,424,862&lt;/span&gt; Units at a price per Unit equal to $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zs7p5aUctQqi" title="Sale of stock, price per share"&gt;1.4726&lt;/span&gt; to settle the bridge loan aggregate
amount of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_z30xhfD2iRh2" title="Sale of stock, value"&gt;2,098,252&lt;/span&gt;. As of June 30, 2024 the Notes balance is zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 5, 2024, the
Company entered into an agreement with RS Bio ApS, a Danish entity controlled by the Company&#x2019;s Chairman, Rene Sindlev
(&#x201c;RS Bio&#x201d;) to issue a &lt;span id="xdx_901_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zJpZ1yRAt5ji" title="Original issue discount promissory note percentage"&gt;5&lt;/span&gt;%
Original Issue Discount Secured Promissory Note for the principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zbd3k9k9P9vc" title="Principal amount"&gt;105,263&lt;/span&gt;.
The Company received $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfDebt_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zvREn5B0qmG1" title="Gross proceeds"&gt;100,000&lt;/span&gt;
in gross proceeds after taking into account the &lt;span id="xdx_90E_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zj82Hp9EAvfl" title="Gross proceeds original issue discount rate"&gt;5&lt;/span&gt;%
original issue discount. The note bears an interest rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zchMHdsRwFN3" title="Interest rate"&gt;12&lt;/span&gt;%
per annum and matured on &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zMcqeKmWlsJa" title="Debt maturity period"&gt;March
1, 2024&lt;/span&gt; and was extended to December 31, 2024. The obligations under this note are secured by the Amended
and Restated Security Agreement. The Company is required to pay interest on the maturity date. The note is accounted for under ASC
470-20, and all proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. For the
year ended June 30, 2024, discount amortization of $&lt;span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zXmxZ1pp5oea" title="Amortization of debt discount"&gt;5,263&lt;/span&gt;
was charged to interest expense. As of June 30, 2024, the Company accrued $&lt;span id="xdx_90E_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zDhup9fSBzmi" title="Accrued interest expense"&gt;6,316&lt;/span&gt;
of interest expense that is included in accrued expenses on the balance sheet. The note balance, net of discount at June 30, 2024
was $&lt;span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--RSBioApSMember_zQD1XR0yIaga" title="Net of debt discount"&gt;105,263&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a &lt;span id="xdx_903_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zNgqXKkLY9t2" title="Original issue discount promissory note percentage"&gt;5&lt;/span&gt;% Original Issue Discount Secured Promissory Note for the principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zprJ9yNX5ZI9" title="Principal amount"&gt;526,315&lt;/span&gt;
(the &#x201c;January 2024 Note&#x201d;). The Company received a total of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zlYx472HH0Tc" title="Gross proceeds"&gt;500,000&lt;/span&gt; in gross proceeds after taking into account the &lt;span id="xdx_90C_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zOaT0QXUFg2k" title="Gross proceeds original issue discount rate"&gt;5&lt;/span&gt;% original
issue discount.&#160;The January 2024 Note bears an interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zU2WDNKwwWnl" title="Interest rate"&gt;12&lt;/span&gt;% per annum and matured on &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_znbqkgXK8jA4" title="Debt maturity period"&gt;March 1, 2024&lt;/span&gt; and was extended to December 31, 2024. The Company
is required to pay interest on the maturity date. The January 2024 Note will be accounted for under ASC 470-20, and all proceeds received
from the issuance will be recognized as a liability on the balance sheet net of discount. For the year ended June 30, 2024, discount amortization
of $&lt;span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zMOD7WyFuTxh" title="Amortization of debt discount"&gt;26,315&lt;/span&gt; was charged to interest expense. As of June 30, 2024, the Company accrued $&lt;span id="xdx_905_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__custom--AccruedExpensesMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zXkp7b5ojcgi" title="Accrued interest expense"&gt;31,579&lt;/span&gt; of interest expense that is included in accrued
expenses on the balance sheet. The Note balance, net of discount at June 30, 2024 was $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zAwEZfPawyW7" title="Net of debt discount"&gt;526,315&lt;/span&gt;. In connection with the entry into the
January 2024 Note, the Company and Paseco ApS agreed to amend and restate a Security Agreement to add the Company&#x2019;s obligations
under the November 2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On November 22, 2023, Renovaro
Cube entered into a loan agreement where the holder agreed to loan the Company up to &#xa3;500,000 (approximately $624,000 USD). The
note had a repayment date occurring the first business day after the first anniversary of the draw down of the loan. The first draw down
of &#xa3;250,000 occurred on November 27, 2023, and the second draw down of &#xa3;250,000 occurred on December 13, 2023. The Company
paid interest on the loan at the rate of &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20231121__20231122__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z21yqa3vCc02" title="Interest rate"&gt;10&lt;/span&gt;%
per annum. Interest was accrued quarterly in arrears on the last business day of March, June, September, and December and was payable
on the repayment date. On June 14, 2024 the Company sold &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdPDkHfWH8T1"&gt;454,708
&lt;/span&gt;Units to the holder and terminated $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zOtixoiodQLg"&gt;665,387
&lt;/span&gt;in aggregate principal amount and accrued interest and received in cash an aggregate amount of $&lt;span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240613__20240614__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zONqHSUkgIRh"&gt;100,400
&lt;/span&gt;in consideration for the Units which was applied against the loan. For the year ended June 30, 2024, the Company recorded $&lt;span id="xdx_903_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember_zRKoThO9EJL6" title="Accrued interest expense"&gt;36,388
&lt;/span&gt;of interest expense related to this loan. The total amount of the loan at June 30, 2024, is zero &lt;b style="display: none"&gt;&lt;span id="xdx_900_ecustom--InterestExpenseRelatedToNoteBalance_c20230701__20240630__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--LongtermDebtTypeAxis__custom--LoanAgreementMember_zYQD5pRu7a3i" title="Interest expense related to note balance"&gt;0&lt;/span&gt;&lt;/b&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On November 3, 2023, the
Company entered into an agreement with RS Bio to issue a &lt;span id="xdx_908_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zZWayyJt9D2b"&gt;5&lt;/span&gt;%
Original Issue Discount Promissory Note for the principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zkFpdUV0hIua"&gt;1,000,000&lt;/span&gt;
(the &#x201c;November 2023 Note&#x201d;). The Company received a total of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zaJWGPOfuhNj"&gt;950,000&lt;/span&gt;
in gross proceeds after taking into account the &lt;span id="xdx_901_ecustom--GrossProceedsDiscountPercentage_iI_dp_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zect0el2ZFYb"&gt;5&lt;/span&gt;%
original issue discount.&#160;The discount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zqKCsOO5C8Vl"&gt;50,000&lt;/span&gt;
will be accreted over the life of the Note. The November 2023 Note bears an interest rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKhLsNSuUiqi"&gt;12&lt;/span&gt;%
per annum and was due to mature on &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20231102__20231103__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zCRB9dwseT18"&gt;January
1, 2024&lt;/span&gt; (the &#x201c;Maturity Date&#x201d;). On January 1, 2024, the Company entered into an amendment with RS
Bio for the November 2023 Note to extend the maturity date to &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--AwardDateAxis__custom--November2023NoteMember__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxF6zffsgI4h"&gt;March
1, 2024&lt;/span&gt; and  was extended to December 31, 2024. The Company is required to pay interest on the maturity
date. The November 2023 Note will be accounted for under ASC 470-20, and all proceeds received from the issuance will be recognized
as a liability on the balance sheet net of discount. On February 16, 2024, the Company received notice from the holder to exercise &lt;span id="xdx_903_ecustom--ExerciseWarrants_iI_c20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_z4u4gDi1kBxl" title="Number of warrants exercised"&gt;471,699&lt;/span&gt;
warrants outstanding at $&lt;span id="xdx_903_ecustom--WarrantsOutstandingPerShare_c20240214__20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_zSuNlCLbsBHh" title="Warrant exercise price per share"&gt;0.53&lt;/span&gt;
per share and apply $&lt;span id="xdx_906_ecustom--ExerciseWarrantsAmount_iI_c20240216__us-gaap--AwardDateAxis__custom--November2023NoteMember_z6yMtNpb0TM9" title="Exercise warrants amount"&gt;250,000&lt;/span&gt;
of the note balance to the exercise price of the warrants. For the year ended June 30, 2024, discount amortization of $&lt;span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_z8Tg8ixJkAu9"&gt;50,000&lt;/span&gt;
was charged to interest expense. As of June 30, 2024, the Company accrued $&lt;span id="xdx_904_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_zet7t18EnN7i"&gt;69,083&lt;/span&gt;
of interest expense that is included in accrued expenses on the balance sheet. The November 2023 Note balance, net of discount at
June 30, 2024 is $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20240630__us-gaap--AwardDateAxis__custom--November2023NoteMember_zLPuGOUM4z48"&gt;750,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Promissory Note &#x2014; &lt;/b&gt;On
March 30, 2020 (the &#x201c;Issuance Date&#x201d;), the Company issued a Promissory Note in the principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zoGUhnOaSSY5" title="Principal amount"&gt;5,000,000&lt;/span&gt; (the &#x201c;Promissory
Note&#x201d;) to the Holder. The principal amount of the Promissory Note was originally payable on &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zFZ2qNerVYw7" title="Maturity date"&gt;November 30, 2021&lt;/span&gt; (the &#x201c;Maturity
Date&#x201d;). The Promissory Note bore interest at a fixed rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zGZfb2eWWoi6" title="Interest rate"&gt;6&lt;/span&gt;% per annum, computed based on the number of days between the Issuance
Date and the Maturity Date, and the interest was prepaid by the Company in full on the Issuance Date through the issuance of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zdaKfHFOG1yk" title="Stock issued for debt conversion, shares"&gt;188,485&lt;/span&gt; shares
of the Company&#x2019;s Common Stock based on the closing market price on that date for a total value of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3VBFVpr0KZ9" title="Stock issued for debt conversion"&gt;501,370&lt;/span&gt;. The Company evaluated
the Promissory Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds
received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount
of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zOA7lNduxW6a" title="Issuance of common stock"&gt;493,192&lt;/span&gt;, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest
method. The discount of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zhMxnugQa1o" title="Issuance of common stock"&gt;493,192&lt;/span&gt; will be accreted over the life of the Promissory Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 11, 2021, the Company
entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory
Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of &lt;span id="xdx_90E_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3MeFF689GN8" title="Interest at the fixed rate"&gt;6&lt;/span&gt;% per annum, which was
prepaid by the Company in full on the date of the amendment through the issuance of &lt;span id="xdx_90F_eus-gaap--SharesIssued_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_pdd" title="Number of shares issued"&gt;74,054&lt;/span&gt; shares of the Company&#x2019;s Common Stock
based on the closing market price on that date for a total value of $&lt;span id="xdx_903_ecustom--MarketPrice_iI_pp0p0_c20210211__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z3Q5ZMzidku7" title="Market price"&gt;298,178&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On May 17, 2022, the Company entered
into a second amendment to the Promissory Note that extended the Maturity Date to &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220516__20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zoMCUly4hPGh" title="Maturity date"&gt;November 30, 2023&lt;/span&gt; and increased the interest rate from
&lt;span id="xdx_903_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20220517__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zKpwnd8unzN6" title="Interest at the fixed rate"&gt;6&lt;/span&gt;% to &lt;span id="xdx_905_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20220517__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zalunitf0fd4" title="Interest at the fixed rate"&gt;12&lt;/span&gt;% per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year
of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022
until May 30, 2023 on the date of the amendment through the issuance of &lt;span id="xdx_903_eus-gaap--SharesIssued_iI_c20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zh8eL3iAPes8" title="Number of shares issued"&gt;47,115&lt;/span&gt; shares of the Company&#x2019;s Common Stock based on the
closing market price on that date for a total value of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220516__20220517__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zyR6sGR2Vsv3" title="Issuance of common stock"&gt;299,178&lt;/span&gt;. All other accrued interest payable from May 30, 2023 to the Maturity
Date was required to be paid by the Company on May 30, 2023, at the option of the Holder in either (i) cash or (ii) shares of the Company&#x2019;s
Common Stock, valued at the closing sale price of the Common Stock on the Nasdaq Capital Market on May 30, 2023. The Holder elected the
interest be paid in cash (the &#x201c;Interest Payment&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Effective December 30, 2022, the
Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company&#x2019;s obligations under
the Promissory Note were secured by a Security Agreement. To secure the Company&#x2019;s obligations under each of the Amended and Restated
Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted
a lien on all assets of the Company (the &#x201c;Collateral&#x201d;) for the benefit of the Holder. Upon an Event of Default (as defined
in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession
of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On June 12, 2023, the Holder notified
the Company that it wanted to apply the Interest Payment due to it towards the Company&#x2019;s next private placement. Therefore, on June
26, 2023, in conjunction with the Company&#x2019;s private placement, the Company issued (i) &lt;span id="xdx_908_eus-gaap--SharesIssued_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zD42HVxZjg9" title="Number of shares issued"&gt;567,588&lt;/span&gt; shares of its Common Stock, par value
$&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zM8sAl8ipnXi" title="Share price"&gt;0.0001&lt;/span&gt; per share and (ii) warrants to purchase &lt;span id="xdx_90E_ecustom--WarrantsPurchased_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGcva7fgxp6l" title="Warrants purchased"&gt;283,794&lt;/span&gt; shares of Common Stock at a purchase price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYXqnayQkbx5" title="Warrant purchase price"&gt;0.53&lt;/span&gt; per share and applied the
Interest Payment of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHFfa8ACjsC5" title="Proceeds from private placement"&gt;300,822&lt;/span&gt; it owed to the Holder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On July 31, 2023, the Company and
the Holder agreed to amend the Promissory Note (the &#x201c;Fourth Amendment&#x201d;) to provide the Holder with limited conversion rights
in connection with the Company&#x2019;s next private placement. Per the terms of the Fourth Amendment, the Holder could elect to convert
$2 million of the outstanding principal balance of the Promissory Note into the Units being offered in a private placement at the price
per Unit being paid by the investors in the private placement (the &#x201c;Conversion Right&#x201d;). On August 1, 2023, the Holder notified
the Company of its election to exercise the Conversion Right. As a result, $2 million of the outstanding principal balance of the Promissory
Note was converted into 280,505 Units at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible Preferred
Stock of the Company and (ii) Warrants to purchase an aggregate of 1,402,525 shares of Common Stock with an exercise price of $0.65 per
share. The Series A Convertible Preferred Stock acquired by the Holder was initially convertible into 2,805,050 shares of Common Stock.
A $3 million principal balance remained outstanding under the Promissory Note after the foregoing conversion. The Company concluded that
in accordance with ASC 470-20-40-4, the difference between the fair value of the Preferred Shares and warrants and the carrying value
of the portion of the Note being converted should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded
in Other Income/Loss in the Statement of Operations. On November 30, 2023, the Company and the Holder agreed to amend the Promissory Note
(the &#x201c;Fifth Amendment&#x201d;) such that the Company and the Holder extended the maturity of the original Promissory Note until February
29, 2024. In addition, all interest payable from November 30, 2023 to the Maturity Date was payable and is currently payable by the Company
as of November 30, 2023. On February 16, 2024, the Company received notice from the Holder to exercise 2,953,700 warrants outstanding
ranging from $0.53 to $0.65 per share and apply $1,750,000 of the note balance to the exercise price of the warrants. On February 29,
2024, the Company and the Holder agreed to amend the Promissory Note (the &#x201c;Sixth Amendment&#x201d;) to where the Company and the
Holder extended the maturity of the original Promissory Note until May 1, 2024. On May 1, 2024, the Company and the Holder agreed to amend
the Promissory Note (the &#x201c;Seventh Amendment&#x201d;) to extend the maturity of the original Promissory Note until August 1, 2024.
On June 14, 2024 the Holder requested the Company repay $&lt;span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zp1Auc8DNYYd" title="Repayment on promissory note"&gt;418,503&lt;/span&gt; of the Promissory Note. The Company applied $&lt;span id="xdx_904_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zdjWj96bwTyb" title="Repayment on promissory note"&gt;100,440&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--RepaymentsOfNotesPayable_c20240613__20240614__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreements1Member_zLwQk7yNLPef" title="Repayment on promissory note"&gt;318,063&lt;/span&gt; owed
to the Company pursuant to certain Subscription Agreements. As such, payment of the 2020 Note Repayment decreased the principal amount
by $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20240614__us-gaap--LongtermDebtTypeAxis__custom--Note2020Member_zCkuYbPTKEge" title="Principal amount"&gt;418,503&lt;/span&gt;. For the year ended June 30, 2024 and 2023, discount amortization of $&lt;span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zs9XfinTrwJh" title="Amortization of debt discount"&gt;393,763&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20220701__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z9IObNqog49d" title="Amortization of debt discount"&gt;348,621&lt;/span&gt; was charged to interest expense.
The Promissory Note balance, net of discount at June 30, 2024 is $&lt;span id="xdx_907_ecustom--PromissoryNoteBalanceNetOfDiscount_iI_c20240630__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zsnCy1CMFHWh" title="Promissory note balance, net of discount"&gt;824,418&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Finance Agreement &lt;/b&gt;&#x2014;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On November 30, 2023, the Company
entered into a premium finance agreement (the &#x201c;Agreement&#x201d;) related to insurance,&#160;&lt;span style="background-color: white"&gt;which
resulted in the recognition of a liability and prepaid expense with a principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20231130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z2w0HAneaCRd" title="Principal amount"&gt;906,834&lt;/span&gt;&#160;at&#160;&lt;span id="xdx_903_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20231130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zsqjdQeqoCe7" title="Rate of interest"&gt;7.90&lt;/span&gt;% interest per annum,
which is reflected on the consolidated balance sheet under &#x201c;other current liabilities&#x201d; and &#x201c;prepaid assets and other
assets&#x201d;, respectively. The repayment of the Agreement will be made in nine equal monthly installments of $&lt;span id="xdx_90A_ecustom--MonthlyInstallments_pp0p0_c20231129__20231130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zYRXt6AFLEC6" title="Monthly instalments amount"&gt;77,127&lt;/span&gt;&#160;after a down
payment of $&lt;span id="xdx_907_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20231129__20231130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zDtbJNOwXWl4" title="Down payment amount"&gt;235,000&lt;/span&gt;.&#160;For the years ended June 30, 2024 and 2023 the Company made payments of $&lt;span id="xdx_905_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zOUuyx8t33U1" title="Down payment amount"&gt;870,073&lt;/span&gt;&#160;and $&lt;span id="xdx_906_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20220701__20230630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zdUheJLEdgy6" title="Down payment amount"&gt;1,121,767&lt;/span&gt;, respectively.
&lt;/span&gt;The remaining balance at June 30, 2024 is $&lt;span id="xdx_90A_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20240630_zzaO2CeeXcN8" title="Other current liabilities"&gt;231,381&lt;/span&gt;; the amount is reflected in other current liabilities. &lt;span style="background-color: white"&gt;For
the years ended June 30, 2024 and 2023 the Company recorded total interest expense in the amount of $&lt;span id="xdx_905_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z2ZpR51JW4Og" title="Accrued interest expense"&gt;20,128&lt;/span&gt; and $&lt;/span&gt;&lt;span id="xdx_908_eus-gaap--InterestAndDebtExpense_c20220701__20230630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zitl49jOc7R" title="Accrued interest expense"&gt;21,180&lt;/span&gt;&lt;span style="background-color: white"&gt;&#160;related
to the Agreement. This amount is reflected in other income and expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;Total
interest expense recorded for the years ended June 30, 2024 and 2023, was $&lt;span id="xdx_901_eus-gaap--InterestExpenseNonoperating_c20230701__20240630_zGSB71TNikb9" title="Total interest expense"&gt;1,011,322&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--InterestExpenseNonoperating_c20220701__20230630_zLTSFcUX6DOk" title="Total interest expense"&gt;580,344&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-03-14_custom_MarchNote2024Member"
      decimals="0"
      id="Fact001088"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-03-14_custom_MarchNote2024Member"
      decimals="INF"
      id="Fact001090"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-03-132024-03-14_custom_MarchNote2024Member"
      id="Fact001092">2025-03-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member"
      decimals="INF"
      id="Fact001094"
      unitRef="Shares">344966</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member"
      decimals="INF"
      id="Fact001096"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_MarchNote2024Member"
      decimals="0"
      id="Fact001098"
      unitRef="USD">512361</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_MarchNote2024Member"
      decimals="INF"
      id="Fact001100"
      unitRef="USDPShares">1.4726</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_MarchNote2024Member"
      decimals="0"
      id="Fact001102"
      unitRef="USD">12361</us-gaap:InterestAndDebtExpense>
    <RENB:InterestExpenseRelatedToNoteBalance
      contextRef="From2023-07-012024-06-30_custom_MarchNote2024Member"
      decimals="0"
      id="Fact001104"
      unitRef="USD">0</RENB:InterestExpenseRelatedToNoteBalance>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-11_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001106"
      unitRef="USD">460000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-11_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001108"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-102024-01-11_custom_JanuaryNote2024Member"
      id="Fact001110">2025-01-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-01-11_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001112"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001114"
      unitRef="USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001116"
      unitRef="USD">125000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001118"
      unitRef="Pure">0.12</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member"
      id="Fact001120">2024-12-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001122"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">325508</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001128"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001130"
      unitRef="USD">483460</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001132"
      unitRef="USDPShares">1.4726</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-06-30_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001134"
      unitRef="USD">125000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-29_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001136"
      unitRef="USD">560000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-12-012023-12-29_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001138"
      unitRef="USD">560000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-12-012023-12-29_custom_PrivatePlacement1Member_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001140"
      unitRef="USD">440000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-12-012023-12-29_custom_PrivatePlacement2Member_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001142"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-302024-01-31_custom_PrivatePlacement3Member_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001144"
      unitRef="USD">20000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2023-12-29_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact001146"
      unitRef="Pure">0.12</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-29_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact001148"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">317715</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001152"
      unitRef="USD">440000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001154"
      unitRef="USD">28453</us-gaap:InterestPayableCurrent>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001156"
      unitRef="USD">66000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact001158"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact001160"
      unitRef="USDPShares">1.4726</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-06-30_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001162"
      unitRef="USD">120000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001164"
      unitRef="USD">67013</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001166"
      unitRef="USD">67013</us-gaap:InterestAndDebtExpense>
    <RENB:InterestExpenseRelatedToNoteBalance
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001168"
      unitRef="USD">245000</RENB:InterestExpenseRelatedToNoteBalance>
    <RENB:InterestExpenseRelatedToNoteBalance
      contextRef="From2023-07-012024-06-30_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001170"
      unitRef="USD">120000</RENB:InterestExpenseRelatedToNoteBalance>
    <RENB:InterestExpenseRelatedToNoteBalance
      contextRef="From2023-07-012024-06-30_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001172"
      unitRef="USD">125000</RENB:InterestExpenseRelatedToNoteBalance>
    <RENB:OriginalIssueDiscountPromissoryNotePercentage
      contextRef="AsOf2023-10-05_custom_Note2023Member"
      decimals="INF"
      id="Fact001174"
      unitRef="Pure">0.05</RENB:OriginalIssueDiscountPromissoryNotePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-10-05_custom_Note2023Member"
      decimals="0"
      id="Fact001176"
      unitRef="USD">2105263</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-09-052023-10-05_custom_Note2023Member"
      decimals="0"
      id="Fact001178"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <RENB:DebtInstrumentOriginalIssueDiscount
      contextRef="AsOf2023-10-05_custom_Note2023Member"
      decimals="INF"
      id="Fact001180"
      unitRef="Pure">0.05</RENB:DebtInstrumentOriginalIssueDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-10-05_custom_Note2023Member"
      decimals="0"
      id="Fact001182"
      unitRef="USD">105263</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-10-05_custom_Note2023Member"
      decimals="INF"
      id="Fact001184"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-09-052023-10-05_custom_Note2023Member"
      id="Fact001186">2024-09-05</us-gaap:DebtInstrumentMaturityDate>
    <RENB:CommonStockAndReceivedGrossProceeds
      contextRef="From2023-09-052023-10-05_custom_Note2023Member"
      decimals="0"
      id="Fact001188"
      unitRef="USD">10000000</RENB:CommonStockAndReceivedGrossProceeds>
    <RENB:OfferingPricePerSharePercentage
      contextRef="From2023-09-052023-10-05_custom_Note2023Member"
      decimals="INF"
      id="Fact001190"
      unitRef="Pure">0.95</RENB:OfferingPricePerSharePercentage>
    <RENB:DebtInstrumentsFloorPricePerShare
      contextRef="AsOf2023-10-05_custom_Note2023Member"
      decimals="INF"
      id="Fact001192"
      unitRef="USDPShares">4.50</RENB:DebtInstrumentsFloorPricePerShare>
    <RENB:DebtInstrumentsFloorPricePerShare
      contextRef="AsOf2023-10-05_custom_Note2023Member"
      decimals="INF"
      id="Fact001194"
      unitRef="USDPShares">4.50</RENB:DebtInstrumentsFloorPricePerShare>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-01-11_custom_Note2023Member"
      decimals="INF"
      id="Fact001199"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_Note2023Member"
      decimals="INF"
      id="Fact001200"
      unitRef="Shares">1546449</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member"
      decimals="0"
      id="Fact001201"
      unitRef="USD">2293825</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_custom_Note2023Member"
      decimals="0"
      id="Fact001202"
      unitRef="USD">443575</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member"
      decimals="0"
      id="Fact001203"
      unitRef="USD">318063</us-gaap:OtherNotesPayable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_custom_Note2023Member"
      decimals="INF"
      id="Fact001204"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MinimumMember"
      decimals="INF"
      id="Fact001205"
      unitRef="USDPShares">1.4726</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-14_us-gaap_WarrantMember_custom_Note2023Member_srt_MaximumMember"
      decimals="INF"
      id="Fact001206"
      unitRef="USDPShares">1.4765</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-06-14_custom_Note2023Member"
      decimals="0"
      id="Fact001208"
      unitRef="USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-012024-06-30_custom_Note2023Member"
      decimals="0"
      id="Fact001210"
      unitRef="USD">78567</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestIncomeExpenseAfterProvisionForLoanLoss
      contextRef="From2023-07-012024-06-30_custom_Note2023Member"
      decimals="0"
      id="Fact001212"
      unitRef="USD">26696</us-gaap:InterestIncomeExpenseAfterProvisionForLoanLoss>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_Note2023Member"
      decimals="0"
      id="Fact001214"
      unitRef="USD">189614</us-gaap:InterestAndDebtExpense>
    <RENB:InterestExpenseRelatedToNoteBalance
      contextRef="From2023-07-012024-06-30_custom_Note2023Member"
      decimals="0"
      id="Fact001216"
      unitRef="USD">0</RENB:InterestExpenseRelatedToNoteBalance>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-02-06_custom_ConvertibleNotesPayablesMember"
      decimals="0"
      id="Fact001218"
      unitRef="USD">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2020-02-052020-02-06_custom_ConvertibleNotesPayablesMember"
      decimals="INF"
      id="Fact001220"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      id="Fact001222">2024-02-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="INF"
      id="Fact001224"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="INF"
      id="Fact001226"
      unitRef="Shares">198439</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="INF"
      id="Fact001228"
      unitRef="Shares">29419</us-gaap:StockIssuedDuringPeriodSharesOther>
    <RENB:PrepaymentShares
      contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="INF"
      id="Fact001230"
      unitRef="Shares">169020</RENB:PrepaymentShares>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="INF"
      id="Fact001232"
      unitRef="USDPShares">1.03</us-gaap:SharePrice>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="0"
      id="Fact001234"
      unitRef="USD">1200000</us-gaap:ContractualObligation>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-12-292022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="0"
      id="Fact001236"
      unitRef="USD">204392</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PrepaidInterest
      contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="0"
      id="Fact001238"
      unitRef="USD">174090</us-gaap:PrepaidInterest>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-30_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="0"
      id="Fact001240"
      unitRef="USD">30302</us-gaap:InterestPayableCurrent>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-06-252023-06-26_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="0"
      id="Fact001242"
      unitRef="USD">1200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-06-252023-06-26_us-gaap_WarrantMember_custom_AmendedAndRestatedSecuredNotesMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Shares">1132075</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-03-262024-06-04_custom_TheNotesMember"
      decimals="0"
      id="Fact001248"
      unitRef="USD">2098252</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-06-04_custom_TheNotesMember"
      decimals="INF"
      id="Fact001250"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-06-132024-06-14_custom_TheNotesMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Shares">1424862</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-06-14_custom_TheNotesMember"
      decimals="INF"
      id="Fact001254"
      unitRef="USDPShares">1.4726</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-06-132024-06-14_custom_TheNotesMember"
      decimals="0"
      id="Fact001256"
      unitRef="USD">2098252</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <RENB:OriginalIssueDiscountPromissoryNotePercentage
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="INF"
      id="Fact001258"
      unitRef="Pure">0.05</RENB:OriginalIssueDiscountPromissoryNotePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="0"
      id="Fact001260"
      unitRef="USD">105263</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-02-042024-02-05_custom_RSBioMember"
      decimals="0"
      id="Fact001262"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <RENB:GrossProceedsDiscountPercentage
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="INF"
      id="Fact001264"
      unitRef="Pure">0.05</RENB:GrossProceedsDiscountPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2024-02-042024-02-05_custom_RSBioMember"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-02-042024-02-05_custom_RSBioMember"
      id="Fact001268">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_RSBioApSMember"
      decimals="0"
      id="Fact001270"
      unitRef="USD">5263</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_RSBioApSMember"
      decimals="0"
      id="Fact001272"
      unitRef="USD">6316</us-gaap:InterestAndDebtExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_RSBioApSMember"
      decimals="0"
      id="Fact001274"
      unitRef="USD">105263</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <RENB:OriginalIssueDiscountPromissoryNotePercentage
      contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="INF"
      id="Fact001276"
      unitRef="Pure">0.05</RENB:OriginalIssueDiscountPromissoryNotePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="0"
      id="Fact001278"
      unitRef="USD">526315</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="0"
      id="Fact001280"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <RENB:GrossProceedsDiscountPercentage
      contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="INF"
      id="Fact001282"
      unitRef="Pure">0.05</RENB:GrossProceedsDiscountPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="INF"
      id="Fact001284"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      id="Fact001286">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001288"
      unitRef="USD">26315</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_AccruedExpensesMember_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001290"
      unitRef="USD">31579</us-gaap:InterestAndDebtExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2024-06-30_us-gaap_BridgeLoanMember_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001292"
      unitRef="USD">526315</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2023-11-212023-11-22_custom_LoanAgreementMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact001294"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">454708</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember"
      decimals="0"
      id="Fact001296"
      unitRef="USD">665387</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-06-132024-06-14_us-gaap_CommonStockMember_us-gaap_BridgeLoanMember"
      decimals="0"
      id="Fact001297"
      unitRef="USD">100400</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_us-gaap_BridgeLoanMember_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001299"
      unitRef="USD">36388</us-gaap:InterestAndDebtExpense>
    <RENB:InterestExpenseRelatedToNoteBalance
      contextRef="From2023-07-012024-06-30_us-gaap_BridgeLoanMember_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001301"
      unitRef="USD">0</RENB:InterestExpenseRelatedToNoteBalance>
    <RENB:OriginalIssueDiscountPromissoryNotePercentage
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="INF"
      id="Fact001302"
      unitRef="Pure">0.05</RENB:OriginalIssueDiscountPromissoryNotePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="0"
      id="Fact001303"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="0"
      id="Fact001304"
      unitRef="USD">950000</us-gaap:ProceedsFromIssuanceOfDebt>
    <RENB:GrossProceedsDiscountPercentage
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="INF"
      id="Fact001305"
      unitRef="Pure">0.05</RENB:GrossProceedsDiscountPercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="0"
      id="Fact001306"
      unitRef="USD">50000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="INF"
      id="Fact001307"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      id="Fact001308">2024-01-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-012024-01-02_custom_November2023NoteMember_custom_RSBioMember"
      id="Fact001309">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <RENB:ExerciseWarrants
      contextRef="AsOf2024-02-16_custom_November2023NoteMember"
      decimals="INF"
      id="Fact001311"
      unitRef="Shares">471699</RENB:ExerciseWarrants>
    <RENB:WarrantsOutstandingPerShare
      contextRef="From2024-02-142024-02-16_custom_November2023NoteMember"
      decimals="INF"
      id="Fact001313"
      unitRef="USDPShares">0.53</RENB:WarrantsOutstandingPerShare>
    <RENB:ExerciseWarrantsAmount
      contextRef="AsOf2024-02-16_custom_November2023NoteMember"
      decimals="0"
      id="Fact001315"
      unitRef="USD">250000</RENB:ExerciseWarrantsAmount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-012024-06-30_custom_November2023NoteMember"
      decimals="0"
      id="Fact001316"
      unitRef="USD">50000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_November2023NoteMember"
      decimals="0"
      id="Fact001317"
      unitRef="USD">69083</us-gaap:InterestAndDebtExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2024-06-30_custom_November2023NoteMember"
      decimals="0"
      id="Fact001318"
      unitRef="USD">750000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001323"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      id="Fact001325">2021-11-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001327"
      unitRef="Pure">0.06</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001329"
      unitRef="Shares">188485</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001331"
      unitRef="USD">501370</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">493192</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001335"
      unitRef="USD">493192</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="AsOf2021-02-11_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Pure">0.06</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-02-11_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001339"
      unitRef="Shares">74054</us-gaap:SharesIssued>
    <RENB:MarketPrice
      contextRef="AsOf2021-02-11_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001341"
      unitRef="USD">298178</RENB:MarketPrice>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-05-162022-05-17_custom_PromissoryNoteMember"
      id="Fact001343">2023-11-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="AsOf2022-05-17_srt_MinimumMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001345"
      unitRef="Pure">0.06</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="AsOf2022-05-17_srt_MaximumMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001347"
      unitRef="Pure">0.12</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-05-17_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">47115</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-05-162022-05-17_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">299178</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Shares">567588</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001355"
      unitRef="USDPShares">0.0001</us-gaap:SharePrice>
    <RENB:WarrantsPurchased
      contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001357"
      unitRef="Shares">283794</RENB:WarrantsPurchased>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-26_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001359"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-06-252023-06-26_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact001361"
      unitRef="USD">300822</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-06-132024-06-14_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001366"
      unitRef="USD">418503</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreementsMember"
      decimals="0"
      id="Fact001368"
      unitRef="USD">100440</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-06-132024-06-14_custom_PromissoryNoteMember_custom_SubscriptionAgreements1Member"
      decimals="0"
      id="Fact001370"
      unitRef="USD">318063</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-06-14_custom_Note2020Member"
      decimals="0"
      id="Fact001372"
      unitRef="USD">418503</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-012024-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">393763</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-07-012023-06-30_us-gaap_InterestExpenseMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001376"
      unitRef="USD">348621</us-gaap:AmortizationOfDebtDiscountPremium>
    <RENB:PromissoryNoteBalanceNetOfDiscount
      contextRef="AsOf2024-06-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001378"
      unitRef="USD">824418</RENB:PromissoryNoteBalanceNetOfDiscount>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2023-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001380"
      unitRef="USD">906834</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="AsOf2023-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember"
      decimals="INF"
      id="Fact001382"
      unitRef="Pure">0.0790</us-gaap:DerivativeFixedInterestRate>
    <RENB:MonthlyInstallments
      contextRef="From2023-11-292023-11-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001384"
      unitRef="USD">77127</RENB:MonthlyInstallments>
    <RENB:RepaymentOnFinanceAgreement
      contextRef="From2023-11-292023-11-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">235000</RENB:RepaymentOnFinanceAgreement>
    <RENB:RepaymentOnFinanceAgreement
      contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001388"
      unitRef="USD">870073</RENB:RepaymentOnFinanceAgreement>
    <RENB:RepaymentOnFinanceAgreement
      contextRef="From2022-07-012023-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">1121767</RENB:RepaymentOnFinanceAgreement>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001392"
      unitRef="USD">231381</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">20128</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2022-07-012023-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">21180</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001398"
      unitRef="USD">1011322</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001400"
      unitRef="USD">580344</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001402">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zseQf7biGuTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_821_zwu0sdUG06Ck"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company accounts for income
taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset
or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and
any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax
assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#x2019;s future earnings, and other future
events, the effects of which cannot be determined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;As of June 30, 2024 and 2023, the Company had net operating loss carryforwards
of approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zjVGt9m2hH22" title="Operating loss carryforwards"&gt;489,177,759&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20230630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z6H9YnsH3ED1" title="Operating loss carryforwards"&gt;476,965,239&lt;/span&gt;, respectively, giving rise to deferred tax assets of $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z2dZIMoIak0j" title="Deferred tax assets"&gt;144,191,530&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20230630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zm7eh49aVwMl" title="Deferred tax assets"&gt;140,547,314&lt;/span&gt;, respectively.
The net operating loss carryforwards generated prior to January 1, 2018 expire over various dates from 2031 to 2038. All subsequent net
operating loss carryforwards are indefinite.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company files Danish and U.S.
income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2020 for the Danish tax returns
and 2021 for the U.S. tax returns.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The temporary differences, tax
credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ztWcSMWdxjSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20240630_zrtimKmuCoh7" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_493_20230630_zsiS1GUd4u15" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_iI_pp0p0_maDTALNzwuT_zy85kfWMavXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Excess of tax over book depreciation of fixed assets&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;8,258&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;8,258&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_zHkoz6FQxJG3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Excess of tax over book depreciation of patents&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,415&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,415&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_zyKcZ9CDZlGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stock/options compensation&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,672,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,885,996&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_zZQ7YsxC6dyd" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;188,422&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;152,059&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_zhXX7JcqYuFd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;144,191,530&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;140,547,314&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPBUAL6t8tS3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Impairment expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;16,188,497&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zqRgsu6xVEva" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,410,678&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zFEx1Nug8bV7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in tax rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_zsOa3FBgqbL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(168,668,052&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(144,602,042&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_d0_mtDTALNzwuT_zXlzkLjANGZf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Deferred Tax Assets (Liabilities)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A1_z5KNx5UUL8jb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;In accordance with prevailing accounting
guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to
recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine
whether the tax position meets the more-likely-than-not condition for recognition, and the second step is to determine the amount to be
recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred
tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#x2019;s future earnings, and other
future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely
than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance
was recorded for all deferred tax assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;A reconciliation of income tax
expense at the federal statutory rate to income tax expense at the Company&#x2019;s effective rate is as follows for the years ended June
30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zye7fHvoq3m9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zioNRtqge65g" style="display: none"&gt;Schedule of reconciliation of income tax expense&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_496_20230701__20240630_zSIkBTY8xu11" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20220701__20230630_zs7bvbPUPSt4" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computed tax at expected statutory rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(24,066,011&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(70,341,751&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zxqPCIjJ4Zm4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-US income taxed at different rates&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zT8grGiUTgcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-deductible expenses / other items&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24,066,011&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;70,341,751&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zDIinjTeozVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A7_z9e9taVSiNSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The components of income tax expense
(benefit) from continuing operations for the years ended June 30, 2024 and 2023 consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z4CIuVvF8H48" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 30pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20230701__20240630_zr2YwIHX5iU6" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20220701__20230630_zesYaS1viu83" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current Income Tax Expense&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zl4O7PzwD6Gj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Danish income tax (benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_zELkXbtmTxTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Current Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred Income Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationFixedAssets_i01_pp0p0_maDITEBzk3M_z85liOo5WeSb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Excess of tax over book depreciation of fixed assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,258&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,258&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationPatents_i01_pp0p0_maDITEBzk3M_z1yauBO3fNuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Excess of tax over book depreciation of patents&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,415&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,415&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_pp0p0_maDITEBzk3M_zG0AXNB2Sh1b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock/options compensation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,672,252&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,885,996&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_i01_pp0p0_maDITEBzk3M_zK3c0RPowwug" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;188,422&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;152,059&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--IncomeTaxExpenseBenefitOperatingLossCarryforwards_i01_pp0p0_maDITEBzk3M_zJa1QBHTfmG3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;144,191,530&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;140,547,314&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--IncomeTaxExpenseBenefitImpairmentExpense_i01_pp0p0_d0_maDITEBzk3M_z2jEHfKiLsj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&#160;Impairment expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;16,188,497&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--IncomeTaxExpenseBenefitContingentConsiderationFairValue_i01_pp0p0_d0_maDITEBzk3M_z8ygs5gtrVLi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&#160;Contingent consideration fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,410,678&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DeferredIncomeTaxExpenseChangeInTaxRate_i01_pp0p0_d0_maDITEBzk3M_zM7EdBLlqlLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0p0_di_msDITEBzk3M_z5Eh1OC24NW5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in the valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(168,668,052&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(144,602,042&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_zT3pXbVezUE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Deferred Tax Expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A2_zYNhkACAc4D" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Deferred income tax expense (benefit)
results primarily from the reversal of temporary timing differences between tax and financial statement income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001404"
      unitRef="USD">489177759</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001406"
      unitRef="USD">476965239</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001408"
      unitRef="USD">144191530</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2023-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001410"
      unitRef="USD">140547314</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001414">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ztWcSMWdxjSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20240630_zrtimKmuCoh7" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_493_20230630_zsiS1GUd4u15" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_iI_pp0p0_maDTALNzwuT_zy85kfWMavXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Excess of tax over book depreciation of fixed assets&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;8,258&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;8,258&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_zHkoz6FQxJG3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Excess of tax over book depreciation of patents&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,415&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,415&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_zyKcZ9CDZlGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stock/options compensation&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,672,252&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,885,996&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_zZQ7YsxC6dyd" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;188,422&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;152,059&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_zhXX7JcqYuFd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;144,191,530&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;140,547,314&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPBUAL6t8tS3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Impairment expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;16,188,497&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zqRgsu6xVEva" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,410,678&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zFEx1Nug8bV7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in tax rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_zsOa3FBgqbL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(168,668,052&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(144,602,042&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_d0_mtDTALNzwuT_zXlzkLjANGZf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Deferred Tax Assets (Liabilities)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001416"
      unitRef="USD">8258</RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets>
    <RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001417"
      unitRef="USD">8258</RENB:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets>
    <RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001419"
      unitRef="USD">8415</RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents>
    <RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001420"
      unitRef="USD">8415</RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents>
    <RENB:StockoptionsCompensation
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001422"
      unitRef="USD">6672252</RENB:StockoptionsCompensation>
    <RENB:StockoptionsCompensation
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001423"
      unitRef="USD">3885996</RENB:StockoptionsCompensation>
    <RENB:DepreciationAndAmortizations
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001425"
      unitRef="USD">188422</RENB:DepreciationAndAmortizations>
    <RENB:DepreciationAndAmortizations
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001426"
      unitRef="USD">152059</RENB:DepreciationAndAmortizations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001428"
      unitRef="USD">144191530</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001429"
      unitRef="USD">140547314</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <RENB:ImpairmentExpense
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001431"
      unitRef="USD">16188497</RENB:ImpairmentExpense>
    <RENB:ImpairmentExpense
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001432"
      unitRef="USD">0</RENB:ImpairmentExpense>
    <RENB:ContingentConsiderationFairValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001434"
      unitRef="USD">1410678</RENB:ContingentConsiderationFairValue>
    <RENB:ContingentConsiderationFairValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001435"
      unitRef="USD">0</RENB:ContingentConsiderationFairValue>
    <RENB:ChangeInTaxRate
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001437"
      unitRef="USD">0</RENB:ChangeInTaxRate>
    <RENB:ChangeInTaxRate
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001438"
      unitRef="USD">0</RENB:ChangeInTaxRate>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001440"
      unitRef="USD">168668052</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001441"
      unitRef="USD">144602042</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001443"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001444"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001446">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zye7fHvoq3m9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zioNRtqge65g" style="display: none"&gt;Schedule of reconciliation of income tax expense&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_496_20230701__20240630_zSIkBTY8xu11" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20220701__20230630_zs7bvbPUPSt4" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computed tax at expected statutory rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(24,066,011&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(70,341,751&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zxqPCIjJ4Zm4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-US income taxed at different rates&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zT8grGiUTgcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-deductible expenses / other items&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24,066,011&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;70,341,751&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zDIinjTeozVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001448"
      unitRef="USD">-24066011</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001449"
      unitRef="USD">-70341751</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001451"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001452"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001454"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001455"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001457"
      unitRef="USD">24066011</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001458"
      unitRef="USD">70341751</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001460"
      unitRef="USD">0</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001461"
      unitRef="USD">0</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001463">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z4CIuVvF8H48" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 30pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20230701__20240630_zr2YwIHX5iU6" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20220701__20230630_zesYaS1viu83" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current Income Tax Expense&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zl4O7PzwD6Gj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Danish income tax (benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_zELkXbtmTxTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Current Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred Income Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationFixedAssets_i01_pp0p0_maDITEBzk3M_z85liOo5WeSb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Excess of tax over book depreciation of fixed assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,258&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,258&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--ExcessTaxBenefitOverDepreciationPatents_i01_pp0p0_maDITEBzk3M_z1yauBO3fNuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Excess of tax over book depreciation of patents&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,415&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,415&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_pp0p0_maDITEBzk3M_zG0AXNB2Sh1b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock/options compensation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,672,252&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,885,996&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_i01_pp0p0_maDITEBzk3M_zK3c0RPowwug" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;188,422&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;152,059&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--IncomeTaxExpenseBenefitOperatingLossCarryforwards_i01_pp0p0_maDITEBzk3M_zJa1QBHTfmG3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;144,191,530&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;140,547,314&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--IncomeTaxExpenseBenefitImpairmentExpense_i01_pp0p0_d0_maDITEBzk3M_z2jEHfKiLsj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&#160;Impairment expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;16,188,497&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--IncomeTaxExpenseBenefitContingentConsiderationFairValue_i01_pp0p0_d0_maDITEBzk3M_z8ygs5gtrVLi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&#160;Contingent consideration fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,410,678&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DeferredIncomeTaxExpenseChangeInTaxRate_i01_pp0p0_d0_maDITEBzk3M_zM7EdBLlqlLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0p0_di_msDITEBzk3M_z5Eh1OC24NW5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in the valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(168,668,052&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(144,602,042&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_zT3pXbVezUE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Deferred Tax Expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001468"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001469"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001471"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001472"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <RENB:ExcessTaxBenefitOverDepreciationFixedAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001477"
      unitRef="USD">8258</RENB:ExcessTaxBenefitOverDepreciationFixedAssets>
    <RENB:ExcessTaxBenefitOverDepreciationFixedAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001478"
      unitRef="USD">8258</RENB:ExcessTaxBenefitOverDepreciationFixedAssets>
    <RENB:ExcessTaxBenefitOverDepreciationPatents
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001480"
      unitRef="USD">8415</RENB:ExcessTaxBenefitOverDepreciationPatents>
    <RENB:ExcessTaxBenefitOverDepreciationPatents
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001481"
      unitRef="USD">8415</RENB:ExcessTaxBenefitOverDepreciationPatents>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001483"
      unitRef="USD">6672252</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001484"
      unitRef="USD">3885996</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001486"
      unitRef="USD">188422</us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001487"
      unitRef="USD">152059</us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <RENB:IncomeTaxExpenseBenefitOperatingLossCarryforwards
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001489"
      unitRef="USD">144191530</RENB:IncomeTaxExpenseBenefitOperatingLossCarryforwards>
    <RENB:IncomeTaxExpenseBenefitOperatingLossCarryforwards
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001490"
      unitRef="USD">140547314</RENB:IncomeTaxExpenseBenefitOperatingLossCarryforwards>
    <RENB:IncomeTaxExpenseBenefitImpairmentExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001492"
      unitRef="USD">16188497</RENB:IncomeTaxExpenseBenefitImpairmentExpense>
    <RENB:IncomeTaxExpenseBenefitImpairmentExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001493"
      unitRef="USD">0</RENB:IncomeTaxExpenseBenefitImpairmentExpense>
    <RENB:IncomeTaxExpenseBenefitContingentConsiderationFairValue
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001495"
      unitRef="USD">1410678</RENB:IncomeTaxExpenseBenefitContingentConsiderationFairValue>
    <RENB:DeferredIncomeTaxExpenseChangeInTaxRate
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001498"
      unitRef="USD">0</RENB:DeferredIncomeTaxExpenseChangeInTaxRate>
    <RENB:DeferredIncomeTaxExpenseChangeInTaxRate
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001499"
      unitRef="USD">0</RENB:DeferredIncomeTaxExpenseChangeInTaxRate>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001501"
      unitRef="USD">168668052</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001502"
      unitRef="USD">144602042</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001504"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001505"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001509">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zETp2fzeaXG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 &#x2014; &lt;span id="xdx_82D_zHs0CpSh7iw7"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Preferred Stock &lt;/b&gt;&#x2014;
The Company has &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zStdSSz8DFTi" title="Preferred stock shares authorized"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3NJ2Wdgwjj6" title="Preferred stock shares authorized"&gt;10,000,000&lt;/span&gt;&lt;/span&gt;
authorized shares of Preferred Stock, par value $&lt;span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zFUMv1LdNuA4" title="Preferred stock, par value"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_pdd" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt;
per share, &lt;span id="xdx_900_ecustom--PreferredStockDesignatedShares_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXrqVFbmkix3" title="Preferred stock designated shares"&gt;&lt;span id="xdx_902_ecustom--PreferredStockDesignatedShares_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAjcMhsCWXpi" title="Preferred stock designated shares"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;
of which have been designated as Series A Convertible Preferred Stock. At June 30, 2024 and 2023, there were zero &lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8VNXDieA7Rk" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLPe8T1l4DSl" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVp1TeIgJfRg" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zbuNJvtIQ4Ha" style="display: none" title="Preferred stock, shares outstanding"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of
Preferred Stock issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Voting &#x2014; &lt;/b&gt;Holders of
Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
holder&#x2019;s shares of Preferred Stock could then be converted in accordance with conversion rights.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;b&gt;Dividends &#x2014; &lt;/b&gt;The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Liquidation Rights &#x2014;&lt;/b&gt;
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all shares held by such holder. The Series A Preferred Stock is not participating preferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Conversion Rights &#x2014; &lt;/b&gt;On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a &#x201c;Series A Election
Notice&#x201d;) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
&#x201c;Conversion Ratio&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Common Stock &lt;/b&gt;&#x2014;
The Company has &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zW3Y4NSXdBc4" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20230630_zIu7vIsRz4Mi" title="Common stock, shares authorized"&gt;350,000,000&lt;/span&gt;&lt;/span&gt; authorized shares of Common Stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zdB9zWIA8U8f" title="Common stock, par value"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230630_zZsIFg9USyDb" title="Common stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt;
per share. At June 30, 2024 and 2023, there were &lt;span id="xdx_902_ecustom--CommonStockShareIssued_iI_c20240630_z4VLYJHgq7Rh" title="Common stock, shares issued"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_z18ifjdFevt4" title="Common stock, shares outstanding"&gt;155,027,245&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90D_ecustom--CommonStockShareIssued_iI_c20230630_zhlGTy00WDDa" title="Common stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230630_zcu4r5C51X4i" title="Common stock, shares outstanding"&gt;63,698,144&lt;/span&gt;&lt;/span&gt; shares issued and outstanding, respectively. At June 30, 2024
the Company has &lt;span id="xdx_90C_ecustom--CommonStockConvertibleSharesIssuable_iI_c20240630_zma3H2pxOvNg" title="Common stock, shares issuable"&gt;2,189,672&lt;/span&gt; shares issuable, which are included in shares outstanding, related to the contingent consideration settlement
(see Notes 3 and 12).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Voting &#x2014; &lt;/b&gt;Holders of
Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Dividends &#x2014; &lt;/b&gt;Holders
of Common Stock are entitled to receive ratably such dividends as the Company&#x2019;s Board of Directors from time to time may declare
out of funds legally available.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Liquidation Rights &#x2014;&lt;/b&gt;
In the event of any liquidation, dissolution or winding-up of the affairs of the Company, after payment of all debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any remaining assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Purchase Agreement with Lincoln
Park Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On June
20, 2023, the Company entered into a purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park, pursuant to which
the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $&lt;span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_ziTc8e9bO4w1" title="Obligation to purchase"&gt;20,000,000&lt;/span&gt; of shares of Common Stock
over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the 2023 Purchase Agreement, the Company also entered
into a registration rights agreement with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration
rights related to the shares issued under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;In consideration for entering into
the 2023 Purchase Agreement, the Company issued &lt;span id="xdx_909_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zdBKGlQzvPT5" title="Number of shares issued"&gt;696,021&lt;/span&gt; shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the years ended June 30,
2024 and June 30, 2023 no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;b&gt;Preferred Stock Issuances&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 1, 2023, the Company
closed a private placement of &lt;span id="xdx_901_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20230729__20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zb7qp816ycJe" title="Closed private placement units"&gt;280,505&lt;/span&gt; units (the &#x201c;&lt;span style="text-decoration: underline"&gt;Units&lt;/span&gt;&#x201d;), each consisting of (i) one share of the Company&#x2019;s
Series A Convertible Preferred Stock, (the &#x201c;&lt;span style="text-decoration: underline"&gt;Preferred Stock&lt;/span&gt;&#x201d;) and (ii) one Common Stock purchase warrant (each, a &#x201c;&lt;span style="text-decoration: underline"&gt;Warrant&lt;/span&gt;&#x201d;,
and together with the Units and the shares of Preferred Stock, the &#x201c;&lt;span style="text-decoration: underline"&gt;Securities&lt;/span&gt;&#x201d;) to purchase five shares of the Company&#x2019;s
Common Stock, at a price per Unit equal to $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pdd" title="Common stock, par value"&gt;7.13&lt;/span&gt; for aggregate proceeds to the Company of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromRepaymentsOfDebt_c20230729__20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pp0p0" title="aggregate proceeds"&gt;2,000,000&lt;/span&gt; in cash. In addition, the Company
issued &lt;span id="xdx_900_eus-gaap--SharesIssued_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_pdd" title="Number of shares issued"&gt;280,505&lt;/span&gt; Units in connection with the conversion of $&lt;span id="xdx_900_ecustom--ConversionOfPromissoryNote_iI_pp0p0_c20230801__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_z4WWDvA5ypBl" title="Conversion of promissory note"&gt;2,000,000&lt;/span&gt; of the Promissory Note (see Note 7).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company issued an
aggregate of &lt;span id="xdx_909_ecustom--AggregatePreferredStockShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zxtlTqyw1Ms" title="Aggregate preferred stock shares"&gt;561,010&lt;/span&gt;
shares of Preferred Stock, which were initially&#160;convertible into an aggregate of &lt;span id="xdx_90A_ecustom--AggregateCommonStockShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zLhOjKInR5D9" title="Aggregate common stock shares"&gt;5,610,100&lt;/span&gt;
shares of Common Stock. In connection with the private placement, the Company sold warrants to purchase an aggregate of &lt;span id="xdx_90E_ecustom--WarrantsSold_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zWxUMCnQVRsh" title="Warrants sold"&gt;2,805,050&lt;/span&gt;
shares of Common Stock. The warrants are exercisable for five years from the date of issuance and have an exercise price of $&lt;span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_c20230701__20240630__us-gaap--StatementClassOfStockAxis__custom--PreferredStockIssuancesMember_zEfGcWA0w4y1" title="Exercise price"&gt;0.65&lt;/span&gt;
per share, payable in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 13, 2024 pursuant
to the acquisition of Renovaro Cube, the &lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zZRts06UIqG8"&gt;561,010 &lt;/span&gt;shares
of Preferred Stock were converted into an aggregate of &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zbnoxENVNuT9"&gt;5,610,100 &lt;/span&gt;shares
of Common Stock. As of June 30, 2024 there were zero shares of Preferred Stock outstanding. The extinguishment loss of $&lt;span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zdpKUxKkO8Tg" title="Extinguishment loss"&gt;120,018&lt;/span&gt; is
recorded in Other Income/Loss in the Statement of Operations (see Note 7).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;b&gt;June
2024 Private Placement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"&gt;On
June 14, 2024, Renovaro Inc., a Delaware corporation (the &#x201c;&lt;span style="text-decoration: underline"&gt;Company&lt;/span&gt;&#x201d;)
closed a private placement of &lt;span id="xdx_908_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3OkmCfsC4i2" title="Closed private placement units"&gt;5,315,215&lt;/span&gt;
of the Company&#x2019;s units, each such Unit consisting of (i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_905_ecustom--ClosedSharesParValue_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXd1Tbwwrbk9" title="Closed shares, par value"&gt;0.0001&lt;/span&gt;
par value per share and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain
investors (the &#x201c;Private Placement&#x201d;). The Warrants are exercisable for five years from the date of issuance and have an
exercise price of $1.4726 and $&lt;span id="xdx_908_ecustom--ExercisePricePerShare_c20240613__20240614__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z9VIBRpcDjEc" title="Exercise price per share"&gt;1.4765&lt;/span&gt;
per share, payable in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;The Private
Placement was completed pursuant to Regulation S promulgated under the Securities Act of 1933, as amended (&#x201c;&lt;span style="text-decoration: underline"&gt;Regulation S&lt;/span&gt;&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"&gt;In the Private Placement, the
Company sold &lt;span style="background-color: white"&gt;&lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwg9J6Rs8KPh" title="Shares sold"&gt;2,325,869&lt;/span&gt;&lt;/span&gt; Units at a price per Unit equal to $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zT2s6IiUhV8f" title="Price per unit"&gt;1.4726 &lt;/span&gt;to a certain investor who
paid in cash and settlement of debt an aggregate amount of $&lt;span style="background-color: white"&gt;&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGec3ElNuo5b" title="Paid in cash and settlement of debt"&gt;3,425,075&lt;/span&gt;&lt;/span&gt; in consideration for
the Units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"&gt;Additionally, the Company sold
&lt;span style="background-color: white"&gt;&lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zyKRJPvjZERb" title="Shares sold"&gt;2,671,631&lt;/span&gt;&lt;/span&gt; Units to certain investors who surrendered and terminated &lt;span style="background-color: white"&gt;$&lt;span id="xdx_90F_ecustom--PrincipalAmountAndInterestAccrued_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zxowiBxASdjj" title="Principal amount and interest accrued"&gt;3,&lt;span style="background-color: white"&gt;955,033&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
in aggregate principal amount and interest accrued thereon of certain convertible promissory notes issued by the Company in 2023 and 2024
and paid in cash an aggregate amount of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zcNtVuvi8co4" title="Paid in cash and settlement of debt"&gt;&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zEuc3KB1Yl06" title="Paid in cash and settlement of debt"&gt;478,060&lt;/span&gt;&lt;/span&gt; to the Company in consideration for the Units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"&gt;Additionally,
the Company sold &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zSAS88AEcZWe" title="Shares sold"&gt;317,715&lt;/span&gt; Units to an investor who surrendered and terminated $&lt;span style="background-color: white"&gt;&lt;span id="xdx_90B_ecustom--PrincipalAmountAndInterestAccrued_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zIzvvrDIgZcc" title="Principal amount and interest accrued"&gt;468,453&lt;/span&gt;&lt;/span&gt; in
aggregate principal amount and interest accrued thereon of a convertible promissory note issued in 2023 and paid in cash an aggregate
amount of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zf3u1VH8Ruc1" title="Paid in cash and settlement of debt"&gt;66,000&lt;/span&gt; to the Company in consideration for the Units.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt; background-color: white"&gt;In relation to the June 14, 2024 Private Placement the Company recognized
a loss on the settlement of debt for $&lt;span id="xdx_909_ecustom--SettlementOfDebt_c20230701__20240630_zinr59qD6xyg" title="Settlement of debt"&gt;1,183,560&lt;/span&gt; which was recorded in other income (expense) in the statement of operations for the year
ended June 30, 2024.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Common Stock Issuances &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On April 5, 2024, the Company issued&#160;&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z04ccZU16SHc" title="Issuance of common stock shares"&gt;33,760&lt;/span&gt;&#160;shares
of common stock for consulting services valued at $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zqlOgRSWx8S9" title="Common stock for consulting services value"&gt;94,190&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On February 20, 2024, &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zEO8isVpn10a" title="Warrants outstanding"&gt;2,953,700&lt;/span&gt;
warrants outstanding were exercised at prices ranging from $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zFglnvxhwkZ6" title="Warrants exercised"&gt;0.53&lt;/span&gt; to $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zySnTpcRpjei" title="Warrants exercised"&gt;0.65&lt;/span&gt; per share and the aggregate $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z3rdTeCL4Oj6" title="Warrants aggregate amount"&gt;1,750,000&lt;/span&gt; of a promissory note
held by the holder was applied to the exercise price of the warrants (see Note 7).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On February 20, 2024, &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zwVp5MBPbrNb" title="Warrants outstanding"&gt;471,699&lt;/span&gt; warrants
outstanding were exercised at $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zKknGuiqGMVb" title="Warrants exercised"&gt;0.53&lt;/span&gt; per share valued at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_ztr69WMQxFGi" title="Warrants aggregate amount"&gt;250,000.&lt;/span&gt; A promissory note held by the holder was applied to the exercise
price of the warrants in lieu of cash proceeds (see Note 8).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On February 15, 2024, the Company
issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240214__20240215_zJJJdyIV0aUa" title="Issuance of common stock shares"&gt;50,000&lt;/span&gt; shares of Common Stock for consulting services valued at $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240214__20240215__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zTvgBPEYBvQ5" title="Common stock for consulting services value"&gt;100,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;On
February 15, 2024, the Company closed a private placement of &lt;span id="xdx_906_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240214__20240215_zELhbbt0sBXf" title="Issuance of common stock under private placement"&gt;344,827&lt;/span&gt; shares of Common Stock, $&lt;span id="xdx_90C_ecustom--CommonStockParValuePrivatePlacement_c20240214__20240215_zt7gWnwyhYwe" title="Common stock par value under private placement"&gt;0.0001&lt;/span&gt; par value, at $2.90 per share for
aggregate proceeds to the Company of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20240214__20240215_zYVvf4r4eHj5" title="Proceeds from issuance of private placement"&gt;1,000,000&lt;/span&gt; in cash. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;On
February 13, 2024, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zFr7sA8xCVJ2" title="Issuance of common stock shares"&gt;70,834,183 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: white"&gt;valued
at $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zKYdZAjUfFx6" title="Issuance of common stock shares, value"&gt;136,001,631 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: white"&gt;(see
Note 12) shares of Common Stock pursuant to the Stock Purchase Agreement of Renovaro Cube.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On December 4, 2023, the Company
issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231203__20231204_zDJTTY1D8lXi" title="Issuance of common stock shares"&gt;525,945&lt;/span&gt; shares of Common Stock pursuant to warrants exercised for cash proceeds of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231203__20231204_zqT6Xm3ZwREk" title="Issuance of common stock shares, value"&gt;341,865&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On October 23, 2023, the
Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--AdvisoryServicesMember_zD7HF5yEiyle" title="Issuance of common stock shares"&gt;1,000,000 &lt;/span&gt;shares
of Common Stock valued at $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--AdvisoryServicesMember_z7fFKHzkMUVj" title="Issuance of common stock shares, value"&gt;2,760,000&lt;/span&gt; for advisory services to Avram Miller, a member of the Company&#x2019;s board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;Between July 28, 2023, and
September 28, 2023, the Company issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230926__20230928__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zCfX0okrNho" title="Issuance of common stock shares"&gt;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230727__20230728__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zNOMtI5jRP6d" title="Issuance of common stock shares"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;
shares of Common Stock for consulting services valued at $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230926__20230928__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z3CExpf9h0El" title="Issuance of common stock shares, value"&gt;&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230727__20230728__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zs1NwoOJLju2" title="Issuance of common stock shares, value"&gt;4,470,000&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;On
June 26, 2023, the Company issued &lt;span id="xdx_90F_eus-gaap--SharesIssued_iI_c20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzbRvSYH6tc6" title="Number of shares issued"&gt;4,718,532&lt;/span&gt; shares of Common Stock and warrants to purchase &lt;span id="xdx_90B_ecustom--NumberOfShareWarrantPurchase_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zdbvj5OJhHPk" title="Number of share warrant purchase"&gt;2,359,266&lt;/span&gt; shares of common stock resulting
in proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCJupqgE204g" title="Proceeds from private placement"&gt;1,300,823&lt;/span&gt; &lt;/span&gt;in a private placement offering and the reduction of notes payable of $&lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_c20230626_zjfTPiQltga2" title="Notes payable"&gt;1,200,000&lt;/span&gt;. The warrants were immediately
exercisable and had an exercise term of five years with an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626_zt4sEvPNS7d9" title="Exercise price"&gt;0.53&lt;/span&gt; per share. The combined purchase price for one share
of Common Stock and one warrant was $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zj8aBvmCPna2" title="Exercise price"&gt;0.53&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;On
June 26, 2023, the Company issued &lt;span id="xdx_905_eus-gaap--SharesIssued_iI_c20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z18h64maPYzi" title="Number of shares issued"&gt;4,718,532&lt;/span&gt; shares of Common Stock and warrants to purchase &lt;span id="xdx_90D_ecustom--NumberOfShareWarrantPurchase_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z3zaJoK17Lw9" title="Number of share warrant purchase"&gt;2,359,266&lt;/span&gt; shares of common stock resulting
in proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230625__20230626__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zVyzK65EnJlk" title="Proceeds from private placement"&gt;1,300,823&lt;/span&gt; &lt;/span&gt;in a private placement offering and the aforementioned reduction of notes payable of $&lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_c20230626_zm3n606Ystf3" title="Notes payable"&gt;1,200,000&lt;/span&gt;. The
warrants were immediately exercisable and had an exercise term of five years with an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626_zcwPAnsgx8d2" title="Exercise price"&gt;0.53&lt;/span&gt; per share. The combined purchase
price for one share of Common Stock and one warrant was $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230626__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zTLwurwLdDl2" title="Exercise price"&gt;0.53&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On June 20, 2023, the Company issued
&lt;span id="xdx_900_eus-gaap--SharesIssued_iI_c20230620__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LincolnParkMember_zrVyZWJRuNFe" title="Shares issued"&gt;696,021&lt;/span&gt; shares of Common Stock to Lincoln Park as a commitment fee as part of a purchase agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;On April 27, 2023, there were &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20230426__20230427__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFZqj0mTzBjj" title="Converted shares of common stock, shares"&gt;100,000&lt;/span&gt;
shares issued that immediately vested and were converted into shares of Common Stock in exchange for consulting services valued at $&lt;span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20230426__20230427__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq2kP7sDkd1f" title="Converted shares of common stock, value"&gt;120,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
March 2023, the Company issued &lt;span id="xdx_908_eus-gaap--SharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z5wLNaPT8bAb" title="Shares issued"&gt;2,378,070&lt;/span&gt; shares of Common Stock and warrants
to purchase &lt;span id="xdx_902_eus-gaap--SharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zjZpbhJPa08" title="Shares issued of common stock"&gt;1,189,036&lt;/span&gt; shares of Common Stock resulting in proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230330__20230331_ziH4PPABULee" title="Proceeds of private placement offering"&gt;2,711,000&lt;/span&gt; in a private placement offering. The Company effected
the issuances of the shares of Common Stock from March 13, 2023 to March 29, 2023. The purchase warrants were immediately exercisable
and had an exercise term of five years with an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331_z6xDB24WUGhb" title="Exercise price"&gt;1.14&lt;/span&gt; per share. The combined purchase price for one share of Common
Stock and one Purchase Warrant was $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--OneWarrantMember_zq6fJMg2Sib4" title="Exercise price"&gt;1.14&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 10, 2023, there were &lt;span id="xdx_902_eus-gaap--SharesIssued_iI_c20230210__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyjhN52b87l1" title="Shares issued"&gt;100,000&lt;/span&gt; restricted share units issued that immediately vested and were converted into shares of Common
Stock in exchange for consulting services valued at $&lt;span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_c20230209__20230210__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbLEbYyAA553" title="Converted shares of common stock, value"&gt;108,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 30, 2022, the Company issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221229__20221230__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zpwFqwKBB5K3" title="Issuance of shares"&gt;198,439&lt;/span&gt; shares of Common stock valued at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueOther_c20221229__20221230__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zDi5TgSvupN3" title="Shares issued of common stock, value"&gt;204,392&lt;/span&gt; based on the closing price of the common stock
on that date, issued in lieu of prepaid interest related to the amended and restated secured notes (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2022, certain of our warrant holders exercised warrants to purchase&#160;&lt;span id="xdx_901_ecustom--PurchaseSharesOfCommonStock_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zolmneUCAEG8" title="Purchase shares of common stock"&gt;1,250,000&lt;/span&gt;&#160;shares of Common Stock for total proceeds
to the Company of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z97ALMTfU8Qf" title="Total Proceeds"&gt;1,625,000&lt;/span&gt;, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences, based on the share price on that date of $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20220714__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroBioPharmaIncMember_z7WgnHhbH8ei" title="Share price"&gt;2.21&lt;/span&gt;. This non-cash earn-out distribution impacted stockholders&#x2019;
equity in the amount of $&lt;span id="xdx_901_ecustom--EarnOutDistribution_c20220713__20220714_zkVqTXgMf2Oj" title="Earn-out distribution"&gt;2,762,500&lt;/span&gt;&#160;based on the share price on July 14, 2022, of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220714_zhX7gnAVdulf" title="Share price"&gt;2.21&lt;/span&gt;.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2017
Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2022, certain of our warrant holders exercised warrants to purchase&#160;&lt;span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zq3Nf6dlObJ" title="Shares purchased"&gt;1,250,000&lt;/span&gt;&#160;shares of Common Stock for total proceeds
to the Company of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zR7J4uOVUpNe" title="Proceeds from common stock"&gt;1,625,000&lt;/span&gt;, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences. This non-cash earn-out distribution impacted stockholders&#x2019; equity in the amount of $&lt;span id="xdx_90C_eus-gaap--NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zPJOm6GrbwSd" title="Non cash earn out distribution"&gt;2,762,500&lt;/span&gt;&#160;based
on the share price on July 14, 2022 of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zs9dyGuOOn4c" title="Share price"&gt;2.21&lt;/span&gt;. The Company recorded a loss on extinguishment of contingent consideration liability of
$&lt;span id="xdx_90D_ecustom--ExtinguishmentOfContingentConsiderationLiability_c20230701__20240630_zesf902ZjZs7" title="Extinguishment of contingent consideration liability"&gt;419,182&lt;/span&gt;&#160;during the year ended June 30, 2024 which reflected the difference between the fair value of the shares and the contingent
consideration liability at the time of extinguishment. As of June 30, 2023, all outstanding warrants as of the date of acquisition of
Renovaro Biosciences (the &#x201c;2017 Warrants&#x201d;) were exercised and there is no further contingent consideration liability related
to the 2017 Warrants remaining as of June 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisition
of Renovaro Biopharma / Contingently issuable shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2018, the acquisition of Renovaro Biosciences was completed. As part of the acquisition, the stockholders of Renovaro Biosciences
received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise
or conversion of warrants, which were outstanding at closing. As of June 30, 2024, &lt;span id="xdx_90E_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_iI_do_c20240630__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember_zT6rXsINFpc4" title="Common shares contingently issuable"&gt;no&lt;/span&gt; further Contingent Shares are issuable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisition
of Renovaro Denmark &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2024 and 2023, the Company maintained a reserve of &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240630_zJZ6NUz8lss9" title="Common stock reserved for issuance"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230630_zFAAoU6Igv42" title="Common stock reserved for issuance"&gt;17,414&lt;/span&gt;&lt;/span&gt; Escrow Shares, all of which are reflected as issued and outstanding
in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Renovaro Denmark held by non-consenting
shareholders of Renovaro Denmark on both June 30, 2024 and 2023, in accordance with Section 70 of the Danish Companies Act and the Articles
of Association of Renovaro Denmark. There have been &lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DanDritDenmarkMember_zkJUEqgzjs73" title="Common stock, shares outstanding"&gt;167,639&lt;/span&gt; shares of Common Stock issued to non-consenting shareholders of Renovaro
Denmark as of June 30, 2024. During the years ended June 30, 2024 and 2023, the Company did &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_do_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroDenmarkMember_zHVrgGiTrXP7" title="Common stock issued"&gt;&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_do_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RenovaroDenmarkMember_zUezR2nR84ek" title="Common stock issued"&gt;no&lt;/span&gt;&lt;/span&gt;t issue any shares of Common Stock to such
non-consenting shareholders of Renovaro Denmark.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based
Compensation &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock
option is estimated on the date of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2024, the weighted-average
assumptions used to estimate the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ziYDjmukkW87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zZekknpnQxkf" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Renovaro Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zxI0mQVwU0w8" title="Expected term (in years)"&gt;5.0&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zTEAG4zVuCO" title="Expected term (in years)"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zil2MGMcU6S2" title="Volatility"&gt;84.33&lt;/span&gt;% &#x2013; &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zLpHcN3GAqie" title="Volatility"&gt;114.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zSI9QmAnsQbf" title="Risk free interest rate"&gt;3.12&lt;/span&gt;%- &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBWEbywJ1kkh" title="Risk free interest rate"&gt;4.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 75%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230701__20240630__dei--LegalEntityAxis__custom--RenovaroMember_zbOyIYpfcVh1" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company recognized stock-based compensation expense related to all equity
instruments of $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20240630_z37t2AO6EzHl" title="Stock based compensation expense"&gt;4,673,129&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20230630_zkOiheIK0TCe" title="Stock based compensation expense"&gt;3,535,051&lt;/span&gt; for the years ended June 30, 2024 and 2023, respectively. At June 30, 2024, the Company had approximately
$&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20240630_z9yUHIT01Lsb" title="Unrecognized compensation cost"&gt;250,373&lt;/span&gt; of unrecognized compensation cost related to non-vested options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Plan Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 6, 2014, the Company&#x2019;s
Board of Directors adopted the Company&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;), and the Company had reserved
&lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_znuUt4vLmYof" title="Common stock reserved for issuance"&gt;1,206,000&lt;/span&gt; shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On October 30, 2019, the Board
approved and on October 31, 2019, the Company&#x2019;s stockholders adopted its 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company&#x2019;s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Effective July 21, 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;). The 2023 Plan replaced the 2019 Plan.
The 2023 Plan provides that the maximum aggregate number of shares of the Company&#x2019;s Common Stock reserved and available for issuance
under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the
effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject
to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;The Company granted options
to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zyhteRw5pGm4" title="Option granted"&gt;369,500&lt;/span&gt; shares of Common Stock to employees with a three-year vesting period during the year June 30, 2024 under the 2019
and 2023 Plan. For the year ended June 30, 2023, the Company granted options to purchase &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_z5kWUAuYYf1d" title="Option granted"&gt;193,000&lt;/span&gt; shares to employees with a three-year
vesting period under the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;During
the year ended June 30, 2024 and 2023, the Company granted options to purchase&#160;zero&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z54F7F7Ikx71" style="display: none" title="Option granted"&gt;0&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zuZ0XgA4u6yi" title="Option granted"&gt;184,800&lt;/span&gt;, respectively, and zero&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zHcUIzLKVAx8" style="display: none" title="Shares forfeited"&gt;0&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zxlTQir4CUn2" title="Shares forfeited"&gt;18,960&lt;/span&gt;
forfeited shares of Common stock to employees with a&#160;six-month vesting period, respectively under the 2019 Plan. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;During
the year ended June 30, 2024 and 2023, the Company granted options to purchase zero&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDm9oK6Sx6R8" style="display: none" title="Option granted"&gt;0&lt;/span&gt; and&#160;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDnZ1FvoSZp1" title="Option granted"&gt;73,200&lt;/span&gt; issued and&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zwCDCtBIsTFl" style="display: none" title="Shares forfeited"&gt;0&lt;/span&gt; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zDLnAzVvdZka" title="Shares forfeited"&gt;12,640&lt;/span&gt; forfeited, and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Employees1Member_zm7WBMgr0PHh" title="Option granted"&gt;65,000&lt;/span&gt;
shares of Common stock, respectively, to employees with a&#160;one-year vesting period,&lt;/span&gt; respectively under the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the years ended June 30,
2024 and 2023, the Company granted options to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardOneMember_zQEnwZH2bvk7" title="Option granted"&gt;424,412&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardOneMember_ziWKvO4mgHxj" title="Option granted"&gt;355,359&lt;/span&gt; shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the years ended June
30, 2024 and 2023, the Company granted options to purchase &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_zOoU06c85NJj" title="Option granted"&gt;329,729&lt;/span&gt;
and zero &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardTwoMember_z73JZCmMqLW6" style="display: none" title="Option granted"&gt;0&lt;/span&gt; shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the
2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the years ended June 30,
2024, and 2023, the Company granted options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultingServicesMember_zN94ONxMQf14" title="Option granted"&gt;10,000&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultingServicesMember_zwSk6DOBDg28" title="Option granted"&gt;75,000&lt;/span&gt; shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;All of the above options are exercisable
at the market price of the Company&#x2019;s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931
eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing
price of the Company&#x2019;s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $921,254 during the year ended June 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;To date the Company has granted
options under the 2014, 2019 and 2023 Plans (&#x201c;Plan Options&#x201d;) to purchase &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zwp6P3jISZH9" title="Option granted"&gt;6,665,821&lt;/span&gt; shares of Common Stock. At June 30, 2024,
the Company has &lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20230701__20240630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zaMI4uZNnEX2" title="Options available to be issued"&gt;4,515,873&lt;/span&gt; options available to be issued under the 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;A summary of the Plan Options outstanding at June 30,
2024 is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zT9pS2QOYL1g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zcvOLyxfHAd1" style="display: none"&gt;Schedule of stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ranges&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 10%; font-size: 11pt; text-align: right; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoj3UP0Zi3ak" title="Exercise Prices, Lower"&gt;0.45&lt;/span&gt;&#x2013;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zL0sWyyJuEz4" title="Exercise Prices, Upper"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjlok0NFGud7" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,244,987&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlGCuS8k9Mp7" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;7.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDpZZNCO6LRb" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z22dzV2B8Kq2" style="width: 9%; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,817,105&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zxuFiyv6UiI9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;7.15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zNTwhPrOcLm7" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zq9vHnGJWQV2" title="Exercise Prices, Lower"&gt;4.51&lt;/span&gt;&#x2013;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zciuoVCxbwIc" title="Exercise Prices, Upper"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zBiexlnMnqN5" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;167,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zOcUyvdWiRYe" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_znLyCeBR1gq" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zG4XmsEVoZtd" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;135,376&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zlLnBvEEgxHl" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;5.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z8XvPUv82eC3" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zxgHQnjms6K9" title="Exercise Prices, Lower"&gt;6.51&lt;/span&gt;&#x2013;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z1iHs4UyFfn" title="Exercise Prices, Upper"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zJDB519dnxl5" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z95XU05DBeYj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;4.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zqGoGpDbGFJg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zd9mGZcrJfqc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;111,585&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zYpGqlOd5Zdi" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;4.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zOBaby8lmIFi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z0FnfEqDYY8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,527,852&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zUtQF25tWt92" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;7.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2njRW3iJke7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSLtYzFUsth9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,064,066&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z56RVX2La7W6" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;7.03&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFXK6LhPxeE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.20&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;A summary of changes  are presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zB5GW3YRRQLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zw9nn7pGElIh" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Average Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zqOYtBsVQHrj" style="width: 13%; text-align: right" title="Options Outstanding at beginning of period"&gt;4,401,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zuydU65POhs6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;4.78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zA0GqPCBt3ef" title="Weighted Average remaining life"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWtzNzpAK1hg" style="width: 13%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zoHzvvRQOfGe" style="text-align: right" title="Granted"&gt;4,983,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zaqAJu6klj2j" style="text-align: right" title="Weighted average exercise price, Granted"&gt;1.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zY7qYMCgsDV" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zVSnrPz3OMOi" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zrixLPhkVI27" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_ztZA2pG3dtv4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired/Canceled &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zSpp8TEe05Zb" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;(3,856,931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z6p89UjP9Uth" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;4.94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z4j7YnkZlqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period"&gt;5,527,852&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zFd7mtnTwQe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period"&gt;2.11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjVPtAU0P3G3" title="Weighted Average remaining life"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxhKc537x1n2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zTcizUH5ETt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;4,064,066&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhiWPKQHagb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period"&gt;2.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zffv5yDgJU66" title="Weighted Average Remaining Life, Exercisable"&gt;7.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zp4eeIM2rhv" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period"&gt;525,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;At June 30, 2024, the Company had Plan Options to purchase 4,064,066 shares
of common stock that were exercisable. The total intrinsic value of options exercisable at June 30, 2024, was $&lt;span&gt;525,943&lt;/span&gt;.
Intrinsic value is measured using the fair value at the date of exercise (for shares exercised) and at June 30, 2024 (for outstanding
options), less the applicable exercise price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Common Stock Purchase Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;A summary of the status of the
Common Stock Purchase Warrants outstanding at June 30, 2024, is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_z15TSkAxnsY5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B9_zKDohMfsJ2Xf" style="display: none"&gt;Schedule of common stock purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zVP8y94nQXYk" style="width: 9%; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.53&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zK4rbHn9NDrg" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;471,698&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zPGq0Ov22cbg" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;1.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z7hyH1ivX6yc" style="width: 9%; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;471,698&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zbFuATanrD0i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;1.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zb7LOW9sKtX" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zGRWikXfOpP8" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z5FKhhbk0KV4" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zz962SNTavV1" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zXQZuEZjvPE7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDWgYmDaVoX7" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zsmq8SZi4Zia" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,189,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDlwyhcY1gt5" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zHQpPrwjKjQi" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,189,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zscw9Uwubqhb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zTCr0coe40u2" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyqBq827QNRb" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;642,128&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zrwVmoHgrzhl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;4.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zqbHHcTCLnba" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;642,128&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z7uoQANbhZ7i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;4.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zarw1JsAZnn2" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zxmv2q80PLIf" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,740&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zfX6NxHlPMfj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zoOIOuAFfvfl" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,740&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z1KgSx9mvVM9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zsRMblqnRRyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,094,876&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zy6LzXLVkzXa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zfj00j7Vcl66" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zpKbBGNg1hDh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,094,876&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zibIj0t3A8Kg" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zRKHO2xYrCzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;A summary of the warrant activity is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_ztFOeXoPMG9e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zU6u061FCDDe" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Outstanding at June 30, 2023&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zW15v1YzQH09" style="width: 11%; text-align: right" title="Outstanding at beginning of period"&gt;3,548,302&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXAGuqsB02k3" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period"&gt;0.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zszXr2mEb9t1" title="Weighted Average remaining life, Outstanding"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkr824MJeNK6" style="text-align: right" title="Granted"&gt;3,497,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_ztJ9eeD9EDDf" style="text-align: right" title="Weighted average exercise price, Granted"&gt;0.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zp9CTBEdlPq8" title="Weighted Average remaining life, Granted"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zojIebZ8mG33" style="text-align: right" title="Exercised"&gt;(3,951,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z4cmo8MvhJAd" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;0.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_znRVOnkAZAql" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zJUKdMhvktH9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding and exercisable at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CommonStockPurchaseWarrant_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zQDiCVjl0PCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period"&gt;3,094,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z2x7roGAMXy8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zzhIRpQ4RLQ4" title="Weighted Average remaining life, Outstanding"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;At June 30, 2024, the Company had &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zc1fvaxgrNVa" title="Common stock purchase warrants exercisable outstanding"&gt;3,094,876&lt;/span&gt; exercisable Common Stock Purchase
Warrants outstanding. The total intrinsic value of warrants exercisable at June 30, 2024, was $&lt;span&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zEDT93Jqtuta" title="Total intrinsic value of options exercisable"&gt;2,309,681&lt;/span&gt;&lt;/span&gt;.
Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at June 30, 2024 (for outstanding
warrants), less the applicable exercise price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Stock Awards (RSA)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;The Company recognized stock-based
compensation expense related to RSAs of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOfIa2Z7Gytk" title="Stock based compensation expense"&gt;1,415,157&lt;/span&gt; for the year ended June 30, 2024. The restricted stock awards are related to&#160;a
grant of&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zSuE10NEYIWd" title="Number of shares grant"&gt;1,000,000&lt;/span&gt;&#160;shares of restricted stock with a 3-year vesting period made to a director as consideration for advisory
services, with a total value of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20230701__20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zIXReW7RcIU8" title="Number of value grant"&gt;2,760,000&lt;/span&gt;. At June 30, 2024, the Company had $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z7yYcpenajc2" title="Unrecognized compensation cost"&gt;1,344,843&lt;/span&gt; of unrecognized stock-based compensation expense
remaining to be amortized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"&gt;The Company recognized stock-based
compensation expense related to other RSAs of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHqKQfLzx4Yl" title="Stock based compensation expense"&gt;108,000&lt;/span&gt; for the year ended June 30, 2023. These restricted stock awards are related to
a grant of&#160;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlcY1JKpLatl" title="Number of shares grant"&gt;100,000&lt;/span&gt;&#160;shares of restricted stock made to a consultant as consideration for consulting services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;







</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001511"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001513"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001515"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001517"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <RENB:PreferredStockDesignatedShares
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001519"
      unitRef="Shares">1000000</RENB:PreferredStockDesignatedShares>
    <RENB:PreferredStockDesignatedShares
      contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001521"
      unitRef="Shares">1000000</RENB:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001523"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001525"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001527"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001529"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001531"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001533"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001535"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001537"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <RENB:CommonStockShareIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001539"
      unitRef="Shares">155027245</RENB:CommonStockShareIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001541"
      unitRef="Shares">155027245</us-gaap:CommonStockSharesOutstanding>
    <RENB:CommonStockShareIssued
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001543"
      unitRef="Shares">63698144</RENB:CommonStockShareIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001545"
      unitRef="Shares">63698144</us-gaap:CommonStockSharesOutstanding>
    <RENB:CommonStockConvertibleSharesIssuable
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001547"
      unitRef="Shares">2189672</RENB:CommonStockConvertibleSharesIssuable>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2023-06-20"
      decimals="0"
      id="Fact001549"
      unitRef="USD">20000000</us-gaap:PurchaseObligation>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-20_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001553"
      unitRef="Shares">696021</us-gaap:SharesIssued>
    <us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement
      contextRef="From2023-07-292023-08-01_custom_PreferredStockIssuancesMember"
      decimals="INF"
      id="Fact001555"
      unitRef="Shares">280505</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-01_custom_PreferredStockIssuancesMember"
      decimals="INF"
      id="Fact001557"
      unitRef="USDPShares">7.13</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="From2023-07-292023-08-01_custom_PreferredStockIssuancesMember"
      decimals="0"
      id="Fact001559"
      unitRef="USD">2000000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-08-01_custom_PreferredStockIssuancesMember"
      decimals="INF"
      id="Fact001561"
      unitRef="Shares">280505</us-gaap:SharesIssued>
    <RENB:ConversionOfPromissoryNote
      contextRef="AsOf2023-08-01_custom_PreferredStockIssuancesMember"
      decimals="0"
      id="Fact001563"
      unitRef="USD">2000000</RENB:ConversionOfPromissoryNote>
    <RENB:AggregatePreferredStockShares
      contextRef="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember"
      decimals="INF"
      id="Fact001565"
      unitRef="Shares">561010</RENB:AggregatePreferredStockShares>
    <RENB:AggregateCommonStockShares
      contextRef="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember"
      decimals="INF"
      id="Fact001567"
      unitRef="Shares">5610100</RENB:AggregateCommonStockShares>
    <RENB:WarrantsSold
      contextRef="AsOf2024-06-30_custom_PreferredStockIssuancesMember"
      decimals="INF"
      id="Fact001569"
      unitRef="Shares">2805050</RENB:WarrantsSold>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-07-012024-06-30_custom_PreferredStockIssuancesMember"
      decimals="INF"
      id="Fact001571"
      unitRef="USDPShares">0.65</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2024-02-13_custom_RenovaroCubeMember"
      decimals="INF"
      id="Fact001572"
      unitRef="Shares">561010</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember"
      decimals="INF"
      id="Fact001573"
      unitRef="Shares">5610100</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012024-06-30_custom_RenovaroCubeMember"
      decimals="0"
      id="Fact001575"
      unitRef="USD">120018</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement
      contextRef="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001577"
      unitRef="Shares">5315215</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
    <RENB:ClosedSharesParValue
      contextRef="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001579"
      unitRef="USDPShares">0.0001</RENB:ClosedSharesParValue>
    <RENB:ExercisePricePerShare
      contextRef="From2024-06-132024-06-14_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001581"
      unitRef="USDPShares">1.4765</RENB:ExercisePricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001583"
      unitRef="Shares">2325869</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-06-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001585"
      unitRef="USDPShares">1.4726</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact001587"
      unitRef="USD">3425075</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001589"
      unitRef="Shares">2671631</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <RENB:PrincipalAmountAndInterestAccrued
      contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001591"
      unitRef="USD">3</RENB:PrincipalAmountAndInterestAccrued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001593"
      unitRef="USD">478060</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-07-012023-06-30_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001595"
      unitRef="USD">478060</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-07-012023-06-30_custom_Investor1Member"
      decimals="INF"
      id="Fact001597"
      unitRef="Shares">317715</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <RENB:PrincipalAmountAndInterestAccrued
      contextRef="From2022-07-012023-06-30_custom_Investor1Member"
      decimals="0"
      id="Fact001599"
      unitRef="USD">468453</RENB:PrincipalAmountAndInterestAccrued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-07-012023-06-30_custom_Investor1Member"
      decimals="0"
      id="Fact001601"
      unitRef="USD">66000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <RENB:SettlementOfDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001603"
      unitRef="USD">1183560</RENB:SettlementOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember"
      decimals="INF"
      id="Fact001607"
      unitRef="Shares">33760</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001609"
      unitRef="USD">94190</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-20_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001611"
      unitRef="Shares">2953700</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001613"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001615"
      unitRef="USDPShares">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized
      contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember"
      id="Fact001617">1,750,000</us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember"
      decimals="INF"
      id="Fact001619"
      unitRef="Shares">471699</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember"
      decimals="INF"
      id="Fact001621"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized
      contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember"
      id="Fact001623">250,000.</us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-02-142024-02-15"
      decimals="INF"
      id="Fact001625"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-02-142024-02-15_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001627"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-02-142024-02-15"
      decimals="INF"
      id="Fact001629"
      unitRef="Shares">344827</RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering>
    <RENB:CommonStockParValuePrivatePlacement
      contextRef="From2024-02-142024-02-15"
      decimals="INF"
      id="Fact001631"
      unitRef="USDPShares">0.0001</RENB:CommonStockParValuePrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-02-142024-02-15"
      decimals="0"
      id="Fact001633"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember"
      decimals="INF"
      id="Fact001635"
      unitRef="Shares">70834183</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember"
      decimals="0"
      id="Fact001637"
      unitRef="USD">136001631</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-12-032023-12-04"
      decimals="INF"
      id="Fact001639"
      unitRef="Shares">525945</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-12-032023-12-04"
      decimals="0"
      id="Fact001641"
      unitRef="USD">341865</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-222023-10-23_custom_AdvisoryServicesMember"
      decimals="INF"
      id="Fact001643"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-222023-10-23_custom_AdvisoryServicesMember"
      decimals="0"
      id="Fact001645"
      unitRef="USD">2760000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-09-262023-09-28_custom_CommonStockIssuancesMember"
      decimals="INF"
      id="Fact001647"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-07-272023-07-28_custom_CommonStockIssuancesMember"
      decimals="INF"
      id="Fact001649"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-09-262023-09-28_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001651"
      unitRef="USD">4470000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-272023-07-28_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001653"
      unitRef="USD">4470000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001655"
      unitRef="Shares">4718532</us-gaap:SharesIssued>
    <RENB:NumberOfShareWarrantPurchase
      contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001657"
      unitRef="Shares">2359266</RENB:NumberOfShareWarrantPurchase>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001659"
      unitRef="USD">1300823</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-06-26"
      decimals="0"
      id="Fact001661"
      unitRef="USD">1200000</us-gaap:NotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-26"
      decimals="INF"
      id="Fact001663"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-26_custom_OneWarrantMember"
      decimals="INF"
      id="Fact001665"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001667"
      unitRef="Shares">4718532</us-gaap:SharesIssued>
    <RENB:NumberOfShareWarrantPurchase
      contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001669"
      unitRef="Shares">2359266</RENB:NumberOfShareWarrantPurchase>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-06-252023-06-26_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001671"
      unitRef="USD">1300823</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-06-26"
      decimals="0"
      id="Fact001673"
      unitRef="USD">1200000</us-gaap:NotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-26"
      decimals="INF"
      id="Fact001675"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-26_custom_OneWarrantMember"
      decimals="INF"
      id="Fact001677"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-20_us-gaap_CommonStockMember_custom_LincolnParkMember"
      decimals="INF"
      id="Fact001679"
      unitRef="Shares">696021</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-04-262023-04-27_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001681"
      unitRef="Shares">100000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-04-262023-04-27_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001683"
      unitRef="USD">120000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001687"
      unitRef="Shares">2378070</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001689"
      unitRef="Shares">1189036</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-03-302023-03-31"
      decimals="0"
      id="Fact001691"
      unitRef="USD">2711000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact001693"
      unitRef="USDPShares">1.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_custom_OneWarrantMember"
      decimals="INF"
      id="Fact001695"
      unitRef="USDPShares">1.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-02-10_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001697"
      unitRef="Shares">100000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-02-092023-02-10_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001699"
      unitRef="USD">108000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-12-292022-12-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001701"
      unitRef="Shares">198439</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-12-292022-12-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001703"
      unitRef="USD">204392</us-gaap:StockIssuedDuringPeriodValueOther>
    <RENB:PurchaseSharesOfCommonStock
      contextRef="AsOf2022-07-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001705"
      unitRef="Shares">1250000</RENB:PurchaseSharesOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-07-132022-07-14_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001707"
      unitRef="USD">1625000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-14_custom_RenovaroBioPharmaIncMember"
      decimals="INF"
      id="Fact001709"
      unitRef="USDPShares">2.21</us-gaap:SharePrice>
    <RENB:EarnOutDistribution
      contextRef="From2022-07-132022-07-14"
      decimals="0"
      id="Fact001711"
      unitRef="USD">2762500</RENB:EarnOutDistribution>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-07-14"
      decimals="INF"
      id="Fact001713"
      unitRef="USDPShares">2.21</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001715"
      unitRef="Shares">1250000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001717"
      unitRef="USD">1625000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
      contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001719"
      unitRef="USD">2762500</us-gaap:NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-14_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001721"
      unitRef="USDPShares">2.21</us-gaap:SharePrice>
    <RENB:ExtinguishmentOfContingentConsiderationLiability
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001723"
      unitRef="USD">419182</RENB:ExtinguishmentOfContingentConsiderationLiability>
    <RENB:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable
      contextRef="AsOf2024-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember"
      decimals="INF"
      id="Fact001725"
      unitRef="Shares">0</RENB:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001727"
      unitRef="Shares">17414</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001729"
      unitRef="Shares">17414</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30_custom_DanDritDenmarkMember"
      decimals="INF"
      id="Fact001731"
      unitRef="Shares">167639</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_custom_RenovaroDenmarkMember"
      decimals="INF"
      id="Fact001733"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30_custom_RenovaroDenmarkMember"
      decimals="INF"
      id="Fact001735"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001739">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ziYDjmukkW87" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zZekknpnQxkf" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Renovaro Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zxI0mQVwU0w8" title="Expected term (in years)"&gt;5.0&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zTEAG4zVuCO" title="Expected term (in years)"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zil2MGMcU6S2" title="Volatility"&gt;84.33&lt;/span&gt;% &#x2013; &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zLpHcN3GAqie" title="Volatility"&gt;114.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zSI9QmAnsQbf" title="Risk free interest rate"&gt;3.12&lt;/span&gt;%- &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBWEbywJ1kkh" title="Risk free interest rate"&gt;4.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 75%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230701__20240630__dei--LegalEntityAxis__custom--RenovaroMember_zbOyIYpfcVh1" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember"
      id="Fact001741">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember"
      id="Fact001743">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001745"
      unitRef="Pure">0.8433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001747"
      unitRef="Pure">1.1488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_srt_MinimumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001749"
      unitRef="Pure">0.0312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_srt_MaximumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001751"
      unitRef="Pure">0.0483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-07-012024-06-30_custom_RenovaroMember"
      decimals="INF"
      id="Fact001753"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001755"
      unitRef="USD">4673129</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001757"
      unitRef="USD">3535051</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001759"
      unitRef="USD">250373</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2014-02-06_custom_EquityIncentivePlan2014Member"
      decimals="INF"
      id="Fact001761"
      unitRef="Shares">1206000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_EmployeesMember"
      decimals="INF"
      id="Fact001763"
      unitRef="Shares">369500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_custom_EmployeesMember"
      decimals="INF"
      id="Fact001765"
      unitRef="Shares">193000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact001767"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact001769"
      unitRef="Shares">184800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact001771"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact001773"
      unitRef="Shares">18960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact001775"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact001777"
      unitRef="Shares">73200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact001779"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-07-012023-06-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact001781"
      unitRef="Shares">12640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_custom_Employees1Member"
      decimals="INF"
      id="Fact001783"
      unitRef="Shares">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember"
      decimals="INF"
      id="Fact001785"
      unitRef="Shares">424412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardOneMember"
      decimals="INF"
      id="Fact001787"
      unitRef="Shares">355359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember"
      decimals="INF"
      id="Fact001789"
      unitRef="Shares">329729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_custom_BoardOfDirectorsAndScientificAdvisoryBoardTwoMember"
      decimals="INF"
      id="Fact001791"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_ConsultingServicesMember"
      decimals="INF"
      id="Fact001793"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_custom_ConsultingServicesMember"
      decimals="INF"
      id="Fact001795"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_PlanOptionsMember"
      decimals="INF"
      id="Fact001799"
      unitRef="Shares">6665821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="From2023-07-012024-06-30_custom_PlanOptionsMember"
      decimals="INF"
      id="Fact001801"
      unitRef="Shares">4515873</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001803">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zT9pS2QOYL1g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zcvOLyxfHAd1" style="display: none"&gt;Schedule of stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ranges&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 10%; font-size: 11pt; text-align: right; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoj3UP0Zi3ak" title="Exercise Prices, Lower"&gt;0.45&lt;/span&gt;&#x2013;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zL0sWyyJuEz4" title="Exercise Prices, Upper"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjlok0NFGud7" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,244,987&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlGCuS8k9Mp7" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;7.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDpZZNCO6LRb" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z22dzV2B8Kq2" style="width: 9%; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,817,105&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zxuFiyv6UiI9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;7.15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zNTwhPrOcLm7" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zq9vHnGJWQV2" title="Exercise Prices, Lower"&gt;4.51&lt;/span&gt;&#x2013;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zciuoVCxbwIc" title="Exercise Prices, Upper"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zBiexlnMnqN5" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;167,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zOcUyvdWiRYe" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_znLyCeBR1gq" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zG4XmsEVoZtd" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;135,376&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zlLnBvEEgxHl" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;5.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z8XvPUv82eC3" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: right; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zxgHQnjms6K9" title="Exercise Prices, Lower"&gt;6.51&lt;/span&gt;&#x2013;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z1iHs4UyFfn" title="Exercise Prices, Upper"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zJDB519dnxl5" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z95XU05DBeYj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;4.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zqGoGpDbGFJg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zd9mGZcrJfqc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;111,585&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zYpGqlOd5Zdi" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;4.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zOBaby8lmIFi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z0FnfEqDYY8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,527,852&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zUtQF25tWt92" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;7.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2njRW3iJke7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSLtYzFUsth9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,064,066&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z56RVX2La7W6" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;7.03&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFXK6LhPxeE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.20&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001805"
      unitRef="USDPShares">0.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001807"
      unitRef="USDPShares">4.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001809"
      unitRef="Shares">5244987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      id="Fact001811">P7Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001813"
      unitRef="USDPShares">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001815"
      unitRef="Shares">3817105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      id="Fact001817">P7Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001819"
      unitRef="USDPShares">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001821"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001823"
      unitRef="USDPShares">6.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001825"
      unitRef="Shares">167634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      id="Fact001827">P6Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001829"
      unitRef="USDPShares">5.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001831"
      unitRef="Shares">135376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      id="Fact001833">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001835"
      unitRef="USDPShares">5.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001837"
      unitRef="USDPShares">6.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001839"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001841"
      unitRef="Shares">115231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      id="Fact001843">P4Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001845"
      unitRef="USDPShares">7.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001847"
      unitRef="Shares">111585</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      id="Fact001849">P4Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001851"
      unitRef="USDPShares">7.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001853"
      unitRef="Shares">5527852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember"
      id="Fact001855">P7Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001857"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001859"
      unitRef="Shares">4064066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_us-gaap_EmployeeStockOptionMember"
      id="Fact001861">P7Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001863"
      unitRef="USDPShares">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001865">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zB5GW3YRRQLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zw9nn7pGElIh" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Average Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zqOYtBsVQHrj" style="width: 13%; text-align: right" title="Options Outstanding at beginning of period"&gt;4,401,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zuydU65POhs6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;4.78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zA0GqPCBt3ef" title="Weighted Average remaining life"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWtzNzpAK1hg" style="width: 13%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zoHzvvRQOfGe" style="text-align: right" title="Granted"&gt;4,983,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zaqAJu6klj2j" style="text-align: right" title="Weighted average exercise price, Granted"&gt;1.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zY7qYMCgsDV" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zVSnrPz3OMOi" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zrixLPhkVI27" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_ztZA2pG3dtv4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired/Canceled &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zSpp8TEe05Zb" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;(3,856,931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z6p89UjP9Uth" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;4.94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_z4j7YnkZlqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period"&gt;5,527,852&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zFd7mtnTwQe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period"&gt;2.11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjVPtAU0P3G3" title="Weighted Average remaining life"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxhKc537x1n2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zTcizUH5ETt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;4,064,066&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhiWPKQHagb9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period"&gt;2.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zffv5yDgJU66" title="Weighted Average Remaining Life, Exercisable"&gt;7.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zp4eeIM2rhv" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period"&gt;525,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001867"
      unitRef="Shares">4401211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001869"
      unitRef="USDPShares">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-07-012023-06-30_custom_EmployeeStockOptionsMember"
      id="Fact001871">P7Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-06-30_custom_EmployeeStockOptionsMember"
      decimals="0"
      id="Fact001873"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001875"
      unitRef="Shares">4983572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001877"
      unitRef="USDPShares">1.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001879"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001881"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001883"
      unitRef="Shares">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001885"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001887"
      unitRef="Shares">3856931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001889"
      unitRef="USDPShares">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001891"
      unitRef="Shares">5527852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001893"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      id="Fact001895">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="0"
      id="Fact001897"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001899"
      unitRef="Shares">4064066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001901"
      unitRef="USDPShares">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      id="Fact001903">P7Y18D</RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="0"
      id="Fact001905"
      unitRef="USD">525943</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001909">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_z15TSkAxnsY5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B9_zKDohMfsJ2Xf" style="display: none"&gt;Schedule of common stock purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                            (years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zVP8y94nQXYk" style="width: 9%; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.53&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zK4rbHn9NDrg" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;471,698&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zPGq0Ov22cbg" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;1.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z7hyH1ivX6yc" style="width: 9%; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;471,698&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zbFuATanrD0i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;1.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zb7LOW9sKtX" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zGRWikXfOpP8" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z5FKhhbk0KV4" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zz962SNTavV1" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zXQZuEZjvPE7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDWgYmDaVoX7" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zsmq8SZi4Zia" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,189,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zDlwyhcY1gt5" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zHQpPrwjKjQi" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,189,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zscw9Uwubqhb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zTCr0coe40u2" style="text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyqBq827QNRb" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;642,128&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zrwVmoHgrzhl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;4.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zqbHHcTCLnba" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;642,128&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z7uoQANbhZ7i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;4.96&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExercisePrices_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zarw1JsAZnn2" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zxmv2q80PLIf" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,740&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zfX6NxHlPMfj" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zoOIOuAFfvfl" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,740&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z1KgSx9mvVM9" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;4.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zsRMblqnRRyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,094,876&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zy6LzXLVkzXa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zfj00j7Vcl66" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zpKbBGNg1hDh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,094,876&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zibIj0t3A8Kg" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zRKHO2xYrCzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock>
    <RENB:ExercisePrices
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001911"
      unitRef="USDPShares">0.53</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001913"
      unitRef="Shares">471698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      id="Fact001915">P1Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001917"
      unitRef="Shares">471698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      id="Fact001919">P1Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001921"
      unitRef="USDPShares">0.65</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001923"
      unitRef="Shares">741274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      id="Fact001925">P3Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001927"
      unitRef="Shares">741274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      id="Fact001929">P3Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001931"
      unitRef="USDPShares">1.14</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001933"
      unitRef="Shares">1189036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      id="Fact001935">P3Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001937"
      unitRef="Shares">1189036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      id="Fact001939">P3Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      decimals="INF"
      id="Fact001941"
      unitRef="USDPShares">1.47</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      decimals="INF"
      id="Fact001943"
      unitRef="Shares">642128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      id="Fact001945">P4Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      decimals="INF"
      id="Fact001947"
      unitRef="Shares">642128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      id="Fact001949">P4Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      decimals="INF"
      id="Fact001951"
      unitRef="USDPShares">1.48</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      decimals="INF"
      id="Fact001953"
      unitRef="Shares">50740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      id="Fact001955">P4Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      decimals="INF"
      id="Fact001957"
      unitRef="Shares">50740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      id="Fact001959">P4Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001961"
      unitRef="Shares">3094876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember"
      id="Fact001963">P3Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001965"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001967"
      unitRef="Shares">3094876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantsMember"
      id="Fact001969">P3Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001971"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <RENB:ScheduleOfWarrantsOutstandingTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001973">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_ztFOeXoPMG9e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zU6u061FCDDe" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Outstanding at June 30, 2023&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zW15v1YzQH09" style="width: 11%; text-align: right" title="Outstanding at beginning of period"&gt;3,548,302&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXAGuqsB02k3" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period"&gt;0.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zszXr2mEb9t1" title="Weighted Average remaining life, Outstanding"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkr824MJeNK6" style="text-align: right" title="Granted"&gt;3,497,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_ztJ9eeD9EDDf" style="text-align: right" title="Weighted average exercise price, Granted"&gt;0.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zp9CTBEdlPq8" title="Weighted Average remaining life, Granted"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zojIebZ8mG33" style="text-align: right" title="Exercised"&gt;(3,951,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z4cmo8MvhJAd" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;0.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_znRVOnkAZAql" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zJUKdMhvktH9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding and exercisable at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CommonStockPurchaseWarrant_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zQDiCVjl0PCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period"&gt;3,094,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_z2x7roGAMXy8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zzhIRpQ4RLQ4" title="Weighted Average remaining life, Outstanding"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</RENB:ScheduleOfWarrantsOutstandingTableTextBlock>
    <RENB:CommonStockPurchaseWarrant
      contextRef="AsOf2023-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001975"
      unitRef="Shares">3548302</RENB:CommonStockPurchaseWarrant>
    <RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001977"
      unitRef="USDPShares">0.73</RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-07-012023-06-30_custom_CommonStockPurchaseWarrantMember"
      id="Fact001979">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001981"
      unitRef="Shares">3497918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001983"
      unitRef="USDPShares">0.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      id="Fact001985">P4Y3M7D</RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001987"
      unitRef="Shares">3951344</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001989"
      unitRef="USDPShares">0.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001991"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001993"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <RENB:CommonStockPurchaseWarrant
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001995"
      unitRef="Shares">3094876</RENB:CommonStockPurchaseWarrant>
    <RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001997"
      unitRef="USDPShares">1.00</RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      id="Fact001999">P3Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact002001"
      unitRef="Shares">3094876</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="0"
      id="Fact002003"
      unitRef="USD">2309681</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact002005"
      unitRef="USD">1415157</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact002007"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact002009"
      unitRef="USD">2760000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-06-30_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact002011"
      unitRef="USD">1344843</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact002013"
      unitRef="USD">108000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-07-012023-06-30_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact002015"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002019">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zY5H7f9mPU1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_82E_z3Ik7uUBKUB"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#x201c;HBV License Agreement&#x201d;) by and among the Company, G-Tech, and
G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute
(&#x201c;SRI&#x201d;) (collectively the &#x201c;Licensors&#x201d;), whereby the Company acquired a perpetual, sublicensable, exclusive license
(the &#x201c;HBV License&#x201d;) for a treatment under development (the &#x201c;Treatment&#x201d;) aimed to treat Hepatitis B Virus (HBV)
infections.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24 month period, and provides for an up-front payment of $&lt;span id="xdx_90B_eus-gaap--PaymentsForFees_pn5n6_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zGGTKxt471r8" title="Payment for license"&gt;1.2&lt;/span&gt; million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a &lt;span id="xdx_906_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zIQvxlumRys3" title="Royalty percentage"&gt;2&lt;/span&gt;% royalty to G-Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $&lt;span id="xdx_90B_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrn3UvWfov12" title="Payment for license"&gt;1.2&lt;/span&gt; million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement in the years ended June 30, 2024, and 2023. The Company
has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section
below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#x201c;License Development Agreement&#x201d;), by and among the Company, G-Tech
and SRI (collectively, the &#x201c;Licensors&#x201d;), whereby the Company acquired a perpetual sublicensable, exclusive license (the &#x201c;Development
License&#x201d;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating pan-coronavirus
or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza
(the &#x201c;Prevention and Treatment&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides
for an up-front payment of $&lt;span id="xdx_90C_ecustom--UpfrontPayment_c20191114__20191115_z8Zm6ad6TGzh" title="Up-front payment"&gt;10,000,000&lt;/span&gt; and a $&lt;span id="xdx_907_ecustom--PaymentForExpenditures_c20191114__20191115_zUiWRwaZbnK6" title="Payment for expenditures"&gt;760,000&lt;/span&gt; payment for expenditures to date prior to the effective date related to research
towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional payments
upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement, in each
case subject to the terms of the Development License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Development License Agreement
provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G-Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product candidates
that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license
(see Contingencies sub-section below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#x201c;ALC License Agreement&#x201d;) with Serhat
G&#xfc;mr&#xfc;kc&#xfc; and SRI (collectively, the &#x201c;Licensors&#x201d;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $&lt;span id="xdx_905_ecustom--InitialPayment_c20210824__20210825_zHdfcMUBnwQh" title="Initial payment"&gt;600,000&lt;/span&gt; and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $&lt;span id="xdx_90C_ecustom--InitialPayment_c20210909__20210910_zllz47s6Fvme" title="Initial payment"&gt;600,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;G-Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Shares held for non-consenting
shareholders&lt;/b&gt; &#x2013; The &lt;span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240630_zOeXKcJ2YHRe" title="Remaining shares"&gt;17,414&lt;/span&gt; remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have been reflected
as issued and outstanding in the accompanying financial statements.&#160;There were zero shares of Common Stock issued to such&#160;non-consenting
stockholders during the years ended June 30, 2024 and 2023 (see Note 9.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Service Agreements&lt;/b&gt; &lt;i&gt;&#x2013;&lt;/i&gt;The
Company maintains employment agreements with certain senior staff in the ordinary course of business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;Securities Class Action Litigation&lt;/i&gt;.
On July 26, 2022 and July 28, 2022, securities class action complaints (the
former, the &#x201c;Chow Action&#x201d; and the latter, the &#x201c;Manici Action&#x201d;) were filed by purported stockholders of the Company
in the United States District Court for the Central District of California against the Company and certain of the Company&#x2019;s current
and former officers and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of
material fact in connection with the Company&#x2019;s relationship with Serhat G&#xfc;mr&#xfc;kc&#xfc; and its commercial prospects. The
complaints seek unspecified damages, interest, fees, and costs. On November 22, 2022, the Manici Action was voluntarily dismissed without
prejudice, but the Chow action remains pending.&#160;On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The
lead plaintiff filed an amended complaint on December 15, 2023. The Company has filed a motion to dismiss the amended complaint on March
15, 2024. The Court denied the Company&#x2019;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, and the
parties have come to an agreement in principle to settle the class action.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;Federal Derivative Litigation&lt;/i&gt;.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action
in the United States District Court for the Central District of California. On January 19, 2023, John Solak filed a substantially similar
shareholder derivative action in the United States District Court for the District of Delaware. Both derivative actions recite similar
underlying facts as those alleged in the Securities Class Action Litigation. The actions, filed on behalf of the Company, name Serhat
G&#xfc;mr&#xfc;kc&#xfc; and certain of the Company&#x2019;s current and former directors as defendants. The actions also name the Company
as a nominal defendant. The actions allege violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also set
out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiffs do
not quantify any alleged injury, but seek damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United
States District Court for the Central District of California stayed the Koenig matter pending resolution of the defendants&#x2019; anticipated
motion to dismiss in the Securities Class Action Litigation. On April 4, 2023, the United States District Court for the District of Delaware
stayed the Solak matter pending resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities Class Action Litigation.
On June 28, 2024, the United States District Court for the Central District of California denied defendants&#x2019; motion to dismiss the
Securities Class Action Litigation. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings in
the Koenig matter is October 21, 2024. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings
in the Solak matter is October 22, 2024. The defendants have not yet responded to either complaint. The Company intends to contest these
matters but expresses no opinion as to the likelihood of favorable outcomes. Management is unable to determine the likelihood of a loss,
including a possible range of losses, if any, arising from this matter as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;State Derivative Litigation&lt;/i&gt;.
On October 20, 2022, Susan Midler filed a shareholder derivative action in
the Superior Court of California, Los Angeles County, reciting similar underlying facts as those alleged in the Securities Class Action
Litigation. The action, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc; and certain of the Company&#x2019;s current
and former directors as defendants. The action also names the Company as a nominal defendant. The action sets out claims for breaches
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the Court stayed the Midler matter
pending resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024,
the United States District Court for the Central District of California denied defendants&#x2019; motion to dismiss the Securities Class
Action Litigation. The deadline for the parties to file a proposed schedule or to continue the stay or proceedings in the Midler matter
is October 23, 2024. The defendants have not yet responded to the complaint. The Company intends
to contest this matter but expresses no opinion as to the likelihood of a favorable outcome. Management is unable to determine the likelihood
of a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#xfc;mr&#xfc;kc&#xfc;, William Anderson Wittekind (&#x201c;Wittekind&#x201d;), G Tech Bio LLC (&#x201c;G Tech&#x201d;), SG &amp;amp; AW Holdings,
LLC, and Seraph Research Institute (&#x201c;SRI&#x201d;) (collectively, the &#x201c;Defendants&#x201d;). The Complaint alleges that the Defendants
engaged in a &#x201c;concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting
its Hepatitis B and SARS-CoV-2/influenza pipelines.&#x201d; Specifically, &#x201c;Defendants manipulated negative results to reflect positive
outcomes from various studies, and even fabricated studies out of whole cloth.&#x201d; As a result of the Defendants&#x2019; conduct, the
Company claims that it &#x201c;paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#x201d;
On April 21, 2023, defendants Wittekind, G Tech, SG &amp;amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all,
of the Company&#x2019;s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending
motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening
deadlines.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On December
4, 2023, the Defendants answered the Company&#x2019;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including,
&lt;i&gt;inter alia&lt;/i&gt;, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp;amp; License
Agreement, effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications,
effective as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial is currently
scheduled to begin on March 3, 2025. The Company denies these allegations and intends to vigorously defend against the cross claims while
pursuing its claims against the Defendants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On March 1, 2021, the Company&#x2019;s
former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District
of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and
Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable
cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The
allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior
Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company&#x2019;s motion to dismiss, dismissing the abuse
of process claim against all defendants and all claims against Mark Dybul and Henrik Gr&#xf8;nfeldt-S&#xf8;rensen. On November 29, 2022,
the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24, 2023,
the court denied the motion for summary judgment. The court vacated the July 15, 2024 trial date and has yet to re-set the trial date.
The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On June
7, 2023, Weird Science LLC (&#x201c;Weird Science&#x201d;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (such trusts, collectively, the
&#x201c;Trusts&#x201d;) (collectively, &#x201c;Plaintiffs&#x201d;) filed a Verified Complaint against the Company in the Court of Chancery
of Delaware. In the Verified Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between
the Company, Weird Science, and RS Group ApS (the &#x201c;Investor Rights Agreement&#x201d;). According to the Verified Complaint, the Investor
Rights Agreement required the Company to (i) notify all &#x201c;Holders&#x201d; of &#x201c;Registrable Securities&#x201d; at least 30 days
prior to filing a registration statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in
such registration statement. Plaintiffs alleged that the Company breached these registration rights by failing to provide the required
notice in connection with S-3 registration statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to
dismiss the Verified Complaint on September 15, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt; background-color: white"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#x201c;FAC&#x201d;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#x2019; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023. The Court scheduled oral argument on the motions to dismiss for November 15, 2024. The Company denies Plaintiffs&#x2019;
allegations and intends to vigorously defend against the claims.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 24, 2023, counsel on
behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company&#x2019;s
books and records (the &#x201c;Demand&#x201d;) pursuant to Delaware General Corporation Law, &#xa7;&#160;220 (&#x201c;Section 220&#x201d;).
The Demand seeks the Company&#x2019;s books and records in connection with various issues identified in the Demand. The Company takes
its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with
those obligations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 19, 2024, Weird Science
and Wittekind sent the Company&#x2019;s Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues
identified therein. On February 27, 2024, Weird Science and Wittekind sent the Company&#x2019;s Board of Directors a supplemental letter
that expanded their demand for corrective actions to twenty-six issues. In response to these demand letters, the Board of Directors initially
formed a Special Committee (&#x201c;Special Committee&#x201d;) of independent directors on February 29, 2024. The Special Committee retained
Stradling Yocca Carlson &amp;amp; Rauth LLP as its counsel to investigate the issues identified in the demand letters. The Special Committee&#x2019;s
investigation is ongoing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States
District Court for the Central District of California against certain officers, directors, and investors of the Company, as well as other
defendants, in connection with, &lt;i&gt;inter alia&lt;/i&gt;, Weird Science and Wittekind&#x2019;s demand for corrective action. Plaintiffs filed
an amended complaint on June 21, 2024. The First Amended Verified Stockholder Derivative Complaint (&#x201c;Derivative Complaint&#x201d;)
alleges, among other claims, violations of Section 13(d) and 14(a) and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934.
The Derivative Complaint also includes claims of breach of fiduciary duty, corporate waste, unjust enrichment, and contribution/indemnification.
Weird Science and Wittekind seek unspecified compensatory, exemplary, and punitive damages and certain injunctive relief. The Derivative
Complaint names the Company as a nominal defendant. On July 19, 2024, certain of the director defendants, who had agreed to waive service
of the summons and Derivative Complaint, filed a motion to dismiss the Derivative Complaint on a variety of procedural and substantive
grounds. A hearing on the motion dismiss was held on October 3, 2024 and the court subsequently took the motion under submission. The
director defendants deny the allegations in the Derivative Complaint and intend to vigorously defend against the claims asserted therein.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On June 21, 2024, the Company
filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, &lt;i&gt;inter alia&lt;/i&gt;, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForFees
      contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact002021"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:RoyaltyPercentage
      contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact002023"
      unitRef="Pure">0.02</RENB:RoyaltyPercentage>
    <us-gaap:PaymentsForFees
      contextRef="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact002025"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:UpfrontPayment
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact002027"
      unitRef="USD">10000000</RENB:UpfrontPayment>
    <RENB:PaymentForExpenditures
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact002029"
      unitRef="USD">760000</RENB:PaymentForExpenditures>
    <RENB:InitialPayment
      contextRef="From2021-08-242021-08-25"
      decimals="0"
      id="Fact002033"
      unitRef="USD">600000</RENB:InitialPayment>
    <RENB:InitialPayment
      contextRef="From2021-09-092021-09-10"
      decimals="0"
      id="Fact002035"
      unitRef="USD">600000</RENB:InitialPayment>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact002037"
      unitRef="Shares">17414</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002043">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcIyhkWtg4Ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 11 &#x2014; &lt;span id="xdx_82B_zXkV8j374a24"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;As of June 30, 2024, the Company
has accrued $&lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_zBrDUJdrcso4" title="Accrued balance"&gt;220,402&lt;/span&gt; of compensation related expenses for the Company&#x2019;s Chief Executive Officer, Mark Dybul, related to budget constraints.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 16, 2024, the Company
received an exercise notice from RS Bio ApS (&#x201c;RS Bio&#x201d;) to exercise &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxelBOoSD492" title="Warrant exercise price"&gt;471,699&lt;/span&gt; warrants outstanding at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zxFYilgpUBpl" title="Warrant exercise price per share"&gt;0.53&lt;/span&gt;
per share. Mr. Rene Sindlev, the Chairman of the Company&#x2019;s Board of Directors, holds the sole voting and disposition power of the
shares owned by RS Bio. RS Bio applied $&lt;span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240214__20240216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z6iC2Jc8pjB7" title="Proceeds from notes payables"&gt;250,000&lt;/span&gt; of one of its outstanding note payable balance to the exercise price (see Note 7.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a &lt;span id="xdx_902_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zhEPEaQp7FTf" title="Original issue discount promissory note percentage"&gt;5&lt;/span&gt;% Original Issue Discount Secured Promissory Note for the principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zQNWH5831WJl" title="Principal amount"&gt;105,263&lt;/span&gt;.
The Company received $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfDebt_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RsBioMember_zCChAn7V4Wl6" title="Gross proceeds"&gt;100,000&lt;/span&gt; in gross proceeds after taking into account the &lt;span id="xdx_909_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RsBioMember_zI4CBiIK6Mb" title="Gross proceeds original issue discount rate"&gt;5&lt;/span&gt;% original issue discount. The Note bears an interest rate
of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z6FoWuOSRzjc" title="Interest rate"&gt;12&lt;/span&gt;% per annum and matured on &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240204__20240205__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKtbh6YbJpbf" title="Debt maturity period"&gt;March 1, 2024&lt;/span&gt; . The obligations under this Note are secured by the Amended and Restated Security Agreement
(see Note 7). The Company is required to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of
$&lt;span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zmMeRmSyfR19" title="Amortization discount"&gt;5,263&lt;/span&gt; was charged to interest expense. As of June 30, 2024, the Company accrued $&lt;span id="xdx_904_eus-gaap--InterestExpense_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zG9yUMYG52e9" title="Interest expense"&gt;6,316&lt;/span&gt; of interest expense that is included in accrued
expenses on the balance sheet. The Note balance, net of discount at June 30, 2024 is $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zKA1FKonUdE3" title="Note balance"&gt;105,263&lt;/span&gt; (see Note 7.)&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 2, 2024, the Company entered into an agreement with RS Bio to issue
a &lt;span id="xdx_90B_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zfYE7otv7BQa" title="Original issue discount promissory note percentage"&gt;5&lt;/span&gt;% Original Issue Discount Secured Promissory Note for the principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zJmohid8rcag" title="Principal amount"&gt;526,315&lt;/span&gt; (the &#x201c;January 2024 Note&#x201d;). The Company
received a total of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z8WJQN2AvyJ6" title="Gross proceeds"&gt;500,000&lt;/span&gt; in gross proceeds after taking into account the &lt;span id="xdx_90F_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zAXbBFSDVRs" title="Gross proceeds original issue discount rate"&gt;5&lt;/span&gt;% original issue discount.&#160;The January 2024 Note bears
an interest rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDS1ufUwWOIi" title="Interest rate"&gt;12&lt;/span&gt;% per annum and shall mature on &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240102__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zd9gR6h8tUw8" title="Debt maturity period"&gt;March 1, 2024&lt;/span&gt; (the &#x201c;Maturity Date&#x201d;) is past due. The Company is required
to pay interest on the maturity date. For the year ended June 30, 2024, discount amortization of $&lt;span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zTestoiqexF3" title="Amortization discount"&gt;26,315&lt;/span&gt; was charged to interest expense.
As of June 30, 2024, the Company accrued $&lt;span id="xdx_90D_eus-gaap--InterestExpense_c20230701__20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_z5qqrIOAIdr2" title="Interest expense"&gt;31,579&lt;/span&gt; of interest expense that is included in accrued expenses on the balance sheet. The January
2024 Note balance, net of discount at June 30, 2024 is $&lt;span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zZ46hv0blwZa" title="Note balance"&gt;526,315&lt;/span&gt; (see Note 7.) In connection with the entry into the January 2024 Note,
the Company and Paseco ApS agreed to amend and restate the Security Agreement (see Note 7) to add the Company&#x2019;s obligations under
the November 2023 Note and the January 2024 Note to the Secured Obligations (as defined in the Amended and Restated Security Agreement).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On November 3, 2023, the Company entered into an agreement with RS Bio to
issue a &lt;span id="xdx_90A_ecustom--OriginalIssueDiscountPromissoryNotePercentage_iI_dp_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_z5XBVS43U0dl" title="Original issue discount promissory note percentage"&gt;5&lt;/span&gt;% Original Issue Discount Promissory Note for the principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zHeOnXLQGWa3" title="Principal amount"&gt;1,000,000&lt;/span&gt; (the &#x201c;November 2023 Note&#x201d;). The
Company received a total of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zxOP8jH5ZVai" title="Gross proceeds"&gt;950,000&lt;/span&gt; in gross proceeds after taking into account the &lt;span id="xdx_904_ecustom--GrossProceedsOriginalIssueDiscountRate_iI_dp_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_ztkv0e4nQLZg" title="Gross proceeds original issue discount rate"&gt;5&lt;/span&gt;% original issue discount.&#160;The discount of
$&lt;span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zaKBj9H1pxM" title="Discount accreted"&gt;50,000&lt;/span&gt; will be accreted over the life of the Note. The Note bears an interest rate of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zX0sZ9nPP2t5" title="Interest rate"&gt;12&lt;/span&gt;% per annum and shall mature on &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20231102__20231103__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember__us-gaap--AwardDateAxis__custom--November2023NoteMember_zWI8zXEdLgbb" title="Debt maturity period"&gt;January 1, 2024&lt;/span&gt;
(the &#x201c;Maturity Date&#x201d;) is past due. The Company is required to pay interest on the maturity date (see Note 7.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On October
10, 2023, the Board of Directors of the Company (the &#x201c;Board&#x201d;) appointed Avram Miller to the Board, effective October 11, 2023,
to fill a vacancy. Mr. Miller will serve until the Company&#x2019;s 2024 Annual Meeting of Stockholders subject to this re-election or
until his successor has been duly elected and qualified. In addition to Mr. Miller&#x2019;s appointment to the Board, Mr. Miller, the co-founder
of Intel Capital, entered into an advisory agreement&#160;with the Company (the &#x201c;Advisory Agreement&#x201d;), pursuant to which Mr.
Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation, business
development, minority investments and licensing arrangements, among others. As compensation for these services, the Company will issue
Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will vest
in 2026, subject to Mr. Miller&#x2019;s continued service through each applicable vesting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 1, 2023, RS Bio, purchased
in a Private Placement 70,126 of the Company&#x2019;s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of
$500,000. &lt;span style="background-color: white"&gt;The Board of Directors (excluding Mr. Sindlev) approved the participation of certain officers
and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement&lt;/span&gt; (see Note
7.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 1, 2023, Paseco ApS,
in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company&#x2019;s Units at a price
per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company&#x2019;s Units at a price per
Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS
was deemed to be an affiliate of the Company (see Note 7.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company currently has a consulting
agreement with Paseco ApS for business advisory services since December of 2019. For the years ended June 30, 2023 and 2024 the Company
issued zero and 1,000,000 restricted common shares, respectively, as payment for services rendered thereunder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The information
set forth above in Note 7&#x2014;Debt&#x2014;Notes Payable&#x2014;Promissory Note relating to the Promissory Note issued to Paseco ApS is
incorporated herein by reference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;







</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-07-012024-06-30_custom_MarkDybulMember"
      decimals="0"
      id="Fact002045"
      unitRef="USD">220402</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-16_custom_RSBioMember"
      decimals="INF"
      id="Fact002047"
      unitRef="Shares">471699</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-16_custom_RSBioMember"
      decimals="INF"
      id="Fact002049"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-02-142024-02-16_custom_RSBioMember"
      decimals="0"
      id="Fact002051"
      unitRef="USD">250000</us-gaap:ProceedsFromNotesPayable>
    <RENB:OriginalIssueDiscountPromissoryNotePercentage
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="INF"
      id="Fact002053"
      unitRef="Pure">0.05</RENB:OriginalIssueDiscountPromissoryNotePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="0"
      id="Fact002055"
      unitRef="USD">105263</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-02-042024-02-05_custom_RSBioMember"
      decimals="0"
      id="Fact002057"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <RENB:GrossProceedsOriginalIssueDiscountRate
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="INF"
      id="Fact002059"
      unitRef="Pure">0.05</RENB:GrossProceedsOriginalIssueDiscountRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-02-05_custom_RSBioMember"
      decimals="INF"
      id="Fact002061"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-02-042024-02-05_custom_RSBioMember"
      id="Fact002063">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-012024-06-30_custom_RSBioMember"
      decimals="0"
      id="Fact002065"
      unitRef="USD">5263</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012024-06-30_custom_RSBioMember"
      decimals="0"
      id="Fact002067"
      unitRef="USD">6316</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2024-06-30_custom_RSBioMember"
      decimals="0"
      id="Fact002069"
      unitRef="USD">105263</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <RENB:OriginalIssueDiscountPromissoryNotePercentage
      contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="INF"
      id="Fact002073"
      unitRef="Pure">0.05</RENB:OriginalIssueDiscountPromissoryNotePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="0"
      id="Fact002075"
      unitRef="USD">526315</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="0"
      id="Fact002077"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <RENB:GrossProceedsOriginalIssueDiscountRate
      contextRef="AsOf2024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="INF"
      id="Fact002079"
      unitRef="Pure">0.05</RENB:GrossProceedsOriginalIssueDiscountRate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      decimals="INF"
      id="Fact002081"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-012024-01-02_custom_JanuaryNote2024Member_custom_RSBioMember"
      id="Fact002083">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-012024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact002085"
      unitRef="USD">26315</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact002087"
      unitRef="USD">31579</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2024-06-30_custom_RSBioMember_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact002089"
      unitRef="USD">526315</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <RENB:OriginalIssueDiscountPromissoryNotePercentage
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="INF"
      id="Fact002091"
      unitRef="Pure">0.05</RENB:OriginalIssueDiscountPromissoryNotePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="0"
      id="Fact002093"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="0"
      id="Fact002095"
      unitRef="USD">950000</us-gaap:ProceedsFromIssuanceOfDebt>
    <RENB:GrossProceedsOriginalIssueDiscountRate
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="INF"
      id="Fact002097"
      unitRef="Pure">0.05</RENB:GrossProceedsOriginalIssueDiscountRate>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="0"
      id="Fact002099"
      unitRef="USD">50000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      decimals="INF"
      id="Fact002101"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-11-022023-11-03_custom_November2023NoteMember_custom_RSBioMember"
      id="Fact002103">2024-01-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002107">&lt;p id="xdx_805_eus-gaap--BusinessCombinationDisclosureTextBlock_zI30BkyMafhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 &#x2014; &lt;span id="xdx_820_zP4MCwf0eON3"&gt;ACQUISITION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On September 28, 2023, the Company, entered into a Stock Purchase Agreement
(the &#x201c;&lt;span style="text-decoration: underline"&gt;Purchase Agreement&lt;/span&gt;&#x201d;) with GEDi Cube Intl Ltd., a private company formed
under the laws of England and Wales (&#x201c;&lt;span style="text-decoration: underline"&gt;GEDi Cube&lt;/span&gt;&#x201d;) to acquire 100% of the equity
interests of GEDi Cube from its equity holders (the &#x201c;&lt;span style="text-decoration: underline"&gt;Sellers&lt;/span&gt;&#x201d;). On September
28, 2023, the Board of Directors of the Company, and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and
on January 25, 2024, the shareholders of the Company approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement.
On February 13, 2024 (the &#x201c;Closing Date&#x201d;), the Company consummated the acquisition of GEDi Cube and the other transactions
contemplated by the Stock Purchase Agreement (collectively, the &#x201c;Transaction&#x201d;). As a result of the Transaction, GEDi Cube
became a wholly-owned subsidiary of the Company. The Company believes the acquisition will provide it with access to the nascent field
of artificial intelligence and machine learning driven diagnostics, which was the primary purpose for the acquisition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a &#x201c;GEDi Cube Share&#x201d; and, collectively, the &#x201c;GEDi Cube Shares&#x201d;)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller&#x2019;s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (&#x201c;Common Stock&#x201d;), which represents the 67,224,089
shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to
a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of
the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the &#x201c;Closing
Consideration&#x201d;) plus 5,610,100 shares of Common Stock representing the Seller&#x2019;s Earnout Shares (defined below) resulting from
the automatic conversion of the Company&#x2019;s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller&#x2019;s
pro rata percentage of the shares of Common Stock (the &#x201c;Earnout Shares&#x201d; and, together with the Closing Consideration, the
&#x201c;Exchange Consideration&#x201d;) to be issued to the Sellers upon the exercise or conversion of any of the Company&#x2019;s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the &#x201c;Closing Derivative Securities&#x201d;).
Each Seller&#x2019;s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
transaction was accounted for in accordance with the provisions of ASC 805-10 -&#160;&lt;i&gt;Business Combinations&lt;/i&gt;. &lt;/span&gt;As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The assets acquired and liabilities assumed were initially recognized provisionally
in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition date. The fair values as of the acquisition
date are based on information that existed as of the acquisition date. The Company completed its accounting for this acquisition during
the period ended June 30, 2024. As a result of the completion of the Company&#x2019;s analysis, the amount of in-process research and development
was determined to have a value of nil. Accordingly, the amount of goodwill recognized was increased to include the previously recognized
amount of in-process research and development. There was no impact to the Company&#x2019;s consolidated statement of operations as a result
of this change to the allocation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The acquisition-date fair value of the consideration transferred totaled approximately
$&lt;span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIyqwjvBZN39" title="Fair value of consideration transferred amount"&gt;156.6&lt;/span&gt; million, which consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_zSVvaUuM9A34" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_8B5_z8PF5HteaUe9" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Schedule of acquisition
date fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zEyPw6ZlO64h" style="width: 18%; text-align: right" title="Common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;136,001,631&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zjoz7V4huMji" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,557,500&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zDGlty6NlcNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;156,559,131&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AA_zHcQhzufb7m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
&lt;span style="background-color: white"&gt;fair value of the Company&#x2019;s
common shares issued as consideration was based on the closing price of the Company&#x2019;s common stock as of the Acquisition Date. The
fair value of the contingent consideration &lt;/span&gt;was based on the Sellers&#x2019; right to receive additional shares of common, pro rata,
upon the exercise or conversion of warrants, options and convertible notes payables outstanding as of the Closing Date. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zhQ1zpvhkhpd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td id="xdx_8BE_zxLldG2RVoqe" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;Schedule of fair value of assets acquired and
liabilities assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zq6XQ3FaWyjk" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_zN7yl1t9V7j1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65,851&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zPtCA0lnhfvl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;151,544&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zaLoQzJniMYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16,243&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zpRE5TOLHeq1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease ROU&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;624,366&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zF7WS3oEDFUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Assets Acquired:&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;858,004&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_ztLBL5Vn73w9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;583,577&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zc8gaUrUdn7a" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;722,508&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zZG1qV9C9zRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating Lease liability&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;624,367&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zXWz0fg8LK64" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notes Payable&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,832,460&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zxGOOPJ2KWs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Liabilities Assumed&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,762,913&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zKwI0eP5MbA4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net Assets Acquired&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,904,909&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--Goodwill_iI_zHRyIik7FMrl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;159,464,040&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zHZX42cQ67G1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;156,559,131&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A9_ze4tEVn648n8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected
to be deductible for income tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The Company
recognized approximately $&lt;span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zz4VgQDDkHod" title="Acquisition related costs"&gt;1.2&lt;/span&gt; million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#x201c;selling, general and administrative expenses&#x201d; in the accompanying condensed consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The amounts
of revenue and loss of GEDi Cube, included in the Company&#x2019;s consolidated statements of operations from the Closing Date through
June 30, 2024 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_zOmaFbuynzC6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_8B8_zeLWSDKMJN96" style="display: none; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Schedule of consolidated
statements of operations&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zp4H0VijRbig" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_z64I3QNoR8ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zcmIUGNg4Swa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="width: 70%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,243,144&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_zaCVFPNFr1Le" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Consolidated unaudited pro forma information: &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the twelve-month
period ended June 30, 2024. These amounts have been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zBEzpRDzvu64" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_zKIHK0PZjQql" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Schedule of consolidated
    proforma information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zXDOVA9dTWZi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_zEgo4gSzun87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zyt8a5cHxpy" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(83,571,822&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month
period ended June 30, 2023. These amounts have been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20220701__20230630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zNchmyR3IVbc" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_z3BVtj2Kxp55" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zdddk2sSnw8g" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 71%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Net loss&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 17%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(42,490,305&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zfIhwl1NJQOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="From2024-02-122024-02-13_custom_GEDiCubeMember"
      decimals="-5"
      id="Fact002109"
      unitRef="USD">156600000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002111">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_zSVvaUuM9A34" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_8B5_z8PF5HteaUe9" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Schedule of acquisition
date fair value&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zEyPw6ZlO64h" style="width: 18%; text-align: right" title="Common stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;136,001,631&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zjoz7V4huMji" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,557,500&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zDGlty6NlcNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;156,559,131&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock>
    <RENB:BusinessCombinationContingentConsiderationCommonStock
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002113"
      unitRef="USD">136001631</RENB:BusinessCombinationContingentConsiderationCommonStock>
    <us-gaap:BusinessCombinationContingentConsiderationAsset
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002115"
      unitRef="USD">20557500</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2024-02-122024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002117"
      unitRef="USD">156559131</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002121">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zhQ1zpvhkhpd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td id="xdx_8BE_zxLldG2RVoqe" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;Schedule of fair value of assets acquired and
liabilities assumed&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20240213__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zq6XQ3FaWyjk" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_zN7yl1t9V7j1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65,851&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zPtCA0lnhfvl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;151,544&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zaLoQzJniMYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16,243&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zpRE5TOLHeq1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease ROU&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;624,366&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zF7WS3oEDFUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Assets Acquired:&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;858,004&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_ztLBL5Vn73w9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;583,577&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zc8gaUrUdn7a" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;722,508&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zZG1qV9C9zRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating Lease liability&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;624,367&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zXWz0fg8LK64" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notes Payable&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,832,460&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zxGOOPJ2KWs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Liabilities Assumed&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,762,913&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zKwI0eP5MbA4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net Assets Acquired&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,904,909&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--Goodwill_iI_zHRyIik7FMrl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;159,464,040&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zHZX42cQ67G1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;156,559,131&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002123"
      unitRef="USD">65851</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002125"
      unitRef="USD">151544</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002127"
      unitRef="USD">16243</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002129"
      unitRef="USD">624366</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002131"
      unitRef="USD">858004</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002133"
      unitRef="USD">583577</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002135"
      unitRef="USD">722508</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002137"
      unitRef="USD">624367</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002139"
      unitRef="USD">1832460</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002141"
      unitRef="USD">3762913</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002143"
      unitRef="USD">-2904909</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002145"
      unitRef="USD">159464040</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2024-02-13_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002147"
      unitRef="USD">156559131</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember"
      decimals="-5"
      id="Fact002149"
      unitRef="USD">1200000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <RENB:ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002151">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_zOmaFbuynzC6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td id="xdx_8B8_zeLWSDKMJN96" style="display: none; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Schedule of consolidated
statements of operations&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zp4H0VijRbig" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_z64I3QNoR8ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zcmIUGNg4Swa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="width: 70%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,243,144&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</RENB:ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock>
    <RENB:BusinessAcquisitionsRevenue
      contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002153"
      unitRef="USD">0</RENB:BusinessAcquisitionsRevenue>
    <RENB:BusinessAcquisitionsNetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002155"
      unitRef="USD">-1243144</RENB:BusinessAcquisitionsNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002157">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zBEzpRDzvu64" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BB_zKIHK0PZjQql" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Schedule of consolidated
    proforma information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zXDOVA9dTWZi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_zEgo4gSzun87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zyt8a5cHxpy" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(83,571,822&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month
period ended June 30, 2023. These amounts have been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20220701__20230630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zNchmyR3IVbc" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessAcquisitionsProFormaRevenue_d0_z3BVtj2Kxp55" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zdddk2sSnw8g" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 71%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Net loss&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; width: 17%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(42,490,305&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002159"
      unitRef="USD">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002161"
      unitRef="USD">-83571822</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="From2022-07-012023-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002163"
      unitRef="USD">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="From2022-07-012023-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact002165"
      unitRef="USD">-42490305</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002169">&lt;p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_zyP6YjorNxXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2014; &lt;span id="xdx_82A_zsAM44MFaptg"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Beginning with the year ended June 30, 2024, the Company has two reportable segments.
Prior to the year ended June 30, 2024, the Company had only a single reportable segment, the acquisition and integration of Renovaro Cube
resulted in the identification of a separate reportable segment by the Company's chief operating decision maker. These segments have different
strategic and economic goals and are managed separately because they require different technology and marketing strategies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; width: 14%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reportable
Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt; white-space: nowrap; width: 84%; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Description
&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;RENB&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; white-space: nowrap; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Developing
new immunotherapies to combat cancer &#160; &#160; &#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding: 0pt; white-space: nowrap; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;RENC&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection &#160; &#160;
&#160; &#160; &#160; &#160; &#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The Company&#x2019;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2024, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zrJ4efp1h77l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BF_z7ruVRAAMsgj" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;Schedule of segment operating loss and
    asset information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--US_ziXHlVMmCpw" style="width: 12%; text-align: right" title="Operating income loss"&gt;80,470,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--US_zaUgX8WbupB4" style="width: 12%; text-align: right" title="Assets"&gt;2,998,311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--NL_zJF1tuPNXmn3" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;1,168,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--NL_zDkx9RGnOlG9" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;160,131,139&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--SegmentOperatingLoss_c20230701__20240630_zcNVmfundOdg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;81,639,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SegmentAsset_iI_c20240630_zspUhtBjXKE7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;163,129,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A8_zj0irXWiTU0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#x2019;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#x2019;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;Information
regarding each reportable segment for the year ended June 30, 2024 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zjCE6BwO8uOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B2_zhAVSfsaNtQj" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;Schedule of information regarding segment reporting&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKlTOHhxf1Ja" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_z4LV39ZVDDz8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230701__20240630_zTY8qzOyXrj7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zdUyiL5QHx4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;23,449,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,108,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;24,557,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zuklrLSSTxF6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,651,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,708,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_d0_zZsHuqTePqke" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible asset impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,611,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,611,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zUmYrLUFHhmc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_z7toYdt2lMGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,450&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SegmentOperatingLoss_zt5FK0XzrPik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;80,470,579&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,168,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;81,639,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_z2BAWHwk3fze" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Geographic
information:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;RENB and RENC are managed on a worldwide basis but operate in offices located
in the United Stated and the Netherlands, respectively. The geographic information analyses the Company's operations and assets based
on the country in which each segment operates. In presenting this geographic information, segment operating results have been based on
the geographic location in which the services were provided to the segment and segment assets were based on the geographic location of
the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002171">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zrJ4efp1h77l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BF_z7ruVRAAMsgj" style="display: none; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;Schedule of segment operating loss and
    asset information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--US_ziXHlVMmCpw" style="width: 12%; text-align: right" title="Operating income loss"&gt;80,470,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--US_zaUgX8WbupB4" style="width: 12%; text-align: right" title="Assets"&gt;2,998,311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SegmentOperatingLoss_c20230701__20240630__srt--StatementGeographicalAxis__country--NL_zJF1tuPNXmn3" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;1,168,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SegmentAsset_iI_c20240630__srt--StatementGeographicalAxis__country--NL_zDkx9RGnOlG9" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;160,131,139&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--SegmentOperatingLoss_c20230701__20240630_zcNVmfundOdg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;81,639,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SegmentAsset_iI_c20240630_zspUhtBjXKE7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;163,129,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <RENB:SegmentOperatingLoss
      contextRef="From2023-07-012024-06-30_country_US"
      decimals="0"
      id="Fact002173"
      unitRef="USD">80470579</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2024-06-30_country_US"
      decimals="0"
      id="Fact002175"
      unitRef="USD">2998311</RENB:SegmentAsset>
    <RENB:SegmentOperatingLoss
      contextRef="From2023-07-012024-06-30_country_NL"
      decimals="0"
      id="Fact002177"
      unitRef="USD">1168716</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2024-06-30_country_NL"
      decimals="0"
      id="Fact002179"
      unitRef="USD">160131139</RENB:SegmentAsset>
    <RENB:SegmentOperatingLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact002181"
      unitRef="USD">81639296</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002183"
      unitRef="USD">163129450</RENB:SegmentAsset>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002185">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zjCE6BwO8uOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B2_zhAVSfsaNtQj" style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt"&gt;Schedule of information regarding segment reporting&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKlTOHhxf1Ja" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230701__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_z4LV39ZVDDz8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230701__20240630_zTY8qzOyXrj7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zdUyiL5QHx4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;23,449,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,108,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;24,557,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zuklrLSSTxF6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,651,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,708,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_d0_zZsHuqTePqke" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible asset impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,611,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,611,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zUmYrLUFHhmc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_z7toYdt2lMGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,450&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SegmentOperatingLoss_zt5FK0XzrPik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;80,470,579&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,168,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;81,639,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-07-012024-06-30_custom_RENBMember"
      decimals="0"
      id="Fact002187"
      unitRef="USD">23449158</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-07-012024-06-30_custom_RENCMember"
      decimals="0"
      id="Fact002188"
      unitRef="USD">1108449</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact002189"
      unitRef="USD">24557608</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30_custom_RENBMember"
      decimals="0"
      id="Fact002191"
      unitRef="USD">2651971</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30_custom_RENCMember"
      decimals="0"
      id="Fact002192"
      unitRef="USD">56858</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact002193"
      unitRef="USD">2708829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-07-012024-06-30_custom_RENBMember"
      decimals="0"
      id="Fact002195"
      unitRef="USD">42611000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-07-012024-06-30_custom_RENCMember"
      decimals="0"
      id="Fact002196"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact002197"
      unitRef="USD">42611000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-07-012024-06-30_custom_RENBMember"
      decimals="0"
      id="Fact002199"
      unitRef="USD">11640000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-07-012024-06-30_custom_RENCMember"
      decimals="0"
      id="Fact002200"
      unitRef="USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact002201"
      unitRef="USD">11640000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-012024-06-30_custom_RENBMember"
      decimals="0"
      id="Fact002203"
      unitRef="USD">118450</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-012024-06-30_custom_RENCMember"
      decimals="0"
      id="Fact002204"
      unitRef="USD">3409</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact002205"
      unitRef="USD">121859</us-gaap:DepreciationDepletionAndAmortization>
    <RENB:SegmentOperatingLoss
      contextRef="From2023-07-012024-06-30_custom_RENBMember"
      decimals="0"
      id="Fact002207"
      unitRef="USD">80470579</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2023-07-012024-06-30_custom_RENCMember"
      decimals="0"
      id="Fact002208"
      unitRef="USD">1168716</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact002209"
      unitRef="USD">81639296</RENB:SegmentOperatingLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact002211">&lt;p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zIepvWb50mCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2014; &lt;span id="xdx_823_zx0Wl5yWp3Rg"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"&gt;Related to the June 14, 2024, Private Placement, ranging from July 3, 2024, to
October 2, 2024, the Company sold &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240703__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbwEal5gqa2j" title="Sale of stock issued"&gt;1,525,316&lt;/span&gt; Units at a price per Unit equal to $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcRyQIjfQ571" title="Sale of stock price per share"&gt;1.4726&lt;/span&gt; to a certain investor who paid in cash an aggregate
amount of $&lt;span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240703__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv5HXwphGswg" title="Sale of stock issued cash consideration"&gt;2,246,181&lt;/span&gt; in consideration of the Units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On August
1, 2024, the Company issued&#160;&lt;span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesIssuedForConsultingServices_c20240731__20240801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWMrTRgQJoEe" title="Issuance of common stock shares"&gt;2,000,000&lt;/span&gt;&#160;shares of common stock for consulting services valued at $&lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueIssuedForConsultingServices_c20240731__20240801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSk3Nizyiu1l" title="Common stock for consulting services value"&gt;1,400,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 23, 2024, the Company
forfeited &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0fUnIDkavkk" title="Forfeited shares of common stock"&gt;833,333&lt;/span&gt; shares of Common Stock from the original &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zg9P0Cn5SV0e" title="Original shares of common stock"&gt;1,000,000&lt;/span&gt; shares of Common Stock for advisory services granted to Avram Miller,
a member of the Company&#x2019;s board of directors on October 11, 2023. As consideration for and subject to such forfeiture, the Company
granted to Mr. Miller, an option to purchase &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zl7AT3tBZE98" title="Option to purchase shares of common stock"&gt;978,261&lt;/span&gt; shares of Common Stock of the Company with a per-share exercise price equal to the
fair market value of a share of the Common Stock on the date thereof, $&lt;span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue_c20240822__20240823__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7g2QBv79GJ5" title="Option to purchase shares of common stock par value"&gt;0.69&lt;/span&gt;. &#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-07-032024-10-02_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002213"
      unitRef="Shares">1525316</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-10-02_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002215"
      unitRef="USDPShares">1.4726</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-07-032024-10-02_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002217"
      unitRef="USD">2246181</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <RENB:StockIssuedDuringPeriodSharesIssuedForConsultingServices
      contextRef="From2024-07-312024-08-01_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002219"
      unitRef="Shares">2000000</RENB:StockIssuedDuringPeriodSharesIssuedForConsultingServices>
    <RENB:StockIssuedDuringPeriodValueIssuedForConsultingServices
      contextRef="From2024-07-312024-08-01_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002221"
      unitRef="USD">1400000</RENB:StockIssuedDuringPeriodValueIssuedForConsultingServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002223"
      unitRef="Shares">833333</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002225"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002227"
      unitRef="Shares">978261</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <RENB:StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue
      contextRef="From2024-08-222024-08-23_custom_RestrictedStockAwardsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002229"
      unitRef="USDPShares">0.69</RENB:StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedParValue>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-04-012024-06-30" id="Fact002230">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-04-012024-06-30" id="Fact002231">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-04-012024-06-30" id="Fact002232">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-04-012024-06-30" id="Fact002233">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
